FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Zhang, X
Williams, S
Suzuki, E
Karam, E
Gikeson, G
AF Zhang, Xian
Williams, Sarah
Suzuki, Eiji
Karam, Eva
Gilkeson, Gary
TI Fli-1 transcription factor affects inflammatory cell infiltration in the
lupus nephritis development by regulating expression of inflammatory
chemokines
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Zhang, Xian; Suzuki, Eiji; Karam, Eva; Gilkeson, Gary] Med Univ S Carolina, Med, Charleston, SC 29425 USA.
[Zhang, Xian; Williams, Sarah; Gilkeson, Gary] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR
PY 2011
VL 186
SU 1
MA 44.12
PG 1
WC Immunology
SC Immunology
GA V44LY
UT WOS:000209751700040
ER
PT J
AU Hatano, H
Hayes, TL
Dahl, V
Sinclair, E
Lee, TH
Hoh, R
Lampiris, H
Hunt, PW
Palmer, S
McCune, JM
Martin, JN
Busch, MP
Shacklett, BL
Deeks, SG
AF Hatano, Hiroyu
Hayes, Timothy L.
Dahl, Viktor
Sinclair, Elizabeth
Lee, Tzong-Hae
Hoh, Rebecca
Lampiris, Harry
Hunt, Peter W.
Palmer, Sarah
McCune, Joseph M.
Martin, Jeffrey N.
Busch, Michael P.
Shacklett, Barbara L.
Deeks, Steven G.
TI A Randomized, Controlled Trial of Raltegravir Intensification in
Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4(+) T
Cell Response
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LOW-LEVEL VIREMIA;
POLYMERASE-CHAIN-REACTION; BLOOD MONONUCLEAR-CELLS; IMMUNE
RECONSTITUTION; TYPE-1 INFECTION; THERAPY; ACTIVATION; SUPPRESSION;
INDIVIDUALS
AB Background. Some human immunodeficiency virus (HIV)-infected individuals are not able to achieve a normal CD4(+) T cell count despite prolonged, treatment-mediated viral suppression. We conducted an intensification study to assess whether residual viral replication contributes to replenishment of the latent reservoir and whether mucosal HIV-specific T cell responses limit the reservoir size.
Methods. Thirty treated subjects with CD4(+) T cell counts of <350 cells/mm(3) despite viral suppression for >= 1 year were randomized to add raltegravir (400 mg twice daily) or matching placebo for 24 weeks. The primary end points were the proportion of subjects with undetectable plasma viremia (determined using an ultrasensitive assay with a lower limit of detection of <.3 copy/mL) and a change in the percentage of CD38(+)HLA-DR(+)CD8(+) T cells in peripheral blood mononuclear cells (PBMCs).
Results. The proportion of subjects with undetectable plasma viremia did not differ between the 2 groups (P = .42). Raltegravir intensification did not have a significant effect on immune activation or HIV-specific responses in PBMCs or gut-associated lymphoid tissue.
Conclusions. Low-level viremia is not likely to be a significant cause of suboptimal CD4(+) T cell gains during HIV treatment.
C1 [Hatano, Hiroyu; Sinclair, Elizabeth; Hoh, Rebecca; Lampiris, Harry; Hunt, Peter W.; McCune, Joseph M.; Martin, Jeffrey N.; Busch, Michael P.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hayes, Timothy L.; Shacklett, Barbara L.] Univ Calif Davis, Davis, CA 95616 USA.
[Dahl, Viktor; Palmer, Sarah] Karolinska Inst, Solna, Sweden.
[Dahl, Viktor; Palmer, Sarah] Swedish Inst Infect Dis Control, Solna, Sweden.
[Lee, Tzong-Hae; Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA.
[Lampiris, Harry] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Hatano, H (reprint author), San Francisco Gen Hosp, Bldg 80,Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA.
EM hhatano@php.ucsf.edu
RI Shacklett, Barbara/A-7288-2009
OI Shacklett, Barbara/0000-0002-7067-732X; Dahl, Viktor/0000-0001-9921-5172
FU National Institute of Allergy and Infectious Diseases [K23AI075985,
K24AI069994, AI052745, AI055273, RR16482, R01 AI087145, R01 AI057020];
American Foundation for AIDS Research [106710-40-RGRL, 107170-44-RGRL];
Universitywide AIDS Research Program [CC99-SF-001]; UCSF/Gladstone
Institute of Virology and Immunology Center for AIDS Research [P30
AI027763]; UCSF Clinical and Translational Research Institute Clinical
Research Center [UL1 RR024131]; Center for AIDS Prevention Studies [P30
MH62246]; Center for HIV/AIDS Vaccine Immunology [U01-AI067854]; NCRR
[C06 RR - 12088]; Swedish Research Council; National Institutes of
Health (NIH) [DPI OD00329]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases (grant numbers K23AI075985, K24AI069994, AI052745,
AI055273, RR16482, R01 AI087145, R01 AI057020), the American Foundation
for AIDS Research (grant number 106710-40-RGRL), the Universitywide AIDS
Research Program (grant number CC99-SF-001), the UCSF/Gladstone
Institute of Virology and Immunology Center for AIDS Research (grant
number P30 AI027763), the Clinical Research Center at San Francisco
General Hospital, supported by the UCSF Clinical and Translational
Research Institute Clinical Research Center (grant number UL1 RR024131),
the Center for AIDS Prevention Studies (P30 MH62246), and the Center for
HIV/AIDS Vaccine Immunology (grant number U01-AI067854). Mucosal samples
were analyzed in a facility constructed with support from NCRR (grant
number C06 RR - 12088). S. P. was funded, in part, by the Swedish
Research Council and by the American Foundation for AIDS Research (grant
number 107170-44-RGRL). J.M.M. is a recipient of the National Institutes
of Health (NIH) Director's Pioneer Award Program, part of the NIH
Roadmap for Medical Research (grant number DPI OD00329).
NR 46
TC 116
Z9 116
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD APR 1
PY 2011
VL 203
IS 7
BP 960
EP 968
DI 10.1093/infdis/jiq138
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 737FF
UT WOS:000288553800011
PM 21402547
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI OSTEONECROSIS OF THE JAW
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
C1 VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA.
RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
EI 1943-4723
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD APR
PY 2011
VL 142
IS 4
BP 370
EP 371
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 749EU
UT WOS:000289447200006
PM 21454841
ER
PT J
AU Sullivan, K
Sherman, O
Eng, C
Ribner, H
Liao, S
AF Sullivan, K.
Sherman, O.
Eng, C.
Ribner, H.
Liao, S.
TI Management recommendations for subtherapeutic international normalized
ratio (INR) and consecutive subtherapeutic INR in an anticoagulation
clinic
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Meeting Abstract
C1 [Sullivan, K.; Sherman, O.; Eng, C.; Ribner, H.; Liao, S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD APR
PY 2011
VL 31
IS 3
SI SI
BP 379
EP 379
PG 1
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 733KZ
UT WOS:000288262900043
ER
PT J
AU Baddley, JW
AF Baddley, John W.
TI Clinical risk factors for invasive aspergillosis
SO MEDICAL MYCOLOGY
LA English
DT Article; Proceedings Paper
CT 4th Advances Against Aspergillosis (AAA) Conference
CY FEB 04-06, 2010
CL Rome, ITALY
DE Aspergillus; clinical risk factors; invasive aspergillosis
ID CRITICALLY-ILL PATIENTS; CELL TRANSPLANT RECIPIENTS; OBSTRUCTIVE
PULMONARY-DISEASE; SOLID-ORGAN TRANSPLANTATION; INTENSIVE-CARE-UNIT;
FUNGAL-INFECTIONS; RESPIRATORY-TRACT; IMMUNOCOMPROMISED PATIENTS; MOLD
INFECTIONS; EPIDEMIOLOGY
AB Despite improvements in the antifungal armamentarium and diagnostic modalities, invasive aspergillosis (IA) remains an important cause of morbidity and mortality in immunocompromised patients. There is an emergence of non-traditional groups at risk for IA, including intensive care unit (ICU) patients, post-operative patients, those with chronic pulmonary diseases, patients with AIDS and patients on immunomodulating drugs (TNF-alpha inhibitors). Identification of clinical risk factors for IA may help in determining which patients require risk modification and other prevention measures.
C1 [Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
NR 57
TC 27
Z9 29
U1 1
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1369-3786
J9 MED MYCOL
JI Med. Mycol.
PD APR
PY 2011
VL 49
SU 1
BP S7
EP S12
DI 10.3109/13693786.2010.505204
PG 6
WC Infectious Diseases; Mycology; Veterinary Sciences
SC Infectious Diseases; Mycology; Veterinary Sciences
GA 734IE
UT WOS:000288327000002
PM 20718606
ER
PT J
AU Hazlett, EA
Goldstein, KE
Tajima-Pozo, K
Speidel, ER
Zelmanova, Y
Entis, JJ
Silverman, JM
New, AS
Koenigsberg, HW
Haznedar, MM
Byne, W
Siever, LJ
AF Hazlett, Erin A.
Goldstein, Kim E.
Tajima-Pozo, Kazuhiro
Speidel, Elizabeth R.
Zelmanova, Yuliya
Entis, Jonathan J.
Silverman, Jeremy M.
New, Antonia S.
Koenigsberg, Harold W.
Haznedar, M. Mehmet
Byne, William
Siever, Larry J.
TI Cingulate and temporal lobe fractional anisotropy in schizotypal
personality disorder
SO NEUROIMAGE
LA English
DT Article
DE Diffusion tensor imaging; Schizotypal personality disorder; Dorsolateral
prefrontal cortex; Temporal lobe; Cingulum; Fractional anisotropy
ID WHITE-MATTER INTEGRITY; THALAMIC MEDIODORSAL NUCLEUS; DIFFUSION TENSOR
ANISOTROPY; EARLY-ONSET SCHIZOPHRENIA; ANTERIOR CINGULATE; GYRUS VOLUME;
GRAY-MATTER; ABNORMALITIES; MRI; SPECTRUM
AB Background: Consistent with the clinical picture of milder symptomatology in schizotypal personality disorder (SPD) than schizophrenia, morphological studies indicate SPD abnormalities in temporal lobe regions but to a much lesser extent in prefrontal regions implicated in schizophrenia. Lower fractional anisotropy (FA), a measure of white-matter integrity within prefrontal, temporal, and cingulate regions has been reported in schizophrenia but has been little studied in SPD.
Aims: The study aim was to examine temporal and prefrontal white matter FA in 30 neuroleptic-naive SPD patients and 35 matched healthy controls (HCs). We hypothesized that compared with HCs, SPD patients would exhibit lower FA in temporal lobe and anterior cingulum regions but relative sparing in prefrontal regions.
Method: We acquired diffusion tensor imaging (DTI) in all participants and examined FA in the white matter underlying Brodmann areas (BAs) in dorsolateral prefrontal (BAs 44, 45, and 46), temporal lobe (BAs 22, 21, and 20), and cingulum (BAs 25, 24, 31, 23, and 29) regions with a series of analyses using multivariate analysis of variance.
Results: Compared with HCs, the SPD group had significantly lower FA in the left temporal lobe but not prefrontal regions. In the cingulum. FA was lower in the SPD group in the posterior regions (BAs 31 and 23), higher in the anterior (BA 25) regions and lower overall in the right but not the left cingulum. Among the SPD group, lower FA in the cingulum was associated with more severe negative symptoms (e.g., odd speech).
Conclusions: Similar to schizophrenia, our results indicate cingulum-temporal lobe FA abnormalities in SPD and suggest that cingulum abnormalities are associated with negative symptoms. Published by Elsevier Inc.
C1 [Hazlett, Erin A.; Goldstein, Kim E.; Tajima-Pozo, Kazuhiro; Speidel, Elizabeth R.; Zelmanova, Yuliya; Entis, Jonathan J.; Silverman, Jeremy M.; New, Antonia S.; Koenigsberg, Harold W.; Haznedar, M. Mehmet; Byne, William; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Hazlett, Erin A.; Silverman, Jeremy M.; New, Antonia S.; Koenigsberg, Harold W.; Haznedar, M. Mehmet; Byne, William; Siever, Larry J.] James J Peters Dept Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN3, Bronx, NY 10468 USA.
RP Hazlett, EA (reprint author), James J Peters Dept Vet Adm Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN3, 130 W Kingsbridge Rd,Room 6A-45, Bronx, NY 10468 USA.
EM erin.hazlett@mssm.edu
FU VA MERIT [7609-28]; NIMH [R01MH073911]; National Center for Research
Resources (NCRR), NIH [M01-Patient Care RR-00071]; Mental Illness,
Research, Education, and Clinical Center, VISN 3 Veterans Health
Administration
FX This study was supported by VA MERIT 7609-28 to Dr. Siever and NIMH
grant R01MH073911 to Dr. Hazlett. Other support came from a grant
(M01-Patient Care RR-00071) from the National Center for Research
Resources (NCRR), a component of the NIH and the Mental Illness,
Research, Education, and Clinical Center, VISN 3 Veterans Health
Administration.
NR 73
TC 16
Z9 17
U1 1
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD APR 1
PY 2011
VL 55
IS 3
BP 900
EP 908
DI 10.1016/j.neuroimage.2010.12.082
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 734DQ
UT WOS:000288313800006
PM 21223999
ER
PT J
AU Harvey, PO
Lee, J
Cohen, MS
Engel, SA
Glahn, DC
Nuechterlein, KH
Wynn, JK
Green, MF
AF Harvey, Philippe-Olivier
Lee, Junghee
Cohen, Mark S.
Engel, Stephen A.
Glahn, David C.
Nuechterlein, Keith H.
Wynn, Jonathan K.
Green, Michael F.
TI Altered dynamic coupling of lateral occipital complex during visual
perception in schizophrenia
SO NEUROIMAGE
LA English
DT Article
DE Functional connectivity/ Dynamic coupling; Lateral occipital complex;
Backward visual masking; Schizophrenia; fMRI
ID BACKWARD-MASKING DEFICITS; MULTIPLE TRIAL TYPES; EVENT-RELATED FMRI;
FUNCTIONAL CONNECTIVITY; OBJECT RECOGNITION; CORTEX; MECHANISMS;
PATTERNS; ENTROPY; HUMANS
AB Introduction: There is mounting evidence that visual perception abnormalities in schizophrenia are partly explained by a dysfunction of the lateral occipital complex (LO). We previously demonstrated that schizophrenia patients had broader topography and reduced magnitude of activity of LO. However, the functional connectivity of LO with other brain regions during visual perception has not been directly investigated in schizophrenia.
Materials and methods: Eighteen patients with schizophrenia and eighteen matched controls performed a backward masking task during functional magnetic resonance imaging (fMRI). Stimulus onset asynchronies were manipulated to change the level of target visibility. To examine connectivity with LO function we conducted psychophysiological interactions (PPI) analyses using: 1) a region of interest (ROI) approach and 2) a whole brain analysis. ROIs were defined based on a contrast of trials on which a target was presented versus null trials in which no stimuli were presented.
Results: Eleven ROIs were identified. Both groups showed similar strength of coupling between LO and the 11 ROIs when visibility was not taken into account. Healthy controls showed clear changes in coupling between LO and prefrontal and parietal regions as a function of target visibility (higher coupling with more visible targets). In comparison, patients showed reduced dynamic coupling with LO in the right superior frontal gyrus (significant after correcting for multiple comparisons) and a trend for reduced coupling in the left precuneus and left inferior frontal regions. Whole brain analysis identified additional regions that showed dynamic coupling with LO in healthy controls, but not in patients.
Discussion: The increased coupling between LO and higher-level parietal and prefrontal regions during visual awareness in healthy controls likely reflects visual reentrant processing. The lack of modulation of coupling between LO and key prefrontal and parietal regions found in schizophrenia may partly reflect abnormalities in LO tuning. The altered LO coupling may contribute to visual perception abnormalities in schizophrenia. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Harvey, Philippe-Olivier; Lee, Junghee; Cohen, Mark S.; Nuechterlein, Keith H.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90073 USA.
[Harvey, Philippe-Olivier; Lee, Junghee; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles, Healthcare Ctr Syst, Los Angeles, CA USA.
[Engel, Stephen A.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA.
[Glahn, David C.] Olin Neuropsychiat Res Ctr, New Haven, CT USA.
[Glahn, David C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
RP Harvey, PO (reprint author), Univ Calif Los Angeles, Semel Inst, W LA VA Healthcare Ctr, 11301 Wilshire Blvd,210A,Room 131, Los Angeles, CA 90073 USA.
EM poharvey@ucla.edu
RI Lee, Junghee/C-5226-2014; Wynn, Jonathan/H-3749-2014; Cohen,
Mark/C-6610-2011
OI Lee, Junghee/0000-0001-9567-8700; Wynn, Jonathan/0000-0002-1763-8540;
Cohen, Mark/0000-0001-6731-4053
FU Canadian Institutes of Health Research; William M. and Linda R Dietel
Philanthropic Fund at the Northern Piedmont Community Foundation;
Northstar Fund; [MH043292]
FX This work was supported by grant MH043292 to Dr. Green. Poorang Non and
Alisa Malin assisted in data collection. Dr. Harvey is supported by a
postdoctoral fellowship from the Canadian Institutes of Health Research.
For generous support of the UCLA Brain Mapping Center, we also thank the
Brain Mapping Medical Research Organization, Brain Mapping Support
Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation,
William M. and Linda R Dietel Philanthropic Fund at the Northern
Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon,
Capital Group Companies Charitable Foundation, Robson Family, and
Northstar Fund.
NR 51
TC 16
Z9 17
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD APR 1
PY 2011
VL 55
IS 3
BP 1219
EP 1226
DI 10.1016/j.neuroimage.2010.12.045
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 734DQ
UT WOS:000288313800035
PM 21194569
ER
PT J
AU Jackson, GL
Lee, SYD
Edelman, D
Weinberger, M
Yano, EM
AF Jackson, George L.
Lee, Shoou-Yih Daniel
Edelman, David
Weinberger, Morris
Yano, Elizabeth M.
TI Employment of mid-level providers in primary care and control of
diabetes
SO PRIMARY CARE DIABETES
LA English
DT Article
DE Diabetes; Mid-level providers; United States Department of Veterans
Affairs
ID NURSE-PRACTITIONERS; NONPHYSICIAN CLINICIAN; PHYSICIAN ASSISTANTS;
CONTROLLED-TRIAL; CASE-MANAGEMENT; UNITED-STATES; VETERANS; OUTCOMES;
QUALITY; ORGANIZATION
AB Aims: Examine potential associations between inclusion of mid-level providers in United States Veterans Affairs (VA) primary care programs and diabetes control.
Methods: We established a cohort of diabetes patients (alive October 1, 1999) using the VA Diabetes Registry and VA corporate databases. 1999 VA Survey of Primary Care Practices data were combined with individual-patient information. We used a two-level hierarchical model to determine the relationship between staffing characteristics and hemoglobin A1c (HbAlc), among 88,682 patients from 198 clinics.
Results: Inclusion of nurse practitioners (NPs) at relatively limited levels (% of all providers who are NPs) in the primary care program was significantly associated with HbA1c lower by 0.31 percentage points (95% CI, -0.50% to -0.12%) compared to programs that did not include NPs. Having some level of NP staffing vs. no NP staffing was associated HbA1c lower by 0.25%. Inclusion of physician assistants (PAs) in primary care programs was generally not associated with a statistically significant difference in HbA1c. The exception is that moderate levels of PA staffing were associated with slightly higher HbA1c [0.18%, 95% CI, 0.02-0.34)].
Conclusions: Diabetes control among primary care patients appeared to benefit from inclusion of NPs, while an analogous association was not found for PAs. Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.
C1 [Jackson, George L.; Edelman, David; Weinberger, Morris] Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Jackson, George L.; Edelman, David] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA.
[Lee, Shoou-Yih Daniel] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
[Weinberger, Morris] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Sepulveda, CA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA.
RP Jackson, GL (reprint author), Durham VA Med Ctr, HSR&D Serv 152, 508 Fulton St, Durham, NC 27705 USA.
EM george.l.jackson@duke.edu
OI Edelman, David/0000-0001-7112-6151
FU VA grant [MRP 05-312]; VA HSRD Service [MPC 97-012]; [2T32HS000079-06]
FX Support: During part of this work, Dr. Jackson was a National Research
Service Award-Agency for Healthcare Research and Quality Postdoctoral
Fellow (institutional training grant 2T32HS000079-06) and a Veterans
Affairs Health Services Research & Development (HSR&D) Merit Review
Entry Program awardee (VA grant MRP 05-312). Dr. Weinberger is a VA
HSR&D Senior Career Scientist awardee. Dr. Yano is a VA HSR&D Research
Career Scientist awardee (RCS 05-195). Survey data collection was funded
by the VA HSR&D Service (Project MPC 97-012).
NR 39
TC 9
Z9 9
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1751-9918
J9 PRIM CARE DIABETES
JI Prim. Care Diabetes
PD APR
PY 2011
VL 5
IS 1
BP 25
EP 31
DI 10.1016/j.pcd.2010.09.005
PG 7
WC Endocrinology & Metabolism; Primary Health Care
SC Endocrinology & Metabolism; General & Internal Medicine
GA 943MR
UT WOS:000304128200004
PM 20980212
ER
PT J
AU Clements, JL
Bouchard, CS
Lee, WB
Dunn, SP
Mannis, MJ
Reidy, JJ
John, T
Hannush, SB
Goins, KM
Wagoner, MD
Adi, MA
Rubenstein, JB
Udell, IJ
Babiuch, AS
AF Clements, John L.
Bouchard, Charles S.
Lee, W. Barry
Dunn, Steven P.
Mannis, Mark J.
Reidy, James J.
John, Thomas
Hannush, Sadeer B.
Goins, Kenneth M.
Wagoner, Michael D.
Adi, Marwa A.
Rubenstein, Jonathan B.
Udell, Ira J.
Babiuch, Amy S.
TI Retrospective Review of Graft Dislocation Rate Associated With Descemet
Stripping Automated Endothelial Keratoplasty After Primary Failed
Penetrating Keratoplasty
SO CORNEA
LA English
DT Review
DE cornea transplant; Descemet stripping endothelial keratoplasty;
penetrating keratoplasty; endothelial keratoplasty
ID CELL LOSS; UNITED-STATES; EYES; OUTCOMES; TRENDS
AB Purpose: To report the rate of graft dislocation in patients who underwent Descemet stripping automated endothelial keratoplasty (DSAEK) after a previous penetrating keratoplasty (PKP).
Methods: Institutional review board-approved, multicenter, retrospective chart review. Inclusion criteria included: prior failed PKP and subsequent DSAEK. The primary outcomes measured in this study were the presence of a graft dislocation, rate of rebubble, and graft attachment. Additional variables included: presence of a prior glaucoma drainage device, graft-to-host size disparity, number of sutures remaining in PKP, and stripping of the Descemet membrane at the time of DSAEK surgery.
Results: Ninety patients (97 eyes) were included in the study. In 31% (30 of 97), the endothelial graft dislocated after surgery. All 30 cases required a rebubble except 1, which reattached spontaneously. Ninety-eight percent (95 of 97) of all grafts remained attached for the duration of the follow-up period. Only 2 eyes (2.2%) required repeat graft. Endothelial grafts dislocated in 67% of patients with glaucoma draining devices. The dislocation rate for grafts larger than the host was 12 of 49 (24%), equal to the host was 3 of 17 (18%), and smaller than the host was 8 of 19 (42%). Dislocations occurred in 5 of 21 (24%) of grafts with sutures remaining and 22 of 76 (29%) of those with all sutures out. Five of 12 (42%) cases of grafts performed without stripping the Descemet had dislocations.
Conclusions: The graft dislocation rate in DSAEK procedures after PKP is comparable to that after primary DSAEK cases. Donor grafts that are smaller than the host PKP and the presence of prior glaucoma drainage devices are risk factors for higher rates of graft dislocation.
C1 [Clements, John L.; Bouchard, Charles S.; John, Thomas] Loyola Univ, Dept Ophthalmol, Med Ctr, Maywood, IL 60153 USA.
[Clements, John L.; Bouchard, Charles S.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Ophthalmol, Hines, IL 60141 USA.
[Lee, W. Barry] Eye Consultants Atlanta Piedmont Hosp, Dept Ophthalmol, Atlanta, GA USA.
[Dunn, Steven P.] William Beaumont Hosp, Dept Ophthalmol, Royal Oak, MI 48072 USA.
[Mannis, Mark J.] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
[Reidy, James J.] SUNY Buffalo, Dept Ophthalmol, Buffalo, NY 14260 USA.
[Hannush, Sadeer B.] Wills Eye Inst, Dept Ophthalmol, Philadelphia, PA USA.
[Goins, Kenneth M.; Wagoner, Michael D.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
[Adi, Marwa A.] Georgetown Univ, Med Ctr, Dept Ophthalmol, Washington, DC 20007 USA.
[Rubenstein, Jonathan B.; Babiuch, Amy S.] Rush Univ, Dept Ophthalmol, Med Ctr, Chicago, IL 60612 USA.
[Udell, Ira J.] Albert Einstein Coll Med, Northshore Long Isl Jewish Hlth Syst, Dept Ophthalmol, Bronx, NY 10467 USA.
RP Bouchard, CS (reprint author), Loyola Univ, Dept Ophthalmol, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM cboucha@lumc.edu
FU Richard A. Perritt Charitable Foundation
FX Supported in part by the Richard A. Perritt Charitable Foundation.
NR 21
TC 28
Z9 30
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD APR
PY 2011
VL 30
IS 4
BP 414
EP 418
DI 10.1097/ICO.0b013e3181f7f163
PG 5
WC Ophthalmology
SC Ophthalmology
GA 732OJ
UT WOS:000288196200009
PM 21099405
ER
PT J
AU Pett, SL
Carey, C
Lin, E
Wentworth, D
Lazovski, J
Miro, JM
Gordin, F
Angus, B
Rodriguez-Barradas, M
Rubio, R
Tambussi, G
Cooper, DA
Emery, S
AF Pett, S. L.
Carey, C.
Lin, E.
Wentworth, D.
Lazovski, J.
Miro, J. M.
Gordin, F.
Angus, B.
Rodriguez-Barradas, M.
Rubio, R.
Tambussi, G.
Cooper, D. A.
Emery, S.
CA INSIGHT-ESPRIT Study Grp
TI Predictors of bacterial pneumonia in Evaluation of Subcutaneous
Interleukin-2 in a Randomized International Trial (ESPRIT)
SO HIV MEDICINE
LA English
DT Article
DE bacterial pneumonia; combination antiretroviral therapy; ESPRIT; rIL-2
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; INCREASED
APOPTOSIS; THERAPY; RISK; INDIVIDUALS; SMOKING; CYCLES; PLASMA; COHORT
AB Background and Objectives
Bacterial pneumonia still contributes to morbidity/mortality in HIV infection despite effective combination antiretroviral therapy (cART). Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT), a trial of intermittent recombinant interleukin-2 (rIL-2) with cART vs. cART alone (control arm) in HIV-infected adults with CD4 counts >= 300 cells/mu L, offered the opportunity to explore associations between bacterial pneumonia and rIL-2, a cytokine that increases the risk of some bacterial infections.
Methods
Baseline and time-updated factors associated with first-episode pneumonia on study were analysed using multivariate proportional hazards regression models. Information on smoking/pneumococcal vaccination history was not collected.
Results
IL-2 cycling was most intense in years 1-2. Over approximate to 7 years, 93 IL-2 [rate 0.67/100 person-years (PY)] and 86 control (rate 0.63/100 PY) patients experienced a pneumonia event [hazard ratio (HR) 1.06; 95% confidence interval (CI) 0.79, 1.42; P=0.68]. Median CD4 counts prior to pneumonia were 570 cells/mu L (IL-2 arm) and 463 cells/mu L (control arm). Baseline risks for bacterial pneumonia included older age, injecting drug use, detectable HIV viral load (VL) and previous recurrent pneumonia; Asian ethnicity was associated with decreased risk. Higher proximal VL (HR for 1 log(10) higher VL 1.28; 95% CI 1.11, 1.47; P < 0.001) was associated with increased risk; higher CD4 count prior to the event (HR per 100 cells/mu L higher 0.94; 95% CI 0.89, 1.0; P=0.04) decreased risk. Compared with controls, the hazard for a pneumonia event was higher if rIL-2 was received < 180 days previously (HR 1.66; 95% CI 1.07, 2.60; P=0.02) vs. >= 180 days previously (HR 0.98; 95% CI 0.70, 1.37; P=0.9). Compared with the control group, pneumonia risk in the IL-2 arm decreased over time, with HRs of 1.41, 1.71, 1.16, 0.62 and 0.84 in years 1, 2, 3-4, 5-6 and 7, respectively.
Conclusions
Bacterial pneumonia rates in cART-treated adults with moderate immunodeficiency are high. The mechanism of the association between bacterial pneumonia and recent IL-2 receipt and/or detectable HIV viraemia warrants further exploration.
C1 [Pett, S. L.] Univ New S Wales, Fac Med, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2034, Australia.
[Pett, S. L.; Cooper, D. A.] St Vincents Hosp, Ctr Appl Med Res, Sydney, NSW 2010, Australia.
[Wentworth, D.] Univ Minnesota, Dept Biostat, Minneapolis, MN USA.
[Lazovski, J.] Fdn ESPRIT, Buenos Aires, DF, Argentina.
[Miro, J. M.] Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Spain.
[Gordin, F.] VA Med Ctr, Dept Infect Dis, Washington, DC USA.
[Angus, B.] John Radcliffe Hosp, Wellcome Trust Ctr Clin Trop Med, Oxford OX3 9DU, England.
[Rodriguez-Barradas, M.] VA Med Ctr, Houston, TX USA.
[Rubio, R.] Hosp 12 Octubre, E-28041 Madrid, Spain.
[Tambussi, G.] Univ Milan, Osped San Raffaele, Div Malattie, I-20127 Milan, Italy.
RP Pett, SL (reprint author), Univ New S Wales, Fac Med, Natl Ctr HIV Epidemiol & Clin Res, UNSW Coogee Campus,45 Beach St, Sydney, NSW 2034, Australia.
EM spett@nchecr.unsw.edu.au
RI ; Yee, Thynn Thynn/H-5862-2012; Beral, Valerie/B-2979-2013; Doerler,
Martin/C-2015-2013; Pulido, Federico/B-8417-2009; Arribas,
Jose/A-1595-2015; Victor, Moreno-Cuerda/G-3851-2016; Bouza,
Emilio/D-8661-2014; Emery, Sean/H-4920-2013
OI Magenta, Lorenzo/0000-0002-7644-3647; Angus, Brian/0000-0003-3598-7784;
Pulido, Federico/0000-0002-7414-8812; Arribas, Jose/0000-0002-7410-9450;
Victor, Moreno-Cuerda/0000-0003-0262-8216; Bouza,
Emilio/0000-0001-6967-9267; Emery, Sean/0000-0001-6072-8309; Okhuysen,
Pablo/0000-0002-1596-3411
FU National Institute of Allergy and Infectious Diseases (NIAID) [U01
AI46957, U01 AI068641]
FX The Writing Group acknowledges the efforts of the many ESPRIT and
SILCAAT investigators who collected these data, and the International
Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
Executive Committee (J. D. Neaton, D. Abrams, A. Babiker, J. Baxter, D.
A. Cooper, C. J. Cohen, D. Cohn, J. H. Darbyshire, W. El-Sadr, S. Emery,
F. Gordin, H. C. Lane, G. Larson, M. H. Losso, J. D. Lundgren, J. Nadler
and A. N. Phillips) for their oversight of the ESPRIT study and valuable
editorial assistance. ESPRIT was supported by grants U01 AI46957 and U01
AI068641 from the National Institute of Allergy and Infectious Diseases
(NIAID). rIL-2 was provided by Chiron and Novartis. This study is
ClinicalTrials.gov number NCT00004978.
NR 25
TC 2
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1464-2662
J9 HIV MED
JI HIV Med.
PD APR
PY 2011
VL 12
IS 4
BP 219
EP 227
DI 10.1111/j.1468-1293.2010.00875.x
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 730GB
UT WOS:000288020700005
PM 20812949
ER
PT J
AU Wang, MJ
Tang, ST
Stryhn, A
Justesen, S
Larsen, MV
Dziegiel, MH
Lewinsohn, DM
Buus, S
Lund, O
Claesson, MH
AF Wang, Mingjun
Tang, Sheila T.
Stryhn, Anette
Justesen, Sune
Larsen, Mette V.
Dziegiel, Morten H.
Lewinsohn, David M.
Buus, Soren
Lund, Ole
Claesson, Mogens H.
TI Identification of MHC class II restricted T-cell-mediated reactivity
against MHC class I binding Mycobacterium tuberculosis peptides
SO IMMUNOLOGY
LA English
DT Article
DE cytotoxic T lymphocyte epitope; HLA-I; HLA-II; Mycobacterium
tuberculosis; vaccine
ID CD8-T-CELL MEMORY; IMMUNE-RESPONSES; CD4-T-CELL HELP; ACUTE INFECTION;
CTL EPITOPES; GENOME-WIDE; MICE; VIVO; MACROPHAGES; VACCINATION
AB P>Major histocompatibility complex (MHC) class I restricted cytotoxic T lymphocytes (CTL) are known to play an important role in the control of Mycobacterium tuberculosis infection so identification of CTL epitopes from M. tuberculosis is of importance for the development of effective peptide-based vaccines. In the present work, bioinformatics technology was employed to predict binding motifs of 9mer peptides derived from M. tuberculosis for the 12 HLA-I supertypes. Subsequently, the predicted peptides were synthesized and assayed for binding to HLA-I molecules in a biochemically based system. The antigenicity of a total of 157 peptides with measured affinity for HLA-I molecules of K(D) <= 500 nm were evaluated using peripheral blood T cells from strongly purified protein derivative reactive healthy donors. Of the 157 peptides, eight peptides (5%) were found to induce T-cell responses. As judged from blocking with HLA class I and II subtype antibodies in the ELISPOT assay culture, none of the eight antigenic peptides induced HLA class I restricted CD8(+) T-cell responses. Instead all responses were blocked by pan-HLA class II and anti-HLA-DR antibodies. In addition, CD4(+) T-cell depletion before the 10 days of expansion, resulted in total loss of reactivity in the ELISPOT culture for most peptide specificities. FACS analyses with intracellular interferon-gamma staining of T cells expanded in the presence of M. tuberculosis peptides confirmed that the responsive cells were indeed CD4(+). In conclusion, T-cell immunity against HLA-I binding 9mer M. tuberculosis-derived peptides might in many cases turn out to be mediated by CD4(+) T cells and restricted by HLA-II molecules. The use of 9mer peptides recognized by both CD8(+) and CD4(+) T cells might be of importance for the development of future M. tuberculosis peptide-based vaccines.
C1 [Claesson, Mogens H.] Univ Copenhagen, Panum Inst, Dept Int Hlth Immunol & Microbiol, Fac Heath Sci, DK-2200 Copenhagen N, Denmark.
[Tang, Sheila T.; Larsen, Mette V.; Lund, Ole] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark.
[Dziegiel, Morten H.] Univ Copenhagen Hosp, HS Blood Bank KI 2034, DK-2100 Copenhagen, Denmark.
[Lewinsohn, David M.] Portland VA Med Ctr, CCM, Portland, OR USA.
RP Claesson, MH (reprint author), Univ Copenhagen, Panum Inst, Dept Int Hlth Immunol & Microbiol, Fac Heath Sci, Bldg 18-3,Blegdamsvej 3C, DK-2200 Copenhagen N, Denmark.
EM claesson@sund.ku.dk
RI Lund, Ole/F-4437-2014; Buus, Soren/F-5446-2010; Lewinsohn,
David/I-4936-2013
OI Lund, Ole/0000-0003-1108-0491; Lewinsohn, David/0000-0001-9906-9494;
Buus, Soren/0000-0001-8363-1999
FU National Institute of Allergy and Infectious Disease [HHSN266200400083C,
HHSN266200400025C]; EU [503231]; National Institutes of Health
[HHSN266200400081C]
FX We are grateful to Ms Maja Udsen and Ms Trine Devantier for excellent
technical assistance. This work was supported by National Institute of
Allergy and Infectious Disease contracts HHSN266200400083C,
HHSN266200400025C, EU 6FP 503231 and National Institutes of Health
contract HHSN266200400081C (DML).
NR 55
TC 11
Z9 13
U1 1
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD APR
PY 2011
VL 132
IS 4
BP 482
EP 491
DI 10.1111/j.1365-2567.2010.03383.x
PG 10
WC Immunology
SC Immunology
GA 732UV
UT WOS:000288216100004
PM 21294723
ER
PT J
AU Teo, KK
Sleight, P
Gao, P
Yusuf, S
Connolly, S
Yusuf, S
Swedberg, K
Pfeffer, MA
Granger, CB
McMurray, JJV
Sjoelie, AK
Massie, BM
Carson, P
Lewis, JB
Wachtell, K
Dahlof, B
Devereux, RB
Kjeldsen, SE
Julius, S
Ibsen, H
Lindholm, LH
Olsen, MH
Okin, PM
Califf, R
Holman, RR
Haffner, SM
Dagenais, G
Probstfield, J
Anderson, C
Diaz, R
Dans, A
Levine, M
Unger, T
Fagard, R
Diener, HC
Sacco, RL
Zanchetti, A
Cohn, JN
Weber, M
AF Teo, Koon K.
Sleight, Peter
Gao, Peggy
Yusuf, Salim
Connolly, Stuart
Yusuf, Salim
Swedberg, Karl
Pfeffer, Marc A.
Granger, Christopher B.
McMurray, John J. V.
Sjoelie, Anne K.
Massie, Barry M.
Carson, Peter
Lewis, Julia B.
Wachtell, Kristian
Dahlof, Bjorn
Devereux, Richard B.
Kjeldsen, Sverre E.
Julius, Stevo
Ibsen, Hans
Lindholm, Lars H.
Olsen, Michael H.
Okin, Peter M.
Califf, Robert
Holman, Rury R.
Haffner, Steven M.
Dagenais, Gilles
Probstfield, Jeffrey
Anderson, Craig
Diaz, Rafael
Dans, Antonio
Levine, Mark
Unger, Thomas
Fagard, Robert
Diener, Hans-Christoph
Sacco, Ralph L.
Zanchetti, Alberto
Cohn, Jay N.
Weber, Michael
CA ARB Trialists Collaboration
TI Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan
on cancers in 15 trials enrolling 138 769 individuals The ARB Trialists
Collaboration
SO JOURNAL OF HYPERTENSION
LA English
DT Review
DE angiotensin receptor blockers; cancer incidence; candesartan; clinical
trials; irbesartan; losartan; meta-analysis; telmisartan; valsartan
ID CONVERTING-ENZYME-INHIBITORS; ANGIOTENSIN-RECEPTOR BLOCKER;
LEFT-VENTRICULAR DYSFUNCTION; CHRONIC HEART-FAILURE; RANDOMIZED
CONTROLLED-TRIALS; HIGH-RISK PATIENTS; CARDIOVASCULAR EVENTS;
PROSTATE-CANCER; ANTIHYPERTENSIVE MEDICATION; MYOCARDIAL-INFARCTION
AB Background Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) reduce cardiovascular disease (CVD) events, but a recent meta-analysis of selected studies suggested that ARBs may increase cancer risks.
Objective Candesartan, irbesartan, telmisartan, valsartan, and losartan were assessed for incident cancers in 15 large parallel long-term multicenter double-blind clinical trials of these agents involving 138 769 participants.
Patients and methods Individuals at high CVD risk were randomized to telmisartan (three trials, n=51 878), irbesartan (three trials, n=14 859), valsartan (four trials, n=44 264), candesartan (four trials, n=18 566), and losartan (one trial, n=9193) and followed for 23-60 months. Incident cancer cases were compared in patients randomized to ARBs versus controls. In five trials (n=42 403), the ARBs were compared to ACEi and in 11 trials (n=63 313) to controls without ACEi. In addition, in seven trials (n=47 020), the effect of ARBs with ACEi was compared to ACEi alone and in two trials ARBs with ACEi versus ARB alone (n=25 712).
Results Overall, there was no excess of cancer incidence with ARB therapy compared to controls in the 15 trials [ 4549 (6.16%) cases of 73 808 allocated to ARB versus 3856 (6.31%) of 61 106 assigned to non-ARB controls; odds ratio (OR) 1.00, 95% confidence interval (CI) 0.95-1.04] overall or when individual ARBs were examined. ORs comparing combination therapy with ARB along with ACEi versus ACEi was 1.01 (95% CI 0.94-1.10), combination versus ARB alone 1.02 (95% CI 0.91-1.13), ARB alone versus ACEi alone 1.06 (95% CI 0.97-1.16) and ARB versus placebo/control without ACEi 0.97 (95% CI 0.91-1.04). There was no excess of lung, prostate or breast cancer, or overall cancer deaths associated with ARB treatment.
Conclusion There was no significant increase in the overall or site-specific cancer risk from ARBs compared to controls. J Hypertens 29: 623-635 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Teo, Koon K.; Gao, Peggy; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.
[Sleight, Peter] Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England.
[Connolly, Stuart; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.
[Swedberg, Karl] Univ Gothenburg, Dept Emergency, Sahlgrenska Acad, Gothenburg, Sweden.
[Swedberg, Karl] Univ Gothenburg, Dept Cardiovasc Med, Sahlgrenska Acad, Gothenburg, Sweden.
[Pfeffer, Marc A.] Harvard Univ, Sch Med, Boston, MA USA.
[McMurray, John J. V.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Granger, Christopher B.] Duke Univ, Med Ctr, Div Cardiovasc Med, Duke Clin Res Inst, Durham, NC USA.
[McMurray, John J. V.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.
[Sjoelie, Anne K.] Odense Hosp, Dept Ophthalmol, Odense, Denmark.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Carson, Peter] Washington VAMC Georgetown Univ, Washington, DC USA.
[Lewis, Julia B.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
[Wachtell, Kristian] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark.
[Dahlof, Bjorn] Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden.
[Okin, Peter M.] Weill Cornell Med Coll, Div Cardiol, Dept Med, New York, NY USA.
[Kjeldsen, Sverre E.] Univ Oslo Hosp, Oslo, Norway.
[Julius, Stevo] Univ Michigan, Ann Arbor, MI 48109 USA.
[Ibsen, Hans] Aarhus Univ, DK-8000 Aarhus C, Denmark.
[Ibsen, Hans] Univ Copenhagen, DK-1168 Copenhagen, Denmark.
[Ibsen, Hans] Hlobaek Hosp, Hlobaek, Denmark.
[Lindholm, Lars H.] Umea Univ, Dept Publ Hlth, S-90187 Umea, Sweden.
[Lindholm, Lars H.] Umea Univ, Dept Clin Med, S-90187 Umea, Sweden.
[Olsen, Michael H.] Glostrup Univ Hosp, Dept Internal Med, Div Cardiol, Glostrup, Denmark.
[Cohn, Jay N.] Duke Univ, Med Ctr, Div Cardiovasc Med, Duke Clin Res Inst, Durham, NC USA.
[Holman, Rury R.] Univ Oxford, OCDEM, Oxford OX1 2JD, England.
[Haffner, Steven M.] Baylor Coll Med, Dept Med, San Antonio, TX USA.
[Dagenais, Gilles] Univ Laval, Laval Hosp, Heart & Lung Inst, Ste Foy, PQ G1V 4G5, Canada.
[Probstfield, Jeffrey] Univ Washington, Dept Med, Seattle, WA USA.
[Anderson, Craig] Royal Prince Alfred Hosp, George Inst Int Hlth, Sydney, NSW, Australia.
[Anderson, Craig] Univ Sydney, Sydney, NSW 2006, Australia.
[Diaz, Rafael] Estudios Clin Latinoamer, Rosario, Santa Fe, Argentina.
[Dans, Antonio] Univ Philippines, Coll Med, Manila, Philippines.
[Levine, Mark] McMaster Univ, Dept Oncol, Hamilton, ON L8V 1C3, Canada.
[Unger, Thomas] Charite, Cardiovasc Res Ctr, D-13353 Berlin, Germany.
[Unger, Thomas] Charite, Inst Pharmacol, D-13353 Berlin, Germany.
[Fagard, Robert] Univ Leuven KU Leuven, Hypertens & Cardiovasc Rehabil Unit, Leuven, Belgium.
[Diener, Hans-Christoph] Univ Hosp Essen, Dept Neurol, Essen, Germany.
[Diener, Hans-Christoph] Univ Hosp Essen, Stroke Ctr, Essen, Germany.
[Sacco, Ralph L.] Univ Miami, Miami, FL USA.
[Zanchetti, Alberto] Univ Milan, Ctr Clin Physiol & Hypertens, Milan, Italy.
[Zanchetti, Alberto] Ist Auxol Italiano, Milan, Italy.
[Cohn, Jay N.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
[Weber, Michael] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA.
RP Teo, KK (reprint author), Hamilton Gen Hosp, Populat Hlth Res Inst, David Braley Cardiac Vasc Stroke Res Inst, Rm C2-106,237 Barton St E, Hamilton, ON L8L 2X2, Canada.
EM koon.teo@phri.ca
RI Granger, Christopher/D-3458-2014; Olsen, Michael/H-8176-2014
OI Granger, Christopher/0000-0002-0045-3291;
FU Boehringer Ingelheim; Bristol-Myers Squibb; Sanofi-Aventis;
Sanofi-Synthelabo; Novartis; AstraZenica; Takeda; Merck
FX K.K.T. and P.S. received consulting and lecture fees and research grants
from Boehringer Ingelheim; S.Y. received grants and honoraria from
Boehringer Ingelheim, Bristol-Myers Squibb, and Sanofi-Aventis. P.G.
does not have relevant information to disclose.; Boehringer-Ingelheim
was the sponsor of the telmisartan trials. The irbesartan trials were
sponsored by Bristol-Myers Squibb and Sanofi-Synthelabo, the valsartan
trials by Novartis, the candesartan trials by AstraZenica (CHARM and
DIRECT were also sponsored by Takeda) and the losartan trial by Merck.
Data for this meta-analysis were obtained from the investigators and
sponsors and were analyzed at PHRI independent of the sponsors.
NR 44
TC 64
Z9 64
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0263-6352
J9 J HYPERTENS
JI J. Hypertens.
PD APR
PY 2011
VL 29
IS 4
BP 623
EP 635
DI 10.1097/HJH.0b013e328344a7de
PG 13
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 732PH
UT WOS:000288199500001
ER
PT J
AU Quinn, TM
Taylor, JJ
Magarik, JA
Vought, E
Kindy, MS
Ellegala, DB
AF Quinn, T. M.
Taylor, J. J.
Magarik, J. A.
Vought, E.
Kindy, M. S.
Ellegala, D. B.
TI Decompressive craniectomy: technical note
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Review
DE cerebral edema; decompressive craniectomy; intracranial pressure;
patient management; traumatic brain injury
ID TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY INFARCTION; INTRACRANIAL
HYPERTENSION; ISCHEMIC-STROKE; MANAGEMENT; MULTICENTER; RECOVERY;
PRESSURE; THERAPY
AB Decompressive craniectomy is a neurosurgical technique in which a portion of the skull is removed to reduce intracranial pressure. The rationale for this procedure is based on the Monro-Kellie Doctrine; expanding the physical space confining edematous brain tissue after traumatic brain injury will reduce intracranial pressure. There is significant debate over the efficacy of decompressive craniectomy despite its sound rationale and historical significance. Considerable variation in the employment of decompressive craniectomy, particularly for secondary brain injury, explains the inconsistent results and mixed opinions of this potentially valuable technique. One way to address these concerns is to establish a consistent methodology for performing decompressive craniectomies. The purpose of this paper is to begin accomplishing this goal and to emphasize the critical points of the hemicraniectomy and bicoronal (Kjellberg type) craniectomy.
C1 [Quinn, T. M.; Taylor, J. J.; Magarik, J. A.; Vought, E.; Ellegala, D. B.] Med Univ S Carolina, Div Neurosurg, Dept Neurosci, Charleston, SC 29425 USA.
[Kindy, M. S.] Med Univ S Carolina, Div Res, Dept Neurosci, Charleston, SC 29425 USA.
[Kindy, M. S.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA.
RP Ellegala, DB (reprint author), Med Univ S Carolina, Div Neurosurg, Dept Neurosci, Room CSB 428,96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM ellegala@musc.edu
FU Veterans Administration
FX The authors do not have any conflicts of interest. This work was
supported in part by grants from the Veterans Administration (MSK).
NR 39
TC 12
Z9 14
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-6314
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD APR
PY 2011
VL 123
IS 4
BP 239
EP 244
DI 10.1111/j.1600-0404.2010.01397.x
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 728GR
UT WOS:000287863100002
PM 20637010
ER
PT J
AU Franklin, TR
Wang, Z
Li, Y
Suh, JJ
Goldman, M
Lohoff, FW
Cruz, J
Hazan, R
Jens, W
Detre, JA
Berrettini, W
O'Brien, CP
Childress, AR
AF Franklin, Teresa R.
Wang, Ze
Li, Yin
Suh, Jesse J.
Goldman, Marina
Lohoff, Falk W.
Cruz, Jeffrey
Hazan, Rebecca
Jens, Will
Detre, John A.
Berrettini, Wade
O'Brien, Charles P.
Childress, Anna Rose
TI Dopamine transporter genotype modulation of neural responses to smoking
cues: confirmation in a new cohort
SO ADDICTION BIOLOGY
LA English
DT Article
DE Addiction; dopamine transporter; genetic variability; neuroimaging;
relapse vulnerability; smoking cues
ID FAGERSTROM TOLERANCE QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIAL;
RECEPTOR PARTIAL AGONIST; DRD4 VNTR POLYMORPHISM; FMRI-BOLD RESPONSES;
NICOTINE-DEPENDENCE; CIGARETTE-SMOKING; ORBITOFRONTAL CORTEX; WITHDRAWAL
SYMPTOMS; PREFRONTAL CORTEX
AB Previously we demonstrated profound effects of dopamine transporter (DAT) SLC6A3 genotype on limbic responses to smoking cues (SCs). Probands carrying at least one copy of the 9-repeat allele (9-repeat carriers) had greater neural responses to SCs in the anatomically interconnected rostral ventral striatum/medial orbitofrontal cortex (VS/mOFC), compared with homozygotes for the 10-repeat allele (10/10-repeats). To test the reliability of the initial findings, we examined perfusion functional magnetic resonance images acquired during SC exposure in a new cohort of smokers (N = 26) who were genotyped for the SLC6A3 polymorphism. In smokers overall, activity was enhanced in the VS/mOFC (t = 3.77). Contrasts between allelic groups revealed that 9-repeat carriers had a greater response to SCs in the VS (t = 3.12) and mOFC (t = 3.19). In separate groups, 9-repeat carriers showed increased activity in the VS (t = 5.47) and mOFC (T = 4.96), while no increases were observed in 10-repeats. Subjective reports of craving correlated with increased activity in reward-related structures including the extended amygdala, insula and post-central gyrus, and decreased activity in the dorsolateral prefrontal cortex, and were DAT-genotype dependent (r = 0.63-0.96). In secondary analyses, we found that The Fagerstrom Test for Nicotine Dependence scores correlated with enhanced SC-induced perfusion in 10/10-repeats in the insula, mOFC, medial temporal and superior frontal gyri (r = 0.50-0.82), while correlations were absent in 9-repeat carriers. Despite heterogeneity introduced by a host of factors, including variance in other genes involved in smoking behavior, we confirm that DAT genotype predicts the direction and location of neural responses to SCs.
C1 [Franklin, Teresa R.; Wang, Ze; Li, Yin; Suh, Jesse J.; Goldman, Marina; Lohoff, Falk W.; Cruz, Jeffrey; Hazan, Rebecca; Jens, Will; Berrettini, Wade; O'Brien, Charles P.; Childress, Anna Rose] Univ Penn, Philadelphia Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Detre, John A.] Univ Penn, Philadelphia Sch Med, Dept Radiol & Neurol, Philadelphia, PA 19104 USA.
[Suh, Jesse J.; O'Brien, Charles P.; Childress, Anna Rose] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Franklin, TR (reprint author), Univ Penn, Dept Psychiat, Addict Treatment Res Ctr, Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM franklin_t@mail.trc.upenn.edu
RI Wang, Ze/A-1043-2007; Lohoff, Falk/M-7951-2016
OI Jens, William/0000-0001-5201-1412
FU NIH [5-P60-DA-005186-18]; Pfizer Pharmaceuticals; Alexander Foundation
FX Work supported by NIH 5-P60-DA-005186-18, Pfizer Pharmaceuticals (an
Investigator-initiated research grant) and The Alexander Foundation.
NR 82
TC 33
Z9 33
U1 3
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-6215
J9 ADDICT BIOL
JI Addict. Biol.
PD APR
PY 2011
VL 16
IS 2
BP 308
EP 322
DI 10.1111/j.1369-1600.2010.00277.x
PG 15
WC Biochemistry & Molecular Biology; Substance Abuse
SC Biochemistry & Molecular Biology; Substance Abuse
GA 730HQ
UT WOS:000288024800012
PM 21299752
ER
PT J
AU Liu, XH
Manzano, G
Kim, HT
Feeley, BT
AF Liu, Xuhui
Manzano, Givenchy
Kim, Hubert T.
Feeley, Brian T.
TI A Rat Model of Massive Rotator Cuff Tears
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE rotator cuff tear; muscular atrophy; fat infiltration
ID SKELETAL-MUSCLE ATROPHY; FACTOR-KAPPA-B; FATTY INFILTRATION;
SUPRASPINATUS MUSCLE; FUNCTIONAL OUTCOMES; TENDON DETACHMENT;
SINGLE-ROW; LONG-TERM; REPAIR; DEGENERATION
AB Rotator cuff tears (RCTs) are the most common tendon injury seen in orthopedic patients. Massive RCT does not heal spontaneously and results in poor clinical outcomes. Muscle atrophy and fatty infiltration in rotator cuff muscles are major complications of chronic massive RCT and are thought to be the key factors responsible for the failure of attempted massive RCT repair. However, the pathophysiology of rotator cuff muscle atrophy and fat infiltration remains largely unknown, and no small animal model has been shown to reproduce the histologic and molecular changes seen in massive RCT. In this article, we report a novel rat massive RCT model, in which significant and consistent muscle atrophy and fat infiltration were observed in the rotator cuff muscles after rotator cuff tendon transection and denervation. The supraspinatus and infraspinatus muscle lost 25.4% and 28.9% of their wet weight 2 weeks after complete tendon transection, respectively. Six weeks after surgery, the average wet weight of supraspinatus and infraspinatus muscles decreased 13.2% and 28.3%, respectively. Significant fat infiltration was only observed in infraspinatus 6 weeks after tendon transection. (C) 2010 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 29:588-595, 2011
C1 [Liu, Xuhui; Manzano, Givenchy; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco Sports Med & Shoulder Su, Dept Orthoped Surg, San Francisco, CA 94153 USA.
[Liu, Xuhui; Manzano, Givenchy; Kim, Hubert T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.
RP Feeley, BT (reprint author), Univ Calif San Francisco Sports Med & Shoulder Su, Dept Orthoped Surg, 1500 Owens Ave, San Francisco, CA 94153 USA.
EM feeleyb@orthosurg.ucsf.edu
FU Orthopaedic Research & Education Foundation
FX This work was supported by the Orthopaedic Research & Education
Foundation. The authors have no personal or financial affiliations that
may have biased the presentation.
NR 42
TC 42
Z9 42
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD APR
PY 2011
VL 29
IS 4
BP 588
EP 595
DI 10.1002/jor.21266
PG 8
WC Orthopedics
SC Orthopedics
GA 731LV
UT WOS:000288109300018
PM 20949443
ER
PT J
AU Landman, AB
Rokos, IC
Burns, K
Van Gelder, CM
Fisher, RM
Dunford, JV
Cone, DC
Bogucki, S
AF Landman, Adam B.
Rokos, Ivan C.
Burns, Kevin
Van Gelder, Carin M.
Fisher, Roger M.
Dunford, James V.
Cone, David C.
Bogucki, Sandy
TI AN OPEN, INTEROPERABLE, AND SCALABLE PREHOSPITAL INFORMATION TECHNOLOGY
NETWORK ARCHITECTURE
SO PREHOSPITAL EMERGENCY CARE
LA English
DT Article
DE emergency medical services communication systems; emergency medical
services; information management; computer communication networks
ID ELEVATION MYOCARDIAL-INFARCTION; TO-BALLOON TIME; HOSPITAL
CARDIAC-ARREST; STANDARDIZED COMMUNICATION; SYNDROMIC SURVEILLANCE;
MEDICINE PROJECT; UTSTEIN STYLE; EMERGENCY; SYSTEMS; INTEGRATION
AB Some of the most intractable challenges in prehospital medicine include response time optimization, inefficiencies at the emergency medical services (EMS)-emergency department (ED) interface, and the ability to correlate field interventions with patient outcomes. Information technology (IT) can address these and other concerns by ensuring that system and patient information is received when and where it is needed, is fully integrated with prior and subsequent patient information, and is securely archived. Some EMS agencies have begun adopting information technologies, such as wireless transmission of 12-lead electrocardiograms, but few agencies have developed a comprehensive plan for management of their prehospital information and integration with other electronic medical records. This perspective article highlights the challenges and limitations of integrating IT elements without a strategic plan, and proposes an open, interoperable, and scalable prehospital information technology (PHIT) architecture. The two core components of this PHIT architecture are 1) routers with broadband network connectivity to share data between ambulance devices and EMS system information services and 2) an electronic patient care report to organize and archive all electronic prehospital data. To successfully implement this comprehensive PHIT architecture, data and technology requirements must be based on best available evidence, and the system must adhere to health data standards as well as privacy and security regulations. Recent federal legislation prioritizing health information technology may position federal agencies to help design and fund PHIT architectures.
C1 [Landman, Adam B.] Yale Univ, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
[Landman, Adam B.; Burns, Kevin; Van Gelder, Carin M.; Cone, David C.; Bogucki, Sandy] Yale Univ, Dept Emergency Med, Sch Med, New Haven, CT 06520 USA.
[Landman, Adam B.] US Dept Vet Affairs, West Haven, CT USA.
[Rokos, Ivan C.] Olive View UCLA Med Ctr, Dept Emergency Med, Sylmar, CA 91342 USA.
[Fisher, Roger M.] San Diego Med Serv, San Diego, CA USA.
[Dunford, James V.] Univ Calif San Diego, Dept Emergency Med, San Diego Med Ctr, La Jolla, CA 92093 USA.
RP Landman, AB (reprint author), Yale Univ, Robert Wood Johnson Fdn Clin Scholars Program, 333 Cedar St,IE 61 SHM,POB 208088, New Haven, CT 06520 USA.
EM adam.landman@yahoo.com
OI Cone, David/0000-0002-7437-959X; Landman, Adam/0000-0002-2166-0521
FU US Department of Veterans Affairs; Robert Wood Johnson Foundation
FX Dr. Landman is a Robert Wood Johnson Foundation Clinical Scholar at Yale
University, supported by the US Department of Veterans Affairs and the
Robert Wood Johnson Foundation.
NR 48
TC 8
Z9 8
U1 0
U2 15
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1090-3127
J9 PREHOSP EMERG CARE
JI Prehosp. Emerg. Care
PD APR-JUN
PY 2011
VL 15
IS 2
BP 149
EP 157
DI 10.3109/10903127.2010.534235
PG 9
WC Emergency Medicine; Public, Environmental & Occupational Health
SC Emergency Medicine; Public, Environmental & Occupational Health
GA 729FG
UT WOS:000287933400002
PM 21294627
ER
PT J
AU Hirano, AA
Brandstatter, JH
Morgans, CW
Brecha, NC
AF Hirano, Arlene A.
Brandstaetter, Johann Helmut
Morgans, Catherine W.
Brecha, Nicholas C.
TI SNAP25 Expression in Mammalian Retinal Horizontal Cells
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Article
DE SNARE complex; exocytosis; immunocytochemistry; retina; vision
ID SYNAPTOSOMAL-ASSOCIATED PROTEIN; CALCIUM-BINDING PROTEINS;
ACTIVITY-DEPENDENT PHOSPHORYLATION; ACID TRANSPORTER EXPRESSION;
VESICULAR GABA TRANSPORTER; SYNAPTIC CORE COMPLEX; MACAQUE MONKEY
RETINA; T-SNARE SNAP-25; RIBBON SYNAPSES; DIFFERENTIAL EXPRESSION
AB Horizontal cells mediate inhibitory feedforward and feedback lateral interactions in the outer retina at photoreceptor terminals and bipolar cell dendrites; however, the mechanisms that underlie synaptic transmission from mammalian horizontal cells are poorly understood. The localization of a vesicular gamma-aminobutyric acid (GABA) transporter (VGAT) to horizontal cell processes in primate and rodent retinae suggested that mammalian horizontal cells release transmitter in a vesicular manner. Toward determining whether the molecular machinery for vesicular transmitter release is present in horizontal cells, we investigated the expression of SNAP25 (synaptosomal-associated protein of 25 kDa), a key SNARE protein, by immunocytochemistry with cell type-specific markers in the retinae of mouse, rat, rabbit, and monkey. Different commercial antibodies to SNAP25 were tested on vertical sections of retina. We report the robust expression of SNAP25 in both plexiform layers. Double labeling with SNAP25 and calbindin antibodies demonstrated that horizontal cell processes and their endings in photoreceptor triad synapses were strongly labeled for both proteins in mouse, rat, rabbit, and monkey retinae. Double labeling with parvalbumin antibodies in monkey retina verified SNAP25 immunoreactivity in all horizontal cells. Pre-embedding immunoelectron microscopy in rabbit retina confirmed expression of SNAP25 in lateral elements within photoreceptor triad synapses. The SNAP25 immunoreactivity in the plexiform layers and outer nuclear layer fell into at least three patterns depending on the antibody, suggesting a differential distribution of SNAP25 isoforms. The presence of SNAP25a and SNAP25b isoforms in mouse retina was established by reverse transcriptase-polymerase chain reaction. SNAP25 expression in mammalian horizontal cells along with other SNARE proteins is consistent with vesicular exocytosis. J. Comp. Neurol. 519:972-988, 2011. (C) 2010 Wiley-Liss, Inc.
C1 [Hirano, Arlene A.; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Hirano, Arlene A.; Brecha, Nicholas C.] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA 90073 USA.
[Brandstaetter, Johann Helmut] Univ Erlangen Nurnberg, Dept Biol, D-91508 Erlangen, Germany.
[Morgans, Catherine W.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
RP Hirano, AA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, 10833 Le Conte Ave,Box 951763, Los Angeles, CA 90095 USA.
EM ahirano@mednet.ucla.edu
FU National Institutes of Health [EY15573]; Veterans Administration;
University of California-Los Angeles; German Research Foundation [BR
1643/4-1]
FX Grant sponsor: National Institutes of Health; Grant number: EY15573;
Grant sponsors: Veterans Administration Career Scientist Award;
University of California-Los Angeles Stein-Oppenheimer Award (to
N.C.B.); German Research Foundation; Grant number: BR 1643/4-1 (to
J.H.B.).
NR 113
TC 23
Z9 23
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021-9967
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD APR
PY 2011
VL 519
IS 5
BP 972
EP 988
DI 10.1002/cne.22562
PG 17
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA 719MR
UT WOS:000287209400010
PM 21280047
ER
PT J
AU Wang, Q
Wu, PC
Roberson, RS
Luk, BV
Ivanova, I
Chu, E
Wu, DY
AF Wang, Qin
Wu, Peter C.
Roberson, Rachel S.
Luk, Belinda V.
Ivanova, Iana
Chu, Elizabeth
Wu, Daniel Y.
TI Survivin and escaping in therapy-induced cellular senescence
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE survivin; accelerated senescence; Cdc2/Cdk1
ID GERANYLGERANYLTRANSFERASE-I INHIBITOR; TERMINAL PROLIFERATION ARREST;
LUNG-CANCER CELLS; TUMOR-CELLS; MITOTIC CATASTROPHE; CARCINOMA-CELLS;
DNA-DAMAGE; APOPTOSIS; PHOSPHORYLATION; EXPRESSION
AB Therapy-induced accelerated cellular senescence (ACS) is a reversible tumor response to chemotherapy that is likely detrimental to the overall therapeutic efficacy of cancer treatment. To further understand the mechanism by which cancer cells can escape the sustained cell cycle arrest in ACS, we established a tissue culture model, in which the p53-null NCI-H1299 cells can be induced into senescence by an abbreviated exposure to a chemotherapeutic agent. Previously, we have reported that senescent cells overexpress Cdc2/Cdk1 when they bypassed the prolonged arrest and their viability is dependent on Cdc2/Cdk1 kinase activity. In our study, we show that human survivin is the immediate downstream effector of the Cdc2/Cdk1 mediated survival signal. Survivin cooperates with Cdc2/Cdk1 to inhibit apoptosis following chemotherapy and promote senescence escape. Using HIV-1 TAT peptides to disrupt survivin phosphorylation by Cdc2/Cdk1, we also found that phosphorylated survivin is necessary both for the escape of senescent cells and for maintenance of subsequent viability after bypassing senescence. These results further propose survivin as an important determinant of senescence reversibility and as a putative molecular target to enforce cell death in ACS.
C1 [Wang, Qin; Wu, Peter C.; Roberson, Rachel S.; Luk, Belinda V.; Ivanova, Iana; Chu, Elizabeth; Wu, Daniel Y.] VA Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, Seattle, WA 98108 USA.
[Wu, Peter C.] VA Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA 98108 USA.
[Wu, Peter C.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Wu, Daniel Y.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA.
[Wu, Daniel Y.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
RP Wang, Q (reprint author), VA Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM proteinss@hotmail.com
FU National Cancer Institute [R01-CA113892-01]
FX Grant sponsor: National Cancer Institute; Grant number: R01-CA113892-01
NR 41
TC 24
Z9 27
U1 1
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 1
PY 2011
VL 128
IS 7
BP 1546
EP 1558
DI 10.1002/ijc.25482
PG 13
WC Oncology
SC Oncology
GA 718XI
UT WOS:000287159400005
PM 20503268
ER
PT J
AU Eccles, MP
Weijer, C
Mittman, B
AF Eccles, Martin P.
Weijer, Charles
Mittman, Brian
TI Requirements for ethics committee review for studies submitted to
Implementation Science
SO IMPLEMENTATION SCIENCE
LA English
DT Editorial Material
AB The requirement for ethics review of studies submitted to Implementation Science has been unclear. Therefore, in this editorial, we set out our requirements for ethics committee review of experimental and non-experimental studies. For any study that meets the criteria of human subject research (which includes research on healthcare providers), irrespective of study design, we will require proof of either satisfactory ethics committee review or of the granting of an official exemption or waiver.
C1 [Eccles, Martin P.] Inst Hlth & Soc, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
[Weijer, Charles] Univ Western Ontario, Rotman Inst Philosophy, London, ON N6A 5B6, Canada.
[Mittman, Brian] VA Greater Los Angeles Healthcare Syst, VA Ctr Implementat Practice & Res Support, Sepulveda, CA 91343 USA.
RP Eccles, MP (reprint author), Inst Hlth & Soc, Baddiley Clark Bldg, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
EM martin.eccles@ncl.ac.uk
OI Mittman, Brian/0000-0003-3589-9178
NR 3
TC 2
Z9 2
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD MAR 31
PY 2011
VL 6
AR 32
DI 10.1186/1748-5908-6-32
PG 3
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 749NN
UT WOS:000289475200001
PM 21453451
ER
PT J
AU Holodniy, M
Brown, ST
Cameron, DW
Kyriakides, TC
Angus, B
Babiker, A
Singer, J
Owens, DK
Anis, A
Goodall, R
Hudson, F
Piaseczny, M
Russo, J
Schechter, M
Deyton, L
Darbyshire, J
AF Holodniy, Mark
Brown, Sheldon T.
Cameron, D. William
Kyriakides, Tassos C.
Angus, Brian
Babiker, Abdel
Singer, Joel
Owens, Douglas K.
Anis, Aslam
Goodall, Ruth
Hudson, Fleur
Piaseczny, Mirek
Russo, John
Schechter, Martin
Deyton, Lawrence
Darbyshire, Janet
CA OPTIMA Team
TI Results of Antiretroviral Treatment Interruption and Intensification in
Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial
SO PLOS ONE
LA English
DT Article
ID STRUCTURED TREATMENT INTERRUPTION; QUALITY-OF-LIFE; CROSS-RESISTANCE;
CLINICAL PROGRESSION; VIROLOGICAL FAILURE; MEGA-HAART; COHORT; THERAPY;
INHIBITORS; VIRUS
AB Background: Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR) and limited retreatment options. We assessed two novel antiretroviral (ARV) treatment approaches in this setting.
Methods and Findings: We conducted a 262 factorial randomized open label controlled trial in patients with a CD4 count <= 300 cells/mu l who had ARV treatment (ART) failure requiring retreatment, to two options (a) re-treatment with either standard (<= 4 ARVs) or intensive (>= 5 ARVs) ART and b) either treatment starting immediately or after a 12-week monitored ART interruption. Primary outcome was time to developing a first AIDS-defining event (ADE) or death from any cause. Analysis was by intention to treat. From 2001 to 2006, 368 patients were randomized. At baseline, mean age was 48 years, 2% were women, median CD4 count was 106/mu l, mean viral load was 4.74 log(10) copies/ml, and 59% had a prior AIDS diagnosis. Median follow-up was 4.0 years in 1249 person-years of observation. There were no statistically significant differences in the primary composite outcome of ADE or death between re-treatment options of standard versus intensive ART (hazard ratio 1.17; CI 0.86-1.59), or between immediate retreatment initiation versus interruption before re-treatment (hazard ratio 0.93; CI 0.68-1.30), or in the rate of non-HIV associated serious adverse events between re-treatment options.
Conclusions: We did not observe clinical benefit or harm assessed by the primary outcome in this largest and longest trial exploring both ART interruption and intensification in advanced MDR HIV infection with poor retreatment options.
C1 [Holodniy, Mark; Owens, Douglas K.] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
[Holodniy, Mark; Owens, Douglas K.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Cameron, D. William] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
[Cameron, D. William; Singer, Joel; Anis, Aslam; Piaseczny, Mirek; Schechter, Martin] St Pauls Hosp, Canadian HIV Trials Network, Vancouver, BC V6Z 1Y6, Canada.
[Kyriakides, Tassos C.; Russo, John] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Angus, Brian] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
[Babiker, Abdel; Goodall, Ruth; Hudson, Fleur; Darbyshire, Janet] MRC Clin Trials Unit, London, England.
[Deyton, Lawrence] Off Publ Hlth & Environm Hazards, Dept Vet Affairs, Washington, DC USA.
RP Holodniy, M (reprint author), VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
EM bcameron@ohri.ca
OI Schechter, Martin/0000-0001-6063-2155; Angus, Brian/0000-0003-3598-7784;
Cameron, Bill/0000-0002-0090-3539; Goodall, Ruth/0000-0003-0622-5035
FU Ontario Ministry of Health/Ontario HIV Treatment Network; CIHR Canadian
HIV Trials Network, Canada
FX DWC is supported with a Career Scientist Award of the Ontario Ministry
of Health/Ontario HIV Treatment Network. The study was supported in part
in Canada through the CIHR Canadian HIV Trials Network. The study
funders (MRC-UK, VACSP, CIHR) reviewed and approved the design and
conduct of the trial, with external expert reviewers who were
represented on the Trial Steering Committee. The OPTIMA Writing
Committee and the OPTIMA team had full access to the statistical report
and to the study data by request and the Writing Committee had final
responsibility for the submitted manuscript. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 30
TC 19
Z9 19
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 31
PY 2011
VL 6
IS 3
AR e14764
DI 10.1371/journal.pone.0014764
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 743YU
UT WOS:000289057200001
PM 21483491
ER
PT J
AU Velez, JM
Miriyala, S
Nithipongvanitch, R
Noel, T
Plabplueng, CD
Oberley, T
Jungsuwadee, P
Van Remmen, H
Vore, M
Clair, DKS
AF Velez, Joyce M.
Miriyala, Sumitra
Nithipongvanitch, Ramaneeya
Noel, Teresa
Plabplueng, Chotiros D.
Oberley, Terry
Jungsuwadee, Paiboon
Van Remmen, Holly
Vore, Mary
Clair, Daret K. St.
TI p53 Regulates Oxidative Stress-Mediated Retrograde Signaling: A Novel
Mechanism for Chemotherapy-Induced Cardiac Injury
SO PLOS ONE
LA English
DT Article
ID MANGANESE SUPEROXIDE-DISMUTASE; GLUTATHIONE TRANSFERASE;
LIPID-PEROXIDATION; NITRIC-OXIDE; CELL-DEATH; ACTIVATION; MICE;
AUTOPHAGY; PROTEINS; HEART
AB The side effects of cancer therapy on normal tissues limit the success of therapy. Generation of reactive oxygen species (ROS) has been implicated for numerous chemotherapeutic agents including doxorubicin (DOX), a potent cancer chemotherapeutic drug. The production of ROS by DOX has been linked to DNA damage, nuclear translocation of p53, and mitochondrial injury; however, the causal relationship and molecular mechanisms underlying these events are unknown. The present study used wild-type (WT) and p53 homozygous knock-out (p53(-/-)) mice to investigate the role of p53 in the crosstalk between mitochondria and nucleus. Injecting mice with DOX (20 mg/kg) causes oxidative stress in cardiac tissue as demonstrated by immunogold analysis of the levels of 4-hydroxy-2'-nonenal (4HNE)-adducted protein, a lipid peroxidation product bound to proteins. 4HNE levels increased in both nuclei and mitochondria of WT DOX-treated mice but only in nuclei of DOX-treated p53((-/-)) mice, implicating a critical role for p53 in causing DOX-induced oxidative stress in mitochondria. The stress-activated protein c-Jun amino-terminal kinase (JNKs) was activated in response to increased 4HNE in WT mice but not p53((-/-)) mice receiving DOX treatment, as determined by co-immunoprecipitation of HNE and pJNK. The activation of JNK in DOX treated WT mice was accompanied by Bcl-2 dissociation from Beclin in mitochondria and induction of type II cell death (autophagic cell death), as evidenced by an increase in LC3-I/LC-3-II ratio and gamma-H2AX, a biomarker for DNA damage. The absence of p53 significantly reduces mitochondrial injury, assessed by quantitative morphology, and decline in cardiac function, assessed by left ventricular ejection fraction and fraction shortening. These results demonstrate that p53 plays a critical role in DOX-induced cardiac toxicity, in part, by the induction of oxidative stress mediated retrograde signaling.
C1 [Velez, Joyce M.; Miriyala, Sumitra; Noel, Teresa; Jungsuwadee, Paiboon; Vore, Mary; Clair, Daret K. St.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40526 USA.
[Oberley, Terry] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
[Oberley, Terry] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Pathol & Lab Med Serv, Madison, WI 53792 USA.
[Nithipongvanitch, Ramaneeya; Plabplueng, Chotiros D.] Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand.
[Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
RP Velez, JM (reprint author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40526 USA.
EM DSTCL00@uky.edu
RI Vore, Mary/E-2177-2012
FU National Institutes of Health [CA 139483, CA 139484, T32 HL072743];
Interdisciplinary Cardiovascular Training Program
FX This work is supported by National Institutes of Health grants CA
139483, CA 139484 and T32 HL072743, Interdisciplinary Cardiovascular
Training Program (Joyce M. Velez). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 37
TC 30
Z9 31
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 30
PY 2011
VL 6
IS 3
AR e18005
DI 10.1371/journal.pone.0018005
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 743YK
UT WOS:000289055700021
PM 21479164
ER
PT J
AU Lo, B
Kelch, RP
Grady, D
AF Lo, Bernard
Kelch, Robert P.
Grady, Deborah
TI Illuminating Physicians' Financial Relationships With Industry
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Lo, Bernard] Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA.
[Lo, Bernard; Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Grady, Deborah] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kelch, Robert P.] Univ Michigan, Off Execut Vice President Med Affairs Emeritus, Ann Arbor, MI 48109 USA.
[Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Lo, B (reprint author), Univ Calif San Francisco, Program Med Eth, 521 Parnassus Ave,Box 0903,Room C-126, San Francisco, CA 94143 USA.
EM bernie@medicine.ucsf.edu
FU NCRR NIH HHS [1UL1RR024131-01]; NIMH NIH HHS [MH062246]
NR 9
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAR 28
PY 2011
VL 171
IS 6
BP 587
EP 589
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 741LB
UT WOS:000288864100019
PM 21444852
ER
PT J
AU Jackevicius, CA
Tu, JV
Ross, JS
Ko, DT
Carreon, D
Krumholz, HM
AF Jackevicius, Cynthia A.
Tu, Jack V.
Ross, Joseph S.
Ko, Dennis T.
Carreon, Daniel
Krumholz, Harlan M.
TI Use of Fibrates in the United States and Canada
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; CORONARY-HEART-DISEASE; TREATMENT PANEL-III;
RHABDOMYOLYSIS; GEMFIBROZIL; CHOLESTEROL; TRIAL; PREVENTION; THERAPY;
EVENTS
AB Context Interest in the role of fibrates intensified after the publication of the negative results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which assessed therapy with fenofibrate plus statins. The evidence for clinical benefit in outcomes with the use of fibrates is heavily weighted on the use of the older fibrates such as gemfibrozil and clofibrate.
Objectives To examine trends in the current use of fibrates and to examine the relationship between differences in the availability and use of brand-name vs generic formulations of fenofibrate and the economic implications in the United States compared with Canada.
Design, Setting, and Patients Population-level, observational cohort study using IMS Health data from the United States and Canada of patients prescribed fibrates between January 2002 and December 2009.
Main Outcome Measures Fibrate prescriptions dispensed and expenditures.
Results In the United States, fibrate prescriptions dispensed increased from 336 prescriptions/100 000 population in January 2002 to 730 prescriptions/100 000 population in December 2009, an increase of 117.1% (95% confidence interval [CI], 116.0%-117.9%), whereas in Canada, fibrate prescriptions increased from 402 prescriptions/100 000 population in January 2002 to 474 prescriptions/100 000 population in December 2009, an increase of 18.1% (95% CI, 17.9%-18.3%) (P<.001). In the United States, fenofibrate prescriptions dispensed increased from 150 prescriptions/100 000 population in January 2002 to 440 prescriptions/100 000 population in December 2009, an increase of 159.3% (95% CI, 157.7%-161.0%), comprising 47.9% of total fibrate prescriptions in 2002 and 65.2% in 2009. In Canada, fenofibrate prescriptions increased from 321 prescriptions/100 000 population in January 2002 to 429 prescriptions/100 000 population in December 2009. The annual ratio of generic to brand-name fenofibrate use in the United States ranged from 0:1 to 0.09:1 between 2002 and 2008, while the ratio in Canada steadily increased from 0.51:1 to 1.89:1 between 2005 and 2008. In the United States, crude fenofibrate expenditures increased from $11 535/100 000 population/month in 2002 to $44 975/100 000 population/month in 2009, while the rates in Canada declined from $17 695/100 000 population/month in 2002 to $16 112/100 000 population/month in 2009. Fibrate expenditures per 100 000 population were 3-fold higher in 2009 in the United States compared with Canada.
Conclusion During the past decade, prescriptions for fibrates (particularly fenofibrate) increased in the United States, while prescriptions for fibrates in Canada remained stable. JAMA. 2011; 305(12): 1217-1224
C1 [Jackevicius, Cynthia A.; Carreon, Daniel] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA.
[Jackevicius, Cynthia A.; Tu, Jack V.; Ko, Dennis T.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Jackevicius, Cynthia A.; Tu, Jack V.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Tu, Jack V.; Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada.
[Ross, Joseph S.] Yale Univ, Sch Med, Dept Med,Sect Gen Internal Med, Ctr Outcomes Res & Evaluat,Yale New Haven Hosp, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth,Sect Hlth Policy & Adm, Ctr Outcomes Res & Evaluat,Yale New Haven Hosp, New Haven, CT 06510 USA.
[Ross, Joseph S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, Ctr Outcomes Res & Evaluat,Yale New Haven Hosp, New Haven, CT USA.
[Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA.
RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, 309 E 2nd St, Pomona, CA 91766 USA.
EM cjackevicius@westernu.edu
OI Ko, Dennis/0000-0001-6840-8051; Tu, Jack/0000-0003-0111-722X
FU College of Pharmacy of Western University of Health Sciences, Pomona,
California; Canadian Institutes of Health Research; Canada Research
Chair in Health Services Research; Heart and Stroke Foundation of
Ontario, Toronto; National Institute on Aging [K08 AG032886]; American
Federation of Aging Research; National Heart, Lung, and Blood Institute
[U01-HL105270]; Ontario Ministry of Health and Long-Term Care, Toronto
FX This study was funded in part by the College of Pharmacy of Western
University of Health Sciences, Pomona, California, and in part by a
Canadian Institutes of Health Research team grant in cardiovascular
outcomes research awarded to the Canadian Cardiovascular Outcomes
Research Team. Dr Tu is supported by a Canada Research Chair in Health
Services Research and by a Career Investigator award of the Heart and
Stroke Foundation of Ontario, Toronto. Dr Ross is currently supported by
the National Institute on Aging grant K08 AG032886 and by the American
Federation of Aging Research through the Paul B. Beeson Career
Development Award Program. Dr Ko is supported by a new investigator
award from the Canadian Institutes of Health Research. Dr Krumholz is
supported by grant U01-HL105270 (awarded to the Center for
Cardiovascular Outcomes Research at Yale University) from the National
Heart, Lung, and Blood Institute. The Institute for Clinical Evaluative
Sciences is supported by an operating grant from the Ontario Ministry of
Health and Long-Term Care, Toronto.
NR 35
TC 46
Z9 46
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 23
PY 2011
VL 305
IS 12
BP 1217
EP 1224
DI 10.1001/jama.2011.353
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 738PA
UT WOS:000288652100017
PM 21427374
ER
PT J
AU Ringman, JM
Gylys, KH
Medina, LD
Fox, M
Kepe, V
Flores, DL
Apostolova, LG
Barrio, JR
Small, G
Silverman, DH
Siu, E
Cederbaum, S
Hecimovic, S
Malnar, M
Chakraverty, S
Goate, AM
Bird, TD
Leverenz, JB
AF Ringman, John M.
Gylys, Karen H.
Medina, Luis D.
Fox, Michelle
Kepe, Vladimir
Flores, Deborah L.
Apostolova, Liana G.
Barrio, Jorge R.
Small, Gary
Silverman, Daniel H.
Siu, Erin
Cederbaum, Stephen
Hecimovic, Silva
Malnar, Martina
Chakraverty, Suma
Goate, Alison M.
Bird, Thomas D.
Leverenz, James B.
TI Biochemical, neuropathological, and neuroimaging characteristics of
early-onset Alzheimer's disease due to a novel PSEN1 mutation (vol 487,
pg 287, 2011)
SO NEUROSCIENCE LETTERS
LA English
DT Correction
C1 [Ringman, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Mary S Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA.
[Fox, Michelle; Cederbaum, Stephen] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA.
[Kepe, Vladimir; Barrio, Jorge R.; Silverman, Daniel H.; Siu, Erin] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Flores, Deborah L.] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA.
[Small, Gary; Cederbaum, Stephen] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Psychiat, Los Angeles, CA 90095 USA.
[Hecimovic, Silva; Malnar, Martina] Rudjer Boskovic Inst, Dept Mol Med, Zogreb, Croatia.
[Chakraverty, Suma; Goate, Alison M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Bird, Thomas D.; Leverenz, James B.] Univ Washington, Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Ringman, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Mary S Easton Ctr Alzheimers Dis Res, 10911 Weyburn Ave,200, Los Angeles, CA 90095 USA.
EM jringman@mednet.ucla.edu
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD MAR 17
PY 2011
VL 491
IS 2
BP 163
EP 163
DI 10.1016/j.neulet.2011.01.021
PG 1
WC Neurosciences
SC Neurosciences & Neurology
GA 739QF
UT WOS:000288732200015
ER
PT J
AU Luikart, BW
Schnell, E
Washburn, EK
Bensen, AL
Tovar, KR
Westbrook, GL
AF Luikart, Bryan W.
Schnell, Eric
Washburn, Eric K.
Bensen, AeSoon L.
Tovar, Kenneth R.
Westbrook, Gary L.
TI Pten Knockdown In Vivo Increases Excitatory Drive onto Dentate Granule
Cells
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID AUTISM SPECTRUM DISORDERS; LHERMITTE-DUCLOS-DISEASE; SOCIAL-INTERACTION;
SOMA SIZE; INHIBITION; MUTATION; GENE; MICE; PROLIFERATION; TRANSMISSION
AB Some cases of autism spectrum disorder have mutations in the lipid phosphatase, phosphatase and tensin homolog on chromosome 10 (Pten). Tissue specific deletion of Pten in the hippocampus and cortex of mice causes anatomical and behavioral abnormalities similar to human autism. However, the impact of reductions in Pten on synaptic and circuit function remains unexplored. We used in vivo stereotaxic injections of lentivirus expressing a short hairpin RNA to knock down Pten in mouse neonatal and young adult dentate granule cells. We then assessed the morphology and synaptic physiology between 2 weeks and 4 months later. Confocal imaging of the hippocampus revealed a marked increase in granule cell size and an increase in dendritic spine density. The onset of morphological changes occurred earlier in neonatal mice than in young adults. We used whole-cell recordings from granule cells in acute slices to assess synaptic function after Pten knockdown. Consistent with the increase in dendritic spines, the frequency of excitatory miniature and spontaneous postsynaptic currents increased. However, there was little or no effect on IPSCs. Thus, Pten knockdown results in an imbalance between excitatory and inhibitory synaptic activity. Because reductions in Pten affected mature granule cells as well as developing granule cells, we suggest that the disruption of circuit function by Pten hypofunction may be ongoing well beyond early development.
C1 [Luikart, Bryan W.; Washburn, Eric K.; Bensen, AeSoon L.; Tovar, Kenneth R.; Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA.
[Schnell, Eric] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA.
[Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesia & Perioperat Med, Portland, OR 97239 USA.
RP Luikart, BW (reprint author), Dartmouth Med Sch, Dept Neurobiol & Physiol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
EM bryan.w.luikart@dartmouth.edu
RI Luikart, Bryan/D-2683-2012
OI Schnell, Eric/0000-0002-5623-5015
FU National Institutes of Health [T32NS007381, F32MH079548, MH46613]
FX This work was supported by National Institutes of Health Grants
T32NS007381, F32MH079548 (B.W.L.), and MH46613 (G.L.W.). We thank Cooper
French, Stephen Magill, Mike Walogorsky, and Karin Mullendorff for their
contributions to this work.
NR 34
TC 61
Z9 61
U1 0
U2 4
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAR 16
PY 2011
VL 31
IS 11
BP 4345
EP 4354
DI 10.1523/JNEUROSCI.0061-11.2011
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 735YC
UT WOS:000288455700041
PM 21411674
ER
PT J
AU Bin Hafeez, B
Zhong, WX
Weichert, J
Dreckschmidt, NE
Jamal, MS
Verma, AK
AF Bin Hafeez, Bilal
Zhong, Weixiong
Weichert, Jamey
Dreckschmidt, Nancy E.
Jamal, Mohammad Sarwar
Verma, Ajit K.
TI Genetic Ablation of PKC Epsilon Inhibits Prostate Cancer Development and
Metastasis in Transgenic Mouse Model of Prostate Adenocarcinoma
SO CANCER RESEARCH
LA English
DT Article
ID PROTEIN-KINASE-C; CONSTITUTIVE ACTIVATION; STAT3; PHOSPHORYLATION;
INTERACTS; SURVIVAL; INTERLEUKIN-6; STAT3SER727; PROGRESSION; EXPRESSION
AB Protein kinase C epsilon (PKC epsilon), a novel PKC isoform, is overexpressed in prostate cancer (PCa) and correlates with disease aggressiveness. However, the functional contribution of PKCe to development or progression of PCa remained to be determined. Here we present the first in vivo genetic evidence that PKCe is essential for both the development and metastasis of PCa in the transgenic mouse model of prostate adenocarcinoma (TRAMP). Heterozygous or homozygous genetic deletions of PKC epsilon in FVB/N TRAMP inhibited PCa development and metastasis as analyzed by positron emission tomography/computed tomography, tumor weight determinations, and histopathology. We also examined biomarkers associated with tumor progression in this model, including markers of survival, proliferation, angiogenesis, inflammation, and metastatic progression. To find clues about the genes regulated by PKC epsilon and linked to the Stat3 signaling pathway, we carried out focused PCR arrays of JAK/STAT signaling in excised PCa tissues from PKCe wild-type and nullizygous TRAMP mice. Notably, PKC epsilon loss was associated with significant downregulation of proliferative and metastatic genes C/EBP beta (CCAAT/enhancer binding protein beta), CRP (C-reactive protein), CMK, EGFR (epidermal growth factor receptor), CD64, Jun B, and gp130. Taken together, our findings offer the first genetic evidence of the role of PKCe in PCa development and metastasis. PKCe may be potential target for prevention and/or treatment of PCa. Cancer Res; 71(6); 2318-27. (C)2011 AACR.
C1 [Bin Hafeez, Bilal; Dreckschmidt, Nancy E.; Jamal, Mohammad Sarwar; Verma, Ajit K.] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Paul Carbone Comprehens Canc Ctr,Wisconsin Inst M, Madison, WI 53792 USA.
[Zhong, Weixiong] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53792 USA.
[Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Weichert, Jamey] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53792 USA.
RP Verma, AK (reprint author), Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Paul Carbone Comprehens Canc Ctr,Wisconsin Inst M, Madison, WI 53792 USA.
EM akverma@facstaff.wisc.edu
RI Jamal, Mohammad/I-1230-2012; Jamal, Mohammad/K-3842-2013
FU DOD [W81XWH]; NIH [CA35368]; UWCCC Cancer Center [2 P30 CA014520-34]
FX This study was supported by DOD grant (W81XWH), NIH grant CA35368, and
UWCCC Cancer Center Support grant 2 P30 CA014520-34 for small animal
imaging facility.
NR 27
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2011
VL 71
IS 6
BP 2318
EP 2327
DI 10.1158/0008-5472.CAN-10-4170
PG 10
WC Oncology
SC Oncology
GA 734YZ
UT WOS:000288381300031
ER
PT J
AU Apfel, BA
Ross, J
Hlavin, J
Meyerhoff, DJ
Metzler, TJ
Marmar, CR
Weiner, MW
Schuff, N
Neylan, TC
AF Apfel, Brigitte A.
Ross, Jessica
Hlavin, Jennifer
Meyerhoff, Dieter J.
Metzler, Thomas J.
Marmar, Charles R.
Weiner, Michael W.
Schuff, Norbert
Neylan, Thomas C.
TI Hippocampal Volume Differences in Gulf War Veterans with Current Versus
Lifetime Posttraumatic Stress Disorder Symptoms
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Depression; Gulf War veterans; hippocampus; magnetic resonance imaging;
posttraumatic stress disorder
ID MAJOR DEPRESSIVE DISORDER; ADMINISTERED PTSD SCALE; ANTIDEPRESSANT
TREATMENT; CHILDHOOD MALTREATMENT; PSYCHIATRIC-DISORDERS; ADULT
NEUROGENESIS; ALCOHOL DEPENDENCE; RAT HIPPOCAMPUS; DENTATE GYRUS;
METAANALYSIS
AB Background: Decreased hippocampal volume is described in posttraumatic stress disorder (PTSD) and depression. However, it is not known whether it is a risk factor for the development of PTSD or a consequence of PTSD. We sought to determine the effects of PTSD and depressive symptoms on hippocampal volume.
Methods: Clinical and magnetic resonance imaging data were collected in a cross sectional study of 244 Gulf War veterans. Measures included lifetime and current Clinician Administered PTSD Scale, Hamilton Depression Scale, Life Stressor Checklist, and Lifetime Drinking History. Magnetic resonance imaging data were acquired with a 1.5-T scanner and analyzed with automated and semiautomated image processing techniques.
Results: Eighty-two veterans had lifetime PTSD, 44 had current PTSD, and 38 had current depression. In the linear regression analysis, current PTSD symptoms (standardized coefficient beta = -.25, p = .03) but neither lifetime PTSD symptoms nor current depression were associated with smaller hippocampal volume. Gender, age, history of early life trauma, education, lifetime and current alcohol use, current marijuana use, and treatment with antidepressants did not have independent effects. Participants with chronic PTSD had, on average, a smaller hippocampus compared with those with remitted PTSD.
Conclusions: The finding that current but not lifetime PTSD symptom severity explains hippocampal size raises two possibilities: either a small hippocampus is a risk factor for lack of recovery from PTSD (trait) or PTSD effects on hippocampal volume are reversible once PTSD symptoms remit and the patient recovers (state).
C1 [Apfel, Brigitte A.; Ross, Jessica; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Meyerhoff, Dieter J.; Weiner, Michael W.; Schuff, Norbert] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Apfel, Brigitte A.; Ross, Jessica; Metzler, Thomas J.; Neylan, Thomas C.] Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA.
[Hlavin, Jennifer; Meyerhoff, Dieter J.; Weiner, Michael W.; Schuff, Norbert] Vet Affairs Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Marmar, Charles R.] NYU, Dept Psychiat, New York, NY 10016 USA.
RP Apfel, BA (reprint author), San Francisco VA Med Ctr, Dept Psychiat, 116A,4150 Clement St, San Francisco, CA 94121 USA.
EM brigitte.apfel@ucsf.edu
RI Schueter, nicos/A-3625-2014
FU Department of Defense [DAMD17-01-1-0764]; US Army Medical Research and
Materiel Command; National Institutes of Health/National Institute of
Environmental Health Sciences [ES09883]; Mental Illness Research,
Education, and Clinical Center of the Department of Veterans Affairs;
Office of Academic Affiliations; Department of Veterans Affairs; [R01
AA 10788]
FX This study was supported by Department of Defense Grant
DAMD17-01-1-0764, entitled, "Magnetic Resonance and Spectroscopy of the
Human Brain in GulfWarIllness," awarded to the Northern California
Institute for Research and Education from the Department of Defense Gulf
War Illnesses Research Program, US Army Medical Research and Materiel
Command. This study was also supported by National Institutes of
Health/National Institute of Environmental Health Sciences Grant ES09883
and the Mental Illness Research, Education, and Clinical Center of the
Department of Veterans Affairs. Resources and the use of facilities were
provided by the Veterans Administration Medical Center, San Francisco,
California. Writing of this manuscript was supported by the Office of
Academic Affiliations, Advanced Fellowship Program in Mental Illness
Research and Treatment, Department of Veterans Affairs, and R01 AA 10788
(DJM). We are grateful to Karl Friedl, Ph.D., for his support, and last
but not least we thank Diana Truran and her staff for MRI scanning. All
authors report no biomedical financial interests or potential conflicts
of interest.
NR 74
TC 44
Z9 47
U1 6
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAR 15
PY 2011
VL 69
IS 6
BP 541
EP 548
DI 10.1016/j.biopsych.2010.09.044
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 732NW
UT WOS:000288193400008
PM 21094937
ER
PT J
AU Wilson, LB
Tregellas, JR
Slason, E
Pasko, BE
Rojas, DC
AF Wilson, Lisa B.
Tregellas, Jason R.
Slason, Erin
Pasko, Bryce E.
Rojas, Donald C.
TI Implicit phonological priming during visual word recognition
SO NEUROIMAGE
LA English
DT Article
DE fMRI; Phonology; Priming; Implicit memory; Superior temporal gyrus;
Supramarginal gyrus; Default-mode network
ID SUPERIOR TEMPORAL GYRUS; VERBAL WORKING-MEMORY; DEFAULT-MODE; FUNCTIONAL
NEUROANATOMY; SENTENCE COMPREHENSION; SPEECH PRODUCTION; LEXICAL ACCESS;
BRAIN-FUNCTION; TIME-COURSE; ACTIVATION
AB Phonology is a lower-level structural aspect of language involving the sounds of a language and their organization in that language. Numerous behavioral studies utilizing priming, which refers to an increased sensitivity to a stimulus following prior experience with that or a related stimulus, have provided evidence for the role of phonology in visual word recognition. However, most language studies utilizing priming in conjunction with functional magnetic resonance imaging (fMRI) have focused on lexical-semantic aspects of language processing. The aim of the present study was to investigate the neurobiological substrates of the automatic, implicit stages of phonological processing. While undergoing fMRI, eighteen individuals performed a lexical decision task (LOT) on prime-target pairs including word-word homophone and pseudoword-word pseudohomophone pairs with a prime presentation below perceptual threshold. Whole-brain analyses revealed several cortical regions exhibiting hemodynamic response suppression due to phonological priming including bilateral superior temporal gyri (STG), middle temporal gyri (MTG), and angular gyri (AG) with additional region of interest (ROI) analyses revealing response suppression in the left lateralized supramarginal gyrus (SMG). Homophone and pseudohomophone priming also resulted in different patterns of hemodynamic responses relative to one another. These results suggest that phonological processing plays a key role in visual word recognition. Furthermore, enhanced hemodynamic responses for unrelated stimuli relative to primed stimuli were observed in midline cortical regions corresponding to the default-mode network (DMN) suggesting that DMN activity can be modulated by task requirements within the context of an implicit task. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Wilson, Lisa B.; Tregellas, Jason R.; Slason, Erin; Pasko, Bryce E.; Rojas, Donald C.] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA.
[Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA.
RP Rojas, DC (reprint author), Univ Colorado Denver, Dept Psychiat, 13001 E 17th Pl, Aurora, CO 80045 USA.
EM lisa.wilson@ucdenver.edu; jason.tregellas@ucdenver.edu;
erin.slason@gmail.com; bryce.pasko@ucdenver.edu; don.rojas@ucdenver.edu
RI Rojas, Don/F-4296-2012; Tregellas, Jason/J-3637-2015
OI Rojas, Don/0000-0001-6560-9616
FU Autism Speaks [2090]; Autism Speaks Weatherstone [6291]; National
Institutes of Health (NIH) [PHS R01 MH082020]; NIH/NCRR Colorado CTSI
[TL1 RR025778]; National Institute of Child Health and Human Development
(NICHHD) [HD041697]
FX Funding for this study was provided by Autism Speaks Grant 2090, Autism
Speaks Weatherstone Grant 6291, the National Institutes of Health (NIH)
Grant PHS R01 MH082020, NIH/NCRR Colorado CTSI Grant TL1 RR025778, and
the National Institute of Child Health and Human Development (NICHHD)
Grant HD041697. The funding sources had no further role in the study
design; in the collection, analysis, and interpretation of data; in the
writing of the report; and in the decision to submit the paper for
publication.
NR 64
TC 13
Z9 15
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAR 15
PY 2011
VL 55
IS 2
BP 724
EP 731
DI 10.1016/j.neuroimage.2010.12.019
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 724DL
UT WOS:000287556200031
PM 21159322
ER
PT J
AU Shlipak, M
AF Shlipak, Michael
TI Diabetic Nephropathy: Preventing Progression
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Editorial Material
C1 San Francisco VA Med Ctr, San Francisco, CA USA.
RP Shlipak, M (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD MAR 15
PY 2011
VL 83
IS 6
BP 732
EP 733
PG 2
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 979ZM
UT WOS:000306863400011
ER
PT J
AU Johansen, KL
AF Johansen, Kirsten L.
TI Time to Rethink the Timing of Dialysis Initiation
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Johansen, Kirsten L.] Univ Calif San Francisco, Nephrol Sect, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94121 USA.
RP Johansen, KL (reprint author), Univ Calif San Francisco, Nephrol Sect, San Francisco VA Med Ctr, 111J,4150 Clement St, San Francisco, CA 94121 USA.
EM Kirsten.johansen@ucsf.edu
NR 10
TC 5
Z9 5
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAR 14
PY 2011
VL 171
IS 5
BP 382
EP U182
DI 10.1001/archinternmed.2010.413
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 734IW
UT WOS:000288328800002
PM 21059965
ER
PT J
AU Zhang, YT
Zhou, L
Gellad, WF
AF Zhang, Yuting
Zhou, Lei
Gellad, Walid F.
TI Potential Savings From Greater Use of $4 Generic Drugs
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Zhang, Yuting; Zhou, Lei] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Div Gen Med, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] RAND Corp, Santa Monica, CA 90406 USA.
RP Zhang, YT (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 De Soto St,Crabtree Hall A664, Pittsburgh, PA 15261 USA.
EM ytzhang@pitt.edu
OI Zhang, Yuting/0000-0002-6460-6779
FU NCATS NIH HHS [KL2 TR000146]; NCRR NIH HHS [KL2 RR024154, KL2
RR024154-04, UL1 RR024153]
NR 5
TC 11
Z9 11
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAR 14
PY 2011
VL 171
IS 5
BP 468
EP 469
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 734IW
UT WOS:000288328800018
PM 21403045
ER
PT J
AU Edderkaoui, M
Nitsche, C
Zheng, L
Pandol, SJ
Gukovsky, I
Gukovskaya, AS
AF Edderkaoui, Mouad
Nitsche, Claudia
Zheng, Ling
Pandol, Stephen J.
Gukovsky, Ilya
Gukovskaya, Anna S.
TI NADPH Oxidase Activation in Pancreatic Cancer Cells Is Mediated through
Akt-dependent Up-regulation of p22(phox)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NF-KAPPA-B; AORTIC SMOOTH-MUSCLE; FACTOR-I RECEPTOR; ENDOTHELIAL-CELLS;
GROWTH; NOX4; APOPTOSIS; ALPHA; EXPRESSION; GENERATION
AB We recently showed that Nox4 NADPH oxidase is highly expressed in pancreatic ductal adenocarcinoma and that it is activated by growth factors and plays a pro-survival, antiapoptotic role. Here we investigate the mechanisms through which insulin-like growth factor I and serum (FBS) activate NADPH oxidase in pancreatic cancer (PaCa) cells. We show that in PaCa cells, NADPH oxidase is composed of Nox4 and p22(phox) catalytic subunits, which are both required for NADPH oxidase activity. Insulin-like growth factor I and FBS activate NADPH oxidase through transcriptional up-regulation of p22(phox). This involves activation of the transcription factor NF-kappa B mediated by Akt kinase. Up-regulation of p22(phox) by the growth factors results in increased Nox4-p22(phox) complex formation and activation of NADPH oxidase. This mechanism is different from that for receptor-induced activation of phagocytic NADPH oxidase, which is mediated by phosphorylation of its regulatory subunits. Upregulation of p22(phox) represents a novel pro-survival mechanism through which growth factors and Akt inhibit apoptosis in PaCa cells.
C1 [Gukovskaya, Anna S.] Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Los Angeles, CA 90073 USA.
RP Gukovskaya, AS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA.
EM agukovsk@ucla.edu
FU National Institutes of Health through NCI [R01CA119025]; NCCAM
[AT003960]; Department of Veterans Affairs Merit Review; CURE-Digestive
Diseases Research Center
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01CA119025 through the NCI (to A. S. G.) and AT003960
through the NCCAM (to S. J. P.). This study was also supported by the
Department of Veterans Affairs Merit Review (to A. S. G.) and the
CURE-Digestive Diseases Research Center Pilot and Feasibility Award (to
M. E.).
NR 32
TC 34
Z9 34
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 11
PY 2011
VL 286
IS 10
BP 7779
EP 7787
DI 10.1074/jbc.M110.200063
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 730DQ
UT WOS:000288013300009
PM 21118808
ER
PT J
AU Roseman, M
Milette, K
Bero, LA
Coyne, JC
Lexchin, J
Turner, EH
Thombs, BD
AF Roseman, Michelle
Milette, Katherine
Bero, Lisa A.
Coyne, James C.
Lexchin, Joel
Turner, Erick H.
Thombs, Brett D.
TI Reporting of Conflicts of Interest in Meta-analyses of Trials of
Pharmacological Treatments
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID CELL LUNG-CANCER; PHARMACEUTICAL-INDUSTRY; RANDOMIZED-TRIALS; DRUG
TRIALS; CARDIOVASCULAR-DISEASE; COMPETING INTERESTS; DIABETES-MELLITUS;
CLINICAL-TRIALS; FINANCIAL TIES; RISK
AB Context Disclosure of conflicts of interest (COIs) from pharmaceutical industry study funding and author-industry financial relationships is sometimes recommended for randomized controlled trials (RCTs) published in biomedical journals. Authors of meta-analyses, however, are not required to report COIs disclosed in original reports of included RCTs.
Objective To investigate whether meta-analyses of pharmacological treatments published in high-impact biomedical journals report COIs disclosed in included RCTs.
Data Sources and Study Selection We selected the 3 most recent meta-analyses of patented pharmacological treatments published January 2009 through October 2009 in each general medicine journal with an impact factor of at least 10; in high-impact journals in each of the 5 specialty medicine areas with the greatest 2008 global therapeutic sales (oncology, cardiology, respiratory medicine, endocrinology, and gastroenterology); and in the Cochrane Database of Systematic Reviews.
Data Extraction Two investigators independently extracted data on disclosed study funding, author-industry financial ties, and author employment from each meta-analysis, from RCTs included in each meta-analysis, and on whether meta-analyses reported disclosed COIs of included RCTs.
Results Of 29 meta-analyses reviewed, which included 509 RCTs, only 2 meta-analyses (7%) reported RCT funding sources; and 0 reported RCT author-industry ties or employment by the pharmaceutical industry. Of 318 meta-analyzed RCTs that reported funding sources, 219 (69%) were industry funded; and 91 of 132 (69%) that reported author financial disclosures had 1 or more authors with pharmaceutical industry financial ties. In 7 of the 29 meta-analyses reviewed, 100% of included RCTs had at least 1 form of disclosed COI (pharmaceutical industry funding, author-industry financial ties, or employment), yet only 1 of these 7 meta-analyses reported RCT funding sources, and 0 reported RCT author-industry ties or employment.
Conclusion Among a group of meta-analyses of pharmacological treatments published in high-impact biomedical journals, information concerning primary study funding and author COIs for the included RCTs were only rarely reported. JAMA. 2011;305(10):1008-1017 www.jama.com
C1 [Roseman, Michelle; Milette, Katherine; Thombs, Brett D.] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E4, Canada.
[Roseman, Michelle; Milette, Katherine; Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Dept Biostat, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada.
[Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada.
[Bero, Lisa A.] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA.
[Bero, Lisa A.] Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
[Coyne, James C.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Coyne, James C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hlth Psychol Sect, NL-9700 AB Groningen, Netherlands.
[Lexchin, Joel] Univ Toronto, Univ Hlth Network, Emergency Dept, Toronto, ON, Canada.
[Lexchin, Joel] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada.
[Lexchin, Joel] York Univ, Sch Hlth Policy & Management, N York, ON M3J 1P3, Canada.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Turner, Erick H.] Portland VA Med Ctr, Portland, OR USA.
RP Thombs, BD (reprint author), Jewish Gen Hosp, Lady Davis Inst Med Res, 4333 Cote Ste Catherine Rd, Montreal, PQ H3T 1E4, Canada.
EM brett.thombs@mcgill.ca
OI Turner, Erick/0000-0002-3522-3357
FU Canadian Institutes of Health Research; McGill University; Canadian
Institutes of Health Research Strategic Training Initiative [SKI 83345];
Fonds de la Recherche en Sante Quebec; Etablissement de Jeunes
Chercheurs
FX Ms Roseman and Ms Milette were supported by Frederick Banting and
Charles Best Canadian Graduate Scholarships-Master's Awards from the
Canadian Institutes of Health Research. Ms Roseman was also supported by
a McGill University Provost's Graduate Fellowship and a McGill
University Principal's Graduate Fellowship. Ms. Milette was also
supported by a Canadian Scleroderma Research Group Studentship (Canadian
Institutes of Health Research Strategic Training Initiative in Health
Research Grant, SKI 83345) and a McGill University Provost's Graduate
Fellowship. Dr Thombs was supported by a New Investigator Award from the
Canadian Institutes of Health Research and an Etablissement de Jeunes
Chercheurs award from the Fonds de la Recherche en Sante Quebec. Funds
from the Etablissement de Jeunes Chercheurs award supported this
project.
NR 69
TC 68
Z9 69
U1 1
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 9
PY 2011
VL 305
IS 10
BP 1008
EP 1017
DI 10.1001/jama.2011.257
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 731SM
UT WOS:000288129600020
PM 21386079
ER
PT J
AU Kacimi, R
Giffard, RG
Yenari, MA
AF Kacimi, Rachid
Giffard, Rona G.
Yenari, Midori A.
TI Endotoxin-activated microglia injure brain derived endothelial cells via
NF-kappa B, JAK-STAT and JNK stress kinase pathways
SO JOURNAL OF INFLAMMATION-LONDON
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; INDUCED INOS EXPRESSION; EXPERIMENTAL STROKE;
MILD HYPOTHERMIA; PROTEIN-KINASE; IMMUNE-SYSTEM; INFLAMMATION; DISEASES;
HYPOXIA; BARRIER
AB Background: We previously showed that microglia damage blood brain barrier (BBB) components following ischemic brain insults, but the underlying mechanism(s) is/are not well known. Recent work has established the contribution of toll-like receptor 4 (TLR4) activation to several brain pathologies including ischemia, neurodegeneration and sepsis. The present study established the requirement of microglia for lipopolysaccharide (LPS) mediated endothelial cell death, and explored pathways involved in this toxicity. LPS is a classic TLR4 agonist, and is used here to model aspects of brain conditions where TLR4 stimulation occurs.
Methods/Results: In monocultures, LPS induced death in microglia, but not brain derived endothelial cells (EC). However, LPS increased EC death when cocultured with microglia. LPS led to nitric oxide (NO) and inducible NO synthase (iNOS) induction in microglia, but not in EC. Inhibiting microglial activation by blocking iNOS and other generators of NO or blocking reactive oxygen species (ROS) also prevented injury in these cocultures. To assess the signaling pathway(s) involved, inhibitors of several downstream TLR-4 activated pathways were studied. Inhibitors of NF-kappa B, JAK-STAT and JNK/SAPK decreased microglial activation and prevented cell death, although the effect of blocking JNK/SAPK was rather modest. Inhibitors of PI3K, ERK, and p38 MAPK had no effect.
Conclusions: We show that LPS-activated microglia promote BBB disruption through injury to endothelial cells, and the specific blockade of JAK-STAT, NF-kappa B may prove to be especially useful anti-inflammatory strategies to confer cerebrovascular protection.
C1 [Kacimi, Rachid; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Kacimi, Rachid; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Giffard, Rona G.] Stanford Univ, Med Ctr, Dept Anesthesia Dept, Stanford, CA 94305 USA.
RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
EM yenari@alum.mit.edu
FU Department of Veterans Affairs [NIH P50 NS014543, R01 NS 40156,
GM049831]; Department of Defense [DAMD17-03-1-0532]
FX This work was supported by the Department of Veterans Affairs (MAY),
grants from the NIH P50 NS014543 (RGG, MAY), R01 NS 40156 (MAY),
GM049831 (RGG) and the Department of Defense DAMD17-03-1-0532 (MAY).
NR 40
TC 65
Z9 71
U1 0
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-9255
J9 J INFLAMM-LOND
JI J. Inflamm.-Lond.
PD MAR 7
PY 2011
VL 8
AR 7
DI 10.1186/1476-9255-8-7
PG 15
WC Immunology
SC Immunology
GA 738BT
UT WOS:000288615000001
PM 21385378
ER
PT J
AU Suzuki, A
Stern, SA
Bozdagi, O
Huntley, GW
Walker, RH
Magistretti, PJ
Alberini, CM
AF Suzuki, Akinobu
Stern, Sarah A.
Bozdagi, Ozlem
Huntley, George W.
Walker, Ruth H.
Magistretti, Pierre J.
Alberini, Cristina M.
TI Astrocyte-Neuron Lactate Transport Is Required for Long-Term Memory
Formation
SO CELL
LA English
DT Article
ID ELEMENT-BINDING PROTEIN; IMMEDIATE-EARLY GENE; D-SERINE; RAT
HIPPOCAMPUS; GLYCOGEN; GLUCOSE; POTENTIATION; PLASTICITY; ACTIN;
CONSOLIDATION
AB We report that, in the rat hippocampus, learning leads to a significant increase in extracellular lactate levels that derive from glycogen, an energy reserve selectively localized in astrocytes. Astrocytic glycogen breakdown and lactate release are essential for long-term but not short-term memory formation, and for the maintenance of long-term potentiation (LTP) of synaptic strength elicited in vivo. Disrupting the expression of the astrocytic lactate transporters monocarboxylate transporter 4 (MCT4) or MCT1 causes amnesia, which, like LTP impairment, is rescued by L-lactate but not equicaloric glucose. Disrupting the expression of the neuronal lactate transporter MCT2 also leads to amnesia that is unaffected by either L-lactate or glucose, suggesting that lactate import into neurons is necessary for long-term memory. Glycogenolysis and astrocytic lactate transporters are also critical for the induction of molecular changes required for memory formation, including the induction of phospho-CREB, Arc, and phospho-cofilin. We conclude that astrocyte-neuron lactate transport is required for long-term memory formation.
C1 [Magistretti, Pierre J.] Univ Lausanne CHUV, Lab Neuroenerget & Cellular Dynam, Brain Mind Inst, EPFL, Lausanne, Switzerland.
[Magistretti, Pierre J.] Univ Lausanne CHUV, Ctr Psychiat Neurosci, Lausanne, Switzerland.
[Suzuki, Akinobu; Stern, Sarah A.; Bozdagi, Ozlem; Huntley, George W.; Alberini, Cristina M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Bozdagi, Ozlem; Alberini, Cristina M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Walker, Ruth H.] James J Peters VAMC, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
RP Magistretti, PJ (reprint author), Univ Lausanne CHUV, Lab Neuroenerget & Cellular Dynam, Brain Mind Inst, EPFL, Lausanne, Switzerland.
EM pierre.magistretti@epfl.ch; cristina.alberini@mssm.edu
FU Department of Veterans Affairs; [R01-MH065635]; [R01-MH074736];
[T32-MH087004]
FX This work was supported by grants R01-MH065635 and R01-MH074736 to C. M.
A., Department of Veterans Affairs Merit Award to R. H. W. and
T32-MH087004 to S. A. S. We thank Rick Koch, Dhananjay Bambah-Mukku,
Dillon Chen, Gabriella Pollonini, and Virginia Gao for technical
support; and Reginald Miller and the Center for Comparative Medicine and
Surgery facility at Mount Sinai School of Medicine for technical
support. P.J.M. is the recipient of the Asterion Chair at Ecole
Polytechnique Federale de Lausanne (EPFL).
NR 64
TC 382
Z9 398
U1 7
U2 52
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAR 4
PY 2011
VL 144
IS 5
BP 810
EP 823
DI 10.1016/j.cell.2011.02.018
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 730CE
UT WOS:000288007100018
PM 21376239
ER
PT J
AU Vitek, WS
Akers, A
Meyn, LA
Switzer, GE
Lee, BY
Beigi, RH
AF Vitek, Wendy S.
Akers, Aletha
Meyn, Leslie A.
Switzer, Galen E.
Lee, Bruce Y.
Beigi, Richard H.
TI Vaccine eligibility and acceptance among ambulatory obstetric and
gynecologic patients
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 35th Annual Scientific Meeting of the
Infectious-Diseases-Society-for-Obstetrics-and-Gynecology
CY AUG 14-16, 2008
CL Seattle, WA
SP Infect Dis Soc Obstetr & Gynecol
DE Patient acceptance of health care; Vaccine; Obstetrics; Gynecology
ID PREGNANCY
AB Objective: To assess vaccine eligibility and factors associated with vaccine acceptance among ambulatory obstetric and gynecologic patients.
Methods: An anonymous office-based survey was administered to women seeking ambulatory obstetric and gynecologic care at a large women's hospital from December 2007 to July 2008. Information collected included: demographics, medical and vaccination history, interest in receiving vaccines and attitudes towards vaccine providers. Vaccine eligibility was based on age and/or self-reported risk factors in accord with the 2007-2008 Center for Disease Control and Prevention (CDC) adult immunization schedule. Vaccine eligibility was examined using descriptive statistics, and demographic characteristics were compared using chi-squared analysis. A multivariable logistic regression model was developed to assess factors associated with participants' willingness to accept vaccines from their obstetrician-gynecologist.
Results: A total of 1441 women completed the survey. The majority of participants (87%) would accept vaccines if recommended by their obstetrician-gynecologist. The primary factors associated with vaccine acceptance were having less than a high school education, being privately insured, currently being pregnant, reporting a history of vaccinations and previously receiving vaccinations from an obstetrician-gynecologist. A significant portion of participants were eligible for the hepatitis B. influenza and HPV vaccines (>= 50% for each). The type of vaccine did not influence willingness to accept vaccines from an obstetrician-gynecologist.
Conclusion: A majority of women appear eligible for, and will accept, vaccinations regardless of specific vaccine, if recommended by their obstetrician-gynecologist. These findings justify ongoing efforts to expand immunization services offered by obstetrician-gynecologists. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Vitek, Wendy S.] Women & Infants Hosp Rhode Isl, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Providence, RI 02908 USA.
[Akers, Aletha; Beigi, Richard H.] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Med Ctr,Div Gynecol Specialties, Pittsburgh, PA 15213 USA.
[Akers, Aletha; Beigi, Richard H.] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Med Ctr,Div Reprod Infect Dis, Pittsburgh, PA 15213 USA.
[Meyn, Leslie A.] Magee Womens Res Inst, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Sch Med, Dept Med & Psychiat, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Sch Med, Dept Clin & Translat Sci, Pittsburgh, PA USA.
[Switzer, Galen E.] VA Pittsburgh Hlth Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA.
[Lee, Bruce Y.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Lee, Bruce Y.] Univ Pittsburgh, Dept Epidemiol, Sch Med, Pittsburgh, PA 15261 USA.
[Lee, Bruce Y.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
RP Vitek, WS (reprint author), Women & Infants Hosp Rhode Isl, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, 90 Plain St, Providence, RI 02908 USA.
EM wvitek@wihri.org
NR 16
TC 13
Z9 13
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAR 3
PY 2011
VL 29
IS 11
BP 2024
EP 2028
DI 10.1016/j.vaccine.2011.01.026
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 739PU
UT WOS:000288731000007
PM 21272604
ER
PT J
AU Rodriguez-Torres, M
Bacon, B
Gordon, S
Rubin, R
Box, T
Kugelmas, M
Vierling, J
Yoffe, B
Pockros, P
Everson, G
Jonas, M
Balart, L
Bohm, O
Castelloe, E
Huyghe, MR
Mento, S
Spada, A
Fox, AW
Chojkier, M
AF Rodriguez-Torres, M.
Bacon, B.
Gordon, S.
Rubin, R.
Box, T.
Kugelmas, M.
Vierling, J.
Yoffe, B.
Pockros, P.
Everson, G.
Jonas, M.
Balart, L.
Bohm, O.
Castelloe, E.
Huyghe, M. R.
Mento, S.
Spada, A.
Fox, A. W.
Chojkier, M.
TI UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A
PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTERFERON/RIBAVIRIN
(SOC) IN NULL RESPONDERS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY 2011
CL Berlin, GERMANY
SP European Assoc Study Liver (EASL)
C1 [Rodriguez-Torres, M.] Fdn Invest Diego, San Juan, PR USA.
[Bacon, B.] St Louis Univ, St Louis, MO 63103 USA.
[Gordon, S.] Henry Ford Hosp, Detroit, MI 48202 USA.
[Rubin, R.] Liver Ctr Atlanta, Atlanta, GA USA.
[Box, T.] Univ Utah, Salt Lake City, UT USA.
[Kugelmas, M.] S Denver Gastroenterol, Denver, CO USA.
[Vierling, J.] Baylor Coll Med, Houston, TX 77030 USA.
[Yoffe, B.] VA Med Ctr, Houston, TX USA.
[Pockros, P.] Scripps Clin, La Jolla, CA USA.
[Everson, G.] Univ Colorado, Aurora, CO USA.
[Jonas, M.] Consultants Clin Res, Cincinnati, OH USA.
[Balart, L.] Tulane Univ Hlth Serv, New Orleans, LA USA.
[Bohm, O.] FGK Clin Res, Munich, Germany.
[Fox, A. W.] EBD Grp, Carlsbad, CA USA.
[Castelloe, E.; Huyghe, M. R.; Mento, S.; Spada, A.] Conatus Pharmaceut, San Diego, CA USA.
[Chojkier, M.] Univ Calif San Diego, San Diego, CA 92103 USA.
EM rodztorres@coqui.net
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD MAR
PY 2011
VL 54
SU 1
MA 468
BP S191
EP S191
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 856GC
UT WOS:000297625601048
ER
PT J
AU Raval, MV
Hamilton, BH
Ingraham, AM
Ko, CY
Hall, BL
AF Raval, Mehul V.
Hamilton, Barton H.
Ingraham, Angela M.
Ko, Clifford Y.
Hall, Bruce L.
TI The Importance of Assessing Both Inpatient and Outpatient Surgical
Quality
SO ANNALS OF SURGERY
LA English
DT Article
ID IMPROVEMENT PROGRAM; RISK ADJUSTMENT; PATIENT SAFETY; AMERICAN-COLLEGE;
SURGERY; CARE; MORTALITY; HOSPITALS; MORBIDITY; CENTERS
AB Objective: We aimed to determine whether hospital-level surgical performance was similar across outpatient and inpatient settings.
Background: The majority of surgical procedures in the United States are performed in an outpatient setting but most quality improvement focuses on inpatient care.
Methods: Using data from the 2006 to 2008 American College of Surgeons-National Surgical Quality Improvement Program, risk-adjusted hospital observed to expected ratios for morbidity and mortality were compared for inpatient and outpatient cases. In addition, hospital outpatient performance in each year was compared with performances in subsequent years.
Results: Hospitals demonstrated variation in outcomes for outpatient morbidity with both good and poor outliers in each year. Outpatient mortality was so rare as to not support robust modeling. There was a lack of congruence between hospital performance for outpatient morbidity and either inpatient morbidity or inpatient mortality in each year, indicating that inpatient performance is not interchangeable with outpatient performance. Outpatient morbidity performance correlation between years was only moderate (correlations 0.449-0.534, all P < 0.001) indicating that although outcomes from 1 year mildly predict subsequent years, substitution of data would likely lead to missed opportunities for improvement.
Conclusions: Assessments of risk-adjusted hospital-level outpatient morbidity performance demonstrate (1) variability across American College of Surgeons-National Surgical Quality Improvement Program sites; (2) a lack of congruence between outpatient morbidity performance and either inpatient morbidity or mortality performance; (3) year-to-year variation of outpatient morbidity performance at individual institutions. Continuing evaluation of both outpatient and inpatient outcomes is supported. Given the substantial volume of outpatient care delivered, outpatient assessments are likely to be an important component of ongoing quality improvement efforts.
C1 [Raval, Mehul V.; Ingraham, Angela M.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Raval, Mehul V.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Hamilton, Barton H.; Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA.
[Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hall, Bruce L.] Washington Univ, Dept Surg, John Cochran Vet Affairs Med Ctr, Ctr Hlth Policy, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA.
EM mraval@facs.org
RI Hamilton, Barton/P-5187-2015
OI Raval, Mehul/0000-0002-1527-2661
FU John Gray Research Fellowship; Daniel F. and Ada L. Rice Foundation;
Health Policy
FX M.V.R is supported by the John Gray Research Fellowship and the Daniel
F. and Ada L. Rice Foundation. B. L. H was supported by the Center for
Health Policy, under the direction of Dr. William Peck, Washington
University in St. Louis, St. Louis, MO.
NR 37
TC 30
Z9 30
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD MAR
PY 2011
VL 253
IS 3
BP 611
EP 618
DI 10.1097/SLA.0b013e318208fd50
PG 8
WC Surgery
SC Surgery
GA 719VF
UT WOS:000287238900026
PM 21183845
ER
PT J
AU Schwab, P
Scalapino, K
AF Schwab, Pascale
Scalapino, Kenneth
TI Exercise for bone health: rationale and prescription
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE bone mass; exercise; mechano-transduction; osteocyte; osteoporosis
ID RANDOMIZED CONTROLLED-TRIALS; QUALITY-OF-LIFE; MECHANICAL SIGNALS;
HIGH-FREQUENCY; OSTEOPOROTIC FRACTURES; PHYSICAL-ACTIVITY;
MUSCLE-ACTIVITY; RISK-FACTORS; IN-VIVO; STRENGTH
AB Purpose of review
Patients frequently inquire about exercise as a means to improve bone strength and reduce osteoporotic fracture. Understanding the biologic mechanisms and the available clinical evidence supporting the role of exercise in bone health is the key to an educated discussion.
Recent findings
Exercise downregulates sclerostin expression by the osteocyte favoring osteoblastogenesis. These changes are enhanced by dynamic cyclical load with rest periods and may be promoted by low-amplitude high-frequency stimuli. In the prepubertal years, exercise results in periosteal gains, whereas exercise later in life maintains bone mass, reduces falls and probably associated fractures, and improves quality-of-life measures.
Summary
Future studies should examine the effect of exercise on bone strength and determine the minimum quantity and frequency and the exercise type most effective to reduce osteoporotic fractures.
C1 [Schwab, Pascale; Scalapino, Kenneth] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA.
RP Schwab, P (reprint author), 3710 SW Vet Hosp Rd, Portland, OR 97239 USA.
EM schwabp@ohsu.edu
NR 44
TC 8
Z9 8
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8711
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD MAR
PY 2011
VL 23
IS 2
BP 137
EP 141
DI 10.1097/BOR.0b013e3283434501
PG 5
WC Rheumatology
SC Rheumatology
GA 715JB
UT WOS:000286879200003
PM 21178629
ER
PT J
AU Campling, BG
Collins, BN
Algazy, KM
Schnoll, RA
Lam, M
AF Campling, Barbara G.
Collins, Bradley N.
Algazy, Kenneth M.
Schnoll, Robert A.
Lam, Miu
TI Spontaneous Smoking Cessation Before Lung Cancer Diagnosis
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Lung neoplasms; Prostate cancer; Myocardial infarction; Smoking
cessation; Veterans
ID CELL-LINES; NICOTINE DEPENDENCE; MORTALITY; CARCINOMA; GROWTH; RISK;
ACETYLCHOLINE; ANGIOGENESIS; TACHYKININS; EXPRESSION
AB Introduction: We have observed that many patients with lung cancer stop smoking before diagnosis, usually before clinical symptoms, and often without difficulty. This led us to speculate that spontaneous smoking cessation may be a presenting symptom of lung cancer.
Methods: Patients from the Philadelphia Veterans Affairs Medical Center with lung cancer and for comparison, prostate cancer and myocardial infarction underwent a structured interview about their smoking habits preceding diagnosis. Severity of nicotine addiction was graded using the Fagerstrom Test for Nicotine Dependence. Among former smokers, dates of cessation, onset of symptoms, and diagnosis were recorded. Difficulty quitting was rated on a scale of 0 to 10. Distributions of intervals from cessation to diagnosis were compared between groups.
Results: All 115 patients with lung cancer had been smokers. Fifty-five (48%) quit before diagnosis, and only six of these (11%) were symptomatic at quitting. Patients with lung cancer who quit were as dependent on nicotine, when smoking the most, as those who continued to smoke, unlike the other groups. Despite this, 31% quit with no difficulty. The median interval from cessation to diagnosis was 2.7 years for lung cancer, 24.3 years for prostate cancer, and 10.0 years for patients with myocardial infarction.
Conclusions: These results challenge the notion that patients with lung cancer usually quit smoking because of disease symptoms. The hypothesis that spontaneous smoking cessation may be a presenting symptom of lung cancer warrants further investigation.
C1 [Campling, Barbara G.; Algazy, Kenneth M.] Univ Penn, Dept Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Collins, Bradley N.] Temple Univ, Dept Publ Hlth, Philadelphia, PA 19122 USA.
[Collins, Bradley N.] Temple Univ, Dept Pediat, Philadelphia, PA 19122 USA.
[Schnoll, Robert A.] Univ Penn, Dept Psychiat, Transdisciplinary Tobacco Use Res Ctr, Philadelphia, PA 19104 USA.
[Lam, Miu] Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON, Canada.
RP Campling, BG (reprint author), 834 Chestnut St,Suite 314, Philadelphia, PA 19107 USA.
EM Campling@jefferson.edu
FU Veterans Affairs Healthcare Network
FX Supported by a Veterans Affairs Healthcare Network Competitive Pilot
Project Grant. The sponsor had no involvement in the study design,
interpretation of results, or preparation of the manuscript. The
opinions expressed herein are those of the authors and do not represent
the views of the Department of Veterans Affairs or the United States
Government.
NR 36
TC 4
Z9 4
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD MAR
PY 2011
VL 6
IS 3
BP 517
EP 524
DI 10.1097/JTO.0b013e318208c7da
PG 8
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 719VR
UT WOS:000287240100015
PM 21258255
ER
PT J
AU Zhang, ZG
Kolm, P
Boden, WE
Hartigan, PM
Maron, DJ
Spertus, JA
O'Rourke, RA
Shaw, LJ
Sedlis, SP
Mancini, GBJ
Berman, DS
Dada, M
Teo, KK
Weintraub, WS
AF Zhang, Zugui
Kolm, Paul
Boden, William E.
Hartigan, Pamela M.
Maron, David J.
Spertus, John A.
O'Rourke, Robert A.
Shaw, Leslee J.
Sedlis, Steven P.
Mancini, G. B. John
Berman, Daniel S.
Dada, Marcin
Teo, Koon K.
Weintraub, William S.
TI The Cost-Effectiveness of Percutaneous Coronary Intervention as a
Function of Angina Severity in Patients With Stable Angina
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE angina; cost effectiveness; quality of life; questionnaires
ID EVALUATION COURAGE TRIAL; OUTCOMES UTILIZING REVASCULARIZATION; OPTIMAL
MEDICAL THERAPY; QUALITY-OF-LIFE; ARTERY-DISEASE; MYOCARDIAL-INFARCTION;
HEART-DISEASE; ANGIOPLASTY; ECONOMICS; SURVIVAL
AB Background-The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial compared percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) to OMT alone in reducing the risk of cardiovascular events in 2287 patients with stable coronary disease. We examined the cost-effectiveness of PCI as a function of angina severity at the time of randomization.
Methods and Results-Angina severity was assessed with the Seattle Angina Questionnaire (SAQ). Patients were grouped into tertiles based on the distribution of baseline scores such that higher tertiles represented better health status. Clinically significant improvement from baseline within individual patients was defined as score increases of > 8 for physical limitation, > 20 for angina frequency, and > 16 for quality-of-life domains. The incremental cost-effectiveness ratio for PCI was calculated as the difference in costs divided by the difference in proportion of patients with clinically significant improvement. Improvement in angina severity was significantly greater for PCI patients in the lowest and middle tertiles. The number of patients needed to treat was much larger for the highest tertile. The added in-trial cost of PCI ranged from $7300 to $13 000. Incremental cost-effectiveness ratios ranged from $80 000 to $330 000 for the lowest and middle tertiles and from $520 000 to > $3 million for the highest tertile for 1 additional patient to achieve significant clinical improvement in health status.
Conclusions-The incremental cost of PCI to provide meaningful clinical benefit above that achieved by OMT alone was lower for patients with severe angina than for those with mild or no angina. However, it is uncertain that at any level of angina severity that PCI as an initial strategy would achieve a socially acceptable cost threshold.
C1 [Zhang, Zugui; Kolm, Paul; Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Boden, William E.] Western New York Vet Affairs Healthcare Network, Buffalo, NY USA.
[Hartigan, Pamela M.] VA Connecticut Healthcare, Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Spertus, John A.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA.
[O'Rourke, Robert A.] San Antonio Vet Affairs Med Ctr, San Antonio, TX USA.
[Shaw, Leslee J.] Emory Univ, Atlanta, GA 30322 USA.
[Sedlis, Steven P.] NYU, New York, NY USA.
[Sedlis, Steven P.] Vet Affairs New York Harbor Hlth Care Network, New York, NY USA.
[Mancini, G. B. John] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Berman, Daniel S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA.
[Teo, Koon K.] McMaster Univ, Hamilton, ON, Canada.
[Boden, William E.] Kaleida Hlth Syst, Buffalo, NY USA.
RP Zhang, ZG (reprint author), Christiana Care Ctr Outcomes Res, 131 Continental Dr,Ste 202, Newark, DE 19713 USA.
EM zzgfang@hotmail.com
RI Library, Woodruff Health/A-6096-2012
OI Sedlis, Steven/0000-0002-8194-8017
FU Sanofi-Aventis; AstraZeneca; Institutions Network for Biomedical
Research Excellence; Bristol-Myers Squibb; Pfizer; Merck; PDL Biopharma;
Abbott; Cardiovascular Therapeutics; Kos Pharmaceuticals; Novartis; CAD;
United Healthcare; Amgen; Lilly; GlaxoSmithKline; Merck Frosst-Schering
(Canada); Boehringer-Ingelheim; Indigo Pharmaceuticals; Otsuka
FX Dr Kolm reports receiving grant support from Sanofi-Aventis,
AstraZeneca, Institutions Network for Biomedical Research Excellence,
Otsuka, and Bristol-Myers Squibb. Dr Boden reports receiving consulting
fees from Pfizer, Merck, PDL Biopharma, Bristol-Myers Squibb, Abbott,
and Cardiovascular Therapeutics and receiving lecture fees from
Sanofi-Aventis, Kos Pharmaceuticals, and Novartis. Dr Maron reports
receiving fees from reviewing a case for a defendant who recommended
medical therapy for patients with CAD. Dr Spertus reports receiving
consulting fees from Otsuka and United Healthcare and grant support from
Amgen, Bristol-Myers Squibb, Sanofi-Aventis, and Lilly and holds a
copyright to the SAQ. Dr Mancini reports receiving grant support from
GlaxoSmithKline, Pfizer, AstraZeneca, and Merck Frosst-Schering
(Canada). Dr Teo reports receiving grant support from
Boehringer-Ingelheim. Dr Weintraub reports receiving consulting fees
from Sanofi-Aventis, GlaxoSmithKline, Indigo Pharmaceuticals, and
Cardiovascular Therapeutics and receiving grant support from
Sanofi-Aventis, AstraZeneca, Otsuka, and Bristol-Myers Squibb. Drs
Zhang, Hartigan, O'Rourke, Shaw, Sedlis, Berman, Dada, and Weintraub
report no conflicts.
NR 29
TC 7
Z9 7
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAR
PY 2011
VL 4
IS 2
BP 172
EP U72
DI 10.1161/CIRCOUTCOMES.110.940502
PG 22
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 734WN
UT WOS:000288372200008
PM 21304091
ER
PT J
AU Fujitani, S
George, WL
Murthy, AR
AF Fujitani, Shigeki
George, W. Lance
Murthy, A. Rekha
TI Comparison of Clinical Severity Score Indices for Clostridium difficile
Infection
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID HOSPITALIZED-PATIENTS; DISEASE; DIARRHEA; STRAIN; METRONIDAZOLE;
VANCOMYCIN; MORTALITY; EPIDEMIC; OUTBREAK; COLITIS
AB OBJECTIVE. To compare 8 severity score indices for Clostridium difficile infection (CDI).
DESIGN. Prospective observational study.
METHODS. This study was conducted from July through October 2006. All hospitalized patients in 3 university-affiliated hospitals with a positive fecal Clostridium difficile toxin assay result were evaluated. Infection was considered severe if patients had at least 1 of the following clinical events during their hospitalization: (1) death attributed to CDI within 30 days after diagnosis, (2) colectomy necessitated by CDI, or (3) intensive care unit admission for management of complications attributed to CDI. Severity was assessed on the basis of 8 severity score indices, using published criteria for severe CDI as the benchmark. The 8 severity score indices studied were Beth Israel, University of Pittsburgh Medical Center version 1, University of Pittsburgh Medical Center version 2, Hines VA, modified University of Illinois, University of Calgary version 1, University of Calgary version 2, and University of Temple.
RESULTS. Of 184 patients with CDI evaluated, 19 had severe cases and 165 had nonsevere cases, as assessed on the basis of the defined severe CDI criteria. Sensitivities of the 8 severity score indices studied ranged from 63.2% to 84.2%, and specificities ranged from 59.4% to 93.9%. The Hines VA index had the highest kappa score (0.69 [95% confidence interval, 0.54-0.83]), followed by the University of Pittsburgh Medical Center version 1 index. Independent risk factors for severe CDI determined by multivariate analysis were abdominal distention (P=.007), fever (temperature, 38.0 degrees C or above; P=.042), white blood cell count of at least 20,000 cells/mm(3) (P=.035), and hypoalbuminemia (serum albumin level less than 3 mg/dL; P=.029).
CONCLUSION. The Hines VA CDI severity score index appeared to display the strongest correlation for predicting more severe forms of CDI.
C1 [Fujitani, Shigeki] Marianna Univ Hosp, Dept Emergency & Crit Care Med, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan.
[George, W. Lance] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA.
[George, W. Lance; Murthy, A. Rekha] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Murthy, A. Rekha] Cedars Sinai Med Ctr, Div Infect Dis, Dept Hosp Epidemiol, Los Angeles, CA 90048 USA.
RP Fujitani, S (reprint author), Marianna Univ Hosp, Dept Emergency & Crit Care Med, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.
EM shigekifujitani@hotmail.com
NR 20
TC 56
Z9 56
U1 0
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAR
PY 2011
VL 32
IS 3
BP 220
EP 228
DI 10.1086/658336
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 790UH
UT WOS:000292614200004
PM 21460506
ER
PT J
AU Mendez, MF
Shapira, JS
Saul, RE
AF Mendez, Mario F.
Shapira, Jill S.
Saul, Ronald E.
TI The Spectrum of Sociopathy in Dementia
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID VENTROMEDIAL PREFRONTAL CORTEX; ANTISOCIAL PERSONALITY-DISORDER;
POSITRON-EMISSION-TOMOGRAPHY; INCREASED GREY-MATTER; FRONTOTEMPORAL
DEMENTIA; ALZHEIMERS-DISEASE; BRAIN ABNORMALITIES; CONDUCT PROBLEMS;
DECISION-MAKING; MORAL JUDGMENTS
AB Although well-known from head trauma and acute strokes, sociopathic behavior from dementia is less known and understood. This study reviewed 33 dementia patients who had been in trouble with the law. They were divided into two groups: 22 who committed impulsive sociopathic acts and 11 who committed non-impulsive acts. The impulsive patients demonstrated nonviolent acts, such as dis-inhibited sexual behavior or pathological stealing, and had disproportionate frontal-caudate atrophy on neuroimaging. The majority of non-impulsive patients demonstrated agitation-paranoia, sometimes with reactive aggression, delusional beliefs, or aphasic paranoia, and had advanced memory and other cognitive impairment. The impulsive patients tended to have frontally predominant illnesses such as frontotemporal dementia or Huntington's disease, whereas the non-impulsive group tended to have Alzheimer's disease or prominent aphasia. Sociopathy has different causes in dementia. Two common mechanisms are disinhibition, with frontally predominant disease, and agitation-paranoia, with greater cognitive impairment. These forms of sociopathy differ significantly from the antisocial/psychopathic personality. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23: 132-140)
C1 [Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@UCLA.edu
FU NIMH [R01AG034499-02]
FX This work was supported by NIMH Grant # R01AG034499-02.
NR 69
TC 9
Z9 10
U1 6
U2 16
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD SPR
PY 2011
VL 23
IS 2
BP 132
EP 140
PG 9
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 777VF
UT WOS:000291652500127
PM 21677240
ER
PT J
AU Yeh, B
Ferrucci, S
AF Yeh, Brenda
Ferrucci, Steven
TI Retinal pigment epithelium tears after bevacizumab injection
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Avastin; Choroidal
neovascularization (CNV); Vascular endothelial growth factor; Pigment
epithelial detachment; Retinal pigment epithelial tear
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION SECONDARY;
INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION; RANIBIZUMAB THERAPY;
LASER TREATMENT; DETACHMENT; AVASTIN; PATHOGENESIS; PREDICTORS
AB BACKGROUND: The advent of anti-vascular endothelial growth factor (VEGF) treatment for choroidal neovascularization has become the standard of care for wet age-related macular degeneration (AMD). Among the choices, intravitreal bevacizumab, for off-label use, has gained popularity. Recent attention has been on the complications of anti-VEGF treatment, one of them being a retinal pigment epithelial (RPE) tear. A tear in the RPE is a visually devastating complication, most commonly associated with fibrovascular pigment epithelial detachments (PED) in AMD, and may develop during the course of intravitreal bevacizumab treatment.
CASE REPORT: We report a case of an 85-year-old white man with decreased visual acuities of 20/70 in the right eye (O.D.) and 20/150 in the left eye (O.S.) secondary to dry AMD O.D. and wet AMD with a fibrovascular PED O.S. The patient underwent treatment with an intravitreal bevacizumab injection O.S. Six weeks after the initial injection, the patient returned with further declining vision in the left eye secondary to an RPE tear.
CONCLUSION: Intravitreal bevacizumab has proven to be an effective treatment for choroidal neovascularization and shows a significant improvement of vision for wet AMD patients. However, there are risks associated with the procedure. One of the most visually significant is an RPE tear, which can occur at an incidence rate as high as 17%. Optometrists should be aware of this rare, but serious, complication associated with anti-VEGF treatment for wet AMD. Optometry 2011;82:152-157
C1 [Yeh, Brenda; Ferrucci, Steven] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Yeh, Brenda; Ferrucci, Steven] Sepulveda Vet Affairs Ambulatory Care Ctr Nursing, Sepulveda, CA USA.
[Ferrucci, Steven] So Calif Coll Optometry, Fullerton, CA USA.
RP Ferrucci, S (reprint author), Sepulveda Vet Affairs Ambulatory Care Ctr, 16111 Plummer St 112E, Sepulveda, CA 91343 USA.
EM Steven.Ferrucci@va.gov
NR 44
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-1839
J9 OPTOMETRY
JI Optometry
PD MAR
PY 2011
VL 82
IS 3
BP 152
EP 157
DI 10.1016/j.optm.2010.09.010
PG 6
WC Ophthalmology
SC Ophthalmology
GA 778MO
UT WOS:000291708600006
PM 21130699
ER
PT J
AU Shahlaie, K
Larson, PS
Starr, PA
AF Shahlaie, Kiarash
Larson, Paul S.
Starr, Philip A.
TI Intraoperative Computed Tomography for Deep Brain Stimulation Surgery:
Technique and Accuracy Assessment
SO NEUROSURGERY
LA English
DT Article
DE Computed tomography; Deep brain stimulation; Intraoperative imaging;
Lead location; Neuronavigation
ID SUBTHALAMIC NUCLEUS; ELECTRODE PLACEMENT; PARKINSONS-DISEASE;
LOCALIZATION; IMPLANTATION; CANCER; EXPERIENCE; LOCATIONS; OUTCOMES;
SHIFT
AB BACKGROUND: The efficacy of deep brain stimulation (DBS) is highly dependent on the accuracy of lead placement.
OBJECTIVE: To describe the use of intraoperative computed tomography (iCT) to confirm lead location before surgical closure and to study the accuracy of this technique.
METHODS: Fifteen patients underwent awake microelectrode-guided DBS surgery in a stereotactic frame. A portable iCT scanner (Medtronic O-arm) was positioned around the patient's head throughout the procedure and was used to confirm lead location before fixation of the lead to the skull. Images were computationally fused with pre-operative magnetic resonance imaging (MRI), and lead tip coordinates with respect to the midpoint of the anterior commissure-posterior commissure line were measured. Tip coordinates were compared with those obtained from postoperative MRI.
RESULTS: iCT was integrated into standard frame-based microelectrode-guided DBS surgery with a minimal increase in surgical time or complexity. Technically adequate 2-dimensional and 3-dimensional images were obtained in all cases. Head positioning and fixation techniques that allow unobstructed imaging are described. Lead tip measurements on iCT fused with preoperative MRI were statistically indistinguishable from those obtained with postoperative MRI.
CONCLUSION: iCT can be easily incorporated into standard DBS surgery, replaces the need for C-arm fluoroscopy, and provides accurate intraoperative 3-dimensional confirmation of electrode tip locations relative to preoperative images and surgical plans. iCT fused to preoperative MRI may obviate the need for routine postoperative MRI in DBS surgery. Technical nuances that must be mastered for the efficient use of iCT during DBS implantation are described.
C1 [Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA USA.
RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,Box 0445, San Francisco, CA 94143 USA.
EM starrp@neurosurg.ucsf.edu
NR 25
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD MAR
PY 2011
VL 68
SU 1
AR ons114
DI 10.1227/NEU.0b013e31820781bc
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 773KU
UT WOS:000291307000032
ER
PT J
AU Ahmadi, N
Nabavi, V
Hajsadeghi, F
Flores, F
Azmoon, S
Ismaeel, H
Shavelle, D
Mao, SS
Ebrahimi, R
Budoff, MJ
AF Ahmadi, Naser
Nabavi, Vahid
Hajsadeghi, Fereshteh
Flores, Ferdinand
Azmoon, Shahdad
Ismaeel, Hussain
Shavelle, David
Mao, Song S.
Ebrahimi, Ramin
Budoff, Matthew J.
TI Impaired aortic distensibility measured by computed tomography is
associated with the severity of coronary artery disease
SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
LA English
DT Article
DE Aortic distensibility index; Computed tomographic angiography; Coronary
artery calcium score; 2D Trans-thoracic echocardiography
ID HEART-DISEASE; ENDOTHELIAL DYSFUNCTION; ELASTIC PROPERTIES;
CLINICAL-PRACTICE; PROGNOSTIC VALUE; III GUIDELINES; ELECTRON-BEAM;
SMOOTH-MUSCLE; STIFFNESS; ATHEROSCLEROSIS
AB Impaired aortic distensibility index (ADI) is associated with cardiovascular risk factors. This study evaluates the relation of ADI measured by computed tomographic angiography (CTA) with the severity of coronary atherosclerosis in subjects with suspected coronary artery disease (CAD). Two hundred and twenty-nine subjects,age 63 +/- A 9 years, 42% female, underwent coronary artery calcium (CAC) scanning and CTA, and their ADI and Framingham risk score (FRS) were measured. End-systolic and end-diastolic (ED) cross-sectional-area(CSA) of ascending-aorta (AAo) was measured 15-mm above the left-main coronary ostium. ADI was defined as: [(Delta lumen-CSA)/(lumen-CSA in ED x systemic-pulse-pressure) x 10(3)]. ADI measured by 2D-trans-thoracic echocardiography (TTE) was compared with CTA-measured ADI in 26 subjects without CAC. CAC was defined as 0, 1-100, 101-400 and 400+. CAD was defined as luminal stenosis 0, 1-49% and 50%+. There was an excellent correlation between CTA- and TTE-measured ADI (r (2) = 0.94, P = 0.0001). ADI decreased from CAC 0 to CAC 400+; similarly from FRS 1-9% to FRS 20% + (P < 0.05). After adjustment for risk factors, the relative risk for each standard deviation decrease in ADI was 1.66 for CAC 1-100, 2.26 for CAC 101-400 and 2.32 for CAC 400+ as compared to CAC 0; similarly, 2.36 for non-obstructive CAD and 2.67 for obstructive CAD as compared to normal coronaries. The area under the ROC-curve to predict significant CAD was 0.68 for FRS, 0.75 for ADI, 0.81 for CAC and 0.86 for the combination (P < 0.05). Impaired aortic distensibility strongly correlates with the severity of coronary atherosclerosis. Addition of ADI to CAC and traditional risk factors provides incremental value to predict at-risk individuals.
C1 [Ahmadi, Naser; Nabavi, Vahid; Hajsadeghi, Fereshteh; Flores, Ferdinand; Ismaeel, Hussain; Mao, Song S.; Budoff, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA.
[Ebrahimi, Ramin] Univ Calif Los Angeles, Sch Med, Greater Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Shavelle, David] Univ So Calif, Los Angeles, CA USA.
[Azmoon, Shahdad] New York Med Coll, Valhalla, NY 10595 USA.
RP Ahmadi, N (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St,RB2, Torrance, CA 90502 USA.
EM nahmadi@labiomed.org
NR 52
TC 14
Z9 15
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1569-5794
J9 INT J CARDIOVAS IMAG
JI Int. J. Cardiovasc. Imaging
PD MAR
PY 2011
VL 27
IS 3
BP 459
EP 469
DI 10.1007/s10554-010-9680-6
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 762OU
UT WOS:000290490100017
PM 20711815
ER
PT J
AU Weintraub, D
Morgan, JC
AF Weintraub, Daniel
Morgan, John C.
TI Both the Body and Brain Benefit from Exercise: Potential Win-Win for
Parkinson's Disease Patients
SO MOVEMENT DISORDERS
LA English
DT Editorial Material
ID COGNITIVE IMPAIRMENT; HIPPOCAMPAL; DEMENTIA
C1 [Weintraub, Daniel] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Morgan, John C.] Georgia Hlth Sci Univ, Augusta, GA USA.
RP Weintraub, D (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RI AUDIFFREN, MICHEL/H-5649-2011
NR 10
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2011
VL 26
IS 4
BP 607
EP 607
DI 10.1002/mds.23726
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 762AO
UT WOS:000290444800008
PM 21506145
ER
PT J
AU Gallagher, CL
Oakes, TR
Johnson, SC
Chung, MK
Holden, JE
Bendlin, BB
McLaren, DG
Xu, GF
Nickles, RJ
Pyzalski, R
DeJesus, O
Brown, WD
AF Gallagher, Catherine L.
Oakes, Terrence R.
Johnson, Sterling C.
Chung, Moo K.
Holden, James E.
Bendlin, Barbara B.
McLaren, Donald G.
Xu, Guofan
Nickles, Robert J.
Pyzalski, Robert
DeJesus, Onofre
Brown, W. Douglas
TI Rate of 6-[18F]Fluorodopa Uptake Decline in Striatal Subregions in
Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; Fluorodopa positron emission tomography; disease
progression; aging; gender
ID POSITRON-EMISSION-TOMOGRAPHY; BRAIN TRANSFER CONSTANTS; TIME UPTAKE
DATA; GRAPHICAL EVALUATION; DOPAMINE TURNOVER; CLINICAL-TRIALS;
PROGRESSION; PET; LEVODOPA
AB Background: Rate of decline in 6-L[(18)F]fluorodopa (FDOPA) uptake within the striatum has been reported as showing regional differences in Parkinson's disease (PD).
Methods: We acquired longitudinal brain FDOPA positron emission tomography (PET) studies in 26 PD subjects and 11 controls over 4.5 years. We analyzed both spatially normalized voxel-wise maps of radiotracer influx (Kocc) and average Kocc values for six non-overlapping volumes of interest (VOIs) encompassing the striatum.
Results: The voxel-wise analysis showed that in PD, FDOPA Kocc decline spanned the striatum but was greatest in the posterior putamen ipsilateral and anterior putamen contralateral to initial symptoms. The VOI approached showed that absolute rates of Kocc decline were significantly greater in PD than control subjects, but that the slope of decline did not differ between subregions. In PD, ratios of uptake between subregions did not change during the study with the exception of the ipsilateral putamen/caudate ratio. Decline rates were marginally greater during earlier time segments. Both male gender and advancing age were associated with lower baseline FDOPA uptake, but no difference in decline rates. VOI Kocc values were significantly correlated with disease duration, but only moderately correlated with clinical measures.
Discussion: We conclude that FDOPA uptake in subregions of the striatum is strongly correlated with disease duration and age, and declines approximately equally from symptom onset in PD. This implies that in idiopathic PD, relative preservation of uptake in the anterior striatum reflects a delay in pathologic involvement of nigrostriatal projections to this region. (C)2011 Movement Disorder Society
C1 [Gallagher, Catherine L.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Gallagher, Catherine L.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Oakes, Terrence R.; Chung, Moo K.] Univ Wisconsin, Waisman Ctr Brain Imaging Lab, Madison, WI USA.
[Johnson, Sterling C.; Bendlin, Barbara B.; Xu, Guofan] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Johnson, Sterling C.; Bendlin, Barbara B.; McLaren, Donald G.; Xu, Guofan] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Chung, Moo K.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
[Holden, James E.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA.
[McLaren, Donald G.; Nickles, Robert J.; DeJesus, Onofre] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA.
[Pyzalski, Robert] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA.
[Brown, W. Douglas] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA.
RP Gallagher, CL (reprint author), William S Middleton VA Hosp, 6112B,2500 Overlook Terrace Dr, Madison, WI 53792 USA.
EM gallagher@neurology.wisc.edu
RI McLaren, Donald/G-9906-2011
OI Bendlin, Barbara/0000-0002-0580-9875; Johnson,
Sterling/0000-0002-8501-545X
FU William S. Middleton Memorial Veterans Hospital Geriatric Research
Education and Clinical Center; Waisman Laboratory for Brain Imaging and
Behavior, Madison, WI, USA
FX This work was supported with use of facilities at the William S.
Middleton Memorial Veterans Hospital Geriatric Research Education and
Clinical Center, and the Waisman Laboratory for Brain Imaging and
Behavior, Madison, WI, USA. Figure preparation by Jennifer Broihahn,
University of Wisconsin Department of Neurology Media Specialist.
NR 31
TC 6
Z9 6
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR
PY 2011
VL 26
IS 4
BP 614
EP 620
DI 10.1002/mds.23503
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 762AO
UT WOS:000290444800010
PM 21449008
ER
PT J
AU Byers, AL
Vittinghoff, E
Lui, LY
Hoang, T
Covinsky, KE
Cauley, JA
Ensrud, KE
Hillier, TA
Fredman, L
Yaffe, K
AF Byers, Amy L.
Vittinghoff, Eric
Lui, Li-Yung
Hoang, Tina
Covinsky, Kenneth E.
Cauley, Jane A.
Ensrud, Kristine E.
Hillier, Teresa A.
Fredman, Lisa
Yaffe, Kristine
TI Characterization of Long-term Depressive Trajectories Among Elderly
Women
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Vittinghoff, Eric; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Byers, Amy L.; Hoang, Tina; Covinsky, Kenneth E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Ensrud, Kristine E.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Fredman, Lisa] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Lui, Li-Yung] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S104
EP S105
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000117
ER
PT J
AU Calleo, JS
Bush, A
Kraus-Schuman, C
Snow, L
Wilson, N
Kunik, ME
Pauker, A
Stanley, MA
AF Calleo, Jessica S.
Bush, Amy
Kraus-Schuman, Cynthia
Snow, Lynn
Wilson, Nancy
Kunik, Mark E.
Pauker, Amber
Stanley, Melinda A.
TI Clinical Characteristics and Associated Anxiety Symptoms in Anxious
Patients with Dementia
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Calleo, Jessica S.; Bush, Amy; Wilson, Nancy; Kunik, Mark E.; Stanley, Melinda A.] Houston VA HSR&D Ctr Excellence, Houston, TX USA.
[Kraus-Schuman, Cynthia; Kunik, Mark E.] Michael E Debakay Vet Affairs Med Ctr, Houston, TX USA.
[Calleo, Jessica S.; Bush, Amy; Wilson, Nancy; Stanley, Melinda A.] Baylor Coll Med, Houston, TX 77030 USA.
[Snow, Lynn] Univ Alabama, Tuscaloosa, AL USA.
[Pauker, Amber] Puget Sound Hlth Care Syst, Dept Vet Affairs, Seatle, WA USA.
[Snow, Lynn] Tuscaloosa Vet Affairs Med Ctr, Tuscaloosa, AL USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S79
EP S80
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000084
ER
PT J
AU Calleo, JS
York, M
Bush, A
Wilson, N
Kraus-Schuman, C
Kunik, ME
Stanley, MA
AF Calleo, Jessica S.
York, Michele
Bush, Amy
Wilson, Nancy
Kraus-Schuman, Cynthia
Kunik, Mark E.
Stanley, Melinda A.
TI Problem Solving Confidence and Executive Functioning in Older Adults
with Generalized Anxiety Disorder
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Calleo, Jessica S.; York, Michele; Bush, Amy; Wilson, Nancy; Kraus-Schuman, Cynthia; Kunik, Mark E.; Stanley, Melinda A.] Baylor Coll Med, Houston, TX 77030 USA.
[Calleo, Jessica S.; York, Michele; Kraus-Schuman, Cynthia] Michael E Debakay Vet Affairs Med Ctr, Houston, TX USA.
[Bush, Amy; Wilson, Nancy; Kunik, Mark E.; Stanley, Melinda A.] Houston VA HRS&D Ctr Excellence, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S65
EP S66
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000063
ER
PT J
AU Chu, SH
Ferrell, R
Roeder, K
Devlin, B
DeMichele-Sweet, MAA
Lopez, OL
Sweet, RA
AF Chu, Su H.
Ferrell, Robert
Roeder, Kathryn
Devlin, Bernie
DeMichele-Sweet, Mary Ann A.
Lopez, Oscar L.
Sweet, Robert A.
TI TOMM40 Poly-T Repeat Length Polymorphism is Independently Associated
with Psychosis Risk, But Not Age of Onset, in Late Onset Alzheimer
Disease
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Chu, Su H.; Roeder, Kathryn] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
[Ferrell, Robert; Devlin, Bernie; DeMichele-Sweet, Mary Ann A.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Pittsburgh, PA USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S125
EP S125
PG 1
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000149
ER
PT J
AU Espinoza, R
Jarvik, L
Read, S
Kaufman, AH
AF Espinoza, Randall
Jarvik, Lissy
Read, Stephen
Kaufman, Aaron H.
TI EDUCATING THE NEXT GENERATION OF PHYSICIANS IN GERIATRIC PSYCHIATRY
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Espinoza, Randall; Kaufman, Aaron H.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Jarvik, Lissy; Read, Stephen] Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S9
EP S9
PG 1
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000003
ER
PT J
AU Feil, D
Rajan, M
Soroka, O
Miller, DR
Pogach, L
AF Feil, Denise
Rajan, Mangala
Soroka, Orysya
Miller, Donald R.
Pogach, Leonard
TI Increased Risk of Hypoglycemia in Older Patients with Dementia and
Cognitive Impairment: Is More Intensive Glycemic Control at the Expense
of Safety?
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Feil, Denise] W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Feil, Denise; Rajan, Mangala; Soroka, Orysya; Miller, Donald R.; Pogach, Leonard] East Orange REAP, E Orange, NJ USA.
[Miller, Donald R.] Bedford VA Ctr Hlth Outcomes, Bedford, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S114
EP S114
PG 1
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000133
ER
PT J
AU Kasckow, J
Brown, C
Morse, J
Begley, A
Bensasi, S
Reynolds, C
AF Kasckow, John
Brown, Charlotte
Morse, Jennifer
Begley, Amy
Bensasi, Salem
Reynolds, Charles
TI Comorbidity in Older Subsyndromally Depressed Participants Presenting
for a Depression Prevention
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
[Kasckow, John; Brown, Charlotte; Morse, Jennifer; Begley, Amy; Bensasi, Salem; Reynolds, Charles] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S106
EP S107
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000119
ER
PT J
AU Kasckow, J
Cohen, CI
Vahia, I
Jeste, DV
AF Kasckow, John
Cohen, Carl I.
Vahia, Ipsit
Jeste, Dilip V.
TI LATE LIFE SCHIZOPHRENIA: RECENT ADVANCES
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
[Kasckow, John] UPMC Western Psychiat Inst & Clin, Pittsburgh, PA USA.
[Vahia, Ipsit; Jeste, Dilip V.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Cohen, Carl I.] Suny Downstate Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S26
EP S27
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000028
ER
PT J
AU Lewis, MS
Huege, S
Boyle, LL
Harmon, AA
AF Lewis, Monica S.
Huege, Steven
Boyle, Lisa L.
Harmon, Ashley A.
TI THE NEW FRONTIER: MOVING GERIATRIC PSYCHIATRY FELLOWSHIP TRAINING INTO
COMMUNITY INTERDISCIPLINARY SETTINGS
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Lewis, Monica S.; Huege, Steven] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Boyle, Lisa L.; Harmon, Ashley A.] Univ Rochester, Sch Med & Dent, Rochester, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S13
EP S13
PG 1
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000009
ER
PT J
AU Peters, ME
Vaidya, V
Drye, LT
Rosenberg, P
Martin, BK
Porsteinsson, AP
Frangakis, CE
Mintzer, J
Weintraub, D
Schneider, LS
Rabins, PV
Munro, CA
Meinert, CL
Lyketsos, C
Avramopoulos, D
AF Peters, Matthew E.
Vaidya, Vijay
Drye, Lea T.
Rosenberg, Paul
Martin, Barbara K.
Porsteinsson, Anton P.
Frangakis, Constantine E.
Mintzer, Jacobo
Weintraub, Daniel
Schneider, Lon S.
Rabins, Peter V.
Munro, Cynthia A.
Meinert, Curtis L.
Lyketsos, Constantine
Avramopoulos, Dimitrios
TI Sertraline for the Treatment of Depression in Alzheimer's Disease:
Genetic Influences
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Peters, Matthew E.; Vaidya, Vijay; Drye, Lea T.; Rosenberg, Paul; Martin, Barbara K.; Frangakis, Constantine E.; Rabins, Peter V.; Munro, Cynthia A.; Meinert, Curtis L.; Lyketsos, Constantine; Avramopoulos, Dimitrios] Johns Hopkins Univ, Baltimore, MD USA.
[Porsteinsson, Anton P.] Univ Rochester, Rochester, NY USA.
[Mintzer, Jacobo] Med Univ S Carolina, Charleston, SC 29425 USA.
[Weintraub, Daniel] Philadelphia Veteran Affairs Med Ctr, Philadelphia, PA USA.
[Schneider, Lon S.] Univ So Calif, Los Angeles, CA USA.
RI Avramopoulos, Dimitrios/J-4392-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S67
EP S68
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000066
ER
PT J
AU Royall, DR
Cordes, JA
AF Royall, Donald R.
Cordes, Jeffrey A.
TI LEWY BODY DISEASE: THE UNDISCOVERED COUNTRY
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Royall, Donald R.] UTHSCSA, San Antonio, TX USA.
[Cordes, Jeffrey A.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S39
EP S39
PG 1
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000045
ER
PT J
AU Seney, M
Devlin, B
Ferrell, R
Klei, L
Lopez, OL
Seltman, H
Sibille, E
Sweet, RA
AF Seney, Marianne
Devlin, Bernie
Ferrell, Robert
Klei, Lambertus
Lopez, Oscar L.
Seltman, Howard
Sibille, Etienne
Sweet, Robert A.
TI Association of NRG1 Genetic Variants with Psychosis in Alzheimer Disease
and with Brain Expression of Neuregulin Isoforms
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Seney, Marianne; Devlin, Bernie; Ferrell, Robert; Klei, Lambertus; Lopez, Oscar L.; Sibille, Etienne; Sweet, Robert A.] Univ Pittsburgh, Pittsburgh, PA USA.
[Sweet, Robert A.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
[Seltman, Howard] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S125
EP S126
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000150
ER
PT J
AU Spira, AP
Rebok, GW
Stone, KL
Kramer, JH
Yaffe, K
AF Spira, Adam P.
Rebok, George W.
Stone, Katie L.
Kramer, Joel H.
Yaffe, Kristine
TI Depressive Symptoms in Oldest-Old Women: Risk of Mild Cognitive
Impairment and Dementia
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Spira, Adam P.; Rebok, George W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Stone, Katie L.] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA.
[Kramer, Joel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S56
EP S57
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000055
ER
PT J
AU Sultzer, D
Melrose, RJ
Harwood, DG
Campa, O
Walston, A
Narvaez, T
Ando, T
Leskin, LS
Mandelkern, MA
AF Sultzer, David
Melrose, Rebecca J.
Harwood, Dylan G.
Campa, Olivia
Walston, Amy
Narvaez, Theresa
Ando, Timothy
Leskin, Lorraine S.
Mandelkern, Mark A.
TI Donepezil Treatment Effects on Regional Cortical Metabolism in
Alzheimer's Disease: FDG-PET Findings
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Sultzer, David; Melrose, Rebecca J.; Harwood, Dylan G.; Campa, Olivia; Walston, Amy; Narvaez, Theresa; Ando, Timothy; Leskin, Lorraine S.; Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Sultzer, David; Melrose, Rebecca J.; Harwood, Dylan G.; Walston, Amy] UCLA Dept Psychiat & Biobehav Sci, Los Angeles, CA USA.
[Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S124
EP S125
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000148
ER
PT J
AU Threlfall, AW
Nie, PH
Moreno, A
Young, JQ
Nelson, C
AF Threlfall, Alexander W.
Nie, Pei-Huey
Moreno, Arnaldo
Young, John Q.
Nelson, Craig
TI From Academia to the Community: a Proposed Library for Use in
Disseminating Evidenced Based Medicine into Underserved Areas of
Geriatric Psychiatry
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry
CY MAR 18-21, 2011
CL San Antonio, TX
SP Amer Assoc Geriat Psychiat
C1 [Threlfall, Alexander W.; Nie, Pei-Huey; Moreno, Arnaldo; Young, John Q.; Nelson, Craig] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Moreno, Arnaldo] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
SU 1
BP S81
EP S82
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 753PD
UT WOS:000289791000086
ER
PT J
AU Sharp, ZD
Richardson, A
AF Sharp, Zelton Dave
Richardson, Arlan
TI Aging and cancer: can mTOR inhibitors kill two birds with one drug?
SO TARGETED ONCOLOGY
LA English
DT Review
DE mTORC1; Aging and cancer; Health span
ID LIFE-SPAN EXTENSION; MESSENGER-RNA TRANSLATION; AMES DWARF MICE; FATAL
NEOPLASTIC DISEASES; EIF2-ALPHA KINASE GCN2; CALORIE RESTRICTION;
DIETARY RESTRICTION; GROWTH-HORMONE; C-ELEGANS; SACCHAROMYCES-CEREVISIAE
AB The main risk factor for a number of diseases, including cancer, is aging. By delaying the effects of aging, many years of research indicate that diseases associated with aging are reduced by prolongevity interventions such as reductions in caloric intake and mice genetically deficient for growth factors. Although studies of dietary and growth factor restriction have been highly informative regarding the aging process, they are both unrealistic for human application. Recent preclinical results with a pharmacological prolongevity agent (rapamycin) provide a proof-of-concept that such an approach is feasible in human populations. Exactly how rapamycin works to extend lifespan is under increasingly intense investigation. In addition, these studies underscore the critical role that the intracellular target of rapamycin (TOR) plays in one of the deepest mysteries of life, aging. How age-associated diseases interface with TOR and its signaling systems, and the tremendous opportunities for discovery of new drugs that target both aging and its associated diseases is one of the most exciting areas of research currently being conducted in this new era of aging research.
C1 [Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA.
[Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Sharp, ZD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA.
EM sharp@uthscsa.edu
FU National Institutes of Health (NIH) [AG036613, AG13319]; Glenn
Foundation; Department of Veterans Affairs
FX Work in Z. D. Sharp's laboratory is supported by a RC2 Grand Opportunity
grant (AG036613) from the National Institutes of Health (NIH) and by the
Glenn Foundation, and work in A. Richardson's laboratory supported by a
RC2 Grand Opportunity (AG036613) and a P30-Shock Center of Excellence in
Basic Biology of Aging (AG13319) grants from the NIH and a Research
Enhancement Award Program grant from the Department of Veterans Affairs.
NR 121
TC 15
Z9 15
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1776-2596
J9 TARGET ONCOL
JI Target. Oncol.
PD MAR
PY 2011
VL 6
IS 1
BP 41
EP 51
DI 10.1007/s11523-011-0168-7
PG 11
WC Oncology
SC Oncology
GA 760KQ
UT WOS:000290323600005
PM 21394528
ER
PT J
AU Walther, K
Bendlin, BB
Glisky, EL
Trouard, TP
Lisse, JR
Posever, JO
Ryan, L
AF Walther, K.
Bendlin, B. B.
Glisky, E. L.
Trouard, T. P.
Lisse, J. R.
Posever, J. O.
Ryan, L.
TI Anti-inflammatory drugs reduce age-related decreases in brain volume in
cognitively normal older adults
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Aging; Alzheimer's disease; Voxel-based morphometry; Magnetic resonance
imaging; Anti-inflammatory agents
ID RANDOMIZED CONTROLLED-TRIAL; VOXEL-BASED MORPHOMETRY;
ALZHEIMERS-DISEASE; NSAID USE; RISK; MRI; DEMENTIA; ATROPHY; APOE;
INFLAMMATION
AB Previous studies have indicated a decreased risk for developing Alzheimer's disease in anti-inflammatory (AI) drug users. Yet few studies have determined whether AT drug use provides a protective effect against normal age-related changes in the brains of older adults. Regional volume changes in gray and white matter were assessed cross-sectionally using optimized voxel-based morphometry in 36 females taking AT drugs as arthritis or pain medication and 36 age- and education-matched female controls. Although mean gray and white matter volume differences between AT drug users and the non-AI group were small, AT drug use interacted with age, such that the non-AI group showed significantly greater age-related volume changes in regions of both gray and white matter compared to the AT drug users. These regions included the superior and medial frontal gyri, middle and inferior temporal gyri, fusiform and parahippocampal gyri, and occipital gray matter as well as temporal, parietal, and midbrain white matter. The results are consistent with the notion that AT drugs provide protection against age-related changes in brain volume. It is possible that inflammation plays a role in volume decreases associated with normal aging, and that suppressing the inflammatory response moderates this decrease. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Walther, K.; Glisky, E. L.; Ryan, L.] Univ Arizona, Dept Psychol, Cognit Lab, Tucson, AZ 85721 USA.
[Walther, K.; Glisky, E. L.; Ryan, L.] Univ Arizona, Dept Psychol, Neuroimaging Lab, Tucson, AZ 85721 USA.
[Bendlin, B. B.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53705 USA.
[Bendlin, B. B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
[Trouard, T. P.] Univ Arizona, Biomed Engn Program, Tucson, AZ 85721 USA.
[Lisse, J. R.] Univ Arizona, Coll Med, Arizona Arthrit Ctr, Tucson, AZ 85724 USA.
[Posever, J. O.] Phoenix Indian Med Ctr, Phoenix, AZ 85016 USA.
RP Ryan, L (reprint author), Univ Arizona, Dept Psychol, Cognit Lab, POB 210068, Tucson, AZ 85721 USA.
EM ryant@email.arizona.edu
OI Bendlin, Barbara/0000-0002-0580-9875
FU Arizona Biomedical Research Commission; Arizona Alzheimer's Research
Consortium [HB 2354]; Evelyn F. McKnight Brain Institute
FX The project was supported by the Arizona Biomedical Research Commission,
the Arizona Alzheimer's Research Consortium (HB 2354, Dept. of Health
Services, Arizona), and the Evelyn F. McKnight Brain Institute. We would
like to thank the Arizona Arthritis Center at the University Medical
Center in Tucson, Arizona for their cooperation and support. We thank
Ms. Kristina Irwin for coordinating and administering neuropsychological
testing.
NR 43
TC 15
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2011
VL 32
IS 3
BP 497
EP 505
DI 10.1016/j.neurobiolaging.2009.03.006
PG 9
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 755PE
UT WOS:000289944800013
PM 19386384
ER
PT J
AU Bekris, LM
Galloway, NM
Millard, S
Lockhart, D
Li, G
Galasko, DR
Farlow, MR
Clark, CM
Quinn, JF
Kaye, JA
Schellenberg, GD
Leverenz, JB
Seubert, P
Tsuang, DW
Peskind, ER
Yu, CE
AF Bekris, L. M.
Galloway, N. M.
Millard, S.
Lockhart, D.
Li, G.
Galasko, D. R.
Farlow, M. R.
Clark, C. M.
Quinn, J. F.
Kaye, J. A.
Schellenberg, G. D.
Leverenz, J. B.
Seubert, P.
Tsuang, D. W.
Peskind, E. R.
Yu, C. E.
TI Amyloid precursor protein (APP) processing genes and cerebrospinal fluid
APP cleavage product levels in Alzheimer's disease
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE APP; ADAM10; BACE1; BACE2; PSEN1; PSEN2; PEN2; NCSTN; APH1B;
Alzheimer's; Cerebrospinal fluid
ID MILD COGNITIVE IMPAIRMENT; GAMMA-SECRETASE COMPLEX; ALPHA-SECRETASE;
MOUSE MODEL; CLINICAL-DIAGNOSIS; PLAQUE-FORMATION; SENILE PLAQUES;
DOWN-SYNDROME; TAU PROTEINS; IN-VIVO
AB The aim of this exploratory investigation was to determine if genetic variation within amyloid precursor protein (APP) or its processing enzymes correlates with APP cleavage product levels: APP alpha, APP beta or A beta 42, in cerebrospinal fluid (CSF) of cognitively normal subjects or Alzheimer's disease (AD) patients. Cognitively normal control subjects (n = 170) and AD patients (n = 92) were genotyped for 19 putative regulatory tagging SNPs within 9 genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN and APH1B) involved in the APP processing pathway. SNP genotypes were tested for their association with CSF APP alpha, APP beta, and A beta 42. AD risk and age-at-onset while taking into account age, gender, race and APOE epsilon 4. After adjusting for multiple comparisons, a significant association was found between ADAM10 SNP rs514049 and APP alpha levels. In controls, the rs514049 CC genotype had higher APP alpha levels than the CA, AA collapsed genotype, whereas the opposite effect was seen in AD patients. These results suggest that genetic variation within ADAM10, an APP processing gene, influences CSF APP alpha levels in an AD specific manner. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Bekris, L. M.; Galloway, N. M.; Yu, C. E.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Bekris, L. M.; Yu, C. E.] Univ Washington, Dept Med, Seattle, WA USA.
[Millard, S.; Lockhart, D.; Leverenz, J. B.; Tsuang, D. W.; Peskind, E. R.] VA Puget Sound Hlth Care Syst, MIRECC, NW Network VISN 20, Seattle, WA USA.
[Li, G.; Leverenz, J. B.; Tsuang, D. W.; Peskind, E. R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Galasko, D. R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Galasko, D. R.] VA Med Ctr, San Diego, CA USA.
[Farlow, M. R.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Clark, C. M.] Univ Penn, Dept Neurol, Inst Aging, Philadelphia, PA 19104 USA.
[Quinn, J. F.; Kaye, J. A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Leverenz, J. B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Seubert, P.] Elan Pharmaceut, San Francisco, CA USA.
[Schellenberg, G. D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
RP Bekris, LM (reprint author), VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
EM lbekris@u.washington.edu
RI ; Tsuang, Debby/L-7234-2016
OI Kaye, Jeffrey/0000-0002-9971-3478; Tsuang, Debby/0000-0002-4716-1894
FU US Department of Veterans Affairs; Biomedical Laboratory; NIH
[1K99AGO34214-01A1, 2P50AG005136-27, 1P50NS062684-01A1]; University of
Washington Alzheimer's Disease Research Center NIH [NIH P50-AG005136];
University of California, San Diego Alzheimer's disease Research Center
[P50AGOO5131-27]
FX This work is supported in part by the US Department of Veterans Affairs,
Office of Research and Development Clinical Research and Development
Program, the Biomedical Laboratory Research Program and NIH grants
1K99AGO34214-01A1, 2P50AG005136-27 and 1P50NS062684-01A1. Additional
support includes University of Washington Alzheimer's Disease Research
Center NIH P50-AG005136 and University of California, San Diego
Alzheimer's disease Research Center P50AGOO5131-27.
NR 74
TC 4
Z9 4
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2011
VL 32
IS 3
AR 556.e13
DI 10.1016/j.neurobiolaging.2010.10.020
PG 11
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 755PE
UT WOS:000289944800048
PM 21196064
ER
PT J
AU DeMichele-Sweet, MAA
Klei, L
Devlin, B
Ferrell, RE
Weamer, EA
Emanuel, JE
Lopez, OL
Sweet, RA
AF DeMichele-Sweet, Mary Ann A.
Klei, Lambertus
Devlin, Bernie
Ferrell, Robert E.
Weamer, Elise A.
Emanuel, James E.
Lopez, Oscar L.
Sweet, Robert A.
TI No association of psychosis in Alzheimer disease with neurodegenerative
pathway genes
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Alzheimer's disease; Psychosis; Amyloid precursor protein (APP);
Beta-site amyloid precursor protein cleaving enzyme (BACE1);
Sortilin-related receptor (SORL1); Microtubule-associated protein tau
(MAPT); Apolipoprotein E e4 (APOE e4)
AB Psychotic symptoms occur in approximately 40% of subjects with Alzheimer disease (AD with psychosis; AD + P) and identify a subgroup with more rapid cognitive decline. We evaluated in 867 AD subjects the association of AD + P with genes which may modify the pathological process via effects on the accumulation of amyloid beta (A beta) protein and/or hyperphosphorylated microtubule-associated protein tau (MAPT): amyloid precursor protein (APP), beta-site amyloid precursor protein cleaving enzyme (BACE1), sortilin-related receptor (SORL1), and MAPT. Each gene was thoroughly interrogated with tag single-nucleotide polymorphisms (SNPs), and gene-based tests were used to enhance power. We found no association of these genes with AD + P. (C) 2011 Elsevier Inc. All rights reserved.
C1 [DeMichele-Sweet, Mary Ann A.; Klei, Lambertus; Devlin, Bernie; Weamer, Elise A.; Emanuel, James E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Ferrell, Robert E.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USA.
[Weamer, Elise A.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res 4, Educ & Clin Ctr MIRECC, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat, 3811 Ohara St, Pittsburgh, PA 15213 USA.
EM SweetRA@upmc.edu
FU National Institute of Aging [AG027224, AG05133]
FX Supported in part by USPHS grants AG027224 and AG05133 from the National
Institute of Aging.
NR 0
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2011
VL 32
IS 3
AR 555.e9
DI 10.1016/j.neurobiolaging.2010.10.003
PG 3
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 755PE
UT WOS:000289944800044
PM 21093110
ER
PT J
AU Damush, TM
Anderson, J
Nicholas, G
Kimmel, B
Kent, T
Williams, LS
AF Damush, Teresa M.
Anderson, Jane
Nicholas, Gloria
Kimmel, Barbara
Kent, Thomas
Williams, Linda S.
TI Implementation of the American Stroke Association Sharegiver Program
(Peer Support)
SO STROKE
LA English
DT Meeting Abstract
CT International Stroke Conference
CY FEB 08-10, 2011
CL Los Angeles, CA
SP Amer Heart Assoc, Amer Stroke Assoc
C1 [Damush, Teresa M.; Nicholas, Gloria] Indiana Univ, Sch Med, VA Stroke QUERI, Indianapolis, IN 46204 USA.
[Kent, Thomas] Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAR
PY 2011
VL 42
IS 3
BP E239
EP E239
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 723AW
UT WOS:000287479401034
ER
PT J
AU Nguyen, VHV
Poon, J
Tokuda, L
Sayers, J
Wallis, RA
Dergalust, S
AF Nguyen, Viet-Huong V.
Poon, John
Tokuda, Lisa
Sayers, Jeffrey
Wallis, Roi-Ann
Dergalust, Sunita
TI Pharmacist Telephone Interventions Improve Adherence to Stroke
Preventive Medications and Reduce Stroke Risk Factors: A Randomized
Controlled Trial
SO STROKE
LA English
DT Meeting Abstract
CT International Stroke Conference
CY FEB 08-10, 2011
CL Los Angeles, CA
SP Amer Heart Assoc, Amer Stroke Assoc
C1 [Nguyen, Viet-Huong V.; Poon, John; Tokuda, Lisa; Sayers, Jeffrey; Wallis, Roi-Ann; Dergalust, Sunita] VA Greater Los Angeles, Los Angeles, CA USA.
NR 0
TC 3
Z9 3
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAR
PY 2011
VL 42
IS 3
BP E244
EP E244
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 723AW
UT WOS:000287479401052
ER
PT J
AU Arar, N
Knight, SJ
Modell, SM
Issa, AM
AF Arar, Nedal
Knight, Sara J.
Modell, Stephen M.
Issa, Amalia M.
CA GAPPNetTM Inaugural Knowledge Synt
TI The Genome-based Knowledge Management in Cycles model: a complex
adaptive systems framework for implementation of genomic applications
SO PERSONALIZED MEDICINE
LA English
DT Article
DE breast cancer; complex-adaptive systems; GAPPNet (TM) initiative;
genomic applications; genomics; knowledge translation; Lynch syndrome
ID NONPOLYPOSIS COLORECTAL-CANCER; REVISED BETHESDA GUIDELINES; EGAPP
WORKING GROUP; LYNCH-SYNDROME; BREAST-CANCER; CLINICAL-PRACTICE;
HEALTH-POLICY; MICROSATELLITE INSTABILITY; TRANSLATIONAL RESEARCH;
REDUCING MORBIDITY
AB The main mission of the Genomic Applications in Practice and Prevention Network (TM) is to advance collaborative efforts involving partners from across the public health sector to realize the promise of genomics in healthcare and disease prevention. We introduce a new framework that supports the Genomic Applications in Practice and Prevention Network mission and leverages the characteristics of the complex adaptive systems approach. We call this framework the Genome-based Knowledge Management in Cycles model (G-KNOMIC). G-KNOMIC proposes that the collaborative work of multidisciplinary teams utilizing genome-based applications will enhance translating evidence-based genomic findings by creating ongoing knowledge management cycles. Each cycle consists of knowledge synthesis, knowledge evaluation, knowledge implementation and knowledge utilization. Our framework acknowledges that all the elements in the knowledge translation process are interconnected and continuously changing. It also recognizes the importance of feedback loops, and the ability of teams to self-organize within a dynamic system. We demonstrate how this framework can be used to improve the adoption of genomic technologies into practice using two case studies of genomic uptake.
C1 [Knight, Sara J.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA USA.
[Modell, Stephen M.] Univ Michigan, Sch Publ Hlth, Ctr Publ Hlth & Community Genom, Ann Arbor, MI 48109 USA.
[Issa, Amalia M.] Univ Houston, Coll Pharm, Program Personalized Med & Targeted Therapeut, Houston, TX 77030 USA.
RP Arar, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, S Texas Vet Hlth Care Syst, 7703 Floyd Curl, San Antonio, TX 78229 USA.
EM ararn@uthscsa.edu
FU InHealth; Institute of Health Technology Studies
FX The authors acknowledge partial support by InHealth, the Institute of
Health Technology Studies (principal investigator: Amalia M Issa).The
authors have no other relevant affiliations or financial involvement
with any organization or entity with a financial interest in or
financial conflict with the subject matter or materials discussed in the
manuscript. This includes employment, consultancies, honoraria, stock
ownership or options, expert testimony, grants or patents received or
pending, or royalties.
NR 92
TC 2
Z9 2
U1 1
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1741-0541
J9 PERS MED
JI Pers. Med.
PD MAR
PY 2011
VL 8
IS 2
BP 191
EP 205
DI 10.2217/PME.11.5
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 747SE
UT WOS:000289338900014
ER
PT J
AU Sher, L
AF Sher, Leo
TI Brain-derived neurotrophic factor and suicidal behavior in patients with
posttraumatic stress disorder
SO REVISTA BRASILEIRA DE PSIQUIATRIA
LA English
DT Letter
ID BDNF
C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
[Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA.
NR 5
TC 1
Z9 1
U1 0
U2 0
PU ASSOC BRASILEIRA PSIQUIATRIA
PI SAO PAULO
PA SUBSCRIPTION DEPARTMENT, RUA PEDRO DE TOLEDO, 967 - CASA 01, SAO PAULO,
SP 04039-032 A, BRAZIL
SN 1516-4446
J9 REV BRAS PSIQUIATR
JI Rev. Bras. Psiquiatr.
PD MAR
PY 2011
VL 33
IS 1
BP 105
EP 106
PG 2
WC Psychiatry
SC Psychiatry
GA 753CG
UT WOS:000289741400025
PM 21537733
ER
PT J
AU Laghi, F
Jubran, A
AF Laghi, Franco
Jubran, Amal
TI Treating the septic muscle with electrical stimulations
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
DE sepsis; intensive care unit; electrical stimulation; myopathy;
ICU-acquired weakness; muscular atrophy; peripheral muscles
ID CRITICALLY-ILL PATIENTS
C1 [Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
Loyola Univ, Maywood, IL 60153 USA.
RP Laghi, F (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
NR 18
TC 2
Z9 2
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAR
PY 2011
VL 39
IS 3
BP 585
EP 586
DI 10.1097/CCM.0b013e31820e2f6f
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 723BB
UT WOS:000287480000026
PM 21330856
ER
PT J
AU Baldwin, ML
Marcus, SC
AF Baldwin, Marjorie L.
Marcus, Steven C.
TI The Effects of Mental and Substance Use Disorders on Employment
Transitions
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Meeting Abstract
C1 Arizona State Univ, WP Carey Sch Business, Dept Econ, Tempe, AZ 85287 USA.
Univ Penn, Ctr Hlth Equ Res & Promot, Sch Social Policy & Practice, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD MAR
PY 2011
VL 14
SU 1
BP S3
EP S3
PG 1
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA 749WR
UT WOS:000289502600007
ER
PT J
AU Ingraham, AM
Cohen, ME
Raval, MV
Ko, CY
Nathens, AB
AF Ingraham, Angela M.
Cohen, Mark E.
Raval, Mehul V.
Ko, Clifford Y.
Nathens, Avery B.
TI Effect Of Trauma Center Status on 30-Day Outcomes After Emergency
General Surgery
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID ACUTE-CARE SURGERY; INJURY-RELATED MORTALITY; NATIONAL EVALUATION; ACUTE
APPENDICITIS; SURGICAL CARE; SYSTEMS; QUALITY; NSQIP; RISK
AB BACKGROUND: Trauma surgeons increasingly care for emergency general surgery (EGS) patients. The extent to which trauma center (TC) performance improvement translates into improved quality for EGS is unknown. We hypothesized that EGS outcomes in TCs would be similar to outcomes in non-trauma centers (NTC); failure to support our hypothesis suggests that the effects of trauma performance improvement have extended beyond trauma patients.
STUDY DESIGN: We retrospectively studied EGS procedures at TCs versus NTCs among American College of Surgeons National Surgical Quality Improvement Program participants (2005-2008). Thirty-day outcomes were overall morbidity, serious morbidity, and mortality. TC versus NTC outcomes were compared using regression modeling, observed-to-expected (O/E) ratios (among hospitals submitting >= 20 EGS procedures), and outlier status (hospitals whose O/E confidence interval excludes 1.0).
RESULTS: Of 68,003 patients at 222 hospitals, 42,264 (62.2%) were treated at 121 TCs; 25,739 (37.8%) were treated at 101 NTCs. TCs had significantly higher overall morbidity (21.4% versus 17.2%; p < 0.0001), serious morbidity (15.8% versus 12.3%; p < 0.0001), and mortality (6.4% versus 4.8%; p < 0.0001) than NTCs. On adjusted analyses, TC status was a significant predictor of overall morbidity (odds ratio = 1.11; 95% CI, 1.01-1.21), but not serious morbidity (odds ratio = 1.08; 95% CI, 0.98-1.19) or mortality (odds ratio = 0.92; 95% CI, 0.82-1.04). Among 211 hospitals assigned O/E ratios, TCs were more likely, although not significantly so, to be high outliers for overall morbidity (7.6% versus 4.3%; p = 0.017), serious morbidity (5.1% versus 4.3%; p = 0.034), and mortality (3.4% versus 2.2%; p > 0.099).
CONCLUSIONS: Although overall morbidity tended to favor NTCs, mortality was no different. This suggests that the trauma performance improvement processes have not been applied to EGS patients, despite being cared for by similar providers. Despite having processes for trauma, there remains the opportunity for quality improvement for EGS care. (J Am Coll Surg 2011;212:277-286. (c) 2011 by the American College of Surgeons)
C1 [Ingraham, Angela M.; Cohen, Mark E.; Raval, Mehul V.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA.
[Raval, Mehul V.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Nathens, Avery B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Div Surg & Trauma, Toronto, ON M5B 1W8, Canada.
RP Ingraham, AM (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,Floor 22NE, Chicago, IL 60611 USA.
EM aingraham@facs.org
OI Raval, Mehul/0000-0002-1527-2661
FU American College of Surgeons; John Gray Research Fellowship; Daniel F
and Ada L Rice Foundation; Canada Research Chair
FX Drs Ingraham and Raval are supported by the Clinical Scholar in
Residence Program at the American College of Surgeons. Dr Raval is also
supported by the John Gray Research Fellowship and the Daniel F and Ada
L Rice Foundation. Dr Nathens is supported by a Canada Research Chair in
Systems of Trauma Care.
NR 22
TC 15
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD MAR
PY 2011
VL 212
IS 3
BP 277
EP 286
DI 10.1016/j.jamcollsurg.2010.12.001
PG 10
WC Surgery
SC Surgery
GA 748XW
UT WOS:000289427400002
PM 21356485
ER
PT J
AU Lehman, LA
Woodbury, M
Velozo, CA
AF Lehman, Leigh A.
Woodbury, Michelle
Velozo, Craig A.
TI Examination of the Factor Structure of the Disabilities of the Arm,
Shoulder, and Hand Questionnaire
SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY
LA English
DT Article
DE data interpretation, statistical; disability evaluation; factor
analysis, statistical; upper extremity
ID CARPAL-TUNNEL-SYNDROME; ADMINISTERED BOSTON QUESTIONNAIRE; DASH OUTCOME
QUESTIONNAIRE; CONSTRUCT-VALIDITY; ELECTROPHYSIOLOGICAL FINDINGS;
RESPONSIVENESS; RELIABILITY; ARTHRITIS; SURGERY; VERSION
AB OBJECTIVE. The Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire is a global scale evaluating the impact of upper-extremity disorders. We sought to validate or challenge the unidimensional factor structure of the DASH.
METHOD. Secondary analysis was performed on data collected from outpatient clinics. Factor analysis was performed in two steps, exploratory factor analysis (EFA) followed by confirmatory factor analysis (CFA). To provide further support for unidimensionality, fit statistics were calculated using the Andrich Rasch rating-scale model.
RESULTS. EFA revealed three potential factors (eigenvalues = 18.40, 1.56, and 1.54). CFA was performed fitting a three-factor model. Tucker-Lewis Index (.99) and standardized root mean square residual (.05) values indicated good fit. Comparative fit index (.89) and root mean square error of approximation (.13) did not. When divided into three constructs, only one item misfit.
CONCLUSION. More research is needed to determine situations in which division of the DASH may enhance interpretability.
C1 [Lehman, Leigh A.] Univ S Carolina Upstate, Dept Psychol, Spartanburg, SC 29303 USA.
[Woodbury, Michelle] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Woodbury, Michelle] Med Univ S Carolina, Dept Hlth & Sci & Res, Div Occupat Therapy, Charleston, SC 29425 USA.
[Velozo, Craig A.] N Florida S Georgia Vet Affairs Syst, Rehabil Outcomes Res Ctr, Gainesville, FL USA.
[Velozo, Craig A.] Univ Florida, Dept Occupat Therapy, Gainesville, FL USA.
RP Lehman, LA (reprint author), Univ S Carolina Upstate, Dept Psychol, 800 Univ Way, Spartanburg, SC 29303 USA.
EM LALehman@aol.com
NR 47
TC 13
Z9 13
U1 0
U2 1
PU AMER OCCUPATIONAL THERAPY ASSOC, INC
PI BETHESDA
PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA
SN 0272-9490
J9 AM J OCCUP THER
JI Am. J. Occup. Ther.
PD MAR-APR
PY 2011
VL 65
IS 2
BP 169
EP 178
DI 10.5014/ajot.2011.000794
PG 10
WC Rehabilitation
SC Rehabilitation
GA 737MP
UT WOS:000288573200007
PM 21476364
ER
PT J
AU Jackson-Malik, P
McLaughlin, MJ
O'Hara, KT
Buxbaum, LU
AF Jackson-Malik, Pamela
McLaughlin, Mary J.
O'Hara, Katherine T.
Buxbaum, Laurence U.
TI Rapid Oral Fluid Testing for HIV in Veterans With Mental Health
Diagnoses and Residing in Community-Assisted Living Facilities
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE Assisted living; HIV; mental health diagnosis; rapid HIV testing;
veterans
ID ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; COST-EFFECTIVENESS;
SEXUAL-BEHAVIOR; HEPATITIS-B; COCAINE USE; ILLNESS; INFECTION; ADULTS;
RISK
AB Veterans with a history of mental health and substance abuse diagnoses, residing in assisted living facilities, are more likely to have an undiagnosed HIV infection related to high-risk behaviors. We determined (a) the cross-sectional prevalence of HIV infection among 65 veterans of unknown HIV serostatus with mental health diagnoses who resided in 11 community-assisted living facilities, and (b) whether patients who had not consented to standard physician-initiated blood testing in the previous 5 years would consent to rapid oral fluid HIV testing by nurses familiar to the subjects. We found an HIV prevalence of 3.1% in the subjects who agreed to be tested (n = 64, 98%). High test acceptance, especially in a group with little HIV screening experience, and the identified high prevalence of disease, suggest that this diagnostic method is effective. Patients' familiarity with the nurses who conducted the testing most likely supported the success of the procedure.
C1 [Jackson-Malik, Pamela] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Jackson-Malik, Pamela] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[McLaughlin, Mary J.] Philadelphia VA Med Ctr, HIV AIDS Program, Philadelphia, PA USA.
[Buxbaum, Laurence U.] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
RP Jackson-Malik, P (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
FU VHA Public Health Strategic Health Care Group; Office of Nursing Service
FX Funding for the HIV tests and prevention materials was provided by a
seed grant from the VHA Public Health Strategic Health Care Group and
Office of Nursing Service.
NR 40
TC 3
Z9 3
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD MAR-APR
PY 2011
VL 22
IS 2
BP 81
EP 89
DI 10.1016/j.jana.2010.07.001
PG 9
WC Nursing
SC Nursing
GA 736VD
UT WOS:000288522200003
PM 20708415
ER
PT J
AU Mendez, MF
AF Mendez, Mario F.
TI Pathological Stealing in Dementia: Poor Response to SSRI Medications
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Letter
ID DOUBLE-BLIND; KLEPTOMANIA
C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol & Psychiat, Los Angeles, CA 90095 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biobehav Sci, Los Angeles, CA 90095 USA.
[Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Dept Neurobehav, Los Angeles, CA USA.
RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol & Psychiat, Los Angeles, CA 90095 USA.
EM mmendez@UCLA.edu
FU NIA NIH HHS [R01 AG034499-03, R01 AG034499, R01AG034499-02]
NR 8
TC 5
Z9 5
U1 0
U2 0
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAR
PY 2011
VL 72
IS 3
BP 418
EP 419
DI 10.4088/JCP.10l06440gry
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 741BM
UT WOS:000288838100025
PM 21450164
ER
PT J
AU Carlson, KF
Kehle, SM
Meis, LA
Greer, N
MacDonald, R
Rutks, I
Sayer, NA
Dobscha, SK
Wilt, TJ
AF Carlson, Kathleen F.
Kehle, Shannon M.
Meis, Laura A.
Greer, Nancy
MacDonald, Roderick
Rutks, Indulis
Sayer, Nina A.
Dobscha, Steven K.
Wilt, Timothy J.
TI Prevalence, Assessment, and Treatment of Mild Traumatic Brain Injury and
Posttraumatic Stress Disorder: A Systematic Review of the Evidence
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Article
DE blast-related injury; comorbidity; military; postconcussive syndrome;
posttraumatic stress disorder; systematic review; traumatic brain
injury; veterans
ID MINOR HEAD-INJURY; MOTOR-VEHICLE ACCIDENTS; WAR VETERANS; SELF-REPORT;
POSTCONCUSSIVE SYMPTOMS; ENDURING FREEDOM; SERVICE MEMBERS; COMBAT
VETERANS; TERROR VICTIMS; PTSD
AB Background: Iraq and Afghanistan war veterans are returning from combat having sustained traumatic brain injury, most commonly mild traumatic brain injury (mTBI), and experiencing posttraumatic stress disorder (PTSD). Clinical guidelines for mTBI and PTSD do not focus on the co-occurrence of these conditions (mTBI/PTSD). A synthesis of the evidence on prevalence, diagnostic accuracy, and treatment effectiveness for mTBI/PTSD would be of use to clinicians, researchers, and policymakers. Methods: We conducted a systematic review of studies identified through PubMed, PsycINFO, REHABDATA, Cochrane Library, pearling, and expert recommendations. Peer-reviewed English language studies published between 1980 and June, 2009 were included if they reported frequencies of traumatic brain injury and PTSD, or diagnostic accuracy or treatment effectiveness specific to mTBI/PTSD. Results: Thirty-four studies met inclusion criteria. None evaluated diagnostic accuracy or treatment effectiveness. Studies varied considerably in design. Frequency of mTBI/PTSD ranged from 0% to 89%. However, in 3 large studies evaluating Iraq and Afghanistan war veterans, frequencies of probable mTBI/PTSD were from 5% to 7%; among those with probable mTBI, frequencies of probable PTSD were from 33% to 39%. Discussion: The wide range of mTBI/PTSD frequency levels was likely due to variation across study parameters, including aims and assessment methods. Studies using consistent, validated methods to define and measure mTBI history and PTSD are needed.
C1 [Carlson, Kathleen F.] Minneapolis VA Med Ctr 152 2E, VA Hlth Serv Res & Dev Serv, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA.
[Carlson, Kathleen F.; Kehle, Shannon M.; Meis, Laura A.; Sayer, Nina A.; Wilt, Timothy J.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
[Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
[Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron ComorbidMental & Phys Di, Portland, OR USA.
RP Carlson, KF (reprint author), Minneapolis VA Med Ctr 152 2E, VA Hlth Serv Res & Dev Serv, Ctr Chron Dis Outcomes Res, 1 Vet Dr, Minneapolis, MN 55417 USA.
EM kathleen.carlson@va.gov
RI Schueter, nicos/A-3625-2014; Sayer, Nina/E-3249-2016
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development [ESP 09-009]; Postdoctoral Training Program
[TPP 67-005]; Career Development Award Program [CDA 08-025]
FX This work was supported by Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development Evidence-based
Synthesis Pilot Program (ESP 09-009), Postdoctoral Training Program (TPP
67-005), and Career Development Award Program (CDA 08-025) grants.
NR 86
TC 104
Z9 104
U1 7
U2 27
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-9701
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD MAR-APR
PY 2011
VL 26
IS 2
BP 103
EP 115
DI 10.1097/HTR.0b013e3181e50ef1
PG 13
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 732OR
UT WOS:000288197200001
PM 20631631
ER
PT J
AU Zeber, JE
Miller, AL
Copeland, LA
McCarthy, JF
Zivin, K
Valenstein, M
Greenwald, D
Kilbourne, AM
AF Zeber, John E.
Miller, Alexander L.
Copeland, Laurel A.
McCarthy, John F.
Zivin, Kara
Valenstein, Marcia
Greenwald, Devra
Kilbourne, Amy M.
TI Medication Adherence, Ethnicity, and the Influence of Multiple
Psychosocial and Financial Barriers
SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES
RESEARCH
LA English
DT Article
DE Medication adherence; Psychosocial barriers; Ethnicity; Bipolar
disorder; Veterans
ID SERIOUS MENTAL-ILLNESS; BIPOLAR DISORDER; TREATMENT NONADHERENCE;
COLLABORATIVE CARE; CLINICAL-OUTCOMES; VETERANS-AFFAIRS; INDIVIDUALS;
COSTS; SCHIZOPHRENIA; INSIGHT
AB Medication adherence is critical for patients with bipolar disorder to avoid symptom exacerbation and diminished quality of life. Most analyses consider adherence barriers individually rather than conjointly, while neglecting potential ethnic differences. 435 patients in the Continuous Improvement for Veterans in Care--Mood Disorders study reported multiple financial and psychosocial factors influencing adherence. Logistic regression modeled adherence as a function of perceived barriers, including cost burden, access, binge drinking, poor therapeutic alliance, and medication beliefs. Nearly half the cohort experienced adherence difficulty, averaging 2.8 barriers, with minority veterans reporting lower adherence than white patients, particularly financial burden and treatment access. Total barriers were significantly associated with worse adherence (OR = 1.24 per barrier), notably poor medication beliefs, binge drinking, and difficulty accessing psychiatric specialists (ORs of 2.41, 1.95 and 1.73, respectively). Veterans with bipolar disorder experience numerous adherence barriers, with certain obstacles proving especially pernicious. Fortunately tailored clinical interventions can improve adherence, particularly by addressing modifiable risk factors.
C1 [Zeber, John E.; Copeland, Laurel A.] S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSR&D, San Antonio, TX 78229 USA.
[Zeber, John E.; Miller, Alexander L.; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[McCarthy, John F.; Zivin, Kara; Valenstein, Marcia; Kilbourne, Amy M.] VA Ann Arbor Healthcare Syst, Serious Mental Illness Treatment Res & Evaluat Ct, Ann Arbor, MI USA.
[McCarthy, John F.; Zivin, Kara; Valenstein, Marcia; Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Greenwald, Devra] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA.
RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSR&D, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM zeber@uthscsa.edu
OI Copeland, Laurel/0000-0002-9478-0209
NR 65
TC 11
Z9 12
U1 0
U2 3
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0894-587X
J9 ADM POLICY MENT HLTH
JI Adm. Policy. Ment. Health
PD MAR
PY 2011
VL 38
IS 2
BP 86
EP 95
DI 10.1007/s10488-010-0304-1
PG 10
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 729BR
UT WOS:000287923100003
PM 20549327
ER
PT J
AU Berman, AE
Chan, WY
Brennan, AM
Reyes, RC
Adler, BL
Suh, SW
Kauppinen, TM
Edling, Y
Swanson, RA
AF Berman, Ari E.
Chan, Wai Yee
Brennan, Angela M.
Reyes, Reno C.
Adler, Brittany L.
Suh, Sang Won
Kauppinen, Tiina M.
Edling, Ylva
Swanson, Raymond A.
TI N-Acetylcysteine Prevents Loss of Dopaminergic Neurons in the EAAC1(-/-)
Mouse
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID GLUTAMATE TRANSPORTER EAAC1; PARKINSONS-DISEASE; GLUTATHIONE LEVELS;
SUBSTANTIA-NIGRA; OXIDATIVE STRESS; BASAL GANGLIA; ANIMAL-MODELS;
RAT-BRAIN; MPTP; MICE
AB Objective: Dopaminergic neuronal death in Parkinson's disease (PD) is accompanied by oxidative stress and preceded by glutathione depletion. The development of disease-modifying therapies for PD has been hindered by a paucity of animal models that mimic these features and demonstrate an age-related progression. The EAAC1(-/-) mouse may be useful in this regard, because EAAC1(-/-) mouse neurons have impaired neuronal cysteine uptake, resulting in reduced neuronal glutathione content and chronic oxidative stress. Here we aimed to (1) characterize the age-related changes in nigral dopaminergic neurons in the EAAC1(-/-) mouse, and (2) use the EAAC1(-/-) mouse to evaluate N-acetylcysteine, a membrane-permeable cysteine pro-drug, as a potential disease-modifying intervention for PD.
Methods: Wild-type mice, EAAC1(-/-) mice, and EAAC1(-/-) mice chronically treated with N-acetylcysteine were evaluated at serial time points for evidence of oxidative stress, dopaminergic cell death, and motor abnormalities.
Results: EAAC1(-/-) mice showed age-dependent loss of dopaminergic neurons in the substantia nigra pars compacta, with more than 40% of these neurons lost by age 12 months. This neuronal loss was accompanied by increased nitrotyrosine formation, nitrosylated alpha-synuclein, and microglial activation. These changes were substantially reduced in mice that received N-acetylcysteine.
Interpretation: These findings suggest that the EAAC1(-/-) mouse may be a useful model of the chronic neuronal oxidative stress that occurs in PD. The salutary effects of N-acetylcysteine in this mouse model provide an impetus for clinical evaluation of glutathione repletion in PD. ANN NEUROL 2011;69:509-520
C1 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
RP Swanson, RA (reprint author), Neurol VAMC, 4150 Clement St, San Francisco, CA 94121 USA.
EM raymond.swanson@ucsf.edu
OI Swanson, Raymond/0000-0002-3664-5359; Kauppinen,
Tiina/0000-0001-7219-9862
FU U.S. Department of Veterans Affairs; Michael J. Fox Foundation for
Parkinson's Research
FX This research was supported by grants from the U.S. Department of
Veterans Affairs (to R. A. S.) and the Michael J. Fox Foundation for
Parkinson's Research (to R. A. S.).
NR 49
TC 52
Z9 54
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD MAR
PY 2011
VL 69
IS 3
BP 509
EP 520
DI 10.1002/ana.22162
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 744FW
UT WOS:000289081300014
PM 21446024
ER
PT J
AU Meredith, LS
Eisenman, DP
Tanielian, T
Taylor, SL
Basurto-Davila, R
Zazzali, J
Diamond, D
Cienfuegos, B
Shields, S
AF Meredith, Lisa S.
Eisenman, David P.
Tanielian, Terri
Taylor, Stephanie L.
Basurto-Davila, Ricardo
Zazzali, James
Diamond, Dickson
Cienfuegos, Barbara
Shields, Sandra
TI Prioritizing "Psychological" Consequences for Disaster Preparedness and
Response: A Framework for Addressing the Emotional, Behavioral, and
Cognitive Effects of Patient Surge in Large-Scale Disasters
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE disaster preparedness and response; health care services; mental health;
surge capacity
ID POSTTRAUMATIC-STRESS-DISORDER; 2003 SARS OUTBREAK; HEALTH-CARE;
SEPTEMBER 11; TERRORISM; EMERGENCY; CAPACITY; TORONTO; ATTACKS; IMPACT
AB While information for the medical aspects of disaster surge is increasingly available, there is little guidance for health care facilities on how to manage the psychological aspects of large-scale disasters that might involve a surge of psychological casualties. In addition, no models are available to guide the development of training curricula to address these needs. This article describes 2 conceptual frameworks to guide hospitals and clinics in managing such consequences. One framework was developed to understand the antecedents of psychological effects or "psychological triggers" (restricted movement, limited resources, limited information, trauma exposure, and perceived personal or family risk) that cause the emotional, behavioral, and cognitive reactions following large-scale disasters. Another framework, adapted from the Donabedian quality of care model, was developed to guide appropriate disaster response by health care facilities in addressing the consequences of reactions to psychological triggers. This framework specifies structural components (internal organizational structure and chain of command, resources and infrastructure, and knowledge and skills) that should be in place before an event to minimize consequences. The framework also specifies process components (coordination with external organizations, risk assessment and monitoring, psychological support, and communication and information sharing) to support evidence-informed interventions. (Disaster Med Public Health Preparedness, 2011;5:73-80)
C1 [Meredith, Lisa S.; Eisenman, David P.] RAND Corp, Santa Monica, CA 90407 USA.
[Eisenman, David P.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Tanielian, Terri] RAND Corp, Arlington, VA USA.
[Taylor, Stephanie L.] VA Greater Los Angeles, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA.
[Basurto-Davila, Ricardo] Ctr Dis Control, Atlanta, GA 30333 USA.
[Zazzali, James] Genentech Inc, San Francisco, CA 94080 USA.
[Diamond, Dickson; Cienfuegos, Barbara] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA.
[Shields, Sandra] Emergency Med Serv, Los Angeles Cty Dept Health Serv, Sante Fe Springs, CA USA.
RP Meredith, LS (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA.
EM lisa_meredith@rand.org
FU US Department of Health and Human Services
FX Funding for this study was provided by the Hospital Preparedness Program
grant (US Department of Health and Human Services).
NR 46
TC 9
Z9 9
U1 5
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 1935-7893
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD MAR
PY 2011
VL 5
IS 1
BP 73
EP 80
DI 10.1001/dmp.2010.47
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 730CP
UT WOS:000288009100012
PM 21402830
ER
PT J
AU Shafer, PO
Buelow, J
Ficker, DM
Pugh, MJ
Kanner, AM
Dean, P
Levisohn, P
AF Shafer, P. O.
Buelow, J.
Ficker, D. M.
Pugh, M. J.
Kanner, A. M.
Dean, P.
Levisohn, P.
TI Risk of adverse events on epilepsy monitoring units: A survey of
epilepsy professionals
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Epilepsy; Seizures; Epilepsy monitoring units; EEG telemetry; Video
monitoring; Patient safety; Injuries; Adverse events; Risks; Seizure
observation
ID INJURIES
AB In 2008 a workgroup of health care professionals from the American Epilepsy Society (AES) was convened to address the lack of consensus regarding patient care in epilepsy monitoring units (EMUs). The group developed a questionnaire designed to identify the extent to which selected adverse events occurred in EMUs, and it was sent via email to all members of the AES. We asked that only one representative from each center report. Seventy responses were received. The number of centers reporting the following adverse events included: falls by 69%, status epilepticus by 63%, and postictal psychosis by 54%. Infrequent events with serious consequences were also reported including pneumonia by 10%, cardiac arrest by 7%, fractures by 6%, and death by 3% (N = 2). Of the 58 respondents who reported using intracranial electrodes, 37.9% (N = 22) reported that patients pulled out or dislodged electrodes. This study highlights the need for EMUs to identify and address potential safety risks in their environment, patient population, and system of care. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Shafer, P. O.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
[Buelow, J.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA.
[Ficker, D. M.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, Cincinnati, OH USA.
[Kanner, A. M.] Rush Univ, Rush Med Coll, Chicago, IL 60612 USA.
[Kanner, A. M.] Rush Univ, Med Ctr, Lab EEG & Video EEG Telemetry, Chicago, IL 60612 USA.
[Pugh, M. J.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Pugh, M. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Dean, P.] Miami Childrens Hosp, Miami, FL USA.
[Levisohn, P.] Univ Colorado, Sch Med, Aurora, CO USA.
[Levisohn, P.] Childrens Univ, Aurora, CO USA.
RP Shafer, PO (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurol, 330 Brookline Ave,KS 457, Boston, MA 02215 USA.
EM pshafer@bidmc.harvard.edu
NR 8
TC 18
Z9 18
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD MAR
PY 2011
VL 20
IS 3
BP 502
EP 505
DI 10.1016/j.yebeh.2010.12.048
PG 4
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 742WN
UT WOS:000288976100015
PM 21306957
ER
PT J
AU Allen, ES
Connelly, EN
Morris, CD
Elmer, PJ
Zwickey, H
AF Allen, Elizabeth S.
Connelly, Erin N.
Morris, Cynthia D.
Elmer, Patricia J.
Zwickey, Heather
TI A TRAIN THE TRAINER MODEL FOR INTEGRATING EVIDENCE-BASED MEDICINE INTO A
COMPLEMENTARY AND ALTERNATIVE MEDICINE TRAINING PROGRAM
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE Complementary and alternative medicine; evidence-based medicine;
teaching
ID ORIENTAL-MEDICINE; RESEARCH LITERACY; OREGON-COLLEGE; EDUCATION;
FACULTY; INITIATIVES
AB Background: Public interest in complementary and alternative medicine (CAM) has grown over the past decade, accompanied by increased demand for evidence-based approaches to CAM practice. In order to define the role evidence-based decision making has in CAM practice, CAM professionals must have a full understanding of evidence-based medicine (EBM) concepts.
Objective: This paper describes the design, implementation, and evaluation of a week-long intensive EBM short course for CAM faculty at a naturopathic and classical Chinese medicine institution.
Intervention: This 20-hour course, entitled Principles of EBM for CAM Professionals, teaches participants how to access and appraise biomedical literature, apply it to their work, and teach these concepts to their students.
Results: Results from precourse and postcourse evaluations suggest that, in a small group of participants, there were significant changes in EBM practice attitudes, self-appraised skills, and objectively assessed skills as a result of this course. Participants indicated they were committed to increasing their use of EBM in practice, enhancing EBM skills, using EBM in teaching, and working to change the culture at their institution to support use of EBM. At six months, 80% of participants had fully or partially followed through on their commitment to change plans.
C1 [Allen, Elizabeth S.] Portland VA Med Ctr, Portland, OR 97207 USA.
[Connelly, Erin N.; Elmer, Patricia J.; Zwickey, Heather] Natl Coll Nat Med, Helfgott Res Inst, Portland, OR USA.
[Morris, Cynthia D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Allen, ES (reprint author), Portland VA Med Ctr, P3 Med,POB 1034, Portland, OR 97207 USA.
EM elizabeth.allen@va.gov
FU National Institutes of Health, National Center for Complementary and
Alternative Medicine [1R25 AT002878-01A1]
FX This work is supported by education grant 1R25 AT002878-01A1 from the
National Institutes of Health, National Center for Complementary and
Alternative Medicine awarded to Heather Zwickey.
NR 28
TC 9
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1550-8307
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD MAR-APR
PY 2011
VL 7
IS 2
BP 88
EP 93
DI 10.1016/j.explore.2010.12.001
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 740VJ
UT WOS:000288822200006
PM 21397869
ER
PT J
AU Singh, JA
Fitzgerald, PM
AF Singh, Jasvinder A.
Fitzgerald, Patrick M.
TI Botulinum Toxin for Shoulder Pain: A Cochrane Systematic Review
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Review
DE BOTULINUM TOXIN; SHOULDER PAIN; BENEFIT SAFETY; COCHRANE SYSTEMATIC
REVIEW
ID MODIFIED RANKIN SCALE; DOUBLE-BLIND; PRIMARY-CARE; SPASTIC HEMIPLEGIA;
SUBSCAPULAR MUSCLE; BARTHEL INDEX; TENNIS ELBOW; INJECTION; STROKE;
DISABILITY
AB Objective. To perform a Cochrane Systematic Review of benefits and harms of botulinum toxin for shoulder pain.
Methods. We included clinical trials of adults with shoulder pain (population), comparing botulinum toxin (intervention) to placebo or other therapies (comparison), and reporting benefits or harms (outcomes). We calculated relative risk (RR) for categorical outcomes and mean differences (MD) for continuous outcomes.
Results. Six randomized controlled trials (RCT) with 164 patients all comparing single botulinum toxin type A injections to placebo were included. Five RCT in patients with post-stroke shoulder pain found that an intramuscular injection of botulinum toxin type A significantly reduced pain at 3-6 months (MD -1.2 points on 0-10 scale, 95% CI -2.4 to -0.07) and improved shoulder external rotation at 1 month (MD 9.8 degrees, 95% CI 0.2 degrees to 19.4 degrees). Number of adverse events did not differ between groups (RR 1.46, 95% CI 0.6 to 24.3). One RCT in arthritis-related shoulder pain showed that single intraarticular botulinum toxin type A injection reduced pain (MD -2.0 on 0-10 scale, 95% Cl -3.7 to -0.3) and shoulder disability (MD -13.4 on 0-100 scale, 95% Cl -24.9 to 1.9) and improved shoulder abduction (MD 13.8 degrees, 95% Cl 3.2 degrees to 44.0 degrees) at 1 month, compared with placebo. Serious adverse events did not differ between groups (RR 0.35, 95% CI 0.11, 1.12).
Conclusion. With evidence from few studies with small sample sizes and medium to high risk of bias, botulinum toxin type A injections decreased pain and improved shoulder function in patients with chronic shoulder pain clue to spastic hemiplegia or arthritis. (First Release Feb 1 2011; J Rheumatol 2011;38:409-18; doi:10.3899/jrheum.101081)
C1 [Singh, Jasvinder A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama, Sch Publ Hlth, Div Epidemiol, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA.
[Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.
[Fitzgerald, Patrick M.] Minneapolis VA Med Ctr, Med Serv, Minneapolis, MN USA.
RP Singh, JA (reprint author), Univ Alabama, Dept Med, Fac Off Tower,Room 805B,510 20th St S, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU National Institutes of Health (NW) [1 KL2 RR024151-01]; Birmingham VA
Medical Center, Alabama, USA; Allergan; Allergan, Takeda; Savient;
Wyeth; Amgen; URL pharmaceuticals; Novartis
FX Supported by National Institutes of Health (NW) Clinical Translational
Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and
Translational Research) and the Birmingham VA Medical Center, Alabama,
USA. Dr. Singh has received speaker honoraria from Abbott; research and
travel grants from Allergan, Takeda, Savient, Wyeth, and Amgen; rind
consultant fees from Savient, URL pharmaceuticals, and Novartis.
NR 50
TC 11
Z9 13
U1 0
U2 3
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAR
PY 2011
VL 38
IS 3
BP 409
EP 418
DI 10.3899/jrheum.101081
PG 10
WC Rheumatology
SC Rheumatology
GA 740DB
UT WOS:000288770700004
PM 21285169
ER
PT J
AU Freeman, WD
Nolte, CM
Matthews, BR
Coleman, M
Corboy, JR
AF Freeman, W. D.
Nolte, C. M.
Matthews, B. R.
Coleman, M.
Corboy, J. R.
TI Results of the American Academy of Neurology Resident Survey
SO NEUROLOGY
LA English
DT Article
ID MILLENNIUM; EDUCATION
AB Background: To assess the effect of neurology residency education as trainees advance into independent practice, the American Academy of Neurology (AAN) elected to survey all graduating neurology residents at time of graduation and in 3-year cycles thereafter.
Methods: A 22-question survey was sent to all neurology residents completing residency training in the United States in 2007.
Results: Of 523 eligible residents, 285 (54.5%) responded. Of these, 92% reported good to excellent quality teaching of basic neurology from their faculty; however, 47% noted less than ideal training in basic neuroscience. Two-thirds indicated that the Residency In-service Training Examination was used only as a self-assessment tool, but reports of misuse were made by some residents. After residency, 78% entered fellowships (with 61% choosing a fellowship based on interactions with a mentor at their institution), whereas 20% entered practice directly. After adjustment for the proportion of residents who worked before the duty hour rules were implemented and after their implementation, more than half reported improvement in quality of life (87%), education (60%), and patient care (62%). The majority of international medical graduates reported wanting to stay in the United States to practice rather than return to their country of residence.
Conclusions: Neurology residents are generally satisfied with training, and most entered a fellowship. Duty hour implementation may have improved resident quality of life, but reciprocal concerns were raised about impact on patient care and education. Despite the majority of international trainees wishing to stay in the United States, stricter immigration laws may limit their entry into the future neurology workforce. Neurology (R) 2011;76:e61-e67
C1 [Freeman, W. D.] Mayo Clin, Coll Med, Dept Neurol, Jacksonville, FL 32224 USA.
[Nolte, C. M.] Vanderbilt Univ, Dept Sleep Med, Nashville, TN USA.
[Matthews, B. R.] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.
[Coleman, M.] Amer Acad Neurol, St Paul, MN USA.
[Corboy, J. R.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA.
[Corboy, J. R.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Corboy, JR (reprint author), 12631 E 17th St,POB 6511,Mailstop B-185, Aurora, CO 80045 USA.
EM john.corboy@ucdenver.edu
FU NIH; Novartis; BioMS Medical; Orasi Medical Inc.; NIH/NINDS; National MS
Society
FX Dr. Freeman has served as officer of the American Academy of Neurology,
Resident & Fellow section. Dr. Nolte has served as officer of the
American Academy of Neurology, Resident & Fellow section. Dr. Matthews
has served as officer of the American Academy of Neurology, Resident &
Fellow section, and receives research support from the NIH. M. Coleman
is an employee of the American Academy of Neurology. Dr. Corboy has
served as Chair of the Graduate Education Subcommittee (GES); serves as
Editor for Neurology: Clinical Practice and as Section Editor for
Neurology Today; serves as a consultant for Bayer Schering Pharma, EMD
Serono, Inc., Advanced Studies in Medicine (ASiM), and Novartis; has
received research support from Novartis, BioMS Medical, Orasi Medical
Inc., the NIH/NINDS, and the National MS Society; and has reviewed files
and give expert testimony in medicolegal cases.
NR 10
TC 12
Z9 12
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAR
PY 2011
VL 76
IS 13
BP E61
EP E67
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 741VD
UT WOS:000288892600001
PM 21444895
ER
PT J
AU Sones, HM
Thorp, SR
Raskind, M
AF Sones, Heather M.
Thorp, Steven R.
Raskind, Murray
TI Prevention of Posttraumatic Stress Disorder
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Posttraumatic stress disorder; Prevention; Mental health; Psychological
distress
ID RANDOMIZED CONTROLLED-TRIAL; NATIONAL COMORBIDITY SURVEY; COMBAT
VETERANS; SEPTIC SHOCK; FUTURE-DIRECTIONS; EMOTIONAL EVENTS; PTSD
PREVENTION; DOUBLE-BLIND; TRAUMA; SLEEP
AB Traumatic events are common, but the psychological distress that may follow usually subsides naturally. For some individuals, distress develops into posttraumatic stress disorder (PTSD). PTSD lends itself to the application of prevention strategies for at-risk individuals. The identification of a causal event may make prevention efforts for PTSD more feasible and effective than for other psychological disorders. For PTSD, these efforts target those traumatized persons who are beginning to exhibit symptoms of PTSD. These interventions could also target individuals meeting criteria for acute stress disorder with the goal of preventing chronic PTSD.
C1 [Thorp, Steven R.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92108 USA.
[Sones, Heather M.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA.
[Thorp, Steven R.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Raskind, Murray] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle Div, Seattle, WA 98108 USA.
[Raskind, Murray] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Thorp, SR (reprint author), VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, 8810 Rio San Diego Dr,Mail Code 116A4Z, San Diego, CA 92108 USA.
EM sthorp@ucsd.edu
NR 81
TC 9
Z9 9
U1 5
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD MAR
PY 2011
VL 34
IS 1
BP 79
EP +
DI 10.1016/j.psc.2010.11.001
PG 17
WC Psychiatry
SC Psychiatry
GA 734OM
UT WOS:000288344200006
PM 21333841
ER
PT J
AU Maust, DT
Mavandadi, S
Klaus, J
Oslin, DW
AF Maust, Donovan T.
Mavandadi, Shahrzad
Klaus, Johanna
Oslin, David W.
TI Missed Opportunities: Fewer Service Referrals After Positive Alcohol
Misuse Screens in VA Primary Care
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID DEPRESSION
AB Objective: The primary purpose of this study was to compare referral to additional clinical services after primary care clinicians screened for and found a positive screen for alcohol misuse, depression, or posttraumatic stress disorder (PTSD). Methods: Results from the Alcohol Use Disorders Identification Test, Patient Health Questionnaire 2, and Primary Care PTSD screens performed over two years at the Philadelphia Veterans Affairs (VA) Medical Center and affiliated VA community sites were analyzed by mixed-effects logistic regression. A total of 9,052 veterans with positive screens were eligible for additional clinical services. Results: Odds of referral to additional clinical services for positive depression or PTSD screens were significantly higher than for positive screens for alcohol misuse (odds ratio=10.60 and 19.49, respectively). Conclusion: Primary care-based screening for alcohol misuse is managed differently than for depression or PTSD. (Psychiatric Services 62:310-312, 2011)
C1 [Maust, Donovan T.; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Mavandadi, Shahrzad; Klaus, Johanna; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Maust, DT (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,2nd floor, Philadelphia, PA 19104 USA.
EM donovan.maust@uphs.upenn.edu
FU National Institute of Mental Health; Department of Psychiatry,
University of Pennsylvania
FX Dr. Maust is supported by the National Institute of Mental
Health-Clinical Research Scholars Program of the Department of
Psychiatry, University of Pennsylvania. The authors thank Kevin Lynch,
Ph.D., and Caroline McKay, Ph.D., for their assistance with the
statistical analysis.
NR 9
TC 8
Z9 8
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD MAR
PY 2011
VL 62
IS 3
BP 310
EP 312
DI 10.1176/appi.ps.62.3.310
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 728AL
UT WOS:000287845800013
PM 21363905
ER
PT J
AU Bergmann, LL
Zimmerman, P
Kaunitz, JD
AF Bergmann, Liisa L.
Zimmerman, Peter
Kaunitz, Jonathan D.
TI Unusual complication: superior mesenteric artery syndrome and closed
loop gastroduodenal obstruction after adjustable gastric banding
SO SURGERY FOR OBESITY AND RELATED DISEASES
LA English
DT Editorial Material
ID BYPASS
C1 [Kaunitz, Jonathan D.] W Los Angeles Vet Affairs Med Ctr, Med Serv, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA.
[Zimmerman, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
[Zimmerman, Peter] W Los Angeles Vet Affairs Med Ctr, Serv Radiol, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA.
[Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90024 USA.
RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Med Serv, Greater Los Angeles Vet Affairs Healthcare Syst, Bldg 114,Suite 217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jake@ucla.edu
FU NIDDK NIH HHS [R01 DK054221]
NR 9
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1550-7289
J9 SURG OBES RELAT DIS
JI Surg. Obes. Relat. Dis.
PD MAR-APR
PY 2011
VL 7
IS 2
BP 237
EP 239
DI 10.1016/j.soard.2010.03.283
PG 3
WC Surgery
SC Surgery
GA 743PT
UT WOS:000289031700022
PM 21130049
ER
PT J
AU Mattocks, KM
Nikolajski, C
Haskell, S
Brandt, C
McCall-Hosenfeld, J
Yano, E
Tan, P
Borrero, S
AF Mattocks, Kristin M.
Nikolajski, Cara
Haskell, Sally
Brandt, Cynthia
McCall-Hosenfeld, Jennifer
Yano, Elizabeth
Tan Pham
Borrero, Sonya
TI Women Veterans' Reproductive Health Preferences and Experiences: A Focus
Group Analysis
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID GENDER DISCRIMINATION; QUALITATIVE RESEARCH; CARE; AFFAIRS; DELIVERY;
IMPACT; RACE
AB Objective: Although women veterans are seeking care at the Veterans Administration (VA) in record numbers, there is little information regarding women veterans' experiences and preferences for reproductive health care services. We sought to characterize women veterans' experiences with, and preferences for, reproductive health services in the VA.
Methods: We conducted five focus groups with a total of 25 participants using a semistructured interview guide to elicit women veterans' experiences and preferences with reproductive health care. Women Veterans' utilizing VA health care at two VA facilities who responded to advertisements were selected on a first-come basis to participate in the study. We analyzed transcripts of these audiorecorded sessions using the constant comparative method of grounded theory.
Results: Five main themes emerged from the focus group discussions: 1) Women veterans prefer VA women's clinics for comprehensive medical care; 2) Women veterans have had both positive and negative reproductive health experiences in the VA; 3) Women veterans experience knowledge gaps regarding VA coverage for reproductive health services; 4) Women veterans believe the VA should provide additional coverage for advanced infertility care and for newborns; and 5) Perceived gender discrimination shapes how women veterans view the VA.
Conclusion: As the VA continues to tailor its services to women veterans, attention should be given to women's reproductive health care needs. Copyright (c) 2011 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Mattocks, Kristin M.; Haskell, Sally; Tan Pham] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Mattocks, Kristin M.; Haskell, Sally; Brandt, Cynthia; Tan Pham] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Nikolajski, Cara; Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Nikolajski, Cara; Borrero, Sonya] Univ Pittsburgh, Ctr Res Hlth Care, Dept Med, Pittsburgh, PA 15260 USA.
[Brandt, Cynthia] Yale Univ, Sch Med, Yale Ctr Med Informat, New Haven, CT USA.
[McCall-Hosenfeld, Jennifer] PennState Milton S Hershey Med Ctr, Hershey, PA USA.
[Yano, Elizabeth] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Excellence Study Healthcare Provider, Sepulveda, CA USA.
[Yano, Elizabeth] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
[Borrero, Sonya] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Mattocks, KM (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave,11-ACSLG, West Haven, CT 06516 USA.
EM Kristin.mattocks@va.gov
FU HSRD VA [I01 HX000915]
NR 23
TC 10
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAR-APR
PY 2011
VL 21
IS 2
BP 124
EP 129
DI 10.1016/j.whi.2010.11.002
PG 6
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA 735NH
UT WOS:000288422100005
PM 21353978
ER
PT J
AU Bradford, A
Upchurch, C
Bass, D
Judge, K
Snow, AL
Wilson, N
Kunik, ME
AF Bradford, Andrea
Upchurch, Christina
Bass, David
Judge, Katherine
Snow, A. Lynn
Wilson, Nancy
Kunik, Mark E.
TI Knowledge of Documented Dementia Diagnosis and Treatment in Veterans and
Their Caregivers
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE dementia; diagnosis; self-report; veterans
ID PRIMARY-CARE PHYSICIANS; GENERAL-PRACTITIONERS; ALZHEIMERS-DISEASE;
FAMILY CAREGIVERS; DISCLOSURE; PERSPECTIVES; ATTITUDES; PATIENT; TRUTH
AB We studied perceptions of dementia diagnosis and treatment in patient-caregiver dyads enrolled in a care coordination intervention trial for veterans with dementia. We compared patient and caregiver perceptions of diagnosis and treatment to information in the medical record and assessed concordance between patient and caregiver perceptions. Data were derived from medical record abstraction and structured interviews with 132 patients and 183 caregivers. Most caregivers, but only about one fourth of patients, reported having received information about a diagnosis related to memory loss. Caregivers were more accurate than patients in recalling the patient's use of memory-enhancing medications. Within dyads there was poor agreement regarding a diagnosis of dementia. Our findings suggest that there is substantial room for improvement in disclosure and education of dementia diagnosis, especially at the level of the patient-caregiver dyad.
C1 [Bradford, Andrea; Upchurch, Christina; Wilson, Nancy; Kunik, Mark E.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Bradford, Andrea; Wilson, Nancy; Kunik, Mark E.] Baylor Coll Med, Houston, TX 77030 USA.
[Kunik, Mark E.] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA.
[Judge, Katherine] Cleveland State Univ, Cleveland, OH 44115 USA.
[Bass, David; Judge, Katherine] Margaret Blenkner Res Inst, Cleveland, OH USA.
[Snow, A. Lynn] Univ Alabama, Tuscaloosa, AL USA.
[Snow, A. Lynn] Tuscaloosa Vet Affairs Med Ctr, Tuscaloosa, AL USA.
RP Kunik, ME (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM mkunik@bcm.edu
OI Bradford, Andrea/0000-0002-8390-8844
FU Robert Wood Johnson Foundation [57816]; Alzheimer's Association
[IIRG-08-89058]; Houston VA HSR&D Center of Excellence [HFP90-020]
FX The authors disclosed receipt of the following financial support for the
research and/or authorship of this article: Grant No. 57816 from the
Robert Wood Johnson Foundation and Grant No. IIRG-08-89058 from the
Alzheimer's Association and was supported in part by the Houston VA
HSR&D Center of Excellence (HFP90-020).
NR 31
TC 5
Z9 5
U1 3
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD MAR
PY 2011
VL 26
IS 2
BP 127
EP 133
DI 10.1177/1533317510394648
PG 7
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 740QG
UT WOS:000288808900007
PM 21273206
ER
PT J
AU Filippi, M
Rocca, MA
Barkhof, F
Bakshi, R
Fazekas, F
Khan, O
Pelletier, D
Rovira, A
Simon, J
AF Filippi, M.
Rocca, M. A.
Barkhof, F.
Bakshi, R.
Fazekas, F.
Khan, O.
Pelletier, D.
Rovira, A.
Simon, J.
TI Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: The
Neuroimaging Perspective
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Editorial Material
ID DEEP GRAY-MATTER; WHITE-MATTER; QUANTITATIVE ASSESSMENT; IRON
DEPOSITION; MS LESIONS; IN-VIVO; MR; PERFUSION; NEURODEGENERATION; FLOW
C1 [Filippi, M.; Rocca, M. A.] Inst Sci, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, Milan, Italy.
[Filippi, M.; Rocca, M. A.] Univ Hosp San Raffaele, Milan, Italy.
[Barkhof, F.] Vrije Univ Amsterdam Med Ctr, Dept Radiol, Amsterdam, Netherlands.
[Bakshi, R.] Harvard Univ, Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Sch Med,Dept Neurol,Lab Neuroimaging Res, Boston, MA 02115 USA.
[Fazekas, F.] Med Univ Graz, Dept Neurol, Graz, Austria.
[Pelletier, D.] Wayne State Univ, Sch Med, Dept Neurol, Multiple Sclerosis Ctr, Detroit, MI 48201 USA.
[Pelletier, D.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Pelletier, D.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
[Rovira, A.] Hosp Valle dHebron, Dept Radiol, Barcelona, Spain.
[Simon, J.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97201 USA.
[Simon, J.] Portland VA Med Ctr, Portland, OR USA.
RP Filippi, M (reprint author), Inst Sci, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, Milan, Italy.
NR 49
TC 12
Z9 14
U1 0
U2 6
PU AMER SOC NEURORADIOLOGY
PI OAK BROOK
PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA
SN 0195-6108
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD MAR
PY 2011
VL 32
IS 3
BP 424
EP 427
DI 10.3174/ajnr.A2348
PG 4
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 738KX
UT WOS:000288639800002
PM 21292801
ER
PT J
AU Ghali, JK
Massie, BM
Mann, DL
Rich, MW
AF Ghali, Jalal K.
Massie, Barry M.
Mann, Douglas L.
Rich, Michael W.
TI Guidelines are Merely Guidelines
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Editorial Material
ID PERFORMANCE-MEASURES; CLINICAL GUIDELINES
C1 [Ghali, Jalal K.] DMC Cardiovasc Inst, Detroit, MI 48201 USA.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Mann, Douglas L.; Rich, Michael W.] Washington Univ, Sch Med, St Louis, MO USA.
RP Ghali, JK (reprint author), DMC Cardiovasc Inst, 3990 John R,Suite 9370, Detroit, MI 48201 USA.
EM jghali@dmc.org
OI Mann, Douglas /0000-0002-2516-0145
NR 7
TC 1
Z9 1
U1 0
U2 1
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD MAR
PY 2011
VL 17
IS 3
BP 208
EP 209
DI 10.1016/j.cardfail.2011.01.004
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 736WN
UT WOS:000288525800005
PM 21362528
ER
PT J
AU Hadley, D
Anderson, BS
Borckardt, JJ
Arana, A
Li, XB
Nahas, Z
George, MS
AF Hadley, Dakota
Anderson, Berry S.
Borckardt, Jeffrey J.
Arana, Ashley
Li, Xingbao
Nahas, Ziad
George, Mark S.
TI Safety, Tolerability, and Effectiveness of High Doses of Adjunctive
Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for
Treatment-Resistant Depression in a Clinical Setting
SO JOURNAL OF ECT
LA English
DT Article
DE rTMS; TMS; transcranial magnetic stimulation; high-dose TMS; safety;
effectiveness; concomitant medication; panic disorder; suicidal
ideation; suicidality; unipolar; bipolar; depression; VNS; VNS implant
ID MAJOR DEPRESSION; FUNCTIONAL CONNECTIVITY; CONTROLLED-TRIAL; MOTOR
THRESHOLD; CORTEX; MOOD; TMS; EXCITABILITY; METAANALYSIS; EFFICACY
AB Objective: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) recently received Food and Drug Administration (FDA) approval for the treatment of depression and offers an alternative to traditional approaches. This approval was based on a study using 3000 stimuli per day (15,000 stimuli per week) in adults with unipolar depression not taking antidepressant medications. Several meta-analyses suggest a dose-response relationship with TMS. This study was carried out before US FDA approval to test the safety, tolerability, and effectiveness of adjunctive high-dose left prefrontal rTMS in a clinical setting with particular attention to safety of higher doses and potential interactions with antidepressant medications, speed of response, and effects on suicidality.
Method: We enrolled 19 patients who were in a current major depressive episode with treatment-resistant unipolar or bipolar depression and treated them in their acute episode and in a maintenance fashion for 18 months. The patients received daily left prefrontal rTMS at 120% resting motor threshold, 10 Hz, 5 seconds on, and 10 seconds off and for a mean of 6800 stimuli per session (34,000 stimuli per week), more than twice the dose delivered in the pivotal FDA trial. All patients continued antidepressant medication throughout the rTMS treatment; thus rTMS was an adjunctive treatment. We measured adverse effects, depression, quality of life, suicidal ideation, and social and physical functioning.
Results: These higher rTMS doses were well tolerated without significant adverse effects or adverse events. All measured dimensions showed improvement, with many showing improvement in 1 to 2 weeks. Of perhaps most importance, suicidal ideation diminished in 67% of the patients after just 1 week.
Conclusions: These uncontrolled data suggest that higher doses of daily left prefrontal rTMS may safely be used in outpatients with major depressive episode even as an adjunctive treatment.
C1 [Hadley, Dakota; Anderson, Berry S.; Borckardt, Jeffrey J.; Arana, Ashley; Li, Xingbao; Nahas, Ziad; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Hadley, D (reprint author), 105 Cottonwood Dr, Summerville, SC 29483 USA.
EM DakotaHadley88@gmail.com
NR 34
TC 44
Z9 48
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1095-0680
J9 J ECT
JI J. ECT
PD MAR
PY 2011
VL 27
IS 1
BP 18
EP 25
DI 10.1097/YCT.0b013e3181ce1a8c
PG 8
WC Behavioral Sciences; Psychiatry
SC Behavioral Sciences; Psychiatry
GA 726CU
UT WOS:000287697100023
PM 21343710
ER
PT J
AU Hostetter, TH
Kochis, DJ
Shaffer, RN
Chertow, G
Harmon, WE
Klotman, PE
Powe, NR
Sedor, JR
Smedberg, PC
Watnick, S
Winkelmayer, WC
AF Hostetter, Thomas H.
Kochis, Daniel J.
Shaffer, Rachel N.
Chertow, Glenn
Harmon, William E.
Klotman, Paul E.
Powe, Neil R.
Sedor, John R.
Smedberg, Paul C.
Watnick, Suzanne
Winkelmayer, Wolfgang C.
CA ASN Public Policy Board
TI World Kidney Day 2011
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
C1 [Kochis, Daniel J.; Shaffer, Rachel N.; Smedberg, Paul C.] Amer Soc Nephrol, Washington, DC 20006 USA.
[Hostetter, Thomas H.] Albert Einstein Coll Med, New York, NY USA.
[Chertow, Glenn] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA.
[Harmon, William E.] Harvard Univ, Sch Med, Boston, MA USA.
[Harmon, William E.] Childrens Hosp, Boston, MA 02115 USA.
[Klotman, Paul E.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Powe, Neil R.] San Francisco Gen Hosp, Med Serv, San Francisco, CA 94110 USA.
[Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Sedor, John R.] Case Western Reserve Univ, Dept Med, Ctr Study Kidney Dis & Biol, Sch Med, Cleveland, OH 44106 USA.
[Watnick, Suzanne] Portland VA Med Ctr, Portland, OR USA.
[Watnick, Suzanne] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Kochis, DJ (reprint author), Amer Soc Nephrol, 1725 1 St NW,Suite 510, Washington, DC 20006 USA.
EM dkochis@asn-online.org
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAR
PY 2011
VL 22
IS 3
BP 397
EP 398
DI 10.1681/ASN.2011020115
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 740GE
UT WOS:000288778800001
PM 21355055
ER
PT J
AU Rassovsky, Y
Horan, WP
Lee, J
Sergi, MJ
Green, MF
AF Rassovsky, Y.
Horan, W. P.
Lee, J.
Sergi, M. J.
Green, M. F.
TI Pathways between early visual processing and functional outcome in
schizophrenia
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Functional outcome; neurocognition; schizophrenia; social cognition;
visual masking
ID BACKWARD-MASKING PERFORMANCE; NEGATIVE SYMPTOMS; SOCIAL COGNITION;
UNAFFECTED SIBLINGS; FIT INDEXES; PERCEPTION; DEFICITS; SCALE; MEDIATOR;
SYMPTOMATOLOGY
AB Background. Early visual processing deficits are reliably detected in schizophrenia and show relationships to poor real-world functioning. However, the nature of this relationship is complex. Theoretical models and recent studies using statistical modeling approaches suggest that multiple intervening factors are involved. We previously reported that a direct and significant association between visual processing and functional status was mediated by a measure of social perception. The present study examined the contribution of negative symptoms to this model.
Method. We employed structural equation modeling (SEM) to test several models of outcome, using data from 174 schizophrenia out-patients. Specifically, we examined the direct and indirect relative contributions of early visual processing, social perception and negative symptoms to functional outcome.
Results. First, we found that, similar to social perception, a measure of negative symptoms mediated the association between visual information processing and functional status. Second, we found that the inclusion of negative symptoms substantially enhanced the explanatory power of the model. Notably, it was the experiential aspect of negative symptoms (avolition and anhedonia) more than the expressive aspect (affective flattening and alogia) that accounted for significant variance in functional outcome, especially in the social component of the construct of functional outcome.
Conclusions. Social perception and negative symptoms play relevant roles in functional impairment in schizophrenia. Both social perception and negative symptoms statistically mediate the connection between visual processing and functional outcome. However, given the lack of association between social perception and negative symptoms, these constructs appear to have an impact on functioning through separate pathways.
C1 [Rassovsky, Y.; Horan, W. P.; Lee, J.; Green, M. F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Horan, W. P.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Sergi, M. J.] Calif State Univ Northridge, Northridge, CA 91330 USA.
RP Rassovsky, Y (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA.
EM yurir@ucla.edu
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU National Institute of Mental Health (NIMH) [MH-43292, MH-65707];
Department of Veterans Affairs, VISN 22 Mental Illness Research,
Education, and Clinical Center
FX This research was supported by National Institute of Mental Health
(NIMH) grants MH-43292 and MH-65707 to M.F.G., and by the Department of
Veterans Affairs, VISN 22 Mental Illness Research, Education, and
Clinical Center. Additional statistical support was provided by Gerhard
Hellemann, Ph.D.
NR 68
TC 39
Z9 40
U1 2
U2 11
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
J9 PSYCHOL MED
JI Psychol. Med.
PD MAR
PY 2011
VL 41
IS 3
BP 487
EP 497
DI 10.1017/S0033291710001054
PG 11
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 725CF
UT WOS:000287622100005
PM 20482936
ER
PT J
AU Hage, FG
Iskandrian, AE
AF Hage, Fadi G.
Iskandrian, Ami E.
TI Cardiac Autonomic Denervation in Diabetes Mellitus
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Editorial Material
DE Editorials; meta-iodobenzylguanidine; heart failure; diabetes mellitus
ID HEART-RATE RESPONSE; VENTRICULAR SYSTOLIC DYSFUNCTION; CORONARY
BLOOD-FLOW; SYMPATHETIC INNERVATION; EJECTION FRACTION; FAILURE;
ARTERIES; REGADENOSON; NEUROPATHY; ADENOSINE
C1 [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
RP Hage, FG (reprint author), Zeigler Res Bldg 1024,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 22
TC 9
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-9651
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD MAR
PY 2011
VL 4
IS 2
BP 79
EP 81
DI 10.1161/CIRCIMAGING.111.963967
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 734WC
UT WOS:000288370500004
PM 21406659
ER
PT J
AU Strom, JL
Lynch, CP
Egede, LE
AF Strom, Joni L.
Lynch, Cheryl P.
Egede, Leonard E.
TI Rural/Urban Variations in Diabetes Self-Care and Quality of Care in a
National Sample of US Adults With Diabetes
SO DIABETES EDUCATOR
LA English
DT Article
ID RURAL AMERICA; EDUCATION; ACCESS; STATE
AB Purpose
The purpose of this study was to examine differences in diabetes self-care and provider-based quality-of-care indicators between rural and urban dwellers in a nationally representative sample of adults with diabetes.
Methods
Data were analyzed on 52 817 individuals with type 2 diabetes from the 2007 Behavioral Risk Factor Surveillance Survey. Rural and urban residence was based on metropolitan statistical area. Self-care behaviors (nutrition, physical activity, self-monitoring) and quality-of-care indicators (clinical visits, glycemic control, preventive measures) were self-reported. Logistic regression analyses were done using STATA 10 to assess the independent effect of rural/urban residence on self-care and each quality measure and to account for the complex survey design.
Results
Rural residents comprised 21% of the sample and were less likely to receive diabetes education (57% vs 51%, P < .001). The final adjusted model showed that foot self-checks (odds ratio, 1.42; 95% confidence interval, 1.27-1.59) and blood glucose testing at least once daily (odds ratio, 1.14; 95% confidence interval, 1.02-1.26) were significantly higher among rural individuals. Provider-based quality of care was not significantly different by rural/urban residence.
Conclusion
Contrary to what has been reported, there were no significant differences in diabetes quality of care between rural and urban dwellers. In addition, rural dwellers appeared to have better self-care behaviors than urban dwellers. Further research is needed to clarify the reasons for these findings.
C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
Ralph H Johnson VA Med Ctr, Vet Affairs Hlth Serv Res & Dev, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.
EM Egedel@musc.edu
NR 20
TC 6
Z9 7
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-7217
J9 DIABETES EDUCATOR
JI Diabetes Educ.
PD MAR-APR
PY 2011
VL 37
IS 2
BP 254
EP 262
DI 10.1177/0145721710394875
PG 9
WC Endocrinology & Metabolism; Public, Environmental & Occupational Health
SC Endocrinology & Metabolism; Public, Environmental & Occupational Health
GA 737KS
UT WOS:000288568300009
PM 21289298
ER
PT J
AU Agarwal, N
Spiegel, BMR
AF Agarwal, Nikhil
Spiegel, Brennan M. R.
TI The Effect of Irritable Bowel Syndrome on Health-Related Quality of Life
and Health Care Expenditures
SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Irritable bowel syndrome; Health-related quality of life; Health care
expenditures
ID GASTROINTESTINAL SYMPTOMS; RESOURCE UTILIZATION; WORK PRODUCTIVITY;
CONTROLLED-TRIAL; UNITED-STATES; IBS-QOL; PREVALENCE; COLONOSCOPY;
IMPACT; VALIDATION
AB Irritable bowel syndrome (IBS) is a highly prevalent condition with a large health economic burden of illness marked by impaired health-related quality of life (HRQOL), diminished work productivity, and high expenditures. Clinicians should routinely screen for diminished HRQOL by performing a balanced biopsychosocial history rather than focusing just on bowel symptoms. HRQOL decrements should be acknowledged and addressed when making treatment decisions.
C1 [Agarwal, Nikhil; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA.
RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
NR 42
TC 53
Z9 57
U1 1
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8553
J9 GASTROENTEROL CLIN N
JI Gastroenterol. Clin. North Am.
PD MAR
PY 2011
VL 40
IS 1
BP 11
EP +
DI 10.1016/j.gtc.2010.12.013
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 734ON
UT WOS:000288344300003
PM 21333898
ER
PT J
AU Hadano, Y
Dhaliwal, G
Saint, S
Tierney, LM
Sakemi, H
AF Hadano, Yoshiro
Dhaliwal, Gurpreet
Saint, Sanjay
Tierney, Lawrence M., Jr.
Sakemi, Hideta
TI Mapping Out the Diagnosis
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Editorial Material
ID KIKUCHI-FUJIMOTO-DISEASE
C1 [Hadano, Yoshiro] Rakuwakai Otowa Hosp, Dept Gen Internal Med, Yamashina Ku, Kyoto 6078062, Japan.
[Dhaliwal, Gurpreet; Tierney, Lawrence M., Jr.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet; Tierney, Lawrence M., Jr.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Saint, Sanjay] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Saint, Sanjay] Univ Michigan, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI 48109 USA.
RP Sakemi, H (reprint author), Rakuwakai Otowa Hosp, Dept Gen Internal Med, Yamashina Ku, Otowachinji Cho, Kyoto 6078062, Japan.
EM rakuwadr073@rakuwadr.com
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD MAR
PY 2011
VL 6
IS 3
BP 167
EP 170
DI 10.1002/jhm.875
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 736AP
UT WOS:000288462200011
PM 21387553
ER
PT J
AU Zeliadt, SB
Hoffman, RM
Etzioni, R
Gore, JL
Kessler, LG
Lin, DW
AF Zeliadt, Steven B.
Hoffman, Richard M.
Etzioni, Ruth
Gore, John L.
Kessler, Larry G.
Lin, Daniel W.
TI Influence of Publication of US and European Prostate Cancer Screening
Trials on PSA Testing Practices
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID SERVICES-TASK-FORCE; MORTALITY; PATTERNS; UPDATE; MEN
AB In 2009, results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial indicated no difference in mortality between the screening and the control groups (rate ratio = 1.13, 95% confidence interval = 0.75 to 1.70), whereas those from the European Randomized study of Screening for Prostate Cancer trial indicated a 20% reduction in mortality among the screening group (rate ratio = 0.80, 95% confidence interval = 0.65 to 0.98). In this study, we examined whether prostate-specific antigen (PSA) testing has changed following these publications. The primary outcome measure was the proportion of men seen at least once in a primary care or urology clinic between August 1, 2004, and March 31, 2010, who received a PSA test. Following the publications, PSA use declined slightly-by 3.0 percentage points and 2.7 percentage points among men aged 40-54 and 55-74 years, respectively. PSA testing among men older than 75 years initially declined slightly following the recommendations by the US Preventive Services Task Force in 2008 and continued to decline after the trial publications.
C1 [Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA.
[Lin, Daniel W.] VA Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA 98101 USA.
[Zeliadt, Steven B.; Etzioni, Ruth; Kessler, Larry G.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Gore, John L.; Lin, Daniel W.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Hoffman, Richard M.] Univ New Mexico, Med Serv, Dept Vet Affairs Med Ctr, Albuquerque, NM 87131 USA.
[Hoffman, Richard M.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA.
[Zeliadt, Steven B.; Etzioni, Ruth; Gore, John L.; Lin, Daniel W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
RP Zeliadt, SB (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA.
EM steven.zeliadt@va.gov
OI Gore, John/0000-0002-2847-5062
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [HSRD SHP 08-165];
Cancer Prevention and Control Research Network, Centers for Disease
Control and Prevention [U48 DP001911]
FX Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs (HSR&D SHP 08-165 to
S.B.Z.); Cancer Prevention and Control Research Network, Centers for
Disease Control and Prevention (U48 DP001911 to Vicky Taylor who was the
principal investigator of the center but had no direct involvement with
the study).
NR 11
TC 31
Z9 31
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD MAR
PY 2011
VL 103
IS 6
BP 520
EP 523
DI 10.1093/jnci/djr007
PG 4
WC Oncology
SC Oncology
GA 737FQ
UT WOS:000288554900012
PM 21357307
ER
PT J
AU Papay, K
Mamikonyan, E
Siderowf, AD
Duda, JE
Lyons, KE
Pahwa, R
Driver-Dunckley, ED
Adler, CH
Weintraub, D
AF Papay, Kimberly
Mamikonyan, Eugenia
Siderowf, Andrew D.
Duda, John E.
Lyons, Kelly E.
Pahwa, Rajesh
Driver-Dunckley, Erika D.
Adler, Charles H.
Weintraub, Daniel
TI Patient versus informant reporting of ICD symptoms in Parkinson's
disease using the QUIP: Validity and variability
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Impulse control disorders; Parkinson's disease; QUIP
ID IMPULSE CONTROL DISORDERS; BEHAVIORS
AB Questions exist regarding the validity of patient-reporting of psychiatric symptoms in Parkinson's disease (PD). We assessed observer variability and validity in reporting of impulse control disorder (ICD) symptoms in PD by using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP). PD patients and their informants (71 pairs) completed the QUIP to assess four ICDs (compulsive gambling, buying, sexual behavior, and eating) in patients. Trained raters then administered a diagnostic interview. Sensitivity of the QUIP for a diagnosed ICD was 100% for both patient- and informant-completed instruments, and specificity was 75% for both raters. Approximately 40% of patients without an ICD diagnosis had a positive QUIP, suggesting that many PD patients experience subsyndromal ICD symptoms that require ongoing monitoring. Agreement between patient- and informant-reporting of any ICD behaviors on the QUIP was moderate (kappa = 0.408), and for individual ICDs was highest for gambling (kappa = 0.550). Overall, a negative QUIP from either the patient or informant rules out the possibility of an ICD, while a positive QUIP requires a follow-up diagnostic interview and ongoing monitoring to determine if symptoms currently are, or in the future become, clinically significant. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Papay, Kimberly; Mamikonyan, Eugenia; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Siderowf, Andrew D.; Duda, John E.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Duda, John E.; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA.
[Lyons, Kelly E.; Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.
[Driver-Dunckley, Erika D.; Adler, Charles H.] Mayo Clin Scottsdale, Dept Neurol, Scottsdale, AZ USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA.
RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
FU NINDS NIH HHS [P50 NS053488, P50 NS053488-02]
NR 17
TC 29
Z9 29
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD MAR
PY 2011
VL 17
IS 3
BP 153
EP 155
DI 10.1016/j.parkreldis.2010.11.015
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 736FC
UT WOS:000288475100004
PM 21186135
ER
PT J
AU Bates-Jensen, BM
MCCreath, HE
Mehrnia, A
Sun, L
Wang, F
Lam, L
Patlan, A
Walker, M
Sarrafzadeh, M
Kaiser, WJ
AF Bates-Jensen, B. M.
MCCreath, H. E.
Mehrnia, A.
Sun, L.
Wang, F.
Lam, L.
Patlan, A.
Walker, M.
Sarrafzadeh, M.
Kaiser, W. J.
TI DEVELOPMENT AND SAFETY TESTING OF THE SEM SCANNER FOR DETECTING EARLY
PRESSURE ULCERS
SO WOUND REPAIR AND REGENERATION
LA English
DT Meeting Abstract
C1 [Bates-Jensen, B. M.; Sun, L.; Patlan, A.; Walker, M.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Bates-Jensen, B. M.; MCCreath, H. E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Bates-Jensen, B. M.] Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA USA.
[Mehrnia, A.; Wang, F.; Lam, L.; Sarrafzadeh, M.; Kaiser, W. J.] Univ Calif Los Angeles, Wireless Hlth Inst, Los Angeles, CA USA.
[Lam, L.; Sarrafzadeh, M.] Univ Calif Los Angeles, Sch Comp Sci, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1067-1927
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD MAR-APR
PY 2011
VL 19
IS 2
BP A12
EP A12
PG 1
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA 728ML
UT WOS:000287878100018
ER
PT J
AU Harman, SM
Vittinghoff, E
Brinton, EA
Budoff, MJ
Cedars, MI
Lobo, RA
Merriam, GR
Miller, VM
Naftolin, F
Pal, L
Santoro, N
Taylor, HS
Black, DM
AF Harman, S. Mitchell
Vittinghoff, Eric
Brinton, Eliot A.
Budoff, Matthew J.
Cedars, Marcelle I.
Lobo, Rogerio A.
Merriam, George R.
Miller, Virginia M.
Naftolin, Frederick
Pal, Lubna
Santoro, Nanette
Taylor, Hugh S.
Black, Dennis M.
TI Timing and Duration of Menopausal Hormone Treatment May Affect
Cardiovascular Outcomes
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Review
DE Cardiovascular disease; Estrogen; Hormones; Menopause; Women's health
ID CORONARY-HEART-DISEASE; ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE
ESTROGENS; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION;
POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; VENOUS THROMBOEMBOLISM;
ARTERY ATHEROSCLEROSIS; CLINICAL-TRIAL
AB Largely on the basis of the first publication of findings of net harm with menopausal hormone treatment in the Women's Health Initiative (WHI) hormone trials, current Food and Drug Administration recommendations limit menopausal hormone treatment to the "... shortest duration consistent with treatment goals ...," with goals generally taken to mean relief of menopausal symptoms and maximal duration as approximately 5 years. The WHI finding of net harm was due largely to the absence of beneficial effects on coronary heart disease incidence rates. Published analyses of WHI data by age or time since menopause find that excess coronary heart disease risk with menopausal hormone treatment is confined to more remotely menopausal or older women, with younger women showing nonsignificant trends toward benefit (the "timing hypothesis"). Moreover, a recently published reexamination of data from the WHI Estrogen plus Progestin trial suggests that reduced coronary heart disease risk may appear only after 5 to 6 years of treatment. Consistent with this finding, risk ratios for coronary heart disease were calculated as 1.08 (95% confidence interval, 0.86-1.36) in years 1 to 6 and as 0.46 (confidence interval, 0.28-0.78) in years 7 to 8+ in the WHI Estrogen Alone trial. Previous studies also support the beneficial effects of menopausal hormone treatment after prolonged exposure. Thus, current analyses do not support a generalized recommendation for short duration of menopausal hormone treatment. Rather, they suggest that current Food and Drug Administration practice guidelines should be reconsidered to allow individualized care based on risk: benefit considerations. New research is urgently needed evaluating influences of timing, duration, dose, route of administration, and agents on menopausal hormone treatment-related risks and benefits to better understand how to optimize recommendations for individual patients. (C) 2011 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2011) 124, 199-205
C1 [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ 85016 USA.
[Vittinghoff, Eric; Cedars, Marcelle I.; Black, Dennis M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Brinton, Eliot A.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Budoff, Matthew J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
[Lobo, Rogerio A.] Columbia Univ, Coll Med, New York, NY USA.
[Merriam, George R.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Merriam, George R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Miller, Virginia M.] Mayo Clin, Rochester, MN USA.
[Naftolin, Frederick] NYU, Sch Med, New York, NY USA.
[Pal, Lubna; Taylor, Hugh S.] Yale Univ, Sch Med, New Haven, CT USA.
[Santoro, Nanette] Univ Colorado, Denver Sch Med, Aurora, CO USA.
RP Harman, SM (reprint author), Kronos Longev Res Inst, 2222 E Camelback,Suite 220, Phoenix, AZ 85016 USA.
EM mitch.harman@kronosinstitute.org
FU Aurora Foundation, Phoenix, Arizona
FX Funding: The Aurora Foundation, a private charitable foundation based in
Phoenix, Arizona, via a grant to the Kronos Longevity Research
Institute.
NR 81
TC 50
Z9 52
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD MAR
PY 2011
VL 124
IS 3
BP 199
EP 205
DI 10.1016/j.amjmed.2010.09.021
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 732QM
UT WOS:000288203700011
PM 21396500
ER
PT J
AU Subotnik, KL
Nuechterlein, KH
Ventura, J
Gitlin, MJ
Marder, S
Mintz, J
Hellemann, GS
Thornton, LA
Singh, IR
AF Subotnik, Kenneth L.
Nuechterlein, Keith H.
Ventura, Joseph
Gitlin, Michael J.
Marder, Stephen
Mintz, Jim
Hellemann, Gerhard S.
Thornton, Leslie A.
Singh, Indira R.
TI Risperidone Nonadherence and Return of Positive Symptoms in the Early
Course of Schizophrenia
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID SUPPORTED EMPLOYMENT; 1ST EPISODE; RELAPSE; MEDICATION; ADHERENCE;
PREDICTORS; DISORDER; CRITERIA
AB Objective: This study examined the effect of medication nonadherence on the return of positive symptoms among recent-onset schizophrenia patients.
Method: Three sets of operational criteria for medication nonadherence with differing levels of severity were compared for their ability to predict relapse. Explicit operational criteria are provided with the hope that they will be adopted by others. Psychotic symptoms were prospectively rated on a frequent basis, and systematic criteria were applied using a computer scoring program to identify periods of psychotic symptom return. In addition, a specialized statistical survival analysis method, optimal for examining risk periods and outcomes that can recur during the follow-up assessment, was used.
Results: As hypothesized, medication nonadherence robustly predicted a return of psychotic symptoms during the early phase of schizophrenia (hazard ratios=3.7-28.5, depending on the severity of nonadherence).
Conclusions: Even brief periods of partial nonadherence lead to greater risk of relapse than what is commonly assumed. Patients in the early phase of schizophrenia should be cautioned about the possible consequences of partial or relatively brief periods of antipsychotic medication nonadherence. (Am J Psychiatry 2011; 168:286-292)
C1 [Subotnik, Kenneth L.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Subotnik, KL (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, 300 UCLA Med Plaza,Rm 2240, Los Angeles, CA 90095 USA.
EM ksubotnik@mednet.ucla.edu
FU Ortho-McNeil Janssen Scientific Affairs; Pfizer; GlaxoSmithKline;
Novartis; National Institute of Mental Health [MH-037705, MH-066286]
FX Dr. Subotnik has received support from Ortho-McNeil Janssen Scientific
Affairs for an investigator-initiated study. Dr. Nuechterlein has
received support from Ortho-McNeil Janssen Scientific Affairs for an
investigator-initiated study; he has also served as a consultant for
Merck. Dr. Ventura has received support from Pfizer for an
investigator-initiated study. Dr. Gitlin has received honoraria from
AstraZeneca, Bristol-Myers Squibb, Lilly, and Servier. Dr. Marder has
served on the advisory boards of Abbott, Otsuka, Pfizer, Sanofi Aventis,
Schering Plough, and Wyeth; he has also received research support from
GlaxoSmithKline and Novartis; and he is a shareholder with MedAvante.
All other authors report no financial relationships with commercial
interests.; Supported by National Institute of Mental Health research
grants MH-037705 and MH-066286 (Dr. Nuechterlein) and a supplementary
grant from Ortho-McNeil Janssen Scientific Affairs. The content of this
article is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Mental Health, the National Institutes of Health, or Ortho-McNeil
Janssen Scientific Affairs.
NR 30
TC 43
Z9 45
U1 1
U2 5
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAR
PY 2011
VL 168
IS 3
BP 286
EP 292
DI 10.1176/appi.ajp.2010.09010087
PG 7
WC Psychiatry
SC Psychiatry
GA 729AG
UT WOS:000287916900012
PM 21205805
ER
PT J
AU Marino, RJ
Burns, S
Graves, DE
Leiby, BE
Kirshblum, S
Lammertse, DP
AF Marino, Ralph J.
Burns, Stephen
Graves, Daniel E.
Leiby, Benjamin E.
Kirshblum, Steven
Lammertse, Daniel P.
TI Upper- and Lower-Extremity Motor Recovery After Traumatic Cervical
Spinal Cord Injury: An Update From the National Spinal Cord Injury
Database
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Outcomes; Recovery; Rehabilitation; Spinal cord injuries; Tetraplegia
ID NEUROLOGICAL CLASSIFICATION; INTERNATIONAL STANDARDS; COMPLETE
QUADRIPLEGIA; CLINICAL-TRIALS; RELIABILITY; PROGNOSIS; TETRAPLEGIA;
MULTICENTER; SCALE
AB Objective: To present upper- (UEMS) and lower-extremity motor score (LEMS) recovery, American Spinal Injury Association Impairment Scale (AIS) change, and motor level change in persons with traumatic tetraplegia from the Spinal Cord Injury Model Systems (SCIMS).
Design: Longitudinal cohort; follow-up to 1 year.
Setting: U.S. SCIMS.
Participants: Subjects (N = 1436; age > 15y) with tetraplegia with at least 2 examinations, the first within 7 days of injury. Subjects were 80% men injured by vehicular collisions (44%), falls (30%), sports (12%), and violence (11%).
Interventions: Not applicable.
Main Outcome Measures: Change in AIS, UEMS, LEMS, and motor levels.
Results: From a baseline of 7 days or less, 22% of subjects with AIS grade A converted to AIS grade B or better by rehabilitation discharge; and 30%, by 1 year, with 8% to AIS grade C and 7.1% to grade D. Conversion from complete to motor incomplete was not related to timing of the initial examination (P=.54) or initial neurologic level (P=.96). For AIS grade B, 34% remained motor complete, 30% became AIS grade C, and 37% became grade D by 1 year. Although 82.5% of those with AIS grade C improved to AIS grades D and E, mean 1-year UEMS score was only 35 points. UEMS scores in patients with AIS grade A increased a mean of 9 to 11 points, except for C1 to C3 and C8 to T1 motor levels (gain, 2-3 points). Motor level was unchanged or ascended in 35% and improved 1 level in 42%, 2 levels in 14%, and more than 2 levels in 9%. Motor zone of partial preservation of 2 segments or more was associated with gain of 2 or more motor levels, with a relative risk of 5.0 (95% confidence interval, 3.2-7.8; P <.001).
Conclusions: More patients with cervical complete spinal cord injury may be converting to AIS grade D compared with earlier reports. Motor level recovery in those with AIS grade A and UEMS recovery in those with AIS grade C injuries are potential outcomes for acute clinical trials.
C1 [Marino, Ralph J.] Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA.
[Leiby, Benjamin E.] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA.
[Burns, Stephen] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Burns, Stephen] Vet Affairs Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA.
[Graves, Daniel E.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
[Kirshblum, Steven] Kessler Inst Rehabil, W Orange, NJ USA.
[Kirshblum, Steven] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
[Lammertse, Daniel P.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA.
[Lammertse, Daniel P.] Craig Hosp, Englewood, CO USA.
RP Marino, RJ (reprint author), Thomas Jefferson Univ, Dept Rehabil Med, 132 S 10th St,Ste 375,Main Bldg, Philadelphia, PA 19107 USA.
EM ralph.marino@jefferson.edu
OI Marino, Ralph/0000-0003-2670-4113; Lammertse, Daniel/0000-0003-4590-2481
FU National Institute on Disability and Rehabilitation Research, Office of
Special Education and Rehabilitative Services, Department of Education
[H133N060011]
FX Supported by the National Institute on Disability and Rehabilitation
Research, Office of Special Education and Rehabilitative Services,
Department of Education (grant no. H133N060011).
NR 27
TC 27
Z9 28
U1 1
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAR
PY 2011
VL 92
IS 3
BP 369
EP 375
DI 10.1016/j.apmr.2010.09.027
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 732NF
UT WOS:000288191400007
PM 21353821
ER
PT J
AU Myaskovsky, L
Burkitt, KH
Lichy, AM
Ljungberg, IH
Fyffe, DC
Ozawa, H
Switzer, GE
Fine, MJ
Boninger, ML
AF Myaskovsky, Larissa
Burkitt, Kelly H.
Lichy, Alison M.
Ljungberg, Inger H.
Fyffe, Denise C.
Ozawa, Haishin
Switzer, Galen E.
Fine, Michael J.
Boninger, Michael L.
TI The Association of Race, Cultural Factors, and Health-Related Quality of
Life in Persons With Spinal Cord Injury
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Health status disparities; Minority health; Quality of life;
Rehabilitation; Spinal cord injuries
ID PRESSURE ULCER PREVALENCE; ASSISTIVE TECHNOLOGY; PERCEIVED
DISCRIMINATION; PSYCHOSOCIAL FACTORS; RACIAL DISPARITIES;
ETHNIC-DIFFERENCES; CARE; SATISFACTION; OUTCOMES; MODEL
AB Objective: To examine the association of race and cultural factors with quality-of-life factors (participation, life satisfaction, perceived health status) in people with spinal cord injury (SCI).
Design: Cross-sectional multisite study using structured questionnaires.
Setting: Six National SO Model Systems centers.
Participants: People with SCI (N=275; age >= 16y; SCI with discernable neurologic impairments; used power or manual wheelchair for > 1y as primary means of mobility; nonambulatory except for exercise purposes).
Interventions: None. Main Outcome Measures: Participation (Craig Handicap Assessment and Reporting Technique Short Form); satisfaction (Satisfaction With Life Scale); and perceived health status (2 items from 36-Item Short Form Health Survey).
Results: African American (n=96) with SCI reported more experiences of discrimination in health care, greater perceived racism, more health care system distrust, and lower health literacy than whites (n=156; P range, <.001-<.05). Participants who reported experiencing more discrimination in health care reported better occupational functioning (odds ratio [OR], 1.5; 95% confidence interval [CI], 1.07-2.09; P <.05). Those who perceived more racism in health care settings reported better occupational functioning (OR, 1.65; 95% CI, 1.12-2.43; P <.05) and greater perceived health (beta=.36; 95% CI,.05.68; P <.05). Those who reported more distrust in the health care system reported better current health compared with 1 year ago (beta=.38; 95% CI,.06.69; P <.05). Those who reported better communication with their health care provider reported higher levels of mobility (OR, 1.5; 95% Cl, 1.05-2.13; P <.05) and better general health (beta=.27; 95% CI, .01.53; P <.05).
Conclusions: In this cross-sectional study of people with SCI, higher levels of perceived discrimination and racism and better communication with health care providers were associated with an increase in participation and functioning and improvements in perceptions of well-being. These associations are different from those reported in other study populations and warrant confirmation in future prospective studies.
C1 [Myaskovsky, Larissa; Burkitt, Kelly H.; Switzer, Galen E.; Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Boninger, Michael L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Associated Rehabil E, Pittsburgh, PA USA.
[Myaskovsky, Larissa; Switzer, Galen E.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Ozawa, Haishin; Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Lichy, Alison M.; Ljungberg, Inger H.] Natl Rehabil Hosp, Spinal Cord Injury Res Ctr, Washington, DC USA.
[Fyffe, Denise C.] Kessler Fdn Res Ctr, Spinal Cord Injury Lab, W Orange, NJ USA.
RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7160 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM larissa.myaskovsky@va.gov
OI Boninger, Michael/0000-0001-6966-919X
FU Department of Education, National Institute on Disability and
Rehabilitation Research [H133N060019, H113N060022, H133N060028];
Veterans Administration [B3142C, MRP04-409, HFP01-063, IIR06-220-3]
FX Supported by the Department of Education, National Institute on
Disability and Rehabilitation Research (grant nos. H133N060019,
H113N060022, H133N060028) and the Veterans Administration (grant nos.
B3142C, MRP04-409, HFP01-063, IIR06-220-3).
NR 47
TC 11
Z9 11
U1 3
U2 16
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAR
PY 2011
VL 92
IS 3
BP 441
EP 448
DI 10.1016/j.apmr.2010.10.007
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 732NF
UT WOS:000288191400016
PM 21353826
ER
PT J
AU McClure, LA
Boninger, ML
Oyster, ML
Roach, MJ
Nagy, J
Nemunaitis, G
AF McClure, Laura A.
Boninger, Michael L.
Oyster, Michelle L.
Roach, Mary Joan
Nagy, Jennifer
Nemunaitis, Gregory
TI Emergency Evacuation Readiness of Full-Time Wheelchair Users With Spinal
Cord Injury
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Disabled persons; Emergency preparedness; Rehabilitation; Self-help
devices; Spinal cord injuries
ID PREPAREDNESS; TERRORISM
AB Objectives: To determine the percentage of full-time wheelchair users with spinal cord injuries who felt they could evacuate from various locations, and the percentage who have a plan for evacuation. Study results will help clinicians and emergency officials understand needs related to evacuation preparedness.
Design: Convenience sample survey.
Setting: Six Spinal Cord Injury Model System centers, part of the national database funded through the Department of Education, National Institute on Disability and Rehabilitation Research.
Participants: People (N=487) with spinal cord injuries who use a wheelchair more than 40 hours a week.
Interventions: Not applicable.
Main Outcome Measures: The percentage of wheelchair users who felt they would be able to safely evacuate, had a plan for safe evacuation, or reported a need for assistive technology and human assistance to evacuate from various locations in the event of an emergency.
Results: The highest percentage of participants felt they would be able to safely evacuate and had a plan for work evacuation. The lowest percentage of participants reported they could evacuate from their city/town in the event of an emergency and had a plan to evacuate their city/town in the event of a natural disaster. A large difference exists between the percentage of participants who felt they could evacuate and those who have a plan for evacuation.
Conclusions: A large discrepancy exists between the perception that one can evacuate and actually having a plan. The perception that one can evacuate without a plan or the use of assistive technology is an area of concern that must be further addressed by educators. Education must emphasize the need to have a defined evacuation plan and effective utilization of assistive technology.
C1 [McClure, Laura A.; Boninger, Michael L.; Oyster, Michelle L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA.
[McClure, Laura A.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Boninger, Michael L.; Oyster, Michelle L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Roach, Mary Joan; Nagy, Jennifer; Nemunaitis, Gregory] MetroHlth Rehabil Inst Ohio, Cleveland, OH USA.
[Roach, Mary Joan; Nemunaitis, Gregory] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 7180 Highland Dr 151R1-H,Bldg 4,2nd Fl, Pittsburgh, PA 15206 USA.
EM boninger@pitt.edu
OI Boninger, Michael/0000-0001-6966-919X
FU National Institute on Disability and Rehabilitation Research, Office of
Special Education and Rehabilitation Services, U.S. Department of
Education [H133N060019]; National Science Foundation Interdisciplinary
Research Training in Assistive Technology [DGE0333420]
FX Supported by the National Institute on Disability and Rehabilitation
Research, Office of Special Education and Rehabilitation Services, U.S.
Department of Education (grant no. H133N060019) and the National Science
Foundation Interdisciplinary Research Training in Assistive Technology
(grant no. DGE0333420). The material presented here is solely the
responsibility of the authors and does not necessarily reflect the
opinions of the funding agency or the United States Department of
Education.
NR 31
TC 7
Z9 7
U1 0
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAR
PY 2011
VL 92
IS 3
BP 491
EP 498
DI 10.1016/j.apmr.2010.08.030
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 732NF
UT WOS:000288191400023
PM 21353832
ER
PT J
AU McClure, LA
Boninger, ML
Ozawa, H
Koontz, A
AF McClure, Laura A.
Boninger, Michael L.
Ozawa, Haishin
Koontz, Alicia
TI Reliability and Validity Analysis of the Transfer Assessment Instrument
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Outcome Assessment (health care); Rehabilitation
ID WHEELCHAIR-RELATED ACCIDENTS; SPINAL-CORD-INJURY; SKILLS TEST; SEVERITY;
USERS; PAIN
AB Objectives: To describe the development and evaluate the reliability and validity of a newly created outcome measure, the Transfer Assessment Instrument (TAI), to assess the quality of transfers performed by full-time wheelchair users.
Design: Repeated measures.
Setting: 2009 National Veterans Wheelchair Games in Spokane, WA.
Participants: A convenience sample of full-time wheelchair users (N=40) who perform sitting pivot or standing pivot transfers.
Interventions: Not applicable.
Main Outcome Measures: Intraclass correlation coefficients (ICCs) for reliability and Spearman correlation coefficients for concurrent validity between the TAI and a global assessment scale (0-100 visual analog scale [VAS]).
Results: No adverse events occurred during testing. Intrarater ICCs for 3 raters ranged between .35 and .89, and the interrater ICC was .642. Correlations between the TAI and a global assessment VAS ranged between .19 (P=.285) and .69 (P >.000). Item analyses of the tool found a wide range of results, from weak to good reliability. Evaluators found the TAI to be safe and able to be completed in a short time.
Conclusions: The TAI is a safe, quick outcome measure that uses equipment typically found in a clinical setting and does not ask participants to perform new skills. Reliability and validity testing found the TAI to have acceptable interrater and a wide range of intrarater reliability. Future work indicates the need for continued refinement including removal or modification of items found to have low reliability, improved education for clinicians, and further reliability and validity analysis with a more diverse subject population. The TAI has the potential to fill a void in assessment of transfers.
C1 [McClure, Laura A.; Boninger, Michael L.; Ozawa, Haishin; Koontz, Alicia] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[McClure, Laura A.; Boninger, Michael L.; Koontz, Alicia] Univ Pittsburgh, Dept Rehabil Sci, Pittsburgh, PA USA.
[McClure, Laura A.; Boninger, Michael L.; Koontz, Alicia] Univ Pittsburgh, Dept Technol, Pittsburgh, PA USA.
[Boninger, Michael L.; Ozawa, Haishin] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr 15IR1-H,Bldg 4,2nd Fl, Pittsburgh, PA 15206 USA.
EM boninger@pitt.edu
OI Boninger, Michael/0000-0001-6966-919X
FU Veterans Affairs Center for Excellence for Wheelchairs; Associated
Rehabilitation Engineering Award [B3142C]
FX Supported by the Veterans Affairs Center for Excellence for Wheelchairs
and Associated Rehabilitation Engineering Award (award no. B3142C).
NR 15
TC 10
Z9 10
U1 2
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAR
PY 2011
VL 92
IS 3
BP 499
EP 508
DI 10.1016/j.apmr.2010.07.231
PG 10
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 732NF
UT WOS:000288191400024
PM 21276957
ER
PT J
AU Harris, DP
Ortiz, F
Adler, FM
Yu, K
Maines, ML
Barba, D
Viggiani, SI
Wolf, SM
Fitten, LJ
Chodosh, J
Vickrey, BG
AF Harris, Dorothy P.
Ortiz, Freddy
Adler, Fredric M.
Yu, Katherine
Maines, Michele L.
Barba, Dora
Viggiani, Sandra I.
Wolf, Sheldon M.
Fitten, L. Jaime
Chodosh, Joshua
Vickrey, Barbara G.
TI Challenges to screening and evaluation of memory impairment among
Hispanic elders in a primary care safety net facility
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE memory screening; Hispanic elders; quality improvement
ID ALZHEIMERS-DISEASE; HEALTH-CARE; INFORMANT QUESTIONNAIRE; COGNITIVE
IMPAIRMENT; MEXICAN-AMERICANS; OLDER-ADULTS; DEMENTIA; PREVALENCE;
DEPRESSION; ACCESS
AB Objective: Implement a memory impairment screening procedure for elderly Hispanic primary care patients, and analyze its yield and challenges to further triage and diagnostic evaluation.
Methods: Three hundred twenty nine Hispanic patients aged >= 60 years or proxy informants were enrolled from outpatient primary care clinics at an urban safety-net medical center. Patients were screened for memory impairment using the WHO-UCLA AVLT; for those without consent capacity, proxies were given the IQCODE. Bilingual research assistants conducted in-person or telephone screening. Age, gender, education, comorbidities, acculturation, overall health, access to care, and memory concerns were assessed as potential predictors of memory impairment. Based on identified implementation challenges, a multi-disciplinary stakeholder committee proposed revised approaches to increase diagnostic evaluation and sustainability.
Results: Of 677 eligible patients approached, 329 (49%) were screened, and 77 (23%) met criteria for memory impairment using the WHO-UCLA AVLT (N = 60) or the IQCODE (N = 17). Only male gender and higher comorbidity uniquely predicted memory impairment (ps < 0.05). Few screen-positive patients declined further triage and evaluation, but a substantial proportion could not be subsequently contacted. Challenges to implementing a memory screening program included staff time and adequate clinic space for in-person screening; challenges to follow-up of positive screening results included inability to contact patients and lack of primary care continuity to facilitate further triage and referral.
Conclusions: Nearly one-fourth of primary care Hispanic elders screened as memory-impaired, but few factors predicted positive screening. Stakeholder-guided adaptations are needed-particularly in resource-constrained settings-to overcome challenges to further diagnostic evaluation and referral. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Harris, Dorothy P.; Ortiz, Freddy; Maines, Michele L.; Wolf, Sheldon M.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Ortiz, Freddy; Fitten, L. Jaime; Chodosh, Joshua; Vickrey, Barbara G.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Ortiz, Freddy; Adler, Fredric M.; Yu, Katherine; Barba, Dora; Viggiani, Sandra I.; Wolf, Sheldon M.] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA.
[Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Fitten, L. Jaime] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
RP Vickrey, BG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
EM bvickrey@ucla.edu
OI Chodosh, Joshua/0000-0001-7784-4306
FU California Department of Health Services [06-55314]
FX The authors would like to thank Stefanie Vassar, MS for programming
assistance and Sandy Cerda for administrative assistance. Karina
Martinez and Farida Kazvinova provided important service in conducting
the screening of study subjects. This work was supported by the
California Department of Health Services (grant number 06-55314) for the
Alzheimer's Disease Research Center of California.
NR 31
TC 2
Z9 3
U1 1
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 26
IS 3
BP 268
EP 276
DI 10.1002/gps.2524
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 731GE
UT WOS:000288093500007
PM 20629169
ER
PT J
AU Johanson, ME
Murray, WM
Hentz, VR
AF Johanson, M. Elise
Murray, Wendy M.
Hentz, Vincent R.
TI Comparison of Wrist and Elbow Stabilization Following Pinch
Reconstruction in Tetraplegia
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Electromyography; lateral pinch; spinal cord injury; tendon transfer;
tetraplegia
ID UPPER EXTREMITY; KEY PINCH; BRACHIORADIALIS; MUSCLES
AB Purpose Individuals with spinal cord injuries resulting in tetraplegia may receive tendon transfer surgery to restore grasp and pinch function. These procedures often involve rerouting the brachioradialis (Br) and the extensor carpi radialis longus tendons volar to the flexion-extension axis of the wrist, leaving the extensor carpi radialis brevis (ECRB) muscle to provide wrist extension strength. The purpose of this study was to determine whether externally stabilizing the wrist after transfer procedures would improve the ability to activate the transferred Br and resulting pinch force, similar to the effect observed when the elbow is externally stabilized.
Methods We used a one-way repeated-measures study design to determine the effect of 3 support conditions on muscle activation and lateral pinch force magnitude in 8 individuals with tetraplegia and previous tendon transfer surgeries. Muscle activation was recorded from Br and ECRB with intramuscular electrodes and from biceps and triceps muscles with surface electrodes. We quantified pinch strength with a 6-axis force sensor and custom grip. We recorded measurements in 3 support conditions: with the arm self-stabilized, with elbow stabilization, and with elbow and wrist stabilization. Pairwise differences were tested using Wilcoxon signed-rank tests.
Results Maximum effort pinch force magnitude and Br activation were significantly increased in both supported conditions compared with the self-supported trials. The addition of wrist stabilization had no significant effect compared with elbow stabilization alone.
Conclusions A strong ECRB has adequate strength to extend the wrist, even after multiple transfers that contribute an additional flexion moment from strong activation of donor muscles. Anatomical and functional differences between the wrist and elbow musculature are important determinants for self-stabilizing joints proximal to the tendon transfer. The ability to increase Br activation and resulting pinch force may be determined, in part, by the individual's ability to develop new coordination strategies. (J Hand Surg 2011;36A:480-485. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.)
C1 [Johanson, M. Elise] VA Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr, Palo Alto, CA 94304 USA.
Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
Northwestern Univ, Dept Phys Med & Rehabil, Evanston, IL 60208 USA.
US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
RP Johanson, ME (reprint author), VA Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr, 3801 Miranda Ave-153, Palo Alto, CA 94304 USA.
EM johanson@va51.stanford.edu
RI Murray, Wendy/B-7629-2009; Murray, Wendy/D-1520-2009
OI Murray, Wendy/0000-0002-7547-621X
FU Department of Veterans Affairs, Rehabilitation Research and Development
Service [A3741R]
FX Supported by the Department of Veterans Affairs, Rehabilitation Research
and Development Service, Project A3741R.
NR 18
TC 4
Z9 4
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD MAR
PY 2011
VL 36A
IS 3
BP 480
EP 485
DI 10.1016/j.jhsa.2010.11.006
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 733AG
UT WOS:000288232200017
PM 21277699
ER
PT J
AU Raval, MV
Bentrem, DJ
Eskandari, MK
Ingraham, AM
Hall, BL
Randolph, B
Ko, CY
Morton, JM
AF Raval, Mehul V.
Bentrem, David J.
Eskandari, Mark K.
Ingraham, Angela M.
Hall, Bruce L.
Randolph, Barbara
Ko, Clifford Y.
Morton, John M.
TI The Role of Surgical Champions in the American College of Surgeons
National Surgical Quality Improvement Program - A National Survey
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE ACS NSQIP; surgeon champion; survey; quality improvement; surgery
ID OF-VETERANS-AFFAIRS; RISK ADJUSTMENT; PRIVATE-SECTOR; NSQIP; CARE;
HOSPITALS
AB Background. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) empowers surgeons and medical centers to reliably collect, analyze, and act on clinically collected outcomes data. How individual ACS NSQIP leaders designated as Surgeon Champions (SC) utilize the ACS NSQIP at the hospital level and the obstacles they encounter are not well studied.
Materials and Methods. All SC representing the 236 hospitals participating in the ACS NSIQP were invited to complete a survey designed to assess the role of the SC, data use, continuous quality improvement (CQI) efforts, CQI culture, and financial implications.
Results. We received responses from 109 (46.2%) SC. The majority (72.5%) of SC were not compensated for their CQI efforts. Factors associated with demonstrable CQI efforts included longer duration of participation in the program, frequent meetings with clinical reviewers, frequent presentation of data to administration, compensation for Surgical Champion efforts and providing individual surgeons with feedback (all P < 0.05). Almost all SC stated ACS NSQIP data improved the quality of care that patients received at the hospital level (92.4%) and that the ACS NSQIP provided data that could not be obtained by other sources (95.2%). All SCs considered future funding for participation in the ACS NSQIP secure.
Conclusions. Active use of ACS NSQIP data provide SC with demonstrable CQI by regularly reviewing data, having frequent interaction with clinical reviewers, and frequently sharing data with hospital administration and colleagues. SC thus play a key role in successful quality improvement at the hospital level. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Raval, Mehul V.; Ingraham, Angela M.; Randolph, Barbara; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA.
[Raval, Mehul V.; Bentrem, David J.; Eskandari, Mark K.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
[Bentrem, David J.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA.
[Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA.
[Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Barnes Jewish Hosp, Ctr Hlth Policy, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Morton, John M.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA.
RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM m-raval@md.northwestern.edu
OI Raval, Mehul/0000-0002-1527-2661
FU John Gray Research Fellowship; Daniel F. and Ada L. Rice Foundation;
Department of Veterans Affairs, Veterans Health Administration, Health
Services Research, and Development Service
FX MVR participates in the American College of Surgeons Clinical Scholars
in Residence Program. MVR is supported by the John Gray Research
Fellowship and the Daniel F. and Ada L. Rice Foundation. DJB is
supported by a career development award from the Department of Veterans
Affairs, Veterans Health Administration, Health Services Research, and
Development Service. The authors thank all SC for participation in the
survey. The authors offer recognition of all ACS NSQIP staff in
conducting this study, especially Matt Fordham and Molly Clear for their
leadership and coordination. MVR thanks Professors Elizabeth Hahn and
Susan Yount for providing feedback on survey design and methodology.
NR 21
TC 7
Z9 7
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD MAR
PY 2011
VL 166
IS 1
BP E15
EP E25
DI 10.1016/j.jss.2010.10.036
PG 11
WC Surgery
SC Surgery
GA 732EI
UT WOS:000288167300002
PM 21176914
ER
PT J
AU Ostrem, JL
Racine, CA
Glass, GA
Grace, JK
Volz, MM
Heath, SL
Starr, PA
AF Ostrem, J. L.
Racine, C. A.
Glass, G. A.
Grace, J. K.
Volz, M. M.
Heath, S. L.
Starr, P. A.
TI Subthalamic nucleus deep brain stimulation in primary cervical dystonia
SO NEUROLOGY
LA English
DT Article
ID PRIMARY GENERALIZED DYSTONIA; GLOBUS-PALLIDUS INTERNUS;
PARKINSONS-DISEASE; NEURONAL-ACTIVITY; BASAL GANGLIA; PATTERNS
AB Objectives: The globus pallidus internus (GPi) has been the primary target for deep brain stimulation (DBS) to treat severe medication-refractory dystonia. Some patients with primary cervical or segmental dystonia develop subtle bradykinesia occurring in previously nondystonic body regions during GPi DBS. Subthalamic nucleus (STN) DBS may provide an alternative target choice for treating dystonia, but has only been described in a few short reports, without blinded rating scales, statistical analysis, or detailed neuropsychological studies.
Methods: In this prospective pilot study, we analyzed the effect of bilateral STN DBS on safety, efficacy, quality of life, and neuropsychological functioning in 9 patients with medically refractory primary cervical dystonia. Severity of dystonia was scored by a blinded rater (unaware of the patient's preoperative or postoperative status) using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) preoperatively and 3, 6, and 12 months postsurgery. Lead location, medications, and adverse events were also measured.
Results: STN DBS was well-tolerated with no serious adverse effects. The TWSTRS total score improved (p < 0.001) from a mean (+/- SEM) of 53.1 (+/- 2.57), to 19.6 (+/- 5.48) at 12 months. Quality of life measures were also improved. STN DBS induced no consistent neuropsychological deficits. Several patients reported depression in the study and 3 had marked weight gain. No patients developed bradykinetic side effects from stimulation, but all patients developed transient dyskinetic movements during stimulation.
Conclusions: This prospective study showed that bilateral STN DBS resulted in improvement in dystonia and suggests that STN DBS may be an alternative to GPi DBS for treating primary cervical dystonia.
Classification of evidence: This study provides Class III evidence that bilateral subthalamic nucleus deep brain stimulation results in significant improvement in cervical dystonia without bradykinetic side effects. Neurology (R) 2011;76:870-878
C1 [Ostrem, J. L.; Glass, G. A.; Grace, J. K.; Volz, M. M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94115 USA.
[Racine, C. A.; Starr, P. A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94115 USA.
[Ostrem, J. L.; Glass, G. A.; Heath, S. L.; Starr, P. A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA.
RP Ostrem, JL (reprint author), Univ Calif San Francisco, Dept Neurol, 1635 Divisadero St,5th Floor,Suites 520-530, San Francisco, CA 94115 USA.
EM jill.ostrem@ucsf.edu
FU Benign Essential Blepharospasm Research Foundation; Ceregene, St. Jude
Medical, Inc.; SurgiVision, Inc.; Allergan, Inc.; NIH; Novartis; UC
Discovery Grant Award; UCSF; Anonymous Foundation; Medtronic, Inc.;
Dystonia Medical Research Foundation
FX Supported by the Benign Essential Blepharospasm Research Foundation and
by private donors Larry and Kana Miao.Dr. Ostrem serves on the speakers'
bureau for and has received funding for travel and speaker honoraria
from Allergan, Inc.; serves as a consultant for Boston Scientific;
performs clinical examinations (80% effort) for the UCSF Surgical
Movement Disorders Center; and receives research support from Ceregene,
St. Jude Medical, Inc., SurgiVision, Inc., Allergan, Inc., the NIH, UC
Discovery Grant, and the Benign Essential Blepharospasm Research
Foundation. Dr. Racine has served as a consultant for Novartis and has
received/receives research support from Novartis, UC Discovery Grant
Award, UCSF Brain Tumor SPORE Developmental Award, private donors, and
the Anonymous Foundation. Dr. Glass serves on the speakers' bureau for
and has received funding for travel and speaker honoraria from Allergan,
Inc. J.K. Grace reports no disclosures. M.M. Volz serves as a consultant
and on the speakers' bureau for and has received funding for travel and
speaker honoraria from Medtronic, Inc.; employs SurgiVision imaging
technology (25% effort) in the UCSF Surgical Movement Disorders
Practice; and receives research support from SurgiVision, Inc. and the
Benign Essential Blepharospasm Research Foundation. S.L. Heath serves as
a consultant and on the speakers' bureau for and has received funding
for travel and speaker honoraria from Medtronic, Inc. Dr. Starr serves
on a scientific advisory board for Protein Therapeutics, Inc.; serves on
the editorial board of Stereotactic and Functional Neurosurgery; serves
as a consultant for Boston Scientific; and receives research support
from SurgiVision, Inc. the NIH, and the Dystonia Medical Research
Foundation.
NR 30
TC 75
Z9 77
U1 1
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAR
PY 2011
VL 76
IS 10
BP 870
EP 878
DI 10.1212/WNL.0b013e31820f2e4f
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 731NZ
UT WOS:000288117500008
PM 21383323
ER
PT J
AU Goldstein, G
Haas, GL
AF Goldstein, Gerald
Haas, Gretchen L.
TI SUICIDAL BEHAVIOR IN HOMELESS VETERANS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA.
[Goldstein, Gerald; Haas, Gretchen L.] VA Pittsburgh HCS, MIRECC, Pittsburgh, PA USA.
[Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 4
EP 4
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000011
ER
PT J
AU Tarbox, SI
Brown, LH
Haas, GL
AF Tarbox, Sarah I.
Brown, Leslie Horton
Haas, Gretchen L.
TI PREMORBID ADJUSTMENT IN AFFECTIVE AND NON-AFFECTIVE PSYCHOSIS: A FIRST
EPISODE STUDY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Tarbox, Sarah I.; Brown, Leslie Horton; Haas, Gretchen L.] Univ Pittsburgh, Pittsburgh, PA USA.
[Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 21
EP 22
PG 2
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000063
ER
PT J
AU Copeland, LA
Zeber, JE
Sako, EY
Flynn, J
MacCarthy, AA
MacCarthy, DJ
Lawrence, VA
AF Copeland, Laurel A.
Zeber, John E.
Sako, E. Y.
Flynn, J.
MacCarthy, A. A.
MacCarthy, D. J.
Lawrence, V. A.
TI EPIDEMIOLOGY OF THREE COMMON SURGERIES IN VETERANS WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Copeland, Laurel A.; Zeber, John E.] Vet Affairs Scott & White, Ctr Appl Hlth Res, Temple, TX USA.
[Sako, E. Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
[Sako, E. Y.; Flynn, J.] Vet Affairs, S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Flynn, J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[MacCarthy, A. A.; MacCarthy, D. J.; Lawrence, V. A.] Vet Affairs, VERDICT, San Antonio, TX USA.
[Lawrence, V. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Epidemiol, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 24
EP 24
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000068
ER
PT J
AU Mathis, KI
Wynn, J
Green, MF
AF Mathis, Kristopher Ian
Wynn, Jonathan
Green, Michael F.
TI ATTENTIONAL BLINK IN SCHIZOPHRENIA: PERFORMANCE AND ERP EVIDENCE FOR
ABNORMALITY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Mathis, Kristopher Ian; Wynn, Jonathan; Green, Michael F.] W Los Angeles VA Healthcare Ctr, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
[Wynn, Jonathan; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 37
EP 37
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000106
ER
PT J
AU Perez, VB
Woods, S
Roach, BJ
Ford, JM
McGlashan, TH
Srihari, VH
Mathalon, DH
AF Perez, Veronica B.
Woods, Scott
Roach, Brian J.
Ford, Judith M.
McGlashan, Thomas H.
Srihari, Vinod H.
Mathalon, Daniel H.
TI GAMMA-BAND ASYNCHRONY ACROSS THE ILLNESS COURSE OF SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Perez, Veronica B.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] UCSF, San Francisco, CA USA.
[Perez, Veronica B.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Woods, Scott; McGlashan, Thomas H.; Srihari, Vinod H.] Yale Univ, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 40
EP 40
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000114
ER
PT J
AU Wynn, J
Mathis, KI
Gibson, C
Altshuler, L
Green, MF
AF Wynn, Jonathan
Mathis, Kristopher Ian
Gibson, C.
Altshuler, L.
Green, Michael F.
TI EVENT-RELATED POTENTIAL FACIAL PROCESSING DEFICITS IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Wynn, Jonathan; Mathis, Kristopher Ian; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA.
[Wynn, Jonathan; Gibson, C.; Altshuler, L.; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 43
EP 43
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000122
ER
PT J
AU Roussos, P
Katsel, P
Siever, LJ
Haroutunian, V
AF Roussos, Panos
Katsel, Pavel
Siever, Larry J.
Haroutunian, Vahram
TI THE NF-KAPPA B PATHWAY IN SCHIZOPHRENIA POSTMORTEM BRAIN TISSUE
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Roussos, Panos; Katsel, Pavel; Siever, Larry J.; Haroutunian, Vahram] Mt Sinai Sch Med, New York, NY USA.
[Roussos, Panos; Siever, Larry J.; Haroutunian, Vahram] James J Peters VA Med Ctr, Bronx, NY USA.
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 75
EP 76
PG 2
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000219
ER
PT J
AU Roussos, P
Katsel, P
Siever, LJ
Davis, KL
Haroutunian, V
AF Roussos, Panos
Katsel, P.
Siever, Larry J.
Davis, K. L.
Haroutunian, Vahram
TI THE NODE OF RANVIER IN SCHIZOPHRENIA POSTMORTEM BRAIN TISSUE
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Roussos, Panos; Katsel, P.; Siever, Larry J.; Davis, K. L.; Haroutunian, Vahram] Mt Sinai Sch Med, New York, NY USA.
[Roussos, Panos; Siever, Larry J.; Haroutunian, Vahram] James J Peters VA Med Ctr, Bronx, NY USA.
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 76
EP 76
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000220
ER
PT J
AU Siever, LJ
Roussos, P
Buxbaum, J
Greenwood, T
Giakoumaki, S
Bitsios, P
Braff, DL
Hardiman, G
AF Siever, Larry J.
Roussos, Panos
Buxbaum, J.
Greenwood, T.
Giakoumaki, S.
Bitsios, P.
Braff, David L.
Hardiman, G.
TI CANDIDATE GENE AND CNV GENOTYPE/PHENOTYPE ASSOCIATIONS IN THE
SCHIZOPHRENIA SPECTRUM
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Siever, Larry J.; Roussos, Panos; Buxbaum, J.] Mt Sinai Sch Med, New York, NY USA.
[Siever, Larry J.] James J Peters VA Med Ctr, VISN MIRECC 3, Bronx, NY USA.
[Roussos, Panos; Giakoumaki, S.; Bitsios, P.] Univ Crete, Iraklion, Greece.
[Greenwood, T.; Braff, David L.; Hardiman, G.] Univ Calif San Diego, San Diego, CA 92103 USA.
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 90
EP 91
PG 2
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000263
ER
PT J
AU Siever, LJ
Roussos, P
Greenwood, T
Braff, DL
Weinstein, S
Hardiman, G
AF Siever, Larry J.
Roussos, Panos
Greenwood, T.
Braff, David L.
Weinstein, S.
Hardiman, G.
TI GENETIC ASSOCIATION AND PATHWAY ANALYSIS OF 94 CANDIDATE GENES IN
SCHIZOTYPAL PERSONALITY DISORDER
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Siever, Larry J.; Roussos, Panos] Mt Sinai Sch Med, New York, NY USA.
[Siever, Larry J.; Weinstein, S.] James J Peters VA Med Ctr, VISN MIRECC 3, Bronx, NY USA.
[Roussos, Panos] James J Peters VA Med Ctr, Psychiat Serv, Bronx, NY USA.
[Greenwood, T.; Braff, David L.; Hardiman, G.] Univ Calif San Diego, San Diego, CA 92103 USA.
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 90
EP 90
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000262
ER
PT J
AU Castillo, DA
Lopez, LA
Manaugh, B
Milam, AC
Boone, H
Dassori, AM
Velligan, DI
Li, X
Scott, L
Miller, AL
AF Castillo, Desiree A.
Lopez, L. A.
Manaugh, B.
Milam, A. C.
Boone, H.
Dassori, A. M.
Velligan, D. I.
Li, X.
Scott, L.
Miller, A. L.
TI CONCORDANCE BETWEEN PHYSICIANS' AND PATIENTS' RATINGS OF COGNITIVE
IMPAIRMENTS AND FUNCTIONING ASSOCIATED WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Castillo, Desiree A.; Dassori, A. M.; Velligan, D. I.; Li, X.; Miller, A. L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Lopez, L. A.; Manaugh, B.; Milam, A. C.; Boone, H.; Scott, L.] Ctr Hlth Care Serv, San Antonio, TX USA.
[Dassori, A. M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 96
EP 97
PG 2
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000279
ER
PT J
AU Yao, JK
Reddy, R
Dougherty, G
Magan, S
Gurklis, J
Sonel, A
Sonel, E
Kisslinger, B
Keshavan, M
Chengappa, K
AF Yao, Jeffrey K.
Reddy, R.
Dougherty, G.
Magan, S.
Gurklis, J.
Sonel, A.
Sonel, E.
Kisslinger, B.
Keshavan, Matcheri
Chengappa, K.
TI ASSOCIATION OF HSCRP WITH HIGH-RISK OF CARDIOVASCULAR DISEASE IN
PATIENTS WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Yao, Jeffrey K.; Reddy, R.; Dougherty, G.; Magan, S.; Gurklis, J.; Sonel, A.; Sonel, E.; Kisslinger, B.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
[Yao, Jeffrey K.; Reddy, R.; Dougherty, G.; Gurklis, J.; Keshavan, Matcheri; Chengappa, K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Keshavan, Matcheri] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
[Keshavan, Matcheri] Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 120
EP 120
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000344
ER
PT J
AU Fryer, SL
Woods, S
Kiehl, K
Calhoun, V
Pearlson, GD
McGlashan, TH
Mathalon, DH
AF Fryer, Susanna L.
Woods, Scott
Kiehl, K.
Calhoun, Vince
Pearlson, Godfrey D.
McGlashan, Thomas H.
Mathalon, Daniel H.
TI FMRI REVEALS DECREASED PREFRONTAL CORTICAL ENGAGEMENT DURING RESPONSE
INHIBITION IN YOUTH AT CLINICAL RISK FOR DEVELOPING SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Fryer, Susanna L.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fryer, Susanna L.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Woods, Scott; Pearlson, Godfrey D.; McGlashan, Thomas H.] Yale Univ, New Haven, CT USA.
[Kiehl, K.; Calhoun, Vince] Univ New Mexico, Albuquerque, NM 87131 USA.
[Kiehl, K.] Mind Res Network, Albuquerque, NM USA.
[Pearlson, Godfrey D.] Inst Living, Olin Neuropsychiat Res Ctr, Hartford, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 136
EP 136
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000386
ER
PT J
AU Hooker, CI
Bruce, L
Fisher, M
Verosky, SC
Miyakawa, A
D'Esposito, M
Vinogradov, S
AF Hooker, Christine I'Lee
Bruce, L.
Fisher, Melissa
Verosky, S. C.
Miyakawa, A.
D'Esposito, M.
Vinogradov, Sophia
TI THE INFLUENCE OF COMBINED COGNITIVE AND SOCIAL-COGNITIVE TRAINING ON
AMYGDALA RESPONSE DURING FACE EMOTION PROCESSING IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Hooker, Christine I'Lee; Bruce, L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Fisher, Melissa; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Fisher, Melissa; Vinogradov, Sophia] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Verosky, S. C.; Miyakawa, A.; D'Esposito, M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 140
EP 140
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000397
ER
PT J
AU Mathalon, DH
Loewy, RL
Ford, JM
Miller, RM
Shanbhag, H
Vinogradov, S
AF Mathalon, Daniel H.
Loewy, Rachel L.
Ford, Judith M.
Miller, R. M.
Shanbhag, H.
Vinogradov, Sophia
TI ABERRANT DEFAULT MODE NETWORK CONNECTIVITY DURING REST IN EARLY
SCHIZOPHRENIA AND IN PATIENTS AT HIGH CLINICAL RISK FOR PSYCHOSIS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Mathalon, Daniel H.; Loewy, Rachel L.; Ford, Judith M.; Miller, R. M.; Shanbhag, H.; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mathalon, Daniel H.; Ford, Judith M.; Miller, R. M.; Shanbhag, H.; Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 145
EP 146
PG 2
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000412
ER
PT J
AU Tregellas, J
Wongngamnit, N
Tanabe, J
Eichman, L
Martin, L
AF Tregellas, Jason
Wongngamnit, N.
Tanabe, J.
Eichman, L.
Martin, L.
TI NICOTINE ENHANCES CEREBELLAR RESPONSE DURING FINGER TAPPING
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Tregellas, Jason; Martin, L.] Denver VA Med Ctr, Res Serv, Denver, CO USA.
[Tregellas, Jason; Wongngamnit, N.; Eichman, L.; Martin, L.] Univ Colorado Denver, Dept Psychiat, Aurora, CO USA.
[Tanabe, J.] Univ Colorado Denver, Dept Radiol, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 154
EP 154
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000435
ER
PT J
AU Siever, LJ
Hazlett, E
McClure, MM
Koenigsberg, H
Thompson, J
Abi-Dargham, A
AF Siever, Larry J.
Hazlett, E.
McClure, M. McNamara
Koenigsberg, H.
Thompson, J.
Abi-Dargham, Anissa
TI PREFRONTAL PROTECTIVE FACTORS IN SCHIZOTYPAL PERSONALITY DISORDER
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Siever, Larry J.; Hazlett, E.; McClure, M. McNamara; Koenigsberg, H.] Mt Sinai Sch Med, New York, NY USA.
[Siever, Larry J.; Hazlett, E.; McClure, M. McNamara] James J Peters Med Ctr, VISN MIRECC 3, Bronx, NY USA.
[Koenigsberg, H.] James J Peters Med Ctr, Psychiat Serv, Bronx, NY USA.
[Thompson, J.; Abi-Dargham, Anissa] Columbia Sch Med, New York State Psychiat Inst, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 177
EP 177
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000501
ER
PT J
AU Green, MF
Lee, J
AF Green, Michael F.
Lee, Junghee
TI EARLY VISUAL PERCEPTION AND SOCIAL COGNITION IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Green, Michael F.; Lee, Junghee] UCLA NPI, Los Angeles, CA USA.
[Green, Michael F.; Lee, Junghee] VA Greater Angeles, MIRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 208
EP 208
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000589
ER
PT J
AU Hoffman, RE
Grasemann, U
Gueorguieva, R
Lane, DW
Miikkulainen, R
AF Hoffman, Ralph Edward
Grasemann, U.
Gueorguieva, R.
Lane, D. W.
Miikkulainen, R.
TI USING COMPUTATIONAL PATIENTS TO EVALUATE ILLNESS MECHANISMS IN
SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Hoffman, Ralph Edward; Gueorguieva, R.] Yale Univ, Sch Med, New Haven, CT USA.
[Grasemann, U.; Miikkulainen, R.] Univ Texas Austin, Austin, TX 78712 USA.
[Lane, D. W.] VA Puget Sound Healthcare Syst, Integrated Gerontol Program, Tacoma, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 211
EP 211
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000596
ER
PT J
AU Lee, J
Harvey, PO
Kern, RS
Kee, K
Green, MF
AF Lee, Junghee
Harvey, Philippe-Olivier
Kern, Robert S.
Kee, K.
Green, Michael F.
TI CONTEXTUAL MODULATION OF FACIAL AFFECT RECOGNITION IN SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Lee, Junghee; Harvey, Philippe-Olivier; Kern, Robert S.; Kee, K.; Green, Michael F.] Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA.
[Lee, Junghee; Harvey, Philippe-Olivier; Kern, Robert S.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 215
EP 216
PG 2
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000610
ER
PT J
AU Bell, MD
Weinstein, A
AF Bell, Morris David
Weinstein, A.
TI COMPUTER-BASED SIMULATED JOB INTERVIEW TRAINING FOR VOCATIONAL
REHABILITATION: FEASIBILITY AND TOLERABILITY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Bell, Morris David; Weinstein, A.] Yale Univ, Sch Med, West Haven, CT 06516 USA.
[Bell, Morris David] US Dept Vet Affairs, West Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 259
EP 259
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000734
ER
PT J
AU Caponigro, J
Valenti, L
Luther, J
Haas, GL
AF Caponigro, Janelle
Valenti, L.
Luther, J.
Haas, Gretchen L.
TI SOCIAL COGNITION IN SCHIZOPHRENIA AND BIPOLAR DISORDER: PRELIMINARY
FINDINGS FROM A CROSS-DIAGNOSTIC COMPARISON STUDY
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Caponigro, Janelle] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Valenti, L.] Arcadia Univ, Glenside, PA USA.
[Luther, J.; Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, VISN MIRECC 4, Pittsburgh, PA USA.
[Luther, J.; Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 261
EP 261
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000740
ER
PT J
AU Haas, GL
Brown, LH
Luther, JF
AF Haas, Gretchen L.
Brown, Leslie Horton
Luther, J. F.
TI COGNITIVE FLEXIBILITY AS A PREDICTOR OF PERSPECTIVE-TAKING IN
SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Haas, Gretchen L.; Brown, Leslie Horton; Luther, J. F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Haas, Gretchen L.; Luther, J. F.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 266
EP 266
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000755
ER
PT J
AU Byun, N
Lawson, K
Gore, JC
Conn, PJ
Jones, CK
AF Byun, Nellie
Lawson, K.
Gore, J. C.
Conn, P. J.
Jones, C. K.
TI ANTIPSYCHOTIC-LIKE PROFILE AND REVERSAL OF COGNITIVE IMPAIRMENT WITH THE
POSITIVE ALLOSTERIC MODULATOR OF THE M4 MUSCARINIC ACETYLCHOLINE
RECEPTOR VU0152100
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Byun, Nellie; Gore, J. C.] Vanderbilt Univ, Inst Imaging Sci, Nashville, TN USA.
[Lawson, K.; Conn, P. J.] Vanderbilt Univ, Program Drug Discovery, Nashville, TN USA.
[Jones, C. K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA.
RI Conn, Peter/D-7848-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 286
EP 286
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000814
ER
PT J
AU Martin, L
Guese, M
Kisley, M
Davalos, D
AF Martin, Laura
Guese, M.
Kisley, M.
Davalos, D.
TI NICOTINE ENHANCES AUTOMATIC TEMPORAL PROCESSING AS MEASURED BY THE
MISMATCH NEGATIVITY WAVEFORM IN INDIVIDUALS WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Martin, Laura; Davalos, D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Martin, Laura; Guese, M.] Univ Colorado, Denver Sch Med, Aurora, CO USA.
[Kisley, M.] Univ Colorado, Colorado Springs, CO 80907 USA.
[Davalos, D.] Colorado State Univ, Ft Collins, CO 80523 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 290
EP 290
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000825
ER
PT J
AU Buller, R
Mittoux, A
Green, MF
Keefe, R
Forray, C
Schooler, N
Marder, S
AF Buller, Raimund
Mittoux, A.
Green, Michael F.
Keefe, Richard
Forray, C.
Schooler, N.
Marder, S.
TI A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY
EXPLORING THE NEUROCOGNITIVE EFFECT OF SERTINDOLE VS. QUETIAPINE IN
PATIENTS WITH SCHIZOPHRENIA USING THE MATRICS CONSENSUS COGNITIVE
BATTERY (MCCB)
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Buller, Raimund; Mittoux, A.] Lundbeck, Issy Les Moulineaux, France.
[Green, Michael F.; Marder, S.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Green, Michael F.; Marder, S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Keefe, Richard] Duke Univ, Med Ctr, Durham, NC USA.
[Forray, C.] Synapt Pharmaceut Corp, Paramus, NJ USA.
[Schooler, N.] Bar Ilan Univ, Ramat Gan, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 298
EP 298
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000845
ER
PT J
AU Garrett, C
Alexander, P
Lee, A
Fisher, M
Loewy, RL
Vinogradov, S
AF Garrett, Coleman
Alexander, P.
Lee, A.
Fisher, Melissa
Loewy, Rachel L.
Vinogradov, Sophia
TI PREDICTORS OF ATTRITION IN NEUROPLASTICITY-BASED AUDITORY TRAINING IN
SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Garrett, Coleman; Alexander, P.; Lee, A.; Fisher, Melissa; Loewy, Rachel L.; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Garrett, Coleman; Alexander, P.; Fisher, Melissa; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 303
EP 303
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000860
ER
PT J
AU Green, MF
AF Green, Michael F.
TI FUNCTIONAL CAPACITY MEASURES IN CLINICAL TRIALS AND MODELS OF FUNCTIONAL
OUTCOME
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Green, Michael F.] UCLA NPI, Los Angeles, CA USA.
[Green, Michael F.] VA Greater Los Angeles, MIRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 304
EP 304
PG 1
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000863
ER
PT J
AU Kasckow, J
Gurklis, J
Haas, G
AF Kasckow, John
Gurklis, J.
Haas, G.
TI A TELEHEALTH INTERVENTION FOR SUICIDAL PATIENTS WITH SCHIZOPHRENIA
SO SCHIZOPHRENIA BULLETIN
LA English
DT Meeting Abstract
CT 13th International Congress on Schizophrenia Research (ICSR)
CY APR 02-06, 2011
CL Colorado Springs, CO
C1 [Kasckow, John; Gurklis, J.; Haas, G.] VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA USA.
[Kasckow, John; Haas, G.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2011
VL 37
SU 1
BP 308
EP 309
PG 2
WC Psychiatry
SC Psychiatry
GA 726SI
UT WOS:000287746000875
ER
PT J
AU Lugli, A
Clemenza, M
Corso, PE
di Costanzo, J
Dirnhofer, R
Fiorini, E
Herborg, C
Hindmarsh, JT
Orvini, E
Piazzoli, A
Previtali, E
Santagostino, A
Sonnenberg, A
Genta, RM
AF Lugli, Alessandro
Clemenza, Massimiliano
Corso, Philip E.
di Costanzo, Jacques
Dirnhofer, Richard
Fiorini, Ettore
Herborg, Costanza
Hindmarsh, John Thomas
Orvini, Edoardo
Piazzoli, Adalberto
Previtali, Ezio
Santagostino, Angela
Sonnenberg, Amnon
Genta, Robert M.
TI The Medical Mystery of Napoleon Bonaparte An Interdisciplinary Expose
SO ADVANCES IN ANATOMIC PATHOLOGY
LA English
DT Review
DE Napoleon Bonaparte gastric cancer; arsenic poisoning; interdisciplinary
taskforce
ID GASTRIC-CANCER; PEPTIC-ULCER; 2 SPECIMENS; HAIR; DEATH; CARCINOMA;
STOMACH; DIE
AB Napoleon Bonaparte (1769 to 1821) is one of the most studied historical figures in European history. Not surprisingly, amongst the many mysteries still surrounding his person is the cause of his death, and particularly the suspicion that he was poisoned, continue to intrigue medical historians. After the defeat of the Napoleonic Army at the battle of Waterloo in 1815, Napoleon was exiled to the small island of Saint Helena in the South Atlantic, where he died 6 years later. Although his personal physician, Dr Francois Carlo Antommarchi, stated in his autopsy report that stomach cancer was the cause of death, this diagnosis was challenged in 1961 by the finding of an elevated arsenic concentration in one of Napoleon's hair samples. At that time it was suggested that Napoleon had been poisoned by one of his companions in exile who was allegedly supported by the British Government. Since then Napoleon's cause of death continues to be a topic of debate. The aim of this review is to use a multi-disciplinary approach to provide a systematic and critical assessment of Napoleon's cause of death.
C1 [Dirnhofer, Richard] Univ Bern, Inst Forens Med, CH-3012 Bern, Switzerland.
[Lugli, Alessandro] Univ Basel Hosp, Inst Pathol, Basel, Switzerland.
[Clemenza, Massimiliano; Fiorini, Ettore; Previtali, Ezio] Univ Milano Bicocca, Dept Phys, GPS Occhialini, Milan, Italy.
[Santagostino, Angela] Univ Milano Bicocca, Dept Environm Sci, Milan, Italy.
[Herborg, Costanza; Orvini, Edoardo] Univ Pavia, Dept Gen Chem, I-27100 Pavia, Italy.
[Piazzoli, Adalberto] Univ INFN, Dept Nucl & Theoret Phys, Pavia, Italy.
[Corso, Philip E.] Yale Univ, Sch Med, Dept Plast Surg, New Haven, CT 06520 USA.
[di Costanzo, Jacques] Hop Conception, Dept Digest Intens Care, Marseilles, France.
[di Costanzo, Jacques] Hop Conception, Nutr Support Unit, Marseilles, France.
[Hindmarsh, John Thomas] Ottawa Hosp, Div Biochem, Ottawa, ON, Canada.
[Hindmarsh, John Thomas] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1N 6N5, Canada.
[Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Genta, Robert M.] Caris Life Sci, Irving, TX USA.
[Genta, Robert M.] VAMC, Dept Pathol, Dallas, TX USA.
[Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Genta, RM (reprint author), Caris Res Inst, 6655 N MacArthur Blvd, Irving, TX 75039 USA.
EM robert.genta@utsouthwestern.edu
OI Clemenza, Massimiliano/0000-0002-8064-8936
NR 51
TC 4
Z9 4
U1 3
U2 34
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-4109
J9 ADV ANAT PATHOL
JI Adv. Anat. Pathol.
PD MAR
PY 2011
VL 18
IS 2
BP 152
EP 158
DI 10.1097/PAP.0b013e31820ca329
PG 7
WC Pathology
SC Pathology
GA 728RD
UT WOS:000287891300004
PM 21326012
ER
PT J
AU Spiegel, BMR
Khanna, D
Bolus, R
Agarwal, N
Khanna, P
Chang, L
AF Spiegel, Brennan M. R.
Khanna, Dinesh
Bolus, Roger
Agarwal, Nikhil
Khanna, Puja
Chang, Lin
TI Understanding Gastrointestinal Distress: A Framework for Clinical
Practice
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; VISCERAL SENSITIVITY INDEX;
COPING STRATEGIES; ILLNESS SEVERITY; PERCEIVED STIGMA; BRAIN RESPONSES;
ABDOMINAL-PAIN; VALIDATION; DISEASE
AB We describe a framework to help clinicians think about health-related quality of life in their gastrointestinal (GI) patients. We introduce "GI distress" as a clinically relevant concept and explain how it may result from physical symptoms, cognitions, and emotions. The GI distress framework suggests that providers should divide GI physical symptoms into four categories: pain, gas/bloat, altered defecation, and foregut symptoms. We describe how these physical symptoms can be amplified by maladaptive cognitions, including external locus of control, catastrophizing, and anticipation anxiety. We suggest determining the level of embarrassment from GI symptoms and asking about stigmatization. GI patients may also harbor emotional distress from their illness and may exhibit visceral anxiety marked by hypervigilance, fear, and avoidance of GI sensations. Look for signs of devitalization, indicated by inappropriate fatigue. When appropriate, screen for suicidal ideations. Finally, we provide a list of high-yield questions to screen for these maladaptive cognitions and emotions, and explain how the GI distress framework can be used in clinical practice.
C1 [Spiegel, Brennan M. R.; Bolus, Roger; Chang, Lin] VA Greater Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA.
[Spiegel, Brennan M. R.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Sci, Los Angeles, CA 90024 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Spiegel, Brennan M. R.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.; Bolus, Roger; Agarwal, Nikhil; Chang, Lin] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
[Khanna, Dinesh; Khanna, Puja] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
RP Spiegel, BMR (reprint author), VA Greater Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ulca.edu
FU National Institutes of Health (NIH)/National Institute of Arthritis and
Musculoskeletal and Skin Diseases [U01 AR057936A]; NIH through NIH
Roadmap for Medical Research [AR052177]; Takeda North America; Rose
Pharmaceuticals; Prometheus Laboratories; Scleroderma Clinical Trial
Consortium
FX Financial support: National Institutes of Health (NIH)/National
Institute of Arthritis and Musculoskeletal and Skin Diseases grant U01
AR057936A and the NIH through NIH Roadmap for Medical Research grant
AR052177.; Potential competing interests: Drs Spiegel and Chang have
served as advisors to Prometheus Laboratories and Ironwood
Pharmaceuticals and have received grant support from Takeda North
America, Rose Pharmaceuticals, and Prometheus Laboratories. Dr Chang has
also served as a consultant to Salix, Movetis, GlaxoSmithKline, and
Ocera. Dr D. Khanna has received grants from the Scleroderma Clinical
Trial Consortium to develop a GI-specific instrument in scleroderma.
NR 47
TC 9
Z9 9
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAR
PY 2011
VL 106
IS 3
BP 380
EP 385
DI 10.1038/ajg.2010.383
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 730VT
UT WOS:000288064200001
PM 21378758
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Starting a Career in Gastroenterology and Breaking All Records
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAR
PY 2011
VL 106
IS 3
BP 393
EP 394
DI 10.1038/ajg.2010.356
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 730VT
UT WOS:000288064200003
PM 21378760
ER
PT J
AU Ioannou, GN
AF Ioannou, George N.
TI Hepatitis B Virus in the United States: Infection, Exposure, and
Immunity Rates in a Nationally Representative Survey
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID AREA VACCINATION COVERAGE; LONG-TERM IMMUNOGENICITY; AGED 19-35 MONTHS;
ADOLESCENTS; PREVENTION; DISEASES; BOOSTER; ADULTS; HEALTH; POLICY
AB Background: Up-to-date estimates of the prevalence of hepatitis B virus (HBV) infection, exposure, and immunity are necessary to assess the effectiveness of ongoing programs aimed at preventing HBV transmission.
Objective: To determine the prevalence and associations of chronic HBV infection, past exposure, and immunity in the United States from 1999 to 2008.
Design: Nationally representative, cross-sectional household survey.
Setting: U.S. civilian, noninstitutionalized population. Participants: 39 787 participants in the National Health and Nutrition Examination Survey (1999 to 2008) aged 2 years or older.
Measurements: Chronic HBV infection was defined by presence of serum HBV surface antigen and past exposure by serum antibody to hepatitis B core antigen among persons aged 6 years or older. Infant immunity was defined by presence of serum antibody to hepatitis B surface antigen among children aged 2 years.
Results: Among persons aged 6 years or older, 0.27% (95% CI, 0.20% to 0.34%) had chronic HBV infection (corresponding to approximately 704 000 persons nationwide), and 4.6% (CI, 4.1% to 5.0%) had been exposed to HBV (approximately 11 993 000 persons). These estimates are lower (P < 0.001) than estimates of HBV infection (0.42%) and exposure (5.1%) in the United States reported from 1988 to 1994. Infection and past exposure were very uncommon among persons aged 6 to 19 years. Children aged 2 years have high rates of immunity (68.6% [CI, 64.1% to 73.2%]). Adults, including those at high risk for infection, have much lower rates of immunity.
Limitations: Incarcerated and homeless persons were not sampled. Categorization of race or ethnicity did not identify high-risk groups, such as persons of Asian and Pacific Islander descent.
Conclusion: A cohort of children and adolescents is growing up in the United States with high rates of immunity against HBV and very low rates of infection. Vaccination of high-risk adults should continue to be emphasized.
C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA.
EM georgei@medicine.washington.edu
FU Veterans Affairs Research Enhancement Award Program
FX Grant Support: By the Veterans Affairs Research Enhancement Award
Program.
NR 32
TC 68
Z9 70
U1 0
U2 3
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAR 1
PY 2011
VL 154
IS 5
BP 319
EP 328
DI 10.7326/0003-4819-154-5-201103010-00006
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 727LA
UT WOS:000287799900004
PM 21357909
ER
PT J
AU Tan, G
Dao, TK
Farmer, L
Sutherland, RJ
Gevirtz, R
AF Tan, Gabriel
Dao, Tam K.
Farmer, Lorie
Sutherland, Roy John
Gevirtz, Richard
TI Heart Rate Variability (HRV) and Posttraumatic Stress Disorder (PTSD): A
Pilot Study
SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
LA English
DT Article
DE Heart rate variability; Posttraumatic stress disorder
ID COGNITIVE-PROCESSING THERAPY; POWER SPECTRAL-ANALYSIS; MENTAL-HEALTH
PROBLEMS; PSYCHOPHYSIOLOGICAL ASSESSMENT; PROLONGED EXPOSURE; ASSAULT
VICTIMS; VETERANS; METAANALYSIS; BIOFEEDBACK; WAR
AB Exposure to combat experiences is associated with increased risk of developing Post Traumatic Stress Disorder. Prolonged exposure therapy and cognitive processing therapy have garnered a significant amount of empirical support for PTSD treatment; however, they are not universally effective with some patients continuing to struggle with residual PTSD symptoms. Heart rate variability (HRV) is a measure of the autonomic nervous system functioning and reflects an individual's ability to adaptively cope with stress. A pilot study was undertaken to determine if veterans with PTSD (as measured by the Clinician-Administered PTSD Scale and the PTSD Checklist) would show significantly different HRV prior to an intervention at baseline compared to controls; specifically, to determine whether the HRV among veterans with PTSD is more depressed than that among veterans without PTSD. The study also aimed at assessing the feasibility, acceptability, and potential efficacy of providing HRV biofeedback as a treatment for PTSD. The findings suggest that implementing an HRV biofeedback as a treatment for PTSD is effective, feasible, and acceptable for veterans. Veterans with combat-related PTSD displayed significantly depressed HRV as compared to subjects without PTSD. When the veterans with PTSD were randomly assigned to receive either HRV biofeedback plus treatment as usual (TAU) or just TAU, the results indicated that HRV biofeedback significantly increased the HRV while reducing symptoms of PTSD. However, the TAU had no significant effect on either HRV or symptom reduction. A larger randomized control trial to validate these findings appears warranted.
C1 [Dao, Tam K.; Sutherland, Roy John] Univ Houston, Houston, TX 77004 USA.
[Tan, Gabriel; Farmer, Lorie; Sutherland, Roy John] Michael E DeBakey Vet Affair Med Ctr, Houston, TX USA.
[Tan, Gabriel; Dao, Tam K.; Sutherland, Roy John] Baylor Coll Med, Houston, TX 77030 USA.
[Gevirtz, Richard] Alliant Int Univ, San Diego, CA USA.
RP Dao, TK (reprint author), Univ Houston, 491 Farish Hall, Houston, TX 77004 USA.
EM tkdao@uh.edu
RI Schueter, nicos/A-3625-2014
NR 41
TC 56
Z9 58
U1 3
U2 29
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-0586
J9 APPL PSYCHOPHYS BIOF
JI Appl. Psychophysiol. Biofeedback
PD MAR
PY 2011
VL 36
IS 1
BP 27
EP 35
DI 10.1007/s10484-010-9141-y
PG 9
WC Psychology, Clinical
SC Psychology
GA 728BW
UT WOS:000287850000003
PM 20680439
ER
PT J
AU Tadros, NN
Garzotto, M
AF Tadros, Nicholas N.
Garzotto, Mark
TI Androgen deprivation therapy for prostate cancer: not so simple
SO ASIAN JOURNAL OF ANDROLOGY
LA English
DT Editorial Material
ID MEN; IMPACT
C1 [Tadros, Nicholas N.; Garzotto, Mark] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97239 USA.
[Garzotto, Mark] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Garzotto, M (reprint author), Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97239 USA.
EM garzotto@ohsu.edu
NR 7
TC 3
Z9 3
U1 0
U2 3
PU SHANGHAI INST MATERIA MEDICA
PI SHANGHAI
PA 555 ZU CHONG ZHI RD, ZHANG JIANG HI-TECH PARK, SHANGHAI, PUDONG 201203,
PEOPLES R CHINA
SN 1008-682X
J9 ASIAN J ANDROL
JI Asian J. Androl.
PD MAR
PY 2011
VL 13
IS 2
BP 187
EP 188
DI 10.1038/aja.2010.174
PG 2
WC Andrology; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 730YV
UT WOS:000288074400006
PM 21278759
ER
PT J
AU Nabavi, V
Ahmadi, N
Bhatia, HS
Flores, F
Ebrahimi, R
Karlsberg, RP
Budoff, MJ
AF Nabavi, Vahid
Ahmadi, Naser
Bhatia, Harpreet S.
Flores, Ferdinand
Ebrahimi, Ramin
Karlsberg, Ronald P.
Budoff, Matthew J.
TI Increased carotid wall thickness measured by computed tomography is
associated with the presence and severity of coronary artery calcium
SO ATHEROSCLEROSIS
LA English
DT Article
DE Coronary artery calcium (CAC); Carotid wall thickness (CWT); Coronary
artery disease (CAD); Cerebrovascular disease (CVD); Carotid computed
tomography; Metabolic syndrome (MetS); Diabetes mellitus (DM)
ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK-FACTORS; CT-ANGIOGRAPHY;
VASCULAR FUNCTION; ATHEROSCLEROTIC DISEASE; METABOLIC SYNDROME;
DIABETES-MELLITUS; HEART-DISEASE; ADVENTITIA; STENOSIS
AB Background: Previous studies have shown that increase in carotid wall thickness (CWT) is associated with cardiovascular risk factors. However, simultaneous systemic and local involvement of atherosclerosis in subjects with high risk of coronary atherosclerosis is not well studied. This study investigates the relation of carotid subclinical atherosclerosis assessed by CWT with the presence and severity of coronary artery calcium(CAC).
Methods: One hundred and twenty nine subjects (age of 69 +/- 10 years, 72% male) underwent CAC, carotid CT angiography, and their metabolic status was evaluated. CAC was defined as 0, 1-100, 101-400, 401-1000 and 1000+. CWT (mm) was calculated as: [mean of both right and left CT measured CWT 10-mm below the common carotid bifurcation].
Results: Modest correlation between CWT and CAC was noted (r = 0.48, p = 0.0001). CWT increased substantially with the severity of CAC from CAC 0 to CAC 1000+ (p < 0.05). Increased CWT(1.0mm+) was more prevalent in subjects with significant CAC (100+) as compared to CAC 0 (44.7% vs. 3.3%, p < 0.05). Increase in CWT was associated with increased rates of metabolic syndrome and diabetes mellitus. After adjustment for cardiovascular risk factors, the risk of metabolic syndrome and DM was 1.7 and 2.3 respectively for each standard deviation (SD) increase in CWT. Similarly, the risk for each SD increase in CWT increased with severity of CAC as compared to CAC 0 (RR: CAC 1-100: 1.2, CAC 101-400: 1.5, CAC 400-1000: 2.1, and CAC 1000+: 3.4, respectively).
Conclusion: Increased CWT is associated with the presence and severity of CAC, metabolic syndrome and DM independent of conventional cardiovascular risk factors; highlighting the important role of comprehensive carotid and coronary atherosclerotic assessment to identify at-risk individuals. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Nabavi, Vahid; Ahmadi, Naser; Flores, Ferdinand; Budoff, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA.
[Ebrahimi, Ramin] Univ Calif Los Angeles, Sch Med, Greater Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Bhatia, Harpreet S.; Karlsberg, Ronald P.] Cardiovasc Res Inst So Calif, Beverly Hills, CA USA.
RP Budoff, MJ (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St,RB2, Torrance, CA 90502 USA.
EM mbudoff@labiomed.org
NR 49
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2011
VL 215
IS 1
BP 103
EP 109
DI 10.1016/j.atherosclerosis.2010.11.034
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 730CN
UT WOS:000288008700015
PM 21196006
ER
PT J
AU Shirai, K
Kaneshiro, T
Wada, M
Furuya, H
Bielawski, J
Hannun, YA
Obeid, LM
Ogretmen, B
Kawamori, T
AF Shirai, Keisuke
Kaneshiro, Tatsuya
Wada, Masayuki
Furuya, Hideki
Bielawski, Jacek
Hannun, Yusuf A.
Obeid, Lina M.
Ogretmen, Besim
Kawamori, Toshihiko
TI A Role of Sphingosine Kinase 1 in Head and Neck Carcinogenesis
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; 4-NITROQUINOLINE 1-OXIDE; ORAL-CAVITY; CANCER;
PROLIFERATION; EXPRESSION; CYCLOOXYGENASE-2; PATHOGENESIS; NIMESULIDE;
INHIBITOR
AB It is important to identify novel and effective targets for cancer prevention and therapy against head and neck squamous cell carcinoma (HNSCC), one of the most lethal cancers. Accumulating evidence suggests that the bioactive sphingolipids, such as sphingosine-1-phosphate (S1P) and its generating enzyme, sphingosine kinase 1 (SphK1) play pivotal roles in several important biological functions including promoting tumor growth and carcinogenesis. However, roles of SphK1/S1P in HNSCC development and/or progression have not been defined previously. Therefore, in this study, we first analyzed the expression of SphK1 in human HNSCC tumor samples and normal head & neck tissues (n = 78 and 17, respectively) using immunohistochemistry. The data showed that SphK1 is overexpressed in all of the HNSCC tumors tested (stages I-IV). We next investigated whether SphK1 is necessary for HNSCC development. To define the role of SphK1/S1P in HNSCC development, we utilized 4-nitroquinoline-1-oxide (4-NQO)-induced HNSCC model in wild-type mice compared with SphK1(-/-) knockout (KO) mice. Remarkably, we found that the genetic loss of SphK1, which reduced S1P generation, significantly prevented 4-NQO-induced HNSCC carcinogenesis, with decreased tumor incidence, multiplicity, and volume when compared with controls. Moreover, our data indicated that prevention of 4-NQO-induced HNSCC development in SphK1(-/-) KO mice might be associated with decreased cell proliferation, increased levels of cleaved (active) caspase 3, and downregulation of phospho (active) AKT expression. Thus, these novel data suggest that SphK1/S1P signaling may play important roles in HNSCC carcinogenesis, and that targeting SphK1/S1P might provide a novel strategy for chemoprevention and treatment against HNSCC. Cancer Prev Res; 4(3); 454-62. (C)2011 AACR.
C1 [Furuya, Hideki; Kawamori, Toshihiko] Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA.
[Shirai, Keisuke] Med Univ S Carolina, Dept Med Hematol Oncol, Charleston, SC 29425 USA.
[Kaneshiro, Tatsuya; Wada, Masayuki; Furuya, Hideki; Kawamori, Toshihiko] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Bielawski, Jacek; Hannun, Yusuf A.; Ogretmen, Besim] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Obeid, Lina M.] Med Univ S Carolina, Dept Internal Med, Charleston, SC 29425 USA.
[Shirai, Keisuke; Bielawski, Jacek; Hannun, Yusuf A.; Obeid, Lina M.; Ogretmen, Besim; Kawamori, Toshihiko] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Obeid, Lina M.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA.
RP Kawamori, T (reprint author), Univ Hawaii, Ctr Canc, 651 Ilalo St,BSB 222H, Honolulu, HI 96813 USA.
EM kawamori@crch.hawaii.edu
RI Kawamori, Toshihiko/G-7636-2012
OI obeid, lina/0000-0002-0734-0847
FU NIH [P01CA097132, R01CA124687, C06RR015455]; Office of Research and
Development, Department of Veterans Affairs, Ralph H. Johnson VA Medical
Center, Charleston, South Carolina
FX NIH grants P01CA097132 (J. Bielawski, Y. A. Hannun, L. M. Obeid, B.
Ogretmen, and T. Kawamori), R01CA124687 (T. Kawamori), R01DE016572 (B.
Ogretmen), and C06RR015455 (Research Facilities Support grant). A MERIT
Award by the Office of Research and Development, Department of Veterans
Affairs, Ralph H. Johnson VA Medical Center, Charleston, South Carolina
(L. M. Obeid).
NR 33
TC 37
Z9 40
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD MAR
PY 2011
VL 4
IS 3
BP 454
EP 462
DI 10.1158/1940-6207.CAPR-10-0299
PG 9
WC Oncology
SC Oncology
GA 729PV
UT WOS:000287963800022
PM 21209394
ER
PT J
AU Crothers, K
Daly, KR
Rimland, D
Goetz, MB
Gibert, CL
Butt, AA
Justice, AC
Djawe, K
Levin, L
Walzer, PD
AF Crothers, Kristina
Daly, Kieran R.
Rimland, David
Goetz, Matthew Bidwell
Gibert, Cynthia L.
Butt, Adeel A.
Justice, Amy C.
Djawe, Kpandja
Levin, Linda
Walzer, Peter D.
TI Decreased Serum Antibody Responses to Recombinant Pneumocystis Antigens
in HIV-Infected and Uninfected Current Smokers
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID MAJOR SURFACE GLYCOPROTEIN; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY
VIRUS-ANTIBODIES; SEROLOGIC RESPONSES; CIGARETTE-SMOKING; IMMUNE-SYSTEM;
UNITED-STATES; ALCOHOL-USE; TOBACCO USE; JIROVECI
AB Serologic studies can provide important insights into the epidemiology and transmission of Pneumocystis jirovecii. Exposure to P. jirovecii can be assessed by serum antibody responses to recombinant antigens from the major surface glycoprotein (MsgC), although factors that influence the magnitude of the antibody response are incompletely understood. We determined the magnitudes of antibody responses to P. jirovecii in comparison to adenovirus and respiratory syncytial virus (RSV) in HIV-infected and uninfected patients and identified predictors associated with the magnitude of the response. We performed a cross-sectional analysis using serum samples and data from 153 HIV-positive and 92 HIV-negative subjects enrolled in a feasibility study of the Veterans Aging Cohort 5 Site Study (VACS 5). Antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Independent predictors of antibody responses were determined using multivariate Tobit regression models. The results showed that serum antibody responses to P. jirovecii MsgC fragments were significantly and independently decreased in current smokers. Antibodies to P. jirovecii also tended to be lower with chronic obstructive pulmonary disease (COPD), hazardous alcohol use, injection drug use, and HIV infection, although these results were not statistically significant. These results were specific to P. jirovecii and did not correlate with adenovirus. Antibody responses to RSV were in the inverse direction. Thus, current smoking was independently associated with decreased P. jirovecii antibody responses. Whether smoking exerts an immunosuppressive effect that affects the P. jirovecii antibody response, colonization, or subsequent risk for disease is unclear; prospective, longitudinal studies are needed to evaluate these findings further.
C1 [Crothers, Kristina] Univ Washington, Harborview Med Ctr, Sch Med, Dept Med,Div Pulm & Crit Care Med, Seattle, WA 98104 USA.
[Daly, Kieran R.; Djawe, Kpandja; Levin, Linda; Walzer, Peter D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Infect Dis, Cincinnati, OH USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
[Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Infect Dis Sect, Dept Med, Los Angeles, CA 90095 USA.
[Gibert, Cynthia L.] George Washington Univ, Infect Dis Sect, Vet Affairs Med Ctr, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Dept Med, Washington, DC USA.
[Butt, Adeel A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Internal Med, Pittsburgh, PA USA.
[Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA.
[Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, Sect Pulm & Crit Care Med, New Haven, CT 06510 USA.
[Justice, Amy C.] Yale Univ, Sch Publ Hlth, Dept Internal Med, Sect Pulm & Crit Care Med, New Haven, CT USA.
[Djawe, Kpandja; Levin, Linda; Walzer, Peter D.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Epidemiol, Cincinnati, OH 45267 USA.
[Walzer, Peter D.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA.
RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Med,Div Pulm & Crit Care Med, 325 9th Ave,Box 359762, Seattle, WA 98104 USA.
EM crothk@uw.edu
OI Goetz, Matthew/0000-0003-4542-992X
FU National Institutes of Health (NIH)/National Heart, Lung, and Blood
Institute (NHLBI) [R01 HL090342]; NIH/National Center for Research
Resources (NCRR) [KL2 RR024138]; National Institute on Alcohol and
Alcohol Abuse [U01 AA 13566, U10 AA 13566]; National Institute of Aging
(NIA) [K23 AG00826]; Robert Wood Johnson Generalist Faculty Scholar
Award; NIH Roadmap for Medical Research
FX Funding for this work was from National Institutes of Health
(NIH)/National Heart, Lung, and Blood Institute (NHLBI) grant R01
HL090342 (K. C.), NIH/National Center for Research Resources (NCRR)
grant KL2 RR024138 (K. C.), National Institute on Alcohol and Alcohol
Abuse grants U01 AA 13566 and U10 AA 13566 (A.C.J.), National Institute
of Aging (NIA) grant K23 AG00826 (A.C.J.), a Robert Wood Johnson
Generalist Faculty Scholar Award (A.C.J.), and an interagency agreement
between the NIA and the National Institute of Mental Health. Funding for
this publication was made possible in part by CTSA grant KL2 RR024138
from the NCRR, a component of the NIH, and NIH Roadmap for Medical
Research. The authors have no commercial or other associations that pose
a conflict of interest.
NR 40
TC 5
Z9 6
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD MAR
PY 2011
VL 18
IS 3
BP 380
EP 386
DI 10.1128/CVI.00421-10
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 729CH
UT WOS:000287925100005
PM 21191078
ER
PT J
AU Wagner, TH
Holman, W
Lee, K
Sethi, G
Ananth, L
Hoang, T
Goldman, S
AF Wagner, Todd H.
Holman, William
Lee, Kelvin
Sethi, Gulshan
Ananth, Lakshmi
Hoang Thai
Goldman, Steven
TI The generalizability of participants in Veterans Affairs Cooperative
Studies Program 474, a multi-site randomized cardiac bypass surgery
trial
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Coronary artery bypass surgery; Study design; Generalizability
ID RADIAL-ARTERY; SAPHENOUS-VEIN; PATENCY; GRAFTS
AB Objective: The Department of Veterans Affairs (VA) Cooperative Studies Program (CSP) initiated a multi-site randomized trial (CSP 474) to determine graph patency between radial artery or saphenous vein grafts in coronary artery bypass surgery (CABG). In this paper, we describe the study and compare participants' baseline characteristics to non-participants who received CABG surgery in the VA.
Method: We identified our participants in the VA administrative databases along with all other CABG patients who did not have a concomitant valve procedure between FY2003 and FY2008. We extracted demographic, clinical information and organizational information at the time of the surgery from the databases. We conducted multiple logistic regression to determine characteristics associated with participation at three levels: between participants and non-participants within participating sites, between participating sites and non-participating sites. between participants and all non-participants.
Results: Enrollment ended in early 2008. Participants were similar to non-participants across many parameters. Likewise, participating sites were also quite similar to non-participating sites, although participating sites had a higher volume of CABG surgery, a lower percentage of CABG patients with a prior inpatient mental health admission than non-participating sites. After controlling for site differences, CSP 474 participants were younger and had fewer co-morbid conditions than non-participants.
Conclusions: Participants were significantly younger than non-participants. Participants also had lower rates of some cardiac-related illness including, congestive heart failure, peripheral vascular disease, and cerebrovascular disease than non-participants. Published by Elsevier Inc.
C1 [Wagner, Todd H.; Ananth, Lakshmi] Stanford Univ, VA Palo Alto Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA.
[Wagner, Todd H.] Stanford Univ, Dept Hlth Res & Policy, Menlo Pk, CA 94025 USA.
[Holman, William] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
[Holman, William] Univ Alabama, VA Med Ctr, Birmingham, AL 35233 USA.
[Lee, Kelvin] VA Palo Alto Cooperat Studies Coordinating Ctr, Menlo Pk, CA 94025 USA.
[Hoang Thai; Goldman, Steven] Univ Arizona, Sarver Heart Ctr, Tucson, AZ 85723 USA.
So Arizona VA Hlth Care Syst, Tucson, AZ 85723 USA.
RP Wagner, TH (reprint author), Stanford Univ, VA Palo Alto Hlth Econ Resource Ctr, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM Todd.Wagner@va.gov; William.Holman@va.gov; Kelvin.Lee@va.gov;
sethi@u.arizona.edu; Lakshmi.Ananth@va.gov
FU VA Cooperative Studies Program
FX The study was funded by the VA Cooperative Studies Program.
NR 16
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAR
PY 2011
VL 32
IS 2
BP 260
EP 266
DI 10.1016/j.cct.2010.11.008
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 730TG
UT WOS:000288056700016
PM 21078416
ER
PT J
AU Ko, CW
Dominitz, JA
Green, P
Kreuter, W
Baldwin, LM
AF Ko, Cynthia W.
Dominitz, Jason A.
Green, Pam
Kreuter, William
Baldwin, Laura-Mae
TI Accuracy of Medicare claims for identifying findings and procedures
performed during colonoscopy
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID POSITIVE PREDICTIVE-VALUE; COLORECTAL-CANCER; ADENOMA DETECTION;
SCREENING COLONOSCOPY; ADMINISTRATIVE DATA; FAMILY PHYSICIAN; POLYP
DETECTION; DETECTION RATES; UNITED-STATES; SURVEILLANCE
AB Background: Administrative claims data are frequently used for quality measurement.
Objective: To examine the accuracy of administrative claims for potential colonoscopy quality measures, including findings (polyp or tumor detection), procedures (biopsy or polypectomy), and incomplete colonoscopy.
Design: Cross-sectional study.
Patients: Patients age 65 and older undergoing colonoscopy in the Clinical Outcomes Research Initiative National Endoscopic Database in 2006. We linked colonoscopy records for these patients to Medicare colonoscopy claims by using patient age, sex, date of procedure, and performing provider's Unique Physician Identification Number.
Main Outcome Measurements: Sensitivity, specificity, positive and negative predictive values of the Medicare claims for potential quality measures, including colonoscopy findings and procedures.
Results: We linked Medicare colonoscopy claims to 15,168 of the 30,011 Clinical Outcomes Research Initiative colonoscopy records. Sensitivity of the claims for colon polyps was 93.4%, with a specificity of 97.8%. Sensitivity of claims for other diagnoses, including colorectal tumors was suboptimal, although specificity was high. In contrast, sensitivity of claims for procedures biopsy (with or without cautery) or polypectomy was high (87.2%-97.6%), with specificity > 97%. Claims had poor sensitivity for identification of incomplete colonoscopy.
Limitations: Potential for inaccurate matching of colonoscopy records and Medicare claims.
Conclusions: Medicare claims have high sensitivity and specificity for polyp detection, biopsy, and polypectomy at colonoscopy, but sensitivity is low for other diagnoses such as tumor detection and for incomplete colonoscopy. Caution is needed when using Medicare claims data for certain important quality measures, in particular tumor detection and incomplete colonoscopy. (Gastrointest Enclose 2011;73:447-53.)
C1 [Ko, Cynthia W.] Univ Washington, Div Gastroenterol, Dept Med, Seattle, WA 98195 USA.
[Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Ko, CW (reprint author), Univ Washington, Div Gastroenterol, Dept Med, Box 356424, Seattle, WA 98195 USA.
EM cwko@u.washington.edu
OI Dominitz, Jason/0000-0002-8070-7086
FU NIH [1R01CA127659]; American Society of Gastrointestinal Endoscopy; VA
Puget Sound Health Care System, Seattle, Washington
FX This work was supported by NM grant 1R01CA127659. Dr. Dominitz is
supported in part by a career development award from the American
Society of Gastrointestinal Endoscopy. This material is the result of
work supported in part by resources from the VA Puget Sound Health Care
System, Seattle, Washington. The views and opinions of authors expressed
herein do not necessarily slate or reflect those of the United States
Government or the Department of Veterans Affairs. All other authors
disclosed no financial relationships relevant to this publication.
NR 29
TC 19
Z9 19
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAR
PY 2011
VL 73
IS 3
BP 447
EP 453
DI 10.1016/j.gie.2010.07.044
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 728VU
UT WOS:000287903400007
PM 20950800
ER
PT J
AU Spiegel, BMR
AF Spiegel, Brennan M. R.
TI Does time of day affect polyp detection rates from colonoscopy?
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Editorial Material
ID COLORECTAL-CANCER; TECHNICAL PERFORMANCE; SLEEP-DEPRIVATION; QUALITY;
POLYPECTOMY; ENDOSCOPY; PATIENT; FATIGUE; SAFETY; IMPACT
C1 [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Vet Affairs Ctr Outcomes Res & Educ, Los Angeles, CA 90095 USA.
RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
NR 23
TC 3
Z9 3
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAR
PY 2011
VL 73
IS 3
BP 476
EP 479
DI 10.1016/j.gie.2010.09.026
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 728VU
UT WOS:000287903400012
PM 21353844
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Arguments against costly quality assurance
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID COLONOSCOPY; INDICATORS; GASTROENTEROLOGY; MANAGEMENT; CANCER
C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 11
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAR
PY 2011
VL 73
IS 3
BP 567
EP 569
DI 10.1016/j.gie.2010.12.020
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 728VU
UT WOS:000287903400028
PM 21353854
ER
PT J
AU Lewinsohn, DA
Gold, MC
Lewinsohn, DM
AF Lewinsohn, Deborah A.
Gold, Marielle C.
Lewinsohn, David M.
TI Views of immunology: effector T cells
SO IMMUNOLOGICAL REVIEWS
LA English
DT Review
DE infectious diseases; T cells; natural killer T cells; antigen
presentation; processing; cytotoxicity
ID TUMOR-NECROSIS-FACTOR; MYCOBACTERIUM-TUBERCULOSIS INFECTION;
LISTERIA-MONOCYTOGENES INFECTION; INTERFERON-GAMMA PRODUCTION;
ANTIGEN-PROCESSING PATHWAY; NITRIC-OXIDE SYNTHASE; IFN-GAMMA; DENDRITIC
CELLS; FACTOR-ALPHA; PROTECTIVE IMMUNITY
AB For many intracellular bacteria, both adaptively acquired and innately encoded effector T cells play a central role in the control, and in some cases, clearance of these pathogens. Through the rapid identification of those cells harboring intracellular bacteria, effector T cells have the capacity to both directly control the infection and shape the immune response to the pathogen. Here, we review the mechanisms by which effector T cells control intracellular infection and emphasize the means by which they recognize their targets. As will become evident, the diversity of both redundant and non-redundant effector mechanisms in conjunction with broad recognition of both protein and non-protein antigens allows for the identification of a broad array of bacterial pathogens and lessens the likelihood of immune evasion.
C1 [Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA.
[Gold, Marielle C.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA.
RP Lewinsohn, DM (reprint author), PVAMC OHSU, R&D 11,3710 SW US Vet Rd, Portland, OR 97239 USA.
EM lewinsod@ohsu.edu
RI Lewinsohn, David/I-4936-2013
OI Lewinsohn, David/0000-0001-9906-9494; Gold, Marielle/0000-0003-2505-3291
NR 160
TC 16
Z9 17
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0105-2896
J9 IMMUNOL REV
JI Immunol. Rev.
PD MAR
PY 2011
VL 240
BP 25
EP 39
DI 10.1111/j.1600-065X.2010.00997.x
PG 15
WC Immunology
SC Immunology
GA 726FO
UT WOS:000287705100003
PM 21349084
ER
PT J
AU Singh, T
Katiyar, SK
AF Singh, Tripti
Katiyar, Santosh K.
TI Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer
cell migration by targeting nitric oxide and cyclooxygenase-2
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE cancer cell migration; cyclooxygenase-2; guanylate cyclase; nitric
oxide; prostaglandin E(2); breast cancer cells; honokiol
ID GRAPE SEED PROANTHOCYANIDINS; PROSTAGLANDIN-H SYNTHASE; TUMOR
PROGRESSION; LUNG-CANCER; MULTIFACETED ROLES; IN-VITRO; KAPPA-B; GROWTH;
EXPRESSION; ANGIOGENESIS
AB In the present study, we report the effects of honokiol, a phytochemical from Magnolia spp., on cancer cell migration capacity and the molecular mechanisms underlying these effects using breast cancer cell lines as an in vitro model. Using cell migration assays, we found that the treatment of human breast cancer cells (MCF-7) and murine mammary cancer cells (4T1) with honokiol resulted in a dose-dependent inhibition of migration of these cells, which was associated with a reduction in nitric oxide (NO) levels. The cell migration capacity was decreased in the presence of N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthase. Honokiol reduced the elevated levels of cyclic guanosine monophosphate (cGMP) in the cells, while the treatment of 4T1 cells with guanylate cyclase (GC) inhibitor 1-H-[1,2,4]oxadiaxolo[4,3-a]quinolalin-1-one (ODQ) reduced the migration of cells and the levels of cGMP. The presence of 8-bromoguanosine 3'5'-cyclic monophosphate, an analogue of cGMP, enhanced the migration of these cells, suggesting a role for GC in the migration of 4T1 cells. Honokiol also inhibited the levels of cyclooxygenase-2 (COX-2) and prostaglandin (PG) E(2) in 4T1 cells. The transfection of 4T1 cells with COX-2 siRNA resulted in a reduction in cell migration. ODQ and L-NAME also decreased the levels of PGE(2) in 4T1 cells suggesting a role for COX-2/PGE(2) in cell migration. Moreover, honokiol inhibited the activation of nuclear factor kappa B (NF-kappa B), an upstream regulator of COX-2 and iNOS, in 4T1 cells. These results indicate that NO and COX-2 are the key targets of honokiol in the inhibition of breast cancer cell migration, an essential step in invasion and metastasis.
C1 [Singh, Tripti; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration
FX This study was supported by funds from the Veterans Administration Merit
Review Award (S.K.K.).
NR 42
TC 17
Z9 20
U1 1
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAR
PY 2011
VL 38
IS 3
BP 769
EP 776
DI 10.3892/ijo.2011.899
PG 8
WC Oncology
SC Oncology
GA 727UV
UT WOS:000287829200019
PM 21225228
ER
PT J
AU Korthuis, PT
Fiellin, DA
Fu, RW
Lum, PJ
Altice, FL
Sohler, N
Tozzi, MJ
Asch, SM
Botsko, M
Fishl, M
Flanigan, TP
Boverman, J
McCarty, D
AF Korthuis, P. Todd
Fiellin, David A.
Fu, Rongwei
Lum, Paula J.
Altice, Frederick L.
Sohler, Nancy
Tozzi, Mary J.
Asch, Steven M.
Botsko, Michael
Fishl, Margaret
Flanigan, Timothy P.
Boverman, Joshua
McCarty, Dennis
CA BHIVES Collaborative
TI Improving Adherence to HIV Quality of Care Indicators in Persons With
Opioid Dependence: The Role of Buprenorphine
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE quality of health care; HIV; quality indicators; health care;
buprertorphine; opioid-related disorders; heroin dependence
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTANCE-ABUSE TREATMENT; RESEARCH
INITIATIVE QUERI; ADDICTION SEVERITY INDEX; HEALTH-CARE; UNITED-STATES;
DRUG-USERS; INTEGRATED BUPRENORPHINE/NALOXONE; ANTIRETROVIRAL ADHERENCE;
SERVICES UTILIZATION
AB Background: Opioid-dependent HIV-infected patients are less likely to receive HIV quality of care indicators (QIs) compared with nondependent patients. Buprenorphine/naloxone maintenance therapy (bup/nx) could affect the quality of HIV care for opioid-dependent patients.
Methods: We abstracted 16 QIs from medical records at nine HIV clinics 12 months before and after initiation of bup/nx versus other treatment for opioid dependence. Summary quality scores (number of QIs received/number eligible X 100) were calculated. We compared change in QIs and summary quality scores in patients receiving bup/nx versus other participants.
Results: One hundred ninety-four of 268 participants summary quality scores increased over 12 months for participants receiving bup/nx (45.6% to 51.6%, P < 0.001) but not other treatment (48.6% to 47.8%, P = 0.788). Bup/nx participants experienced improvements in six of 16 HIV QIs versus three of 16 QIs in other participants. Improvements were mostly in preventive and monitoring care domains. In multivariable analysis, bup/nx was associated with improved summary quality score (beta 8.55; 95% confidence interval, 2.06-15.0).
Conclusions: In this observational cohort study, HIV-infected patients with opioid dependence received approximately half of HIV QIs at baseline. Buprenorphine treatment was associated with improvement in HIV QIs at 12 months. Integration of bup/nx into HIV clinics may increase receipt of high-quality HIV care. Further research is required to assess the effect of improved quality of HIV care on clinical outcomes.
C1 [Korthuis, P. Todd; Boverman, Joshua] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Korthuis, P. Todd; Fu, Rongwei; McCarty, Dennis] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97239 USA.
[Fiellin, David A.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA.
[Fiellin, David A.] Yale Univ, Sch Med, Dept Invest Med, New Haven, CT 06510 USA.
[Altice, Frederick L.] AIDS Program, Infect Dis Sect, New Haven, CT USA.
[Lum, Paula J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA USA.
[Sohler, Nancy] CUNY City Coll, Sophie Davis Sch Biomed Educ, New York, NY 10031 USA.
[Tozzi, Mary J.] CORE Ctr, Chicago, IL USA.
[Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Botsko, Michael] Ctr HIV Educ Studies & Training, New York, NY USA.
[Fishl, Margaret] Univ Miami, Sch Med, Miami, FL USA.
[Flanigan, Timothy P.] Miriam Hosp, Providence, RI 02906 USA.
[Flanigan, Timothy P.] Brown Med Sch, Providence, RI USA.
RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA.
EM korthuis@ohsu.edu
FU US Department of Health and Human Services, Health Resources and
Services Administration; HIV/AIDS Bureau's Special Project of National
Significance [H97HA03799]; National Institutes of Health, National
Institute on Drug Abuse [K23 DA019809, K24 DA 0170720]
FX This publication was funded by grants from the US Department of Health
and Human Services, Health Resources and Services Administration,
HIV/AIDS Bureau's Special Project of National Significance (H97HA03799),
and the National Institutes of Health, National Institute on Drug Abuse
(K23 DA019809 for P.T.K. and K24 DA 0170720 for F.L.A.). The contents of
the publication are solely the responsibility of the authors and do not
necessarily represent the views of the funding agencies or the US
government.
NR 41
TC 22
Z9 22
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAR 1
PY 2011
VL 56
SU 1
BP S83
EP S90
DI 10.1097/QAI.0b013e31820bc9a5
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 729YL
UT WOS:000287990500013
PM 21317600
ER
PT J
AU Attardi, BJ
Marck, BT
Matsumoto, AM
Koduri, S
Hild, SA
AF Attardi, Barbara J.
Marck, Brett T.
Matsumoto, Alvin M.
Koduri, Sailaja
Hild, Sheri A.
TI Long-Term Effects of Dimethandrolone 17 beta-Undecanoate and 11
beta-Methyl-19-Nortestosterone 17 beta-Dodecylcarbonate on Body
Composition, Bone Mineral Density, Serum Gonadotropins, and
Androgenic/Anabolic Activity in Castrated Male Rats
SO JOURNAL OF ANDROLOGY
LA English
DT Article
DE Synthetic androgens; DEXA; lean body mass; fat body mass
ID TESTOSTERONE THERAPY; ANDROGENS; MEN
AB The potent androgens dimethandrolone 17 beta-undecanoate (DMAU) and 11 beta-methyl-19-nortestosterone 17 beta-dodecylcarbonate (11 beta-MNTDC) are in development for androgen replacement therapy and hormonal contraception in men. They can be delivered either orally or as long-acting injectables. In the current study, their long-term effects on body composition (percentage lean and fat mass); bone mineral density (BMD); serum gonadotropin levels; and weights of the prostate, seminal vesicles, and levator ani muscle were assessed. Four-week-old male rats were sham-operated (intact) or castrated (Cx) and treated subcutaneously for 16 weeks postsurgery with vehicle (Cx, intact), DMAU, or 11 beta-MNTDC every 4 weeks; testosterone enanthate (TE) every 2 weeks; or a testosterone (T) implant. There were significant differences in body weights over time with a general trend of intact = Cx + T = Cx + TE > Cx + 11 beta-MNTDC > Cx > Cx + DMAU. At week 18, rats were evaluated by dual-energy x-ray absorptiometry using the whole-body function of the Hologic software. The percentage lean body mass and BMD were lower (P<.05) in Cx rats than intact rats but equivalent in all groups of androgen-treated Cx rats and intact rats (P>.05). The highest percentage body fat was observed in Cx rats. Only DMAU- and 11 beta-MNTDC treated rats had lower percentage body fat compared with Cx rats (P<.05). Prostate, seminal vesicles, and levator ani muscle weights, corrected for final body weight, were decreased (P<.05) in Cx compared with intact rats and increased to varying extents in androgen-treated Cx rats compared with Cx rats (P<.05). The most marked increases were observed in the DMAU-treated rats in which prostate and seminal vesicle weights/kg body weight were 2.4 to 2.7 times those of intact rats, and levator ani muscle weights were increased approximately 1.5-fold. Blood was collected from the tail vein at weeks 4, 8, 12, and 16 for measurement of serum levels of androgens and at necropsy at week 18 for measurement of serum gonadotropins. Serum levels of luteinizing hormone and follicle-stimulating hormone were greatly elevated in Cx rats at week 18 and suppressed to levels comparable to those in intact rats by DMAU, 11 beta-MNTDC, and T implants (P>.05). Collectively, our data indicate that androgen replacement with DMAU or 11 beta-MNTDC in Cx rats resulted in favorable changes in body composition and maintenance of BMD comparable to those of T.
C1 [Attardi, Barbara J.] BIOQUAL Inc, Mol Endocrinol Lab, Div Reprod Endocrinol & Toxicol, Rockville, MD 20850 USA.
[Marck, Brett T.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Marck, Brett T.; Matsumoto, Alvin M.] Univ Washington, Sch Med, Seattle, WA USA.
RP Attardi, BJ (reprint author), BIOQUAL Inc, Mol Endocrinol Lab, Div Reprod Endocrinol & Toxicol, 9600 Med Ctr Dr, Rockville, MD 20850 USA.
EM bjattardi@bioqual.com
FU NICHD [NO1-HD-2-3338]
FX This work was supported by NICHD contract NO1-HD-2-3338 awarded to
BIOQUAL Inc.
NR 16
TC 9
Z9 10
U1 0
U2 2
PU AMER SOC ANDROLOGY, INC
PI LAWRENCE
PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA
SN 0196-3635
J9 J ANDROL
JI J. Androl.
PD MAR-APR
PY 2011
VL 32
IS 2
BP 183
EP 192
DI 10.2164/jandrol.110.010371
PG 10
WC Andrology
SC Endocrinology & Metabolism
GA 724BA
UT WOS:000287549900011
PM 20798389
ER
PT J
AU Gradman, AH
Basile, JN
Carter, BL
Bakris, GL
AF Gradman, Alan H.
Basile, Jan N.
Carter, Barry L.
Bakris, George L.
CA Amer Soc Hypertension Writing Grp
TI Combination Therapy in Hypertension
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID BLOOD-PRESSURE CONTROL; LOW-DOSE HYDROCHLOROTHIAZIDE; FELODIPINE
EXTENDED-RELEASE; CONVERTING-ENZYME-INHIBITOR; HIGH CARDIOVASCULAR RISK;
CALCIUM-CHANNEL BLOCKER; DOUBLE-BLIND; RANDOMIZED-TRIAL;
ANTIHYPERTENSIVE TREATMENT; SYSTEMIC HYPERTENSION
AB The goal of antihypertensive therapy is to abolish the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular (CV) end points, including stroke, myocardial infarction, and heart failure. Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. Available data suggest that at least 75% of patients will require combination therapy to achieve contemporary BP targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. It is within this context that the American Society of Hypertension presents this Position Paper on Combination Therapy for Hypertension. It will address the scientific basis of combination therapy, present the pharmacologic rationale for choosing specific drug combinations, and review patient selection criteria for initial and secondary use. The advantages and disadvantages of single-pill (fixed) drug combinations and the implications of recent clinical trials involving specific combination strategies will also be discussed. J Clin Hypertens (Greenwich). 2011;13:146-154. (C) 2010 Wiley Periodicals, Inc.
C1 [Gradman, Alan H.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Carter, Barry L.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA.
[Bakris, George L.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
[Gradman, Alan H.] Western Penn Hosp, Pittsburgh, PA 15224 USA.
RP Gradman, AH (reprint author), 4800 Friendship Ave,Suite 3411N, Pittsburgh, PA 15224 USA.
EM gradmanmd@aol.com
NR 64
TC 41
Z9 43
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAR
PY 2011
VL 13
IS 3
BP 146
EP 154
DI 10.1111/j.1751-7176.2010.00397.x
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 729FD
UT WOS:000287933100004
PM 21366845
ER
PT J
AU Basile, J
Babazadeh, S
Lillestol, M
Botha, J
Yurkovic, C
Weitzman, R
AF Basile, Jan
Babazadeh, Simon
Lillestol, Michael
Botha, Jaco
Yurkovic, Carol
Weitzman, Richard
TI Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy With
Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic
Hypertension: Results of the ACTION Study
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID BLOOD-PRESSURE; DOUBLE-BLIND; NATIONAL-HEALTH; ALISKIREN; TRIAL; AGE;
PREVALENCE; PREVENTION; GUIDELINES; MANAGEMENT
AB Patients with stage 2 systolic hypertension require sizable blood pressure (BP) reductions to achieve recommended targets. This randomized double-blind study compared a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (aliskiren/HCTZ) with HCTZ monotherapy in older patients (older than 55 years) with systolic BP >= 160 mm Hg and < 200 mm Hg. After a 1- to 4-week washout, 451 patients were randomized to once-daily aliskiren/HCTZ 150/12.5 mg or HCTZ 12.5 mg for 1 week, and then double the doses for 7 weeks. Overall baseline BP was 168.8/91.4 mm Hg. At week 4 (primary) end point, aliskiren/HCTZ provided significantly greater BP reductions from baseline than HCTZ monotherapy (29.6/9.3 mm Hg vs 22.3/6.8 mm Hg) and resulted in a greater proportion of patients achieving BP goal of < 140/90 mm Hg (51.1% vs 33.3%). Aliskiren/HCTZ therapy provides substantial BP reductions and may thus be a useful treatment option for older patients with stage 2 hypertension. J Clin Hypertens (Greenwich). 2011;13:162-169. (C) 2011 Wiley Periodicals, Inc.
C1 [Basile, Jan] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29401 USA.
[Lillestol, Michael] Lillestol Res LLC, Fargo, ND USA.
[Botha, Jaco] Novartis Pharma AG, Basel, Switzerland.
[Yurkovic, Carol; Weitzman, Richard] Novartis Pharmaceut, E Hanover, NJ USA.
[Babazadeh, Simon] Crest Clin Trials Inc, Santa Ana, CA USA.
RP Basile, J (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29401 USA.
EM basilejn@musc.edu
FU Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis;
National Heart, Lung and Blood Institute; Boehringer-Ingelheim
FX This work was funded by Novartis Pharmaceuticals Corporation, East
Hanover, NJ. Jan Basile has received research support from Novartis, The
National Heart, Lung and Blood Institute and Boehringer-Ingelheim; has
acted as a consultant for Novartis, Abbott Laboratories,
Boehringer-Ingelheim, Forest Laboratories, Daiichi-Sankyo and Takeda
Pharmaceuticals; and has been a member of the speakers' bureau for
Novartis, Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Forest
Laboratories, GSK, Merck, Pfizer and Daiichi-Sankyo. Michael Lillestol
has received research support from Novartis. Jaco Botha, Carol Yurkovic,
and Richard Weitzman are employees of Novartis and are therefore
eligible for Novartis stock and stock options.
NR 21
TC 7
Z9 8
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAR
PY 2011
VL 13
IS 3
BP 162
EP 169
DI 10.1111/j.1751-7176.2010.00418.x
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 729FD
UT WOS:000287933100006
PM 21366847
ER
PT J
AU Gros, DF
Simms, LJ
Antony, MM
AF Gros, Daniel F.
Simms, Leonard J.
Antony, Martin M.
TI A Hybrid Model of Social Phobia: An Analysis of Social Anxiety and
Related Symptoms of Anxiety
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE social anxiety; social phobia; component analysis; hybrid model
ID DSM-IV ANXIETY; MOOD DISORDERS; SCALE DEVELOPMENT; SPECIAL SECTION;
RISK-FACTORS; VALIDITY; CLASSIFICATION; COMORBIDITY; DIMENSIONS;
SPECTRUM
AB The categorical underpinnings of the current diagnostic nomenclature have been the subject of repeated criticism. Recently, researchers have proposed several alternatives to the current system, including hybrid models of combined diagnostic categories and symptom dimensions. In the present study, we investigated the symptoms associated with a hybrid model of social phobia. The study included (a) the development of the initial set of symptom dimensions, generation of an item pool, and review by an expert panel, and (b) data collection and component analysis of the item pool to determine the structure of the symptoms. Six separate theoretically relevant symptom dimensions were identified. Implications of these findings on the development of a new hybrid model of social phobia were discussed. (C) 2010 Wiley Periodicals, Inc. J Clin Psychol 67:293-307, 2011.
C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA.
[Gros, Daniel F.] Med Univ S Carolina, Charleston, SC USA.
[Simms, Leonard J.] SUNY Buffalo, Buffalo, NY 14260 USA.
[Antony, Martin M.] Ryerson Univ, Toronto, ON, Canada.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
RI Antony, Martin/K-1991-2012
OI Antony, Martin/0000-0002-3508-377X
NR 43
TC 13
Z9 13
U1 4
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAR
PY 2011
VL 67
IS 3
BP 293
EP 307
DI 10.1002/jclp.20763
PG 15
WC Psychology, Clinical
SC Psychology
GA 712VG
UT WOS:000286693800008
PM 21254057
ER
PT J
AU Wu, S
Harber, P
Yun, D
Bansal, S
Li, YA
Santiago, S
AF Wu, Samantha
Harber, Philip
Yun, David
Bansal, Siddharth
Li, Yuan
Santiago, Silverio
TI Anxiety During Respirator Use: Comparison of Two Respirator Types
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE
LA English
DT Article
DE anxiety; personal protective equipment; respirator
ID HEALTH-CARE WORKERS; PHYSIOLOGICAL IMPACT; INDUSTRIAL RESPIRATORS;
SUBJECTIVE RESPONSE; SIMULATED WORK; MENTAL STRESS; PERFORMANCE;
VENTILATION; PREDICTION; EXERCISE
AB Anxiety may interfere with proper respirator use. This study directly compares the effect of two types of respirators-elastomeric half-face mask with dual-cartridges (HFM) and N95 filtering facepiece-on anxiety levels. Twelve volunteers with normal or mildly impaired respiratory conditions performed a series of simulated work tasks using the HFM and N95 on different days. The State-Trait Anxiety Inventory (STAI) measured state anxiety (SA) before and during respirator use. STAI also measured trait anxiety (TA), a stable personal characteristic. The effect of the respirator was measured as the difference between SA pre-use and during use. Work with HFM was associated with an increase in SA (2.92 units, p < .01), whereas work with the N95 had no observed effect. Anxiety should be considered in the selection of the best respirator for a user. Impact on anxiety should be considered for respirator design and certification purposes, particularly if the device is to be widely used in workplace and community settings.
C1 [Wu, Samantha; Harber, Philip; Yun, David; Bansal, Siddharth; Li, Yuan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Occupat & Environm Med Div, Los Angeles, CA 90095 USA.
[Harber, Philip; Santiago, Silverio] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Div Pulm Med, Los Angeles, CA USA.
RP Harber, P (reprint author), UCLA Occupat & Environm Med, 10880 Wilshire,1800, Los Angeles, CA 90024 USA.
EM pharber@ucla.edu
FU CDC/NIOSH [R01 OH-8119]
FX The authors acknowledge and thank David Liu for data collection, Yihang
Liu, M.D., for statistical assistance, and Johnny Bontemps for
assistance in manuscript preparation. This work was supported by Grant #
R01 OH-8119 from CDC/NIOSH.
NR 27
TC 5
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1545-9624
J9 J OCCUP ENVIRON HYG
JI J. Occup. Environ. Hyg.
PD MAR
PY 2011
VL 8
IS 3
BP 123
EP 128
DI 10.1080/15459624.2011.549780
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA 731KX
UT WOS:000288106600001
PM 21318920
ER
PT J
AU Smith, D
Caragian, N
Kazlo, E
Bernstein, J
Richardson, D
Casarett, D
AF Smith, Dawn
Caragian, Nicole
Kazlo, Elena
Bernstein, Jennie
Richardson, Diane
Casarett, David
TI Can We Make Reports of End-of-Life Care Quality More Consumer-Focused?
Results of a Nationwide Quality Measurement Program
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID BEREAVED FAMILY-MEMBERS; SERIOUSLY ILL PATIENTS; HOSPICE CARE;
SATISFACTION; PERCEPTIONS; VALIDATION; SERVICES; DEATH
AB Objectives: The goal of this study was to define families' priorities for various aspects of end-of-life care, and to determine whether scores that reflect these priorities alter facilities' quality rankings.
Design: Nationwide telephone survey.
Setting: 62 VA medical centers, including acute and long term care.
Participants: For each patient who died in a participating facility, one family member was invited to participate.
Measurements: A survey included 14 items describing key aspects of the patient's care in his or her last month of life, and one global rating. A weighted score was calculated based on the association between each item and the global rating.
Results: Interviews were completed with family members for 3,897 of 7,110 patients (55%). Items showed an approximately 5-fold range of weights, indicating a wide variation in the importance that families placed on aspects of palliative care (low: pain management, weight 0.54, 95% CI 0.38-0.70; /P/< 0.001; high: providers were "kind, caring, and respectful: weight 2.46, 95% CI 2.24-2.68; /P/< 0.001). Weights were homogeneous across patient subgroups, and there were no significant changes in facilities' quality rankings when weights were used. Both weighted and unweighted scores showed similar evidence of the impact of process measures.
Conclusion: There appears to be wide variation in the importance that families place on several aspects of end-of-life care. However, the impact of weighting was generally even across patient subgroups and facilities. Therefore, the use of weights to account for families' priorities is not likely to alter a facility's quality score.
C1 [Casarett, David] Univ Penn, Sch Med, Div Geriatr Med, Philadelphia, PA 19104 USA.
[Smith, Dawn; Caragian, Nicole; Kazlo, Elena; Bernstein, Jennie; Richardson, Diane; Casarett, David] Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
RP Casarett, D (reprint author), Univ Penn, Penn Wissahickon Hosp, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM Casarett@mail.med.upenn.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, HSRD
FX This material is based upon work supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, HSR&D.
NR 29
TC 6
Z9 7
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD MAR
PY 2011
VL 14
IS 3
BP 301
EP 307
DI 10.1089/jpm.2010.0321
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 728ZZ
UT WOS:000287915700013
PM 21288125
ER
PT J
AU Lee, SR
Kardos, KW
Schiff, E
Berne, CA
Mounzer, K
Banks, AT
Tatum, HA
Friel, TJ
DeMicco, MP
Lee, WM
Eder, SE
Monto, A
Yearwood, GD
Guillon, GB
Kurtz, LA
Fischl, M
Unangst, JL
Kriebel, L
Feiss, G
Roehler, M
AF Lee, Stephen R.
Kardos, Keith W.
Schiff, Eugene
Berne, Cheryl A.
Mounzer, Karam
Banks, Alpha T.
Tatum, Harvey A.
Friel, Timothy J.
DeMicco, Michael P.
Lee, William M.
Eder, Scott E.
Monto, Alexander
Yearwood, Graham D.
Guillon, Geraldine B.
Kurtz, Lisa A.
Fischl, Mark
Unangst, Jay Lynn
Kriebel, Laura
Feiss, Gary
Roehler, Michele
TI Evaluation of a new, rapid test for detecting HCV infection, suitable
for use with blood or oral fluid
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HCV; Rapid test; Oral fluid
ID HEPATITIS-C VIRUS; UNITED-STATES; DRUG-USERS; ENZYME-IMMUNOASSAY;
VIRAL-HEPATITIS; ASSAY; POPULATION; ANTIBODIES; RISK; PERFORMANCE
AB The availability of a highly accurate, rapid, point-of-care test for hepatitis C virus (HCV) may be useful in addressing the problem of under-diagnosis of HCV, by increasing opportunities for testing outside of traditional clinical settings. A new HCV rapid test device (OraQuick (R) HCV Rapid Antibody Test), approved recently in Europe for use with venous blood, fingerstick blood, serum, plasma, or oral fluid was evaluated in a multi-center study and performance compared to established laboratory-based tests for detection of HCV.
The HCV rapid test was evaluated in prospective testing of subjects with signs and/or symptoms of hepatitis, or who were at risk for hepatitis C using all 5 specimen types. Performance was assessed relative to HCV serostatus established by laboratory methods (EIA. RIBA and PCR) approved in Europe for diagnosis of hepatitis C infection. Sensitivity to antibody in early infection was also compared to EA in 27 seroconversion panels. In addition, the reliability of the oral fluid sample for accurate detection of anti-HCV was assessed by studying the impact of various potentially interfering conditions of oral health, use of oral care products and consumption of food and drink.
In this large study of at-risk and symptomatic persons, the overall specificities of the OraQuick (R) HCV Rapid Antibody Test were equivalent (99.6-99.9%) for all 5 specimen types and the 95% CIs substantially overlapped. Overall sensitivities were virtually identical for venous blood, fingerstick blood, serum and plasma (99.7-99.9%). Observed sensitivity was slightly lower for oral fluid at 98.1% though the upper Cl (99.0%) was equal to the lower CI for venous blood and fingerstick blood. Most of the HCV positive subjects which gave nonreactive results in oral fluid had serological and virological results consistent with resolved infection. Sensitivity for anti-HCV in early seroconversion was virtually identical between the HCV rapid test and EIA. Detection of anti-HCV in oral fluid appeared generally robust to conditions of oral health, consumption of food and drink and use of oral care products.
The OraQuick (R) HCV Rapid Antibody Test demonstrated clinical performance that was equivalent to current laboratory-based EIA. This new, HCV rapid test appears suitable as an aid in the diagnosis of HCV infection and may increase testing opportunities due to its simplicity and flexibility to use multiple specimen types, including fingerstick blood and oral fluid. (C) 2010 Elsevier BM. All rights reserved.
C1 [Lee, Stephen R.; Kardos, Keith W.; Yearwood, Graham D.; Guillon, Geraldine B.; Kurtz, Lisa A.; Fischl, Mark; Unangst, Jay Lynn; Kriebel, Laura; Feiss, Gary; Roehler, Michele] OraSure Technol Inc, Bethlehem, PA 18015 USA.
[Schiff, Eugene] Univ Miami, Miller Sch Med, Hepatol Diagnost Lab, Miami, FL 33136 USA.
[Berne, Cheryl A.] Biol Specialty Corp, Reading, PA 19602 USA.
[Mounzer, Karam] Philadelphia FIGHT, Philadelphia, PA 19107 USA.
[Banks, Alpha T.] Banks Hepatol Inst, College Pk, MD 20740 USA.
[Tatum, Harvey A.] Opt Hlth Res LLC, Tulsa, OK 74104 USA.
[Friel, Timothy J.] Lehigh Valley Hosp, Allentown, PA 18102 USA.
[DeMicco, Michael P.] Associated Gastroenterol Med Grp, Anaheim, CA 92801 USA.
[Lee, William M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Eder, Scott E.] Womens Hlth Res Ctr, Plainsboro, NJ 08536 USA.
[Monto, Alexander] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA.
RP Lee, SR (reprint author), OraSure Technol Inc, 220 E 1st St, Bethlehem, PA 18015 USA.
EM slee@orasure.com
NR 30
TC 39
Z9 39
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD MAR
PY 2011
VL 172
IS 1-2
BP 27
EP 31
DI 10.1016/j.jviromet.2010.12.009
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Virology
GA 728YB
UT WOS:000287909300005
PM 21182871
ER
PT J
AU Ippolito, A
Wallace, DJ
Gladman, D
Fortin, PR
Urowitz, M
Werth, V
Costner, M
Gordon, C
Alarcon, GS
Ramsey-Goldman, R
Maddison, P
Clarke, A
Bernatsky, S
Manzi, S
Bae, SC
Merrill, JT
Ginzler, E
Hanly, JG
Nived, O
Sturfelt, G
Sanchez-Guerrero, J
Bruce, I
Aranow, C
Isenberg, D
Zoma, A
Magder, LS
Buyon, J
Kalunian, K
Dooley, MA
Steinsson, K
van Vollenhoven, RF
Stoll, T
Weisman, M
Petri, M
AF Ippolito, A.
Wallace, D. J.
Gladman, D.
Fortin, P. R.
Urowitz, M.
Werth, V.
Costner, M.
Gordon, C.
Alarcon, G. S.
Ramsey-Goldman, R.
Maddison, P.
Clarke, A.
Bernatsky, S.
Manzi, S.
Bae, S-C
Merrill, J. T.
Ginzler, E.
Hanly, J. G.
Nived, O.
Sturfelt, G.
Sanchez-Guerrero, J.
Bruce, I.
Aranow, C.
Isenberg, D.
Zoma, A.
Magder, L. S.
Buyon, J.
Kalunian, K.
Dooley, M. A.
Steinsson, K.
van Vollenhoven, R. F.
Stoll, T.
Weisman, M.
Petri, M.
TI Autoantibodies in systemic lupus erythematosus: comparison of historical
and current assessment of seropositivity
SO LUPUS
LA English
DT Article
DE ANA; autoantibodies; systemic lupus erythematosus
ID B-CELL DEPLETION; REVISED CRITERIA; ANTIBODY-TITERS; NEPHRITIS;
CLASSIFICATION; FLUCTUATION; PROFILES; EFFICACY; THERAPY; SM
AB Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and complement activation. Recent studies have suggested that anti-nuclear antibody (ANA) positivity may disappear over time in some SLE patients. Anti-double-stranded DNA (dsDNA) antibody titers and complement levels may vary with time and immunosuppressive treatment, while the behavior of anti-extractable nuclear antigen (ENA) over time is less well understood. This study sought to determine the correlation between historical autoantibody tests and current testing in patients with SLE. Three hundred and two SLE patients from the ACR Reclassification of SLE (AROSE) database with both historical and current laboratory data were selected for analysis. The historical laboratory data were compared with the current autoantibody tests done at the reference laboratory and tested for agreement using percent agreement and Kappa statistic. Serologic tests included ANA, anti-dsDNA, anti-Smith, anti-ribonucleoprotein (RNP), anti-Ro, anti-La, rheumatoid factor (RF), C3 and C4. Among those historically negative for immunologic markers, a current assessment of the markers by the reference laboratory generally yielded a low percentage of additional positives (3-13%). However, 6/11 (55%) of those historically negative for ANA were positive by the reference laboratory, and the reference laboratory test also identified 20% more patients with anti-RNP and 18% more with RF. Among those historically positive for immunologic markers, the reference laboratory results were generally positive on the same laboratory test (range 57% to 97%). However, among those with a history of low C3 or C4, the current reference laboratory results indicated low C3 or C4 a low percentage of the time (18% and 39%, respectively). ANA positivity remained positive over time, in contrast to previous studies. Anti-Ro, La, RNP, Smith and anti-dsDNA antibodies had substantial agreement over time, while complement had less agreement. This variation could partially be explained by variability of the historical assays, which were done by local laboratories over varying periods of time. Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials. Lupus (2011) 20, 250-255.
C1 [Ippolito, A.; Isenberg, D.] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21205 USA.
[Wallace, D. J.; Weisman, M.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA.
[Gladman, D.; Fortin, P. R.; Urowitz, M.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada.
[Werth, V.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA.
[Costner, M.] N Dallas Dermatol Associates, Dallas, TX USA.
[Gordon, C.] Univ Birmingham, Sch Med, Dept Rheumatol, Birmingham, W Midlands, England.
[Alarcon, G. S.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Ramsey-Goldman, R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Maddison, P.] Ysbyty Gwynedd, Dept Rheumatol, Bangor, Gwynedd, Wales.
[Clarke, A.; Bernatsky, S.] McGill Univ, Div Clin Epidemiol, Montreal, PQ, Canada.
[Manzi, S.] Univ Pittsburgh, Sch Med, Dept Med, Div Rheumatol, Pittsburgh, PA USA.
[Bae, S-C] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea.
[Merrill, J. T.] Oklahoma Med Res Fdn, Dept Clin Pharmacol, Oklahoma City, OK 73104 USA.
[Ginzler, E.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Hanly, J. G.] Capital Hlth & Dalhousie Univ, Div Rheumatol, Dept Med, Halifax, NS, Canada.
[Hanly, J. G.] Capital Hlth & Dalhousie Univ, Div Rheumatol, Dept Pathol, Halifax, NS, Canada.
[Nived, O.; Sturfelt, G.] Univ Hosp, Dept Rheumatol, Lund, Sweden.
[Bruce, I.] Univ Manchester, ARC Epidemiol Unit, Manchester, Lancs, England.
[Aranow, C.] Feinstein Inst Med Res, Manhasset, NY USA.
[Isenberg, D.] Ctr Rheumatol Res, Div Med, London, England.
[Zoma, A.] Hairmyres Hosp, Lanarkshire Ctr Rheumatol, E Kilbride, Lanark, Scotland.
[Magder, L. S.] Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.
[Buyon, J.] NYU Med Ctr, New York, NY 10016 USA.
[Kalunian, K.] UCSD Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA USA.
[Dooley, M. A.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA.
[Steinsson, K.] Univ Hosp, Landspitali, Dept Rheumatol, Reykjavik, Iceland.
[Steinsson, K.] Ctr Rheumatol Res, Reykjavik, Iceland.
[van Vollenhoven, R. F.] Karolinska Univ Hosp, Dept Rheumatol, Stockholm, Sweden.
[Stoll, T.] Kantonsspital Schaffhausen, Schaffhausen, Switzerland.
RP Ippolito, A (reprint author), Johns Hopkins Univ, Sch Med, Div Rheumatol, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA.
EM ippolitoa@mail.nih.gov
OI Isenberg, David/0000-0001-9514-2455; Bruce, Ian/0000-0003-3047-500X
FU Institute for Clinical and Translational Research [UL1RR025005]; NIH
[AR43727]
FX This study was supported by the Institute for Clinical and Translational
Research (UL1RR025005) and NIH AR43727.
NR 30
TC 31
Z9 32
U1 4
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0961-2033
J9 LUPUS
JI Lupus
PD MAR
PY 2011
VL 20
IS 3
BP 250
EP 255
DI 10.1177/0961203310385738
PG 6
WC Rheumatology
SC Rheumatology
GA 728BN
UT WOS:000287849000004
PM 21362750
ER
PT J
AU Sun, HY
Singh, N
AF Sun, Hsin-Yun
Singh, Nina
TI Potential role of statins for the management of immune reconstitution
syndrome
SO MEDICAL HYPOTHESES
LA English
DT Article
ID REGULATORY T-CELLS; VERSUS-HOST-DISEASE; HMG-COA REDUCTASE; EXPERIMENTAL
AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY SYNDROME; ANTIRETROVIRAL
THERAPY; PARADOXICAL RESPONSE; RESTORATION SYNDROME; INFECTED PATIENTS;
DOUBLE-BLIND
AB It has become evident that while a robust inflammatory response plays a critical role in eradicating invading microbes, dysregulated immunity can be detrimental to the host if an optimal balance between the inflammatory and anti-inflammatory reactions is disrupted. Opportunistic infection-associated immune reconstitution syndrome is characterized by an aggressive inflammatory immune response and its management remains challenging and largely unknown. Statins, in addition to their lipid lower effects have anti-inflammatory attributes and there is precedence for the use of these agents as a therapeutic modality for autoimmune inflammatory disorders which have similar underlying pathogenesis as immune reconstitution syndrome. We hypothesize that statins may have a potential role for the management of immune reconstitution syndrome. Our proposal has biologic and translational implications for optimizing outcomes in patients with immune reconstitution syndrome. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Sun, Hsin-Yun] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
OI SUN, HSIN-YUN/0000-0003-0074-7721
NR 55
TC 4
Z9 4
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAR
PY 2011
VL 76
IS 3
BP 307
EP 310
DI 10.1016/j.mehy.2010.09.019
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 728QK
UT WOS:000287888600001
PM 20965666
ER
PT J
AU Winthrop, KL
Baxter, R
Liu, LY
McFarland, B
Austin, D
Varley, C
Radcliffe, L
Suhler, E
Choi, D
Herrinton, LJ
AF Winthrop, Kevin L.
Baxter, Roger
Liu, Liyan
McFarland, Bentson
Austin, Donald
Varley, Cara
Radcliffe, Leann
Suhler, Eric
Choi, Dongsoek
Herrinton, Lisa J.
TI The reliability of diagnostic coding and laboratory data to identify
tuberculosis and nontuberculous mycobacterial disease among rheumatoid
arthritis patients using anti-tumor necrosis factor therapy
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE tuberculosis; nontuberculous mycobacteria; biologic therapy; tumor
necrosis factor-alpha; electronic medical records; case-finding
ID GRANULOMATOUS INFECTIONS; MANAGEMENT; BLOCKADE; RISK
AB Purpose Anti-tumor necrosis factor-alpha (anti-TNF) therapies are associated with severe mycobacterial infections in rheumatoid arthritis patients. We developed and validated electronic record search algorithms for these serious infections.
Methods The study used electronic clinical, microbiologic, and pharmacy records from Kaiser Permanente Northern California (KPNC) and the Portland Veterans Affairs Medical Center (PVAMC). We identified suspect tuberculosis and nontuberculous mycobacteria (NTM) cases using inpatient and outpatient diagnostic codes, culture results, and anti-tuberculous medication dispensing. We manually reviewed records to validate our case-finding algorithms.
Results We identified 64 tuberculosis and 367 NTM potential cases, respectively. For tuberculosis, diagnostic code positive predictive value (PPV) was 54% at KPNC and 9% at PVAMC. Adding medication dispensings improved these to 87% and 46%, respectively. Positive tuberculosis cultures had a PPV of 100% with sensitivities of 79% (KPNC) and 55% (PVAMC). For NTM, the PPV of diagnostic codes was 91% (KPNC) and 76% (PVAMC). At KPNC, >= 1 positive NTM culture was sensitive (100%) and specific (PPV, 74%) if non-pathogenic species were excluded; at PVAMC, >= 1 positive NTM culture identified 76% of cases with PPV of 41%. Application of the American Thoracic Society NTM microbiology criteria yielded the highest PPV (100% KPNC, 78% PVAMC).
Conclusions The sensitivity and predictive value of electronic microbiologic data for tuberculosis and NTM infections is generally high, but varies with different facilities or models of care. Unlike NTM, tuberculosis diagnostic codes have poor PPV, and in the absence of laboratory data, should be combined with anti-tuberculous therapy dispensings for pharmacoepidemiologic research. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Winthrop, Kevin L.; McFarland, Bentson; Austin, Donald; Varley, Cara; Suhler, Eric; Choi, Dongsoek] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Winthrop, Kevin L.; Austin, Donald; Radcliffe, Leann; Suhler, Eric] Portland VA Med Ctr, Portland, OR USA.
[Baxter, Roger; Liu, Liyan; Herrinton, Lisa J.] Kaiser Permanente No Calif, Oakland, CA USA.
RP Winthrop, KL (reprint author), CEI OHSU, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM winthrop@ohsu.edu
OI McFarland, Bentson/0000-0001-9149-5616
FU UCB pharmaceuticals; Agency for Healthcare Research and Quality (AHRQ)
[1K08HS017552-01]
FX This work was funded by a grant from UCB pharmaceuticals. KL Winthrop's
work on this manuscript was funded by an Agency for Healthcare Research
and Quality (AHRQ) grant (1K08HS017552-01).
NR 19
TC 20
Z9 20
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1053-8569
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD MAR
PY 2011
VL 20
IS 3
BP 229
EP 235
DI 10.1002/pds.2049
PG 7
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA 731BZ
UT WOS:000288082600002
PM 21351303
ER
PT J
AU Zampighi, GA
Schietroma, C
Zampighi, LM
Woodruff, M
Wright, EM
Brecha, NC
AF Zampighi, Guido A.
Schietroma, Cataldo
Zampighi, Lorenzo M.
Woodruff, Michael
Wright, Ernest M.
Brecha, Nicholas C.
TI Conical Tomography of a Ribbon Synapse: Structural Evidence for Vesicle
Fusion
SO PLOS ONE
LA English
DT Article
ID RETINAL BIPOLAR CELLS; FROG NEUROMUSCULAR-JUNCTION; SENSITIVE
CALCIUM-CHANNEL; SALAMANDER ROD SYNAPSE; OUTER PLEXIFORM LAYER; ACTIVE
ZONE PROTEINS; SACCULAR HAIR-CELLS; TRANSMITTER RELEASE; ELECTRON
TOMOGRAPHY; PHOTORECEPTOR TERMINALS
AB To characterize the sites of synaptic vesicle fusion in photoreceptors, we evaluated the three-dimensional structure of rod spherules from mice exposed to steady bright light or dark-adapted for periods ranging from 3 to 180 minutes using conical electron tomography. Conical tilt series from mice retinas were reconstructed using the weighted back projection algorithm, refined by projection matching and analyzed using semiautomatic density segmentation. In the light, rod spherules contained similar to 470 vesicles that were hemi-fused and similar to 187 vesicles that were fully fused (omega figures) with the plasma membrane. Active zones, defined by the presence of fully fused vesicles, extended along the entire area of contact between the rod spherule and the horizontal cell ending, and included the base of the ribbon, the slope of the synaptic ridge and ribbon-free regions apposed to horizontal cell axonal endings. There were transient changes of the rod spherules during dark adaptation. At early periods in the dark (3-15 minutes), there was a) an increase in the number of fully fused synaptic vesicles, b) a decrease in rod spherule volume, and c) an increase in the surface area of the contact between the rod spherule and horizontal cell endings. These changes partially compensate for the increase in the rod spherule plasma membrane following vesicle fusion. After 30 minutes of dark-adaptation, the rod spherules returned to dimensions similar to those measured in the light. These findings show that vesicle fusion occurs at both ribbon-associated and ribbon-free regions, and that transient changes in rod spherules and horizontal cell endings occur shortly after dark onset.
C1 [Zampighi, Guido A.; Schietroma, Cataldo; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
[Zampighi, Guido A.; Zampighi, Lorenzo M.; Wright, Ernest M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
[Woodruff, Michael] Univ Calif Los Angeles, Coll Letters & Sci, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Zampighi, GA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
EM nbrecha@ucla.edu
FU National Institutes of Health [EY04410, DK44602, EY15573]; Jules Stein
Eye Institute
FX This work was supported by National Institutes of Health EY04410 (GZ),
DK44602 (EMW), EY15573 (NCB) and the Jules Stein Eye Institute. NCB is a
VA Career Scientist. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 119
TC 22
Z9 22
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2011
VL 6
IS 3
AR e16944
DI 10.1371/journal.pone.0016944
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 729ET
UT WOS:000287932100008
PM 21390245
ER
PT J
AU Quan, SF
Chan, CS
Dement, WC
Gevins, A
Goodwin, JL
Gottlieb, DJ
Green, S
Guilleminault, C
Hirshkowitz, M
Hyde, PR
Kay, GG
Leary, EB
Nichols, DA
Schweitzer, PK
Simon, RD
Walsh, JK
Kushida, CA
AF Quan, Stuart F.
Chan, Cynthia S.
Dement, William C.
Gevins, Alan
Goodwin, James L.
Gottlieb, Daniel J.
Green, Sylvan
Guilleminault, Christian
Hirshkowitz, Max
Hyde, Pamela R.
Kay, Gary G.
Leary, Eileen B.
Nichols, Deborah A.
Schweitzer, Paula K.
Simon, Richard D.
Walsh, James K.
Kushida, Clete A.
TI The Association between Obstructive Sleep Apnea and Neurocognitive
Performance-The Apnea Positive Pressure Long-term Efficacy Study
(APPLES)
SO SLEEP
LA English
DT Article
DE Obstructive sleep apnea; neurocognition; epidemiology; sleep; oxygen
desaturation
ID HEART HEALTH; COGNITIVE FUNCTION; AIRWAY PRESSURE; BREATHING DISORDERS;
EXECUTIVE FUNCTIONS; DAYTIME SLEEPINESS; CPAP TREATMENT; RISK-FACTOR;
DEFICITS; HYPOPNEA
AB Study Objectives: To determine associations between obstructive sleep apnea (OSA) and neurocognitive performance in a large cohort of adults.
Study Design: Cross-sectional analyses of polysomnographic and neurocognitive data from 1204 adult participants with a clinical diagnosis of obstructive sleep apnea (OSA) in the Apnea Positive Pressure Long-term Efficacy Study (APPLES), assessed at baseline before randomization to either continuous positive airway pressure (CPAP) or sham CPAP.
Measurements: Sleep and respiratory indices obtained by laboratory polysomnography and several measures of neurocognitive performance.
Results: Weak correlations were found for both the apnea hypopnea index (AHI) and several indices of oxygen desaturation and neurocognitive performance in unadjusted analyses. After adjustment for level of education, ethnicity, and gender, there was no association between the AHI and neurocognitive performance. However, severity of oxygen desaturation was weakly associated with worse neurocognitive performance on some measures of intelligence, attention, and processing speed.
Conclusions: The impact of OSA on neurocognitive performance is small for many individuals with this condition and is most related to the severity of hypoxemia.
C1 [Quan, Stuart F.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02215 USA.
[Quan, Stuart F.] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA.
[Quan, Stuart F.; Goodwin, James L.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA.
[Chan, Cynthia S.; Gevins, Alan] San Francisco Brain Res Inst, San Francisco, CA USA.
[Dement, William C.; Guilleminault, Christian; Hyde, Pamela R.; Leary, Eileen B.; Nichols, Deborah A.; Kushida, Clete A.] Stanford Univ, Stanford, CA 94305 USA.
[Gottlieb, Daniel J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Hirshkowitz, Max] Baylor Coll Med, Houston, TX 77030 USA.
[Hirshkowitz, Max] VA Med Ctr, Houston, TX USA.
[Kay, Gary G.] Cogscreen LLC, Washington, DC USA.
[Schweitzer, Paula K.; Walsh, James K.] St Lukes Hosp, Chesterfield, MO USA.
[Simon, Richard D.] St Mary Hosp, Walla Walla, WA USA.
[Green, Sylvan] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA.
[Chan, Cynthia S.; Gevins, Alan] SAM Technol, San Francisco, CA USA.
RP Quan, SF (reprint author), Harvard Univ, Sch Med, Div Sleep Med, 401 Pk Dr,2nd Floor E, Boston, MA 02215 USA.
EM squan@arc.arizona.edu
FU Pfizer; Merck; Somaxon; Evotec; Actelion; Vanda; Neurogen;
Sanofi-Aventis; Ventus Medical; Respironics; Jazz; Cephalon; Pacific
Medico; GlaxoSmithKline; Xenoport
FX Respironics, Inc. supplied the CPAP and sham CPAP devices for this
study. There was no other industry support. Dr. Walsh has received
research support through grants to his institution from Pfizer, Merck,
Somaxon, Evotec, Actelion, Vanda, Neurogen, Sanofi-Aventis, Ventus
Medical, Respironics, and Jazz. He has consulted for Pfizer,
Sanofi-Aventis, Cephalon, Schering-Plough/Organon, Neurocrine, Takeda,
Actelion, Sepracor, Jazz, Respironics, Transcept, Neurogen,
GlaxoSmithKline, Somaxon, Eli Lilly, Evotec, Merck, Kingsdown, Vanda,
Ventus Medical, and Somnus. Dr. Schweitzer has been the principal
investigator by studies sponsored through grants to his institution from
Neurogen, Pfizer, Merck, Somnus, and Ventus Medical. Dr. Simon has
received research support from Ventus Medical and has participated in
speaking engagements for Asante Communications. Dr. Kay has received
research support from Cephalon and Merck; he is a 50% owner of
CogScreen, which provided licenses and tests to the APPLES study at
cost. Dr. Dement has participated in paid speaking engagements. Dr.
Kushida Has received research support through grants to Stanford
University from Ventus Medical, Merck, Respironics, Jazz, Cephalon,
GlaxoSmithKline, Pacific Medico, and Xenoport. Dr. Hirshkowitz has
participated in speaking engagements for Cephalon and Takeda and has
consulted for Cephalon and Sanofi-Aventis.
NR 49
TC 69
Z9 72
U1 3
U2 9
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD MAR 1
PY 2011
VL 34
IS 3
BP 303
EP U207
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 729AK
UT WOS:000287917600010
PM 21358847
ER
PT J
AU Zariffa, J
Kramer, JLK
Fawcett, JW
Lammertse, DP
Blight, AR
Guest, J
Jones, L
Burns, S
Schubert, M
Bolliger, M
Curt, A
Steeves, JD
AF Zariffa, J.
Kramer, J. L. K.
Fawcett, J. W.
Lammertse, D. P.
Blight, A. R.
Guest, J.
Jones, L.
Burns, S.
Schubert, M.
Bolliger, M.
Curt, A.
Steeves, J. D.
TI Characterization of neurological recovery following traumatic
sensorimotor complete thoracic spinal cord injury
SO SPINAL CORD
LA English
DT Article
DE thoracic; pin-prick; light touch; motor score; level; safety
ID CLINICAL-TRIALS; ICCP PANEL; INTERNATIONAL STANDARDS; INDEPENDENCE
MEASURE; OUTCOME MEASURES; MULTICENTER; GUIDELINES; CONDUCT;
ASSESSMENTS; VERSION
AB Study design: Retrospective, longitudinal analysis of sensory, motor and functional outcomes from individuals with thoracic (T2-T12) sensorimotor complete spinal cord injury (SCI).
Objectives: To characterize neurological changes over the first year after traumatic thoracic sensorimotor complete SCI.
Methods: A dataset of 399 thoracic complete SCI subjects from the European Multi-center study about SCI (EMSCI) was examined for neurological level, sensory levels and sensory scores (pin-prick and light touch), lower extremity motor score (LEMS), ASIA Impairment Scale (AIS) grade, and Spinal Cord Independence Measure (SCIM) over the first year after SCI.
Results: AIS grade conversions were limited. Sensory scores exhibited minimal mean change, but high variability in both rostral and caudal directions. Pin-prick and light touch sensory levels, as well as neurological level, exhibited minor changes (improvement or deterioration), but most subjects remained within one segment of their initial injury level after 1 year. Recovery of LEMS occurred predominantly in subjects with low thoracic SCI. The sensory zone of partial preservation (ZPP) had no prognostic value for subsequent recovery of sensory levels or LEMS. However, after mid or low thoracic SCI, >= 3 segments of sensory ZPP correlated with an increased likelihood for AIS grade conversion.
Conclusion: The data suggest that a sustained deterioration of three or more thoracic sensory levels or loss of upper extremity motor function are rare events and may be useful for tracking the safety of a therapeutic intervention in early phase acute SCI clinical trials, if a significant proportion of study subjects exhibit such an ascent. Spinal Cord (2011) 49, 463-471; doi:10.1038/sc.2010.140; published online 12 October 2010
C1 [Zariffa, J.; Kramer, J. L. K.; Steeves, J. D.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, Vancouver, BC V5Z 1M9, Canada.
[Fawcett, J. W.] Univ Cambridge, Ctr Brain Repair, Cambridge, England.
[Lammertse, D. P.] Craig Hosp, Englewood, CO USA.
[Blight, A. R.] Acorda Therapeut, Hawthorne, NY USA.
[Guest, J.] Neurol Surg & Miami Project Cure Paralysis, Miami, FL USA.
[Jones, L.] Geron Corp, Menlo Pk, CA USA.
[Burns, S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Schubert, M.; Bolliger, M.; Curt, A.] Balgrist Univ Hosp, Spinal Cord Injury Ctr, Zurich, Switzerland.
RP Steeves, JD (reprint author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, 818 W 10th Ave, Vancouver, BC V5Z 1M9, Canada.
EM steeves@icord.org
RI Bolliger, Marc/I-9315-2012; Zariffa, Jose/A-6954-2016
OI Zariffa, Jose/0000-0002-8842-745X; Lammertse,
Daniel/0000-0003-4590-2481; Fawcett, James/0000-0002-7990-4568
FU ICCP; SCOPE; International Foundation for Research in Paraplegia,
Zurich, Switzerland (IFP-Zurich)
FX The authors are grateful for the support of ICCP
(www.campaignforcure.org) and SCOPE (www.scopesci.org). EMSCI is
supported by the International Foundation for Research in Paraplegia,
Zurich, Switzerland (IFP-Zurich).
NR 28
TC 38
Z9 38
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD MAR
PY 2011
VL 49
IS 3
BP 463
EP 471
DI 10.1038/sc.2010.140
PG 9
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 730ZH
UT WOS:000288075600027
PM 20938451
ER
PT J
AU Hosmer, W
Malin, J
Wong, M
AF Hosmer, Wylie
Malin, Jennifer
Wong, Mitchell
TI Development and validation of a prediction model for the risk of
developing febrile neutropenia in the first cycle of chemotherapy among
elderly patients with breast, lung, colorectal, and prostate cancer
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Elderly patients; Febrile neutropenia; Prediction rule; SEER-Medicare
dataset
ID NON-HODGKINS-LYMPHOMA; COLONY-STIMULATING FACTOR; COMORBIDITY INDEX;
CHOP CHEMOTHERAPY; EARLY LYMPHOPENIA; DOSE-INTENSITY; CLAIMS DATA;
MORTALITY; MEDICARE; WOMEN
AB Current guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSF) when febrile neutropenia (FN) risk is greater than 20%. Advanced age is a risk factor for FN; however, little is known about the impact of other factors on the incidence of FN in an older population.
We analyzed SEER-Medicare data (1994-2005) to develop and validate a prediction model for hospitalization with fever, infection, or neutropenia occurring after chemotherapy initiation for patients with breast, colorectal, prostate, and lung cancer.
In multivariate analysis (N = 58,053) independent predictors of FN included advanced stage at diagnosis [stage 2 (OR 1.29; 95% CI: 1.09-1.53), stage 3 (1.38; 95% CI: 1.19-1.60), and stage 4 (1.57; 95% CI: 1.35-1.83)], number of associated comorbid conditions [one condition (1.13; 95% CI: 1.02-1.28), two conditions (1.39; 95% CI: 1.22-1.57), and three or more conditions (1.81; 95% CI: 1.61-2.04)], receipt of myelosuppressive chemotherapy (1.11; 95% CI: 0.94-1.32), and receipt of chemotherapy within 1 month of diagnosis [1 to 3 months (0.70; 95% CI: 0.62-0.80) and greater than 3 months (0.63; 95% CI: 0.55-0.73)].
We created a prediction model for febrile neutropenia with first cycle of chemotherapy in a large population of elderly patients with common malignancies.
C1 [Wong, Mitchell] Univ Calif Los Angeles, Div GIM & HSR, Los Angeles, CA 90024 USA.
[Malin, Jennifer] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Hosmer, Wylie; Wong, Mitchell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Wong, M (reprint author), Univ Calif Los Angeles, Div GIM & HSR, 911 Broxton Ave, Los Angeles, CA 90024 USA.
EM mitchellwong@mednet.ucla.edu
RI Lee, Yee Mei/H-1143-2011
OI Wong, Mitchell/0000-0002-4800-8410
FU Amgen, Inc.
FX This study was funded by a grant from Amgen, Inc.
NR 33
TC 24
Z9 24
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAR
PY 2011
VL 19
IS 3
BP 333
EP 341
DI 10.1007/s00520-010-0821-1
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 728CL
UT WOS:000287851500003
PM 20179995
ER
PT J
AU Butt, AA
Wang, XQ
Fried, LF
AF Butt, Adeel A.
Wang, Xiaoqiang
Fried, Linda F.
TI HCV Infection and the Incidence of CKD
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Hepatitis C virus (HCV); chronic kidney disease (CKD); renal; liver
disease; Electronically Retrieved Cohort of HCV Infected Veteran
(ERCHIVES)
ID HEPATITIS-C VIRUS; CHRONIC KIDNEY-DISEASE; FATTY LIVER-DISEASE; STAGE
RENAL-DISEASE; HEMODIALYSIS-PATIENTS; SUBSTANCE-ABUSE; INCREASED RISK;
PREVALENCE; ASSOCIATION; PREDICTORS
AB Background: The risk of hepatitis C virus (HCV) infection upon incident chronic kidney disease (CKD) in the presence of traditional risk factors and renal-modifying therapy is not well known. Study Design: National cohort study.
Study Design: National cohort study.
Setting & Participants: HCV-infected and -uninfected veterans in ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) in 2001-2006.
Predictor: HCV infection.
Outcomes: Incident CKD stages 3-5
Results: We identified 18,002 patients with HCV infection and 25,137 controls with estimated glomerular filtration rate >60 mL/min/1.73 m(2) at baseline. HCV-infected patients had a lower prevalence of several CKD risk factors, including diabetes (22.9% vs 26.6%), hypertension (52.4% vs 60.8%), and dyslipidemia (39.3% vs 73.9%; P < 0.001). HCV infection was associated with a higher risk of developing CKD stages 3-5 (HR, 1.30; 95% CI, 1.23-1.37). Increasing age, hypertension, and diabetes were associated with significantly higher risks of developing CKD in HCV-infected patients and controls. Decompensated liver disease was a strong predictor of CKD in HCV-infected patients (HR, 3.37; 95% CI, 3.10-3.66) and HCV-uninfected controls (HR, 2.04; 95% CI, 1.84-2.25). In Kaplan-Meier analysis, HCV-infected persons had a shorter time to CKD.
Limitations: Lack of proteinuria data; small number of women.
Conclusions: HCV infection is associated with higher risk and shorter time to CKD despite having a lower prevalence of many CKD risk factors. HCV-infected persons should have targeted monitoring for the development and progression of CKD. Am J Kidney Dis. 57(3): 396-402. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Butt, Adeel A.] Univ Pittsburgh, Med Ctr, Sch Med, Pittsburgh, PA 15213 USA.
[Butt, Adeel A.; Wang, Xiaoqiang; Fried, Linda F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Butt, Adeel A.; Wang, Xiaoqiang; Fried, Linda F.] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Sch Med, 3601 5th Ave,Ste 3A, Pittsburgh, PA 15213 USA.
EM butta@dom.pitt.edu
NR 27
TC 40
Z9 41
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAR
PY 2011
VL 57
IS 3
BP 396
EP 402
DI 10.1053/j.ajkd.2010.09.023
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 722NR
UT WOS:000287439500008
PM 21185632
ER
PT J
AU Bhargava, P
Vaidya, S
Dick, AAS
Dighe, M
AF Bhargava, Puneet
Vaidya, Sandeep
Dick, Andre A. S.
Dighe, Manjiri
TI Imaging of Orthotopic Liver Transplantation: Self-Assessment Module
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE liver transplantation; orthotopic liver transplantation
ID HEPATIC-ARTERY THROMBOSIS; VASCULAR COMPLICATIONS; SONOGRAPHY; SPECTRUM;
CT; US
AB The educational objectives for this self-assessment module are for the participant to exercise, self-assess, and improve his or her understanding of imaging of orthotopic liver transplant recipients and to improve familiarity with the complications of orthotopic liver transplantation.
C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Dick, Andre A. S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-114 Radiol,Mail Stop 35828, Seattle, WA 98108 USA.
EM bhargp@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
OI Bhargava, Puneet/0000-0002-3849-9666
NR 17
TC 5
Z9 5
U1 0
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAR
PY 2011
VL 196
IS 3
SU S
BP S35
EP S38
DI 10.2214/AJR.10.7296
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 724KU
UT WOS:000287575800009
PM 21343534
ER
PT J
AU Bhargava, P
Vaidya, S
Dick, AAS
Dighe, M
AF Bhargava, Puneet
Vaidya, Sandeep
Dick, Andre A. S.
Dighe, Manjiri
TI Imaging of Orthotopic Liver Transplantation: Review
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE liver disease; liver transplantation; liver transplantation
complications; orthotopic liver transplantation
ID HEPATIC-ARTERY THROMBOSIS; VASCULAR COMPLICATIONS; BILIARY
COMPLICATIONS; RANDOMIZED TRIAL; SONOGRAPHY; MANAGEMENT; DIAGNOSIS; US;
CT; EXPERIENCE
C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Dick, Andre A. S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-114 Radiol,Mail Stop 35828, Seattle, WA 98108 USA.
EM bhargp@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
OI Bhargava, Puneet/0000-0002-3849-9666
NR 43
TC 8
Z9 8
U1 0
U2 4
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAR
PY 2011
VL 196
IS 3
SU S
BP WS15
EP WS25
DI 10.2214/AJR.09.7221
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 724KU
UT WOS:000287575800002
PM 21343537
ER
PT J
AU Conhaim, RL
Dovi, WF
Watson, KE
Spiegel, CA
Harms, BA
AF Conhaim, Robert L.
Dovi, William F.
Watson, Kal E.
Spiegel, Carol A.
Harms, Bruce A.
TI Bacteremia Does Not Affect Cellular Uptake of Ultrafine Particles in the
Lungs of Rats
SO ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY
BIOLOGY
LA English
DT Article
DE ultrafine particles; lung injury; bacteremia; sepsis; alveolar
epithelium; alveolar endothelium; neutrophils
ID ALVEOLAR; MECHANISMS; TRANSPORT; BARRIER; SEPSIS; INJURY; CELLS; PORE
AB To assess the effects of intra-abdominal bacteremia on lung cellular function in vivo, we used electron microscopy to quantify the uptake of 6 nm diameter, albumin-coated colloidal gold particles (overall diam. 20.8 nm) by cells in the lungs of rats made septic by the introduction of live bacteria (E.coli and B. fragilis) into their abdomens. Gold particles were instilled into the trachea 24 hr after bacteremia induction, and lungs were harvested and prepared for electron microscopy 24 hr later. Because bacteremia produces an increase in metabolism, we hypothesized that this might be associated with increased cellular uptake of these particles and also with increased permeability of the alveolar epithelial barrier to them, as bacteremia is also associated with lung injury. We quantified particle uptake by counting particle densities (particles/mu m(2)) within type I and type II epithelial cells, capillary endothelial cells, erythrocytes and neutrophils in the lungs of five septic rats and five sham-sepsis controls. We also counted particle densities within organelles of these cells (nuclei, mitochondria, type II cell lamellar bodies) and within the alveolar interstitium. We found particles to be present within all of these compartments, although we found no differences in particle densities between bacteremic rats and sham-sepsis controls. Our results suggest that these 6 nm particles were able to freely cross cell and organelle membranes, and further suggest that this ability was not altered by bacteremia. Anat Rec, 294:550-557, 2011. (C) 2010 Wiley-Liss, Inc.
C1 [Conhaim, Robert L.; Dovi, William F.; Watson, Kal E.; Harms, Bruce A.] William S Middleton Mem Vet Adm Med Ctr, Dept Surg, Madison, WI USA.
[Conhaim, Robert L.; Watson, Kal E.; Harms, Bruce A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
RP Conhaim, RL (reprint author), H5-301-BX3236,600 Highland Ave, Madison, WI 53792 USA.
EM conhaim@surgery.wisc.edu
FU Veterans Health Administration, Office of Research and Development,
Department of Veterans Affairs, Biomedical Laboratory Research and
Development Service
FX Grant sponsor: Veterans Health Administration, Office of Research and
Development, Department of Veterans Affairs, Biomedical Laboratory
Research and Development Service.
NR 22
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1932-8486
J9 ANAT REC
JI Anat. Rec.
PD MAR
PY 2011
VL 294
IS 3
BP 550
EP 557
DI 10.1002/ar.21326
PG 8
WC Anatomy & Morphology
SC Anatomy & Morphology
GA 725UN
UT WOS:000287671700020
PM 21337717
ER
PT J
AU de la Cruz, KI
Bakaeen, FG
Wang, XL
Huh, J
LeMaire, SA
Coselli, JS
Chu, D
AF de la Cruz, Kim I.
Bakaeen, Faisal G.
Wang, Xing Li
Huh, Joseph
LeMaire, Scott A.
Coselli, Joseph S.
Chu, Danny
TI Hypoalbuminemia and Long-Term Survival After Coronary Artery Bypass: A
Propensity Score Analysis
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID LOW SERUM-ALBUMIN; PREOPERATIVE HYPOALBUMINEMIA; CARDIAC-SURGERY;
HOSPITAL STAY; RISK-FACTORS; MORTALITY; MORBIDITY; NUTRITION;
COMPLICATIONS; INFLAMMATION
AB Background. Hypoalbuminemia is associated with increased morbidity in surgical patients. The impact of low albumin level on survival in cardiac surgical patients is unknown. We hypothesized that a low preoperative albumin level negatively affects long-term survival after coronary artery bypass graft (CABG) surgery.
Methods. We reviewed prospectively gathered data from the records of 1,164 consecutive patients who underwent primary isolated CABG at our institution between 1997 and 2007. Propensity score analysis of 18 preoperative and intraoperative variables balanced potential confounding factors between the two groups of patients, so that the final study cohort consisted of 588 patients: 294 with a preoperative albumin level less than 3.5 g/dL (ie, hypoalbuminemia) and 294 patients with a preoperative albumin level of 3.5 g/dL or greater. We assessed long-term survival by using Kaplan-Meier curves generated by log rank tests.
Results. The two groups of patients were well matched in terms of preoperative and intraoperative covariates. Both groups had similar early outcomes, including 30-day mortality rates (2.0% versus 1.7%; p = 0. 76) and the incidence of major adverse cardiac events (2.7% versus 2.7%; p = 1.0). However, patients with hypoalbuminemia had a significantly worse 8-year survival rate (65% +/- 7% versus 86% +/- 3%; hazard ratio 2.2; 95% confidence interval: 1.4 to 3.6; p = 0.001) than patients without hypoalbuminemia.
Conclusions. Although preoperative hypoalbuminemia did not predict increased early postoperative mortality or morbidity in CABG patients, it did independently predict poor long-term survival after CABG. Identifying the mechanism that underlies this relationship is essential in improving overall survival among patients with low serum albumin levels who are undergoing surgical myocardial revascularization.
C1 [de la Cruz, Kim I.; Bakaeen, Faisal G.; Wang, Xing Li; Huh, Joseph; LeMaire, Scott A.; Coselli, Joseph S.; Chu, Danny] St Lukes Episcopal Hosp, Texas Heart Inst, Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Chu, D (reprint author), St Lukes Episcopal Hosp, Texas Heart Inst, Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM dchumd@gmail.com
NR 29
TC 22
Z9 22
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAR
PY 2011
VL 91
IS 3
BP 671
EP 676
DI 10.1016/j.athoracsur.2010.09.004
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 726CZ
UT WOS:000287697700013
PM 21352977
ER
PT J
AU Bai, Q
Burton, EA
AF Bai, Qing
Burton, Edward A.
TI Zebrafish models of Tauopathy
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Review
DE Tau; Tauopathy; Progressive supranuclear palsy; Zebrafish; Alzheimer's
disease; Transgenic; Neurodegeneration
ID PAIRED HELICAL FILAMENTS; PROGRESSIVE SUPRANUCLEAR PALSY; ALZHEIMER-LIKE
PHOSPHORYLATION; REDUCES TAU PHOSPHORYLATION; PROTEIN PHOSPHATASE 2A;
NEURONAL CELL-DEATH; TRANSGENIC ZEBRAFISH; IN-VIVO; DANIO-RERIO;
NEUROFIBRILLARY TANGLES
AB Tauopathies are a group of incurable neurodegenerative diseases, in which loss of neurons is accompanied by intracellular deposition of fibrillar material composed of hyperphosphorylated forms of the microtubule-associated protein Tau. A zebrafish model of Tauopathy could complement existing murine models by providing a platform for genetic and chemical screens, in order to identify novel therapeutic targets and compounds with disease-modifying potential. In addition, Tauopathy zebrafish would be useful for hypothesis-driven experiments, especially those exploiting the potential to deploy in vivo imaging modalities. Several considerations, including conservation of specialized neuronal and other cellular populations, and biochemical pathways implicated in disease pathogenesis, suggest that the zebrafish brain is an appropriate setting in which to model these complex disorders. Novel transgenic zebrafish lines expressing wild-type and mutant forms of human Tau in CNS neurons have recently been reported. These studies show evidence that human Tau undergoes disease-relevant changes in zebrafish neurons, including somato-dendritic relocalization, hyperphosphorylation and aggregation. In addition, preliminary evidence suggests that Tau transgene expression can precipitate neuronal dysfunction and death. These initial studies are encouraging that the zebrafish holds considerable promise as a model in which to study Tauopathies. Further studies are necessary to clarify the phenotypes of transgenic lines and to develop assays and models suitable for unbiased high-throughput screening approaches. This article is part of a Special Issue entitled Zebrafish Models of Neurological Diseases. Published by Elsevier B.V.
C1 [Bai, Qing; Burton, Edward A.] Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15260 USA.
[Bai, Qing; Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA.
[Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA.
[Burton, Edward A.] Univ Pittsburgh, Med Ctr, Div Movement Disorders, Pittsburgh, PA 15260 USA.
[Burton, Edward A.] VA Pittsburgh Healthcare Syst, Dept Neurol, Pittsburgh, PA USA.
[Burton, Edward A.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Burton, EA (reprint author), 7015 BST-3 3501 5th Ave, Pittsburgh, PA 15217 USA.
EM eab25@pitt.edu
OI Burton, Edward/0000-0002-8072-4636
FU CurePSP - The Society for Progressive Supranuclear Palsy [441-05,
468-08]; NINDS [NS058369]
FX We gratefully acknowledge research grant support from CurePSP - The
Society for Progressive Supranuclear Palsy (grants #441-05 and #468-08)
and NINDS (NS058369).
NR 127
TC 5
Z9 5
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD MAR
PY 2011
VL 1812
IS 3
BP 353
EP 363
DI 10.1016/j.bbadis.2010.09.004
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 725CZ
UT WOS:000287624100010
PM 20849952
ER
PT J
AU Qin, GS
Jin, XP
Zhou, XH
AF Qin, Gengsheng
Jin, Xiaoping
Zhou, Xiao-Hua
TI Non-parametric interval estimation for the partial area under the ROC
curve
SO CANADIAN JOURNAL OF STATISTICS-REVUE CANADIENNE DE STATISTIQUE
LA English
DT Article
DE AUC; diagnostic test; partial AUC; ROC curve
ID EMPIRICAL LIKELIHOOD; DIAGNOSTIC-TESTS; METHODOLOGY; REGRESSION
AB Accurate diagnosis of disease is a critical part of health care. New diagnostic and screening tests must be evaluated based on their abilities to discriminate diseased conditions from non-diseased conditions. For a continuous-scale diagnostic test, a popular summary index of the receiver operating characteristic (ROC) curve is the area under the curve (AUC). However, when our focus is on a certain region of false positive rates, we often use the partial AUC instead. In this paper we have derived the asymptotic normal distribution for the non-parametric estimator of the partial AUC with an explicit variance formula. The empirical likelihood (EL) ratio for the partial AUC is defined and it is shown that its limiting distribution is a scaled chi-square distribution. Hybrid bootstrap and EL confidence intervals for the partial AUC are proposed by using the newly developed EL theory. We also conduct extensive simulation studies to compare the relative performance of the proposed intervals and existing intervals for the partial AUC. A real example is used to illustrate the application of the recommended intervals. The Canadian Journal of Statistics 39: 17-33; 2011 (C) 2011 Statistical Society of Canada
C1 [Qin, Gengsheng; Jin, Xiaoping] Georgia State Univ, Dept Math & Stat, Atlanta, GA 30302 USA.
[Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98101 USA.
[Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Qin, GS (reprint author), Georgia State Univ, Dept Math & Stat, Atlanta, GA 30302 USA.
EM gqin@gsu.edu
FU NSF [DMS 0603913]
FX This work is supported in part by NSF DMS 0603913. We would like to
thank the editor, associate editor, and referees for their valuable
comments which led to substantial improvements in this paper.
NR 18
TC 2
Z9 2
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0319-5724
J9 CAN J STAT
JI Can. J. Stat.-Rev. Can. Stat.
PD MAR
PY 2011
VL 39
IS 1
BP 17
EP 33
DI 10.1002/cjs.10093
PG 17
WC Statistics & Probability
SC Mathematics
GA 727GQ
UT WOS:000287786500002
ER
PT J
AU Horesh, Y
Katsel, P
Haroutunian, V
Domany, E
AF Horesh, Y.
Katsel, P.
Haroutunian, V.
Domany, E.
TI Gene expression signature is shared by patients with Alzheimer's disease
and schizophrenia at the superior temporal gyrus
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE autophagy; Alzheimer's disease; Schizophrenia; Brodmann area 22;
superior temporal gyrus; neurodegenerative diseases
ID MULTIPLE BRAIN-REGIONS; AUTOPHAGY; PROTEIN; ASSOCIATION; POSTMORTEM;
MECHANISMS; PATHOLOGY; DEMENTIA; HOMOLOG
AB Background: Alzheimer's disease and Schizophrenia are two common diseases of the brain with significant differences in neuropathology, etiology and symptoms. This dissimilarity in the two diseases makes a comparison of the two ideal for detecting molecular substrates that are common to brain disorders in general.
Methods: In this study, we compared gene expression profiles across multiple brain areas, taken postmortem from patients with well-characterized Alzheimer's disease and Schizophrenia, and from cognitively normal control group with no neuro-or psychopathology.
Results: Although the totality of gene expression changes in the two diseases is dissimilar, a subset of genes appears to play a role in both diseases in specific brain regions. We find at Brodmann area 22, the superior temporal gyrus, a statistically significant number of genes with apparently disregulated expression in both diseases. Furthermore, we found genes that differentiate the two diseases from the control across multiple brain regions, and note that these genes were usually down-regulated. Brodmann area 8, part of the superior frontal cortex, is relatively abundant with them.
Conclusion: We show overwhelming statistical evidence for Alzheimer's and Schizophrenia sharing a specific molecular background at the superior temporal gyrus. We suggest that impairment of the regulation of autophagy pathway is shared, in BA 22, by the two diseases.
C1 [Horesh, Y.; Domany, E.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel.
[Katsel, P.; Haroutunian, V.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Haroutunian, V.] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA.
RP Domany, E (reprint author), Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel.
EM vahram.har-outunian@mssm.edu; eytan.domany@weiz-mann.ac.il
RI DOMANY, EYTAN/K-1560-2012
FU Leir Charitable Foundation; Veterans Administration; [MH066392];
[MH064673]
FX This research was supported by a grant from the Leir Charitable
Foundation (ED, YH) and MH066392, MH064673 and Veterans Administration
Merit and MIRECC programs (VH). We thank Edna Schechtman for statistical
advice, and Adi Kimchi for sharing her knowledge of the autophagy
pathway.
NR 40
TC 14
Z9 14
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD MAR
PY 2011
VL 18
IS 3
BP 410
EP 424
DI 10.1111/j.1468-1331.2010.03166.x
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 722RB
UT WOS:000287450900010
PM 20695885
ER
PT J
AU Gocke, SP
Rottier, FJ
Havey, RM
Renner, SM
Patwardhan, AG
Carandang, G
AF Gocke, Sean P.
Rottier, Francis J.
Havey, Robert M.
Renner, Susan M.
Patwardhan, Avinash G.
Carandang, Gerard
TI Quantitative Analysis of the Long- and Short-arm Crescentic Shelf
Bunionectomy Osteotomies in Fresh Cadaveric Matched Pair Specimens
SO JOURNAL OF FOOT & ANKLE SURGERY
LA English
DT Article
DE basilar crescentic osteotomy; bunionectomy; crescentic shelf osteotomy
ID PROXIMAL METATARSAL OSTEOTOMY; HALLUX-VALGUS CORRECTION; 1ST RAY
MOBILITY; FIXATION; STIFFNESS; STRENGTH
AB Two variations of crescentic shelf osteotomies have been described for the treatment of moderate to severe hallux abductovalgus: a short arm and a long arm. This study tested the hypothesis that the short-arm osteotomy will have a greater moment to failure and angular stiffness than the long arm. Eighteen first metatarsal specimens were dissected from 9 matched pairs of fresh frozen cadaveric specimens. One metatarsal from each pair received a short-arm osteotomy, whereas the other received a long-arm osteotomy. Each osteotomy was fixed with 2 screws. The short arm was fixed with 1 oblique screw and 1 dorsal-to-plantar screw. The long arm was fixed with 2 dorsal-to-plantar screws: 1 at the proximal aspect and 1 at the distal aspect of the shelf. Each specimen was loaded in a materials testing machine to measure moment to failure and angular stiffness. The base of the first metatarsal was potted and load applied to the plantar aspect of the metatarsal head at a constant rate until failure of the osteotomy. The mean maximum moment to failure of the short arm was significantly greater than the long arm (2.04 +/- 0.96 Newton meter [Nm] vs. 1.48 +/- 0.67 Nm, P = .03). The mean angular stiffness was significantly greater for short arm versus long arm (23.8 +/- 19.11 Nm/radian vs. 0.98 +/- 9.08 Nm/radian, P = .01). We report statistically significant data supporting the short-arm crescentic shelf osteotomy to have a greater moment to failure and angular stiffness compared with the long-arm crescentic shelf osteotomy. (C) 2011 by the American College of Foot and Ankle Surgeons. All rights reserved.
C1 [Gocke, Sean P.] Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maguire Ctr, Maywood, IL 60153 USA.
[Havey, Robert M.; Renner, Susan M.; Patwardhan, Avinash G.; Carandang, Gerard] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Musculoskeletal Biomech Lab, Hines, IL 60141 USA.
RP Gocke, SP (reprint author), Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maguire Ctr, 3rd Year Resident PM&S 36,Suite 1700,2160 S 1st A, Maywood, IL 60153 USA.
EM seannddpm@ameritech.net
NR 27
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1067-2516
J9 J FOOT ANKLE SURG
JI J. Foot Ankle Surg.
PD MAR-APR
PY 2011
VL 50
IS 2
BP 158
EP 164
DI 10.1053/j.jfas.2010.12.006
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 726NR
UT WOS:000287730300006
PM 21353999
ER
PT J
AU Lotrich, FE
Loftis, JM
Ferrell, RE
Rabinovitz, M
Hauser, P
AF Lotrich, Francis E.
Loftis, Jennifer M.
Ferrell, Robert E.
Rabinovitz, Mordechai
Hauser, Peter
TI IL28B Polymorphism Is Associated with Both Side Effects and Clearance of
Hepatitis C During Interferon-Alpha Therapy
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID VIRAL CLEARANCE; VIROLOGICAL RESPONSE; DEPRESSIVE SYMPTOMS; RIBAVIRIN
THERAPY; PLUS RIBAVIRIN; RECEPTOR GENE; MANAGEMENT; TRIAL
AB Interferon-alpha (IFN-alpha) treatment for hepatitis C virus (HCV) is complicated by depression and related neurovegetative side effects. Recent genome-wide scans identified IL28B gene polymorphisms that associated with HCV clearance. Whether the IL28B polymorphism is also associated with these adverse effects of IFN-alpha would affect its clinical usefulness. One hundred thirty-three patients were prospectively examined using the Beck Depression Inventory-II and a Structured Clinical Interview for Diagnostic and Statistical Manual-IV (DSM-IV) during IFN-alpha treatment. The candidate C/T single-nucleotide polymorphism upstream from IL28B (rs1297860) was genotyped and assessed for association with individual items from the Beck Depression Inventory-II. We confirmed that the IL28B polymorphism was associated with differences in sustained viral response (F = 3.38; P < 0.05), with the T/T genotype faring worst. However, the T/T genotype was associated with less appetite (P < 0.05), energy (P < 0.05), and sleep complaints (P < 0.05) during treatment. Only 3.1% of patients with T/T developed major appetite complaints, whereas 10.1% and 8.9% of those with the C/T and C/C genotype did, respectively. Only 10.8% of patients with T/T developed major sleep complaints, whereas 16.1% and 20.7% of those with the C/T and C/C genotype did. However, IL28B genotype did not predict development of major depressive disorder (chi(2) = 0.12; P = 0.94). The allele (C) was associated with both better viral clearance and more subjective appetite, energy, and sleep complaints. This has implications for the management of patients with HCV. If genotyping is used to better target therapy, this may co-enrich the population for likelihood of also suffering from these side effects.
C1 [Lotrich, Francis E.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
[Ferrell, Robert E.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USA.
[Rabinovitz, Mordechai] Univ Pittsburgh, Div Gastroenterol & Hepatol, Pittsburgh, PA 15213 USA.
[Hauser, Peter] VISN 22 Network Off, Long Beach, CA USA.
[Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Dept Psychiat, Res & Dev Serv, Portland, OR 97201 USA.
RP Lotrich, FE (reprint author), Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, 3811 Ohara St, Pittsburgh, PA 15213 USA.
EM lotrichfe@upmc.edu
FU NIMH [K23MH074012]; VA [08-1904]
FX This study was funded by NIMH K23MH074012 (to F.E.L.) and VA#08-1904 (to
P.H.).
NR 31
TC 17
Z9 17
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1079-9907
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD MAR
PY 2011
VL 31
IS 3
BP 331
EP 336
DI 10.1089/jir.2010.0074
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 727KY
UT WOS:000287799700006
PM 21133812
ER
PT J
AU Kang, GA
Heath, S
Rothlind, J
Starr, PA
AF Kang, Gail A.
Heath, Susan
Rothlind, Johannes
Starr, Philip A.
TI Long-term follow-up of pallidal deep brain stimulation in two cases of
Huntington's disease
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID PRIMARY GENERALIZED DYSTONIA; GLOBUS-PALLIDUS; SUBTHALAMIC NUCLEUS;
PARKINSONS-DISEASE; TECHNICAL APPROACH; IMPLANTATION; LOCATIONS;
INTERNUS
AB Background Deep brain stimulator (DBS) implantation has been shown to be effective in the treatment of various movement disorders including Parkinson's disease, essential tremor and dystonia. However, there is limited information regarding the potential use of DBS in Huntington's disease (HD). In this study, the authors present their findings on the long-term motor and neurocognitive results of two HD patients (patient 1: 57 years, 42 cytosine-adenine guanine (CAG) repeats; patient 2: 50 years, 41 CAG repeats) who underwent staged bilateral globus pallidus interna DBS surgery.
Methods The patients were evaluated at baseline and at five timepoints throughout a 2-year postoperative during which motoric ratings ((Unified Huntington's Disease Rating Scale), Activities of Daily Living scores (HD-ADL) and neurocognitive testing) were obtained.
Results Both patients had a sustained decline in chorea 2 years after initial DBS surgery. Despite this improvement in chorea, one patient has had continuing deterioration in gait, bradykinesia and dystonia scores, which has caused his ability to perform activities of daily living to return to his baseline level of functioning prior to DBS surgery. Both patients have experienced further gradual decline in neurocognitive functioning, which appears to be independent of DBS and most likely related to disease progression.
Conclusion DBS implantation may be a potential treatment option for a subset of HD patients who have significant functional deficits due to chorea. However, appropriate selection of the best candidates for DBS appears to be challenging, given the difficulty in predicting disease course in HD due to its variable nature.
C1 [Kang, Gail A.; Heath, Susan; Starr, Philip A.] Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[Kang, Gail A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Rothlind, Johannes] San Francisco VA Med Ctr, Dept Mental Hlth Serv, San Francisco, CA USA.
[Starr, Philip A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
RP Kang, GA (reprint author), Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, 4150 Clement St 127P, San Francisco, CA 94121 USA.
EM gakang@comcast.net
FU Parkinson's Disease Research Education Clinical Center
FX Parkinson's Disease Research Education Clinical Center
NR 32
TC 30
Z9 30
U1 1
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD MAR
PY 2011
VL 82
IS 3
BP 272
EP 277
DI 10.1136/jnnp.2009.202903
PG 6
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 721KK
UT WOS:000287351900009
PM 20974647
ER
PT J
AU Prieto-Jimenez, CA
Cardenas, VM
Fischbach, LA
Mulla, ZD
Rivera, JO
Dominguez, DC
Graham, DY
Ortiz, M
AF Prieto-Jimenez, Carmen A.
Cardenas, Victor M.
Fischbach, Lori A.
Mulla, Zuber D.
Rivera, Jose O.
Dominguez, Delfina C.
Graham, David Y.
Ortiz, Melchor
TI Double-blind Randomized Trial of Quadruple Sequential Helicobacter
pylori Eradication Therapy in Asymptomatic Infected Children in El Paso,
Texas
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE child; drug therapy; Helicobacter infections; preschool; United States
ID UNITED-STATES; TRIPLE THERAPY; BREATH TEST; METAANALYSIS; EFFICACY;
CARE; RESIDENTS; PURCHASE; MEXICO; BORDER
AB Objectives: We assessed the efficacy of a novel quadruple sequential 10-day eradication therapy, its compliance, and reported adverse events in a sample of asymptomatically Helicobacter pylori-infected children in El Paso, Texas, as part of a study aiming to assess the influence of this infection on the levels of markers of iron stores.
Patients and Methods: Using a double-blind randomized trial design, 110 asymptomatic children ages 3 to 11 with H pylori infection were randomly assigned to receive either a 10-day course of sequential eradication therapy plus 6 weeks of iron supplementation, eradication therapy plus placebo, iron supplementation plus placebo, or placebo only. H pylori infection status was assessed >= 45 days after treatment using the urea breath test. Analyses compared the proportion of subjects cured according to assignment to and completion of the sequential eradication therapy.
Results: Intent-to-treat and per-protocol analyses indicated that 44.3% and 52.9%, respectively, of the children receiving the novel quadruple sequential therapy had their infection eradicated compared with 12.2% and 15.4% in the arms receiving iron or placebo only, respectively (P < 0.001 in both analyses). Study medications were taken with no or only mild adverse events in most children.
Conclusions: A quadruple sequential regimen eradicated H pylori in only half the asymptomatic children receiving this treatment. There was no difference in the cure rates of those receiving iron supplementation and those receiving placebo.
C1 [Prieto-Jimenez, Carmen A.] Dept Pediat, El Paso, TX USA.
[Mulla, Zuber D.] Dept Obstet & Gynecol, El Paso, TX USA.
[Ortiz, Melchor] Dept Biomed Sci, Div Biostat & Epidemiol, El Paso, TX USA.
[Cardenas, Victor M.] Houston Sch Publ Hlth, UT HSC, El Paso, TX USA.
[Fischbach, Lori A.] Univ N Texas, HSC Sch Publ Hlth, Ft Worth, TX USA.
[Rivera, Jose O.] Univ Texas El Paso, UTEP UT Austin Collaborat Pharm Program, El Paso, TX USA.
[Dominguez, Delfina C.] Univ Texas El Paso, Clin Sci Lab, Coll Hlth Sci, El Paso, TX USA.
[Graham, David Y.] Baylor Coll Med, DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Cardenas, VM (reprint author), UT Sch Publ Hlth, El Paso Reg Campus,1100 Stanton Ave,Suite 110F, El Paso, TX 79902 USA.
EM victor.cardenas@uth.tmc.edu
FU Thrasher Research Fund, Salt Lake City, UT [02823-9]; Meretek
Diagnostics; Takeda Pharmaceuticals North America, Deerfield, IL
[MA-L-185]
FX The present study was funded through an award (number 02823-9) of the
Thrasher Research Fund, Salt Lake City, UT. We received an in-kind
donation of lansoprazole (Prevacid Solutab) and its placebo (contract
MA-L-185) from Takeda Pharmaceuticals North America, Deerfield, IL.;
D.Y.G. is a member of the board of and has received funding from Meretek
Diagnostics. The other authors report no conflicts of interest.
NR 26
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD MAR
PY 2011
VL 52
IS 3
BP 319
EP 325
DI 10.1097/MPG.0b013e318206870e
PG 7
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 723AH
UT WOS:000287477100012
PM 21336156
ER
PT J
AU Cardenas, VM
Prieto-Jimenez, CA
Mulla, ZD
Rivera, JO
Dominguez, DC
Graham, DY
Ortiz, M
AF Cardenas, Victor M.
Prieto-Jimenez, Carmen A.
Mulla, Zuber D.
Rivera, Jose O.
Dominguez, Delfina C.
Graham, David Y.
Ortiz, Melchor
TI Helicobacter pylori Eradication and Change in Markers of Iron Stores
Among Non-iron-deficient Children in El Paso, Texas: An Etiologic
Intervention Study
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE Helicobacter infections; child; ferritins/blood; iron deficiency;
preschool; United States/epidemiology
ID SERUM FERRITIN; UNITED-STATES; ANEMIA; INFECTION; POPULATION; TRIAL;
SUPPLEMENTATION; METAANALYSIS; ASSOCIATION
AB Objectives: We assessed whether Helicobacter pylori eradication was followed by changes in iron stores among non-iron-deficient children.
Materials and Methods: Double-blind randomized intervention trial on 110 asymptomatic 3-to 10-year-olds with H pylori infection assigned to any of the following 4 arms: both quadruple eradication and iron supplementation, either quadruple sequential eradication or iron supplementation, or placebo only. Hemoglobin, transferrin saturation, and serum ferritin were measured at baseline and 8 months later to assess changes according to study arm, H pylori infection status at >= 45 days, and cytotoxin-associated gene product A status.
Results: Intent-to-treat (n = 110) and per-protocol (n 90) analyses revealed no differences across study arms in changes of iron stores. However, we found that those who had their infection eradicated had a 3-fold increased average change from baseline serum ferritin compared with that of children who remained infected (P < 0.05). Eradication of infection by cytotoxin-associated gene product A negative strains was associated with a larger ferritin increase.
Conclusions: In this double-blind randomized trial, the first among non-iron-deficient, asymptomatic H pylori-infected children living in the contiguous United States, we found no effect of H pylori eradication regarding changes in iron stores. However, those who had their infection eradicated at follow-up had a significantly larger increase in serum ferritin from baseline.
C1 [Cardenas, Victor M.] Houston Sch Publ Hlth, UT HSC, Houston, TX USA.
[Prieto-Jimenez, Carmen A.; Mulla, Zuber D.; Ortiz, Melchor] TTU HSC Paul L Foster Sch Med, Dept Pediat, El Paso, TX USA.
[Mulla, Zuber D.] Dept Obstet & Gynecol, Lubbock, TX USA.
[Ortiz, Melchor] Dept Obstet & Gynecol, Lubbock, TX USA.
[Rivera, Jose O.] Dept Surg, Galveston, TX USA.
[Rivera, Jose O.; Dominguez, Delfina C.] Univ Texas El Paso, El Paso, TX USA.
[Rivera, Jose O.] UTEP UT Austin Collaborat Pharm Program, El Paso, TX USA.
[Dominguez, Delfina C.] Coll Hlth Sci, Clin Sci Lab, El Paso, TX USA.
[Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Cardenas, VM (reprint author), UT Sch Publ Hlth, El Paso Reg Campus,1100 Stanton Ave,Suite 110F, El Paso, TX 79902 USA.
EM victor.cardenas@uth.tmc.edu
RI Gough, Ethan/B-8633-2012
FU Thrasher Research Fund, Salt Lake City UT [02823-9]; Takeda
Pharmaceuticals North America, Deerfield, IL [MA-L-185]
FX The present study was funded through an award (no. 02823-9) of the
Thrasher Research Fund, Salt Lake City UT). We received an in-kind
donation of lansoprazole (Prevacid Solutab) and its placebo (contract
MA-L-185) from Takeda Pharmaceuticals North America, Deerfield, IL.;
D.Y.G. is a member of the board of and has received funding from Meretek
NR 35
TC 19
Z9 20
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD MAR
PY 2011
VL 52
IS 3
BP 326
EP 332
DI 10.1097/MPG.0b013e3182054123
PG 7
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 723AH
UT WOS:000287477100013
PM 21336159
ER
PT J
AU Shahlaie, K
Larson, PS
Starr, PA
AF Shahlaie, Kiarash
Larson, Paul S.
Starr, Philip A.
TI Intraoperative Computed Tomography for Deep Brain Stimulation Surgery:
Technique and Accuracy Assessment
SO NEUROSURGERY
LA English
DT Article
DE Computed tomography; Deep brain stimulation; Intraoperative imaging;
Lead location; Neuronavigation
ID GLOBUS-PALLIDUS INTERNUS; SUBTHALAMIC NUCLEUS; ELECTRODE PLACEMENT;
PARKINSONS-DISEASE; IMPLANTATION; LOCALIZATION; MRI; CANCER; SHIFT;
EXPERIENCE
AB BACKGROUND: The efficacy of deep brain stimulation (DBS) is highly dependent on the accuracy of lead placement.
OBJECTIVE: To describe the use of intraoperative computed tomography (iCT) to confirm lead location before surgical closure and to study the accuracy of this technique.
METHODS: Fifteen patients underwent awake microelectrode-guided DBS surgery in a stereotactic frame. A portable iCT scanner (Medtronic O-arm) was positioned around the patient's head throughout the procedure and was used to confirm lead location before fixation of the lead to the skull. Images were computationally fused with preoperative magnetic resonance imaging (MRI), and lead tip coordinates with respect to the midpoint of the anterior commissure-posterior commissure line were measured. Tip coordinates were compared with those obtained from postoperative MRI.
RESULTS: iCT was integrated into standard frame-based microelectrode-guided DBS surgery with a minimal increase in surgical time or complexity. Technically adequate 2-dimensional and 3-dimensional images were obtained in all cases. Head positioning and fixation techniques that allow unobstructed imaging are described. Lead tip measurements on iCT fused with preoperative MRI were statistically indistinguishable from those obtained with postoperative MRI.
CONCLUSION: iCT can be easily incorporated into standard DBS surgery, replaces the need for C-arm fluoroscopy, and provides accurate intraoperative 3-dimensional confirmation of electrode tip locations relative to preoperative images and surgical plans. iCT fused to preoperative MRI may obviate the need for routine postoperative MRI in DBS surgery. Technical nuances that must be mastered for the efficient use of iCT during DBS implantation are described.
C1 [Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA USA.
RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,Box 0445, San Francisco, CA 94143 USA.
EM starrp@neurosurg.ucsf.edu
NR 28
TC 35
Z9 36
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD MAR
PY 2011
VL 68
IS 3
SU 3
BP 114
EP 124
DI 10.1227/NEU.0b013e31820781bc
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 726OR
UT WOS:000287734500017
PM 21206322
ER
PT J
AU Bokhari, MB
Patel, CB
Ramos-Valadez, DI
Ragupathi, M
Haas, EM
AF Bokhari, Malak B.
Patel, Chirag B.
Ramos-Valadez, Diego I.
Ragupathi, Madhu
Haas, Eric M.
TI Learning curve for robotic-assisted laparoscopic colorectal surgery
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE Cumulative sum analysis; Learning curve; Rectosigmoid; Robotic-assisted
laparoscopic surgery
ID CANCER; CUSUM
AB Robotic-assisted laparoscopic surgery (RALS) is evolving as an important surgical approach in the field of colorectal surgery. We aimed to evaluate the learning curve for RALS procedures involving resections of the rectum and rectosigmoid.
A series of 50 consecutive RALS procedures were performed between August 2008 and September 2009. Data were entered into a retrospective database and later abstracted for analysis. The surgical procedures included abdominoperineal resection (APR), anterior rectosigmoidectomy (AR), low anterior resection (LAR), and rectopexy (RP). Demographic data and intraoperative parameters including docking time (DT), surgeon console time (SCT), and total operative time (OT) were analyzed. The learning curve was evaluated using the cumulative sum (CUSUM) method.
The procedures performed for 50 patients (54% male) included 25 AR (50%), 15 LAR (30%), 6 APR (12%), and 4 RP (8%). The mean age of the patients was 54.4 years, the mean BMI was 27.8 kg/m(2), and the median American Society of Anesthesiologists (ASA) classification was 2. The series had a mean DT of 14 min, a mean SCT of 115.1 min, and a mean OT of 246.1 min. The DT and SCT accounted for 6.3% and 46.8% of the OT, respectively. The SCT learning curve was analyzed. The CUSUM(SCT) learning curve was best modeled as a parabola, with equation CUSUM(SCT) in minutes equal to 0.73 x case number(2) - 31.54 x case number - 107.72 (R = 0.93). The learning curve consisted of three unique phases: phase 1 (the initial 15 cases), phase 2 (the middle 10 cases), and phase 3 (the subsequent cases). Phase 1 represented the initial learning curve, which spanned 15 cases. The phase 2 plateau represented increased competence with the robotic technology. Phase 3 was achieved after 25 cases and represented the mastery phase in which more challenging cases were managed.
The three phases identified with CUSUM analysis of surgeon console time represented characteristic stages of the learning curve for robotic colorectal procedures. The data suggest that the learning phase was achieved after 15 to 25 cases.
C1 [Haas, Eric M.] Univ Texas Houston, Div Minimally Invas Colon & Rectal Surg, Dept Surg, Colorectal Surg Associates Ltd LLP,Med Sch Housto, Houston, TX 77054 USA.
[Bokhari, Malak B.] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA 15240 USA.
RP Haas, EM (reprint author), Univ Texas Houston, Div Minimally Invas Colon & Rectal Surg, Dept Surg, Colorectal Surg Associates Ltd LLP,Med Sch Housto, 7900 Fannin St,Suite 2700, Houston, TX 77054 USA.
EM ehaasmd@houstoncolon.com
OI Ragupathi, Madhu/0000-0002-1371-2926
NR 14
TC 105
Z9 109
U1 2
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
J9 SURG ENDOSC
JI Surg. Endosc.
PD MAR
PY 2011
VL 25
IS 3
BP 855
EP 860
DI 10.1007/s00464-010-1281-x
PG 6
WC Surgery
SC Surgery
GA 726TU
UT WOS:000287749900027
PM 20734081
ER
PT J
AU Forquer, MR
Hashimoto, JG
Roberts, ML
Wiren, KM
AF Forquer, Melissa R.
Hashimoto, Joel G.
Roberts, Melissa L.
Wiren, Kristine M.
TI Elevated testosterone in females reveals a robust sex difference in
altered androgen levels during chronic alcohol withdrawal
SO ALCOHOL
LA English
DT Article
DE Ethanol; Androgen; Estrogen; Withdrawal; Sexually dimorphic; Abstinence
ID PITUITARY-ADRENAL AXIS; SEIZURE-RESISTANT MICE; ETHANOL WITHDRAWAL;
POSTMENOPAUSAL WOMEN; REPRODUCTIVE FUNCTION; INDUCED HYPOGONADISM;
PREMENOPAUSAL WOMEN; INDUCED CONVULSIONS; GENDER-DIFFERENCES; GONADAL
AXIS
AB The endocrine disruption associated with alcohol (ethanol) abuse in both males and females is widely recognized. Ethanol intoxication and withdrawal in males results in significant reductions in androgen levels. Less is known about female alcoholics, and because the changes in testosterone concentrations remain controversial, we systematically characterized changes in sex steroids after chronic ethanol exposure and withdrawal in both sexes. Testosterone and 17 beta-estradiol concentrations were determined during chronic high intoxication, over a withdrawal time course, and following a period of abstinence using a genetic model of withdrawal vulnerability, the Withdrawal Seizure-Resistant (WSR) and -Prone (WSP) selected lines. In males, testosterone concentrations were significantly lower in intoxicated WSP mice after chronic ethanol exposure, and were dramatically and transiently reduced during the withdrawal period in both WSR and WSP lines. In contrast, testosterone levels were increased in intoxicated WSP females and in both WSR and WSP mice during withdrawal. Chronic ethanol exposure disrupted normal estrous cycling in WSP mice, associated with hyperandrogenemia while intoxicated. In abstinence, elevated testosterone was observed in both sexes but only in WSR mice. Estrogen levels were modestly reduced during withdrawal in both WSR and WSP lines, predominantly in males. These findings identify a mechanism based on altered androgen signaling that likely contributes to sex-specific responses during withdrawal. However, only WSR mice showed similar elevations in androgen long after withdrawal in both sexes, suggesting that genotype is an important determinant of steroid responses after abstinence. Increased androgen signaling in females as a consequence of chronic ethanol exposure may play an important and relatively uncharacterized role in sexually dimorphic responses to alcohol abuse. Published by Elsevier Inc.
C1 [Forquer, Melissa R.; Hashimoto, Joel G.; Roberts, Melissa L.; Wiren, Kristine M.] Portland VA Med Ctr, Res Serv P3 R&D39, Portland, OR 97239 USA.
[Hashimoto, Joel G.; Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
RP Wiren, KM (reprint author), Portland VA Med Ctr, Res Serv P3 R&D39, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA.
EM wirenk@ohsu.edu
OI Wiren, Kristine/0000-0002-6159-4450
FU Department of Veterans Affairs; National Institute of Alcoholism and
Alcohol Abuse [R01 AA013194]
FX The authors would like to thank Dr. Deborah Finn for advice on alcohol
exposure paradigms and careful reading of the article. They also thank
Drs. John Crabbe and Pamela Metten for providing the WSP and WSR mice
and help with the chamber studies. This publication was made possible by
grants from the Department of Veterans Affairs Merit Review program (K.
M. W.) and the National Institute of Alcoholism and Alcohol Abuse R01
AA013194 (K. M. W.). All work was performed in facilities provided by
the Department of Veterans Affairs.
NR 68
TC 9
Z9 9
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-8329
J9 ALCOHOL
JI Alcohol
PD MAR
PY 2011
VL 45
IS 2
BP 161
EP 171
DI 10.1016/j.alcohol.2010.08.013
PG 11
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA 722GZ
UT WOS:000287421900007
PM 20843636
ER
PT J
AU Korcheva, VB
Levine, J
Beadling, C
Warrick, A
Countryman, G
Olson, NR
Heinrich, MC
Corless, CL
Troxell, ML
AF Korcheva, Veselina B.
Levine, Judith
Beadling, Carol
Warrick, Andrea
Countryman, Gayle
Olson, Neal R.
Heinrich, Michael C.
Corless, Christopher L.
Troxell, Megan L.
TI Immunohistochemical and Molecular Markers in Breast Phyllodes Tumors
SO APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
LA English
DT Article
DE breast; phyllodes; MDM2; TP53; phospho-H3; KIT; FBX4; cyclin D1
ID COMPARATIVE GENOMIC HYBRIDIZATION; P53 PROTEIN EXPRESSION; SPINDLE-CELL
CARCINOMA; F-BOX PROTEINS; C-KIT; FIBROEPITHELIAL LESIONS;
CYSTOSARCOMA-PHYLLODES; COPY NUMBER; MUTATIONS; FEATURES
AB Phyllodes tumors of the breast are diagnostically and managerially enigmatic, as their malignant potential is difficult to predict based on the standard morphologic criteria. Thus, there is a need for additional markers of biologic potential. Although a number of ancillary tests have been reported, consensus in the literature is lacking. We studied 38 cellular fibroadenomas and phyllodes tumors of various grade (World Health Organization benign, borderline, and malignant) with a panel of immunohistochemical stains (p53, CD117, phospho-Histone3, mdm2, cdk4) and screened 26 of the tumors for mutations across 30 cancer-related genes using PCR and mass-spectrometry based methods. p53 and phospho-Histone3 (mitotic marker) showed increased staining in higher grade phyllodes tumors. CD117, mdm2, and cdk4 showed no difference in expression across different grades of phyllodes tumors. Mutational analysis revealed an S8R substitution in FBX4 (an E3 ubiquitin ligase) in 3 cases: 1 benign and 2 borderline. The S8R substitution seems to be more common in phyllodes tumors (11.5%) as compared with other cancers. FBX4 S8R cases had high cyclin D1 expression, but this finding was not specific. Our data support earlier studies showing that p53 has potential use in pathologic assessment of phyllodes tumors, and we newly characterized phospho-Histone3 for this application. Further studies are needed to characterize the molecular pathogenesis of the phyllodes tumors, as we were unable to identify activating mutations despite screening for a large panel of activating hotspot mutations. The significance of the FBX4 substitution deserves further investigation.
C1 [Korcheva, Veselina B.; Corless, Christopher L.; Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
[Levine, Judith; Beadling, Carol; Warrick, Andrea; Countryman, Gayle; Heinrich, Michael C.; Corless, Christopher L.; Troxell, Megan L.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97239 USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Olson, Neal R.] Kaiser Permanente NW, Dept Pathol, Portland, OR USA.
[Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA.
RP Troxell, ML (reprint author), Oregon Hlth & Sci Univ, Dept Pathol, L471,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM troxellm@ohsu.edu
FU Department of Veteran's Affairs; Oregon Health & Science University
Medical Research Foundation; Sequenom, Inc.
FX Supported in part by a VA Merit Review Grant from the Department of
Veteran's Affairs (M.C.H.) and by a grant from the Oregon Health &
Science University Medical Research Foundation (M.L.T). C.L.C. has
received honoraria and research support from Sequenom, Inc.
NR 43
TC 17
Z9 17
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1062-3345
J9 APPL IMMUNOHISTO M M
JI Appl. Immunohistochem.
PD MAR
PY 2011
VL 19
IS 2
BP 119
EP 125
DI 10.1097/PAI.0b013e3181f5349a
PG 7
WC Anatomy & Morphology; Medical Laboratory Technology; Pathology
SC Anatomy & Morphology; Medical Laboratory Technology; Pathology
GA 719GO
UT WOS:000287190000006
PM 21030860
ER
PT J
AU Shin, JM
Vagin, O
Munson, K
Kidd, M
Modlin, IM
Sachs, G
AF Shin, J. M.
Vagin, O.
Munson, K.
Kidd, M.
Modlin, I. M.
Sachs, G.
TI Molecular mechanisms in therapy of acid-related diseases (vol 65, pg
264, 2008)
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Correction
C1 [Shin, J. M.; Vagin, O.; Munson, K.; Sachs, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
[Shin, J. M.; Vagin, O.; Munson, K.; Sachs, G.] VA Greater Los Angeles Healthcare Syst, W LA Med Ctr, Los Angeles, CA 90073 USA.
[Kidd, M.; Modlin, I. M.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA.
RP Sachs, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
EM gsachs@ucla.edu
NR 1
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2011
VL 68
IS 5
BP 921
EP 921
DI 10.1007/s00018-010-0621-2
PG 1
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 719WY
UT WOS:000287243400014
ER
PT J
AU Beard, JA
Bearden, A
Striker, R
AF Beard, Jeremy A.
Bearden, Allison
Striker, Rob
TI Vitamin D and the anti-viral state
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Review
DE Vitamin D; LL-37; Anti-viral; Human beta defensin 2; RTIs
ID RESPIRATORY SYNCYTIAL VIRUS; EPSTEIN-BARR-VIRUS; ACTIVE ANTIRETROVIRAL
THERAPY; ANTIMICROBIAL PEPTIDE LL-37; D-RECEPTOR POLYMORPHISMS;
HIV-POSITIVE PATIENTS; 1,25-DIHYDROXYVITAMIN D-3; D DEFICIENCY;
MULTIPLE-SCLEROSIS; HUMAN CATHELICIDIN
AB Vitamin D has long been recognized as essential to the skeletal system. Newer evidence suggests that it also plays a major role regulating the immune system, perhaps including immune responses to viral infection. Interventional and observational epidemiological studies provide evidence that vitamin D deficiency may confer increased risk of influenza and respiratory tract infection. Vitamin D deficiency is also prevalent among patients with HIV infection. Cell culture experiments support the thesis that vitamin D has direct anti-viral effects particularly against enveloped viruses. Though vitamin D's anti-viral mechanism has not been fully established, it may be linked to vitamin D's ability to up-regulate the anti-microbial peptides LL-37 and human beta defensin 2. Additional studies are necessary to fully elucidate the efficacy and mechanism of vitamin D as an anti-viral agent. Published by Elsevier B.V.
C1 [Beard, Jeremy A.; Bearden, Allison; Striker, Rob] Univ Wisconsin, Dept Med, Madison, WI 53706 USA.
[Bearden, Allison; Striker, Rob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Striker, R (reprint author), Univ Wisconsin, Dept Med, 1550 Linden Dr, Madison, WI 53706 USA.
EM rtstriker@wisc.edu
FU NIH [T32 GM07215]; Clinical Science Development Service of the
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development [I01CX000117]
FX This review was supported by Award Number I01CX000117 to R. S. from the
Clinical Science Development Service of the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development and the UW-Madison Molecular Biosciences Training Grant to
J.B. (NIH T32 GM07215).
NR 108
TC 68
Z9 71
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD MAR
PY 2011
VL 50
IS 3
BP 194
EP 200
DI 10.1016/j.jcv.2010.12.006
PG 7
WC Virology
SC Virology
GA 719SO
UT WOS:000287229500003
PM 21242105
ER
PT J
AU Denneson, LM
Lasarev, MR
Dickinson, KC
Dobscha, SK
AF Denneson, Lauren M.
Lasarev, Michael R.
Dickinson, Kathryn C.
Dobscha, Steven K.
TI Alcohol Consumption and Health Status in Very Old Veterans
SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
LA English
DT Article
DE alcohol; old age; mental health; physical health; veterans
ID COGNITIVE FUNCTION; PRIMARY-CARE; AUDIT-C; COMMUNITY; MORTALITY;
DEMENTIA; PREDICTORS; DECLINE; COHORT; LIGHT
AB Previous research has linked drinking with health, but has yet to address alcohol consumption and the relationship between drinking and health among very old veterans. To help fill this gap, the authors present a cross-sectional self-report study on 1105 veterans age 90 and older who completed the national Veteran's Affairs (VA) Survey of the Health Experiences of Patients (SHEP) for fiscal year (FY) 2005. Alcohol consumption was measured using Alcohol Use Disorders Identification Test scores (AUDIT-C). 1 Health status was measured using the Veterans Rand Health Survey: VR-12.(2) Among men (n = 1063), 60% were abstainers. No significant differences in mental health component (MCS; F(3,1040) - 1.80, P - .15) or physical health component (PCS; F(3,1040) - 1.48, P = .22) scores were detected across consumption categories. Among women (n = 42), 47% were abstainers. These results suggest many very old veterans abstain from alcohol and, among men, the associations between health status and drinking observed in younger groups may not be present in very old age.
C1 [Denneson, Lauren M.; Dickinson, Kathryn C.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA.
[Lasarev, Michael R.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA.
[Denneson, Lauren M.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
RP Denneson, LM (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, POB 1034,P3DEP PC, Portland, OR 97207 USA.
EM lauren.denneson@va.gov
OI Lasarev, Michael R/0000-0002-1896-2705
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [PMI 03-195, RCD 04129, REA
06-174]
FX The authors disclosed receipt of the following financial support for the
research and/or authorship of this article: the Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development Service Projects PMI 03-195, RCD 04129, and REA 06-174.
NR 31
TC 5
Z9 6
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0891-9887
J9 J GERIATR PSYCH NEUR
JI J. Geriatr. Psychiatry Neurol.
PD MAR
PY 2011
VL 24
IS 1
BP 39
EP 43
DI 10.1177/0891988710390814
PG 5
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 720SK
UT WOS:000287300600006
PM 21156988
ER
PT J
AU Cafardi, JA
Shafi, R
Athar, M
Elmets, CA
AF Cafardi, Jennifer A.
Shafi, Rubina
Athar, Mohammad
Elmets, Craig A.
TI Prospects for Skin Cancer Treatment and Prevention: The Potential
Contribution of an Engineered Virus
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Editorial Material
ID T4 ENDONUCLEASE-V; DNA-REPAIR; BASAL-CELL; DAMAGE; CARCINOGENESIS;
DERMATOLOGY
AB Nonmelanoma skin cancers are among the most common human malignancies. Although typically not lethal, they are responsible for tissue deformity and substantial morbidity, particularly in high-risk populations. Solar UVB radiation-a major etiologic factor for this kind of malignancy-produces DNA lesions such as cyclobutane pyrimidine dimers and 6-4 photoproducts in skin. These lesions are removed through nucleotide excision repair because humans lack a DNA glycosylase required to initiate base excision repair of pyrimidine-pyrimidine photoproducts but produce all the other proteins required for this process. In this issue, Johnson et al. show that a DNA glycosylase derived from Chlorella virus and engineered to enhance tissue penetration and nuclear localization can remove UVB-induced DNA lesions in a human skin equivalent model and that the protein can be incorporated into a topical formulation for the prevention and treatment of UVB-induced DNA damage. These results suggest that such an enzyme may be incorporated into regimens for the chemoprevention of skin cancers.
C1 [Cafardi, Jennifer A.; Shafi, Rubina; Athar, Mohammad; Elmets, Craig A.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Shafi, Rubina] Univ Alabama, UAB Skin Dis Res Ctr, Birmingham, AL USA.
[Athar, Mohammad] Univ Alabama, UAB Comprehens Canc Ctr, Birmingham, AL USA.
[Elmets, Craig A.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Elmets, CA (reprint author), Univ Alabama, Dept Dermatol, 1530 3rd Ave S, Birmingham, AL 35294 USA.
EM celmets@uab.edu
FU NCI NIH HHS [P30 CA013148, R01 CA138998]; NIAMS NIH HHS [P30AR050948,
P30 AR050948]; NIEHS NIH HHS [R01 ES015323]
NR 16
TC 4
Z9 4
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAR
PY 2011
VL 131
IS 3
BP 559
EP 561
DI 10.1038/jid.2010.394
PG 4
WC Dermatology
SC Dermatology
GA 719SQ
UT WOS:000287229700005
PM 21307952
ER
PT J
AU Quesada, A
Ogi, J
Schultz, J
Handforth, A
AF Quesada, Arnulfo
Ogi, Julie
Schultz, James
Handforth, Adrian
TI C-Terminal Mechano-Growth Factor Induces Heme Oxygenase-1-Mediated
Neuroprotection of SH-SY5Y Cells Via the Protein Kinase C epsilon/Nrf2
Pathway
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE Parkinson's disease; apoptosis; oxidative stress; PKC; Nrf2; HO-1
ID OXIDATIVE STRESS; PARKINSONS-DISEASE; NEURODEGENERATIVE DISEASES;
DOPAMINERGIC-NEURONS; EXPRESSION; 6-HYDROXYDOPAMINE; OXYGENASE; NRF2;
BRAIN; PI3K
AB Recently, a variant of insulin-like growth factor-1, mechano-growth factor (MGF), has been discovered whose 24-amino-acid carboxy end is protective in models of stroke, nerve injury, and amyotrophic lateral sclerosis, suggesting broad-spectrum neuroprotective properties. Moreover, we recently demonstrated in vitro and in vivo that a modified protease-resistant 24-amino-acid MGF derivative (MGF24) protects dopaminergic neurons from oxidative stress-induced apoptosis via induction of the stress response protein heme oxygenase-1. However, the underlying mechanism by which MGF24 up-regulates heme oxygenase-1 expression is unknown. In this study, we demonstrate that MGF24-induced heme oxygenase-1 up-regulation is dependent on activation of protein kinase C epsilon and NF-E2-related factor-2 (Nrf2). MGF24 induces nuclear translocation of Nrf2, and siRNA knockdown of Nrf2 or of heme oxygenase-1 prevents MGF24-induced heme oxygenase-1 up-regulation and neuroprotection of SH-SY5Y cells against 6-hydroxydopamine-induced cell death. Pharmacological inhibition of ERK, p38 MAPK, PI3K/Akt, or PKC signaling revealed that only PKC inhibition by GF109203X prevents MGF24's ability to protect against 6-hydroxydopamine-induced cell death. GF109203X also prevented MGF24-induced Nrf2 nuclear translocation and heme oxygenase-1 up-regulation. siRNA knockdown of protein kinase C epsilon blocks MGF24-induced Nfr2 nuclear translocation, heme oxygenase-1 expression, and neuroprotection. Taken together, these results demonstrate that PKC activity is needed for MGF24's activation of Nrf2, which in turn increases heme oxygenase-1 expression, a critical event in mediating MGF24's neuroprotection against 6-hydroxydopamine-induced apoptosis. Published (C) 2011 Wiley-Liss, Inc.(dagger)
C1 [Quesada, Arnulfo; Ogi, Julie; Schultz, James] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Handforth, Adrian] VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA.
[Quesada, Arnulfo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
RP Quesada, A (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, 11301 Wilshire Blvd 151, Los Angeles, CA 90073 USA.
EM arnulfo.quesada@va.gov
FU Department of Veterans Affairs
FX Contract grant sponsor: Department of Veterans Affairs (to A.Q.).
NR 56
TC 27
Z9 33
U1 1
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0360-4012
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD MAR
PY 2011
VL 89
IS 3
BP 394
EP 405
DI 10.1002/jnr.22543
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 717RG
UT WOS:000287064500012
PM 21259326
ER
PT J
AU Snarr, BS
Rowley, CP
Phan, SV
Achanti, A
Hendrix, GH
AF Snarr, Brian S.
Rowley, Christopher P.
Phan, Stephanie V.
Achanti, Anand
Hendrix, Grady H.
TI Prolonged Sinus Pauses with Hydromorphone in the Absence of Cardiac
Conduction Disease
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Article
DE bradycardia; hydromorphone; opioid receptor; sinus pause; vagal response
AB A 49-year-old male had open sigmoid colectomy with colorectal anastomosis for sigmoid diverticulitis. The patient was given patient-controlled analgesia (PCA) hydromorphone and subsequently developed bradycardia with prolonged sinus pauses up to 7.1 seconds. The pauses resolved shortly after the hydromorphone was discontinued. This is the first case report to our knowledge of reversible prolonged sinus pauses associated with the use of hydromorphone. Animal studies support a role for opioid signaling at the sinoatrial (SA) node. Hydromorphone is a potential cause of prolonged sinus pauses and should be taken into consideration when monitoring a patient on hydromorphone for pain control.
C1 [Snarr, Brian S.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Snarr, BS (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, 173 Ashley Ave,Room BSB 648,POB 250508, Charleston, SC 29425 USA.
EM snarr@musc.edu
NR 7
TC 1
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0038-4348
J9 SOUTH MED J
JI South.Med.J.
PD MAR
PY 2011
VL 104
IS 3
BP 239
EP 240
DI 10.1097/SMJ.0b013e318206f6d3
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 722ZE
UT WOS:000287473400017
PM 21297541
ER
PT J
AU Crenshaw, K
Shewchuk, RM
Qu, HY
Staton, LJ
Bigby, JA
Houston, TK
Allison, J
Estrada, CA
AF Crenshaw, Katie
Shewchuk, Richard M.
Qu, Haiyan
Staton, Lisa J.
Bigby, Judy Ann
Houston, Thomas K.
Allison, Jeroan
Estrada, Carlos A.
TI What Should We Include in a Cultural Competence Curriculum? An Emerging
Formative Evaluation Process to Foster Curriculum Development
SO ACADEMIC MEDICINE
LA English
DT Article
ID NOMINAL GROUP TECHNIQUE; WARD-ATTENDING ROUNDS; MEDICAL-EDUCATION;
HEALTH-CARE; PERSPECTIVES; JUDGMENTS; TOOL; PERCEPTIONS; ATTRIBUTES;
FACULTY
AB Purpose
To identify, prioritize, and organize components of a cultural competence curriculum to address disparities in cardiovascular disease.
Method
In 2006, four separate nominal group technique sessions were conducted with medical students, residents, community physicians, and academic physicians to generate and prioritize a list of concepts (i.e., ideas) to include in a curriculum. Afterward, 45 educators and researchers organized and prioritized the concepts using a card-sorting exercise. Multidimensional scaling (MDS) and hierarchical cluster analysis produced homogeneous groupings of related concepts and generated a cognitive map. The main outcome measures were the number of cultural competence concepts, their relative ranks, and the cognitive map.
Results
Thirty participants generated 61 concepts; 29 were identified by at least two participants. The cognitive map organized concepts into four clusters, interpreted as (1) patient's cultural background (e.g., information on cultures, habits, values), (2) provider and health care (e.g., clinical skills, awareness of one's bias, patient centeredness, professionalism), communication skills (e.g., history, stereotype avoidance, health disparities epidemiology), (3) cross-culture (e.g., idiomatic expressions, examples of effective communication), and (4) resources to manage cultural diversity (e.g., translator guides, instructions, community resources). The MDS two-dimensional solution demonstrated a good fit (stress = 0.07; R(2) = 0.97).
Conclusions
A novel, combined approach allowed stakeholders' inputs to identify and cognitively organize critical domains used to guide development of a cultural competence curriculum. Educators may use this approach to develop and organize educational content for their target audiences, especially in ill-defined areas like cultural competence.
C1 [Estrada, Carlos A.] Univ Alabama, Div Gen Internal Med, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, REAP Ctr Surg Med Acute Care Res & Transit, Deep S Ctr Effectiveness, Birmingham, AL USA.
[Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
[Crenshaw, Katie] Univ Alabama, Div Continuing Med Educ, Birmingham, AL USA.
[Shewchuk, Richard M.; Qu, Haiyan] Univ Alabama, Sch Hlth Related Profess, Hlth Serv Adm, Birmingham, AL USA.
[Staton, Lisa J.] Univ Tennessee, Coll Med Chattanooga, Chattanooga, TN USA.
[Staton, Lisa J.] Dept Internal Med, Chattanooga, TN USA.
[Bigby, Judy Ann] Commonwealth Massachusetts, Execut Off Hlth & Human Serv, Hlth & Human Serv, Boston, MA USA.
[Houston, Thomas K.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA.
[Allison, Jeroan] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
RP Estrada, CA (reprint author), Univ Alabama, Div Gen Internal Med, Birmingham Vet Affairs Med Ctr, 732 Fac Off Tower,510 20th St S, Birmingham, AL USA.
EM cestrada@uab.edu
RI liu, jing/D-9482-2012; Houston, Thomas/F-2469-2013
OI Allison, Jeroan/0000-0003-4472-2112
FU National Heart, Lung, and Blood Institute as part of the National
Consortium for Multicultural Education for Health Professionals [K07
HL081373-01]
FX This study was funded by a National Heart, Lung, and Blood Institute
(K07 HL081373-01) grant to Dr. Estrada as part of the National
Consortium for Multicultural Education for Health Professionals. The
funding source did not make any restrictions on the scope or reporting
of the study.
NR 46
TC 24
Z9 24
U1 5
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD MAR
PY 2011
VL 86
IS 3
BP 333
EP 341
DI 10.1097/ACM.0b013e3182087314
PG 9
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 726AZ
UT WOS:000287690700021
PM 21248602
ER
PT J
AU Huddle, TS
AF Huddle, Thomas S.
TI Perspective: Medical Professionalism and Medical Education Should Not
Involve Commitments to Political Advocacy
SO ACADEMIC MEDICINE
LA English
DT Article
ID US PHYSICIANS; SCHOLARSHIP; IGNORANCE
AB It is increasingly suggested that political advocacy is a core professional responsibility for physicians. The author argues that this is an error. Advocacy on behalf of societal goals, even those goals as unexceptionable as the betterment of human health, is inevitably political. Claims that political advocacy are a professional responsibility are mistaken, the author argues, because (1) civic virtues are outside the professional realm, (2) even if civic virtues were professionally obligatory, it is unclear that civic participation is necessary for such virtue, and (3) the profession of medicine ought not to require any particular political stance of its members. Claims that academic health centers should systematically foster advocacy are also deeply problematic. Although advocacy may coexist alongside the core university activities of research and education, insofar as it infects those activities, advocacy is likely to subvert them, as advocacy seeks change rather than knowledge. And official efforts on behalf of advocacy will undermine university aspirations to objectivity and neutrality. American society has conferred remarkable success and prosperity on its medical profession. Physicians are deserving of such success only insofar as they succeed in offering society excellence and dedication in professional work. Mandatory professional advocacy must displace such work but cannot substitute for it. The medical profession should steadfastly resist attempts to add advocacy to its essential professional commitments.
C1 [Huddle, Thomas S.] UAB Sch Med, Div Gen Internal Med, Dept Med, Birmingham, AL 35294 USA.
[Huddle, Thomas S.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Huddle, TS (reprint author), UAB Sch Med, Div Gen Internal Med, Dept Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA.
EM thuddle@uab.edu
RI liu, jing/D-9482-2012
NR 22
TC 33
Z9 33
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD MAR
PY 2011
VL 86
IS 3
BP 378
EP 383
DI 10.1097/ACM.0b013e3182086efe
PG 6
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 726AZ
UT WOS:000287690700028
PM 21248605
ER
PT J
AU Hanlon, JT
Sloane, RJ
Pieper, CF
Schmader, KE
AF Hanlon, Joseph T.
Sloane, Richard J.
Pieper, Carl F.
Schmader, Kenneth E.
TI Association of adverse drug reactions with drug-drug and drug-disease
interactions in frail older outpatients
SO AGE AND AGEING
LA English
DT Article
ID MEDICATION; APPROPRIATENESS; MANAGEMENT; EVENTS; ADULTS
C1 [Hanlon, Joseph T.] Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Sloane, Richard J.; Pieper, Carl F.; Schmader, Kenneth E.] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC USA.
[Pieper, Carl F.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
[Schmader, Kenneth E.] Duke Univ, Med Ctr, Dept Geriatr Med, Durham, NC USA.
[Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufman Med Bldg Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM jth14@pitt.edu
FU National Institutes of Health [R01-AG-15432]; Veterans Affairs
Cooperative Study Program 006; National Institute of Aging [P30AG024827,
T32 AG021885, 3U01 AG012553 K07AG033174, R01AG034056, 2R56AG027017];
National Institute of Mental Health [R34 MH082682]; National Institute
of Nursing Research [R01 NR010135]; Agency for Healthcare Research and
Quality [R01 HS017695, R01HS018721]; VA Health Services Research
[IIR-06-062]
FX This study was not funded by outside sources. The original GEM Drug
Study [8] was supported by the National Institutes of Health
[R01-AG-15432] and the Veterans Affairs Cooperative Study Program 006.
J.T.H. was supported by the following: National Institute of Aging
grants (P30AG024827, T32 AG021885, 3U01 AG012553 K07AG033174,
R01AG034056, 2R56AG027017), a National Institute of Mental Health grant
(R34 MH082682), a National Institute of Nursing Research grant (R01
NR010135), an Agency for Healthcare Research and Quality grants (R01
HS017695 and R01HS018721) and a VA Health Services Research grant
(IIR-06-062).
NR 16
TC 15
Z9 16
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
J9 AGE AGEING
JI Age Ageing
PD MAR
PY 2011
VL 40
IS 2
BP 274
EP 277
DI 10.1093/ageing/afq158
PG 4
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 723DA
UT WOS:000287485200025
PM 21177281
ER
PT J
AU Lin, JC
Karno, MP
Grella, CE
Warda, U
Liao, DH
Hu, PF
Moore, AA
AF Lin, James C.
Karno, Mitchell P.
Grella, Christine E.
Warda, Umme
Liao, Diana H.
Hu, Peifung
Moore, Alison A.
TI Alcohol, Tobacco, and Nonmedical Drug Use Disorders in US Adults Aged 65
Years and Older: Data From the 2001-2002 National Epidemiologic Survey
of Alcohol and Related Conditions
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Substance use disorder; alcohol; tobacco; nonmedical drug use
ID AT-RISK DRINKERS; DSM-IV ALCOHOL; UNITED-STATES; SUBSTANCE USE; NICOTINE
DEPENDENCE; COOCCURRING ALCOHOL; PREVALENCE; COMORBIDITY; ABUSE;
DISABILITY
AB Objectives: To examine the prevalence, sociodemographic, and health-related correlates of substance use disorders, including alcohol, tobacco, and nonmedical drug use among adults aged 65 years and older. Design: The 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions, a cross-sectional survey of a population-based sample. Setting: The United States. Participants: Eight thousand two hundred five adults aged 65 years and older. Measurements: Prevalence of lifetime and past 12-month Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, determined alcohol, tobacco, and nonmedical drug use disorders. Results: Prevalence of any substance use disorder was 21.1% during the lifetime and 5.4% in the past 12 months. Lifetime and past 12-month alcohol use disorders were 16.1% and 1.5%; tobacco use disorders were 8.7% and 4.0%; and nonmedical drug use disorders were 0.6% and 0.2%, respectively. Younger age was associated with greater odds of any lifetime or past 12-month substance use disorders. Men and those who were divorced or separated had greater odds of both lifetime alcohol and tobacco use disorders. Very good or excellent self-rated health was associated with lower odds of lifetime and past 12-month tobacco use disorders. Younger age and being divorced or separated were associated with greater odds of lifetime nonmedical drug use disorder. Conclusions: More than one in five older adults ever had a substance use disorder, and more than 1 in 20 had a disorder in the past 12 months, primarily involving alcohol or tobacco. Older adults have increased comorbidities and use of medications, which can increase risks associated with substance use. (Am J Geriatr Psychiatry 2011; 19:292-299)
C1 [Lin, James C.] VA Greater Los Angeles Healthcare Syst, Dept Geriatr Med, Special Fellowship Adv Geriatr, Los Angeles, CA USA.
[Lin, James C.; Liao, Diana H.; Hu, Peifung; Moore, Alison A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Lin, James C.] Cheng Ching Hosp, Dept Med, Taichung, Taiwan.
[Karno, Mitchell P.; Grella, Christine E.; Warda, Umme; Moore, Alison A.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Integrated Subst Abuse Programs, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
RP Lin, JC (reprint author), 11301 Wilshire Ave,Bldg 220, Los Angeles, CA 90073 USA.
EM jlin1207@ucla.edu
FU National Institute on Drug Abuse [R01DA020944]; National Institute on
Alcoholism and Alcohol Abuse [K24AA15957]; National Institute on Aging
[P30AG028748]; VA
FX This work was supported by National Institute on Drug Abuse
(R01DA020944), the National Institute on Alcoholism and Alcohol Abuse
(K24AA15957), the National Institute on Aging (P30AG028748), and VA
Special Fellowship in Advanced Geriatrics.
NR 48
TC 29
Z9 29
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAR
PY 2011
VL 19
IS 3
BP 292
EP 299
DI 10.1097/JGP.0b013e3181e898b4
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 725QE
UT WOS:000287659900013
PM 20808122
ER
PT J
AU Perry, TW
Pugh, MJV
Waterer, GW
Nakashima, B
Orihuela, CJ
Copeland, LA
Restrepo, MI
Anzueto, A
Mortensen, EM
AF Perry, Theodore W.
Pugh, Mary Jo V.
Waterer, Grant W.
Nakashima, Brandy
Orihuela, Carlos J.
Copeland, Laurel A.
Restrepo, Marcos I.
Anzueto, Antonio
Mortensen, Eric M.
TI Incidence of Cardiovascular Events After Hospital Admission for
Pneumonia
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Cardiac arrhythmia; Cardiovascular disease; Congestive heart failure;
Myocardial infarction; Pneumonia
ID COMMUNITY-ACQUIRED PNEUMONIA; ACUTE MYOCARDIAL-INFARCTION; RECENT
RESPIRATORY-INFECTION; DISEASE; RISK; ASSOCIATION; INFLUENZA; OUTCOMES;
COMPLICATION; EXPRESSION
AB OBJECTIVE: Several studies have suggested an increased risk of cardiovascular events, primarily acute myocardial infarction, around the time of hospital admission for pneumonia. Therefore, we examined cardiovascular events, including myocardial infarction, congestive heart failure, unstable angina, stroke, and serious cardiac arrhythmias, within 90 days after hospitalization for pneumonia.
METHODS: By using data from the administrative databases of the Department of Veterans Affairs, we examined a cohort of subjects hospitalized with pneumonia between October 2001 and September 2007. Subjects were at least 65 years of age. We examined the incidence of myocardial infarction, congestive heart failure, cardiac arrhythmias, unstable angina, and stroke by International Classification of Diseases, Ninth Revision codes, excluding those with a diagnosis before the admission for pneumonia.
RESULTS: The cohort comprised 50,119 subjects with a mean age of 77.5 years (standard deviation 6.7 years), 98% of whom were male. The 90-day incidence of cardiovascular events was 1.5% for myocardial infarction, 10.2% for congestive heart failure, 9.5% for arrhythmia, 0.8% for unstable angina, and 0.2% for stroke. The majority of events occurred during the hospitalization for pneumonia.
CONCLUSION: A clinically important number of subjects in this cohort had a cardiovascular event within 90 days of hospital admission, suggesting that such events may have an important role in post-pneumonia mortality. Additional research is needed to determine whether interventions may reduce the number of cardiovascular events after pneumonia. Published by Elsevier Inc. . The American Journal of Medicine (2011) 124, 244-251
C1 [Perry, Theodore W.; Nakashima, Brandy; Copeland, Laurel A.; Restrepo, Marcos I.; Anzueto, Antonio; Mortensen, Eric M.] VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Internal Med, Dept Med, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Orihuela, Carlos J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Waterer, Grant W.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
[Waterer, Grant W.] Northwestern Univ, Evanston, IL USA.
RP Mortensen, EM (reprint author), VERDICT Res Program 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM mortensene@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563;
Copeland, Laurel/0000-0002-9478-0209
FU National Institute of Nursing Research [R01NR010828]; Department of
Veteran Affairs Veterans Integrated Service Network [17]; National
Health Institutes [KL2 RR025766]
FX The project described was supported by Grant R01NR010828 from the
National Institute of Nursing Research. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institute of Nursing Research or the
National Institutes of Health. This material is the result of work
supported with resources and the use of facilities at the South Texas
Veterans Health Care System. Dr Restrepo is supported by a Department of
Veteran Affairs Veterans Integrated Service Network 17 new faculty grant
and National Health Institutes Grant KL2 RR025766. The funding agencies
had no role in conducting the study or in the preparation, review, or
approval of the manuscript. The views expressed in this article are
those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs.
NR 37
TC 35
Z9 37
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD MAR
PY 2011
VL 124
IS 3
BP 244
EP 251
DI 10.1016/j.amjmed.2010.11.014
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 732QM
UT WOS:000288203700020
PM 21396508
ER
PT J
AU Bunni, MA
Kramarenko, II
Walker, L
Raymond, JR
Garnovskaya, MN
AF Bunni, Marlene A.
Kramarenko, Inga I.
Walker, Linda
Raymond, John R.
Garnovskaya, Maria N.
TI Role of integrins in angiotensin II-induced proliferation of vascular
smooth muscle cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE G protein-coupled receptors; signal transduction; extracellular
signal-regulated protein kinase 1 and 2
ID ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; RECEPTOR ANTAGONIST;
ADHESION RECEPTORS; FOCAL ADHESIONS; BALLOON INJURY; EGF RECEPTOR;
ALPHA(V)BETA(3); HYPERTROPHY; EXPRESSION
AB Bunni MA, Kramarenko II, Walker L, Raymond JR, Garnovskaya MN. Role of integrins in angiotensin II-induced proliferation of vascular smooth muscle cells. Am J Physiol Cell Physiol 300: C647-C656, 2011. First published December 9, 2010; doi: 10.1152/ajpcell.00179.2010.-Angiotensin II (AII) binds to G protein-coupled receptor AT(1) and stimulates extracellular signal-regulated kinase (ERK), leading to vascular smooth muscle cells (VSMC) proliferation. Proliferation of mammalian cells is tightly regulated by adhesion to the extracellular matrix, which occurs via integrins. To study cross-talk between G protein-coupled receptor-and integrin-induced signaling, we hypothesized that integrins are involved in AII-induced proliferation of VSMC. Using Oligo GEArray and quantitative RT-PCR, we established that messages for alpha(1)-, alpha(5)-, alpha(V)-, and beta(1)-integrins are predominant in VSMC. VSMC were cultured on plastic dishes or on plates coated with either extracellular matrix or poly-D-lysine (which promotes electrostatic cell attachment independent of integrins). AII significantly induced proliferation in VSMC grown on collagen I or fibronectin, and this effect was blocked by the ERK inhibitor PD-98059, suggesting that AII-induced proliferation requires ERK activity. VSMC grown on collagen I or on fibronectin demonstrated approximately three-and approximately sixfold increases in ERK phosphorylation after stimulation with 100 nM AII, respectively, whereas VSMC grown on poly-D-lysine demonstrated no significant ERK activation, supporting the importance of integrin-mediated adhesion. AII-induced ERK activation was reduced by > 65% by synthetic peptides containing an RGD (arginine-glycine-aspartic acid) sequence that inhibit alpha(5)beta(1)-integrin, and by similar to 60% by the KTS (lysine-threonine-serine)-containing peptides specific for integrin-alpha(1)beta(1). Furthermore, neutralizing antibody against beta(1)-integrin and silencing of alpha(1), alpha(5), and beta(1) expression by transfecting VSMC with short interfering RNAs resulted in decreased AII-induced ERK activation. This work demonstrates roles for specific integrins (most likely alpha(5)beta(1) and alpha(1)beta(1)) in AII-induced proliferation of VSMC.
C1 Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA.
Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA.
RP Garnovskaya, MN (reprint author), Med Univ S Carolina, Dept Med Nephrol, 96 Jonathan Lucas St,MSC 629, Charleston, SC 29425 USA.
EM garnovsk@musc.edu
FU Department of Veterans Affairs Basic Laboratory RD Service; American
Heart Association [GIA 0655445U]; National Institutes of Health
[DK52448, GM63909]; Medical University of South Carolina Division of
Nephrology; Dialysis Clinics, Inc.
FX This work was supported by grants from the Department of Veterans
Affairs Basic Laboratory R&D Service (Merit Awards and a Research
Enhancement Award Program Award to M. N. Garnovskaya and J. R. Raymond),
American Heart Association (GIA 0655445U to M. N. Garnovskaya), the
National Institutes of Health (DK52448 and GM63909 to J. R. Raymond),
and a laboratory endowment jointly supported by the Medical University
of South Carolina Division of Nephrology and Dialysis Clinics, Inc. (J.
R. Raymond).
NR 41
TC 8
Z9 8
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD MAR
PY 2011
VL 300
IS 3
BP C647
EP C656
DI 10.1152/ajpcell.00179.2010
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 727MI
UT WOS:000287803800027
PM 21148411
ER
PT J
AU David, V
Martin, A
Hedge, AM
Drezner, MK
Rowe, PSN
AF David, Valentin
Martin, Aline
Hedge, Anne-Marie
Drezner, Marc K.
Rowe, Peter S. N.
TI ASARM peptides: PHEX-dependent and -independent regulation of serum
phosphate
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE matrix extracellular phosphoglycoprotein; dentin matrix protein-1;
mineralization; osteomalacia; SIBLING proteins; fibroblast growth factor
23; X-linked hypophosphatemic rickets; 1,25 dihydroxy vitamin D3
ID MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; LINKED GLYCOPROTEINS SIBLINGS;
HUMAN OSTEOBLAST CELLS; BRUSH-BORDER; PHOSPHORYLATED OSTEOPONTIN;
PHOSPHONOCARBOXYLIC ACIDS; HYPOPHOSPHATEMIC RICKETS; PHOSPHONOFORMIC
ACID; BONE SIALOPROTEIN; KNOCKOUT MICE
AB David V, Martin A, Hedge A-M, Drezner MK, Rowe PS. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol 300: F783-F791, 2011. First published December 22, 2010; doi:10.1152/ajprenal.00304.2010.-Increased acidic serine aspartate-rich MEPE-associated motif (ASARM) peptides cause mineralization defects in X-linked hypophosphatemic rickets mice (HYP) and "directly" inhibit renal phosphate uptake in vitro. However, ASARM peptides also bind to phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) and are a physiological substrate for this bone-expressed, phosphate-regulating enzyme. We therefore tested the hypothesis that circulating ASARM peptides also "indirectly" contribute to a bone-renal PHEX-dependent hypophosphatemia in normal mice. Male mice (n = 5; 12 wk) were fed for 8 wk with a normal phosphorus and vitamin D(3) diet (1% P(i) diet) or a reduced phosphorus and vitamin D(3) diet (0.1% P(i) diet). For the final 4 wk, transplantation of mini-osmotic pumps supplied a continuous infusion of either ASARM peptide (5 mg.day(-1).kg(-1)) or vehicle. HYP, autosomal recessive hypophosphatemic rickets (ARHR), and normal mice (no pumps or ASARM infusion; 0.4% P(i) diet) were used in a separate experiment designed to measure and compare circulating ASARM peptides in disease and health. ASARM treatment decreased serum phosphate concentration and renal phosphate cotransporter (NPT2A) mRNA with the 1% P(i) diet. This was accompanied by a twofold increase in serum ASARM and 1,25-dihydroxy vitamin D(3) [1,25 (OH)(2)D(3)] levels without changes in parathyroid hormone. For both diets, ASARM-treated mice showed significant increases in serum fibroblast growth factor 23 (FGF23; +50%) and reduced serum osteocalcin (-30%) and osteopontin (-25%). Circulating ASARM peptides showed a significant inverse correlation with serum P(i) and a significant positive correlation with fractional excretion of phosphate. We conclude that constitutive overexpression of ASARM peptides plays a "component" PHEX-independent part in the HYP and ARHR hypophosphatemia. In contrast, with wild-type mice, ASARM peptides likely play a bone PHEX-dependent role in renal phosphate regulation and FGF23 expression. They may also coordinate FGF23 expression by competitively modulating PHEX/DMP1 interactions and thus bone-renal mineral regulation.
C1 [Rowe, Peter S. N.] Univ Kansas, Dept Internal Med, Div Nephrol & Hypertens, Kidney Inst,Med Ctr, Kansas City, KS 66160 USA.
[David, Valentin; Martin, Aline] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.
[Drezner, Marc K.] Univ Wisconsin, Dept Med, Madison, WI USA.
[Drezner, Marc K.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53792 USA.
RP Rowe, PSN (reprint author), Univ Kansas, Dept Internal Med, Div Nephrol & Hypertens, Kidney Inst,Med Ctr, MS 3018,3901 Rainbow Blvd, Kansas City, KS 66160 USA.
EM prowe@kumc.edu
FU National Institutes of Health (National Institute of Arthritis and
Musculoskeletal and Skin Diseases) [RO-1-AR51598-01, R01-AR-27032-26,
1K12-RR-017614, R01-SK-65830-1, M01-RR-03186-21]
FX We thank the National Institutes of Health (National Institute of
Arthritis and Musculoskeletal and Skin Diseases) for grant support to P.
S. N. Rowe (Grant RO-1-AR51598-01) and M. K. Drezner (Grants
R01-AR-27032-26, 1K12-RR-017614, R01-SK-65830-1, and M01-RR-03186-21).
NR 65
TC 30
Z9 30
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD MAR
PY 2011
VL 300
IS 3
BP F783
EP F791
DI 10.1152/ajprenal.00304.2010
PG 9
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 730ZS
UT WOS:000288076700024
PM 21177780
ER
PT J
AU Xiang, M
Yin, LH
Li, YH
Xiao, GZ
Vodovotz, Y
Billiar, TR
Wilson, MA
Fan, J
AF Xiang, Meng
Yin, Lianhua
Li, Yuehua
Xiao, Guozhi
Vodovotz, Yoram
Billiar, Timothy R.
Wilson, Mark A.
Fan, Jie
TI Hemorrhagic Shock Activates Lung Endothelial Reduced Nicotinamide
Adenine Dinucleotide Phosphate (NADPH) Oxidase Via Neutrophil NADPH
Oxidase
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE High mobility group box 1 (HMGB1); inflammation; lung; oxidants;
Toll-like receptor
ID OXYGEN SPECIES PRODUCTION; GLYCATION END-PRODUCTS;
TUMOR-NECROSIS-FACTOR; TLR2 UP-REGULATION; NAD(P)H OXIDASE;
CONFORMATIONAL-CHANGES; ALVEOLAR MACROPHAGES; LIVER ISCHEMIA;
ANGIOTENSIN-II; CUTTING EDGE
AB The vascular endothelium plays an important role in the regulation of inflammatory responses after trauma and hemorrhage. Interactions of neutrophils with endothelial cells (ECs) contribute to the activation of specific EC responses involved in innate immunity. We have previously reported that oxidants derived from the neutrophil reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a critical regulator to EC activation. Our objective was to test the role of neutrophil NADPH oxidase-derived oxidants in mediating and enhancing hemorrhagic shock (HS)-induced activation of lung endothelial NADPH oxidase. Mice were subjected to HS and neutrophil depletion. The mice were also replenished with the neutrophil from NADPH oxidase-deficient mice. The resultant activation of lung NADPH oxidase was analyzed. The in vivo studies were also recapitulated with in vitro neutrophil-EC coculture system. HS induces NADPH oxidase activation in neutrophils and lung through high-mobility group box 1/Toll-like receptor 4-dependent signaling. In neutropenic mice, shock-induced NADPH oxidase activation in the lung was reduced significantly, but was restored upon repletion with neutrophils obtained from wild-type mice subjected to shock, but not with neutrophils from shock mice lacking the gp91(phox) subunit of NADPH oxidase. The findings were recapitulated in mouse lung vascular ECs cocultured with neutrophils. The data further demonstrate that neutrophil-derived oxidants are key factors mediating augmented High mobility group box 1 (HMGB1)-induced endothelial NADPH oxidase activation through a Rac1-dependent, but p38 mitogen-activated protein kinase-independent, pathway. Oxidant signaling by neutrophil NADPH oxidase is an important determinant of activation of endothelial NADPH oxidase after HS.
C1 [Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Xiang, Meng; Li, Yuehua; Vodovotz, Yoram; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA.
[Xiang, Meng; Yin, Lianhua] Fudan Univ, Dept Pathophysiol, Shanghai 200433, Peoples R China.
[Xiao, Guozhi] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
RP Fan, J (reprint author), VAPHS, Bldg 1,Room 2W109,Univ Dr, Pittsburgh, PA 15240 USA.
EM fanj2@upmc.edu
FU National Institutes of Health [R01-HL-079669]; National Institutes of
Health Center [P50-GM-53789]; U.S. Department of Veterans Affairs;
National Heart, Lung, and Blood Institute (NHLBI); National Institute of
General Medical Sciences; Department of Veterans Affairs; National
Institutes of Health (NIH)/NHLBI [R33-HL-089082]; NIH/National Institute
of Allergy and Infectious Diseases [R01-AI080799]; NIH/National
Institute of General Medical Sciences [P50-GM-53789]; NIH/National
Institute on Disability and Rehabilitation Research [H133E070024];
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
[UO1 DK072146]
FX This work was supported by the National Institutes of Health grant
R01-HL-079669 (J.F. and M.A.W.), National Institutes of Health Center
grant P50-GM-53789 (T.R.B., Y.V. and J.F.), and a U.S. Department of
Veterans Affairs merit award (J.F.).; J.F. has received sponsored grants
from the National Heart, Lung, and Blood Institute (NHLBI) (more than
$100,000), National Institute of General Medical Sciences (more than
$100,000), and Department of Veterans Affairs (more than $100,000); Y.V.
owns stock in Immunetrics, Inc. (more than $100,000), and has served as
a principal investigator (PI) for the National Institutes of Health
(NIH)/NHLBI (PI of grant R33-HL-089082, more than $100,000),
NIH/National Institute of Allergy and Infectious Diseases (co-PI of
grant R01-AI080799, more than $100,000), NIH/National Institute of
General Medical Sciences (Project V PI on grant P50-GM-53789, more than
$100,000), NIH/National Institute on Disability and Rehabilitation
Research (Project 1 PI on grant H133E070024, more than $100,000), and
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
(Supplement PI on grant UO1 DK072146, $50,001-100,000); none of the
other authors has a financial relationship with a commercial entity that
has an interest in the subject of this manuscript.
NR 48
TC 11
Z9 12
U1 0
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAR
PY 2011
VL 44
IS 3
BP 333
EP 340
DI 10.1165/rcmb.2009-0408OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 753KN
UT WOS:000289772400012
PM 20418360
ER
PT J
AU Shi, M
Bradner, J
Hancock, AM
Chung, KA
Quinn, JF
Peskind, ER
Galasko, D
Jankovic, J
Zabetian, CP
Kim, HM
Leverenz, JB
Montine, TJ
Ginghina, C
Kang, UJ
Cain, KC
Wang, Y
Aasly, J
Goldstein, D
Zhang, J
AF Shi, Min
Bradner, Joshua
Hancock, Aneeka M.
Chung, Kathryn A.
Quinn, Joseph F.
Peskind, Elaine R.
Galasko, Douglas
Jankovic, Joseph
Zabetian, Cyrus P.
Kim, Hojoong M.
Leverenz, James B.
Montine, Thomas J.
Ginghina, Carmen
Kang, Un Jung
Cain, Kevin C.
Wang, Yu
Aasly, Jan
Goldstein, David
Zhang, Jing
TI Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and
Progression
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID MULTIPLE SYSTEM ATROPHY; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN;
TAU-PROTEIN; FRACTALKINE-RECEPTOR; LEWY BODIES; CSF; DEMENTIA;
INFLAMMATION; MICROGLIA
AB Objective: There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of Parkinsonian disorders, and monitoring disease progression. We and others have demonstrated that a decrease in DJ-1 and/or alpha-synuclein in the cerebrospinal fluid (CSF) is a potential index for Parkinson disease diagnosis, but not for PD severity.
Methods: Using highly sensitive and quantitative Luminex assays, we measured total tau, phosphorylated tau, amyloid beta peptide 1-42 (A beta(1-42)), Flt3 ligand, and fractalkine levels in CSF in a large cohort of PD patients at different stages as well as healthy and diseased controls. The utility of these 5 markers was evaluated for disease diagnosis and severity/progression correlation alone, as well as in combination with DJ-1 and alpha-synuclein. The major results were further validated in an independent cohort of cross-sectional PD patients as well as in PD cases with CSF samples collected longitudinally.
Results: The results demonstrated that combinations of these biomarkers could differentiate PD patients not only from normal controls but also from patients with Alzheimer disease (AD) and multiple system atrophy. Particularly, with CSF Flt3 ligand, PD could be clearly differentiated from multiple system atrophy, a disease that overlaps with PD clinically, with excellent sensitivity (99%) and specificity (95%). In addition, we identified CSF fractalkine/A beta(1-42) that positively correlated with PD severity in cross-sectional samples as well as with PD progression in longitudinal samples.
Interpretation: We have demonstrated that this panel of 7 CSF proteins could aid in Parkinson disease diagnosis, differential diagnosis, and correlation with disease severity and progression. ANN NEUROL 2011;69:570-580
C1 [Shi, Min; Bradner, Joshua; Hancock, Aneeka M.; Montine, Thomas J.; Ginghina, Carmen; Wang, Yu; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA.
[Peskind, Elaine R.; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA.
[Zabetian, Cyrus P.; Kim, Hojoong M.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA.
[Cain, Kevin C.] Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98104 USA.
[Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Peskind, Elaine R.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Zabetian, Cyrus P.; Kim, Hojoong M.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Jankovic, Joseph] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA.
[Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA.
[Kang, Un Jung] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA.
[Wang, Yu] Huazhong Univ Sci & Technol, Dept Neurosurg, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
[Aasly, Jan] St Olavs Hosp, Dept Neurol, Trondheim, Norway.
[Goldstein, David] NINDS, Clin Neurocardiol Sect, CNP, DIR,NIH, Bethesda, MD 20892 USA.
RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA.
EM zhangj@uw.edu
RI Shi, Min/G-6165-2012
OI Shi, Min/0000-0002-6901-2558; Zabetian, Cyrus/0000-0002-7739-4306
FU NIH [NIEHS] [ES004696]; NIH [NINDS] [NS057567, NS060252, NS062684]; NIH
[NIA] [AG025327, AG033398, AG005136, AG008017]; NIH [NCRR]
[UL1RR025014]; Dana Foundation; Parkinson's Disease Foundation; Michael
J. Fox Foundation; Friends of Alzheimer's Research; Alzheimer's
Association of Western and Central Washington; Department of Veterans
Affairs; NIH; Oregon Health and Science Univeristy; American Parkinson
Disease Association; Alzheimer's center, NIH; Center of Excellence of
the National Parkinson Foundation; Michael J Fox Foundation
FX This research was supported by the NIH [ES004696 (J.Z.) from NIEHS,
NS057567 (J.Z.), NS060252 (J.Z.), NS062684 (T.J.M., C.P.Z., J.B.L. and
J.Z.) from NINDS, AG025327 (J.Z.), AG033398 (J.Z.), AG005136 (E. R. P
and T.J.M.), AG008017 (K. A. C. and J.F.Q.) from NIA and UL1RR025014 (K.
C. C) from NCRR]; Dana Foundation (J.F.Q.); Parkinson's Disease
Foundation (C.P.Z.); Michael J. Fox Foundation (C.P.Z. and J.Z.);
Friends of Alzheimer's Research (E. R. P.); Alzheimer's Association of
Western and Central Washington (E. R. P.); Department of Veterans
Affairs (C.P.Z. and E. R. P.).; K. C. C. and J.Z. received grant(s) from
the NIH. A. M. H., C. G., J. B. and M. S. were supported by the NIH
grants. K. A. C. received grant(s) from the Oregon Health and Science
Univeristy; C.P.Z. received grants from The American Parkinson Disease
Association, Department of Veterans Affairs, Michael J. Fox Foundation,
NIH, and The Parkinson's Disease Foundation. J. F. Q. received an
Alzheimer's center grant from the NIH. J. J. has grant(s) pending from
the Center of Excellence of the National Parkinson Foundation. T. J. M.
received grant funding and has grant(s) pending from the NIH. U. J. K.
has been a consultant for CVS/caremark and has grants pending from the
Michael J Fox Foundation and the NIH. All other authors had nothing to
report.
NR 54
TC 168
Z9 174
U1 1
U2 23
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD MAR
PY 2011
VL 69
IS 3
BP 570
EP 580
DI 10.1002/ana.22311
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 744FW
UT WOS:000289081300020
PM 21400565
ER
PT J
AU Waltz, P
Carchman, EH
Young, AC
Rao, J
Rosengart, MR
Kaczorowski, D
Zuckerbraun, BS
AF Waltz, Paul
Carchman, Evie H.
Young, Atalie C.
Rao, Jayashree
Rosengart, Matthew R.
Kaczorowski, David
Zuckerbraun, Brian S.
TI Lipopolysaccaride induces autophagic signaling in macrophages via a
TLR4, heme oxygenase-1 dependent pathway
SO AUTOPHAGY
LA English
DT Article
DE sepsis; tumor necrosis factoralpha; RAW 264.7; peritoneal macrophages
ID CARBON-MONOXIDE; MYCOBACTERIUM-TUBERCULOSIS; INNATE IMMUNITY;
GENE-TRANSFER; CELLS; LIVER; EXPRESSION; PROTECTION; IL-1-BETA; PROTEINS
AB Toll-like receptor (TLR) signaling is an important part of the innate immune response. One of the downstream responses to TLR4 signaling upon lipopolysaccharide (LPS) stimulation is the induction of autophagy, which is a key response to multiple stressors. An additional adaptive signaling molecule that is involved in the response to stress is heme oxygenase-1 (HO-1). HO-1 signaling is essential to limit inflammation and restore homeostasis. We found that LPS induced autophagic signaling in macrophages via a TLR4, HO-1 dependent pathway in macrophages. These data add to the developing contribution of autophagic signaling as part of the inflammatory response.
C1 [Zuckerbraun, Brian S.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA.
[Waltz, Paul; Carchman, Evie H.; Young, Atalie C.; Rao, Jayashree; Rosengart, Matthew R.; Kaczorowski, David; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA.
EM zuckerbraunbs@upmc.edu
FU NIGMS NIH HHS [R01 GM082830]
NR 41
TC 38
Z9 38
U1 1
U2 12
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD MAR
PY 2011
VL 7
IS 3
BP 315
EP 320
DI 10.4161/auto.7.3.14044
PG 6
WC Cell Biology
SC Cell Biology
GA 728BU
UT WOS:000287849800009
PM 21307647
ER
PT J
AU Groblewski, PA
Franken, FH
Cunningham, CL
AF Groblewski, Peter A.
Franken, Frederick H.
Cunningham, Christopher L.
TI Inhibition of extracellular signal-regulated kinase (ERK) activity with
SL327 does not prevent acquisition, expression, and extinction of
ethanol-seeking behavior in mice
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Extinction; ERK; SL327; Conditioned place preference; Ethanol; DBA/2J
ID CONDITIONED PLACE PREFERENCE; FEAR-POTENTIATED STARTLE; ACTIVATED
PROTEIN-KINASE; D-CYCLOSERINE; NUCLEUS-ACCUMBENS; INDUCED SENSITIZATION;
AMYGDALA DOPAMINE; PATHWAY; RECEPTORS; AVERSION
AB Although extracellular signal-regulated kinase (ERK) activity is essential for the acquisition of a variety of associative learning tasks, its involvement in the acquisition and extinction of ethanol (EtOH)-induced conditioned place preference (CPP) remains unknown. Therefore, in these experiments we examined the effects of the ERK-kinase (MEK)-inhibitor SL327 on acquisition and expression of EtOH-CPP as well as the dose- and time-dependent effects of SL327 on CPP extinction. The parametric findings of Experiment 1 showed that three 30-min (but not 15- or 5-min) non-reinforced trials were required to completely extinguish EtOH-CPP in male, DBA/2J mice. In Experiments 2 and 3, SL327 (30 and 50 mg/kg), administered 30 or 90 min prior to extinction trials, was unable to impair EtOH-CPP extinction. Experiment 4 showed that SL327 (50 mg/kg) had no effect on acquisition of EtOH-CPP or the development of EtOH-induced sensitization during conditioning. When administered prior to testing in Experiments 5 and 6, SL327 did not alter expression of EtOH-CPP but did reduce test activity. Importantly, SL327 significantly reduced pERK protein levels when assessed in the dorsal striatum and motor cortex (Experiment 7). Together, these data suggest that EtOH-related learning and EtOH reward in mice, as assessed with CPP, are not impaired by the systemically administered MEK-inhibitor SL327. Published by Elsevier B.V.
C1 [Groblewski, Peter A.; Franken, Frederick H.; Cunningham, Christopher L.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
[Groblewski, Peter A.; Cunningham, Christopher L.] Portland Alcohol Res Ctr, Portland, OR 97239 USA.
[Franken, Frederick H.] Portland VA Med Ctr, Portland, OR USA.
RP Groblewski, PA (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, L470,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM groblews@ohsu.edu
FU National Institutes of Health [AA018052, AA007702, DA07262]; American
Psychological Association; N.L. Tartar Research Fund
FX This research was supported by grants from the National Institutes of
Health (AA018052, AA007702, DA07262), the American Psychological
Association, and the N.L. Tartar Research Fund. We would like to thank
Courtney Zerizef for her contributions to Experiment 6.
NR 46
TC 11
Z9 12
U1 2
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD MAR 1
PY 2011
VL 217
IS 2
BP 399
EP 407
DI 10.1016/j.bbr.2010.11.018
PG 9
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 712WZ
UT WOS:000286698300018
PM 21074569
ER
PT J
AU Kuranov, RV
Qiu, JZ
McElroy, AB
Estrada, A
Salvaggio, A
Kiel, J
Dunn, AK
Duong, TQ
Milner, TE
AF Kuranov, Roman V.
Qiu, Jinze
McElroy, Austin B.
Estrada, Arnold
Salvaggio, Anthony
Kiel, Jeffrey
Dunn, Andrew K.
Duong, Timothy Q.
Milner, Thomas E.
TI Depth-resolved blood oxygen saturation measurement by dual-wavelength
photothermal (DWP) optical coherence tomography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID SIGNALS; SCATTERING; SPECTROSCOPY; ABSORPTION; RESOLUTION; VELOCITY;
OXIMETRY; TISSUE; CORTEX; MEDIA
AB Non-invasive depth-resolved measurement of hemoglobin oxygen saturation (SaO(2)) levels in discrete blood vessels may have implications for diagnosis and treatment of various pathologies. We introduce a novel Dual-Wavelength Photothermal (DWP) Optical Coherence Tomography (OCT) for non-invasive depth-resolved measurement of SaO(2) levels in a blood vessel phantom. DWP OCT SaO(2) is linearly correlated with blood-gas SaO(2) measurements. We demonstrate 6.3% precision in SaO(2) levels measured a phantom blood vessel using DWP-OCT with 800 and 765 nm excitation wavelengths. Sources of uncertainty in SaO(2) levels measured with DWP-OCT are identified and characterized. (C) 2011 Optical Society of America
C1 [Kuranov, Roman V.; Kiel, Jeffrey; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Kuranov, Roman V.; Qiu, Jinze; McElroy, Austin B.; Estrada, Arnold; Salvaggio, Anthony; Dunn, Andrew K.; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Kuranov, RV (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
EM kuranov@uthscsa.edu
RI Qiu, Jinze /I-2272-2013; Dunn, Andrew/I-9527-2014
OI Qiu, Jinze /0000-0001-8466-1460;
FU NIH [UL1RR025767, KL2RR025766, R01 EY018855, R01 EY014211]; San Antonio
Area Foundation [130977]; Department of Veterans Affairs
FX This research was partially supported by NIH KL2 training grants (parent
grants UL1RR025767 and KL2RR025766), San Antonio Area Foundation grant
130977 to RVK, Department of Veterans Affairs (VA MERIT Award) to T. Q.
Duong and NIH (R01 EY018855 and R01 EY014211) to T. Q. Duong.
NR 41
TC 20
Z9 20
U1 1
U2 9
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAR 1
PY 2011
VL 2
IS 3
BP 491
EP 504
DI 10.1364/BOE.2.000491
PG 14
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 886SW
UT WOS:000299875200009
PM 21412455
ER
PT J
AU Saless, N
Litscher, SJ
Vanderby, R
Demant, P
Blank, RD
AF Saless, Neema
Litscher, Suzanne J.
Vanderby, Ray
Demant, Peter
Blank, Robert D.
TI Linkage mapping of principal components for femoral biomechanical
performance in a reciprocal HCB-8 x HCB-23 intercross
SO BONE
LA English
DT Article
DE Principal components; Biomechanics; Linkage; Recombinant congenic mice;
Osteoporosis
ID QUANTITATIVE TRAIT LOCI; RECOMBINANT CONGENIC STRAINS; INBRED MOUSE
STRAINS; BONE-MINERAL DENSITY; MICE; PRECISION; C57BL/6J; STRENGTH;
GEOMETRY; CROSSES
AB Studies of bone genetics have addressed an array of related phenotypes, including various measures of biomechanical performance, bone size, bone, shape, and bone mineral density. These phenotypes are not independent, resulting in redundancy of the information they provide. Principal component (PC) analysis transforms multiple phenotype data to a new set of orthogonal "synthetic" phenotypes. We performed PC analysis on 17 femoral biomechanical, anatomic, and body size phenotypes in a reciprocal intercross of HcB-8 and HcB-23, accounting for 80% of the variance in 4 PCs. Three of the 4 PCs were mapped in the cross. The linkage analysis revealed a quantitative trait locus (QTL) with LOD = 4.7 for PC2 at 16 cM on chromosome 19 that was not detected using the directly measured phenotypes. The chromosome 19 QTL falls within a similar to 10 megabase interval, with Osf1 as a positional candidate gene. PC QTLs were also found on chromosomes 1, 2, 4, 6, and 10 that coincided with those identified for directly measured or calculated material property phenotypes. The novel chromosome 19 QTL illustrates the power advantage that attends use of PC phenotypes for linkage mapping. Constraint of the chromosome 19 candidate interval illustrates an important advantage of experimental crosses between recombinant congenic mouse strains. Published by Elsevier Inc.
C1 [Saless, Neema; Blank, Robert D.] Univ Wisconsin, Cellular & Mol Biol Program, Madison, WI USA.
[Litscher, Suzanne J.] Univ Wisconsin, Dept Med, Madison, WI USA.
[Vanderby, Ray] Univ Wisconsin, Dept Orthoped Surg, Madison, WI USA.
[Demant, Peter] Roswell Pk Canc Inst, Dept Genet, Buffalo, NY 14263 USA.
[Blank, Robert D.] Univ Wisconsin, Dept Med, Madison, WI USA.
[Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, GRECC Serv, Madison, WI USA.
RP Blank, RD (reprint author), H4-556 CSC 5148,600 Highland Ave, Madison, WI 53792 USA.
EM rdb@medicine.wisc.edu
FU Office of Research and Development, Biomedical Laboratory R&D Service,
Department of Veterans Affairs (RDB); NIH [AR-54753]
FX This material is based upon work supported by the Office of Research and
Development, Biomedical Laboratory R&D Service, Department of Veterans
Affairs (RDB) and performed in the Geriatrics Research, Education, and
Clinical Center at the William S. Middleton Memorial Veterans Hospital.
This report is Madison GRECC manuscript 2010-09. This work is supported
by NIH grant AR-54753 (R.D.B.).
NR 42
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD MAR 1
PY 2011
VL 48
IS 3
BP 647
EP 653
DI 10.1016/j.bone.2010.10.165
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 740EG
UT WOS:000288773800029
PM 20969983
ER
PT J
AU Wasif, N
Etzioni, D
Maggard, MA
Tomlinson, JS
Ko, CY
AF Wasif, Nabil
Etzioni, David
Maggard, Melinda A.
Tomlinson, James S.
Ko, Clifford Y.
TI Trends, Patterns, and Outcomes in the Management of Malignant Colonic
Polyps in the General Population of the United States
SO CANCER
LA English
DT Article
DE malignant colon polyps; lymph nodes; survival; colon cancer; surgical
resection
ID COLORECTAL-CANCER; QUALITY MEASURES; RISK-FACTORS; SURVEILLANCE;
POLYPECTOMY; COLECTOMY; SOCIETY
AB BACKGROUND: Colonoscopic screening has increased detection of malignant colonic polyps (MPs). The goal of this study was to analyze trends and patterns in the surgical treatment of MPs and to assess outcomes as measured by lymph node retrieval and patient survival. METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was queried to identify 19,743 patients with MPs from 1988 to 2003. RESULTS: The majority of MPs were present in the sigmoid and descending colon (54%), and 38% were tubular, 40% were tubulovillous, and 22% were villous. During the study period, the incidence of MPs increased from 29% to 42% and surgical resection (SR) was increasingly used for treatment, from 54% to 70%. Predictors of SR were aged <70 years (odds ratio [OR], 1.3; 95% confidence interval [95% CI], 1.2-1.4), high-grade tumors (OR, 1.5; 95% Cl, 1.2-1.9), diagnosis in 1999 through 2003 (OR, 1.7; 95% Cl, 1.5-1.9), villous subtype (OR, 2.3; 95% Cl, 2.0-2.6), and right colon location (OR, 8.1; 95% Cl, 7.0-9.4). In patients undergoing SR, the mean and median number of lymph nodes was only 4 and 1, respectively. A significant percentage of patients (49%) had no lymph nodes retrieved and a worse overall survival at 5 years compared with patients who had at least 1 lymph node examined (64% vs 74%; P<001). CONCLUSIONS: MPs appear to be increasing in incidence, and there is a trend toward increased use of SR for treatment. However, patients undergoing SR for MPs undergo suboptimal assessment of lymph nodes, with a detrimental impact on survival. Adequate lymphadenectomy and lymph node evaluation are crucial to improve outcomes in patients with these potentially curable lesions. Cancer 2011;117:931-7. (C) 2010 American Cancer Society
C1 [Wasif, Nabil] St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA USA.
[Wasif, Nabil; Etzioni, David] Mayo Clin Scottsdale, Dept Surg, Scottsdale, AZ USA.
[Maggard, Melinda A.; Tomlinson, James S.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Tomlinson, James S.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
RP Wasif, N (reprint author), Mayo Clin, Dept Surg, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA.
EM wasif.nabil@mayo.edu
NR 19
TC 12
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 1
PY 2011
VL 117
IS 5
BP 931
EP 937
DI 10.1002/cncr.25657
PG 7
WC Oncology
SC Oncology
GA 725LM
UT WOS:000287646200010
PM 20960490
ER
PT J
AU Cheng, EM
Cunningham, WE
Towfighi, A
Sanossian, N
Bryg, RJ
Anderson, TL
Guterman, JJ
Gross-Schulman, SG
Beanes, S
Jones, AS
Liu, HH
Ettner, SL
Saver, JL
Vickrey, BG
AF Cheng, Eric M.
Cunningham, William E.
Towfighi, Amytis
Sanossian, Nerses
Bryg, Robert J.
Anderson, Thomas L.
Guterman, Jeffrey J.
Gross-Schulman, Sandra G.
Beanes, Sylvia
Jones, Andrea S.
Liu, Honghu
Ettner, Susan L.
Saver, Jeffrey L.
Vickrey, Barbara G.
TI Randomized, Controlled Trial of an Intervention to Enable Stroke
Survivors Throughout the Los Angeles County Safety Net to "Stay With the
Guidelines"
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE stroke; secondary prevention; risk factors; self-management; care
coordination
ID TRANSIENT ISCHEMIC ATTACK; IMPROVING PRIMARY-CARE; RISK-FACTORS;
BLOOD-PRESSURE; GROUP VISITS; SECONDARY PREVENTION; SELF-MANAGEMENT;
CHRONIC ILLNESS; CHRONIC DISEASE; WARNING SIGNS
AB Background-Stroke is the leading cause of adult disability. Inpatient programs optimize secondary stroke prevention care at the time of hospital discharge, but such care may not be continued after hospital discharge.
Methods-To improve the delivery of secondary stroke preventive services after hospital discharge, we have designed a chronic care model-based program called SUSTAIN (Systemic Use of STroke Averting INterventions). This care intervention includes group clinics, self-management support, report cards, decision support through care guides and protocols, and coordination of ongoing care. The first specific aim is to test, in a randomized, controlled trial, whether SUSTAIN improves blood pressure control among an analytic sample of 268 patients with a recent stroke or transient ischemic attack discharged from 4 Los Angeles County public hospitals. Secondary outcomes consist of control of other stroke risk factors, lifestyle habits, medication adherence, patient perceptions of care quality, functional status, and quality of life. A second specific aim is to conduct a cost analysis of SUSTAIN from the perspective of the Los Angeles County Department of Health Services by using direct costs of the intervention, cost equivalents of associated utilization of county system resources, and cost equivalents of the observed and predicted averted vascular events.
Conclusions-If SUSTAIN is effective, we will have the expertise and findings to advocate for its continued support at Los Angeles County hospitals and to disseminate the SUSTAIN program to other settings serving indigent, minority populations.
C1 [Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, VA Greater Angeles UCLA, Los Angeles, CA 90073 USA.
[Cheng, Eric M.; Vickrey, Barbara G.] VA Greater Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Cunningham, William E.; Guterman, Jeffrey J.; Liu, Honghu; Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA.
[Towfighi, Amytis] Rancho Los Amigos Natl Rehabil Ctr, Dept Neurol, Los Angeles, CA USA.
[Towfighi, Amytis; Sanossian, Nerses] Univ So Calif, Dept Neurol, Los Angeles, CA USA.
[Bryg, Robert J.] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA.
[Anderson, Thomas L.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Dept Neurol, Torrance, CA 90509 USA.
[Guterman, Jeffrey J.; Gross-Schulman, Sandra G.] Olive View UCLA Med Ctr, Los Angeles Cty Dept Hlth Serv, Sylmar, CA 91342 USA.
[Beanes, Sylvia] Amer Heart Assoc, Los Angeles, CA USA.
[Jones, Andrea S.] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA.
RP Cheng, EM (reprint author), Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, VA Greater Angeles UCLA, 11301 Wilshire Blvd,ML 127, Los Angeles, CA 90073 USA.
EM eric.cheng@va.gov
OI Saver, Jeffrey/0000-0001-9141-2251
FU American Heart Association; National Institutes of Health/National
Institute of Neurological Disorders and Stroke [K23NS058571]; UCLA/DREW
[P20MD000148/P20MD000182]; UCLA Center for Health Improvement of
Minority Elderly/Resource Centers for Minority Aging Research (National
Institute on Aging) [P30AG021684]
FX This work was supported by an award from the American Heart Association
Pharmaceutical Roundtable and David and Stevie Spina. There are no
sponsor-imposed restrictions on publication of this article and any
subsequent articles about this study. Dr Eric Cheng is supported by a
Career Development Award from the National Institutes of Health/National
Institute of Neurological Disorders and Stroke (K23NS058571). Drs Cheng
and Cunningham also received partial support from the UCLA/DREW project
EXPORT (NCMHD grants No. P20MD000148/P20MD000182). Dr Cunningham also
receives partial support from the UCLA Center for Health Improvement of
Minority Elderly/Resource Centers for Minority Aging Research (National
Institute on Aging grant No. P30AG021684).
NR 50
TC 13
Z9 13
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAR
PY 2011
VL 4
IS 2
BP 229
EP 234
DI 10.1161/CIRCOUTCOMES.110.951012
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 734WN
UT WOS:000288372200016
PM 21406671
ER
PT J
AU Musher, DM
Sampath, R
Rodriguez-Barradas, MC
AF Musher, Daniel M.
Sampath, Rahul
Rodriguez-Barradas, Maria C.
TI The Potential Role for Protein-Conjugate Pneumococcal Vaccine in Adults:
What Is the Supporting Evidence?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
ID HIV-INFECTED ADULTS; RENAL-TRANSPLANT RECIPIENTS; COST-EFFECTIVENESS
ANALYSIS; PLACEBO-CONTROLLED TRIAL; POLYSACCHARIDE VACCINE;
STREPTOCOCCUS-PNEUMONIAE; DOUBLE-BLIND; OLDER-ADULTS; CAPSULAR
POLYSACCHARIDES; HEMOPHILUS-INFLUENZAE
AB Vaccination with protein-conjugate pneumococcal vaccine (PCV) provides children with extraordinary protection against pneumococcal disease, although the protective effect may be blunted by the emergence of replacement strains. Studies in adults have compared PCV with pneumococcal polysaccharide vaccine (PPV) using surrogate markers of protection, namely, serum anticapsular IgG antibody and opsonic activity. Results suggest that PCV is at least as effective as PPV for the strains covered, but a definitive and consistent advantage has not been demonstrated. Unfortunately, persons who are most in need of vaccine do not respond as well as otherwise healthy adults to either vaccine. Newer formulations of PCV will protect against the most prevalent of the current replacement strains, but replacement strains will create a moving target for PCVs. Unless an ongoing trial comparing 13-valent PCV with placebo (not to PPV) demonstrates a clearly better effect than that seen in the past with PPV, cost-effectiveness considerations are likely to prevent widespread use of PCV in adults.
C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Med Care Line Infect Dis Sect, Houston, TX 77030 USA.
Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA.
Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA.
RP Musher, DM (reprint author), Michael E DeBakey VAMC, Infect Dis Sect, Houston, TX 77030 USA.
EM dmusher@bcm.edu
NR 65
TC 44
Z9 44
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 1
PY 2011
VL 52
IS 5
BP 633
EP 640
DI 10.1093/cid/ciq207
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 716RR
UT WOS:000286991700017
PM 21292668
ER
PT J
AU von Kanel, R
Carney, RM
Zhao, SJ
Whooley, MA
AF von Kaenel, Roland
Carney, Robert M.
Zhao, Shoujun
Whooley, Mary A.
TI Heart rate variability and biomarkers of systemic inflammation in
patients with stable coronary heart disease: findings from the Heart and
Soul Study
SO CLINICAL RESEARCH IN CARDIOLOGY
LA English
DT Article
DE Autonomic nervous system; Biomarkers; Cardiac autonomic function;
Cardiovascular disease; Heart rate variability; Inflammation
ID C-REACTIVE PROTEIN; ACUTE MYOCARDIAL-INFARCTION; ARTERY-DISEASE;
CARDIOVASCULAR-DISEASES; AUTONOMIC FUNCTION; PROGNOSTIC VALUE;
ANGINA-PECTORIS; UNSTABLE ANGINA; INTERLEUKIN-6; MARKERS
AB Chronic low-grade systemic inflammation is a key component in atherogenesis. Decreased heart rate variability (HRV), a strong predictor of cardiovascular events, has been associated with elevations in circulating levels of C-reactive protein (CRP), interleukin (IL)-6, and fibrinogen in apparently healthy individuals. We investigated whether decreased HRV is associated with inflammatory markers in patients with coronary heart disease (CHD).
We studied the relationship between HRV and CRP, IL-6, and fibrinogen in 862 outpatients with CHD. All participants provided fasting blood samples and underwent 24-h ambulatory monitoring to assess time-domain measures of HRV (MeanNN, SDNN, SDANN, and RMSSD). Regression analyses were adjusted for age, sex, ethnicity, body mass index, smoking, diabetes, beta blocker use, and cardiopulmonary history.
MeanNN, SDNN, and SDANN were significantly and inversely associated with CRP and IL-6 levels in age-adjusted models and after adjustment for all covariates (p a parts per thousand currency sign 0.02). MeanNN, SDNN, and SDANN were also inversely associated with fibrinogen levels in age-adjusted models (p < 0.03), but not significantly so in multivariable-adjusted models. Reduced vagal modulation of heart rate (RMSSD) was not significantly associated with any inflammatory measures.
Reduced cardiac autonomic control is associated with increased systemic inflammation in patients with stable CHD. This relationship was largely independent of important covariates.
C1 [von Kaenel, Roland] Univ Bern, Dept Gen Internal Med, Div Psychosomat Med, Inselspital,Bern Univ Hosp, CH-3010 Bern, Switzerland.
[Carney, Robert M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Zhao, Shoujun] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA.
[Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP von Kanel, R (reprint author), Univ Bern, Dept Gen Internal Med, Div Psychosomat Med, Inselspital,Bern Univ Hosp, CH-3010 Bern, Switzerland.
EM roland.vonkaenel@insel.ch
FU Department of Veterans Affairs, Washington, DC; Robert Wood Johnson
Foundation, Princeton, New Jersey; American Federation for Aging
Research, New York, NY; Ischemia Research and Education Foundation, San
Bruno, CA
FX The Heart and Soul Study was supported by grants from the Department of
Veterans Affairs (Epidemiology Merit Review Program), Washington, DC;
The Robert Wood Johnson Foundation (Generalist Physician Faculty
Scholars Program), Princeton, New Jersey; the American Federation for
Aging Research Paul Beeson Faculty Scholars in Aging Research Program),
New York, NY; and the Ischemia Research and Education Foundation, San
Bruno, CA.
NR 45
TC 24
Z9 24
U1 2
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1861-0684
EI 1861-0692
J9 CLIN RES CARDIOL
JI Clin. Res. Cardiol.
PD MAR
PY 2011
VL 100
IS 3
BP 241
EP 247
DI 10.1007/s00392-010-0236-5
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 723KQ
UT WOS:000287505800008
PM 20857123
ER
PT J
AU Singh, JA
Reddy, SG
Kundukulam, J
AF Singh, Jasvinder A.
Reddy, Supriya G.
Kundukulam, Joseph
TI Risk factors for gout and prevention: a systematic review of the
literature
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE alcohol; chronic diseases; diet; gout; gouty arthritis; medications;
risk factors; systematic review
ID URIC-ACID LEVEL; NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH;
INCIDENT GOUT; FOLLOW-UP; TAIWAN ABORIGINES; PROSPECTIVE COHORT; HIGH
PREVALENCE; RENAL-FAILURE; DIURETIC USE
AB Purpose of review
Our objective was to perform a systematic review of risk factors and prevention of gout. We searched Medline for fully published reports in English using keywords including but not limited to 'gout', 'epidemiology', 'primary prevention', 'secondary prevention', 'risk factors'. Data from relevant articles meeting inclusion criteria were extracted using standardized forms.
Recent findings
Of the 751 titles and abstracts, 53 studies met the criteria and were included in the review. Several risk factors were studied. Alcohol consumption increased the risk of incident gout, especially beer and hard liquor. Several dietary factors increased the risk of incident gout, including meat intake, seafood intake, sugar sweetened soft drinks, and consumption of foods high in fructose. Diary intake, folate intake, and coffee consumption were each associated with a lower risk of incident gout and in some cases a lower rate of gout flares. Thiazide and loop diuretics were associated with higher risk of incident gout and higher rate of gout flares. Hypertension, renal insufficiency, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, diabetes, obesity, and early menopause were each associated with a higher risk of incident gout and/or gout flares.
Summary
Several dietary risk factors for incident gout and gout flares are modifiable. Prevention and optimal management of comorbidities are likely to decreased risk of gout. Research in preventive strategies for the treatment of gout is needed.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.; Reddy, Supriya G.; Kundukulam, Joseph] Univ Alabama, Dept Med, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.
[Reddy, Supriya G.] Univ Alabama, Dept Hlth Sci, Tuscaloosa, AL USA.
RP Singh, JA (reprint author), Univ Alabama, Dept Med, Sch Publ Hlth, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Allergan; Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals; Novartis;
Birmingham VA Medical Center, Alabama, USA
FX We thank Louise Falzon, of the Cochrane Library, for performing and
updating the search for this systematic review and April DeMedicis, of
the Birmingham VA Medical Center, for reviewing titles and abstracts
prior to conducting the full text review as well as assisting with the
data abstraction process. This material is the result of work supported
with the resources and the use of facilities at the Birmingham VA
Medical Center, Alabama, USA.; There are no financial conflicts related
to this work. J.A.S. has received speaker honoraria from Abbott;
research and travel grants from Allergan, Takeda, Savient, Wyeth and
Amgen; and consultant fees from Savient, URL pharmaceuticals and
Novartis.
NR 73
TC 43
Z9 60
U1 4
U2 58
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8711
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD MAR
PY 2011
VL 23
IS 2
BP 192
EP 202
DI 10.1097/BOR.0b013e3283438e13
PG 11
WC Rheumatology
SC Rheumatology
GA 715JB
UT WOS:000286879200013
PM 21285714
ER
PT J
AU Boyko, EJ
Meigs, JB
AF Boyko, Edward J.
Meigs, James B.
TI Does Diabetes Always Confer Coronary Heart Disease Risk Equivalent to a
Prior Myocardial Infarction? Implications for prevention
SO DIABETES CARE
LA English
DT Editorial Material
ID BLOOD-GLUCOSE CONTROL; SCIENTIFIC STATEMENT; TYPE-2; COMPLICATIONS;
ASPIRIN; INTERVENTION; METAANALYSIS; ASSOCIATION; INFORMATION; METFORMIN
C1 [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Meigs, James B.] Harvard Univ, Sch Med, Div Gen Med, Boston, MA USA.
RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
EM eboyko@uw.edu
OI Boyko, Edward/0000-0002-3695-192X
FU NIDDK NIH HHS [K24 DK080140, K24-DK080140, P30 DK017047, P30-DK17047]
NR 17
TC 8
Z9 8
U1 1
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAR
PY 2011
VL 34
IS 3
BP 782
EP 784
DI 10.2337/dc10-1958
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 731YA
UT WOS:000288145400051
PM 21357366
ER
PT J
AU Bains, SS
Egede, LE
AF Bains, Sujeev S.
Egede, Leonard E.
TI Associations Between Health Literacy, Diabetes Knowledge, Self-Care
Behaviors, and Glycemic Control in a Low Income Population with Type 2
Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID MEDICATION ADHERENCE; MORTALITY; OUTCOMES; EDUCATION; DISEASE; RISK;
COMPLICATIONS; METAANALYSIS; MELLITUS; PEOPLE
AB Objective: This study assessed associations among health literacy, diabetes knowledge, self-care, and glycemic control in a low income, predominately minority population with type 2 diabetes.
Methods: One hundred twenty-five adults with diabetes were recruited from a primary care clinic. Subjects completed validated surveys to measure health literacy, diabetes knowledge, and self-care (medication adherence, diet, exercise, blood sugar testing, and foot care). Hemoglobin A1c values were extracted from the medical record. Spearman's correlation and multiple linear regression were used to assess the relationship among health literacy, diabetes knowledge, self-care, and glycemic control controlling for covariates.
Results: Cronbach's alpha was 0.95 for the Revised Rapid Estimate of Adult Literacy in Medicine. The majority of the sample was < 65 years old (50.7%), female (72.5%), and African American (71.4%), had less than a high school education (68.2%) and a household income <$15,000 (64.2%), and reported their health status as worse than last year (73.9%). In adjusted models that examined the associations among health literacy, diabetes knowledge, medication adherence, and self-care, health literacy was only significantly associated with diabetes knowledge (beta = 0.55; 95% confidence interval [CI] 0.29, 0.82). In the final adjusted model for independent factors associated with glycemic control, both diabetes knowledge (beta = 0.12; 95% CI 0.01, 0.23) and perceived health status (beta = 1.14; 95% CI 0.13, 2.16) were significantly associated with glycemic control, whereas health literacy was not associated with glycemic control (beta = -0.03; 95% CI -0.19, 0.13).
Conclusions: Diabetes knowledge and perceived health status are the most important factors associated with glycemic control in this population. Health literacy appears to exert its influence through diabetes knowledge and is not directly related to self-care or medication adherence.
C1 [Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU NIDDK NIH HHS [R01 DK081121, T35 DK007431]
NR 50
TC 57
Z9 60
U1 2
U2 21
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD MAR
PY 2011
VL 13
IS 3
BP 335
EP 341
DI 10.1089/dia.2010.0160
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 727KO
UT WOS:000287798200007
PM 21299402
ER
PT J
AU Hildebrandt, T
Lai, JK
Langenbucher, JW
Schneider, M
Yehuda, R
Pfaff, DW
AF Hildebrandt, Tom
Lai, Justine K.
Langenbucher, James W.
Schneider, Melanie
Yehuda, Rachel
Pfaff, Donald W.
TI The diagnostic dilemma of pathological appearance and performance
enhancing drug use
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Review
DE Anabolic-androgenic steroids; Appearance and performance enhancing
drugs; Substance use disorder; Diagnosis; Body image disturbance;
Compulsive exercise
ID ANDROGENIC STEROID USE; SUBSTANCE USE DISORDERS; MALE NORMAL VOLUNTEERS;
ITEM RESPONSE THEORY; OF-THE-LITERATURE; ANABOLIC-STEROIDS;
EXERCISE-DEPENDENCE; DSM-V; MUSCLE DYSMORPHIA; BODY-IMAGE
AB Appearance and performance enhancing drug (APED) use includes the use of a range of pharmacologically distinct substances and concurrent investment in outward appearance or achievement, dietary control, and frequent exercise. A number of existing reviews and conceptual papers have defined pathological forms of APED use within the APED class of anabolic-androgenic steroids (AASs) and using the framework of AAS dependence. We review published data on APED use including human studies of AAS users and identified three defining phenomenological features associated with increased health risk and pathology. These features included (1) polypharmacy or the concurrent use of several pharmacologically distinct substances used to change outward appearance or increase likelihood of personal achievement: (2) significant body image disturbance: (3) rigid practices and preoccupations with diet and exercise. Investigations into the latent structure of APED use suggest these features cluster together in a homogenous group of APED users who have the highest health risk and most psychopathology. These features are discussed in the context of AAS dependence and problems with defining classic tolerance-withdrawal symptoms among APED users. Suggestions for a resolution and outline for future research needed to determine the best system for identifying and diagnosing pathological APED use are discussed. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Hildebrandt, Tom; Lai, Justine K.] Mt Sinai Sch Med, Eating & Weight Disorders Program, New York, NY 10029 USA.
[Langenbucher, James W.; Schneider, Melanie] Rutgers State Univ, Piscataway, NJ 08854 USA.
[Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Pfaff, Donald W.] Rockefeller Univ, New York, NY 10128 USA.
RP Hildebrandt, T (reprint author), Mt Sinai Sch Med, Eating & Weight Disorders Program, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
EM tom.hildebrandt@mssm.edu
OI Hildebrandt, Thomas/0000-0001-7054-9590
FU National Institute on Drug Abuse [K23 024034]
FX Dr. Hildebrandt's time was supported by National Institute on Drug Abuse
grant K23 024034.
NR 146
TC 12
Z9 12
U1 16
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD MAR 1
PY 2011
VL 114
IS 1
BP 1
EP 11
DI 10.1016/j.drugalcdep.2010.09.018
PG 11
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 734CZ
UT WOS:000288312100001
PM 21115306
ER
PT J
AU van Ryn, M
Burgess, DJ
Dovidio, JF
Phelan, SM
Saha, S
Malat, J
Griffin, JM
Fu, SS
Perry, S
AF van Ryn, Michelle
Burgess, Diana J.
Dovidio, John F.
Phelan, Sean M.
Saha, Somnath
Malat, Jennifer
Griffin, Joan M.
Fu, Steven S.
Perry, Sylvia
TI THE IMPACT OF RACISM ON CLINICIAN COGNITION, BEHAVIOR, AND CLINICAL
DECISION MAKING
SO DU BOIS REVIEW-SOCIAL SCIENCE RESEARCH ON RACE
LA English
DT Article
DE Racial Inequity; Health Care Disparities; Racial Bias; Providers;
Racism; Stereotypes; Discrimination; Interracial Interaction
ID HEALTH-CARE DISPARITIES; IMPLICIT ASSOCIATION TEST; STEREOTYPE THREAT;
CULTURAL COMPETENCE; PHYSICIANS PERCEPTIONS; AFRICAN-AMERICANS; AVERSIVE
RACISM; PUBLIC-HEALTH; ATTITUDES; RACE
AB Over the past two decades, thousands of studies have demonstrated that Blacks receive lower quality medical care than Whites, independent of disease status, setting, insurance, and other clinically relevant factors. Despite this, there has been little progress towards eradicating these inequities. Almost a decade ago we proposed a conceptual model identifying mechanisms through which clinicians' behavior, cognition, and decision making might be influenced by implicit racial biases and explicit racial stereotypes, and thereby contribute to racial inequities in care. Empirical evidence has supported many of these hypothesized mechanisms, demonstrating that White medical care clinicians: (1) hold negative implicit racial biases and explicit racial stereotypes, (2) have implicit racial biases that persist independently of and in contrast to their explicit (conscious) racial attitudes, and (3) can be influenced by racial bias in their clinical decision making and behavior during encounters with Black patients. This paper applies evidence from several disciplines to further specify our original model and elaborate on the ways racism can interact with cognitive biases to affect clinicians' behavior and decisions and in turn, patient behavior and decisions. We then highlight avenues for intervention and make specific recommendations to medical care and grant-making organizations.
C1 [van Ryn, Michelle; Phelan, Sean M.] Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Minneapolis, MN 55414 USA.
[Burgess, Diana J.; Griffin, Joan M.; Fu, Steven S.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55414 USA.
[Dovidio, John F.; Perry, Sylvia] Yale Univ, Dept Psychol, New Haven, CT 06520 USA.
[Saha, Somnath] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97201 USA.
[Saha, Somnath] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA.
[Malat, Jennifer] Univ Cincinnati, Dept Sociol, Cincinnati, OH 45221 USA.
[Burgess, Diana J.; Griffin, Joan M.; Fu, Steven S.] Univ Minnesota, Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55414 USA.
RP van Ryn, M (reprint author), Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Room 221,925 Delaware St SE, Minneapolis, MN 55414 USA.
EM vanry001@umn.edu
RI Burgess, Diana/A-1946-2016
FU NHLBI NIH HHS [R01 HL085631]
NR 89
TC 43
Z9 44
U1 12
U2 43
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1742-058X
J9 DU BOIS REV
JI Du Bois Rev.
PD SPR
PY 2011
VL 8
IS 1
SI SI
BP 199
EP 218
DI 10.1017/S1742058X11000191
PG 20
WC Ethnic Studies; Sociology
SC Ethnic Studies; Sociology
GA 051ZD
UT WOS:000312166600015
PM 24761152
ER
PT J
AU Kind, A
Anderson, P
Hind, J
Robbins, J
Smith, M
AF Kind, Amy
Anderson, Paul
Hind, Jacqueline
Robbins, JoAnne
Smith, Maureen
TI Omission of Dysphagia Therapies in Hospital Discharge Communications
SO DYSPHAGIA
LA English
DT Article
DE Care management; Communication; Continuity of care; Hospital discharge;
Deglutition; Deglutition disorders
ID MEDICAL REHABILITATION REPORT; RANDOMIZED CONTROLLED-TRIAL; UNIFORM DATA
SYSTEM; GENERAL-PRACTITIONERS; ACUTE STROKE; ALZHEIMERS-DISEASE; PATIENT
SAFETY; CLINICAL-TRIAL; HIP FRACTURE; FOLLOW-UP
AB Despite the wide implementation of dysphagia therapies, it is unclear whether these therapies are successfully communicated beyond the inpatient setting. The aim of this study was to examine the rate of dysphagia recommendation omissions in hospital discharge summaries for high-risk subacute care (i.e., skilled nursing facility, rehabilitation, long-term care) populations. We performed a retrospective cohort study that included all stroke and hip fracture patients billed for inpatient dysphagia evaluations by speech-language pathologists (SLPs) and discharged to subacute care from 2003 through 2005 from a single large academic medical center (N = 187). Dysphagia recommendations from final SLP hospital notes and from hospital (physician) discharge summaries were abstracted, coded, and compared for each patient. Recommendation categories included dietary (food and liquid), postural/compensatory techniques (e.g., chin tuck), rehabilitation (e.g., exercise), meal pacing (e.g., small bites), medication delivery (e.g., crush pills), and provider/supervision (e.g., 1-to-1 assist). Forty-five percent of discharge summaries omitted all SLP dysphagia recommendations. Forty-seven percent (88/186) of patients with SLP dietary recommendations, 82% (93/114) with postural, 100% (16/16) with rehabilitation, 90% (69/77) with meal pacing, 95% (21/22) with medication, and 79% (96/122) with provider/supervision recommendations had these recommendations completely omitted from their discharge summaries. Discharge summaries omitted all categories of SLP recommendations at notably high rates. Improved post-hospital communication strategies are needed for discharges to subacute care.
C1 [Kind, Amy] Univ Wisconsin, Geriatr Sect, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Kind, Amy; Anderson, Paul; Hind, Jacqueline; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, United States Dept Vet Affairs, Geriatr Res Educ & Clin Ctr GRECC, Madison, WI 53705 USA.
[Kind, Amy] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Hind, Jacqueline; Robbins, JoAnne] Univ Wisconsin, Gastroenterol & Hepatol Sect, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Smith, Maureen] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
[Smith, Maureen] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI 53726 USA.
RP Kind, A (reprint author), Univ Wisconsin, Geriatr Sect, Dept Med, Sch Med & Publ Hlth, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM ajk@medicine.wisc.edu
FU University of Wisconsin (UW) Hartford Center of Excellence in
Geriatrics; UW Health Innovation Program; UW Shapiro Summer Medical
Student Research Fellowship; K-L2 through the NIH [1KL2RR025012-01];
Community-Academic Partnerships core of the University of Wisconsin
Institute for Clinical and Translational Research (UW ICTR); National
Center for Research Resources, National Institutes of Health
[IUL1RR025011]
FX Special thanks to UW Health Innovation Program staff Geoff Wodtke and
Wen-Jan Tuan for data management and cleaning, Inna Larsen for
administrative support, Colleen Brown and Kristin Slovenkay for
manuscript formatting, and Peggy Munson for IRB assistance, and to Bruce
Grau and Tim Kamps for assistance with data collection. Funding for this
project was provided by the University of Wisconsin (UW) Hartford Center
of Excellence in Geriatrics, the UW Health Innovation Program, and the
UW Shapiro Summer Medical Student Research Fellowship. Dr. Kind is
supported by a K-L2 through the NIH grant 1KL2RR025012-01 [Institutional
Clinical and Translational Science Award (UW-Madison) (KL2)]. This
project was also supported by the Community-Academic Partnerships core
of the University of Wisconsin Institute for Clinical and Translational
Research (UW ICTR), grant IUL1RR025011 from the Clinical and
Translational Science Award (CTSA) program of the National Center for
Research Resources, National Institutes of Health. The UW Health
Innovation Program provided assistance with IRB application, Medicare
outcomes variable creation and linkage, data management and cleaning,
and manuscript formatting. No other funding source had a role in the
design or conduct data collection, management, analysis, or
interpretation; or preparation, review, or approval of the manuscript.
NR 73
TC 14
Z9 14
U1 5
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-051X
J9 DYSPHAGIA
JI Dysphagia
PD MAR
PY 2011
VL 26
IS 1
BP 49
EP 61
DI 10.1007/s00455-009-9266-4
PG 13
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 732VQ
UT WOS:000288218200008
PM 20098999
ER
PT J
AU Hershman, JM
Okunyan, A
Rivina, Y
Cannon, S
Hogen, V
AF Hershman, Jerome M.
Okunyan, Armen
Rivina, Yelena
Cannon, Sophie
Hogen, Victor
TI Prevention of DNA Double-Strand Breaks Induced by Radioiodide-I-131 in
FRTL-5 Thyroid Cells
SO ENDOCRINOLOGY
LA English
DT Article
ID REPAIR; RADIATION; CANCER; REARRANGEMENT; CHROMOSOMES; SYMPORTER; IODIDE
AB Radioiodine-131 released from nuclear reactor accidents has dramatically increased the incidence of papillary thyroid cancer in exposed individuals. The deposition of ionizing radiation in cells results in double-strand DNA breaks (DSB) at fragile sites, and this early event can generate oncogenic rearrangements that eventually cause cancer. The aims of this study were to develop a method to show DNA DSBs induced by I-131 in thyroid cells; to test monovalent anions that are transported by the sodium/iodide symporter to determine whether they prevent I-131-induced DSB; and to test other radioprotective agents for their effect on irradiated thyroid cells. Rat FRTL-5 thyroid cells were incubated with I-131. DSBs were measured by nuclear immunofluorescence using antibodies to p53-binding protein 1 or gamma H2AX. Incubation with 1-10 mu Ci I-131 per milliliter for 90 min resulted in a dose-related increase of DSBs; the number of DSBs increased from a baseline of 4-15% before radiation to 65-90% after radiation. GH3 or CHO cells that do not transport iodide did not develop DSBs when incubated with I-131. Incubation with 20-100 mu M iodide or thiocyanate markedly attenuated DSBs. Perchlorate was about 6 times more potent than iodide or thiocyanate. The effects of the anions were much greater when each was added 30-120 min before the I-131. Two natural organic compounds recently shown to provide radiation protection partially prevented DSBs caused by I-131 and had an additive effect with perchlorate. In conclusion, we developed a thyroid cell model to quantify the mitogenic effect of I-131. I-131 causes DNA DSBs in FRTL-5 cells and had no effect on cells that do not transport iodide. Perchlorate, iodide, and thiocyanate protect against DSBs induced by I-131. (Endocrinology 152: 1130-1135, 2011)
C1 [Hershman, Jerome M.] W Los Angeles Vet Affairs Med Ctr, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90073 USA.
RP Hershman, JM (reprint author), W Los Angeles Vet Affairs Med Ctr, Endocrinol & Diabet Div, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jhershmn@ucla.edu
OI Cannon, Sophie M/0000-0003-1643-6944
FU University of California, Los Angeles, Center of Biological
Radioprotectors; National Institutes of Health
FX This work was supported by a research grant from the University of
California, Los Angeles, Center of Biological Radioprotectors and the
National Institutes of Health.
NR 20
TC 7
Z9 7
U1 1
U2 3
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD MAR
PY 2011
VL 152
IS 3
BP 1130
EP 1135
DI 10.1210/en.2010-1163
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 723QC
UT WOS:000287520900038
PM 21190956
ER
PT J
AU Liu, YY
Nakatani, T
Kogai, T
Mody, K
Brent, GA
AF Liu, Yan-Yun
Nakatani, Teruyo
Kogai, Takahiko
Mody, Kaizeen
Brent, Gregory A.
TI Thyroid Hormone and COUP-TF1 Regulate Kallikrein-Binding Protein (KBP)
Gene Expression
SO ENDOCRINOLOGY
LA English
DT Article
ID PROMOTER-TRANSCRIPTION FACTORS; HUMAN TISSUE KALLIKREIN; RECEPTOR
DNA-BINDING; COREPRESSOR N-COR; NEGATIVE REGULATION; RETINOIC ACID;
HISTONE DEACETYLASE; ESTROGEN-RECEPTOR; RESPONSE ELEMENTS;
GROWTH-HORMONE
AB Kallikrein-binding protein (KBP) is a component of the kallikrein-kinin system that mediates vasodilation and inhibits tumor growth by antagonizing vascular endothelial growth factor-mediated angiogenesis. We demonstrate that KBP gene expression is repressed by T(3) and modulated by the orphan nuclear receptor, chicken ovalbumin upstream promoter transcription factor 1 (COUP-TF1). In hypothyroid mice, KBP mRNA expression in the testis was increased 2.1-fold compared with euthyroid mice. We have identified two negative thyroid hormone response elements (nTREs) in the mouse KBP gene, nTRE1 located in the 5' flanking region (-53 to -29) and nTRE2, located in the first intron (104-132). We used functional assays, cofactor knockdown, and chromatin immunoprecipitation assays to characterize nTRE1 and nTRE2 in hepatic (HepG2) and testes (GC-1spg) cell lines. Reporter expression directed by both elements was enhanced with addition of thyroid hormone receptor and repressed with the addition of T(3). COUP-TF1 enhanced basal expression of both elements but blunted unliganded thyroid hormone receptor enhancement and T(3) repression of nTRE1 but not nTRE2. Both nTREs bound nuclear corepressor and binding increased in response to T(3). Nuclear corepressor knockdown resulted in loss of T(3) repression of both nTRE1 and nTRE2. COUP-TF1, which usually represses T(3) induction of positive thyroid hormone response elements, reverses T(3) repression mediated by nTRE1 in the mouse KBP gene. Endogenous KBP expression is repressed by T(3) and two functional nTREs, both of which are required, have been characterized in the KBP gene. COUP-TF1 may be an important factor to modulate expression of genes that are repressed by T(3). (Endocrinology 152: 1143-1153, 2011)
C1 [Brent, Gregory A.] Vet Affairs Greater Los Angeles Hlth Care Syst, Mol Endocrinol Lab, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90073 USA.
RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst, Mol Endocrinol Lab, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM gbrent@ucla.edu
FU Department of Veterans Affairs; National Institutes of Health [RO1
DK67233]
FX This work was supported by Merit Review funds from the Department of
Veterans Affairs and Grant RO1 DK67233 from the National Institutes of
Health.
NR 63
TC 4
Z9 4
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD MAR
PY 2011
VL 152
IS 3
BP 1143
EP 1153
DI 10.1210/en.2010-0580
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 723QC
UT WOS:000287520900040
PM 21266512
ER
PT J
AU Garavalia, L
Ho, PM
Garavalia, B
Foody, JM
Kruse, H
Spertus, JA
Decker, C
AF Garavalia, Linda
Ho, P. Michael
Garavalia, Brian
Foody, JoAnne M.
Kruse, Heather
Spertus, John A.
Decker, Carole
TI Clinician-patient discord: Exploring differences in perspectives for
discontinuing clopidogrel
SO EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Article
DE Myocardial infarction; Medication discontinuance; Patient-provider
communication; Qualitative research
ID ACUTE CORONARY SYNDROMES; HEALTH BELIEF MODEL; PREMATURE
DISCONTINUATION; MEDICATION; PHYSICIANS; ADHERENCE; OUTCOMES; THERAPY;
COMMUNICATION; METAANALYSIS
AB Background: Premature stopping of anti-platelet therapy has potentially fatal consequences for myocardial infarction (MI) patients who have received a drug-eluting stent (DES). Exploring multiple perspectives to identify contributing factors to the problem is essential.
Aim: We gained patient and clinician perspectives as to why MI patients prematurely stop anti-platelet therapy (clopidogrel) after DES implantation.
Methods: This qualitative, descriptive study of DES-treated MI patients (n=22) and of clinicians (physicians and nurse practitioners; n=17) from multiple U.S. cities used content analysis of interview data. Findings across patients and clinicians were then compared to examine congruent and contrasting reasons for premature clopidogrel discontinuance.
Findings: Patients frequently identified communication and education (e.g. unaware they should be taking clopidogrel, unaware of intended duration of therapy) as the primary reasons for having stopped. Patients rarely cited cost, while clinicians most commonly cited cost as a reason for premature stopping.
Conclusions: The discrepancy in perceptions of patients and clinicians as to the primary reason for early discontinuance suggests an important opportunity for improving persistence. Rather than focusing on the high costs of medications, something outside of their control, physicians should consider communicating more effectively the importance and intended duration of clopidogrel to their patients. (C) 2010 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
C1 [Garavalia, Brian; Spertus, John A.; Decker, Carole] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Garavalia, Linda] Univ Missouri Kansas City, Sch Pharm, Kansas City, MO USA.
[Ho, P. Michael] Univ Colorado Denver, Denver VA Med Ctr, Denver, CO USA.
[Ho, P. Michael] Hlth Sci Ctr, San Antonio, TX USA.
[Foody, JoAnne M.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Kruse, Heather] Univ Missouri Kansas City, Dept Psychol, Kansas City, MO USA.
[Spertus, John A.] Univ Missouri Kansas City, Sch Med, Kansas City, MO USA.
[Decker, Carole] Univ Missouri Kansas City, Sch Nursing, Kansas City, MO USA.
RP Decker, C (reprint author), St Lukes Hosp, Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA.
EM cldecker@saint-lukes.org
FU Sanofi-Aventis; NIH SCCOR [P50 HL077113]
FX Funding was received from Sanofi-Aventis and NIH SCCOR (P50 HL077113)
grants. The sponsors were not involved in the conduct of the study,
analysis of the data, or preparation of the manuscript.
NR 29
TC 11
Z9 11
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1474-5151
J9 EUR J CARDIOVASC NUR
JI Eur. J. Cardiovasc. Nurs.
PD MAR
PY 2011
VL 10
IS 1
BP 50
EP 55
DI 10.1016/j.ejcnurse.2010.04.002
PG 6
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA 734TL
UT WOS:000288361600008
PM 20483665
ER
PT J
AU Hsia, TY
Ringewald, JM
Stroud, RE
Forbus, GA
Bradley, SM
Chung, WK
Spinale, FG
AF Hsia, Tain-Yen
Ringewald, Jeremy M.
Stroud, Robert E.
Forbus, Geoffrey A.
Bradley, Scott M.
Chung, Wendy K.
Spinale, Francis G.
TI Determinants of extracellular matrix remodelling are differentially
expressed in paediatric and adult dilated cardiomyopathy
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Cardiomyopathy; Extracellular matrix; Matrix metalloproteinase;
Paediatrics
ID LEFT-VENTRICULAR FUNCTION; CONGESTIVE-HEART-FAILURE; TISSUE INHIBITORS;
METALLOPROTEINASE INHIBITION; CARDIOPULMONARY BYPASS; RELEASE;
FIBROBLASTS; MYOCARDITIS; INDUCTION; SYSTEM
AB Aims The left ventricular phenotype of idiopathic dilated cardiomyopathy (DCM) can appear similar in paediatric and adult patients. However, the aetiology of paediatric DCM is usually idiopathic, and often leads an aggressive clinical course. A structural underpinning of DCM is extracellular matrix changes, which are determined by a balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs). This study tested the hypothesis that different MMP/TIMP profiles occur in paediatric and adult DCM patients.
Methods and results Left ventricular samples from paediatric (age 9 +/- 5 years; n = 10) and adult (age 62 +/- 3 years; n = 20) DCM (at time of transplant) were subjected to an MMP/TIMP multiplex array and immunoassay in order to measure the MMP subclasses; collagenases (MMP-8, -13), gelatinases (MMP-2, -9), stromelysin/matrilysin (MMP-3, -7), membrane type (MT1-MMP), as well as for the four known TIMPs. MMP-8 and -9 levels increased by over 150% (P < 0.05), whereas MMP-3 and -7 levels decreased by over 30% (P < 0.05) in paediatric DCM when compared with adult DCM. TIMP-1 and -2 levels increased two-fold (P < 0.05), but TIMP-3 fell by 41% (P < 0.05) in paediatric DCM. Myocardial levels of specific interleukins (IL-1beta, IL-2, IL-8) were increased by approximately 50% in paediatric DCM.
Conclusions These unique findings demonstrated that a specific MMP/TIMP profile occurs in paediatric DCM when compared with adult DCM, and that local cytokine induction may contribute to this process. These distinct differences in the determinants of myocardial matrix structure and function may contribute to the natural history of DCM in children.
C1 [Hsia, Tain-Yen; Ringewald, Jeremy M.; Stroud, Robert E.; Forbus, Geoffrey A.; Bradley, Scott M.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29403 USA.
[Hsia, Tain-Yen; Ringewald, Jeremy M.; Stroud, Robert E.; Forbus, Geoffrey A.; Bradley, Scott M.; Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Chung, Wendy K.] Columbia Univ, Dept Pediat, New York, NY 10027 USA.
RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, 114 Doughty St, Charleston, SC 29403 USA.
EM wilburnm@musc.edu
FU NIH [HL059165-09, HL057952-08]; Veterans' Affairs Health Administration;
Children's Cardiomyopathy Foundation, USA
FX This work was supported by NIH grants HL059165-09, HL057952-08, a Merit
Award from the Veterans' Affairs Health Administration and the
Children's Cardiomyopathy Foundation, USA.
NR 33
TC 6
Z9 7
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAR
PY 2011
VL 13
IS 3
BP 271
EP 277
DI 10.1093/eurjhf/hfq184
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 723HG
UT WOS:000287496800007
PM 21147820
ER
PT J
AU Sandoval, KE
Farr, SA
Banks, WA
Niehoff, ML
Morley, JE
Crider, AM
Witt, KA
AF Sandoval, Karin E.
Farr, Susan A.
Banks, William A.
Niehoff, Michael L.
Morley, John E.
Crider, Albert M.
Witt, Ken A.
TI Chronic peripheral administration of somatostatin receptor subtype-4
agonist NNC 26-9100 enhances learning and memory in SAMP8 mice
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Somatostatin subtype-4 receptor agonist; NNC 26-9100; Alzheimer's
disease; Learning; Memory
ID AMYLOID-BETA PEPTIDE; BLOOD-BRAIN-BARRIER; FOOTSHOCK AVOIDANCE
ACQUISITION; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE;
SENILE-DEMENTIA; A-BETA; PROTEIN; NEPRILYSIN; RETENTION
AB Selective somatostatin receptor subtype agonists have been proposed as a means to mitigate learning and memory loss associated with Alzheimer's disease. The first aim of this study evaluated blood-to-brain transport and regional brain distribution of NNC 26-9100, a selective somatostatin subtype-4 (sst4) receptor agonist. The entry rate of I-131-NNC 26-9100 was K-i = 0.25 mu l/g min, with an similar to 93% association with the parenchymal component. The second goal of this study was to evaluate the effect of chronic NNC 26-9100 administration (i.p.) on learning and memory, brain A beta(x-42) levels, and protein expression of sst4 receptor and amyloid precursor protein (APP) in the senescence-accelerated mouse p8 (SAMP8) model of Alzheimer's disease. Mice chronically treated with NNC 26-9100 showed improved learning (day 21) and memory (day 28) using the T-maze paradigm (20 and 200 mu g). Ex vivo tissue analyses showed a decline in A beta(x-42) levels at the 20 mu g dose, while no alterations were observed in sst4 receptor or APP protein expression compared to vehicle controls. These findings indicate NNC 26-9100 is taken up into key brain regions associated with learning and memory. Furthermore, chronic administration of NNC 26-9100 improved learning and memory and decreased A beta(x-42) brain levels. These results suggest sst4 receptor agonists may provide a viable therapy in the treatment of Alzheimer's disease and other forms of cognitive impairment. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Witt, Ken A.] So Illinois Univ, Sch Pharm, Dept Pharmaceut Sci, Edwardsville, IL 62026 USA.
[Farr, Susan A.; Niehoff, Michael L.; Morley, John E.] Vet Affairs Med Ctr St Louis, Ctr Geriatr Res Educ & Clin, St Louis, MO USA.
[Farr, Susan A.; Niehoff, Michael L.; Morley, John E.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Witt, KA (reprint author), So Illinois Univ, Sch Pharm, Dept Pharmaceut Sci, Campus Box 2000, Edwardsville, IL 62026 USA.
EM kwitt@siue.edu
RI morley, john/F-9177-2011
OI morley, john/0000-0001-6444-2965
FU Alzheimer's Drug Discovery Foundation [261105.01]; VA; National
Institutes of Health National Institute on Aging [R21AG029318]
FX This work was supported by the Alzheimer's Drug Discovery Foundation
(Grant: 261105.01), VA merit review, and the National Institutes of
Health National Institute on Aging (Grant: R21AG029318).
NR 42
TC 11
Z9 13
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAR 1
PY 2011
VL 654
IS 1
BP 53
EP 59
DI 10.1016/j.ejphar.2010.12.013
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 720OY
UT WOS:000287291200008
PM 21185826
ER
PT J
AU Bubber, P
Hartounian, V
Gibson, GE
Blass, JP
AF Bubber, P.
Hartounian, V.
Gibson, G. E.
Blass, J. P.
TI Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of
schizophrenia patients
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE Mitochondria; Tricarboxylic acid cycle; Energy metabolism; Postmortem
interval; Schizophrenia
ID ALPHA-KETOGLUTARATE DEHYDROGENASE; MITOCHONDRIAL DYSFUNCTION;
ALZHEIMERS-DISEASE; OXIDATIVE STRESS; GLUCOSE-TOLERANCE; PREFRONTAL
CORTEX; ENZYMES; METABOLISM; COMPLEX; GLYCOLYSIS
AB Images of brain metabolism and measurements of activities of components of the electron transport chain support earlier studies that suggest that brain glucose oxidation is inherently abnormal in a significant proportion of persons with schizophrenia. Therefore, we measured the activities of enzymes of the tricarboxylic (TCA) cycle in dorsolateral-prefrontal-cortex from schizophrenia patients (N=13) and non-psychiatric disease controls (N=13): the pyruvate dehydrogenase complex (PDHC), citrate synthase (CS), aconitase, isocitrate dehydrogenase (ICDH), the alpha-ketoglutarate dehydrogenase complex (KGDHC), succinate thiokinase (STH), succinate dehydrogenase (SDH), fumarase and malate dehydrogenase (MDH). Activities of aconitase (18.4%, p<0.05), KGDHC (26%) and STH (28.2%, p<0.05), enzymes in the first half of the TCA cycle, were lower, but SDH (18.3%, p<0.05) and MDH (34%, p<0.005), enzymes in the second half, were higher than controls. PDHC, CS, ICDH and fumarase activities were unchanged. There were no significant correlations between enzymes of TCA cycle and cognitive function, age or choline acetyl transferase activity, except for aconitase activity which decreased slightly with age (r = 0.55, p = 003). The increased activities of dehydrogenases in the second half of the TCA cycle may reflect a compensatory response to reduced activities of enzymes in the first half. Such alterations in the components of TCA cycle are adequate to alter the rate of brain metabolism. These results are consistent with the imaging studies of hypometabolism in schizophrenia. They suggest that deficiencies in mitochondrial enzymes can be associated with mental disease that takes the form of schizophrenia. (C) 2010 Elsevier B.V. and ECNP. All rights reserved.
C1 [Gibson, G. E.] Cornell Univ, Weill Cornell Med Sch, Burke Med Res Inst, Weill Med Coll, White Plains, NY 10605 USA.
[Hartounian, V.] Mt Sinai Sch Med, New York, NY USA.
[Hartounian, V.] Bronx Vet Affairs Med Ctr, MIRECC, Bronx, NY 10468 USA.
RP Gibson, GE (reprint author), Cornell Univ, Weill Cornell Med Sch, Burke Med Res Inst, Weill Med Coll, 785 Mamaroneck Ave, White Plains, NY 10605 USA.
EM ggibson@med.cornell.edu
FU Burke Medical Research Institute; NIH [AG14600, AG11921, AG14930];
[MH064673]; [MH066392]
FX This work was supported by grants MH064673 and MH066392, AG14600,
AG11921, AG14930, AG11921 and Burke Medical Research Institute. The
funding sources were not involved in study design, collection analysis
or interpretation of the data, the writing of the report nor submission
to Schizophrenia Research.; This work was supported by NIH grants
AG14600, AG11921 and AG14930.
NR 49
TC 28
Z9 29
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
EI 1873-7862
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD MAR
PY 2011
VL 21
IS 3
BP 254
EP 260
DI 10.1016/j.euroneuro.2010.10.007
PG 7
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 728UU
UT WOS:000287900800005
PM 21123035
ER
PT J
AU Bhattacharya, A
Lustgarten, M
Shi, Y
Liu, YH
Jang, YC
Pulliam, D
Jernigan, AL
Van Remmen, H
AF Bhattacharya, Arunabh
Lustgarten, Michael
Shi, Yun
Liu, Yuhong
Jang, Youngmok C.
Pulliam, Daniel
Jernigan, Amanda L.
Van Remmen, Holly
TI Increased mitochondrial matrix-directed superoxide production by fatty
acid hydroperoxides in skeletal muscle mitochondria
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Oxidative stress; Superoxide; Fatty acid hydroperoxides; Hydrogen
peroxide; Mitochondria; Free radicals
ID ELECTRON-TRANSPORT CHAIN; RAT-HEART MITOCHONDRIA; NADH-UBIQUINONE
OXIDOREDUCTASE; OXYGEN SPECIES PRODUCTION; REACTIVE OXYGEN; COMPLEX-I;
ARACHIDONIC-ACID; OXIDATIVE STRESS; BRAIN MITOCHONDRIA; RESPIRATORY
CHAIN
AB Previous studies have shown that muscle atrophy is associated with mitochondrial dysfunction and an increased rate of mitochondrial reactive oxygen species production. We recently demonstrated that fatty acid hydroperoxides (FA-OOHs) are significantly elevated in mitochondria isolated from atrophied muscles. The purpose of this study was to determine whether FA-OOHs can alter skeletal muscle mitochondrial function. We found that FA-OOHs (at low-micromolar concentrations) induce mitochondrial dysfunction assessed by a decrease in the rate of ATP production, oxygen consumption, and activity of respiratory chain complexes land Ill. Using methods to distinguish superoxide release toward the matrix and toward the intermembrane space, we demonstrate that FA-OOHs significantly elevate oxidative stress in the mitochondrial matrix (and not the intermembrane space), with complex I as the major site of superoxide production (most probably from a site upstream of the ubiquinone binding site but downstream from the flavin binding site the-iron sulfur clusters). Our results are the first to indicate that FA-OOHs are, important modulators of mitochondrial function and oxidative stress in skeletal muscle mitochondria and may play an important role in muscle atrophies that are associated with increased generation of FA-OOHs, e.g., denervation-induced muscle atrophy. (C) 2010 Published by Elsevier Inc.
C1 [Bhattacharya, Arunabh; Lustgarten, Michael; Shi, Yun; Liu, Yuhong; Jang, Youngmok C.; Pulliam, Daniel; Jernigan, Amanda L.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Bhattacharya, Arunabh; Liu, Yuhong; Pulliam, Daniel; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Shi, Yun; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
EM vanremmen@uthscsa.edu
FU National Institute of Aging [AG20591]; Muscular Dystrophy Association
[MDA 10047]
FX This work was supported by the National Institute of Aging (Grant
AG20591 to H.V.R.) and the Muscular Dystrophy Association (Grant MDA
10047 to H.V.R.). We greatly appreciate the editorial support provided
by Ms. Corinne Price.
NR 67
TC 10
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAR 1
PY 2011
VL 50
IS 5
BP 592
EP 601
DI 10.1016/j.freeradbiomed.2010.12.014
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 719BQ
UT WOS:000287174700005
PM 21172427
ER
PT J
AU Lugea, A
Tischler, D
Nguyen, J
Gong, J
Gukovsky, I
French, SW
Gorelick, FS
Pandol, SJ
AF Lugea, Aurelia
Tischler, David
Nguyen, Janie
Gong, Jun
Gukovsky, Ilya
French, Samuel W.
Gorelick, Fred S.
Pandol, Stephen J.
TI BASIC-LIVER, PANCREAS, AND BILIARY TRACT
SO GASTROENTEROLOGY
LA English
DT Article
DE Alcohol Disease; Transcription Factors; ER Protein Folding; Organelle
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; OXIDATIVE
STRESS; TRANSCRIPTION FACTOR; ER STRESS; TRANSLATIONAL CONTROL;
IN-VITRO; ETHANOL; XBP1; CELL
AB BACKGROUND & AIMS: Endoplasmic reticulum (ER) stress responses (collectively known the unfolded protein response [UPR]) have important roles in several human disorders, but their contribution to alcoholic pancreatitis is not known. We investigated the role of X-box binding protein 1 (XBP1), a UPR regulator, in prevention of alcohol-induced ER stress in the exocrine pancreas. METHODS: Wild-type and Xbp1(+/-) mice were fed control or ethanol diets for 4 weeks. Pancreatic tissue samples were then examined by light and electron microscopy to determine pancreatic alterations; UPR regulators were analyzed biochemically. RESULTS: In wild-type mice, ethanol activated a UPR, increasing pancreatic levels of XBP1 and XBP1 targets such as protein disulfide isomerase (PDI). In these mice, pancreatic damage was minor. In ethanol-fed Xbp1(+/-) mice, XBP1 and PDI levels were significantly lower than in ethanol-fed-wild-type mice. The combination of XBP1 deficiency and ethanol feeding reduced expression of regulators of ER function and the up-regulation of proapoptotic signals. Moreover, ethanol feeding induced oxidation of PDI, which might compromise PDI-mediated disulfide bond formation during ER protein folding. In ethanol-fed Xbp1(+/-) mice, ER stress was associated with disorganized and dilated ER, loss of zymogen granules, accumulation of autophagic vacuoles, and increased acinar cell death. CONCLUSIONS: Long-term ethanol feeding causes oxidative ER stress, which activates a UPR and increases XBP1 levels and activity. A defective UPR due to XBP1 deficiency results in ER dysfunction and acinar cell pathology.
C1 [Lugea, Aurelia; Tischler, David; Nguyen, Janie; Gong, Jun; Gukovsky, Ilya; Pandol, Stephen J.] Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, So Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA 90073 USA.
[French, Samuel W.] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA.
[Gorelick, Fred S.] Yale Univ, VA Med Ctr, West Haven, CT USA.
RP Lugea, A (reprint author), Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, So Calif Res Ctr ALPD & Cirrhosis, 11301 Wilshire Blvd,Bldg 258,R339, Los Angeles, CA 90073 USA.
EM alugea@ucla.edu
FU National Institute on Alcohol Abuse and Alcoholism [R21 AA016010];
National Center for Complementary and Alternative Medicine
[1P01AT003960]
FX Supported by the National Institute on Alcohol Abuse and Alcoholism
(grant R21 AA016010) and the National Center for Complementary and
Alternative Medicine (grant 1P01AT003960).
NR 53
TC 49
Z9 50
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAR
PY 2011
VL 140
IS 3
BP 987
EP U415
DI 10.1053/j.gastro.2010.11.038
PG 19
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 730EC
UT WOS:000288014700039
PM 21111739
ER
PT J
AU Zatzick, D
Rivara, F
Jurkovich, G
Russo, J
Trusz, SG
Wang, J
Wagner, A
Stephens, K
Dunn, C
Uehara, E
Petrie, M
Engel, C
Davydow, D
Katon, W
AF Zatzick, Douglas
Rivara, Frederick
Jurkovich, Gregory
Russo, Joan
Trusz, Sarah Geiss
Wang, Jin
Wagner, Amy
Stephens, Kari
Dunn, Chris
Uehara, Edwina
Petrie, Megan
Engel, Charles
Davydow, Dimitri
Katon, Wayne
TI Enhancing the population impact of collaborative care interventions:
mixed method development and implementation of stepped care targeting
posttraumatic stress disorder and related comorbidities after acute
trauma
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE PTSD; Stepped collaborative care; Acute care; Population impact;
Traumatic injury
ID RANDOMIZED CONTROLLED-TRIAL; POST-CABG DEPRESSION; FUNCTIONAL OUTCOMES;
ANXIETY DISORDERS; PREVENTIVE INTERVENTIONS; BEHAVIORAL ACTIVATION;
CLINICAL-RESEARCH; PHYSICAL INJURY; ALCOHOL-ABUSE; FOLLOW-UP
AB Objective: The objective of the study was to develop and implement a stepped collaborative care intervention targeting posttraumatic stress disorder (PTSD) and related comorbidities to enhance the population impact of early trauma-focused interventions.
Method: We describe the design and implementation of the Trauma Survivors Outcomes and Support study. An interdisciplinary treatment development team was composed of trauma surgical, clinical psychiatric and mental health services "change agents" who spanned the boundaries between frontline trauma center clinical care and acute care policy. Mixed method clinical epidemiologic and clinical ethnographic studies informed the development of PTSD screening and intervention procedures.
Results: Two hundred seven acutely injured trauma survivors with high early PTSD symptom levels were randomized into the study. The stepped collaborative care model integrated care management (i.e., posttraumatic concern elicitation and amelioration, motivational interviewing and behavioral activation) with cognitive behavioral therapy and pharmacotherapy targeting PTSD. The model was feasibly implemented by frontline acute care masters in social work and nurse practioner providers.
Conclusions: Stepped care protocols targeting PTSD may enhance the population impact of early interventions developed for survivors of individual and mass trauma by extending the reach of collaborative care interventions to acute care medical settings and other nonspecialty posttraumatic contexts. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Zatzick, Douglas; Dunn, Chris] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA.
[Rivara, Frederick] Univ Washington, Sch Med, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA.
[Jurkovich, Gregory] Univ Washington, Sch Med, Dept Surg, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA.
[Russo, Joan; Davydow, Dimitri; Katon, Wayne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Trusz, Sarah Geiss; Stephens, Kari; Petrie, Megan] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA.
[Wang, Jin] Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA.
[Wagner, Amy] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97207 USA.
[Uehara, Edwina] Univ Washington, Sch Med, Sch Social Work, Seattle, WA 98104 USA.
[Engel, Charles] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA.
RP Zatzick, D (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA.
EM dzatzick@u.washington.edu
FU National Institute of Mental Health [MH073613, MH086814]
FX This work was funded by grants MH073613 and MH086814 from the National
Institute of Mental Health. The authors thank Jeffrey Love, B.A., for
his assistance with the preparation of the manuscript. The views
expressed in this article are those of the authors and do not reflect
official policy or position of the Department of the Army, The
Department of Defense, or any other U.S. Government agency or
department.
NR 138
TC 31
Z9 31
U1 12
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAR-APR
PY 2011
VL 33
IS 2
BP 123
EP 134
DI 10.1016/j.genhosppsych.2011.01.001
PG 12
WC Psychiatry
SC Psychiatry
GA 745RP
UT WOS:000289183700006
PM 21596205
ER
PT J
AU Subramanian, S
Yates, M
Vandenbark, AA
Offner, H
AF Subramanian, Sandhya
Yates, Melissa
Vandenbark, Arthur A.
Offner, Halina
TI Oestrogen-mediated protection of experimental autoimmune
encephalomyelitis in the absence of Foxp3+regulatory T cells implicates
compensatory pathways including regulatory B cells
SO IMMUNOLOGY
LA English
DT Article
DE B cells; experimental autoimmune encephalomyelitis; Foxp3-DTR; Foxp3;
oestrogen
ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; PRODUCE
CXCL13; CUTTING EDGE; MICE; INDUCTION; TOLERANCE; ARTHRITIS; RESPONSES;
SEVERITY
AB P>Oestrogen (17 beta-oestradiol, E(2)) is a highly effective treatment for experimental autoimmune encephalomyelitis (EAE) that may potentiate Foxp3+ regulatory T (Treg) cells, which in turn limit the expansion of encephalitogenic T-cell specificities. To determine if Treg cells constitute the major non-redundant protective pathway for E(2), we evaluated E(2) protection of EAE after targeted deletion of Foxp3 expression in Foxp3-DTR mice. Unexpectedly, E(2)-treated Foxp3-deficient mice were completely protected against clinical and histological myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide-induced EAE before succumbing to diphtheria toxin-induced mortality. This finding indicated the presence of alternative E(2)-dependent EAE-protective pathways that could compensate for the lack of Treg cells. Further investigation revealed that E(2) treatment inhibited proliferation and expression of CCL2 and CXCL2, but enhanced secretion of interleukin-10 (IL-10) and IL-13 by MOG-35-55-specific spleen cells. These changes occurred concomitantly with increased expression of several chemokines and receptors, including CXCL13 and CXCR5, and the negative co-activation molecules, PD-L1 and B7.2, by B cells and dendritic cells. Furthermore, E(2) treatment resulted in higher percentages of spleen and lymph node T cells expressing IL-17, interferon-gamma and tumour necrosis factor-alpha, but with lower expression of CCR6, suggesting sequestration of MOG-35-55 peptide-specific T cells in peripheral immune organs. Taken together, these data suggest that E(2)-induced mechanisms that provide protection against EAE in the absence of Foxp3+ Treg cells include induction of regulatory B cells and peripheral sequestration of encephalitogenic T cells.
C1 [Subramanian, Sandhya; Yates, Melissa; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA.
[Yates, Melissa; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
[Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU National Institutes of Health [NS45445, NS49210]; National Multiple
Sclerosis Society [RG3405-C-6, FG1832-A-1]; Biomedical Laboratory R&D
Service, Department of Veterans' Affairs
FX The authors wish to thank Dr Sushmita Sinha for helpful discussions and
Ms Eva Niehaus for assistance with manuscript preparation. This work was
supported by National Institutes of Health grants NS45445 and NS49210;
National Multiple Sclerosis Society grant RG3405-C-6; and the Biomedical
Laboratory R&D Service, Department of Veterans' Affairs. Dr Melissa
Yates is a Postdoctoral Fellow of the National Multiple Sclerosis
Society and this work was supported in part by the National Multiple
Sclerosis Society Postdoctoral Fellowship FG1832-A-1.
NR 37
TC 24
Z9 28
U1 1
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD MAR
PY 2011
VL 132
IS 3
BP 340
EP 347
DI 10.1111/j.1365-2567.2010.03380.x
PG 8
WC Immunology
SC Immunology
GA 714WI
UT WOS:000286839300004
PM 21091909
ER
PT J
AU Wu, XX
Patki, A
Lara-Castro, C
Cui, XQ
Zhang, K
Walton, RG
Osier, MV
Gadbury, GL
Allison, DB
Martin, M
Garvey, WT
AF Wu, Xuxia
Patki, Amit
Lara-Castro, Cristina
Cui, Xiangqin
Zhang, Kui
Walton, R. Grace
Osier, Michael V.
Gadbury, Gary L.
Allison, David B.
Martin, Mitchell
Garvey, W. Timothy
TI Genes and biochemical pathways in human skeletal muscle affecting
resting energy expenditure and fuel partitioning
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE microarray; human; skeletal muscle; G protein-coupled receptor;
ubiquitin; protein phosphatase 2A; mitochondrial function; respiratory
quotient
ID BODY-WEIGHT GAIN; BROWN ADIPOSE-TISSUE; BETA-ADRENERGIC-BLOCKADE;
PROTEIN MESSENGER-RNA; METABOLIC-RATE; UNCOUPLING PROTEINS; RESPIRATORY
QUOTIENT; UBIQUITIN-PROTEASOME; INSULIN-RESISTANCE; DIABETES-MELLITUS
AB Wu X, Patki A, Lara-Castro C, Cui X, Zhang K, Walton RG, Osier MV, Gadbury GL, Allison DB, Martin M, Garvey WT. Genes and biochemical pathways in human skeletal muscle affecting resting energy expenditure and fuel partitioning. J Appl Physiol 110: 746-755, 2011. First published November 25, 2010; doi:10.1152/japplphysiol.00293.2010.-Genes influencing resting energy expenditure (REE) and respiratory quotient (RQ) represent candidate genes for obesity and the metabolic syndrome because of the involvement of these traits in energy balance and substrate oxidation. We aim to explore the molecular basis for individual variation in REE and fuel partitioning as reflected by RQ. We performed microarray studies in human vastus lateralis muscle biopsies from 40 healthy subjects with measured REE and RQ values. We identified 2,392 and 1,115 genes significantly correlated with REE and RQ, respectively. Genes correlated with REE and RQ encompass a broad array of functions, including carbohydrate and lipid metabolism, gene expression, mitochondrial processes, and membrane transport. Microarray pathway analysis revealed that REE was positively correlated with upregulation of G protein-coupled receptor signaling (meet criteria/total genes: 65 of 283) involved in autonomic nervous system functions, including those receptors mediating adrenergic, dopamine, gamma-aminobutyric acid (GABA), neuropeptide Y (NPY), and serotonin action (meet criteria/total genes: 46 of 176). Reduced REE was associated with an increase in genes participating in ubiquitin-proteasome-dependent proteolytic pathways (58 of 232). Serine-type peptidase activity (9 of 76) was positively correlated with RQ, while genes involved in the protein phosphatase type 2A complex (4 of 9), mitochondrial function and cellular respiration (38 of 315), and unfolded protein binding (19 of 97) were associated with reduced RQ values and a preference for lipid fuel metabolism. Individual variations in whole body REE and RQ are regulated by differential expressions of specific genes and pathways intrinsic to skeletal muscle.
C1 [Wu, Xuxia; Lara-Castro, Cristina; Walton, R. Grace; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Patki, Amit; Cui, Xiangqin; Zhang, Kui; Allison, David B.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Osier, Michael V.] Rochester Inst Technol, Sch Biol & Med Sci, Rochester, NY 14623 USA.
[Gadbury, Gary L.] Kansas State Univ, Dept Stat, Manhattan, KS 66506 USA.
[Martin, Mitchell] Roche, Mol Med Labs, Nutley, NJ USA.
RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA.
EM garveyt@uab.edu
OI Cui, Xiangqin/0000-0003-0621-9313; Allison, David/0000-0003-3566-9399
FU National Institutes of Health [DK-038764, DK-083562, HL-055782];
American Heart Association; Department of Veterans Affairs; University
of Alabama at Birmingham (UAB) Center for Clinical and Translational
Science [UL1-RR-025777]; UAB Nutrition and Obesity Research Center
[P30-DK-56336]; UAB Diabetes Research and Training Center
[P60-DK-079626]
FX This work was supported by grants from the National Institutes of Health
(DK-038764, DK-083562, and HL-055782 to W. T. Garvey), by an American
Heart Association Beginning Grant-in-Aid (X. Wu), and by the Merit
Review program of the Department of Veterans Affairs (W. T. Garvey). We
gratefully acknowledge the support of the research core facilities of
the University of Alabama at Birmingham (UAB) Center for Clinical and
Translational Science (UL1-RR-025777), the UAB Nutrition and Obesity
Research Center (P30-DK-56336), and the UAB Diabetes Research and
Training Center (P60-DK-079626).
NR 78
TC 8
Z9 8
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD MAR
PY 2011
VL 110
IS 3
BP 746
EP 755
DI 10.1152/japplphysiol.00293.2010
PG 10
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 731RN
UT WOS:000288127100023
PM 21109598
ER
PT J
AU Porterfield, JE
Larson, ER
Jenkins, JT
Escobedo, D
Valvano, JW
Pearce, JA
Feldman, MD
AF Porterfield, John E.
Larson, Erik R.
Jenkins, James T.
Escobedo, Daniel
Valvano, Jonathan W.
Pearce, John A.
Feldman, Marc D.
TI Left ventricular epicardial admittance measurement for detection of
acute LV dilation
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE early detection of heart failure; bioimpedance; left ventricular
preload; end-diastolic volume; conductance
ID CHRONIC HEART-FAILURE; CARDIAC-RESYNCHRONIZATION; IMPLANTABLE
DEFIBRILLATOR; CONDUCTANCE CATHETER; HEMODYNAMIC MONITOR; VOLUME;
SYSTEM; ALPHA; RESISTIVITY; FEASIBILITY
AB There are two implanted heart failure warning systems incorporated into biventricular pacemakers/automatic implantable cardiac defibrillators and tested in clinical trials: right heart pressures, and lung conductance measurements. However, both warning systems postdate measures of the earliest indicator of impending heart failure: left ventricular (LV) volume. There are currently no proposed implanted technologies that can perform LV blood volume measurements in humans. We propose to solve this problem by incorporating an admittance measurement system onto currently deployed biventricular and automatic implantable cardiac defibrillator leads. This study will demonstrate that an admittance measurement system can detect LV blood conductance from the epicardial position, despite the current generating and sensing electrodes being in constant motion with the heart, and with dynamic removal of the myocardial component of the returning voltage signal. Specifically, in 11 pigs, it will be demonstrated that 1) a physiological LV blood conductance signal can be derived; 2) LV dilation in response to dose-response intravenous neosynephrine can be detected by blood conductance in a similar fashion to the standard of endocardial crystals when admittance is used, but not when only traditional conductance is used; 3) the physiological impact of acute left anterior descending coronary artery occlusion and resultant LV dilation can be detected by blood conductance, before the anticipated secondary rise in right ventricular systolic pressure; and 4) a pleural effusion simulated by placing saline outside the pericardium does not serve as a source of artifact for blood conductance measurements.
C1 [Jenkins, James T.; Escobedo, Daniel; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78248 USA.
[Porterfield, John E.; Larson, Erik R.; Valvano, Jonathan W.; Pearce, John A.] Univ Texas Austin, Austin, TX 78712 USA.
[Jenkins, James T.; Escobedo, Daniel; Feldman, Marc D.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Rm 5-642,7703 Floyd Curl Dr, San Antonio, TX 78248 USA.
EM feldmanm@uthscsa.edu
FU National Institutes of Health [R21 HL 079926]; National Center for
Research Resources [UL 1RR025767]; University of Texas Health Science
Center in San Antonio (Biscoe Division of Cardiology and South Texas
Technology Management); Medtronic Corporation (Minneapolis, MN)
FX This study was supported in part by National Institutes of Health Grant
R21 HL 079926, Grant UL 1RR025767 from the National Center for Research
Resources, and grants from the University of Texas Health Science Center
in San Antonio (Biscoe Division of Cardiology and South Texas Technology
Management). Research was funded in part by a grant given by Medtronic
Corporation (Minneapolis, MN).
NR 33
TC 3
Z9 3
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD MAR
PY 2011
VL 110
IS 3
BP 799
EP 806
DI 10.1152/japplphysiol.01047.2010
PG 8
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 731RN
UT WOS:000288127100029
PM 21148342
ER
PT J
AU Zhao, XF
Burger, M
Liu, Y
Das, MK
Combs, W
Wenk, JF
Guccione, JM
Kassab, GS
AF Zhao, Xuefeng
Burger, Mike
Liu, Yi
Das, Mithilesh K.
Combs, William
Wenk, Jonathan F.
Guccione, Julius M.
Kassab, Ghassan S.
TI Simulation of LV Pacemaker Lead in Marginal Vein: Potential Risk Factors
for Acute Dislodgement
SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
DE pacing lead; lead dislodgement; dynamic analysis
ID CORONARY-SINUS; STABILITY; MODEL
AB Although left ventricular (LV) coronary sinus lead dislodgement remains a problem, the risk factors for dislodgement have not been clearly defined. In order to identify potential risk factors for acute lead dislodgement, we conducted dynamic finite element simulations of pacemaker lead dislodgement in marginal LV vein. We considered factors such as mismatch in lead and vein diameters, velocity of myocardial motion, branch angle between the insertion vein and the coronary sinus, degree of slack, and depth of insertion. The results show that large lead-to-vein diameter mismatch, rapid myocardial motion, and superficial insertion are potential risk factors for lead dislodgement. In addition, the degree of slack presents either a positive or negative effect on dislodgement risk depending on the branch angle. The prevention of acute lead dislodgment can be enforced by inducing as much static friction force as possible at the lead-vein interface, while reducing the external force. If the latter exceeds the former, dislodgement will occur. The present findings underscore the major risk factors for lead dislodgment, which may improve implantation criterion and future lead design. [DOI: 10.1115/1.4003323]
C1 [Kassab, Ghassan S.] Indiana Univ Purdue Univ Indianapolis, Dept Surg, Indianapolis, IN 46202 USA.
[Kassab, Ghassan S.] Indiana Univ Purdue Univ Indianapolis, Dept Biomed Engn, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
[Burger, Mike] Livermore Software Technol Corp, Livermore, CA 94550 USA.
[Das, Mithilesh K.] Indiana Univ Sch Med, Roudebush VA Med Ctr, Krannert Inst Cardiol, Indianapolis, IN 46202 USA.
[Wenk, Jonathan F.; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA.
[Wenk, Jonathan F.; Guccione, Julius M.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Kassab, GS (reprint author), Indiana Univ Purdue Univ Indianapolis, Dept Surg, Indianapolis, IN 46202 USA.
EM gkassab@iupui.edu
RI Zhao, Xuefeng/A-3260-2013
OI Zhao, Xuefeng/0000-0003-3834-9091
NR 10
TC 2
Z9 2
U1 0
U2 0
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0148-0731
J9 J BIOMECH ENG-T ASME
JI J. Biomech. Eng.-Trans. ASME
PD MAR
PY 2011
VL 133
IS 3
AR 031006
DI 10.1115/1.4003323
PG 7
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 718BY
UT WOS:000287096100006
ER
PT J
AU McCurdy, MR
Sharafkhaneh, A
Abdel-Monem, H
Rojo, J
Tittel, FK
AF McCurdy, Matthew R.
Sharafkhaneh, Amir
Abdel-Monem, Hanan
Rojo, Javier
Tittel, Frank K.
TI Exhaled nitric oxide parameters and functional capacity in chronic
obstructive pulmonary disease
SO JOURNAL OF BREATH RESEARCH
LA English
DT Article
ID COPD; ASTHMA; EXCHANGE; BIOMARKERS; DIFFUSION; MARKERS; MODEL; AIR
AB The extended exhaled nitric oxide (eNO) parameters, including peripheral or alveolar eNO, are investigational biomarkers in COPD. In this study, the hypothesis was tested that elevated peripheral eNO correlates with decreased functional capacity and lower global health status. Twenty-seven subjects with the Global Initiative for Chronic Obstructive Lung Disease stage 3 and 4 COPD were enrolled. Functional capacity and health status were tested using the 6 min walk test and St George's Respiratory Questionnaire (SGRQ) respectively. eNO parameters were estimated using multiple exhalation flow rates and were corrected for axial diffusion. The extended NO measurements were FE(NO)0.05 14.2 ppb (range 5.1-23.2), C(ANO) 4.6 ppb (2.2-6.9), D(awNO) 8.8 ml s(-1) (4.8-12.9), C(awNO) 83.2 ppb (29.9-128.7) and J'(awNO) 405 pl s(-1) (111-731). The distance traveled in the 6 min walk test was correlated with peripheral nitric oxide (r = -0.59, p = 0.03). SGRQ symptom score was correlated with maximum airway NO flux (r = -0.73, p = 0.01). SGRQ total score was correlated with maximum airway NO flux (r = -0.56, p = 0.05). In this study of subjects with severe COPD, peripheral nitric oxide correlated with functional capacity while large airway NO parameters correlated with symptom scores.
C1 [McCurdy, Matthew R.; Tittel, Frank K.] Rice Univ, Rice Quantum Inst, Houston, TX 77251 USA.
[McCurdy, Matthew R.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Radiat Oncol, Houston, TX 77030 USA.
[Sharafkhaneh, Amir; Abdel-Monem, Hanan] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Pulm Crit Care & Sleep Med, Houston, TX 77030 USA.
[Rojo, Javier] Rice Univ, Dept Stat, Houston, TX 77251 USA.
RP Tittel, FK (reprint author), Rice Univ, Rice Quantum Inst, Houston, TX 77251 USA.
EM fkt@rice.edu
NR 34
TC 28
Z9 28
U1 0
U2 4
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 1752-7155
J9 J BREATH RES
JI J. Breath Res.
PD MAR
PY 2011
VL 5
IS 1
AR 016003
DI 10.1088/1752-7155/5/1/016003
PG 6
WC Biochemical Research Methods; Respiratory System
SC Biochemistry & Molecular Biology; Respiratory System
GA 732SM
UT WOS:000288210000004
PM 21378438
ER
PT J
AU Shih, YYI
Wey, HY
De La Garza, BH
Duong, TQ
AF Shih, Yen-Yu I.
Wey, Hsiao-Ying
De La Garza, Bryan H.
Duong, Timothy Q.
TI Striatal and cortical BOLD, blood flow, blood volume, oxygen
consumption, and glucose consumption changes in noxious forepaw
electrical stimulation
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE CBF; CBV; CMRglc; CMRO(2); high-field fMRI; striatum
ID FUNCTIONAL MRI; BASAL GANGLIA; SOMATOSENSORY STIMULATION;
NEURONAL-ACTIVITY; NEURAL ACTIVITY; RAT; FMRI; ORGANIZATION; ARTERIAL;
DYNAMICS
AB Recent reports showed noxious forepaw stimulation in rats evoked an unexpected sustained decrease in cerebral blood volume (CBV) in the bilateral striatum, whereas increases in spike activity and Fos-immunoreactive cells were observed. This study aimed to further evaluate the hemodynamic and metabolic needs in this model and the sources of negative functional magnetic resonance imaging (fMRI) signals by measuring blood oxygenation-level-dependent (BOLD), cerebral-blood-flow (CBF), CBV, and oxygen-consumption (i.e., cerebral metabolic rate of oxygen (CMRO(2))) changes using an 11.7-T MRI scanner, and glucose-consumption (i.e., cerebral metabolic rate of glucose (CMRglc)) changes using micro-positron emission tomography. In the contralateral somatosensory cortex, BOLD, CBF, CBV, CMRO(2) (n = 7, P < 0.05), and CMRglc (n = 5, P < 0.05) increased. In contrast, in the bilateral striatum, BOLD, CBF, and CBV decreased (P < 0.05), CMRO(2) decreased slightly, although not significantly from baseline, and CMRglc was not statistically significant from baseline (P > 0.05). These multimodal functional imaging findings corroborate the unexpected negative hemodynamic changes in the striatum during noxious forepaw stimulation, and support the hypothesis that striatal hemodynamic response is dominated by neurotransmitter-mediated vasoconstriction, overriding the stimulus-evoked fMRI signal increases commonly accompany elevated neuronal activity. Multimodal functional imaging approach offers a means to probe the unique attributes of the striatum, providing novel insights into the neurovascular coupling in the striatum. These findings may have strong implications in fMRI studies of pain. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 832-841; doi:10.1038/jcbfm.2010.173; published online 13 October 2010
C1 [Shih, Yen-Yu I.; Wey, Hsiao-Ying; De La Garza, Bryan H.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Wey, Hsiao-Ying; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA.
RP Shih, YYI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM shihy@uthscsa.edu; duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Wey, Hsiao-Ying/G-3031-2012
OI Shih, Yen-Yu Ian/0000-0001-6529-911X
FU NIH [R01-NS45879]; American Heart Association [10POST4290091]; San
Antonio Area Foundation; Defense Advanced Research Projects Agency
[HR0011-07-C-0027]; NIH/NCRR [S10 RR023038]
FX This work is supported by NIH R01-NS45879 to TQD, American Heart
Association (10POST4290091), and San Antonio Area Foundation to YYIS.;
The authors acknowledge Dr Fuqiang Zhao and Dr Ai-Ling Lin for valuable
discussion and Mr David A Lewis and Dr Kihak Lee for their assistance
with the PET scans. The authors acknowledge the resource supports of the
Defense Advanced Research Projects Agency (Comprehensive Facility for
Animal Imaging Research (CFAIR), HR0011-07-C-0027) and NIH/NCRR (S10
RR023038).
NR 42
TC 26
Z9 26
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD MAR
PY 2011
VL 31
IS 3
BP 832
EP 841
DI 10.1038/jcbfm.2010.173
PG 10
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 727ZS
UT WOS:000287842700006
PM 20940730
ER
PT J
AU Caroff, SN
Davis, VG
Miller, DD
Davis, SM
Rosenheck, RA
McEvoy, JP
Campbell, EC
Saltz, BL
Riggio, S
Chakos, MH
Swartz, MS
Keefe, RSE
Stroup, TS
Lieberman, JA
AF Caroff, Stanley N.
Davis, Vicki G.
Miller, Del D.
Davis, Sonia M.
Rosenheck, Robert A.
McEvoy, Joseph P.
Campbell, E. Cabrina
Saltz, Bruce L.
Riggio, Silvana
Chakos, Miranda H.
Swartz, Marvin S.
Keefe, Richard S. E.
Stroup, T. Scott
Lieberman, Jeffrey A.
CA CATIE Investigators
TI Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic
Schizophrenia
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID OUTPATIENT HEALTH OUTCOMES; FOLLOW-UP; 2ND-GENERATION ANTIPSYCHOTICS;
RANDOMIZED-TRIAL; HALOPERIDOL; CATIE; OLANZAPINE; CLOZAPINE; BLIND;
RISPERIDONE
AB Objective: We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD.
Method: This analysis compared 200 patients with DSM-IV defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to all-cause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbaseline or showing changes in AIMS scores were evaluated with chi(2) tests. Data were collected from January 2001 to December 2004.
Results: Time to treatment discontinuation for any cause was not significantly different between the TD and non-TD groups (chi(2)(1) = 0.11, P=.743). Changes in PANSS scores were not significantly different (F-1,F-974 = 0.82, P=.366), but patients with TD showed less improvement in neurocognitive scores (F-1,F-359=6.53, P=.011). Among patients with TD, there were no significant differences between drugs in the decline in AIMS scores (F-3,F-151 = 0.32, P=.811); 55% met criteria for TD at 2 consecutive visits postbaseline, 76% met criteria for TD at some or all postbaseline visits, 24% did not meet criteria for TD at any subsequent visit, 32% showed a >= 50% decrease in AIMS score, and 7% showed a >= 50% increase in AIMS score.
Conclusions: Schizophrenia patients with and without TD were similar in time to discontinuation of treatment for any cause and improvement in psychopathology, but differed in neurocognitive response. There were no significant differences between treatments in the course of TD, with most patients showing either persistence of or fluctuation in observable symptoms. Trial Registration: clinicaltrials.gov Identifier: NCT00014001 J Clin Psychiatry 2011;72(3):295-303 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
C1 [Caroff, Stanley N.; Campbell, E. Cabrina] Dept Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA.
[Caroff, Stanley N.; Campbell, E. Cabrina] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Davis, Vicki G.] Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
[Miller, Del D.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.
[Davis, Sonia M.] Quintiles Inc, Res Triangle Pk, NC USA.
[Davis, Sonia M.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Rosenheck, Robert A.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA.
[McEvoy, Joseph P.] Duke Univ, Med Ctr, Dept Biol Psychiat, John Umstead Hosp, Durham, NC USA.
[McEvoy, Joseph P.; Swartz, Marvin S.; Keefe, Richard S. E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Saltz, Bruce L.] Mental Hlth Advocates Inc, Boca Raton, FL USA.
[Riggio, Silvana] James J Peter Vet Affairs Med Ctr, New York, NY USA.
[Riggio, Silvana] Mt Sinai Sch Med, New York, NY USA.
[Chakos, Miranda H.] SUNY Hlth Sci Ctr, Dept Psychiat, Brooklyn, NY 11203 USA.
[Stroup, T. Scott; Lieberman, Jeffrey A.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York State Psychiat Inst, New York, NY USA.
RP Caroff, SN (reprint author), Vet Affairs Med Ctr 116A, Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM stanley.caroff@va.gov
RI Stroup, Thomas/F-9188-2014
OI Stroup, Thomas/0000-0002-3123-0672
FU National Institute of Mental Health [NO1 MH90001]; Department of
Veterans Affairs, Veterans Health Administration, Office of Research
Development; Pfizer; Bristol-Myers Squibb; Ortho-McNeil Neurologics;
National Institute of Mental Health; Foundation for the National
Institute of Health; Eli Lilly; Janssen; AstraZeneca; Wyeth; Forest;
Dainippon Sumitomo; Indevus; Cephalon; Novartis; Solvay; Roche; Organon;
Allon; Singapore National Medical Research Council
FX Dr Caroff has been a consultant for Eli Lilly and has received
grant/research support from Pfizer, Bristol-Myers Squibb, and
Ortho-McNeil Neurologics. Dr V. G. Davis is an employee of the
Collaborative Studies Coordinating Center in the Department of
Biostatistics, University of North Carolina. Dr Miller has been a
consultant for Otsuka, Hoffmann-La Roche, and Schering Plough and has
received research funds from the National Institute of Mental Health and
the Foundation for the National Institute of Health. Dr S. M. Davis is
an employee of Quintiles. Dr Rosenheck has been a consultant for Eli
Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Organon, and Janssen; has
received research support from Bristol-Myers Squibb, Eli Lilly, Janssen,
AstraZeneca, and Wyeth; and provided expert testimony for the plaintiffs
in UFCW Local 1776 and Participating Employers Health and Welfare Fund,
et al vs Eli Lilly and Company; for the respondent in Eli Lilly Canada
Inc vs Novapharm Ltd and Minister of Health, respondent; and for the
Patent Medicines Prices Review Board, Canada, in the matter of Janssen
Ortho Inc. and "Risperdal Consta." Dr McEvoy has received research
funding from AstraZeneca, Forest, Eli Lilly, Janssen, Pfizer,
Sanofi-Aventis, and Dainippon Sumitomo; consulting or advisory board
fees from Pfizer, Bristol-Myers Squibb, Indevus, and Eli Lilly; lecture
fees from Janssen and Bristol-Myers Squibb; and honoraria from Eli
Lilly. Dr Saltz has received research funds from Cephalon, AstraZeneca,
and Novartis and lecture fees from Janssen and Novartis. Dr Chakos has
been a consultant for Roche and has received grant/research support from
Pfizer, Solvay, AstraZeneca, Janssen, Roche, and Organon. Dr Swartz has
received consulting and education fees from AstraZeneca, Bristol-Myers
Squibb, Pfizer, Eli Lilly, and Comprehensive Neuroscience and has
received grant/research support and honoraria from Eli Lilly. Dr Keefe
is currently receiving or in the past 12 months has received
investigator-initiated research funding support from the National
Institute of Mental Health, Allon, Novartis, and the Singapore National
Medical Research Council and an unrestricted educational grant from
AstraZeneca; and has received honoraria from or served as a consultant
or advisory board member for Abbott, AstraZeneca, BiolineRx,
Bristol-Myers Squibb, Cephalon, Dainippon Sumitomo, Eli Lilly, Johnson &
Johnson, Lundbeck, Memory, Merck, Neurosearch, Orion, Orexigen, Otsuka,
Pfizer, Roche, Targacept, Sanofi-Aventis, Shire, Wyeth, and Xenoport. In
the past, he has received honoraria from or served as a consultant or
advisory board member for Acadia, Cortex, Cyberonics, Forest, Gabriel,
GlaxoSmithKline, Repligen, Saegis, and Schering Plough and has received
research funding from AstraZeneca, Eli Lilly, Janssen, and Pfizer. He
receives royalties from the Brief Assessment of Cognition in
Schizophrenia (BACS) testing battery and the MATRICS Battery (BACS
Symbol Coding). Dr Stroup has received research funding from Eli Lilly
and consulting fees from Janssen, Eli Lilly, Lundbeck, Solvay,
GlaxoSmithKline, and Bristol-Myers Squibb. Dr Lieberman has received
research funding from AstraZeneca, Bristol-Myers Squibb,
GlaxoSmithKline, Janssen, and Pfizer and consulting and educational fees
from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest,
GlaxoSmithKline, Janssen, Novartis, Pfizer, and Solvay. Drs Campbell and
Riggio report no financial or other relationship relevant to the subject
of this article.; Supported by the Clinical Antipsychotic Trials of
Intervention Effectiveness project, National Institute of Mental Health
(NO1 MH90001). This article was based on results from the Clinical
Antipsychotic Trials of Intervention Effectiveness project, supported by
the National Institute of Mental Health (NO1 MH90001). The aim of this
project is to examine the comparative effectiveness of antipsychotic
drugs in conditions for which their use is clinically indicated
including schizophrenia and Alzheimer's disease. The project was carried
out by principal investigators from Columbia University, the University
of North Carolina, Duke University, the University of Southern
California, the University of Rochester, and Yale University in
association with Quintiles, Inc.; the program staff of the Division of
Interventions and Services Research of the National Institute of Mental
Health; and investigators from 57 sites in the United States (CATIE
Investigators Group). AstraZeneca Pharmaceuticals LP, Bristol-Myers
Squibb Company, Forest Pharmaceuticals, Inc., Janssen Pharmaceutics
Products, L.P., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd.,
Pfizer Inc., and Zenith Goldline Pharmaceuticals, Inc., provided
medications for the studies. This material is based upon work also
supported in part by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research Development, with resources and the
use of facilities at the Philadelphia Veterans Affairs Medical Center.
NR 53
TC 10
Z9 10
U1 1
U2 1
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAR
PY 2011
VL 72
IS 3
BP 295
EP 303
DI 10.4088/JCP.09m05793yel
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 741BM
UT WOS:000288838100004
PM 20816031
ER
PT J
AU Klein, RL
Carter, RE
Jenkins, AJ
Lyons, TJ
Baker, NL
Gilbert, GE
Virella, G
Lopes-Virella, MF
AF Klein, Richard L.
Carter, Rickey E.
Jenkins, Alicia J.
Lyons, Timothy J.
Baker, Nathaniel L.
Gilbert, Gregory E.
Virella, Gabriel
Lopes-Virella, Maria F.
CA DCCT-EDIC Res Grp
TI LDL-containing immune complexes in the DCCT/EDIC cohort: associations
with lipoprotein subclasses
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Diabetes; Lipoprotein subclasses; LDL autoantibodies; Intima-media
thickness; Statistical mediation analysis
ID INTIMA-MEDIA THICKNESS; CORONARY-ARTERY-DISEASE;
LOW-DENSITY-LIPOPROTEIN; OXIDIZED LDL; ATHEROSCLEROTIC LESIONS;
DIABETES-MELLITUS; HUMAN MACROPHAGES; COMPLICATIONS; ANTIBODIES;
GLYCOXIDATION
AB Immune complexes containing modified LDL (LDL-IC) and NMR-detennined Total LDL particle concentrations are significantly associated with intima-media thickness (IMT). We analyzed the associations between concentrations of NMR-determined lipoprotein subclasses and LDL-IC in the DCCT/EDIC cohort. LDL-IC concentrations in women and men of the DCCT/EDIC cohort did not differ significantly and were positively associated with Total LDL particle concentrations in men and women (r=0.34, r=0.32, respectively; P<.01) and with Small LDL concentration (r=0.22, r=0.13, respectively; P<.01). In women, Large LDL concentrations were also associated with LDL-IC (r=0.20, P<.01) while in men, the association was more modest (r=0.11, P<.05). Thus, both Small and Large LDL are associated with LDL-IC formation. Based on the results from statistical mediation analyses, we concluded that plasma concentrations of LDL-1C may provide a physiological link between the statistically significant association of Total LDL particle concentration with carotid artery IMT in subjects with Type 1 diabetes. Furthermore, after adjusting for conventional risk factors, there was a decrease in LDL-1C concentration even in the presence of high Total LDL particle concentrations in those women with high concentrations of Large HDL, but the association was not evident in men. This suggests that the associations between Large HDL and Total LDL particle concentrations, and their associations with LDL-IC levels, differ by gender and suggest that LDL-1C partially mediate the contribution of Total LDL particle concentration to increased carotid IMT in diabetic men. Published by Elsevier Inc.
C1 [Klein, Richard L.; Jenkins, Alicia J.; Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol Metab & Med Genet, Dept Med, Charleston, SC 29403 USA.
[Klein, Richard L.; Lopes-Virella, Maria F.] Vet Affairs Med Ctr, Res Serv, Ralph H Johnson Dept, Charleston, SC 29403 USA.
[Carter, Rickey E.; Baker, Nathaniel L.; Gilbert, Gregory E.] Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29403 USA.
[Jenkins, Alicia J.] Univ Melbourne, Dept Med, St Vincents Hosp, Fitzroy, Vic 3065, Australia.
[Jenkins, Alicia J.; Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Endocrinol Sect, Oklahoma City, OK USA.
[Jenkins, Alicia J.; Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA.
[DCCT-EDIC Res Grp] Box NDIC DCCT, Bethesda, MD USA.
RP Klein, RL (reprint author), Med Univ S Carolina, Div Endocrinol Metab & Med Genet, Dept Med, 114 Doughty St,STB 501, Charleston, SC 29403 USA.
EM kleinrl@musc.edu
RI Jenkins, Alicia/N-2482-2015; Gilbert, Gregory/C-7735-2016
OI Gilbert, Gregory/0000-0003-0879-5496
FU American Diabetes Association; Juvenile Diabetes Research Foundation
[4-1998-272, 996001]; National Institutes of Health [PO1 HL55782];
Diabetes Research and Wellness Foundation (Fairfax, VA, USA); Department
of Veterans Affairs; National Institute of Diabetes, Endocrinology and
Metabolic Diseases of the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK)
FX This research was supported by funding by the American Diabetes
Association, Juvenile Diabetes Research Foundation (4-1998-272, 996001),
National Institutes of Health (PO1 HL55782), The Diabetes Research and
Wellness Foundation (Fairfax, VA, USA), and the Merit Review Program of
the Department of Veterans Affairs. The DCCT/EDIC Research Group is
sponsored through research contracts from the National Institute of
Diabetes, Endocrinology and Metabolic Diseases of the National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National
Institutes of Health.
NR 30
TC 6
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAR-APR
PY 2011
VL 25
IS 2
BP 73
EP 82
DI 10.1016/j.jdiacomp.2010.03.001
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 736WH
UT WOS:000288525200001
PM 20605479
ER
PT J
AU Sarkar, U
Schillinger, D
Lopez, A
Sudore, R
AF Sarkar, Urmimala
Schillinger, Dean
Lopez, Andrea
Sudore, Rebecca
TI Validation of Self-Reported Health Literacy Questions Among Diverse
English and Spanish-Speaking Populations
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE health literacy; limited English proficiency; Hispanic American;
validation studies
ID VULNERABLE PATIENTS; HOSPITAL ADMISSION; MANAGEMENT SUPPORT; DIABETES
PATIENTS; IDENTIFY PATIENTS; LIMITED LITERACY; GLYCEMIC CONTROL;
PRIMARY-CARE; KNOWLEDGE; RISK
AB Limited health literacy (HL) contributes to poor health outcomes and disparities, and direct measurement is often time-intensive. Self-reported HL questions have not been validated among Spanish-speaking and diverse English-speaking populations.
To evaluate three self-reported questions:1 "How confident are you filling out medical forms?";2 "How often do you have problems learning about your medical condition because of difficulty understanding written information?"; and3 "How often do you have someone help you read hospital materials?" Answers were based on a 5-point Likert scale.
This was a validation study nested within a trial of diabetes self-management support in the San Francisco Department of Public Health.
English and Spanish-speaking adults with type 2 diabetes receiving primary care.
Using the Test of Functional Health Literacy in Adults (s-TOFHLA) in English and Spanish as the reference, we classified HL as inadequate, marginal, or adequate. We calculated the C-index and test characteristics of the three questions and summative scale compared to the s-TOFHLA and assessed variations in performance by language, race/ethnicity, age, and education.
Of 296 participants, 48% were Spanish-speaking; 9% were White, non-Hispanic; 47% had inadequate HL and 12% had marginal HL. Overall, 57% reported being confident with forms "somewhat" or less. The "confident with forms" question performed best for detecting inadequate (C-index = 0.82, (0.77-0.87)) and inadequate plus marginal HL (C index = 0.81, (0.76-0.86); p < 0.01 for differences from other questions), and performed comparably to the summative scale. The "confident with forms" question and scale also performed best across language, race/ethnicity, educational attainment, and age.
A single self-reported HL question about confidence with forms and a summative scale of three questions discriminated between Spanish and English speakers with adequate HL and those with inadequate and/or inadequate plus marginal HL. The "confident with forms" question or the summative scale may be useful for estimating HL in clinical research involving Spanish-speaking and English-speaking, chronically-ill, diverse populations.
C1 [Sarkar, Urmimala; Schillinger, Dean; Lopez, Andrea] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Sarkar, Urmimala; Schillinger, Dean; Lopez, Andrea] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco Ctr Vulnerable Populat, San Francisco, CA 94143 USA.
[Sudore, Rebecca] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94143 USA.
RP Sarkar, U (reprint author), Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Box 1364,1001 Potrero,Bldg 10,3rd Floor, San Francisco, CA 94143 USA.
EM usarkar@medsfgh.ucsf.edu
FU San Francisco Veterans' Affairs Medical Center; National Center for
Research Resources [KL2RR024130]; Agency for Healthcare Research and
Quality [R18 HS01726101, K08 HS017594]; NIH [ULRR024131]; Veterans
Affairs; Pfizer
FX We gratefully acknowledge the data analysis performed by Kathy Z. Fung,
MS, (funded by the San Francisco Veterans' Affairs Medical Center) and
the biostatistical advice provided by John Boscardin, Ph.D (funded by
the National Center for Research Resources KL2RR024130). Funds were
provided by Agency for Healthcare Research and Quality R18 HS01726101
(to DS), a NIH Clinical and Translational Science Award ULRR024131 (to
DS), the National Center for Research Resources KL2RR024130 (to US.) and
Agency for Healthcare Research and Quality K08 HS017594 (to US), a
Veterans Affairs Career Development Award and a Pfizer Fellowship in
Clear Health Communication (RS). None of the funders had any role in
study design; in the collection, analysis, and interpretation of data;
in the writing of the manuscript; or in the decision to submit the
manuscript for publication.
NR 37
TC 59
Z9 59
U1 2
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAR
PY 2011
VL 26
IS 3
BP 265
EP 271
DI 10.1007/s11606-010-1552-1
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 725QV
UT WOS:000287661800013
PM 21057882
ER
PT J
AU Pol, S
Ghalib, RH
Rustgi, VK
Martorell, C
Everson, GT
Tatum, HA
Hezode, C
Lim, JK
Bronowicki, JP
Abrams, GA
Brau, N
Morris, DW
Thuluvath, P
Reindollar, R
Yin, PD
Diva, U
Hindes, R
McPhee, F
Gao, M
Thiry, A
Schnittman, S
Hughes, EA
AF Pol, S.
Ghalib, R. H.
Rustgi, V. K.
Martorell, C.
Everson, G. T.
Tatum, H. A.
Hezode, C.
Lim, J. K.
Bronowicki, J. -P.
Abrams, G. A.
Brau, N.
Morris, D. W.
Thuluvath, P.
Reindollar, R.
Yin, P. D.
Diva, U.
Hindes, R.
McPhee, F.
Gao, M.
Thiry, A.
Schnittman, S.
Hughes, E. A.
TI FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR,
BMS-790052 IN COMBINATION WITH PEG-IFN alpha-2A AND RBV: PHASE 2A TRIAL
IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY 2011
CL Berlin, GERMANY
SP European Assoc Study Liver (EASL)
C1 [Pol, S.] Hop Cochin, F-75674 Paris, France.
[Ghalib, R. H.] Methodist Hlth Syst, Liver Inst, Dallas, TX USA.
[Rustgi, V. K.] Metropolitan Res, Fairfax, VA USA.
[Martorell, C.] Res Inst, Springfield, MA USA.
[Everson, G. T.] Univ Colorado, Aurora, CO USA.
[Tatum, H. A.] Opt Hlth Res LLC, Tulsa, OK USA.
[Hezode, C.] CHU Henri Mondor, F-94010 Creteil, France.
[Lim, J. K.] Yale Univ, Sch Med, New Haven, CT USA.
[Bronowicki, J. -P.] Hop Adultes Braboios, Vandoeuvre Les Nancy, France.
[Abrams, G. A.] Alabama Liver & Digest Specialists, Montgomery, AL USA.
[Brau, N.] James J Peters VAMC, Bronx, NY USA.
[Morris, D. W.] Healthcare Res Consultants, Tulsa, OK USA.
[Thuluvath, P.] St Johns Mercy Med Ctr, Baltimore, MD USA.
[Reindollar, R.] Carolinas Ctr Liver Dis Res Dept, Statesville, NC USA.
[Yin, P. D.; Diva, U.; Hindes, R.; McPhee, F.; Gao, M.; Thiry, A.; Schnittman, S.; Hughes, E. A.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
EM stanislas.pol@cch.aphp.fr
NR 0
TC 10
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD MAR
PY 2011
VL 54
SU 1
MA 1373
BP S544
EP S545
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 856GC
UT WOS:000297625603057
ER
PT J
AU Chang, LM
Maheshwari, P
Werth, S
Schaffer, L
Head, SR
Kovarik, C
Werth, VP
AF Chang, Laura M.
Maheshwari, Prateesh
Werth, Sheila
Schaffer, Lana
Head, Steven R.
Kovarik, Carrie
Werth, Victoria P.
TI Identification and Molecular Analysis of Glycosaminoglycans in Cutaneous
Lupus Erythematosus and Dermatomyositis
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE chondroitin sulfate; cutaneous lupus erythematosus; dermatomyositis;
glycosaminoglycans; hyaluronan
ID CHONDROITIN-SULFATE; HUMAN SKIN; HYALURONAN METABOLISM;
MONOCLONAL-ANTIBODIES; CD44; CELLS; EXPRESSION; ADHESION; INJURY;
PROTEOGLYCANS
AB Glycosaminoglycans (GAGs), also known histologically as dermal mucin, accumulate in several inflammatory skin conditions. Because different GAG species have distinct immunologic effects, the authors examined two GAGs, hyaluronan (HA) and chondroitin sulfate (CS), using specific stains in cutaneous lupus erythematosus (CLE) and dermatomyositis (DM). In the dermis of one CLE subtype, tumid LE (TLE), they found only increased HA, but both HA and CS were significantly elevated in another CLE subtype, discoid LE (DLE). DM lesional dermis accumulated mainly CS but not HA. The authors then used glycomic gene expression microarrays to assess the expression of HA-and CS-related genes in CLE skin. Real-time quantitative PCR confirmed significantly increased expression of HAS2, CHSY1, and C4ST1 in the combined groups of CLE lesions (n = 8) compared to healthy controls (n = 4). Thus, the increase in HA in CLE presumably results from upregulation of HAS2, whereas CHSY1 and C4ST1 appear to contribute to increased CS. Based on their known immunomodulatory effects in other systems, HA and CS may thus participate in the pathophysiology of these inflammatory skin conditions. (J Histochem Cytochem 59:336-345, 2011)
C1 [Chang, Laura M.; Maheshwari, Prateesh; Werth, Sheila; Kovarik, Carrie; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Chang, Laura M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Maheshwari, Prateesh] Univ Penn, Coll Arts & Sci, Philadelphia, PA 19104 USA.
[Kovarik, Carrie; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Schaffer, Lana; Head, Steven R.] Consortium Funct Glyc, DNA Array Core Facil, La Jolla, CA USA.
[Schaffer, Lana; Head, Steven R.] Scripps Res Inst, La Jolla, CA 92037 USA.
RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, 2 Maloney Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU Lupus Foundation of American; Department of Veterans Affairs Veterans
Health Administration, Office of Research and Development, Biomedical
Laboratory Research and Development; National Institutes of Health [NIH
K24-AR 02207, NIH T32-AR007465-25, GM-62116]
FX The author(s) disclosed receipt of the following financial support for
the research and/or authorship of this article: This work was supported
by the Lupus Foundation of American; in part by a Merit Review Grant
from the Department of Veterans Affairs Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; the National Institutes of Health (grant number NIH K24-AR
02207) to VPW; the National Institutes of Health training grant (grant
number NIH T32-AR007465-25) to LMC; and the Consortium for Functional
Glycomics Grant (grant number GM-62116) from the National Institutes of
Health.
NR 44
TC 10
Z9 10
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD MAR
PY 2011
VL 59
IS 3
BP 336
EP 345
DI 10.1369/0022155410398000
PG 10
WC Cell Biology
SC Cell Biology
GA 805CC
UT WOS:000293703000010
PM 21378287
ER
PT J
AU Zhou, XY
Shapiro, L
Fellingham, G
Willardson, BM
Burton, GF
AF Zhou, Xueyuan
Shapiro, Leland
Fellingham, Gilbert
Willardson, Barry M.
Burton, Gregory F.
TI HIV Replication in CD4(+) T Lymphocytes in the Presence and Absence of
Follicular Dendritic Cells: Inhibition of Replication Mediated by
alpha-1-Antitrypsin through Altered I kappa B alpha Ubiquitination
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; TRANSCRIPTION
FACTORS; INFECTION; TYPE-1; ACTIVATION; ACTIN; PATHOGENESIS; PROTEINS;
NUCLEUS
AB Follicular dendritic cells (FDCs) increase HIV replication and virus production in lymphocytes by increasing the activation of NF-kappa B in infected cells. Because alpha-1-antitrypsin (AAT) decreases HIV replication in PBMCs and monocytic cells and decreases NF-kappa B activity, we postulated that AAT might also block FDC-mediated HIV replication. Primary CD4(+) T cells were infected with HIV and cultured with FDCs or their supernatant with or without AAT, and ensuing viral RNA and p24 production were monitored. NF-kappa B activation in the infected cells was also assessed. Virus production was increased in the presence of FDC supernatant, but the addition of AAT at concentrations >0.5 mg/ml inhibited virus replication. AAT blocked the nuclear translocation of NF-kappa B p50/p65 despite an unexpected elevation in associated phosphorylated and ubiquitinated I kappa B alpha (Ub-I kappa B alpha). In the presence of AAT, degradation of cytoplasmic I kappa B alpha was dramatically inhibited compared with control cultures. AAT did not inhibit the proteasome; however, it altered the pattern of ubiquitination of I kappa B alpha. AAT decreased I kappa B alpha polyubiquitination linked through ubiquitin lysine residue 48 and increased ubiquitination linked through lysine residue 63. Moreover, lysine reside 63-linked Ub-I kappa B alpha degradation was substantially slower than lysine residue 48-linked Ub-I kappa B alpha in the presence of AAT, correlating altered ubiquitination with a prolonged I kappa B alpha t(1/2). Because AAT is naturally occurring and available clinically, examination of its use as an inhibitory agent in HIV-infected subjects may be informative and lead to the development of similar agents that inhibit HIV replication using a novel mechanism. The Journal of Immunology, 2011, 186: 3148-3155.
C1 [Zhou, Xueyuan; Willardson, Barry M.; Burton, Gregory F.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.
[Shapiro, Leland] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
[Shapiro, Leland] Univ Colorado, Div Infect Dis, Dept Med, Denver, CO 80220 USA.
[Fellingham, Gilbert] Brigham Young Univ, Dept Stat, Provo, UT 84602 USA.
RP Burton, GF (reprint author), Brigham Young Univ, Dept Chem & Biochem, Room C104B BNSN, Provo, UT 84602 USA.
EM gburton@chem.byu.edu
FU National Institute of Allergy and Infectious Disease [AI39963, AI91517];
National Institute of General Medical Sciences [GM078550]; Campbell
Foundation; College of Physical and Mathematical Sciences
FX This work was supported by Public Health Service Grants AI39963 and
AI91517 from the National Institute of Allergy and Infectious Disease
(to G.F.B.), GM078550 from the National Institute of General Medical
Sciences (to B.M.W.), the Campbell Foundation (to L.S.), and by a
Brigham Young University grant from the College of Physical and
Mathematical Sciences (to G.F.B.).
NR 35
TC 19
Z9 20
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2011
VL 186
IS 5
BP 3148
EP 3155
DI 10.4049/jimmunol.1001358
PG 8
WC Immunology
SC Immunology
GA 721LT
UT WOS:000287356900053
PM 21263074
ER
PT J
AU Mendez, MF
Shapira, JS
AF Mendez, Mario F.
Shapira, Jill S.
TI Internet Pornography and Frontotemporal Dementia
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Letter
ID SEXUAL-BEHAVIOR; DEGENERATION
C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Ctr, Dept Neurol, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Ctr, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Ctr, Dept Neurol, Los Angeles, CA 90095 USA.
NR 5
TC 0
Z9 0
U1 1
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD SPR
PY 2011
VL 23
IS 2
BP E3
EP E3
PG 1
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 777VF
UT WOS:000291652500093
ER
PT J
AU Fung, SJ
Xi, MC
Zhang, JH
Torterolo, P
Sampogna, S
Morales, FR
Chase, MH
AF Fung, Simon J.
Xi, MingChu
Zhang, JianHua
Torterolo, Pablo
Sampogna, Sharon
Morales, Francisco R.
Chase, Michael H.
TI Projection Neurons From the Central Nucleus of the Amygdala to the
Nucleus Pontis Oralis
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE amygdalofugal projection; glutamate; cholera toxin B; retrograde;
reticular formation
ID VESICULAR GLUTAMATE TRANSPORTER-2; TRIGEMINAL MOTOR NUCLEUS; ACTIVE REM
SLEEP; RETICULAR-FORMATION; BRAIN-STEM; HYPOGLOSSAL MOTONEURONS;
MEDULLA-OBLONGATA; PARADOXICAL SLEEP; GUINEA-PIG; RAT
AB The present retrograde labeling study was designed to determine the presence and pattern of projections from individual subdivisions of the central nucleus of the amygdala (CNA) to the nucleus pontis oralis (NPO), which is a critical brainstem site involved in the generation and maintenance of active (REM) sleep. Projections from the CNA were labeled with the retrograde tracer cholera toxin B-subunit (CTB), which was injected, unilaterally, via microiontophoresis, into the NPO. Sections of the amygdala were immunostained in order to identify CTB-labeled CNA neurons and CNA neurons that contained CTB plus the vesicular glutamate transporter 2 (VGLUT2), which is a marker for glutamatergic neurons. Histological analyses revealed that retrogradely labeled neurons that project to the NPO were localized, ipsilaterally, within the medial, lateral, and capsular subdivisions of the CNA. In addition, a substantial proportion (24%) of all retrogradely labeled CNA neurons also exhibited VGLUT2 immunoreactivity. The present study demonstrates that glutamatergic neurons, which are present within various subdivisions of the CNA, project directly to the NPO. These data lend credence to the hypothesis that NPO neurons that are involved in the control of active sleep are activated by glutamatergic projections from the amygdala. (C) 2010 Wiley-Liss, Inc.
C1 [Fung, Simon J.; Xi, MingChu; Zhang, JianHua; Torterolo, Pablo; Sampogna, Sharon; Morales, Francisco R.; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA.
[Fung, Simon J.; Xi, MingChu; Zhang, JianHua; Chase, Michael H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Torterolo, Pablo; Morales, Francisco R.; Chase, Michael H.] Univ Republica, Dept Fisiol, Fac Med, Montevideo, Uruguay.
[Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA.
RP Fung, SJ (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA.
EM sfung@websciences.org
FU NIH [NS 60917]
FX Contract grant sponsor: NIH; Contract grant number: NS 60917.
NR 51
TC 15
Z9 15
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0360-4012
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD MAR
PY 2011
VL 89
IS 3
BP 429
EP 436
DI 10.1002/jnr.22554
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 717RG
UT WOS:000287064500015
PM 21259329
ER
PT J
AU Morasco, BJ
Corson, K
Turk, DC
Dobscha, SK
AF Morasco, Benjamin J.
Corson, Kathryn
Turk, Dennis C.
Dobscha, Steven K.
TI Association Between Substance Use Disorder Status and Pain-Related
Function Following 12 Months of Treatment in Primary Care Patients With
Musculoskeletal Pain
SO JOURNAL OF PAIN
LA English
DT Article
DE Chronic pain; substance use disorder; pain functioning; treatment;
collaborative care intervention
ID LOW-BACK-PAIN; MORRIS DISABILITY QUESTIONNAIRE; CHRONIC NONMALIGNANT
PAIN; CHRONIC NONCANCER PAIN; ABUSE SCREENING-TEST;
METHADONE-MAINTENANCE; COLLABORATIVE CARE; DEPENDENT PATIENTS;
RANDOMIZED-TRIAL; PERSISTENT PAIN
AB The goal of this study was to examine relationships between substance use disorder (SUD) history and 12-month outcomes among primary care patients with chronic noncancer pain (CNCP). Patients were enrolled in a randomized trial of collaborative care intervention (CCI) versus treatment as usual (TAU) to improve pain-related physical and emotional function. At baseline, 72 of 362 patients (20.0%) had a history of SUD. Compared to CNCP patients without SUD, those with comorbid SUD had poorer pain-related function and were more likely to meet criteria for current major depression and post-traumatic stress disorder (all P values <.05). Logistic regression analyses were conducted to examine whether SUD status was associated with clinically significant change over 12 months in pain-related function (30% reduction in Roland Morris Disability Questionnaire Score). The overall model was not significant in the CCI group. However, within the TAU group, participants with a SUD history were significantly less likely to show improvements in pain-related function (OR = .30, 95% CI = .11-.82). CNCP patients with comorbid SUD reported greater functional impairment at baseline. Patients with SUD who received usual care were 70% less likely to have clinically significant improvements in pain-related function 12 months postbaseline, and SUD status did not impede improvement for the CCI group.
Perspective: Chronic noncancer pain patients with a history of a substance use disorder (SUD) report poorer pain-related functioning and are less likely to experience clinically significant improvements from usual pain treatment. Providers should assess for SUD status and provide more intensive interventions for these patients. (C) 2011 by the American Pain Society
C1 [Morasco, Benjamin J.; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA.
[Corson, Kathryn; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Med & Psychiat, Portland, OR USA.
[Morasco, Benjamin J.; Corson, Kathryn; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Turk, Dennis C.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA.
RP Morasco, BJ (reprint author), Portland VA Med Ctr R&D99, 3710 SW US Vet Hop Rd, Portland, OR 97239 USA.
EM benjamin.morasco@va.gov
FU Department of Veterans Affairs, Veterans Health Administration; Health
Services Research and Development Service Projects [PMI 03-195,
RCD04129]; National Institute on Drug Abuse [K23DA023467]; Endo; Johnson
Johnson; Philips Respironics; National Institutes of Health; Eli Lilly;
Empi; Pfizer; SK Life Science; Oregon Clinical and Translational
Research Institute at OHSU; National Center for Research Resources, a
component of the National Institutes of Health and NIH Roadmap for
Medical Research [UI1RR024140]
FX Supported in part by the Department of Veterans Affairs, Veterans Health
Administration, and Health Services Research and Development Service
Projects PMI 03-195 and RCD04129, awarded to Dr Dobscha. Dr Morasco also
received support from award K23DA023467 from the National Institute on
Drug Abuse. During the past 12 months, Dr Turk has received research
support from Endo, Johnson & Johnson, Philips Respironics, and the
National Institutes of Health, and consulting fees from Eli Lilly, Empi,
Johnson & Johnson, Pfizer, Philips Respironics, and SK Life Science. He
is also a Special Government Employee of the U.S. Food and Drug
Administration. The authors also appreciate support provided from the
Oregon Clinical and Translational Research Institute at OHSU, grant
number UI1RR024140 from the National Center for Research Resources, a
component of the National Institutes of Health and NIH Roadmap for
Medical Research.
NR 49
TC 16
Z9 16
U1 2
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD MAR
PY 2011
VL 12
IS 3
BP 352
EP 359
DI 10.1016/j.jpain.2010.07.010
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 738HS
UT WOS:000288631500006
PM 20851057
ER
PT J
AU Wood, GJ
Morrison, RS
AF Wood, Gordon J.
Morrison, R. Sean
TI Writing Abstracts and Developing Posters for National Meetings
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID STRUCTURED ABSTRACTS; PUBLICATION; PRESENTATIONS; ELABORATION;
EXPLANATION; PRESENTERS; ARTICLES; CONSORT; TRIALS; IMPACT
AB Presenting posters at national meetings can help fellows and junior faculty members develop a national reputation. They often lead to interesting and fruitful networking and collaboration opportunities. They also help with promotion in academic medicine and can reveal new job opportunities. Practically, presenting posters can help justify funding to attend a meeting. Finally, this process can be invaluable in assisting with manuscript preparation. This article provides suggestions and words of wisdom for palliative care fellows and junior faculty members wanting to present a poster at a national meeting describing a case study or original research. It outlines how to pick a topic, decide on collaborators, and choose a meeting for the submission. It also describes how to write the abstract using examples that present a general format as well as writing tips for each section. It then describes how to prepare the poster and do the presentation. Sample poster formats are provided as are talking points to help the reader productively interact with those that visit the poster. Finally, tips are given regarding what to do after the meeting. The article seeks to not only describe the basic steps of this entire process, but also to highlight the hidden curriculum behind the successful abstracts and posters. These tricks of the trade can help the submission stand out and will make sure the reader gets the most out of the hard work that goes into a poster presentation at a national meeting.
C1 [Wood, Gordon J.] Univ Pittsburgh, Sch Med, Inst Enhance Palliat Care, Sect Palliat Care & Med Eth,Dept Med, Pittsburgh, PA 15213 USA.
[Morrison, R. Sean] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Morrison, R. Sean] James J Peters VA, Bronx, NY USA.
RP Wood, GJ (reprint author), Univ Pittsburgh, Sch Med, Inst Enhance Palliat Care, Sect Palliat Care & Med Eth,Dept Med, 200 Lothrop St,Suite 933 W, Pittsburgh, PA 15213 USA.
EM woodgj@upmc.edu
FU National Institute on Aging [K24 AG022345]; National Palliative Care
Research Center
FX Dr. Morrison is supported by a Mid-Career Investigator Award in Patient
Oriented Research from the National Institute on Aging (K24 AG022345). A
portion of this work was funded by the National Palliative Care Research
Center.
NR 31
TC 5
Z9 5
U1 0
U2 11
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD MAR
PY 2011
VL 14
IS 3
BP 353
EP 359
DI 10.1089/jpm.2010.0171
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 728ZZ
UT WOS:000287915700021
PM 21241194
ER
PT J
AU Crane, DA
Little, JW
Burns, SP
AF Crane, Deborah A.
Little, James W.
Burns, Stephen P.
TI Weight gain following spinal cord injury: a pilot study
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Spinal cord injury; Obesity
ID BODY-MASS INDEX; ENERGY-EXPENDITURE; DISEASE RISK; FAT MASS; OBESITY;
ADULTS; PARAPLEGIA; COMMUNITY; TIME; MEN
AB Study design: Retrospective chart review.
Objective: To define the temporal course of weight gain in persons with new spinal cord injury (SCI), and to identify predictors of weight gain in this population.
Setting: A United States Department of Veterans Affairs (VA) SCI Unit.
Methods: A retrospective chart review in a VA SCI Unit was conducted. Participants (n = 85) included all persons with new SCI completing initial rehabilitation at the center between 1998 and 2006. Outcome measures were mean change in body mass index (BMI) between rehabilitation admission and final follow-up, time of greatest BMI change, and distribution of participants by BMI classification. These measures were also examined relative to SCI level, American Spinal Injury Association Impairment Scale (AIS) grade, primary mode of mobility, and age at rehabilitation admission.
Results: Mean BMI increased by 2.3 kg/m(2) between rehabilitation admission (mean 45 days post-injury) and final follow-up (mean 5 years post-injury). The distribution of participants shifted from lower BMI classifications at rehabilitation admission to higher BMI classifications at final follow-up. For participants transitioning from normal to overweight or obese, the greatest increase occurred during the first year after acute rehabilitation. Neurological level, impairment category, primary mode of mobility, and age at rehabilitation admission did not significantly predict BMI change. BMI at rehabilitation admission correlated significantly with BMI at final follow-up (P < 0.0005).
Conclusions: These findings confirm a significant increase in BMI after new SCI and suggest that persons with new SCI are at greatest weight gain risk during the first year following acute rehabilitation.
C1 [Crane, Deborah A.; Little, James W.; Burns, Stephen P.] Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA.
[Crane, Deborah A.; Little, James W.; Burns, Stephen P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Crane, DA (reprint author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.
EM dacrane@uw.edu
NR 22
TC 11
Z9 11
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD MAR
PY 2011
VL 34
IS 2
BP 227
EP 232
DI 10.1179/2045772311Y.0000000001
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 744FR
UT WOS:000289080800011
PM 21675361
ER
PT J
AU Okura, T
Plassman, BL
Steffens, DC
Llewellyn, DJ
Potter, GG
Langa, KM
AF Okura, Toru
Plassman, Brenda L.
Steffens, David C.
Llewellyn, David J.
Potter, Guy G.
Langa, Kenneth M.
TI Neuropsychiatric Symptoms and the Risk of Institutionalization and
Death: The Aging, Demographics, and Memory Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE neuropsychiatric symptoms; caregiver distress; institutionalization;
mortality
ID MILD COGNITIVE IMPAIRMENT; NURSING-HOME PLACEMENT; ALZHEIMERS-DISEASE;
OLDER-ADULTS; DEMENTIA CARE; UNITED-STATES; FOLLOW-UP; PREVALENCE;
MORTALITY; DEPRESSION
AB OBJECTIVES
To examine the association between neuropsychiatric symptoms and risk of institutionalization and death.
DESIGN
Analysis of longitudinal data.
SETTING
The Aging, Demographics, and Memory Study (ADAMS).
PARTICIPANTS
Five hundred thirty-seven adults aged 71 and older with cognitive impairment drawn from the Health and Retirement Study (HRS).
MEASUREMENTS
Neuropsychiatric symptoms (delusions, hallucinations, agitation, depression, apathy, elation, anxiety, disinhibition, irritation, and aberrant motor behaviors) and caregiver distress were identified using the Neuropsychiatric Inventory. A consensus panel in the ADAMS assigned cognitive category. Date of nursing home placement and information on death, functional limitations, medical comorbidity, and sociodemographic characteristics were obtained from the HRS and ADAMS.
RESULTS
Overall, the presence of one or more neuropsychiatric symptoms was not associated with a significantly higher risk for institutionalization or death during the 5-year study period, although when assessing each symptom individually, depression, delusions, and agitation were each associated with a significantly higher risk of institutionalization (hazard rate (HR)=3.06, 95% confidence interval (CI)=1.09-8.59 for depression; HR=5.74, 95% CI=1.94-16.96 for clinically significant delusions; HR=4.70, 95% CI=1.07-20.70 for clinically significant agitation). Caregiver distress mediated the association between delusions and agitation and institutionalization. Depression and hallucinations were associated with significantly higher mortality (HR=1.56, 95% CI=1.08-2.26 for depression; HR=2.59, 95% CI=1.09-6.16 for clinically significant hallucinations).
CONCLUSION
Some, but not all, neuropsychiatric symptoms are associated with a higher risk of institutionalization and death in people with cognitive impairment, and caregiver distress also influences institutionalization. Interventions that better target and treat depression, delusions, agitation, and hallucinations, as well as caregiver distress, may help delay or prevent these negative clinical outcomes.
C1 [Okura, Toru] Bajikoen Clin, Geriatr Sect, Tokyo 1580098, Japan.
[Steffens, David C.] Duke Univ, Med Ctr, Div Geriatr Psychiat, Durham, NC USA.
[Potter, Guy G.] Duke Univ, Med Ctr, Div Med Psychol, Durham, NC USA.
[Plassman, Brenda L.; Steffens, David C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Llewellyn, David J.] Univ Exeter, Peninsula Coll Med & Dent, Exeter, Devon, England.
[Langa, Kenneth M.] Univ Michigan, Dept Internal Med, Div Gen Med, Ann Arbor, MI 48109 USA.
[Langa, Kenneth M.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA.
RP Okura, T (reprint author), Bajikoen Clin, Geriatr Sect, 1-22-23 Kami Yoga Setagaya Ward, Tokyo 1580098, Japan.
EM t-ohkura@t3.rim.or.jp
FU National Institute on Aging (NIA) [R01 AG027010, R01 AG030155]
FX Conflict of Interest: The National Institute on Aging (NIA) provided
funding for the HRS and the ADAMS (U01 AG09740). Additional funding
support was provided by NIA Grants R01 AG027010 and R01 AG030155.
NR 45
TC 37
Z9 38
U1 1
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAR
PY 2011
VL 59
IS 3
BP 473
EP 481
DI 10.1111/j.1532-5415.2011.03314.x
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 732UQ
UT WOS:000288215600012
PM 21391937
ER
PT J
AU Salanitro, AH
Safford, MM
Houston, TK
Williams, JH
Ovalle, F
Payne-Foster, P
Allison, JJ
Estrada, CA
AF Salanitro, Amanda H.
Safford, Monika M.
Houston, Thomas K.
Williams, Jessica H.
Ovalle, Fernando
Payne-Foster, Pamela
Allison, Jeroan J.
Estrada, Carlos A.
TI Patient Complexity and Diabetes Quality of Care in Rural Settings
SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
LA English
DT Article
DE diabetes; quality of care; primary care
AB Purpose: Even though pay-for-performance programs are being rapidly implemented, little is known about how patient complexity affects practice-level performance assessment in rural settings. We sought to determine the association between patient complexity and practice-level performance in the rural United States.
Basic procedures: Using baseline data from a trial aimed at improving diabetes care, we determined factors associated with a practice's proportion of patients having controlled diabetes (hemoglobin A(lc) <= 7%): patient socioeconomic factors, clinical factors, difficulty with self-testing of blood glucose, and difficulty with keeping appointments. We used linear regression to adjust the practice-level proportion with A(lc) controlled for these factors. We compared practice rankings using observed and expected performance and classified practices into hypothetical pay-for-performance categories.
Main Findings: Rural primary care practices (n = 135) in 11 southeastern states provided information for 1641 patients with diabetes. For practices in the best quartile of observed control, 76.1% of patients had controlled diabetes vs 19.3% of patients in the worst quartile. After controlling for other variables, proportions of diabetes control were 10% lower in those practices whose patients had the greatest difficulty with either self testing or appointment keeping (p < .05 for both). Practice rankings based on observed and expected proportion of AI, control showed only moderate agreement in pay-for-performance categories (kappa = 0.47; 95% confidence interval, 0.32-0.56; p < .001).
Principal Conclusions: Basing public reporting and resource allocation on quality assessment that does not account for patient characteristics may further harm this vulnerable group of patients and physicians.
C1 [Salanitro, Amanda H.] Vanderbilt Univ, VA Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA.
[Salanitro, Amanda H.] Vanderbilt Univ, Sect Hosp Med, Nashville, TN USA.
[Estrada, Carlos A.] Univ Alabama, Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
[Estrada, Carlos A.] Univ Alabama, Ctr Surg Med Acute Care Res & Transit CSMART, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Houston, Thomas K.; Allison, Jeroan J.] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Payne-Foster, Pamela] Univ Alabama, Tuscaloosa, AL USA.
RP Salanitro, AH (reprint author), Room A-414,1310 24th Ave S, Nashville, TN 37212 USA.
EM amanda.salanitro@vanderbilt.edu
RI Houston, Thomas/F-2469-2013
OI Allison, Jeroan/0000-0003-4472-2112
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[5R18DK065001]; Veterans Affairs
FX Dr Allison was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK, 5R18DK065001). Dr Salanitro was
supported by a Veterans Affairs National Quality Scholars fellowship.
NR 1
TC 3
Z9 3
U1 1
U2 2
PU NATL MED ASSOC
PI WASHINGON
PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA
SN 0027-9684
J9 J NATL MED ASSOC
JI J. Natl. Med. Assoc.
PD MAR
PY 2011
VL 103
IS 3
BP 234
EP 240
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 755UO
UT WOS:000289964400006
PM 21671526
ER
PT J
AU Jones, EG
AF Jones, Elizabeth Geiger
TI Recognizing Hospital-Acquired Burn Injury in Patients After Coronary
Artery Bypass Surgery
SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING
LA English
DT Article
AB BACKGROUND: Nosocomial injury is a constant threat in the hospital setting. While there is growing awareness surrounding hospital-acquired pressure ulcers, little information is available on burns associated with intraoperative procedures.
CASES: We identified perineal lesions on 4 patients who underwent coronary artery bypass with grafting. These injuries were initially classified as pressure ulcers but subsequent investigation revealed that the injuries were intraoperative burns attributable to pooling of isopropyl alcohol underneath patients who were placed on intraoperative heating pads.
CONCLUSIONS: Differentiating between hospital-acquired pressure ulcers and burns can be difficult. Our facility's experience with intraoperative burn injuries now mandates that this etiologic factor be considered in the differential diagnosis of postoperative patients with atypical cutaneous injuries.
C1 Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Jones, EG (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM Gwammyliz@heavi.tv
NR 12
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1071-5754
J9 J WOUND OSTOMY CONT
JI J. Wound Ostomy Cont. Nurs.
PD MAR-APR
PY 2011
VL 38
IS 2
BP 193
EP 195
DI 10.1097/WON.0b013e31820bc479
PG 3
WC Nursing
SC Nursing
GA 732PZ
UT WOS:000288201900014
PM 21389831
ER
PT J
AU Ratnam, KK
Feng, XB
Chuang, PY
Verma, V
Lu, TC
Wang, JS
Jin, YM
Farias, EF
Napoli, JL
Chen, N
Kaufman, L
Takano, T
D'Agati, VD
Klotman, PE
He, JC
AF Ratnam, Krishna K.
Feng, Xiaobei
Chuang, Peter Y.
Verma, Vikram
Lu, Ting-Chi
Wang, Jinshan
Jin, Yuanmeng
Farias, Eduardo F.
Napoli, Joseph L.
Chen, Nan
Kaufman, Lewis
Takano, Tomoko
D'Agati, Vivette D.
Klotman, Paul E.
He, John C.
TI Role of the retinoic acid receptor-alpha in HIV-associated nephropathy
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE HIV; kidney disease; podocytes; proteinuria; retinoic acid receptor
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IN-VITRO; HIV-1-ASSOCIATED
NEPHROPATHY; PATHOLOGICAL CLASSIFICATION; PODOCYTE PROLIFERATION;
ANTIRETROVIRAL THERAPY; GLOMERULAR-DISEASE; EXPRESSION; MICE;
DIFFERENTIATION
AB All-trans retinoic acid protects against the development of HIV-associated nephropathy (HIVAN) in HIV-1 transgenic mice (Tg26). In vitro, all-trans retinoic acid inhibits HIV-induced podocyte proliferation and restores podocyte differentiation markers by activating its receptor-alpha (RAR alpha). Here, we report that Am580, a water-soluble RAR alpha-specific agonist, attenuated proteinuria, glomerosclerosis, and podocyte proliferation, and restored podocyte differentiation markers in kidneys of Tg26 mice. Furthermore, RAR alpha-/- Tg26 mice developed more severe kidney and podocyte injury than did RAR alpha-/- Tg26 mice. Am580 failed to ameliorate kidney injury in RAR alpha-/- Tg26 mice, confirming our hypothesis that Am580 acts through RAR alpha. Although the expression of RAR alpha-target genes was suppressed in the kidneys of Tg26 mice and of patients with HIVAN, the expression of RAR alpha in the kidney was not different between patients with HIVAN and minimal change disease. However, the tissue levels of retinoic acid were reduced in the kidney cortex and isolated glomeruli of Tg26 mice. Consistent with this, the expression of two key enzymes in the retinoic acid synthetic pathway, retinol dehydrogenase type 1 and 9, and the overall enzymatic activity for retinoic acid synthesis were significantly reduced in the glomeruli of Tg26 mice. Thus, a defect in the endogenous synthesis of retinoic acid contributes to loss of the protection by retinoic acid in HIVAN. Hence, RAR alpha agonists may be potential agents for the treatment of HIVAN. Kidney International (2011) 79, 624-634; doi: 10.1038/ki.2010.470; published online 8 December 2010
C1 [He, John C.] Mt Sinai Sch Med, Dept Med Nephrol, Div Nephrol, New York, NY 10029 USA.
[Feng, Xiaobei; Jin, Yuanmeng; Chen, Nan] Shanghai Jiao Tong Univ, RuiJin Hosp, Sch Med, Shanghai 200030, Peoples R China.
[Wang, Jinshan; Napoli, Joseph L.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
[Farias, Eduardo F.] Mt Sinai Sch Med, Dept Med, Div Hematol, New York, NY 10029 USA.
[Takano, Tomoko] McGill Univ, Ctr Hlth, Div Nephrol, Montreal, PQ, Canada.
[D'Agati, Vivette D.] Columbia Univ, Dept Pathol, New York, NY USA.
[He, John C.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[He, John C.] James J Peters VA Med Ctr, New York, NY USA.
RP He, JC (reprint author), Mt Sinai Sch Med, Dept Med Nephrol, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM cijiang.he@mssm.edu
FU National Institutes of Health [R01 DK078897, K08DK082760]; VA
[1I01BX000345]
FX This work was supported by National Institutes of Health grant R01
DK078897 to JCH. JCH is also supported by a VA Merit Award
(1I01BX000345). PYC is a recipient of the NIH career development award
(K08DK082760).
NR 42
TC 31
Z9 31
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD MAR
PY 2011
VL 79
IS 6
BP 624
EP 634
DI 10.1038/ki.2010.470
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA 727MO
UT WOS:000287804600007
PM 21150871
ER
PT J
AU Lane, MA
McDonald, JR
Zeringue, AL
Caplan, L
Curtis, JR
Ranganathan, P
Eisen, SA
AF Lane, Michael A.
McDonald, Jay R.
Zeringue, Angelique L.
Caplan, Liron
Curtis, Jeffrey R.
Ranganathan, Prabha
Eisen, Seth A.
TI TNF-alpha Antagonist Use and Risk of Hospitalization for Infection in a
National Cohort of Veterans With Rheumatoid Arthritis
SO MEDICINE
LA English
DT Article
ID ANTITUMOR-NECROSIS-FACTOR; MODIFYING ANTIRHEUMATIC DRUGS; SERIOUS
BACTERIAL-INFECTIONS; BRITISH-SOCIETY; ELDERLY-PATIENTS; FACTOR THERAPY;
AFFAIRS; BIOLOGICS; PNEUMONIA; MORTALITY
AB Medications used to treat rheumatoid arthritis (RA) may confer an increased risk of infection. We conducted a retrospective cohort study of veterans with RA followed in the United States Department of Veterans Affairs health care system from October 1998 through September 2005. Risk of hospitalization for infection associated with tumor necrosis factor (TNF)-alpha antagonists therapy was measured using an extension of Cox proportional hazards regression, adjusting for demographic characteristics, comorbid illnesses, and other medications used to treat RA.
A total of 20,814 patients met inclusion criteria, including 3796 patients who received infliximab, etanercept, or adalimumab. Among the study cohort, 1465 patients (7.0%) were hospitalized at least once for infection. There were 1889 hospitalizations for infection. The most common hospitalized infections were pneumonia, bronchitis, and cellulitis. Age and several comorbid medical conditions were associated with hospitalization for infection. Prednisone (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.88Y2.43) and TNF-alpha antagonist use (HR, 1.24; 95% CI, 1.02-1.50) were associated with hospitalization for infection, while the use of disease-modifying antirheumatic drugs (DMARDs) other than TNF-alpha antagonists was not. Compared to etanercept, infliximab was associated with risk for hospitalization for infection (HR, 1.51; 95% CI, 1.14-2.00), while adalimumab use was not (HR, 0.95; 95% CI, 0.68-1.33). In all treatment groups, rate of hospitalization for infection was highest in the first 8 months of therapy.
We conclude that patients with RA who are treated with TNF-alpha antagonists are at higher risk for hospitalization for infection than those treated with other DMARDs. Prednisone use is also a risk factor for hospitalization for infection.
C1 [Lane, Michael A.] Washington Univ, Sch Med, St Louis, MO 63110 USA.
[McDonald, Jay R.; Zeringue, Angelique L.] St Louis Vet Affairs Med Ctr, St Louis, MO USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Curtis, Jeffrey R.] Univ Alabama, Ctr Educ & Res Therapeut, Birmingham, AL USA.
[Eisen, Seth A.] Vet Affairs Hlth Serv Res & Dev, Washington, DC USA.
RP Lane, MA (reprint author), Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8051, St Louis, MO 63110 USA.
EM mlane@dom.wustl.edu
RI Zeringue, Angelique/I-1755-2012
OI Lane, Michael/0000-0003-2426-8186
FU Department of Veterans Affairs; Veterans Health Administration; Health
Services Research and Development [IAF 06-026]; Goldfarb Patient Safety
& Quality Fellowship; Barnes-Jewish Hospital Foundation; NIH
[K12RR023249, KL2RR024994]; VA [07-221]
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development Service project number IAF 06-026 (PI: Dr. McDonald). Dr.
Lane has received career development support from the Goldfarb Patient
Safety & Quality Fellowship program and the Barnes-Jewish Hospital
Foundation. The career development of Dr. McDonald has been supported by
NIH K12RR023249 and KL2RR024994. Dr. Caplan is supported by VA HSR&D
Career Development Award 07-221.
NR 35
TC 39
Z9 41
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7974
J9 MEDICINE
JI Medicine (Baltimore)
PD MAR
PY 2011
VL 90
IS 2
BP 139
EP 145
DI 10.1097/MD.0b013e318211106a
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 729BC
UT WOS:000287920600007
PM 21358439
ER
PT J
AU Ren, XF
Akiyoshi, K
Vandenbark, AA
Hurn, PD
Offner, H
AF Ren, Xuefang
Akiyoshi, Kozaburo
Vandenbark, Arthur A.
Hurn, Patricia D.
Offner, Halina
TI CD4(+)FoxP3(+) regulatory T-cells in cerebral ischemic stroke
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE Cerebral ischemia; T lymphocyte; T regulatory cells; Middle cerebral
artery occlusion; Stroke
AB Experimental cerebral ischemic stroke is exacerbated by inflammatory T-cells and is accompanied by systemic increases in CD4(+)CD25(+)Foxp3(+) regulatory T-cells (Treg). To determine their effect on ischemic brain injury, Treg were depleted in Foxp3(DTR) mice prior to stroke induction. In contrast to a recent Nature Medicine report, our results demonstrate unequivocally that Treg depletion did not affect stroke infarct volume, thus failing to implicate this regulatory pathway in limiting stroke damage.
C1 [Ren, Xuefang; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, R&D 31, Portland, OR 97239 USA.
[Ren, Xuefang; Akiyoshi, Kozaburo; Hurn, Patricia D.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
[Vandenbark, Arthur A.; Hurn, Patricia D.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
RI wu, peihua/F-8818-2012
FU NIH [NR03521]; Biomedical Laboratory R&D Service, Department of Veterans
Affairs
FX The authors wish to thank Dr. Sushmita Sinha, Ms. Sandhya Subramanian
and Dr. Suzan Dziennis for helpful discussions and Ms. Eva Niehaus and
Heather Hoem for assistance in preparing the manuscript. This work was
supported by NIH grant NR03521 and the Biomedical Laboratory R&D
Service, Department of Veterans Affairs.
NR 7
TC 56
Z9 57
U1 1
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD MAR
PY 2011
VL 26
IS 1
BP 87
EP 90
DI 10.1007/s11011-010-9226-6
PG 4
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 745DR
UT WOS:000289146100010
PM 21082336
ER
PT J
AU Ko, S
Ahn, J
Song, CS
Kim, S
Knapczyk-Stwora, K
Chatterjee, B
AF Ko, Soyoung
Ahn, Jungmi
Song, Chung S.
Kim, Soyoung
Knapczyk-Stwora, Katarzyna
Chatterjee, Bandana
TI Lysine Methylation and Functional Modulation of Androgen Receptor by
Set9 Methyltransferase
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID PROSTATE-CANCER; COACTIVATOR COMPLEX; HISTONE H3; ACETYLATION;
EXPRESSION; BINDING; ALPHA; AKT; P53; MYB
AB Lysine methyltransferases modulate activities of transcription factors and transcription coregulators by methylating specific lysine residue(s). We report that the androgen receptor (AR) is methylated at lysine-630 by Set9, which was originally identified as a histone H3K4 monomethyltransferase. Alanine substitution of lysine-630 prevented AR methylation in vitro and in vivo. Set9 methylated the nuclear and cytoplasmic AR utilizing the cofactor S-adenosyl-methionine. A panmethyllysine antibody recognized endogenous AR, and Set9 coimmunoprecipitated with nuclear and cytoplasmic AR. Set9 overexpression potentiated AR-mediated transactivation of the probasin promoter, whereas Set9 depletion inhibited AR activity and target gene expression. Similar to AR, chromatin occupancy of Set9 at androgen response elements (AREs) was androgen dependent, and associated with methylated histone H3K4 chromatin activation marks and p300/CBP associated factor acetyltransferase recruitment. Set9 depletion increased the histone H3K9-dimethyl repressive mark at AREs and reduced histone activation marks and occupancy of p300/CBP associated factor. K630A mutation reduced amino-and carboxy-terminal (N-C) interaction in Set9-intact cells, whereas N-C interaction for wild-type AR was reduced upon Set9 depletion. The K630A mutant was resistant to loss of activity from Set9 silencing and to increase of activity from Set9 overexpression. The K630 dependence of Set9-regulated N-C interaction and AR activity suggests that Set9 directly acts on AR at the amino acid level. Chromatin recruitment of Set9 to AREs is suggestive of its additional role as a transcriptional coactivator. Because the cellular metabolic state determines the level of S-adenosylmethionine and consequently the activity of Set9, the enhanced activity of methylated AR may have special significance in certain metabolic contexts. (Molecular Endocrinology 25: 433-444, 2011)
C1 [Ko, Soyoung; Ahn, Jungmi; Song, Chung S.; Kim, Soyoung; Knapczyk-Stwora, Katarzyna; Chatterjee, Bandana] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA.
[Chatterjee, Bandana] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chatterjee@uthscsa.edu
FU National Institutes of Health [R01-AG10486, R01-AG19660]; Veterans
Affairs; Department of Defense [XWH-08-1-0067]; Clinical and
Translational Science Award-Translational Science Training predoctoral
fellowship
FX The study was supported by National Institutes of Health Grants
R01-AG10486 and R01-AG19660; a Veterans Affairs Merit-Review grant, a
Department of Defense predoctoral fellowship, XWH-08-1-0067 (to S. Ko.);
and a Clinical and Translational Science Award-Translational Science
Training predoctoral fellowship (to J.A.).
NR 26
TC 34
Z9 35
U1 1
U2 8
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD MAR
PY 2011
VL 25
IS 3
BP 433
EP 444
DI 10.1210/me.2010-0482
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 726CX
UT WOS:000287697500006
PM 21273441
ER
PT J
AU Neuwelt, EA
Bauer, B
Fahlke, C
Fricker, G
Iadecola, C
Janigro, D
Leybaert, L
Molnar, Z
O'Donnell, ME
Povlishock, JT
Saunders, NR
Sharp, F
Stanimirovic, D
Watts, RJ
Drewes, LR
AF Neuwelt, Edward A.
Bauer, Bjoern
Fahlke, Christoph
Fricker, Gert
Iadecola, Constantino
Janigro, Damir
Leybaert, Luc
Molnar, Zoltan
O'Donnell, Martha E.
Povlishock, John T.
Saunders, Norman R.
Sharp, Frank
Stanimirovic, Danica
Watts, Ryan J.
Drewes, Lester R.
TI Engaging neuroscience to advance translational research in brain barrier
biology
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID CENTRAL-NERVOUS-SYSTEM; BINDING CASSETTE TRANSPORTERS; P-GLYCOPROTEIN
EXPRESSION; HUMAN BLOOD-BRAIN; HEREDITARY CEREBRAL-HEMORRHAGE; GREEN
FLUORESCENT PROTEIN; AMINO-ACID TRANSPORTERS; NECROSIS-FACTOR-ALPHA;
INDUCED UP-REGULATION; MULTIPLE-SCLEROSIS
AB The delivery of many potentially therapeutic and diagnostic compounds to specific areas of the brain is restricted by brain barriers, of which the most well known are the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier. Recent studies have shown numerous additional roles of these barriers, including an involvement in neurodevelopment, in the control of cerebral blood flow, and-when barrier integrity is impaired-in the pathology of many common CNS disorders such as Alzheimer's disease, Parkinson's disease and stroke.
C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Bauer, Bjoern] Univ Minnesota, Coll Pharm, Duluth, MN 55812 USA.
[Fahlke, Christoph] Hannover Med Sch, Inst Neurophysiol, OE 4230, D-30625 Hannover, Germany.
[Fricker, Gert] Univ Heidelberg, Abt Pharmazeut Technol & Pharmakol Neuenheimer, D-69120 Heidelberg, Germany.
[Iadecola, Constantino] Weill Cornell Med Coll, Div Neurobiol, New York, NY 10065 USA.
[Janigro, Damir] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Leybaert, Luc] Univ Ghent, Dept Basic Med Sci, B-9000 Ghent, Belgium.
[Molnar, Zoltan] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England.
[O'Donnell, Martha E.] Univ Calif Davis, Sch Med, Dept Physiol & Membrane Biol, Davis, CA 95616 USA.
[Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA.
[Saunders, Norman R.] Univ Melbourne, Dept Pharmacol Parkville, Melbourne, Vic 3010, Australia.
[Sharp, Frank] Univ Calif Davis, UC Davis MIND Inst, Sacramento, CA 95817 USA.
[Stanimirovic, Danica] Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R7, Canada.
[Watts, Ryan J.] Genentech Inc, Dept Neurosci, San Francisco, CA 94080 USA.
[Drewes, Lester R.] Univ Minnesota, Sch Med, Duluth, MN 55812 USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
RI Fahlke, Christoph/G-3635-2013; Leybaert, Luc/F-4079-2015
OI Fahlke, Christoph/0000-0001-8602-9952; Janigro,
Damir/0000-0003-2165-5826; Leybaert, Luc/0000-0001-6452-6982; Molnar,
Zoltan/0000-0002-6852-6004; Saunders, Norman/0000-0001-6660-7639
FU US National Institutes of Health [5 R13 CA086959-10]
FX The meeting on which this report was based was partially funded by an
R13 grant from the US National Institutes of Health (Grant 5 R13
CA086959-10). We would like to thank all of the people who attended the
Engaging Neuroscience to Advance Brain Barriers Translational Research
meeting (March 19-21, 2009), Gleneden Beach, Oregon, USA. Special thanks
to Lester Drewes, Martha O'Donnell, Leslie Muldoon and Aliana Kim who
were instrumental in the development of this report.
NR 218
TC 193
Z9 198
U1 2
U2 58
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-003X
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD MAR
PY 2011
VL 12
IS 3
BP 169
EP 182
DI 10.1038/nrn2995
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 722ZM
UT WOS:000287474900004
PM 21331083
ER
PT J
AU Montine, TJ
Peskind, ER
Quinn, JF
Wilson, AM
Montine, KS
Galasko, D
AF Montine, Thomas J.
Peskind, Elaine R.
Quinn, Joseph F.
Wilson, Angela M.
Montine, Kathleen S.
Galasko, Douglas
TI Increased Cerebrospinal Fluid F-2-Isoprostanes are Associated with Aging
and Latent Alzheimer's Disease as Identified by Biomarkers
SO NEUROMOLECULAR MEDICINE
LA English
DT Article
DE Alzheimer's disease; Cerebrospinal fluid; Biomarkers; A beta(42); Tau;
F-2-isoprostanes
ID MILD COGNITIVE IMPAIRMENT; IN-VIVO; AMYLOID DEPOSITION;
LIPID-PEROXIDATION; OXIDATIVE STRESS; OLDER-ADULTS; BRAIN; AD;
F-4-NEUROPROSTANES; NEUROPATHOLOGY
AB Alzheimer's disease (AD) is a common age-related chronic illness with latent, prodrome, and fully symptomatic dementia stages. Increased free radical injury to regions of brain is one feature of prodrome and dementia stages of AD; however, it also is associated with advancing age. This raises the possibility that age-related free radical injury to brain might be caused in part or in full by latent AD. We quantified free radical injury in the central nervous system with cerebrospinal fluid (CSF) F-2-isoprostanes (IsoPs) in 421 clinically normal individuals and observed a significant increase over the adult human lifespan (P < 0.001). Using CSF amyloid (A) beta(42) and tau, we defined normality using results from 28 clinically normal individuals < 50 years old, and then stratified 74 clinically normal subjects a parts per thousand yen60 years into those with CSF that had normal CSF A beta(42) and tau (n = 37); abnormal CSF A beta(42) and tau, the biomarker signature of AD (n = 24); decreased A beta(42) only (n = 4); or increased tau only (n = 9). Increased CSF F-2-IsoPs were present in clinically normal subjects with the biomarker signature of AD (P < 0.05) and those subjects with increased CSF tau (P < 0.001). Finally, we analyzed the relationship between age and CSF F-2-IsoPs for those clinically normal adults with normal CSF (n = 37) and those with abnormal CSF A beta(42) and/or tau (n = 37); only those with normal CSF demonstrated a significant increase with age (P < 0.01). These results show that CSF F-2-IsoPs increased across the human lifespan and that this age-related increase in free radical injury to brain persisted after culling those with laboratory evidence of latent AD.
C1 [Montine, Thomas J.; Wilson, Angela M.; Montine, Kathleen S.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA.
[Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
EM tmontine@u.washington.edu
FU NIH [AG05131, AG05136]; Fidelity Foundation; Nancy and Buster Alvord
Endowment
FX This work was supported by grants from the NIH (AG05131 and AG05136),
the Fidelity Foundation, and the Nancy and Buster Alvord Endowment.
NR 41
TC 32
Z9 32
U1 1
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1535-1084
J9 NEUROMOL MED
JI Neuromol. Med.
PD MAR
PY 2011
VL 13
IS 1
BP 37
EP 43
DI 10.1007/s12017-010-8126-6
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 726VB
UT WOS:000287753400012
PM 20632131
ER
PT J
AU Morasco, BJ
Gritzner, S
Lewis, L
Oldham, R
Turk, DC
Dobscha, SK
AF Morasco, Benjamin J.
Gritzner, Susan
Lewis, Lynsey
Oldham, Robert
Turk, Dennis C.
Dobscha, Steven K.
TI Systematic review of prevalence, correlates, and treatment outcomes for
chronic non-cancer pain in patients with comorbid substance use disorder
SO PAIN
LA English
DT Review
DE Chronic pain; Substance use disorder; Treatment outcomes; Opioids;
Systematic review; Quality of life
ID LOW-BACK-PAIN; CHRONIC NONMALIGNANT PAIN; TERM OPIOID THERAPY;
DRUG-RELATED BEHAVIORS; PRIMARY-CARE; IMMPACT RECOMMENDATIONS;
MEDICATION MISUSE; CLINICAL-TRIALS; ALCOHOL-ABUSE; RISK-FACTORS
AB Recent data suggest that comorbid substance use disorders (SUDs) are common among chronic non-cancer pain (CNCP) patients; however, prevalence rates vary across studies and findings are limited regarding treatment options for CNCP patients with comorbid SUD. The purpose of this systematic review is to assess the prevalence, associated demographic and clinical characteristics, and treatment outcomes for CNCP patients with comorbid SUD. We conducted searches from Ovid MEDLINE, PsychINFO, and PubMED from 1950 through February 2010 and retrieved the references. Thirty-eight studies met inclusion criteria and provided data that addressed our key questions. Three to forty-eight percent of CNCP patients have a current SUD. There are no demographic or clinical factors that consistently differentiate CNCP patients with comorbid SUD from patients without SUD, though SUD patients appear to be at greater risk for aberrant medication-related behaviors. CNCP patients with SUD are more likely to be prescribed opioid medications and at higher doses than CNCP patients without a history of SUD. CNCP patients with comorbid SUD do not significantly differ in their responses to treatment compared to CNCP patients without SUD, though the quality of this evidence is low. Limited data are available to identify predictors of treatment outcome. Although clinical experience and research suggests that SUDs are common among CNCP patients, only limited data are available to guide clinicians who treat this population. Research is needed to increase understanding of the prevalence, correlates, and responses to treatment of CNCP patients with comorbid SUDs. Published by Elsevier B. V. on behalf of International Association for the Study of Pain.
C1 [Morasco, Benjamin J.; Gritzner, Susan; Lewis, Lynsey; Oldham, Robert; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Morasco, Benjamin J.; Oldham, Robert; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA.
[Gritzner, Susan] Univ Pacific, Sch Profess Psychol, Stockton, CA 95211 USA.
[Turk, Dennis C.] Univ Washington Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA.
[Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Med & Psychiat, Portland, OR USA.
RP Morasco, BJ (reprint author), Portland VA Med Ctr R&D99, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM benjamin.morasco@va.gov
FU National Institute on Drug Abuse [K23DA023467]; Endo; Johnson Johnson;
Philips Respironics; National Institutes of Health; Eli Lilly; Empi;
Pfizer; SK LifeScience
FX This study was supported in part by award K23DA023467 from the National
Institute on Drug Abuse to Dr. Morasco. During the past 12 months, Dr.
Turk has received research support from Endo, Johnson & Johnson, Philips
Respironics, and the National Institutes of Health, and consulting fees
from Eli Lilly, Empi, Johnson & Johnson, Pfizer, Philips Respironics,
and SK LifeScience. He is also a Special Government Employee of the US
Food and Drug Administration. We appreciate the assistance of Mark
Helfand, M. D., Devan Kansagara, M. D., and Roger Chou, M. D., for help
in drafting or editing the key questions, Michele Freeman, M. P. H. for
technical assistance, and research librarians Rose Campbell and Andrew
Hamilton for developing the literature search strategies. The content of
this manuscript is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health, Department of Veterans Affairs, US Food and Drug Administration,
or another private entity.
NR 65
TC 50
Z9 52
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3959
J9 PAIN
JI Pain
PD MAR
PY 2011
VL 152
IS 3
BP 488
EP 497
DI 10.1016/j.pain.2010.10.009
PG 10
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 719GZ
UT WOS:000287192200009
PM 21185119
ER
PT J
AU Sosenko, JM
Mahon, J
Rafkin, L
Lachin, JM
Krause-Steinrauf, H
Krischer, JP
Cuthbertson, D
Palmer, JP
Thompson, C
Greenbaum, CJ
Skyler, JS
AF Sosenko, Jay M.
Mahon, Jeffrey
Rafkin, Lisa
Lachin, John M.
Krause-Steinrauf, Heidi
Krischer, Jeffrey P.
Cuthbertson, David
Palmer, Jerry P.
Thompson, Clinton
Greenbaum, Carla J.
Skyler, Jay S.
CA Diabet Prevention Trial-Type 1 Grp
TrialNet Study Grp
TI A comparison of the baseline metabolic profiles between Diabetes
Prevention Trial-Type 1 and TrialNet Natural History Study participants
SO PEDIATRIC DIABETES
LA English
DT Article
DE C-peptide; glucose; prevention; trials; T1D
ID ISLET-CELL ANTIBODIES; INSULIN; MELLITUS; RISK; AUTOANTIBODIES;
SPECIFICITIES; RELATIVES; ANTIGEN; ONSET
AB Objective: We assessed whether differing autoantibody screening criteria for type 1 diabetes (T1D) prevention trials result in different baseline metabolic profiles of those who screen positive.
Methods: Diabetes Prevention Trial-Type 1 (DPT-1) participants were screened for islet cell autoantibodies, whereas TrialNet Natural History Study (TNNHS) participants were screened for biochemical autoantibodies. In both studies, those determined to be autoantibody positive underwent baseline oral glucose tolerance tests (OGTTs) in which glucose and C-peptide were measured.
Results: The percentage of those with an OGTT in the diabetic range was higher among the DPT-1 participants (10.0% of 956 vs. 6.4% of 645, p < 0.01). In a logistic regression analysis with adjustments for age and gender, the difference persisted (p < 0.01). Among those in the non-diabetic range (n = 860 for DPT-1 and n = 604 for the TNNHS), glucose levels were similar at all time points, except for higher fasting glucose levels in the TNNHS participants (p < 0.001). There was a higher percentage of impaired fasting glucose (IFG) in the TNNHS participants (10.9 vs. 6.7%, p < 0.01); however, with adjustments for age and gender, there was no longer a significant difference. There was no significant difference in the percentages with impaired glucose tolerance. C-peptide levels were much lower in the DPT-1 cohort at all OGTT time points (p < 0.001 for all).
Discussion: Differing criteria for autoantibody screening can result in marked differences in the baseline metabolic profiles of prospective participants of T1D prevention trials.
C1 [Sosenko, Jay M.] Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol, Miami, FL 33101 USA.
[Mahon, Jeffrey] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON N6A 3K7, Canada.
[Lachin, John M.; Krause-Steinrauf, Heidi; Thompson, Clinton] George Washington Univ, Ctr Biostat, Rockville, MD USA.
[Krischer, Jeffrey P.] Univ S Florida, Div Informat & Biostat, Tampa, FL USA.
[Cuthbertson, David] Univ S Florida, Pediatr Epidemiol Ctr, Tampa, FL USA.
[Palmer, Jerry P.] Univ Washington, Div Endocrinol & Metab, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Greenbaum, Carla J.] Benaroya Res Inst, Seattle, WA USA.
RP Sosenko, JM (reprint author), Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol, POB 016960, Miami, FL 33101 USA.
EM jsosenko@med.miami.edu
RI Skyler, Jay/F-4211-2016
OI Lachin, John/0000-0001-9838-2841
FU National Institutes of Health through the National Institute of Diabetes
and Digestive and Kidney Diseases; National Institute of Allergy and
Infectious Diseases; National Institute of Child Health and Human
Development; General Clinical Research Centers; Juvenile Diabetes
Research Foundation International; ADA
FX TrialNet is funded by the National Institutes of Health through the
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institute of Allergy and Infectious Diseases, National
Institute of Child Health and Human Development, and General Clinical
Research Centers Program; the Juvenile Diabetes Research Foundation
International; and the ADA.
NR 17
TC 5
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1399-543X
J9 PEDIATR DIABETES
JI Pediatr. Diabetes
PD MAR
PY 2011
VL 12
IS 2
BP 85
EP 90
DI 10.1111/j.1399-5448.2010.00662.x
PG 6
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 726DZ
UT WOS:000287700300003
PM 20522170
ER
PT J
AU Goebel, M
Stengel, A
Lambrecht, NWG
Sachs, G
AF Goebel, M.
Stengel, A.
Lambrecht, N. W. G.
Sachs, G.
TI Selective gene expression by rat gastric corpus epithelium
SO PHYSIOLOGICAL GENOMICS
LA English
DT Article
DE transcriptome; stomach
ID PROTEIN DISULFIDE-ISOMERASE; ACID-SECRETION; HELICOBACTER-PYLORI;
PARIETAL-CELLS; MESSENGER-RNA; MOLECULAR CHARACTERIZATION;
ALCOHOL-DEHYDROGENASE; OXYNTIC MUCOSA; MOUSE STOMACH; ECL CELLS
AB Goebel M, Stengel A, Lambrecht NW, Sachs G. Selective gene expression by rat gastric corpus epithelium. Physiol Genomics 43: 237-254, 2011. First published December 21, 2010; doi:10.1152/physiolgenomics.00193.2010.-The gastrointestinal (GI) tract is divided into several segments that have distinct functional properties, largely absorptive. The gastric corpus is the only segment thought of as largely secretory. Microarray hybridization of the gastric corpus mucosal epithelial cells was used to compare gene expression with other segments of the columnar GI tract followed by statistical data subtraction to identify genes selectively expressed by the rat gastric corpus mucosa. This provides a means of identifying less obvious specific functions of the corpus in addition to its secretion-related genes. For example, important properties found by this GI tract comparative transcriptome reflect the energy demand of acid secretion, a role in lipid metabolism, the large variety of resident neuroendocrine cells, responses to damaging agents and transcription factors defining differentiation of its epithelium. In terms of overlap of gastric corpus genes with the rest of the GI tract, the distal small bowel appears to express many of the gastric corpus genes in contrast to proximal small and large bowel. This differential map of gene expression by the gastric corpus epithelium will allow a more detailed description of major properties of the gastric corpus and may lead to the discovery of gastric corpus cell differentiation genes and those mis-regulated in gastric carcinomas.
C1 [Goebel, M.; Stengel, A.; Sachs, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Lambrecht, N. W. G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Lambrecht, N. W. G.; Sachs, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
[Sachs, G.] W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Los Angeles, CA 90073 USA.
RP Lambrecht, NWG (reprint author), VA Long Beach Hlth Care Syst, Bldg 1,Rm 200M,E 7th St 09-113, Long Beach, CA 90822 USA.
EM Nils.Lambrecht2@va.gov
OI Lambrecht, Nils/0000-0002-1275-1384
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK-058333, DK-053642]; US Department of Veterans Affairs; German
Research Foundation [STE 1765/1-1, GO 1718/1-1]
FX This work was supported by National Institute of Diabetes and Digestive
and Kidney Diseases Grants DK-058333 (G. Sachs) and DK-053642 (G.
Sachs), the US Department of Veterans Affairs (G. Sachs), and German
Research Foundation Grants STE 1765/1-1 (A. Stengel) and Grant GO
1718/1-1 (M. Goebel).
NR 92
TC 5
Z9 5
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1094-8341
J9 PHYSIOL GENOMICS
JI Physiol. Genomics
PD MAR
PY 2011
VL 43
IS 5
BP 237
EP 254
DI 10.1152/physiolgenomics.00193.2010
PG 18
WC Cell Biology; Genetics & Heredity; Physiology
SC Cell Biology; Genetics & Heredity; Physiology
GA 735ZI
UT WOS:000288458900001
PM 21177383
ER
PT J
AU Chan, WM
Dicianno, BE
AF Chan, Wendy M.
Dicianno, Brad E.
TI Virtual Socialization in Adults With Spina Bifida
SO PM&R
LA English
DT Article
ID QUALITY-OF-LIFE; YOUNG-ADULTS; HYDROCEPHALUS; ADOLESCENTS; ADJUSTMENT;
DISABILITY; MOBILITY; CHILDREN; HEALTH; WORLD
AB Objective: To use spina bifida (SB) as a model of chronic physical disability to study the associations of virtual socialization, friendships, and quality of life (QOL) in adults.
Design: Cross-sectional survey.
Setting: Subjects were recruited from residential living facilities, outpatient clinics, and the University of Pittsburgh Medical Center (UPMC) research registry.
Patients: Inclusion criteria were age between 18 and 80 years and clinical diagnoses of SB cystica (myelomeningocele) and hydrocephalus. The exclusion criterion was the diagnosis of SB occulta. Sixty-three eligible adults were enrolled, and all completed the study.
Methods: The survey via questionnaire was performed in person or over the telephone.
Main Outcome Measurements: Data collected included the World Health Organization's Medical Outcomes Study 26-item Short Form, Economic Self-Sufficiency from the Craig Handicap Assessment and Reporting Technique Short Form, virtual socializing habits, and number of friends. Three linear regression models were performed, each with a unique dependent variable: number of friends, psychological QOL, or social QOL. The following independent variables were included in all models: age, gender, ethnicity, economic self-sufficiency, marital status, education level, lesion level, health status, user group, collection method, and time spent virtually socializing. In addition, each regression model included the dependent variables from the other 2 models in its independent variables.
Results: Increased degree of virtual socialization (VS) was associated with a greater number of friends (P = .003, r = .684). Mean (standard deviation) numbers of friends by VS groups were the following: users, n = 4.9 +/- 2.7; semi-users, n = 3.8 +/- 2.7; and nonusers, n = 2.1 +/- 2.3, which represent a 2.3 times greater number of friends between the users and nonusers. The effect of virtual socialization on QOL was also positive, however, not statistically significant.
Conclusions: People with chronic physical disabilities, such as SB, are at high risk for peer rejection and long-term social avoidance. Users of the most immersive forms of virtual socialization, have more real world friends than both semi-users and nonusers. Any form of VS, whether immersive or real time, may improve the opportunity for meaningful social encounters. Prospective intervention studies are needed to elucidate whether a causal positive relationship between virtual socialization and friendships exists. Further research is needed to clarify virtual socialization's impact on QOL; however, the upward trend in all 4 domains of QOL across user groups suggests similar potential benefits. PM R 2011;3:219-225
C1 [Dicianno, Brad E.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Adult Spina Bifida Clin, Pittsburgh, PA 15260 USA.
[Dicianno, Brad E.] VA Pittsburgh HealthCare Syst, Pittsburgh, PA USA.
[Chan, Wendy M.] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
RP Dicianno, BE (reprint author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Adult Spina Bifida Clin, 201 Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15260 USA.
EM dicianno@pitt.edu
OI Dicianno, Brad/0000-0003-0738-0192
FU Human Engineering Research Laboratories
FX This research benefited from the support of Annmarie Kelleher MS, OTR/L,
ATP, CCRP, and Stacy Eckstein BS, MT(ASCP) from the Human Engineering
Research Laboratories.
NR 38
TC 4
Z9 4
U1 3
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAR
PY 2011
VL 3
IS 3
BP 219
EP 225
DI 10.1016/j.pmrj.2010.12.002
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 961AX
UT WOS:000305437400006
PM 21402368
ER
PT J
AU Reddy, R
Fleet-Michaliszyn, S
Condray, R
Yao, JK
Keshavan, MS
Reddy, R
AF Reddy, R.
Fleet-Michaliszyn, S.
Condray, R.
Yao, J. K.
Keshavan, M. S.
Reddy, R.
TI Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic
acid in patients with schizophrenia: Preliminary study
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE Schizophrenia; Omega-3 fatty acid; Eicosapentaenoic acid; WCST;
Executive function
ID PLACEBO-CONTROLLED TRIAL; CELL MEMBRANE DYNAMICS; COGNITIVE DYSFUNCTION;
FATTY-ACIDS; ANTIPSYCHOTIC MEDICATIONS; 1ST-EPISODE SCHIZOPHRENIA;
NEUROCOGNITIVE DEFICITS; MEMORY PERFORMANCE; EXECUTIVE FUNCTION;
OMEGA-3-FATTY-ACIDS
AB Introduction: Patients with schizophrenia have significant cognitive deficits, generally resistant to conventional treatment. This preliminary study examined the effects of ethyl-eicosapentanoate (EPA) on an executive function in early course patients.
Patients and methods: Patients with schizophrenia were given, after an informed consent, 2 g of an EPA daily for 24 weeks, in an open-label study. The Wisconsin Card Sort Test (WCST) was administered at baseline, weeks 4, 12 and 24.
Results: The 27 patients, with a mean duration of illness of 4.2 years, were all receiving atypical antipsychotics; treatment remained unchanged for the study. Perseverative errors - the key measure derived from WCST - were significantly reduced from the baseline mean of 28.2 to 18.4 errors at week 24. Positive symptoms also improved significantly. There were no correlations between EPA levels and any clinical or other neuropsychological measures.
Conclusion: These findings suggest that an EPA has procognitive effects for patients with schizophrenia, but controlled trials are required. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Reddy, R.; Condray, R.; Yao, J. K.; Reddy, R.] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
[Reddy, R.] Univ Toledo, Sch Med, Toledo, OH 43606 USA.
[Fleet-Michaliszyn, S.] Univ Arizona, Tucson, AZ USA.
[Condray, R.; Yao, J. K.; Reddy, R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Keshavan, M. S.] Harvard Univ, Boston, MA 02115 USA.
RP Reddy, R (reprint author), Univ Pittsburgh, 3811 OHara St, Pittsburgh, PA 15213 USA.
EM reddyr@upmc.edu
FU NIMH [MH-46118, MH-58141, MH-45203]; VA Research Career Scientist Award;
NIH/NCRR/GCRC [M01 RR00056]
FX Sources of support: this publication was supported by funds received
from NIMH Grants MH-46118 (RR), MH-58141 (JKY) and MH-45203 (MSK), VA
Research Career Scientist Award (JKY), and the NIH/NCRR/GCRC Grant #M01
RR00056.
NR 54
TC 9
Z9 9
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
EI 1532-2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD MAR-APR
PY 2011
VL 84
IS 3-4
BP 79
EP 83
DI 10.1016/j.plefa.2010.12.001
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
GA 727EJ
UT WOS:000287780100002
PM 21211955
ER
PT J
AU Reise, SP
Ventura, J
Keefe, RSE
Baade, LE
Gold, JM
Green, MF
Kern, RS
Mesholam-Gately, R
Nuechterlein, KH
Seidman, LJ
Bilder, R
AF Reise, Steven P.
Ventura, Joseph
Keefe, Richard S. E.
Baade, Lyle E.
Gold, James M.
Green, Michael F.
Kern, Robert S.
Mesholam-Gately, Raquelle
Nuechterlein, Keith H.
Seidman, Larry J.
Bilder, Robert
TI Bifactor and Item Response Theory Analyses of Interviewer Report Scales
of Cognitive Impairment in Schizophrenia
SO PSYCHOLOGICAL ASSESSMENT
LA English
DT Article
DE item response theory; CGI-CogS; SCoRS; schizophrenia and cognitive
deficits; computerized adaptive testing
ID CLINICAL-TRIALS; RATING-SCALE; DIMENSIONALITY; RELIABILITY; VALIDITY;
BATTERY; MODELS
AB A psychometric analysis of 2 interview-based measures of cognitive deficits was conducted: the 21-item Clinical Global Impression of Cognition in Schizophrenia (CGI-CogS; Ventura et al., 2008), and the 20-item Schizophrenia Cognition Rating Scale (SCoRS; Keefe et al., 2006), which were administered on 2 occasions to a sample of people with schizophrenia. Traditional psychometrics, bifactor analysis, and item response theory methods were used to explore item functioning and dimensionality and to compare instruments. Despite containing similar item content, responses to the CGI-CogS demonstrated superior psychometric properties (e.g., higher item intercorrelations, better spread of ratings across response categories) relative to the SCoRS. The authors argue that these differences arise mainly from the differential use of prompts and how the items are phrased and scored. Bifactor analysis demonstrated that although both measures capture a broad range of cognitive functioning (e.g., working memory, social cognition), the common variance on each is overwhelmingly explained by a single general factor. Item response theory analyses of the combined pool of 41 items showed that measurement precision is peaked in the mild to moderate range of cognitive impairment. Finally, simulated adaptive testing revealed that only about 10 to 12 items are necessary to achieve latent trait level estimates with reasonably small standard errors for most individuals. This suggests that these interview-based measures of cognitive deficits could be shortened without loss of measurement precision.
C1 [Reise, Steven P.; Nuechterlein, Keith H.; Bilder, Robert] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Ventura, Joseph; Green, Michael F.; Kern, Robert S.; Nuechterlein, Keith H.; Bilder, Robert] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Keefe, Richard S. E.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27706 USA.
[Baade, Lyle E.] Univ Kansas, Sch Med, Lawrence, KS 66045 USA.
[Gold, James M.] Univ Maryland, Maryland Psychiat Res Ctr, Sch Med, Baltimore, MD 21201 USA.
[Green, Michael F.; Kern, Robert S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Mesholam-Gately, Raquelle; Seidman, Larry J.] Harvard Univ, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Beth Israel Deaconess Med Ctr,Dept Psychiat,Med S, Cambridge, MA 02138 USA.
RP Reise, SP (reprint author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
EM reise@psych.ucla.edu
RI Bilder, Robert/A-8894-2008
OI Bilder, Robert/0000-0001-5085-7852
FU NIDA NIH HHS [RL1 DA024853, RL1DA024853, RL1 DA024853-04]; NIDCR NIH HHS
[UL1 DE019580, UL1 DE019580-05, UL1-DE019580]; NIMH NIH HHS
[1R21MH073971, MH37705, N01MH22006, P50 MH066286, R01 MH037705, R21
MH073971, R21 MH073971-01A2, R21 MH073971-02]
NR 34
TC 21
Z9 23
U1 2
U2 12
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1040-3590
EI 1939-134X
J9 PSYCHOL ASSESSMENT
JI Psychol. Assess.
PD MAR
PY 2011
VL 23
IS 1
BP 245
EP 261
DI 10.1037/a0021501
PG 17
WC Psychology, Clinical
SC Psychology
GA 729KT
UT WOS:000287949200021
PM 21381848
ER
PT J
AU Spampinato, MV
Rumboldt, Z
Hosker, RJ
Mintzer, JE
AF Spampinato, Maria Vittoria
Rumboldt, Zoran
Hosker, Robert J.
Mintzer, Jacobo E.
CA Alzheimer's Dis Neuroimaging
TI Apolipoprotein E and Gray Matter Volume Loss in Patients with Mild
Cognitive Impairment and Alzheimer Disease
SO RADIOLOGY
LA English
DT Article
ID VOXEL-BASED MORPHOMETRY; CEREBROSPINAL-FLUID TAU; E EPSILON-4 ALLELE; E
GENOTYPE; TRANSGENIC MICE; CHOLINERGIC DEFICITS; CORTICAL THICKNESS;
AMYLOID DEPOSITION; CLINICAL-DIAGNOSIS; TACRINE THERAPY
AB Purpose: To examine the influence of apoliprotein E epsilon 4 allele (APOE 4) carrier status on disease progression by evaluating the rate of regional gray matter (GM) volume loss and disease severity in patients with newly diagnosed Alzheimer disease (AD) and stable amnestic mild cognitive impairment (MCI).
Materials and Methods: This study was approved by the institutional review board and was HIPAA compliant. All subjects or their legal representatives gave informed consent for participation. Ninety-five subjects (63 male; average age, 77.1 years; age range, 58-91 years; 51 APOE4 carriers; 44 noncarriers) with either documented MCI to AD conversion or stable amnestic MCI underwent three yearly magnetic resonance imaging examinations. Voxel-based morphometry for image postprocessing and Clinical Dementia Rating (CDR) scale for cognitive assessment were used.
Results: In APOE 4 carriers, GM volume loss affected the hippocampi, temporal and parietal lobes, right caudate nucleus, and insulae in patients with MCI to AD conversion and the insular and temporal lobes in patients in whom MCI was stable. In subjects who were not APOE 4 carriers, there was no significant GM volume change. There were no differences in CDR scores between APOE 4 carriers and noncarriers.
Conclusion: APOE 4 carriers with cognitive decline undergo faster GM atrophy than do noncarriers. The involvement of APOE 4 in the progression of hippocampal atrophy, neocortical atrophy, or both has potential important implications for diagnosis and therapeutic approaches in patients with AD and should be considered in clinical trials. The present results and the results of prior studies indicate that the rate of hippocampal and neocortical atrophy is greater in association with APOE 4 in nondemented elderly subjects, subjects with MCI, and those with AD. (C)RSNA, 2010
C1 [Spampinato, Maria Vittoria; Rumboldt, Zoran; Hosker, Robert J.] Med Univ S Carolina, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA.
[Mintzer, Jacobo E.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Spampinato, MV (reprint author), Med Univ S Carolina, Dept Radiol & Radiol Sci, 96 Jonathan Lucas St,MSC 323, Charleston, SC 29425 USA.
EM spampin@musc.edu
RI Scharre, Douglas/E-4030-2011
FU Bracco Diagnostics; Bayer; Siemens; National Institute on Aging
FX M.V.S. Financial activities related to the present article: none to
disclose. Financial activities not related to the present article: none
to disclose. Other relationships: institution received compensation from
Bayer HealthCare and Bracco Diagnostics. Z.R. Financial activities
related to the present article: none to disclose. Financial activities
not related to the present article: none to disclose. Other
relationships: is a consultant for Bracco Diagnostics; provides research
support for Bracco Diagnostics, Bayer, and Siemens. R.J.H. No potential
conflicts of interest to disclose. J.E.M. Financial activities related
to the present article: institution received funding from National
Institute on Aging. Financial activities not related to the present
article: is on the board of ADNI. Other relationships: none to disclose.
NR 53
TC 25
Z9 27
U1 0
U2 3
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD MAR
PY 2011
VL 258
IS 3
BP 843
EP 852
DI 10.1148/radiol.10100307
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 724JX
UT WOS:000287573100021
PM 21163916
ER
PT J
AU Chattergoon, NN
Louey, S
Giraud, GD
Thornburg, KL
AF Chattergoon, Natasha N.
Louey, Samantha
Giraud, George D.
Thornburg, Kent L.
TI Thyroid Hormone Deprivation Disrupts the IGF-I System in the Fetal Heart
SO REPRODUCTIVE SCIENCES
LA English
DT Meeting Abstract
C1 [Chattergoon, Natasha N.; Louey, Samantha; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA.
[Giraud, George D.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
J9 REPROD SCI
JI Reprod. Sci.
PD MAR
PY 2011
VL 18
IS 3
SU S
MA F115
BP 205A
EP 205A
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 778RE
UT WOS:000291721701042
ER
PT J
AU Baker-LePain, JC
Nakamura, MC
Shepherd, J
von Scheven, E
AF Baker-LePain, Julie C.
Nakamura, Mary C.
Shepherd, John
von Scheven, Emily
TI Assessment of bone remodelling in childhood-onset systemic lupus
erythematosus
SO RHEUMATOLOGY
LA English
DT Article
DE Bone turnover; Systemic lupus erythematosus; Children; Cytokines;
Interferon
ID RESISTANT ACID-PHOSPHATASE; JUVENILE RHEUMATOID-ARTHRITIS; CHRONIC
KIDNEY-DISEASE; MINERAL-DENSITY; IDIOPATHIC ARTHRITIS; KNEE
OSTEOARTHRITIS; PREMENOPAUSAL WOMEN; NUTRITIONAL-STATUS;
INTERFERON-BETA; GROWTH FAILURE
AB Methods. Ninety subjects with SLE aged 8-22 years underwent yearly measurements of height, bone age, bone turnover markers, serum Type I IFNs, SLEDAI and BMD. Predictors of bone turnover were examined using serum osteocalcin as a marker of bone formation and both serum tartrate-resistant acid phosphatase (TRAP) and urine N-telopeptide (NTx) as markers of bone resorption.
Results. Subjects demonstrated short stature, high BMI and bone age delay. A spine BMD Z-score of less than -2.0 was seen in 16.1% of subject visits. Serum osteocalcin was negatively correlated with glucocorticoid dose (Spearman rank correlation coefficient R = -0.34, P < 0.0001) but was not associated with SLEDAI after adjustment for confounders. Serum TRAP was negatively associated with SLEDAI, even after controlling for confounders (P = 0.04). Similar results were obtained for urine NTx. There was a negative association between TRAP and serum IFN-beta (P = 0.03).
Conclusions. In this population of children and young adults with moderate lupus disease activity, glucocorticoid dose was a negative predictor of bone formation, whereas lupus disease activity was not. Interestingly, lupus disease activity was a negative predictor of bone resorption, suggesting that lupus disease activity is not the primary factor contributing to the bone deficits of childhood-onset SLE. The potential protective role of IFN-beta and the effects of SLE treatment on bone loss require further study.
C1 [von Scheven, Emily] Univ Calif San Francisco, Childrens Hosp, Dept Pediat, San Francisco, CA 94143 USA.
[Baker-LePain, Julie C.; Nakamura, Mary C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Nakamura, Mary C.] San Francisco VA Med Ctr, Dept Rheumatol, San Francisco, CA USA.
[Shepherd, John] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
RP von Scheven, E (reprint author), Univ Calif San Francisco, Childrens Hosp, Dept Pediat, San Francisco, CA 94143 USA.
EM evonsche@peds.ucsf.edu
FU National Institutes of Health/National Center for Research Resources
UCSF-Clinical and Translational Science Institute [UL1 RR024131];
NIH/NCRR [16319]; NIH [AR007304]; Department of Veterans' Affairs
FX Funding: This publication was supported by National Institutes of
Health/National Center for Research Resources UCSF-Clinical and
Translational Science Institute Grant Number UL1 RR024131 and NIH/NCRR
grant number 16319. Its contents are solely the responsibility of the
authors and do not necessarily represent the official views of the NIH.
J.C.B.-L. was supported by NIH Academic Rheumatology and Clinical
Immunology Training Grant Number AR007304. M.C.N. was supported by the
Department of Veterans' Affairs.
NR 42
TC 10
Z9 10
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAR
PY 2011
VL 50
IS 3
BP 611
EP 619
DI 10.1093/rheumatology/keq307
PG 9
WC Rheumatology
SC Rheumatology
GA 726SE
UT WOS:000287745600025
PM 21098573
ER
PT J
AU Varghese, M
Zhao, W
Wang, J
Cheng, A
Qian, XJ
Chaudhry, A
Ho, L
Pasinetti, GM
AF Varghese, Merina
Zhao, Wei
Wang, Jun
Cheng, Alice
Qian, Xianjuan
Chaudhry, Amna
Ho, Lap
Pasinetti, Giulio Maria
TI MITOCHONDRIAL BIOENERGETICS IS DEFECTIVE IN PRESYMPTOMATIC TG2576 AD
MICE
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Alzheimer's disease; Amyloid; Dementia; Energy Metabolism; Memory;
Mitochondria; Oxidative phosphorylation; Oxygen Consumption; Tg2576
ID DEHYDROGENASE COMPLEX ACTIVITY; ALZHEIMERS-DISEASE BRAIN;
CYTOCHROME-C-OXIDASE; MOUSE MODEL; PYRUVATE-DEHYDROGENASE; SYNAPTIC
MITOCHONDRIA; TRANSGENIC MICE; PROTEIN; MEMORY; ACCUMULATION
AB Alzheimer's disease (AD) is an age-related dementia, with the pathological hallmarks of neuritic plaques and neurofibrillary tangles, brain atrophy and loss of synaptic terminals. Dysfunctional mitochondrial bioenergetics is implicated as a contributing factor to the cognitive decline observed in AD. We hypothesized that, in the presence of the AD neurotoxic peptide beta-amyloid, mitochondrial respiration is impaired early in synaptic terminals, which are vital to cognitive performance, preferentially in cognitive centers of the brain. We compared oxygen consumption in synaptosomal and perikaryal mitochondria prepared from the cerebral cortex and cerebellum of wild type (WT) and AD transgenic Tg2576 mice. Compared to WT mice, Tg2576 mice showed decreased mitochondrial respiration in the cerebral cortex specifically in synaptosomal fraction, while the perikaryal mitochondria were unaffected. Neither mitochondrial fraction was affected in the cerebellum of Tg2576 mice as compared to WT. The occurrence of a bioenergetic defect in synaptic terminals of mice over-expressing mutant beta-amyloid, in particular in an area of the brain important to cognition, points to an early role of mitochondrial defects in the onset of cognitive deficits in AD.
C1 [Varghese, Merina; Zhao, Wei; Wang, Jun; Cheng, Alice; Qian, Xianjuan; Chaudhry, Amna; Ho, Lap; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Varghese, Merina; Zhao, Wei; Wang, Jun; Cheng, Alice; Qian, Xianjuan; Ho, Lap; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Educ & Clin Ctr, Bronx, NY 10468 USA.
RP Varghese, M (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
OI Varghese, Merina/0000-0002-1517-3903
FU National Institutes of Health (NIH) [AG02219]; Department of Veterans
Affairs
FX We are grateful to Dr David B. Hicks for technical assistance. This
project was funded by grants from the National Institutes of Health (NIH
AG02219 Project 2) and the Department of Veterans Affairs.
NR 23
TC 8
Z9 8
U1 1
U2 4
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD MAR
PY 2011
VL 2
IS 1
BP 1
EP 5
DI 10.2478/s13380-011-0011-8
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 873MD
UT WOS:000298886500001
ER
PT J
AU Zuleger, CL
Macklin, MD
Bostwick, BL
Pei, QL
Newton, MA
Albertini, MR
AF Zuleger, Cindy L.
Macklin, Michael D.
Bostwick, Bret L.
Pei, Qinglin
Newton, Michael A.
Albertini, Mark R.
TI In vivo 6-thioguanine-resistant T cells from melanoma patients have
public TCR and share TCR beta amino acid sequences with
melanoma-reactive T cells
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE T cell receptor; CDR3 sequencing; Tumor immunity; Hypoxanthine-guanine;
phosphoribosyltransferase
ID MYELIN BASIC-PROTEIN; PERIPHERAL-BLOOD; RECEPTOR REPERTOIRE; LYMPHOCYTE
RECOGNITION; MULTIPLE-SCLEROSIS; MUTANT FREQUENCY; ANTIGEN RECEPTOR;
SELF-ANTIGEN; ALPHA-CHAIN; INFLUENZA-A
AB vivo hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient T cells (MT) from melanoma patients are enriched for T cells with in vivo clonal amplifications that traffic between blood and tumor tissues. Melanoma is thus a model cancer to test the hypothesis that in vivo MT from cancer patients can be used as immunological probes for immunogenic tumor antigens. MT were obtained by 6-thioguanine (TG) selection of lymphocytes from peripheral blood and tumor tissues, and wild-type T cells (WT) were obtained analogously without TG selection. cDNA sequences of the T cell receptor beta chains (TRB) were used as unambiguous biomarkers of in vivo clonality and as indicators of T cell specificity. Public TRB were identified in MT from the blood and tumor of different melanoma patients. Such public TRB were not found in normal control MT or WT. As an indicator of T cell specificity for melanoma, the > 2600 MT and WT TRB, including the public TRB from melanoma patients, were compared to a literature-derived empirical database of > 1270 TRB from melanoma-reactive T cells. Various degrees of similarity, ranging from 100% conservation to 3-amino acid motifs (3-mer), were found between both melanoma patient MT and WT TRBs and the empirical database. The frequency of 3-mer and 4-mer TRB matching to the empirical database was significantly higher in MT compared with WT in the tumor (p = 0.0285 and p = 0.006, respectively). In summary, in vivo MT from melanoma patients contain public TRB as well as T cells with specificity for characterized melanoma antigens. We conclude that in vivo MT merit study as novel probes for uncharacterized immunogenic antigens in melanoma and other malignancies. Published by Elsevier B.V.
C1 [Albertini, Mark R.] Univ Wisconsin, Dept Med, Carbone Canc Ctr, Madison, WI 53792 USA.
[Pei, Qinglin; Newton, Michael A.] Univ Wisconsin, Dept Stat, Madison, WI 53792 USA.
[Bostwick, Bret L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53792 USA.
[Newton, Michael A.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA.
[Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Albertini, MR (reprint author), Univ Wisconsin, Dept Med, Carbone Canc Ctr, 600 Highland Ave,K6-530, Madison, WI 53792 USA.
EM mralbert@wisc.edu
FU National Cancer Institute [P30 CA014520]; Gretchen and Andrew Dawes
Melanoma Research Fund; Ann's Hope Foundation; Steve Leuthold Family;
Tim Eagle Memorial
FX This material is based on work supported in part by the Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development Service;
grant P30 CA014520 from the National Cancer Institute; the Gretchen and
Andrew Dawes Melanoma Research Fund; Ann's Hope Foundation; the Jay Van
Sloan Memorial from the Steve Leuthold Family; and the Tim Eagle
Memorial. The funding sources had no involvement in the study design; in
the collection, analysis and interpretation of data; in the writing of
the manuscript; or in the decision to submit the manuscript for
publication. We also thank Drs. David Mahvi, Sharon Weber, and Tracey
Weigel for identifying appropriate surgical specimens; Ms. Susi Nehls
for assistance with manuscript preparation; and Dr. Richard Albertini
for stimulating discussions. The authors have no financial or other
conflicts of interests to disclose related to this publication. The
contents do not represent the views of the Dept of Veterans Affairs or
the United States Government.
NR 56
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD FEB 28
PY 2011
VL 365
IS 1-2
BP 76
EP 86
DI 10.1016/j.jim.2010.12.007
PG 11
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 738DW
UT WOS:000288620600008
PM 21182840
ER
PT J
AU Parchman, ML
Scoglio, CM
Schumm, P
AF Parchman, Michael L.
Scoglio, Caterina M.
Schumm, Phillip
TI Understanding the implementation of evidence-based care: A structural
network approach
SO IMPLEMENTATION SCIENCE
LA English
DT Article
ID HEALTH-CARE; DISSEMINATION; INNOVATION; DIFFUSION; BEHAVIOR; SPREAD
AB Background: Recent study of complex networks has yielded many new insights into phenomenon such as social networks, the internet, and sexually transmitted infections. The purpose of this analysis is to examine the properties of a network created by the 'co-care' of patients within one region of the Veterans Health Affairs.
Methods: Data were obtained for all outpatient visits from 1 October 2006 to 30 September 2008 within one large Veterans Integrated Service Network. Types of physician within each clinic were nodes connected by shared patients, with a weighted link representing the number of shared patients between each connected pair. Network metrics calculated included edge weights, node degree, node strength, node coreness, and node betweenness. Log-log plots were used to examine the distribution of these metrics. Sizes of k core networks were also computed under multiple conditions of node removal.
Results: There were 4,310,465 encounters by 266,710 shared patients between 722 provider types (nodes) across 41 stations or clinics resulting in 34,390 edges. The number of other nodes to which primary care provider nodes have a connection (172.7) is 42% greater than that of general surgeons and two and one-half times as high as cardiology. The log-log plot of the edge weight distribution appears to be linear in nature, revealing a 'scale-free' characteristic of the network, while the distributions of node degree and node strength are less so. The analysis of the k-core network sizes under increasing removal of primary care nodes shows that about 10 most connected primary care nodes play a critical role in keeping the k-core networks connected, because their removal disintegrates the highest k-core network.
Conclusions: Delivery of healthcare in a large healthcare system such as that of the US Department of Veterans Affairs (VA) can be represented as a complex network. This network consists of highly connected provider nodes that serve as 'hubs' within the network, and demonstrates some 'scale-free' properties. By using currently available tools to explore its topology, we can explore how the underlying connectivity of such a system affects the behavior of providers, and perhaps leverage that understanding to improve quality and outcomes of care.
C1 [Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Family & Community Med Dept, San Antonio, TX 78229 USA.
[Parchman, Michael L.] S Texas Vet Healthcare Syst, VERDICT Hlth Serv Res Program 11C6, San Antonio, TX 78229 USA.
[Scoglio, Caterina M.; Schumm, Phillip] Kansas State Univ, Elect & Comp Engn Dept, Manhattan, KS 66506 USA.
RP Parchman, ML (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Family & Community Med Dept, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM parchman@uthscsa.edu
OI Parchman, Michael/0000-0001-7129-2889
FU National Academies Keck Futures Initiative (NAKFI) [CS15]; Department of
Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service
FX Funding for this study provided by the National Academies Keck Futures
Initiative (NAKFI CS15) and the Department of Veterans Affairs, Veterans
Health Administration, Health Services Research and Development Service.
The views expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs.
NR 31
TC 10
Z9 10
U1 1
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD FEB 24
PY 2011
VL 6
AR 14
DI 10.1186/1748-5908-6-14
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 734LJ
UT WOS:000288335300001
PM 21349194
ER
PT J
AU Engers, DW
Field, JR
Le, U
Zhou, Y
Bolinger, JD
Zamorano, R
Blobaum, AL
Jones, CK
Jadhav, S
Weaver, CD
Conn, PJ
Lindsley, CW
Niswender, CM
Hopkins, CR
AF Engers, Darren W.
Field, Julie R.
Le, Uyen
Zhou, Ya
Bolinger, Julie D.
Zamorano, Rocio
Blobaum, Anna L.
Jones, Carrie K.
Jadhav, Satyawan
Weaver, C. David
Conn, P. Jeffrey
Lindsley, Craig W.
Niswender, Colleen M.
Hopkins, Corey R.
TI Discovery, Synthesis, and Structure-Activity Relationship Development of
a Series of N-(4-Acetamido)phenylpicolinamides as Positive Allosteric
Modulators of Metabotropic Glutamate Receptor 4 (mGlu(4)) with CNS
Exposure in Rats
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PARKINSONS-DISEASE; MGLUR4; PHARMACOLOGY; MECHANISM; PAMS
AB Herein we report the discovery, synthesis, and evaluation of a series of N-(4-acetamido)-phenylpico-linamides as positive allosteric modulators of mGlu(4). Compounds from the series show submicromolar potency at both human and rat mGlu(4). In addition, pharmacokinetic studies utilizing subcutaneous dosing demonstrated good brain exposure in rats.
C1 [Engers, Darren W.; Field, Julie R.; Le, Uyen; Zhou, Ya; Bolinger, Julie D.; Zamorano, Rocio; Blobaum, Anna L.; Jones, Carrie K.; Jadhav, Satyawan; Weaver, C. David; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Engers, Darren W.; Zhou, Ya; Zamorano, Rocio; Blobaum, Anna L.; Jones, Carrie K.; Jadhav, Satyawan; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA.
[Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.
[Lindsley, Craig W.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Weaver, C. David; Conn, P. Jeffrey] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA.
[Engers, Darren W.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Specialized Chem Ctr Accelerated Probe, Nashville, TN 37232 USA.
RP Niswender, CM (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 2213 Garland Ave, Nashville, TN 37232 USA.
EM colleen.niswender@vanderbilt.edu; corey.r.hopkins@vanderbilt.edu
RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013
FU National Institute of Mental Health, National Institute of Neurological
Disorders and Stroke; Michael J. Fox Foundation; Vanderbilt Department
of Pharmacology; Vanderbilt Institute of Chemical Biology
FX We thank Emily L. Days, Tasha Nalywajko, Cheryl A. Austin, and Michael
Baxter Williams for their critical contributions to the HTS portion of
the project. In addition, we thank Katrina Brewer, Ryan Morrison, and
Matt Mulder for technical assistance with the PK assays and Chris
Denicola, Nathan Kett, and Sichen Chang for the purification of
compounds utilizing the mass-directed HPLC system. This work was
supported by the National Institute of Mental Health, National Institute
of Neurological Disorders and Stroke, the Michael J. Fox Foundation, the
Vanderbilt Department of Pharmacology, and the Vanderbilt Institute of
Chemical Biology. Vanderbilt is a member of the MLPCN and houses the
Vanderbilt Specialized Chemistry Center for Accelerated Probe
Development (NIH/MLPCN; 5U54MH084659-02).
NR 19
TC 22
Z9 22
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 24
PY 2011
VL 54
IS 4
BP 1106
EP 1110
DI 10.1021/jm101271s
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 721FE
UT WOS:000287338200019
PM 21247167
ER
PT J
AU Leykum, LK
Palmer, R
Lanham, H
Jordan, M
McDaniel, RR
Noel, PH
Parchman, M
AF Leykum, Luci K.
Palmer, Ray
Lanham, Holly
Jordan, Michelle
McDaniel, Reuben R.
Noel, Polly H.
Parchman, Michael
TI Reciprocal learning and chronic care model implementation in primary
care: results from a new scale of learning in primary care
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
ID DECISION-SUPPORT-SYSTEM; CHRONIC ILLNESS CARE; CLINICAL-PRACTICE;
HEALTH-CARE; MANAGEMENT; COMPLEXITY; ORGANIZATIONS; IMPROVEMENT;
GUIDELINES; DELIVERY
AB Background: Efforts to improve the care of patients with chronic disease in primary care settings have been mixed. Application of a complex adaptive systems framework suggests that this may be because implementation efforts often focus on education or decision support of individual providers, and not on the dynamic system as a whole. We believe that learning among clinic group members is a particularly important attribute of a primary care clinic that has not yet been well-studied in the health care literature, but may be related to the ability of primary care practices to improve the care they deliver. To better understand learning in primary care settings by developing a scale of learning in primary care clinics based on the literature related to learning across disciplines, and to examine the association between scale responses and chronic care model implementation as measured by the Assessment of Chronic Illness Care (ACIC) scale.
Methods: Development of a scale of learning in primary care setting and administration of the learning and ACIC scales to primary care clinic members as part of the baseline assessment in the ABC Intervention Study. All clinic clinicians and staff in forty small primary care clinics in South Texas participated in the survey.
Results: We developed a twenty-two item learning scale, and identified a five-item subscale measuring the construct of reciprocal learning (Cronbach alpha 0.79). Reciprocal learning was significantly associated with ACIC total and sub-scale scores, even after adjustment for clustering effects.
Conclusions: Reciprocal learning appears to be an important attribute of learning in primary care clinics, and its presence relates to the degree of chronic care model implementation. Interventions to improve reciprocal learning among clinic members may lead to improved care of patients with chronic disease and may be relevant to improving overall clinic performance.
C1 [Leykum, Luci K.; Palmer, Ray; Lanham, Holly; Noel, Polly H.; Parchman, Michael] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Leykum, Luci K.; Lanham, Holly; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Palmer, Ray; Parchman, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Jordan, Michelle] Arizona State Univ, Mary Lou Fulton Teachers Coll, Phoenix, AZ USA.
[Lanham, Holly; McDaniel, Reuben R.] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA.
RP Leykum, LK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
EM Leykum@uthscsa.edu
RI Jordan, Michelle/K-8757-2012
OI Parchman, Michael/0000-0001-7129-2889
FU National Institute of Health (NIDDK) [R18DK075692]; Department of
Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service; South Texas Veterans Health Care
System; IC2 Institute of the University of Texas at Austin
FX The research reported here was supported by the National Institute of
Health (NIDDK Grant R18DK075692) and the Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
Service. Investigator salary support is provided through this funding,
and through the South Texas Veterans Health Care System. Dr. McDaniel
receives support from the IC2 Institute of the University of
Texas at Austin. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs.
NR 58
TC 12
Z9 12
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD FEB 23
PY 2011
VL 11
AR 44
DI 10.1186/1472-6963-11-44
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 730JU
UT WOS:000288030400001
PM 21345225
ER
PT J
AU Bourdette, D
Yadav, V
AF Bourdette, Dennis
Yadav, Vijayshree
TI The radiologically isolated syndrome revisited When is it presymptomatic
multiple sclerosis?
SO NEUROLOGY
LA English
DT Editorial Material
ID DIAGNOSTIC-CRITERIA
C1 [Bourdette, Dennis; Yadav, Vijayshree] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Bourdette, Dennis] Portland VA Med Ctr, VA Multiple Sclerosis Ctr Excellence W, Portland, OR USA.
RP Bourdette, D (reprint author), Oregon Hlth & Sci Univ, Dept Neurol L226, Portland, OR 97239 USA.
EM bourdett@ohsu.edu
NR 11
TC 7
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD FEB 22
PY 2011
VL 76
IS 8
BP 680
EP 681
DI 10.1212/WNL.0b013e31820e7769
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 724KH
UT WOS:000287574500005
PM 21270414
ER
PT J
AU Dell'Italia, LJ
AF Dell'Italia, Louis J.
TI The Forgotten Left Ventricle in Right Ventricular Pressure Overload
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE atrophy; pulmonary hypertension; right ventricular failure
ID CONTRACTILE FUNCTION; HYPERTENSION; HEARTS
C1 [Dell'Italia, Louis J.] Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Dell'Italia, LJ (reprint author), UAB, Ctr Heart Failure Res, Div Cardiol, 434 BMR2,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM loudell@uab.edu
NR 7
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 22
PY 2011
VL 57
IS 8
BP 929
EP 930
DI 10.1016/j.jacc.2010.08.647
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 725NB
UT WOS:000287650900008
PM 21329839
ER
PT J
AU Cooke, CR
Joo, MJ
Anderson, SM
Lee, TA
Udris, EM
Johnson, E
Au, DH
AF Cooke, Colin R.
Joo, Min J.
Anderson, Stephen M.
Lee, Todd A.
Udris, Edmunds M.
Johnson, Eric
Au, David H.
TI The validity of using ICD-9 codes and pharmacy records to identify
patients with chronic obstructive pulmonary disease
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Chronic Obstructive Pulmonary Disease; Statistical Models; Epidemiology;
Veterans; Sensitivity and Specificity; Logistic Models
ID ARTIFICIAL NEURAL-NETWORKS; INHALED CORTICOSTEROIDS;
LOGISTIC-REGRESSION; ADMINISTRATIVE DATABASES; MEDICAID POPULATION;
AIRWAY-OBSTRUCTION; COPD; MORTALITY; BURDEN; DIAGNOSIS
AB Background: Administrative data is often used to identify patients with chronic obstructive pulmonary disease (COPD), yet the validity of this approach is unclear. We sought to develop a predictive model utilizing administrative data to accurately identify patients with COPD.
Methods: Sequential logistic regression models were constructed using 9573 patients with postbronchodilator spirometry at two Veterans Affairs medical centers (2003-2007). COPD was defined as: 1) FEV1/FVC < 0.70, and 2) FEV1/FVC < lower limits of normal. Model inputs included age, outpatient or inpatient COPD-related ICD-9 codes, and the number of metered does inhalers (MDI) prescribed over the one year prior to and one year post spirometry. Model performance was assessed using standard criteria.
Results: 4564 of 9573 patients (47.7%) had an FEV1/FVC < 0.70. The presence of >= 1 outpatient COPD visit had a sensitivity of 76% and specificity of 67%; the AUC was 0.75 (95% CI 0.74-0.76). Adding the use of albuterol MDI increased the AUC of this model to 0.76 (95% CI 0.75-0.77) while the addition of ipratropium bromide MDI increased the AUC to 0.77 (95% CI 0.76-0.78). The best performing model included: >= 6 albuterol MDI, >= 3 ipratropium MDI, >= 1 outpatient ICD-9 code, >= 1 inpatient ICD-9 code, and age, achieving an AUC of 0.79 (95% CI 0.78-0.80).
Conclusion: Commonly used definitions of COPD in observational studies misclassify the majority of patients as having COPD. Using multiple diagnostic codes in combination with pharmacy data improves the ability to accurately identify patients with COPD.
C1 [Cooke, Colin R.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.
[Cooke, Colin R.] Univ Michigan, Robert Wood Johnson Fdn Clin Scholars Program, Ann Arbor, MI 48109 USA.
[Joo, Min J.; Lee, Todd A.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA.
[Joo, Min J.] Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL USA.
[Anderson, Stephen M.; Udris, Edmunds M.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Lee, Todd A.] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL USA.
[Lee, Todd A.] Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Chicago, IL USA.
[Johnson, Eric] Grp Hlth Res Inst, Seattle, WA USA.
[Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
RP Cooke, CR (reprint author), Univ Michigan, Div Pulm & Crit Care Med, 6312 Med Sci Bldg 1,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM cookecr@umich.edu; joo@uic.edu; stephen.anderson@va.gov;
todd.lee@va.gov; Ed.Udris@va.gov; johnson.ex@ghc.org;
dau@u.washington.edu
OI Cooke, Colin/0000-0001-9713-5371
FU Department of Veterans Affairs, Health Services Research and Development
(DHA); American Lung Association [CI-51755-N]; American Thoracic
Society; Robert Wood Johnson Foundation; University of Michigan COPE
FX This study was supported by the Department of Veterans Affairs, Health
Services Research and Development (DHA), American Lung Association
(CI-51755-N) awarded to DHA, the American Thoracic Society Fellow Career
Development Award (CRC), and the Robert Wood Johnson Foundation Clinical
Scholar's Program (CRC). The funding bodies had no role in study design
analysis, interpretation and writing of the manuscript, and in the
decision to submit the manuscript for publication. The authors would
also like to acknowledge the referees for their thoughtful contributions
to the manuscript.; This article was made available as Open Access with
the support of the University of Michigan COPE Fund,
http://lib.umich.edu/cope
NR 46
TC 41
Z9 41
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD FEB 16
PY 2011
VL 11
AR 37
DI 10.1186/1472-6963-11-37
PG 25
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 730JS
UT WOS:000288030200001
PM 21324188
ER
PT J
AU Wang, LX
Million, M
Rivier, J
Rivier, C
Craft, N
Stenzel-Poore, MP
Tache, Y
AF Wang, Lixin
Million, Mulugeta
Rivier, Jean
Rivier, Catherine
Craft, Noah
Stenzel-Poore, Mary P.
Tache, Yvette
TI CRF Receptor Antagonist Astressin-B Reverses and Prevents Alopecia in
CRF Over-Expressing Mice
SO PLOS ONE
LA English
DT Article
ID CORTICOTROPIN-RELEASING HORMONE; HAIR-GROWTH; TRANSGENIC MICE;
DIFFERENTIAL EXPRESSION; CUTANEOUS EXPRESSION; STRESS-RESPONSE; MOUSE
MODELS; HPA AXIS; SKIN; UROCORTIN
AB Corticotropin-releasing factor (CRF) signaling pathways are involved in the stress response, and there is growing evidence supporting hair growth inhibition of murine hair follicle in vivo upon stress exposure. We investigated whether the blockade of CRF receptors influences the development of hair loss in CRF over-expressing (OE)-mice that display phenotypes of Cushing's syndrome and chronic stress, including alopecia. The non-selective CRF receptors antagonist, astressin-B (5 mu g/mouse) injected peripherally once a day for 5 days in 4-9 months old CRF-OE alopecic mice induced pigmentation and hair re-growth that was largely retained for over 4 months. In young CRF-OE mice, astressin-B prevented the development of alopecia that occurred in saline-treated mice. Histological examination indicated that alopecic CRF-OE mice had hair follicle atrophy and that astressin-B revived the hair follicle from the telogen to anagen phase. However, astressin-B did not show any effect on the elevated plasma corticosterone levels and the increased weights of adrenal glands and visceral fat in CRF-OE mice. The selective CRF2 receptor antagonist, astressin(2)-B had moderate effect on pigmentation, but not on hair regrowth. The commercial drug for alopecia, minoxidil only showed partial effect on hair re-growth. These data support the existence of a key molecular switching mechanism triggered by blocking peripheral CRF receptors with an antagonist to reset hair growth in a mouse model of alopecia associated with chronic stress.
C1 [Wang, Lixin; Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Div Digest Dis,Dept Med,CURE, Los Angeles, CA 90095 USA.
[Wang, Lixin; Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Rivier, Jean; Rivier, Catherine] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, San Diego, CA 92138 USA.
[Craft, Noah] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Div Dermatol,Dept Med,Los Angeles Biomed Res Inst, Torrance, CA USA.
[Craft, Noah] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Div Infect Dis,Dept Med,Los Angeles Biomed Res In, Torrance, CA USA.
[Stenzel-Poore, Mary P.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Wang, LX (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Div Digest Dis,Dept Med,CURE, Los Angeles, CA 90095 USA.
EM milllionmulugeta@mednet.ucla.edu
FU Department of Veterans Affairs; NIH [R01 DK-57238, R21 DK-068155, RO1
DK-078676, R01 DK-33061, P50 DK-64539, DK PO1-26741]
FX This work was supported by the Research Career Scientist Award,
Department of Veterans Affairs (Y. Tache); and the following NIH grants:
R01 DK-57238 (Y. Tache); R21 DK-068155 and RO1 DK-078676 (M. Million);
R01 DK-33061 (Y. Tache, M. Million); P50 DK-64539 (Y. Tache, M.
Million); DK PO1-26741 (J. Rivier). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 38
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 16
PY 2011
VL 6
IS 2
AR e16377
DI 10.1371/journal.pone.0016377
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 721YC
UT WOS:000287392700017
PM 21359208
ER
PT J
AU Traugott, KA
Maxwell, PR
Green, K
Frei, C
Lewis, JS
AF Traugott, Kristi A.
Maxwell, Pamela R.
Green, Kay
Frei, Christopher
Lewis, James S., II
TI Effects of therapeutic drug monitoring criteria in a computerized
prescriber-order-entry system on the appropriateness of vancomycin level
orders
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE Antibiotics; Blood levels; Computers; Dosage; Medication orders;
Prescribing; Protocols; Rational therapy; Vancomycin
AB Purpose. The effects of therapeutic drug monitoring (TDM) criteria in a computerized prescriber-order-entry (CPOE) system on the appropriateness of orders for vancomycin levels were evaluated.
Methods. Vancomycin TDM criteria were developed and implemented in a CPOE system. These criteria were displayed via a pop-up alert message when vancomycin levels were ordered and included directions for appropriate timing and justification for routine monitoring. Data for two groups of adult inpatients who had vancomycin levels ordered before and after criteria implementation were compared. Medical records were retrospectively reviewed for these patients to collect information regarding patient demographics, vancomycin dosage and indication, concurrent antibiotics and nephrotoxic agents during vancomycin therapy, length of stay, duration of vancomycin therapy, and number of vancomycin levels drawn, The primary outcome was the percent change in appropriate vancomycin levels ordered after criteria implementation.
Results. A total of 200 patients were analyzed, 100 in each group. The percentage of appropriate orders for vancomycin levels significantly increased after criteria implementation (from 58% to 68%, p = 0.02). The greatest effect on appropriateness occurred with the first level ordered (52% versus 70% in the preimplementation and postimplementation groups, respectively; p = 0.01). The majority of inappropriate levels were due to improper timing of sample collections, accounting for 55% of the inappropriate levels evaluated.
Conclusion. A significant increase in the number of appropriately ordered and drawn serum vancomycin levels occurred after implementation of TDM criteria in the hospital's CPOE system. The majority of orders that were deemed inappropriate were due to improper timing of laboratory collection.
C1 [Traugott, Kristi A.] Ochsner Hlth Syst, New Orleans, LA 70121 USA.
[Traugott, Kristi A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Frei, Christopher] Univ Texas Austin, Coll Pharm, Pharmacotherapy Div, Austin, TX 78712 USA.
[Frei, Christopher] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA.
[Frei, Christopher] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA.
RP Traugott, KA (reprint author), Ochsner Hlth Syst, 1514 Jefferson Highway, New Orleans, LA 70121 USA.
EM ktraugott@ochsner.org
NR 18
TC 13
Z9 13
U1 1
U2 5
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD FEB 15
PY 2011
VL 68
IS 4
BP 347
EP 352
DI 10.2146/ajhp090661
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 858CC
UT WOS:000297772500012
PM 21289330
ER
PT J
AU Arif, SA
Mitchell, MM
AF Arif, Sally A.
Mitchell, Melissa M.
TI Iloperidone: A new drug for the treatment of schizophrenia
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE Absorption; Antipsychotic agents; Dosage; Drugs; availability;
Iloperidone; Mechanism of action; Pharmacogenetics; Pharmacokinetics;
Schizophrenia; Toxicity
ID ANTIPSYCHOTIC ILOPERIDONE; SAFETY PROFILE; RATING-SCALE; EFFICACY;
AGENTS; TOLERABILITY; METABOLITES; DISORDERS; RECEPTORS; BINDING
AB Purpose. The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety and tolerability profile of iloperidone for the treatment of schizophrenia are reviewed.
Summary. Iloperidone is an atypical antipsychotic that recently received marketing approval from the Food and Drug Administration for the acute treatment of schizophrenia. Iloperidone is a pure antagonist and the first antipsychotic to have pharmacogenomic studies indicate predictive response based on six identified polymorphisms. Pharmacokinetic studies have determined that iloperidone is well absorbed orally, with a bioavailability of 96%. Phase II and III clinical trials have shown iloperidone to improve symptoms of schizophrenia, based on the Positive and Negative Symptom Scale, Brief Psychiatric Rating Scale, and Clinical Global Impressions Severity scores (p < 0.05). Iloperidone has established tolerability at recommended dosages of up to 24 mg daily; however, the dosage must be slowly increased over seven days, and twice-daily administration is required to avoid orthostatic hypotension. The most common adverse effects associated with iloperidone were dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight gain. Safety studies have also found that iloperidone increases the risk of Q-Tc interval prolongation, similar to that seen with ziprasidone. Minimal changes in glucose and lipid abnormalities were seen in short-term (4- and 6-week) and long-term (52-week) studies, indicating a low chance of metabolic disturbance with iloperidone. Conclusion. Iloperidone may be a viable and safe option for the treatment of schizophrenia in adult patients, especially for patients who cannot tolerate other antipsychotic agents. However, iloperidone lacks a clear benefit over other antipsychotic agents.
C1 [Arif, Sally A.] Midwestern Univ, Chicago Coll Pharm, Downers Grove, IL 60515 USA.
[Arif, Sally A.; Mitchell, Melissa M.] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA.
[Arif, Sally A.] James J Peters Vet Affairs Med Ctr, Dept Pharm, Bronx, NY USA.
[Mitchell, Melissa M.] Riverside Cty Reg Med Ctr, Moreno Valley, CA USA.
[Mitchell, Melissa M.] St Vincents Hosp, Dept Pharm, New York, NY USA.
RP Arif, SA (reprint author), Midwestern Univ, Chicago Coll Pharm, 555 31st St, Downers Grove, IL 60515 USA.
EM sarif@midwestern.edu
NR 41
TC 14
Z9 15
U1 0
U2 7
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD FEB 15
PY 2011
VL 68
IS 4
BP 301
EP 308
DI 10.2146/ajhp100079
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 858CC
UT WOS:000297772500006
PM 21289324
ER
PT J
AU Levine, S
Biswas, C
Dierov, J
Barsotti, R
Shrager, JB
Taitan, N
Sonnad, S
Kucharchzuk, JC
Kaiser, LR
Singhal, S
Budak, MT
AF Levine, Sanford
Biswas, Chhanda
Dierov, Jamil
Barsotti, Robert
Shrager, Joseph B.
Taitan Nguyen
Sonnad, Seema
Kucharchzuk, John C.
Kaiser, Larry R.
Singhal, Sunil
Budak, Murat T.
TI Increased Proteolysis, Myosin Depletion, and Atrophic AKT-FOXO Signaling
in Human Diaphragm Disuse
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE AKT; FOXO; ubiquitination; proteasome; myosin heavy chains
ID SKELETAL-MUSCLE ATROPHY; MECHANICAL VENTILATION; OXIDATIVE STRESS;
PROTEIN-DEGRADATION; DYSFUNCTION; PATHWAYS; PHOSPHORYLATION; ACTIVATION;
PROTEASOME; CACHEXIA
AB Rationale: Patients on mechanical ventilation who exhibit diaphragm inactivity for a prolonged time (case subjects) develop decreases in diaphragm force-generating capacity accompanied by diaphragm myofiber atrophy.
Objectives: Our objectives were to test the hypotheses that increased proteolysis by the ubiquitin-proteasome pathway, decreases in myosin heavy chain (MyHC) levels, and atrophic AKT-FOXO signaling play major roles in eliciting these pathological changes associated with diaphragm disuse.
Methods: Biopsy specimens were obtained from the costal diaphragms of 18 case subjects before harvest (cases) and compared with intraoperative specimens from the diaphragms of 11 patients undergoing surgery for benign lesions or localized lung cancer (control subjects). Case subjects had diaphragm inactivity and underwent mechanical ventilation for 18 to 72 hours, whereas this state in controls was limited to 2 to 4 hours.
Measurements and Main Results: With respect to proteolysis in cytoplasm fractions, case diaphragms exhibited greater levels of ubiquitinated-protein conjugates, increased activity of the 265 proteasome, and decreased levels of MyHCs and a-actin. With respect to atrophic signaling in nuclear fractions, case diaphragms exhibited decreases in phosphorylated AKT, phosphorylated FOXO1, increased binding to consensus DNA sequence for Atrogin-1 and MuRF-1, and increased supershift of DNA-FOXO1 complexes with specific antibodies against FOXO1, as well as increased Atrogin-1 and MuRF-1 transcripts in whole myofiber lysates.
Conclusions: Our findings suggest that increased activity of the ubiquitin-proteasome pathway, marked decreases in MyHCs, and atrophic AKT-FOXO signaling play important roles in eliciting the myofiber atrophy and decreases in diaphragm force generation associated with prolonged human diaphragm disuse.
C1 [Levine, Sanford; Biswas, Chhanda; Dierov, Jamil; Shrager, Joseph B.; Taitan Nguyen; Sonnad, Seema; Kucharchzuk, John C.; Kaiser, Larry R.; Singhal, Sunil; Budak, Murat T.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
[Levine, Sanford; Biswas, Chhanda; Barsotti, Robert; Shrager, Joseph B.; Budak, Murat T.] Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA.
[Levine, Sanford] Gift Life Donor Program, Philadelphia, PA USA.
[Levine, Sanford; Biswas, Chhanda; Dierov, Jamil; Shrager, Joseph B.; Taitan Nguyen; Singhal, Sunil; Budak, Murat T.] Dept Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA 19104 USA.
[Levine, Sanford; Biswas, Chhanda; Dierov, Jamil; Shrager, Joseph B.; Taitan Nguyen; Singhal, Sunil; Budak, Murat T.] Dept Vet Affairs Med Ctr, Med Res Serv, Philadelphia, PA 19104 USA.
[Barsotti, Robert] Philadelphia Coll Osteopath Med, Philadelphia, PA USA.
[Shrager, Joseph B.] Palo Alto Vet Affairs Med Ctr, Palo Alto, CA USA.
[Shrager, Joseph B.] Stanford Univ, Dept Cardiothorac Surg, Palo Alto, CA 94304 USA.
[Kaiser, Larry R.] Univ Texas Hlth Sci Ctr Houston, Off President, Houston, TX USA.
RP Levine, S (reprint author), 1495 Wesleys Run, Gladwyne, PA 19035 USA.
EM sdlevine@mail.med.upenn.edu
RI Budak, Murat/I-8358-2013
OI Budak, Murat/0000-0002-5059-9651
FU NHLBI [R01-HL-078834]; Ventalis, Inc.; GlaxoSmithKline; Imedex;
aparoscopic Institute of Gynecologic Oncology; Hall; Hieatt; Connelly;
NIH
FX Supported by NHLBI grant R01-HL-078834 (S.L.).; S.L. does not have a
financial relationship with a commercial entity that has an interest in
the subject of this manuscript. C.B. does not have a financial
relationship with a commercial entity that has an interest in the
subject of this manuscript. I.D. does not have a financial relationship
with a commercial entity that has an interest in the subject of this
manuscript. R.B. does not have a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript. J.B.S. was employed by Projects in Knowledge for development
of an online lung cancer course, received $1,001-$5,000 from Ventalis,
Inc. in consultancy fees as own founders stock, $1,001 $5,000 from
GlaxoSmithKline for serving on the MAGRIT study advisory board,
51,001-55,000 from Imedex and $1,001 $5,000 from Laparoscopic Institute
of Gynecologic Oncology in lecture fees, $1,001 $5,000 from Hall,
Hieatt, and Connelly, LLP for serving as an expert witness on legal case
reviews, 510,001-550,000 from the NIH in sponsored grants as a
coinvestigator on R01, and more than $100,001 from the Merit Review
Board in sponsored grants for serving as a PI on a Merit Review Grant.
T.N. does not have a financial relationship with a commercial entity
that has an interest in the subject of this manuscript. S.S. does not
have a financial relationship with a commercial entity that has an
interest in the subject of this manuscript. J.C.K. does not have a
financial relationship with a commercial entity that has an interest in
the subject of this manuscript. L.R.K. does not have a financial
relationship with a commercial entity that has an interest in the
subject of this manuscript. S.S. does not have a financial relationship
with a commercial entity that has an interest in the subject of this
manuscript. M.T.B. does not have a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript.
NR 40
TC 63
Z9 65
U1 2
U2 8
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 15
PY 2011
VL 183
IS 4
BP 483
EP 490
DI 10.1164/200910-1487OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 724IE
UT WOS:000287568500012
PM 20833824
ER
PT J
AU Kelley, AS
Ettner, SL
Morrison, RS
Du, QL
Wenger, NS
Sarkisian, CA
AF Kelley, Amy S.
Ettner, Susan L.
Morrison, R. Sean
Du, Qingling
Wenger, Neil S.
Sarkisian, Catherine A.
TI Determinants of Medical Expenditures in the Last 6 Months of Life
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID QUALITY-OF-CARE; REGIONAL-VARIATIONS; PATIENT PREFERENCES; TREATMENT
INTENSITY; END; DISABILITY; CANCER; DEATH; AGE; HOSPITALIZATION
AB Background: End-of-life medical expenditures exceed costs of care during other years, vary across regions, and are likely to be unsustainable. Identifying determinants of expenditure variation may reveal opportunities for reducing costs.
Objective: To identify patient-level determinants of Medicare expenditures at the end of life and to determine the contributions of these factors to expenditure variation while accounting for regional characteristics. It was hypothesized that race or ethnicity, social support, and functional status are independently associated with treatment intensity and controlling for regional characteristics, and that individual characteristics account for a substantial proportion of expenditure variation.
Design: Using data from the Health and Retirement Study, Medicare claims, and The Dartmouth Atlas of Health Care, relationships were modeled between expenditures and patient and regional characteristics.
Setting: United States, 2000 to 2006.
Participants: 2394 Health and Retirement Study decedents aged 65.5 years or older.
Measurements: Medicare expenditures in the last 6 months of life were estimated in a series of 2-level multivariable regression models that included patient, regional, and patient and regional characteristics.
Results: Decline in function (rate ratio [RR], 1.64 [95% CI, 1.46 to 1.83]); Hispanic ethnicity (RR, 1.50 [CI, 1.22 to 1.85]); black race (RR, 1.43 [CI, 1.25 to 1.64]); and certain chronic diseases, including diabetes (RR, 1.16 [CI, 1.06 to 1.27]), were associated with higher expenditures. Nearby family (RR, 0.90 [CI, 0.82 to 0.98]) and dementia (RR, 0.78 CI, 0.71 to 0.87]) were associated with lower expenditures, and advance care planning had no association. Regional characteristics, including end-of-life practice patterns (RR, 1.09 [CI, 1.06 to 1.14]) and hospital beds per capita (RR, 1.01 [CI, 1.00 to 1.02]), were associated with higher expenditures. Patient characteristics explained 10% of overall variance and retained statistically significant relationships with expenditures after regional characteristics were controlled for.
Limitation: The study limitations include the decedent sample, proxy informants, and a large proportion of unexplained variation.
Conclusion: Patient characteristics, such as functional decline, race or ethnicity, chronic disease, and nearby family, are important determinants of expenditures at the end of life, independent of regional characteristics.
C1 [Kelley, Amy S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA.
RP Kelley, AS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM amy.kelley@mssm.edu
FU Brookdale Foundation; National Institute on Aging [K24 AG022345];
National Palliative Care Research Center; Veterans Affairs Greater Los
Angeles Healthcare System Geriatric Research Education Clinical Center
FX Grant Support: By the Brookdale Foundation. Dr. Kelley is a Brookdale
Leadership in Aging Fellow. Dr. Morrison is the recipient of a MidCareer
Investigator Award in Patient-Oriented Research (K24 AG022345) from the
National Institute on Aging and is supported by the National Palliative
Care Research Center. Dr. Sarkisian is supported by the Veterans Affairs
Greater Los Angeles Healthcare System Geriatric Research Education
Clinical Center.
NR 49
TC 63
Z9 63
U1 6
U2 25
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 15
PY 2011
VL 154
IS 4
BP 235
EP W78
DI 10.7326/0003-4819-154-4-201102150-00004
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 720VF
UT WOS:000287310000015
PM 21320939
ER
PT J
AU Qaseem, A
Humphrey, LL
Chou, R
Snow, V
Shekelle, P
AF Qaseem, Amir
Humphrey, Linda L.
Chou, Roger
Snow, Vincenza
Shekelle, Paul
CA Amer Coll Phys
TI Use of Intensive Insulin Therapy for the Management of Glycemic Control
in Hospitalized Patients: A Clinical Practice Guideline From the
American College of Physicians
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED
CONTROLLED-TRIAL; TYPE-2 DIABETES-MELLITUS; GLUCOSE-INSULIN;
CARDIAC-SURGERY; ISCHEMIC-STROKE; OLDER PATIENTS; HYPERGLYCEMIA;
HYPOGLYCEMIA
AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence for the link between the use of intensive insulin therapy to achieve different glycemic targets and health outcomes in hospitalized patients with or without diabetes mellitus.
Methods: Published literature on this topic was identified by using MEDLINE and the Cochrane Library. Additional articles were obtained from systematic reviews and the reference lists of pertinent studies, reviews, and editorials, as well as by consulting experts; unpublished studies on ClinicalTrials.gov were also identified. The literature search included studies published from 1950 through March 2009. Searches were limited to English-language publications. The primary outcomes of interest were short-term mortality and hypoglycemia. This guideline grades the evidence and recommendations by using the ACP clinical practice guidelines grading system.
Recommendation 1: ACP recommends not using intensive insulin therapy to strictly control blood glucose in non-surgical intensive care unit (SICU)/medical intensive care unit (MICU) patients with or without diabetes mellitus (Grade: strong recommendation, moderate-quality evidence).
Recommendation 2: ACP recommends not using intensive insulin therapy to normalize blood glucose in SICU/MICU patients with or without diabetes mellitus (Grade: strong recommendation, high-quality evidence).
Recommendation 3: ACP recommends a target blood glucose level of 7.8 to 11.1 mmol/L (140 to 200 mg/dL) if insulin therapy is used in SICU/MICU patients (Grade: weak recommendation, moderate-quality evidence).
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
Pfizer, Collegeville, PA USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
FU ACP operating budget; Agency for Healthcare Research and Quality
FX Financial support for the development of this guideline comes
exclusively from the ACP operating budget.; Any financial and
nonfinancial conflicts of interest of the group members were declared,
discussed, and resolved. Dr. Vincenza Snow was an employee of the
American College of Physicians at the time of the writing of this
guideline. Dr. Snow: Employment: American College of Physicians, Pfizer.
Dr. Shekelle: Grants/grants pending (money to institution): Agency for
Healthcare Research and Quality; Royalties: UpToDate. Disclosures can
also be viewed at
www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-272
5.
NR 59
TC 131
Z9 145
U1 3
U2 14
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 15
PY 2011
VL 154
IS 4
BP 260
EP W81
DI 10.7326/0003-4819-154-4-201102150-00007
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 720VF
UT WOS:000287310000018
PM 21320941
ER
PT J
AU Kansagara, D
Fu, RW
Freeman, M
Wolf, F
Helfand, M
AF Kansagara, Devan
Fu, Rongwei
Freeman, Michele
Wolf, Fawn
Helfand, Mark
TI Intensive Insulin Therapy in Hospitalized Patients: A Systematic Review
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Review
ID CRITICALLY-ILL PATIENTS; BLOOD-GLUCOSE CONTROL; TIGHT GLYCEMIC CONTROL;
ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; PREDICTIVE
CONTROL ALGORITHM; CLINICAL-PRACTICE GUIDELINES; DEPENDENT
DIABETES-MELLITUS; CARDIAC SURGICAL-PROCEDURES; STERNAL WOUND-INFECTION
AB Background: The benefits and harms of intensive insulin therapy (IIT) titrated to strict glycemic targets in hospitalized patients remain uncertain.
Purpose: To evaluate the benefits and harms of IIT in hospitalized patients.
Data Sources: MEDLINE and Cochrane Database of Systematic Reviews from 1950 to January 2010, reference lists, experts, and unpublished sources.
Study Selection: English-language randomized, controlled trials comparing protocols titrated to strict or less strict glycemic targets.
Data Extraction: Two reviewers independently abstracted data from each study on sample, setting, glycemic control interventions, glycemic targets, mean glucose levels achieved, and outcomes. Results were grouped by patient population or setting. A random-effects model was used to combine trial data on short-term mortality (<= 28 days), long-term mortality (90 or 180 days), infection, length of stay, and hypoglycemia. The Grading of Recommendations Assessment, Development, and Evaluation system was used to rate the overall body of evidence for each outcome.
Data Synthesis: In a meta-analysis of 21 trials in intensive care unit, perioperative care, myocardial infarction, and stroke or brain injury settings, IIT did not affect short-term mortality (relative risk, 1.00 [95% CI, 0.94 to 1.07]). No consistent evidence showed that IIT reduced long-term mortality, infection rates, length of stay, or the need for renal replacement therapy. No evidence of benefit from IIT was reported in any hospital setting, although the best evidence for lack of benefit was in intensive care unit settings. Data combined from 10 trials showed that IIT was associated with a high risk for severe hypoglycemia (relative risk, 6.00 [CI, 4.06 to 8.87]; P < 0.001). Risk for IIT-associated hypoglycemia was increased in all hospital settings.
Limitations: Methodological shortcomings and inconsistencies limit the data in perioperative care, myocardial infarction, and stroke or brain injury settings. Differences in insulin protocols and patient and hospital characteristics may affect generalizability across treatment settings.
Conclusion: No consistent evidence demonstrates that IIT targeted to strict glycemic control compared with less strict glycemic control improves health outcomes in hospitalized patients. Furthermore, IIT is associated with an increased risk for severe hypoglycemia.
C1 [Kansagara, Devan] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland Diabet & Endocrinol Ctr, Portland, OR 97239 USA.
RP Kansagara, D (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, 3710 SW US Vet Hosp Rd,Mailcode R&D 71, Portland, OR 97239 USA.
EM kansagar@ohsu.edu
FU Department of Veterans Affairs, Veterans Health Administration [ESP
05-225, 01-0206]; American College of Physicians
FX Financial Support: By the Department of Veterans Affairs, Veterans
Health Administration (VHA Project ESP 05-225, VA #01-0206). The
American College of Physicians provided funding for the preparation of
this manuscript.
NR 143
TC 86
Z9 94
U1 4
U2 14
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 15
PY 2011
VL 154
IS 4
BP 268
EP W89
DI 10.7326/0003-4819-154-4-201102150-00008
PG 23
WC Medicine, General & Internal
SC General & Internal Medicine
GA 720VF
UT WOS:000287310000019
PM 21320942
ER
PT J
AU Hallahan, B
Newell, J
Soares, JC
Brambilla, P
Strakowski, SM
Fleck, DE
Kieseppa, T
Altshuler, LL
Fornito, A
Malhi, GS
McIntosh, AM
Yurgelun-Todd, DA
Labar, KS
Sharma, V
MacQueen, GM
Murray, RM
McDonald, C
AF Hallahan, Brian
Newell, John
Soares, Jair C.
Brambilla, Paolo
Strakowski, Stephen M.
Fleck, David E.
Kieseppa, Tuula
Altshuler, Lori L.
Fornito, Alex
Malhi, Gin S.
McIntosh, Andrew M.
Yurgelun-Todd, Deborah A.
Labar, Kevin S.
Sharma, Verinder
MacQueen, Glenda M.
Murray, Robin M.
McDonald, Colm
TI Structural Magnetic Resonance Imaging in Bipolar Disorder: An
International Collaborative MegaAnalysis of Individual Adult Patient
Data
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT 8th International Conference on Bipolar Disorder
CY JUN 25-27, 2009
CL Pittsburgh, PA
SP NIMH
DE Amygdala; bipolar disorder; hippocampus; lateral ventricles; lithium;
mega-analysis
ID SUBGENUAL PREFRONTAL CORTEX; TEMPORAL-LOBE STRUCTURES; BRAIN
GRAY-MATTER; HIPPOCAMPAL VOLUME; MOOD DISORDERS; WHITE-MATTER; LITHIUM
TREATMENT; BASAL GANGLIA; HEALTHY-INDIVIDUALS; NEUROTROPHIC FACTOR
AB Background: There is substantial inconsistency in results of brain structural magnetic resonance imaging studies in adult bipolar disorder. This is likely consequent upon limited statistical power of studies together with their clinical and methodological heterogeneity. The current study was undertaken to perform an international collaborative mega-analysis of regional volumetric measurements of individual patient and healthy subject data, to optimize statistical power, detect case-control differences, assess the association of psychotropic medication usage with brain structural variation, and detect other possible sources of heterogeneity.
Methods: Eleven international research groups contributed published and unpublished data on 321 individuals with bipolar disorder land 442 healthy subjects. We used linear mixed effects regression models to evaluate differences in brain structure between patient groups.
Results: Individuals with bipolar disorder had increased right lateral ventricular, left temporal lobe, and right putamen volumes. Bipolar patients taking lithium displayed significantly increased hippocampal and amygdala volume compared with patients not treated with lithium and healthy comparison subjects. Cerebral volume reduction was significantly associated with illness duration in bipolar individuals.
Conclusions: The application of mega-analysis to bipolar disorder imaging identified lithium use and illness duration as substantial and consistent sources of heterogeneity, with lithium use associated with regionally specific increased brain volume.
C1 [Hallahan, Brian; McDonald, Colm] Natl Univ Ireland Galway, Dept Psychiat, Inst Clin Sci, Galway, Ireland.
Natl Univ Ireland Galway, Hlth Res Board, Clin Res Facil, Galway, Ireland.
[Newell, John] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland.
[Brambilla, Paolo] Univ N Carolina, Sch Med, Dept Psychiat, Ctr Excellence Res & Treatment Bipolar Disorders, Chapel Hill, NC USA.
[Brambilla, Paolo] Univ Udine, DPMSC, Sect Psychiat, I-33100 Udine, Italy.
IRCCS E Medea, Inst Sci, Udine, Italy.
[Strakowski, Stephen M.; Fleck, David E.] Univ Cincinnati, Coll Med, Div Bipolar Disorder Res, Cincinnati, OH USA.
[Strakowski, Stephen M.; Fleck, David E.] Univ Cincinnati, Coll Med, Ctr Imaging Res, Cincinnati, OH USA.
[Kieseppa, Tuula] Univ Helsinki, Cent Hosp, Natl Inst Hlth & Welf, Dept Mental Hlth & Alcohol Res, Helsinki, Finland.
Univ Helsinki, Dept Psychiat, Cent Hosp, Helsinki, Finland.
[Altshuler, Lori L.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, W Los Angeles Healthcare Ctr, Los Angeles, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Fornito, Alex] Univ Cambridge, Addenbrookes Hosp, Brain Mapping Unit, Dept Psychiat, Cambridge CB2 2QQ, England.
Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Natl Neurosci Facil, Melbourne, Vic 3010, Australia.
[Malhi, Gin S.] Univ Sydney, Discipline Psychol Med, Sydney, NSW 2006, Australia.
[McIntosh, Andrew M.] Univ Edinburgh, Royal Edinburgh Hosp, Div Psychiat, Edinburgh, Midlothian, Scotland.
[Yurgelun-Todd, Deborah A.] Univ Utah, Dept Psychiat, Utahs Sch Med, Cognit Imaging Lab,Brain Inst, Salt Lake City, UT USA.
[Labar, Kevin S.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Labar, Kevin S.] Duke Univ, Med Ctr, Ctr Cognit Neurosci, Durham, NC USA.
[Sharma, Verinder] Univ Western Ontario, Dept Psychiat, Reg Mental Hlth Care London, London, ON N6A 3K7, Canada.
[MacQueen, Glenda M.] Univ Calgary, Dept Psychiat, Calgary, AB, Canada.
[Murray, Robin M.; McDonald, Colm] Inst Psychiat, Div Psychol Med, London, England.
[Soares, Jair C.] Univ Texas Hlth Sci Ctr, Ctr Excellence Mood Disorders, Houston, TX USA.
Harris Cty Psychiat Ctr, Houston, TX USA.
RP Hallahan, B (reprint author), Natl Univ Ireland, Dept Psychiat, Inst Clin Sci, Galway, Ireland.
EM brian.hallahan@nuigalway.ie
RI McIntosh, Andrew/B-9379-2008; McDonald, Colm/C-1430-2009; Murray,
Robin/F-8658-2012; Alex, Fornito/N-8214-2013
OI McIntosh, Andrew/0000-0002-0198-4588; Murray, Robin/0000-0003-0829-0519;
Alex, Fornito/0000-0001-9134-480X; Newell, John/0000-0001-7685-6655;
Hallahan, Brian/0000-0003-0518-9757
NR 72
TC 123
Z9 125
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD FEB 15
PY 2011
VL 69
IS 4
BP 326
EP 335
DI 10.1016/j.biopsych.2010.08.029
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 718JV
UT WOS:000287118300006
PM 21030008
ER
PT J
AU Carlson, CM
Kirby, KA
Casadei, MA
Partin, MR
Kistler, CE
Walter, LC
AF Carlson, Charlotte M.
Kirby, Katharine A.
Casadei, Michele A.
Partin, Melissa R.
Kistler, Christine E.
Walter, Louise C.
TI Lack of Follow-up After Fecal Occult Blood Testing in Older Adults
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID PRIMARY-CARE PHYSICIANS; COMPLETE DIAGNOSTIC EVALUATION;
COLORECTAL-CANCER; COMORBIDITY INDEX; ELDERLY-PATIENTS; COLON
EVALUATION; NATIONAL-SURVEY; HEALTH-CARE; PATIENT; VETERANS
AB Background: It is unclear whether lack of follow-up after screening fecal occult blood testing (FOBT) in older adults is due to screening patients whose comorbidity or preferences do not permit follow-up vs failure to complete follow-up in healthy patients.
Methods: A prospective cohort study of 2410 patients 70 years or older screened with FOBT was conducted at 4 Veteran Affairs (VA) medical centers from January 1 to December 31, 2001. The main outcome measure was receipt of follow-up within 1 year of FOBT based on national VA and Medicare data. For patients with positive FOBT results, age and Charlson comorbidity scores were evaluated as potential predictors of receiving a complete colon evaluation (colonoscopy or sigmoidoscopy plus barium enema), and medical records were reviewed to determine reasons for lack of follow-up.
Results: A total of 212 patients (9%) had positive FOBT results; 42% received a complete colon evaluation within 1 year. Age and comorbidity were not associated with receipt of a complete follow-up, which was similar among patients 70 to 74 years old with a Charlson score of 0 compared with patients 80 years or older with a Charlson score of 1 or higher (48% vs 41%; P=.28). The VA site, number of positive FOBT cards, and number of VA outpatient visits were predictors. Of 122 patients who did not receive a complete follow-up within 1 year, 38% had documentation that comorbidity or preferences did not permit follow-up, and over the next 5 years 76% never received a complete follow-up.
Conclusions: While follow-up after positive FOBT results was low regardless of age or comorbidity, screening patients in whom complete evaluation would not be pursued substantially contributes to lack of follow-up. Efforts to improve follow-up should address the full chain of decision making, including decisions to screen and decisions to follow up.
C1 [Carlson, Charlotte M.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Kirby, Katharine A.; Casadei, Michele A.; Kistler, Christine E.; Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Partin, Melissa R.] Univ Minnesota, Ctr Chron Dis Outcomes Res, Minneapolis VA Med Ctr, Minneapolis, MN 55455 USA.
[Partin, Melissa R.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
RP Walter, LC (reprint author), VA Med Ctr 181G, Div Geriatr, 4150 Clement St, San Francisco, CA 94121 USA.
EM Louise.Walter@ucsf.edu
FU VA Health Services Research and Development [IIR-04-427]; National
Cancer Institute [1R01CA134425]; Center for Chronic Disease Outcomes
Research [HFP 98-001]; [AG000212-16]
FX Dr Walter is supported by a VA Health Services Research and Development
grant IIR-04-427 and by grant 1R01CA134425 from the National Cancer
Institute and is a Robert Wood Johnson Physician Faculty Scholar. Dr
Kistler is supported by a T-32 Training Grant AG000212-16. Dr Partin is
supported by the Center for Chronic Disease Outcomes Research, VA Health
Services Research and Development grant HFP 98-001.
NR 37
TC 20
Z9 20
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD FEB 14
PY 2011
VL 171
IS 3
BP 249
EP 256
DI 10.1001/archinternmed.2010.372
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 721CI
UT WOS:000287328700012
PM 20937917
ER
PT J
AU Tao, H
Manak, JR
Sowers, L
Mei, X
Kiyonari, H
Abe, T
Dandaleh, NS
Yang, TA
Wu, S
Chen, S
Fox, MH
Gurnett, C
Montine, T
Bird, T
Shaffer, LG
Rosenfeld, JA
McConne, J
Madan-Khetarpal, S
Berry-Kravis, E
Griesbach, H
Saneto, RP
Scott, MP
Antic, D
Reed, J
Boland, R
Ehaideb, SN
El-Shanti, H
Mahajan, VB
Ferguson, PJ
Axelrod, JD
Lehesjoki, AE
Fritzsch, B
Slusarski, DC
Wemmie, J
Ueno, N
Bassuk, AG
AF Tao, Hirotaka
Manak, J. Robert
Sowers, Levi
Mei, Xue
Kiyonari, Hiroshi
Abe, Takaya
Dandaleh, Nader S.
Yang, Tian
Wu, Shu
Chen, Shan
Fox, Mark H.
Gurnett, Christina
Montine, Thomas
Bird, Thomas
Shaffer, Lisa G.
Rosenfeld, Jill A.
McConne, Juliann
Madan-Khetarpal, Suneeta
Berry-Kravis, Elizabeth
Griesbach, Hilary
Saneto, Russell P.
Scott, Matthew P.
Antic, Dragana
Reed, Jordan
Boland, Riley
Ehaideb, Salleh N.
El-Shanti, Hatem
Mahajan, Vinit B.
Ferguson, Polly J.
Axelrod, Jeffrey D.
Lehesjoki, Anna-Elina
Fritzsch, Bernd
Slusarski, Diane C.
Wemmie, John
Ueno, Naoto
Bassuk, Alexander G.
TI Mutations in Prickle Orthologs Cause Seizures in Flies, Mice, and Humans
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID PROGRESSIVE MYOCLONUS EPILEPSY; PLANAR CELL POLARITY;
DROSOPHILA-MELANOGASTER; NEURON MIGRATION; MOUSE PRICKLE1; GENE;
ZEBRAFISH; GASTRULATION; MOVEMENTS; CHANNEL
AB Epilepsy is heritable, yet few causative gene mutations have been identified, and thus far no human epilepsy gene mutations have been found to produce seizures in invertebrates. Here we show that mutations in prickle genes are associated with seizures in humans, mice, and flies. We identified human epilepsy patients with heterozygous mutations in either PRICKLE1 or PRICKLE2. In overexpression assays in zebrafish, prickle mutations resulted in aberrant prickle function. A seizure phenotype was present in the Prickle1-null mutant mouse, two Prickle1 point mutant (missense and nonsense) mice, and a Prickle2-null mutant mouse. Drosophila with prickle mutations displayed seizures that were responsive to anti-epileptic medication, and homozygous mutant embryos showed neuronal defects. These results suggest that prickle mutations have caused seizures throughout evolution.
C1 [Tao, Hirotaka; Ueno, Naoto] Natl Inst Basic Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan.
[Manak, J. Robert; Mei, Xue; Yang, Tian; Reed, Jordan; Boland, Riley; Ehaideb, Salleh N.; Fritzsch, Bernd; Slusarski, Diane C.] Univ Iowa, Dept Biol, Iowa City, IA 52242 USA.
[Sowers, Levi; Wu, Shu; Chen, Shan; Fox, Mark H.; El-Shanti, Hatem; Ferguson, Polly J.; Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Carver Coll Med, Iowa City, IA 52242 USA.
[Kiyonari, Hiroshi; Abe, Takaya] RIKEN Ctr Dev Biol, Lab Anim Resources & Genet Engn, Chuo Ku, Kobe, Hyogo 650047, Japan.
[Dandaleh, Nader S.] Univ Iowa, Dept Neurosurg, Carver Coll Med, Iowa City, IA 52242 USA.
[Gurnett, Christina] Washington Univ, Dept Neurol, St Louis, MO 63310 USA.
[Montine, Thomas] Univ Washington, Dept Pathol, Seattle, WA 98104 USA.
[Bird, Thomas] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98104 USA.
[Shaffer, Lisa G.; Rosenfeld, Jill A.] Signature Genom Labs, Spokane, WA 99202 USA.
[McConne, Juliann; Madan-Khetarpal, Suneeta] Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA 15224 USA.
[Berry-Kravis, Elizabeth] Rush Presbyterian St Lukes Med Ctr, Dept Pediat, Chicago, IL 60612 USA.
[Berry-Kravis, Elizabeth] Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Berry-Kravis, Elizabeth] Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
[Saneto, Russell P.] Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98105 USA.
[Scott, Matthew P.; Antic, Dragana] Stanford Univ, Sch Med, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.
[Scott, Matthew P.; Antic, Dragana] Stanford Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, Stanford, CA 94305 USA.
[Scott, Matthew P.; Antic, Dragana] Stanford Univ, Sch Med, Dept Bioengn, Howard Hughes Med Inst, Stanford, CA 94305 USA.
[Antic, Dragana; Axelrod, Jeffrey D.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
[El-Shanti, Hatem] Shafallah Med Genet Ctr, Doha 33123, Qatar.
[Mahajan, Vinit B.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA 52242 USA.
[Lehesjoki, Anna-Elina] Univ Helsinki, Folkhalsan Inst Genet, FIN-00014 Helsinki, Finland.
[Lehesjoki, Anna-Elina] Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland.
[Wemmie, John] Univ Iowa, Dept Psychiat, Ia City, IA 52242 USA.
[Wemmie, John] Univ Iowa, Dept Neurosurg, Neurosci Program, Roy J & Lucille A Carver Coll Med, Ia City, IA 52242 USA.
[Wemmie, John] Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA.
[Ueno, Naoto] Grad Univ Adv Studies SOKENDAI, Dept Basic Biol, Sch Life Sci, Okazaki, Aichi 4448585, Japan.
RP Ueno, N (reprint author), Natl Inst Basic Biol, Div Morphogenesis, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.
EM nueno@nibb.ac.jp; alexander-bassuk@uiowa.edu
RI Kiyonari, Hiroshi/N-7936-2015; EL-SHANTI, HATEM/Q-4932-2016
OI EL-SHANTI, HATEM/0000-0001-6230-8316; Fritzsch,
Bernd/0000-0002-4882-8398
FU National Institutes of Health [R01 NS064159, 3R01NS064159-02S1, R01
GM059823, RO1 CA112369, P50 AG05136, 1R21NS058309-01A1]; VA; Howard
Hughes Medical Institute
FX This work was supported by National Institutes of Health grants R01
NS064159 and 3R01NS064159-02S1 (to A.G.B.), R01 GM059823 (to J.D.A.),
RO1 CA112369 (to D.C.S.), and P50 AG05136 (to T.M.), by
1R21NS058309-01A1 (to J.W.), by a VA Merit Review Award (to J.W.), and
by a grant from the Howard Hughes Medical Institute (to M.S.). We thank
Jeff Murray, Jeff Neul, Val Sheffield, Bev Davidson, Zoha Kibar, Heather
Mefford, and Sam Berkovic for their thoughtful reviews. We thank Jeff
Murray for access to the CEPH-HGD samples and Taqman assay. L.G.S. and
J.A.R. are employed by Signature Genomics Laboratories.
NR 57
TC 46
Z9 50
U1 2
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD FEB 11
PY 2011
VL 88
IS 2
BP 138
EP 149
DI 10.1016/j.ajhg.2010.12.012
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 725YZ
UT WOS:000287684100002
PM 21276947
ER
PT J
AU Nichols, FC
Yao, XD
Bajrami, B
Downes, J
Finegold, SM
Knee, E
Gallagher, JJ
Housley, WJ
Clark, RB
AF Nichols, Frank C.
Yao, Xudong
Bajrami, Bekim
Downes, Julia
Finegold, Sydney M.
Knee, Erica
Gallagher, James J.
Housley, William J.
Clark, Robert B.
TI Phosphorylated Dihydroceramides from Common Human Bacteria Are Recovered
in Human Tissues
SO PLOS ONE
LA English
DT Article
ID PORPHYROMONAS-GINGIVALIS LIPIDS; SYSTEMIC INNATE IMMUNITY;
RHEUMATOID-ARTHRITIS; MICROBIOTA; PERIODONTITIS; ASSOCIATION; DISEASE
AB Novel phosphorylated dihydroceramide (PDHC) lipids produced by the periodontal pathogen Porphyromonas gingivalis include phosphoethanolamine (PE DHC) and phosphoglycerol dihydroceramides (PG DHC) lipids. These PDHC lipids mediate cellular effects through Toll-like receptor 2 (TLR2) including promotion of IL-6 secretion from dendritic cells and inhibition of osteoblast differentiation and function in vitro and in vivo. The PE DHC lipids also enhance (TLR2)-dependent murine experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. The unique non-mammalian structures of these lipids allows for their specific quantification in bacteria and human tissues using multiple reaction monitoring (MRM)-mass spectrometry (MS). Synthesis of these lipids by other common human bacteria and the presence of these lipids in human tissues have not yet been determined. We now report that synthesis of these lipids can be attributed to a small number of intestinal and oral organisms within the Bacteroides, Parabacteroides, Prevotella, Tannerella and Porphyromonas genera. Additionally, the PDHCs are not only present in gingival tissues, but are also present in human blood, vasculature tissues and brain. Finally, the distribution of these TLR2-activating lipids in human tissues varies with both the tissue site and disease status of the tissue suggesting a role for PDHCs in human disease.
C1 [Nichols, Frank C.; Knee, Erica] Univ Connecticut, Sch Dent Med, Dept Oral Hlth & Diagnost Sci, Farmington, CT 06032 USA.
[Yao, Xudong; Bajrami, Bekim] Univ Connecticut, Dept Chem, Storrs, CT USA.
[Downes, Julia; Finegold, Sydney M.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA.
[Gallagher, James J.] Univ Connecticut, Sch Med, Dept Surg, Farmington, CT 06032 USA.
[Gallagher, James J.] Connecticut Vasc Inst, Hartford, CT USA.
[Housley, William J.; Clark, Robert B.] Univ Connecticut, Sch Med, Dept Immunol, Farmington, CT 06032 USA.
[Housley, William J.; Clark, Robert B.] Univ Connecticut, Sch Med, Dept Med, Farmington, CT 06032 USA.
RP Nichols, FC (reprint author), Univ Connecticut, Sch Dent Med, Dept Oral Hlth & Diagnost Sci, Farmington, CT 06032 USA.
EM nichols@nso.uchc
FU National Multiple Sclerosis Society [RG4070-A-6]
FX This work was supported by a grant from the National Multiple Sclerosis
Society (RG4070-A-6). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 21
TC 10
Z9 11
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 11
PY 2011
VL 6
IS 2
AR e16771
DI 10.1371/journal.pone.0016771
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 721OO
UT WOS:000287364500005
PM 21347306
ER
PT J
AU Choy, HA
Kelley, MM
Croda, J
Matsunaga, J
Babbitt, JT
Ko, AI
Picardeau, M
Haake, DA
AF Choy, Henry A.
Kelley, Melissa M.
Croda, Julio
Matsunaga, James
Babbitt, Jane T.
Ko, Albert I.
Picardeau, Mathieu
Haake, David A.
TI The Multifunctional LigB Adhesin Binds Homeostatic Proteins with
Potential Roles in Cutaneous Infection by Pathogenic Leptospira
interrogans
SO PLOS ONE
LA English
DT Article
ID IMMUNOGLOBULIN-LIKE PROTEINS; STAPHYLOCOCCUS-AUREUS; CLUMPING FACTOR;
EXTRACELLULAR-MATRIX; MUCOSAL IMMUNOLOGY; CRYSTAL-STRUCTURE;
HUMAN-FIBRINOGEN; GENE-EXPRESSION; TISSUE-REPAIR; MODEL
AB Leptospirosis is a potentially fatal zoonotic disease in humans and animals caused by pathogenic spirochetes, such as Leptospira interrogans. The mode of transmission is commonly limited to the exposure of mucous membrane or damaged skin to water contaminated by leptospires shed in the urine of carriers, such as rats. Infection occurs during seasonal flooding of impoverished tropical urban habitats with large rat populations, but also during recreational activity in open water, suggesting it is very efficient. LigA and LigB are surface localized proteins in pathogenic Leptospira strains with properties that could facilitate the infection of damaged skin. Their expression is rapidly induced by the increase in osmolarity encountered by leptospires upon transition from water to host. In addition, the immunoglobulin-like repeats of the Lig proteins bind proteins that mediate attachment to host tissue, such as fibronectin, fibrinogen, collagens, laminin, and elastin, some of which are important in cutaneous wound healing and repair. Hemostasis is critical in a fresh injury, where fibrinogen from damaged vasculature mediates coagulation. We show that fibrinogen binding by recombinant LigB inhibits fibrin formation, which could aid leptospiral entry into the circulation, dissemination, and further infection by impairing healing. LigB also binds fibroblast fibronectin and type III collagen, two proteins prevalent in wound repair, thus potentially enhancing leptospiral adhesion to skin openings. LigA or LigB expression by transformation of a nonpathogenic saprophyte, L. biflexa, enhances bacterial adhesion to fibrinogen. Our results suggest that by binding homeostatic proteins found in cutaneous wounds, LigB could facilitate leptospirosis transmission. Both fibronectin and fibrinogen binding have been mapped to an overlapping domain in LigB comprising repeats 9-11, with repeat 11 possibly enhancing binding by a conformational effect. Leptospirosis patient antibodies react with the LigB domain, suggesting applications in diagnosis and vaccines that are currently limited by the strain-specific leptospiral lipopolysaccharide coats.
C1 [Choy, Henry A.; Matsunaga, James; Babbitt, Jane T.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Choy, Henry A.; Kelley, Melissa M.; Matsunaga, James; Babbitt, Jane T.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Croda, Julio; Ko, Albert I.] Brasilian Minist Hlth, Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
[Croda, Julio] Fed Univ Grande Dourados, Fac Hlth Sci, Dourados, MS, Brazil.
[Ko, Albert I.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Epidemiol Microbial Dis, New Haven, CT 06510 USA.
[Picardeau, Mathieu] Inst Pasteur, Unite Biol Spirochetes, Paris, France.
[Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA.
[Haake, David A.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.
[Haake, David A.] Univ Calif Los Angeles, Dept Mol Genet Microbiol & Immunol, Los Angeles, CA USA.
RP Choy, HA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
EM hachoy@ucla.edu
RI Ko, Albert/P-2343-2015
OI Ko, Albert/0000-0001-9023-2339
FU National Institutes of Health [R01 AI34431, U01 AI088752, D43 TW00919,
R01 AI052473]; VA Medical Research Funds; Institut Pasteur, Paris,
France; French Ministry of Research [ANR-08-MIE-018]; Oswaldo Cruz
Foundation [PDTIS RVR05]
FX This study was supported by the National Institutes of Health (R01
AI34431, U01 AI088752, D43 TW00919, and R01 AI052473), VA Medical
Research Funds (to D. A. H.), the Institut Pasteur, Paris, France, the
French Ministry of Research (ANR-08-MIE-018), and the Fiocruz-Pasteur
Scientific Cooperation Agreement, Oswaldo Cruz Foundation (PDTIS RVR05).
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 51
TC 27
Z9 28
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2011
VL 6
IS 2
AR e16879
DI 10.1371/journal.pone.0016879
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 721NN
UT WOS:000287361700049
PM 21347378
ER
PT J
AU Tallaj, JA
Cadeiras, M
AF Tallaj, Jose A.
Cadeiras, Martin
TI Mechanical Rescue of the Heart in Shock
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE assist devices; cardiogenic shock; heart failure; myocardial infarction
ID ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR ASSIST DEVICE;
CARDIOGENIC-SHOCK; COUNTERPULSATION; DYSFUNCTION; MORTALITY; EFFICACY;
FAILURE; SUPPORT; SAFETY
AB Cardiogenic shock (CS) is a state of extreme hypoperfusion owing to pump failure manifested by altered mental status, cool extremities, and/or renal failure. This hypoperfusion leads to release of catecholamines and other inflammatory mediators, which further perpetuates myocardial ischemia and injury, resulting in additional impairment in systemic and tissue perfusion. Any cause of acute severe cardiac failure may lead to CS.
C1 [Tallaj, Jose A.; Cadeiras, Martin] Univ Alabama, Dept Med, Div Cardiol, Birmingham, AL 35294 USA.
[Tallaj, Jose A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA.
RP Tallaj, JA (reprint author), Univ Alabama, Dept Med, Div Cardiol, THT 338,1900 Univ Blvd, Birmingham, AL 35294 USA.
EM jtallaj@uab.edu
NR 13
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 8
PY 2011
VL 57
IS 6
BP 697
EP 699
DI 10.1016/j.jacc.2010.10.015
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 715JH
UT WOS:000286880100009
PM 21292128
ER
PT J
AU Wilken, R
Veena, MS
Wang, MB
Srivatsan, ES
AF Wilken, Reason
Veena, Mysore S.
Wang, Marilene B.
Srivatsan, Eri S.
TI Curcumin: A review of anti-cancer properties and therapeutic activity in
head and neck squamous cell carcinoma
SO MOLECULAR CANCER
LA English
DT Review
ID NF-KAPPA-B; BREAST-CANCER CELLS; MALIGNANT GLIOMA-CELLS;
LIPOSOME-ENCAPSULATED CURCUMIN; ISCHEMIA-REPERFUSION INJURY; TYROSINE
KINASE INHIBITOR; HUMAN NEUROBLASTOMA-CELLS; SOUTHWEST-ONCOLOGY-GROUP;
NITRIC-OXIDE SYNTHASE; PHASE-II TRIAL
AB Curcumin (diferuloylmethane) is a polyphenol derived from the Curcuma longa plant, commonly known as turmeric. Curcumin has been used extensively in Ayurvedic medicine for centuries, as it is nontoxic and has a variety of therapeutic properties including anti-oxidant, analgesic, anti-inflammatory and antiseptic activity. More recently curcumin has been found to possess anti-cancer activities via its effect on a variety of biological pathways involved in mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis and metastasis. Curcumin has shown anti-proliferative effect in multiple cancers, and is an inhibitor of the transcription factor NF-kappa B and downstream gene products (including c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF-alpha, interleukins and MMP-9). In addition, curcumin affects a variety of growth factor receptors and cell adhesion molecules involved in tumor growth, angiogenesis and metastasis. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and treatment protocols include disfiguring surgery, platinum-based chemotherapy and radiation, all of which may result in tremendous patient morbidity. As a result, there is significant interest in developing adjuvant chemotherapies to augment currently available treatment protocols, which may allow decreased side effects and toxicity without compromising therapeutic efficacy. Curcumin is one such potential candidate, and this review presents an overview of the current in vitro and in vivo data supporting its therapeutic activity in head and neck cancer as well as some of the challenges concerning its development as an adjuvant chemotherapeutic agent.
C1 [Wilken, Reason; Veena, Mysore S.; Wang, Marilene B.; Srivatsan, Eri S.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Los Angeles, CA 90095 USA.
[Veena, Mysore S.; Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
RP Srivatsan, ES (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
EM esrivats@ucla.edu
FU VAGLAHS; West Los Angeles Surgical Education Research Center; NIH [R21
CA116826-01]; Veterans Administration, Washington, DC
FX We thank Eugene Han for help with figures. The study was supported by
funds from VAGLAHS, West Los Angeles Surgical Education Research Center,
NIH (R21 CA116826-01 to M. B. Wang) and Merit grant from the Veterans
Administration, Washington, DC (E.S. Srivatsan).
NR 217
TC 223
Z9 228
U1 11
U2 76
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD FEB 7
PY 2011
VL 10
AR 12
DI 10.1186/1476-4598-10-12
PG 19
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 729DX
UT WOS:000287929900001
PM 21299897
ER
PT J
AU Axon, RN
Williams, MV
AF Axon, R. Neal
Williams, Mark V.
TI Hospital Readmission as an Accountability Measure
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID INPATIENT CARE; QUALITY; ASSOCIATION
C1 [Axon, R. Neal] Ralph H Johnson VAMC, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Axon, R. Neal] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC USA.
[Williams, Mark V.] Northwestern Univ, Feinberg Sch Med, Div Hosp Med, Chicago, IL 60611 USA.
RP Axon, RN (reprint author), 135 Rutledge Ave,MSC 591, Charleston, SC 29425 USA.
EM axon@musc.edu
NR 10
TC 138
Z9 138
U1 0
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 2
PY 2011
VL 305
IS 5
BP 504
EP 505
DI 10.1001/jama.2011.72
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 714LI
UT WOS:000286810700026
PM 21285430
ER
PT J
AU Holschneider, DP
Bradesi, S
Mayer, EA
AF Holschneider, Daniel P.
Bradesi, Sylvie
Mayer, Emeran A.
TI The role of experimental models in developing new treatments for
irritable bowel syndrome
SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
DE functional gastrointestinal disorders; intestinal transit; neuroimaging;
visceral pain
ID C-FOS EXPRESSION; 5-HT3 RECEPTOR ANTAGONIST; FUNCTIONAL GASTROINTESTINAL
DISORDERS; REGIONAL BRAIN ACTIVATION; KAPPA-AGONIST FEDOTOZINE;
ROBALZOTAN TARTRATE MONOHYDRATE; NOXIOUS COLORECTAL DISTENSION;
LUMBOSACRAL SPINAL-CORD; COLONIC DISTENSION; VISCERAL PAIN
AB Irritable bowel syndrome (IBS) is characterized by chronic, recurrent abdominal pain and altered bowel habits and is currently defined by symptom criteria and the absence of detectable organic disease. The underlying pathophysiology remains incompletely understood. Despite considerable efforts by the scientific community and the pharmaceutical industry to develop novel pharmacological treatments aimed at chronic visceral pain, the traditional approach to identifying and evaluating novel drugs for this target have largely failed to translate into effective IBS treatments. However, several novel drugs aimed at normalizing bowel movements have produced clinical effects, not only on the primary target, but also on pain and discomfort. While some of the commonly used experimental animal models for the pain dimension of IBS have some face and construct validity, the predictive validity of most of the models is either unknown, or has been disappointing. A reverse translational approach is proposed, which is based on identification and characterization of brain endophenotypes in patients, followed by translation of these endophenotypes for pharmacological studies in rodent models.
C1 [Holschneider, Daniel P.; Bradesi, Sylvie; Mayer, Emeran A.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Holschneider, Daniel P.] Univ So Calif, Dept Psychiat, Los Angeles, CA USA.
[Holschneider, Daniel P.] Univ So Calif, Dept Behav Sci Neurol Cell & Neurobiol, Los Angeles, CA USA.
[Bradesi, Sylvie; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, UCLA Ctr Neurobiol Stress, Los Angeles, CA 90024 USA.
[Bradesi, Sylvie; Mayer, Emeran A.] Univ Calif Los Angeles, Sch Med, Dept Physiol, UCLA Ctr Neurobiol Stress, Los Angeles, CA 90024 USA.
[Bradesi, Sylvie; Mayer, Emeran A.] Univ Calif Los Angeles, Sch Med, Dept Psychiat, UCLA Ctr Neurobiol Stress, Los Angeles, CA 90024 USA.
RP Bradesi, S (reprint author), VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
EM sbradesi@ucla.edu
FU NIH [DK 48351, DK 64539, DA026597]
FX The work discussed in this paper is supported by NIH grants DK 48351, DK
64539, DA026597. The authors have no other relevant affiliations or
financial involvement with any organization or entity with a financial
interest in or financial conflict with the subject matter or materials
discussed in the manuscript apart from those disclosed.
NR 133
TC 15
Z9 16
U1 1
U2 3
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1747-4124
J9 EXPERT REV GASTROENT
JI Expert Rev. Gastroenterol. Hepatol.
PD FEB
PY 2011
VL 5
IS 1
BP 43
EP 57
DI 10.1586/EGH.10.88
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 861SL
UT WOS:000298039400011
PM 21309671
ER
PT J
AU Biagtan, MJ
Viswanathan, RK
Mathur, SK
AF Biagtan, M. J.
Viswanathan, R. K.
Mathur, S. K.
TI The Chronic Urticaria Index as a Predictor of Responsiveness to Therapy
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Biagtan, M. J.; Viswanathan, R. K.; Mathur, S. K.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.
[Mathur, S. K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB104
EP AB104
DI 10.1016/j.jaci.2010.12.417
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846400400
ER
PT J
AU Parikh, N
Verma, P
Lee, S
Klaustermeyer, WB
AF Parikh, N.
Verma, P.
Lee, S.
Klaustermeyer, W. B.
TI Inhaler Use and Effect on Asthma Control
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Parikh, N.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
[Verma, P.; Lee, S.; Klaustermeyer, W. B.] Univ Calif Los Angeles, Div Allergy Immunol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB159
EP AB159
DI 10.1016/j.jaci.2010.12.631
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846400613
ER
PT J
AU Verma, P
Randhawa, I
Klaustermeyer, WB
AF Verma, P.
Randhawa, I.
Klaustermeyer, W. B.
TI Severe Geriatric Asthma: Efficacy of Omalizumab in a VA population
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Verma, P.; Klaustermeyer, W. B.] Univ Calif Los Angeles, Div Allergy Immunol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB160
EP AB160
DI 10.1016/j.jaci.2010.12.634
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846400616
ER
PT J
AU Viswanathan, RK
Biagtan, MJ
Kelly, JT
Moss, MH
Mathur, SK
AF Viswanathan, R. K.
Biagtan, M. J.
Kelly, J. T.
Moss, M. H.
Mathur, S. K.
TI Phenotypic Profile of Potential Responders to Omalizumab in Chronic
Idiopathic Urticaria
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Viswanathan, R. K.; Biagtan, M. J.; Kelly, J. T.; Moss, M. H.; Mathur, S. K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Mathur, S. K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB103
EP AB103
DI 10.1016/j.jaci.2010.12.414
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846400397
ER
PT J
AU Selinger, S
Restrepo, MI
Copeland, LA
Pugh, MJV
Nakashima, B
Downs, JR
Anzueto, A
Mortensen, EM
AF Selinger, Scott
Restrepo, Marcos I.
Copeland, Laurel A.
Pugh, Mary Jo V.
Nakashima, Brandy
Downs, John R.
Anzueto, Antonio
Mortensen, Eric M.
TI Pneumonia in the Elderly Hospitalized in the Department of Veteran
Affairs Health Care System
SO MILITARY MEDICINE
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; VALIDATION; FACILITIES; MORTALITY;
OUTCOMES; THERAPY; IMPACT
AB Pneumonia is a major cause of hospital admissions and deaths worldwide. Our aim was to examine the trends in admissions for pneumonia in the Department of Veterans Affairs (VA). We examined data for the fiscal years 2002 through 2007 on patients aged 65 years and older hospitalized with pneumonia by using VA administrative databases. The numbers of hospital admissions for pneumonia were relatively stable during this period. However, length of hospital stay and 30- and 90-day mortality decreased during this period. The proportion of patients admitted to the intensive care unit remained relatively constant, but fewer received mechanical ventilation; there was substantial increase in noninvasive ventilation. In the VA, pneumonia-related admissions are being managed more effectively even as the overall number of admissions remains stable.
C1 [Selinger, Scott; Downs, John R.; Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Gen Internal Med, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.; Copeland, Laurel A.; Pugh, Mary Jo V.; Nakashima, Brandy; Downs, John R.; Anzueto, Antonio; Mortensen, Eric M.] VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
[Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
RP Selinger, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Gen Internal Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
RI Restrepo, Marcos/H-4442-2014
OI Mortensen, Eric/0000-0002-3880-5563; Copeland,
Laurel/0000-0002-9478-0209
FU National Institute of Nursing Research [R01NR0I0828]; Department of
Veteran Affairs Veterans Integrated Service Network [17]; National
Health Institute [KL2 RR025766]; Veterans Health Administration
[MRP-05-145]
FX This project was supported by grant number R01NR0I0828 from the National
Institute of Nursing Research. Dr. Restrepo is supported by a Department
of Veteran Affairs Veterans Integrated Service Network 17 new faculty
grant and National Health Institute Grant KL2 RR025766. Dr. Copeland is
supported by Veterans Health Administration Grant MRP-05-145. The
funding agencies had no role in conducting the study or in the
preparation, review, or approval of the manuscript.
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD FEB
PY 2011
VL 176
IS 2
BP 214
EP 217
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 825BL
UT WOS:000295245800020
PM 21366087
ER
PT J
AU Benvenga, S
Itri, E
Hauser, P
De Tolla, L
Yu, SF
Testa, G
Pappalardo, MA
Trimarchi, F
Amato, A
AF Benvenga, Salvatore
Itri, Elenora
Hauser, Peter
De Tolla, Louis
Yu, Sui-Foh
Testa, Giuseppe
Pappalardo, Maria Angela
Trimarchi, Francesco
Amato, Antonino
TI Gender Differences in Locomotor and Stereotypic Behavior Associated With
L-Carnitine Treatment in Mice
SO GENDER MEDICINE
LA English
DT Article
DE gender differences; L-carnitine; locomotor activity; stereotypic
activity
ID ACETYL-L-CARNITINE; CATION/CARNITINE TRANSPORTER FAMILY; ORGANIC CATION
TRANSPORTERS; THYROID-HORMONE ACTION; RAT-BRAIN; SEXUAL-DIFFERENTIATION;
PALMITOYLTRANSFERASE-I; CHAKRAGATI MOUSE; AGED RATS; OLD RATS
AB Background: The carnitines exert neuroprotective and neuromodulatory actions, and carnitine supplementation increases locomotor activity (LMA) in experimental animals.
Methods: We measured 13 indexes of LMA and 3 indexes of stereotypic activity (STA) in adult male and female caged mice. In a randomized 4-week trial, 10 males and 10 females received SO mg/kg body weight PO L-carnitine, and another 10 males and 10 females received placebo.
Results: Compared with placebo-treated females, placebo-treated males had a greater number of stereotypies (NSTs), stereotypy counts (STCs), stereotypy time (STT), and right front time (RFT), but smaller total distance traveled (TDT), margin distance (MD), number of vertical movements (NVMs), and left rear time (LRT). Compared with placebo-treated males, carnitine-treated males had greater horizontal activity (HA), movement time (MT), NVM, STT, TDT, SIC, MD, LRT, and clockwise revolutions (CRs), but smaller left front time (LFT) and RFT. Compared with placebo-treated females, carnitine-treated females had greater NST, STC, STT, LFT, and RFT, but smaller NM, HA, NVM, VA, MT, anticlockwise revolutions (ACRs), CR, TDT, and MD; right rear time (RRT) remained statistically insignificant across all comparisons.
Conclusions: In summary, L-carnitine caused gender differences to persist for STC, diminish for NST and STT, disappear for LRT and NVM, change in the opposite direction for TDT and MD, appear de novo for HA, VA, NM, MT, and LFT, and remain absent for RRT and ACR. Some indexes of LMA and STA are sexually dimorphic in adult mice, and L-carnitine differentially maintains, diminishes/cancels, inverts, or creates the sexual dimorphism of particular indexes. (Gend Med. 2011;8:1-13) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
C1 [Benvenga, Salvatore; Itri, Elenora; Pappalardo, Maria Angela; Trimarchi, Francesco] Univ Messina, Sez Endocrinol, Dipartimento Clin Sperimentale Med & Farmacol, Messina, Italy.
[Benvenga, Salvatore] AOU Policlin G Martino, Programma Endocrinol Mol Clin, Messina, Italy.
[Hauser, Peter] Oregon Hlth & Sci Univ, NW Hepatitis C Resource Ctr, VA Med Ctr, Res & Dev Serv & Behav Hlth & Clin, Portland, OR 97201 USA.
[Hauser, Peter] Oregon Hlth & Sci Univ, Div Neurosci, Portland VA Med Ctr, Portland, OR 97201 USA.
[Hauser, Peter] Oregon Hlth & Sci Univ, JENS Lab, Portland VA Med Ctr, Portland, OR 97201 USA.
[Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Dept Behav Neurosci, Portland, OR 97201 USA.
[Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Div Gastroenterol, Portland, OR 97201 USA.
[De Tolla, Louis; Yu, Sui-Foh] Univ Maryland, Sch Med, Comparat Med Program & Vet Resources, Baltimore, MD 21201 USA.
[Testa, Giuseppe; Amato, Antonino] Sigma Tau Res, Gaithersburg, MD USA.
RP Benvenga, S (reprint author), Univ Messina Policlin, Sez Endocrinol, Dip Clin Sperimentale Med & Farmacol, 4 Piano, I-98125 Messina, Italy.
EM s.benvenga@me.nettuno.it
FU Ministero dell'Universita e della Ricerca, Rome, Italy [2004062391_01];
Sigma-Tau Research, Inc, Gaithersburg, Maryland
FX This work was funded in part by the Ministero dell'Universita e della
Ricerca, Rome, Italy, (PRIN2004 project 2004062391_01) and in part by
Sigma-Tau Research, Inc, Gaithersburg, Maryland. The authors have
indicated that they have no other conflicts of interest regarding the
content of this article.
NR 44
TC 1
Z9 1
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1550-8579
J9 GENDER MED
JI Gend. Med.
PD FEB
PY 2011
VL 8
IS 1
BP 1
EP 13
DI 10.1016/j.genm.2011.02.003
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 761CB
UT WOS:000290371400001
PM 21497767
ER
PT J
AU Yang, E
Nucifora, PG
Melhem, ER
AF Yang, Edward
Nucifora, Paolo G.
Melhem, Elias R.
TI Diffusion MR Imaging: Basic Principles
SO NEUROIMAGING CLINICS OF NORTH AMERICA
LA English
DT Article
DE MRI; Diffusion MRI; Diffusion tensor imaging; Clinical neurology
ID WHITE-MATTER TRACTS; ANISOTROPIC WATER DIFFUSION; VOXEL-BASED
MORPHOMETRY; CENTRAL-NERVOUS-SYSTEM; NORMAL-APPEARING WHITE;
AMYOTROPHIC-LATERAL-SCLEROSIS; DEFORMATION-BASED MORPHOMETRY; INTRAVOXEL
INCOHERENT MOTION; AXON DIAMETER DISTRIBUTION; HIGH-FIELD-STRENGTH
AB From their origin as simple techniques primarily used for detecting acute cerebral ischemia, diffusion MR imaging techniques have rapidly evolved into a versatile set of tools that provide the only noninvasive means of characterizing brain microstructure and connectivity, becoming a mainstay of both clinical and investigational brain MR imaging. In this article, the basic principles required for understanding diffusion MR imaging techniques are reviewed with clinical neuroradiologists in mind.
C1 [Yang, Edward; Nucifora, Paolo G.; Melhem, Elias R.] Univ Penn, Hosp Univ Penn, Sch Med, Div Neuroradiol,Dept Radiol, Philadelphia, PA 19104 USA.
[Nucifora, Paolo G.] Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Melhem, ER (reprint author), Univ Penn, Hosp Univ Penn, Sch Med, Div Neuroradiol,Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM Elias.melhem@uphs.upenn.edu
RI Melhem, Elias/E-5205-2013
NR 212
TC 11
Z9 15
U1 2
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1052-5149
J9 NEUROIMAG CLIN N AM
JI Neuroimaging Clin. N. Am.
PD FEB
PY 2011
VL 21
IS 1
BP 1
EP +
DI 10.1016/j.nic.2011.02.001
PG 26
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 757ZJ
UT WOS:000290128200002
PM 21477749
ER
PT J
AU Mortazavi, F
Rettig, MB
Dubinett, SM
AF Mortazavi, Fariborz (Fred)
Rettig, Matthew B.
Dubinett, Steven M.
TI c-Crk proto-oncogene and TGF-beta signaling pathway contribute to
transcriptional repression of p120ctn in non-small cell lung cancer
cells
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Meeting Abstract
C1 [Mortazavi, Fariborz (Fred); Rettig, Matthew B.] Univ Calif Los Angeles, W Los Angeles VA, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD FEB
PY 2011
VL 28
IS 2
BP 186
EP 186
PG 1
WC Oncology
SC Oncology
GA 753RB
UT WOS:000289796200094
ER
PT J
AU Peron, EP
Marcum, ZA
Boyce, R
Hanlon, JT
Handler, SM
AF Peron, Emily P.
Marcum, Zachary A.
Boyce, Richard
Hanlon, Joseph T.
Handler, Steven M.
TI Year in Review: Medication Mishaps in the Elderly
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Editorial Material
DE adverse drug events; aged; drug monitoring; medication adherence;
medication errors; suboptimal prescribing.
ID ADVERSE DRUG-REACTIONS; POTENTIALLY INAPPROPRIATE MEDICATIONS; CLINICAL
DECISION-SUPPORT; NURSING-HOME RESIDENTS; COMPREHENSIVE GERIATRIC
ASSESSMENT; PROTON-PUMP INHIBITORS; PROVIDER ORDER ENTRY; OLDER-ADULTS;
HOSPITALIZED-PATIENTS; EXPLICIT CRITERIA
AB Objective: This paper reviews articles from 2010 that examined medication mishaps (ie, medication errors and adverse drug events [ADEs]) in the elderly.
Methods: The MEDLINE and EMBASE databases were searched for English-language articles published in 2010 using a combination of search terms including medication errors, medication adherence, medication compliance, suboptimal prescribing, monitoring, adverse drug events, adverse drug withdrawal events, therapeutic failures, and aged. A manual search of the reference lists of the identified articles and the authors' article files, book chapters, and recent reviews was conducted to identify additional publications. Five studies of note were selected for annotation and critique. From the literature search, this paper also generated a selected bibliography of manuscripts published in 2010 (excluding those previously published in the American Journal of Geriatric Pharmacotherapy or by one of the authors) that address various types of medication errors and ADEs in the elderly.
Results: Three studies focused on types of medication errors. One study examined underuse (due to prescribing) as a type of medication error. This before-and-after study from the Netherlands reported that those who received comprehensive geriatric assessments had a reduction in the rate of undertreatment of chronic conditions by over one third (from 32.9% to 22.3%, P < 0.05). A second study focused on reducing medication errors due to the prescribing of potentially inappropriate medications. This quasi-experimental study found that a computerized provider order entry clinical decision support system decreased the number of potentially inappropriate medications ordered for patients 65 years of age who were hospitalized (11.56 before to 9.94 orders per day after, P < 0.001). The third medication error study was a cross-sectional phone survey of managed-care elders, which found that more blacks than whites had low antihypertensive medication adherence as per a self-reported measure (18.4% vs 12.3%, respectively; P < 0.001). Moreover, blacks used more complementary and alternative medicine (CAM) than whites for the treatment of hypertension (30.5% vs 24.7%, respectively; P = 0.005). In multivariable analyses stratified by race, blacks who used CAM were more likely than. those who did not to have low antihypertensive medication adherence (prevalence rate ratio = 1.56; 95% CI, 1.14-2.15; P = 0.006).
The remaining two studies addressed some form of medication-related adverse patient events. A case-control study of Medicare Advantage patients revealed for the first time that the use of skeletal muscle relaxants was associated significantly with an increased fracture risk (adjusted odds ratio = 1.40; 95% CI, 1.15-1.72; P < 0.001). This increased risk was even more pronounced with the concomitant use of benzodiazepines. Finally, a randomized controlled trial across 16 centers in France used a 1-week educational intervention about high-risk medications and ADEs directed at rehabilitation health care teams. Results indicated that the rate of ADEs in the intervention group was lower than that in the usual care group (22% vs 36%, respectively, P = 0.004).
Conclusion: Information from these studies may advance health professionals' understanding of medication errors and ADEs and may help guide research and clinical practices in years to come. (Am J Geriatr Pharmacother. 2011;9: 1-10) (C) 2011 Published by Elsevier HS Journals, Inc.
C1 [Peron, Emily P.; Marcum, Zachary A.; Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Dept Med, Sch Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Boyce, Richard; Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Dept Biomed Informat, Sch Med, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Hlth Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med Geriatr, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM jth14@pitt.edu
OI Handler, Steven/0000-0002-3940-3224; Boyce, Richard/0000-0002-2993-2085
FU AHRQ HHS [K12 HS019461, R01 HS017695, R01 HS018721]; NIA NIH HHS [K07
AG033174, K07AG033174, P30 AG024827, P30AG024827, R01 AG027017, R01
AG034056, R01AG027017, R01AG034056, R56 AG027017, R56AG027017, T32
AG021885]; NIMH NIH HHS [R34 MH082682]; NINR NIH HHS [R01 NR010135]
NR 111
TC 6
Z9 6
U1 4
U2 13
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD FEB
PY 2011
VL 9
IS 1
BP 1
EP 10
DI 10.1016/j.amjopharm.2011.01.003
PG 10
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 754PA
UT WOS:000289866600001
PM 21459304
ER
PT J
AU Aspinall, SL
Zhao, XH
Good, CB
Stone, RA
Boresi, J
Cox, S
Bartholomew, C
Jansen, D
Guterman, S
Patino, M
Rivera-Miranda, G
Burlingame, M
Frazer, J
Sellers, J
Steele, VS
Witt, L
Cunningham, FE
AF Aspinall, Sherrie L.
Zhao, Xinhua
Good, Chester B.
Stone, Roslyn A.
Boresi, Joy
Cox, Sarah
Bartholomew, Chad
Jansen, David
Guterman, Sarah
Patino, Mauricio
Rivera-Miranda, Giselle
Burlingame, Mark
Frazer, Justin
Sellers, Janelle
Steele, Valerie Stanard
Witt, Lauri
Cunningham, Francesca E.
TI Intervention to Decrease Glyburide Use in Elderly Patients With Renal
Insufficiency
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Article
DE elderly; diabetes mellitus; glyburide; outcome assessment; renal
insufficiency
ID DIABETIC-PATIENTS; HYPOGLYCEMIA; SULFONYLUREAS; THERAPY; DISEASE; DRUGS
AB Objectives: The objectives of this study were to describe changes in glyburide prescribing in cohorts that were and were not targeted by a risk reduction project, assess factors associated with glyburide discontinuation, and evaluate changes in glycated hemoglobin (ie, HbA(1c)) levels and rates of serious hypoglycemia.
Methods: This historical cohort study included a targeted cohort of 4368 outpatient veterans aged years with active prescriptions for glyburide between April 1, 2007 and June 30, 2007 and serum creatinine (SCr)>= 2 mg/dL and a nontargeted cohort of 1886 outpatients meeting these same criteria between July I, 2007 and September 3, 2007. The intervention in the risk reduction project took place on September 4, 2007 and entailed giving regional pharmacy leaders information about the increased risk of hypoglycemia with glyburide and the list of targeted patients for follow up with providers. For each patient, the study period was the time between the date they first met the eligibility criteria and March 31, 2008. All data were obtained from Veterans Affairs (VA) administrative databases. The primary outcome was the discontinuation of glyburide. Secondary outcomes were the change in HbA(1c) after stopping glyburide and the rate of serious hypoglycemia after intervention.
Results: Incidence rate ratios (IRRs) for glyburide discontinuation in targeted versus nontargeted cohorts were statistically significantly elevated in September (IRR 2.1; 95% CI 1.7-2.5), October (IRR 1.3; 95% CI 1.1-1.6), and November 2007 (IRR 1.4; 95% CI 1.1-1.7). The intervention, black race, SCr, Charlson comorbidity score, new glyburide use, and VA region were independently associated with discontinuation. Among patients in the targeted cohort who discontinued glyburide, mean (SD) HbA(1c) at baseline and after discontinuation were 7.17% (1.35%), and 7.22% (1.34%), respectively (P = 0.36). The hypoglycemia rates/1000 person-days were 0.093 before the intervention and 0.070 afterwards (P = 0.10).
Conclusion: A one-time intervention in a risk reduction project decreased glyburide use over a 3-month period in elderly outpatients with renal insufficiency without compromising glucose control. (Am J Geriatr Pharmacother. 2011;9:58-68) Published by Elsevier HS Journals, Inc.
C1 [Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Stone, Roslyn A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Cunningham, Francesca E.] VA Ctr Medicat Safety, Hines, IL USA.
[Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
[Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Boresi, Joy; Jansen, David] St Louis VA Med Ctr, St Louis, MO USA.
[Cox, Sarah; Witt, Lauri] Kansas City VA Med Ctr, Kansas City, MO USA.
[Bartholomew, Chad; Sellers, Janelle] VA Nebraska Western Iowa Hlth Care Syst, Grand Isl, NE USA.
[Guterman, Sarah; Burlingame, Mark] N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA.
[Patino, Mauricio; Steele, Valerie Stanard] Bay Pines VA Hlth Care Syst, Bay Pines, FL USA.
[Rivera-Miranda, Giselle] VA Caribbean Healthcare Syst, San Juan, PR USA.
[Frazer, Justin] VA Eastern Kansas Hlth Care Syst, Topeka, KS USA.
RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM sherrie.aspinall@va.gov
NR 20
TC 11
Z9 11
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD FEB
PY 2011
VL 9
IS 1
BP 58
EP 68
DI 10.1016/j.amjopharm.2011.02.001
PG 11
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 754PA
UT WOS:000289866600006
PM 21459309
ER
PT J
AU Prentice, JC
Fincke, BG
Miller, DR
Pizer, SD
AF Prentice, Julia C.
Fincke, B. Graeme
Miller, Donald R.
Pizer, Steven D.
TI Outpatient Wait Time and Diabetes Care Quality Improvement
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID CASE-MANAGEMENT; HEALTH-CARE; GLYCEMIC CONTROL; DISEASE; STRATEGIES;
MORTALITY; ACCESS; TRIAL; RISK
AB Objective: To examine the relationship between glycated hemoglobin (A1C) levels and the number of days spent waiting for primary care appointments.
Study Design: Retrospective observational study that relied on Department of Veterans Affairs (VA) utilization data and Medicare claims data from 2001 to 2003. The outcome was A1C levels. The main explanatory variable of interest was facility-level primary care wait times measured in days.
Methods: Heckman selection models simultaneously predicted the presence of an A1C value and its level. Models were risk adjusted for prior individual health status. Separate models were estimated on the entire sample and on subsamples stratified by baseline A1C levels.
Results: Veterans who visited VA facilities with wait times of longer than 32.5 days had small significant increases in A1C levels of 0.14 percentage point for the whole sample, 0.07 percentage point for patients with baseline A1C levels less than 7%, 0.11 percentage point for patients with baseline A1C levels between 7% and 8%, and 0.18 percentage point for patients with baseline A1C levels greater than 8%.
Conclusions: Decreasing wait times has the potential to reduce A1C levels by 0.18 percentage point for patients with baseline A1C levels exceeding 8%. This effect is roughly one-third of what is achieved with the most successful existing quality improvement strategies. Ensuring timely access to outpatient care could be an important addition to future diabetes care quality improvement programs. (Am J Manag Care. 2011; 17(2): e43-e54)
C1 [Prentice, Julia C.; Fincke, B. Graeme; Miller, Donald R.] US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, Boston, MA 02130 USA.
Boston Univ, Sch Publ Hlth, Boston, MA USA.
RP Prentice, JC (reprint author), US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, 150 S Huntington Ave,Mail Stop 152H, Boston, MA 02130 USA.
EM julia.prentice@va.gov
FU Health Services Research and Development Service, Department of Veterans
Affairs [IAD-06-112, IIR 04-233]; Health Care Financing and Organization
Initiative under the Robert Wood Johnson Foundation [62967]
FX Funding Source: Funding for this research was provided by grants
IAD-06-112 and IIR 04-233 from the Health Services Research and
Development Service, Department of Veterans Affairs, and by grant 62967
from the Health Care Financing and Organization Initiative under the
Robert Wood Johnson Foundation.
NR 31
TC 0
Z9 0
U1 0
U2 1
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD FEB
PY 2011
VL 17
IS 2
PG 12
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 747XR
UT WOS:000289355100003
ER
PT J
AU Oujiri, J
Hakeem, A
Pack, Q
Holland, R
Meyers, D
Hildebrand, C
Bridges, A
Roach, MA
Vogelman, B
AF Oujiri, James
Hakeem, Abdul
Pack, Quinn
Holland, Robert
Meyers, David
Hildebrand, Christopher
Bridges, Alan
Roach, Mary A.
Vogelman, Bennett
TI Resident-initiated interventions to improve inpatient heart-failure
management
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID ELECTRONIC HEALTH RECORD; ACUTE MYOCARDIAL-INFARCTION; CLINICAL
DECISION-SUPPORT; QUALITY-OF-CARE; IMPLEMENTATION; PERFORMANCE;
INDICATORS; MORTALITY; SYSTEMS; SAFETY
AB Background: Third-year internal medicine residents participating in a quality improvement rotation identified gaps between the Joint Commission's ORYX quality guidelines and clinical practices for the inpatient management of heart failure (HF) at the William S. Middleton Memorial Veterans Hospital. Residents focused on the performance metrics associated with tobacco-cessation counselling documentation, ejection fraction assessment and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker prescriptions.
Methods: After analysing data collected by the External Peer Review Program, residents reviewed the institution's admissions and discharge processes with the aim of improving quality and compliance. In redesigning these processes, residents created an admissions template and a discharge face sheet, and compared specific ORYX measure compliance rates before and after institution-wide implementation.
Results: Following implementation of the tobacco-cessation admissions template, 100% of HF patients who used tobacco received documented cessation counselling, compared with 59% prior to intervention (p<0.01, n=32). Following implementation of the mandatory discharge face sheet, 97% of HF patients (compared with 92% preintervention, p>0.05) received comprehensive discharge instruction; LV function assessment went from 98% to 100% (p>0.05); and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker prescription for left ventricular systolic dysfunction at discharge (or documentation of a contra-indication) went from 82% to 100% (p<0.01, n=48).
Discussion: By implementing a standardised admissions template and a mandatory discharge face sheet, the hospital improved its processes of documentation and increased adherence to quality-performance measures. By strengthening residents' learning and commitment to quality improvement, the hospital created a foundation for future changes in the systems that affect patient care.
C1 [Oujiri, James; Holland, Robert; Meyers, David; Hildebrand, Christopher; Bridges, Alan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Oujiri, James; Roach, Mary A.; Vogelman, Bennett] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Hakeem, Abdul] Univ Cincinnati, Coll Med, Div Cardiovasc Dis, Cincinnati, OH USA.
[Pack, Quinn] Div Cardiovasc Dis, Detroit, MI USA.
RP Vogelman, B (reprint author), Internal Med Residency Program, Educ Program Off, Suite 5000,1685 Highland Ave, Madison, WI 53705 USA.
EM bsv@medicine.wisc.edu
FU Medical Education and Research Committee (MERC) of the University of
Wisconsin-Madison School of Medicine and Public Health; Residency Review
Committee for Internal Medicine; William S Middleton Memorial Veterans
Administration Hospital; NIH [1 UL1RR025011]
FX Completion of this paper was made possible by a grant from the Medical
Education and Research Committee (MERC) of the University of
Wisconsin-Madison School of Medicine and Public Health as well as by the
support of the Education Innovation Project of the Residency Review
Committee for Internal Medicine, of which we are a participating
residency. These QI projects received widespread support from the
William S Middleton Memorial Veterans Administration Hospital,
especially the director, D Thompson, and personnel in the Information
Technology, Pharmacy, Nursing, and Organisation Improvement departments.
Results of these projects were shared at the Association of Program
Directors in Internal Medicine (APDIM) meeting in April, 2009. We also
wish to acknowledge the support of the University of Wisconsin Institute
for Clinical and Translational Research, funded through an NIH Clinical
and Translational Science Award (CTSA), grant no 1 UL1RR025011.
NR 18
TC 3
Z9 3
U1 1
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD FEB
PY 2011
VL 20
IS 2
BP 181
EP 186
DI 10.1136/bmjqs.2009.039339
PG 6
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 752WT
UT WOS:000289726900012
PM 21303773
ER
PT J
AU Barnes, DE
Yaffe, K
AF Barnes, Deborah E.
Yaffe, Kristine
TI Accuracy of Summary Risk Score for Prediction of Alzheimer Disease:
Better Than Demographics Alone?
SO ARCHIVES OF NEUROLOGY
LA English
DT Letter
ID DEMENTIA RISK
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
RP Barnes, DE (reprint author), 4150 Clement St,151R, San Francisco, CA 94121 USA.
EM deborah.barnes@ucsf.edu
NR 5
TC 2
Z9 2
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD FEB
PY 2011
VL 68
IS 2
BP 268
EP 268
DI 10.1001/archneurol.2011.4
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 721CY
UT WOS:000287330300022
PM 21321000
ER
PT J
AU McElroy, SL
Frye, MA
Hellemann, G
Altshuler, L
Leverich, GS
Suppes, T
Keck, PE
Nolen, WA
Kupka, R
Post, RM
AF McElroy, Susan L.
Frye, Mark A.
Hellemann, Gerhard
Altshuler, Lori
Leverich, Gabriele S.
Suppes, Trisha
Keck, Paul E.
Nolen, Willem A.
Kupka, Ralph
Post, Robert M.
TI Prevalence and correlates of eating disorders in 875 patients with
bipolar disorder
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Eating disorders; Bipolar disorder; Binge
ID COMORBIDITY SURVEY REPLICATION; TREATMENT ENHANCEMENT PROGRAM;
ANOREXIA-NERVOSA; STEP-BD; PSYCHIATRIC-DISORDERS; METABOLIC SYNDROME;
CO-MORBIDITY; I-DISORDER; SPECTRUM; ILLNESS
AB Objective: Relatively little is known about the co-occurrence of bipolar and eating disorders. We therefore assessed the prevalence and clinical correlates of eating disorders in 875 patients with bipolar disorder.
Method: 875 outpatients with DSM-IV bipolar I or II disorder were evaluated with structured diagnostic interviews and clinician- and self-administered questionnaires to determine bipolar and eating disorder diagnoses, other comorbid Axis I disorder diagnoses, and demographic and historical illness characteristics.
Results: 125 (14.3%) patients met DSM-IV criteria for at least one comorbid lifetime Axis I eating disorder, with binge eating disorder (N = 77) being more common than bulimia nervosa (n = 42) and anorexia nervosa (N = 27). There were no significant eating disorder comorbidity differences between bipolar I and bipolar II patients. Presence of a lifetime comorbid eating disorder was associated with female gender, younger age, earlier age of onset of mood symptoms and of bipolar disorder, presentation in a mixed episode, greater number of prior mood episodes, history of rapid cycling and suicide attempts, greater mean BMI, obesity and severe obesity, and family history of depression, bipolar disorder, alcoholism, and drug abuse. When the three eating disorder groups were compared, lifetime anorexia nervosa was associated with normal weight and a lifetime anxiety disorder, lifetime bulimia nervosa was associated with overweight, and lifetime binge eating disorder was associated with obesity and severe obesity.
Conclusions: Patients with bipolar disorder, especially women, not infrequently have comorbid eating disorders, and this comorbidity is associated with an earlier age of onset and more severe course of bipolar illness. (C) 2010 Elsevier B.V. All rights reserved.
C1 [McElroy, Susan L.; Keck, Paul E.] Craig & Frances Lindner Ctr HOPE, Mason, OH USA.
[McElroy, Susan L.; Keck, Paul E.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA.
[Frye, Mark A.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA.
[Hellemann, Gerhard; Altshuler, Lori] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA.
[Altshuler, Lori] VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA.
[Leverich, Gabriele S.; Post, Robert M.] Bipolar Collaborat Network, Bethesda, MD USA.
[Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Suppes, Trisha] VA Palo Alto Hlth Care Syst, Bipolar Disorder Res Program, Palo Alto, CA USA.
[Nolen, Willem A.] Univ Groningen, Dept Psychiat, Univ Med Ctr Groningen, Groningen, Netherlands.
[Kupka, Ralph] Altrech Inst Mental Hlth Care, Utrecht, Netherlands.
[Post, Robert M.] George Washington Sch Med, Washington, DC USA.
RP McElroy, SL (reprint author), Linder Ctr HOPE, 4075 Old Western Row Rd, Mason, OH 45040 USA.
EM susan.mcelroy@lindnercenter.org
RI Nolen, Willem/E-9006-2014
FU Astra Zeneca Pharmaceuticals; National Institute of Mental Health
(NIMH); Pfizer; Pharma Solutions (CNS Drug Supplement); Wolters Kluwer;
Theodore and Vada Stanley Foundation
FX T Suppes receives honoraria and/or research support from Astra Zeneca
Pharmaceuticals, National Institute of Mental Health (NIMH), Pfizer,
Pharma Solutions (CNS Drug Supplement), and Wolters Kluwer.; Supported
by a generous grant from The Theodore and Vada Stanley Foundation.
NR 49
TC 58
Z9 58
U1 7
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD FEB
PY 2011
VL 128
IS 3
BP 191
EP 198
DI 10.1016/j.jad.2010.06.037
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 743JG
UT WOS:000289014000002
PM 20674033
ER
PT J
AU Bhambhvani, P
Scott, J
Heo, J
Iskandrian, A
AF Bhambhvani, Pradeep
Scott, Johnny
Heo, Jaekyeong
Iskandrian, Ami
TI Unusual intrathoracic activity of Tc-99m sestamibi in a patient with
chest pains
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Article
ID MYOCARDIAL-PERFUSION SCINTIGRAPHY; EMISSION COMPUTED-TOMOGRAPHY;
INTESTINAL ACTIVITY; SPECT
C1 [Bhambhvani, Pradeep; Scott, Johnny; Iskandrian, Ami] Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA.
[Scott, Johnny] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
[Heo, Jaekyeong; Iskandrian, Ami] Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Scott, Johnny] Birmingham VA Med Ctr, Dept Nucl Med, Birmingham, AL USA.
RP Bhambhvani, P (reprint author), Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA.
EM pbhambhvani@uabmc.edu
NR 8
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD FEB
PY 2011
VL 18
IS 1
BP 185
EP 186
DI 10.1007/s12350-010-9289-0
PG 2
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 745LK
UT WOS:000289166700022
PM 20848255
ER
PT J
AU Makin-Byrd, K
Gifford, E
McCutcheon, S
Glynn, S
AF Makin-Byrd, Kerry
Gifford, Elizabeth
McCutcheon, Susan
Glynn, Shirley
TI Family and Couples Treatment for Newly Returning Veterans
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE family; couples; treatment; veteran; military
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-ILLNESS; LED EDUCATION;
SCHIZOPHRENIA; IMPACT; INTERVENTION; DEPLOYMENT; COMBAT;
PSYCHOEDUCATION; SATISFACTION
AB Civilian psychologists are being called on to assist the thousands of service members returning from Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF). Newly returning veterans are at risk for depression, posttraumatic stress disorder, and alcohol use disorders. In addition, veteran partners and families are at increased risk for stress and conflict. The following article provides clinicians with information on the impact of military service on the veteran and the family, then reviews ongoing family services available to veterans through the Veterans Health Administration (VHA). Finally, we describe recovery-oriented implications for practicing psychologists when treating veterans and their families.
C1 [Makin-Byrd, Kerry] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA.
[Makin-Byrd, Kerry] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Gifford, Elizabeth] Vet Hlth Adm, Menlo Pk, CA USA.
[McCutcheon, Susan] Dept Vet Affairs, Off Mental Hlth Serv, Washington, DC USA.
[Glynn, Shirley] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Glynn, Shirley] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA.
[Gifford, Elizabeth] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA.
RP Makin-Byrd, K (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat MPD 152, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM Kerry.Makin-Byrd@va.gov
OI Makin-Byrd, Kerry/0000-0003-0670-3826
NR 57
TC 18
Z9 18
U1 4
U2 10
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD FEB
PY 2011
VL 42
IS 1
SI SI
BP 47
EP 55
DI 10.1037/a0022292
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA 733TE
UT WOS:000288285100007
ER
PT J
AU Sautter, FJ
Armelie, AP
Glynn, SM
Wielt, DB
AF Sautter, Frederic J.
Armelie, Aaron P.
Glynn, Shirley M.
Wielt, Dustin B.
TI The Development of a Couple-Based Treatment for PTSD in Returning
Veterans
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE couple therapy; posttraumatic stress disorder; behavior therapy;
psychotherapy; relationship problem
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; MALE VIETNAM
VETERANS; SOCIAL SUPPORT; SYMPTOMS; THERAPY; IRAQ; AFGHANISTAN;
EXPOSURE; METAANALYSIS
AB Military personnel deployed in Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) show high levels of emotional distress and posttraumatic stress disorder (PTSD), and these deployment-related problems may be expected to have a devastating impact on their relationships. It is urgent that researchers develop couple-based treatments to reduce PTSD in OEF/OIF veterans and to reduce PTSD-related relationship problems. This article describes the development of a novel couple-based treatment for PTSD, called Structured Approach Therapy (SAT), that uses empathic communication training and stress inoculation procedures to help couples improve their ability to cope with trauma-related anxiety and a multicomponent emotion activation program to help couples reduce emotional numbing. The theoretical basis of the SAT Treatment Model is described, and the various treatment components are presented. The authors recommend that couple-based interventions be used to provide OEF/OIF veterans and their partners with empathic communication skills to discuss their thoughts and feelings about deployment and with dyadic coping skills to confront trauma-related aversive emotions and emotional numbing and return intimacy to their lives.
C1 [Sautter, Frederic J.; Armelie, Aaron P.; Wielt, Dustin B.] SE Louisiana Vet Hlth Care Syst, New Orleans, LA USA.
[Glynn, Shirley M.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
RP Sautter, FJ (reprint author), Tulane Univ, Dept Psychiat & Behav Sci, Sch Med, 1440 Canal St TB 53, New Orleans, LA 70112 USA.
EM fredericsautter@msn.com
NR 39
TC 14
Z9 14
U1 2
U2 8
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD FEB
PY 2011
VL 42
IS 1
SI SI
BP 63
EP 69
DI 10.1037/a0022323
PG 7
WC Psychology, Multidisciplinary
SC Psychology
GA 733TE
UT WOS:000288285100009
ER
PT J
AU Terrio, HP
Nelson, LA
Betthauser, LM
Harwood, JE
Brenner, LA
AF Terrio, Heidi P.
Nelson, Lonnie A.
Betthauser, Lisa M.
Harwood, Jeri E.
Brenner, Lisa A.
TI Postdeployment Traumatic Brain Injury Screening Questions: Sensitivity,
Specificity, and Predictive Values in Returning Soldiers
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE concussion; military; postdeployment; screening; traumatic brain injury
ID POSTTRAUMATIC-STRESS-DISORDER; IRAQ; IDENTIFICATION; RELIABILITY;
AFGHANISTAN; POPULATION; DEPRESSION; DEPLOYMENT; SYMPTOMS; VALIDITY
AB Objective: To evaluate the sensitivity, specificity, and predictive values of Post-Deployment Health Assessment traumatic brain injury (TBI) screening questions employed by the Department of Defense (DOD). Participants: Complete data was obtained from 3,072 soldiers upon return from a 15-month deployment to Iraq. Method: Comparisons were made between responses to the DOD four-item screener and a brief structured clinical interview for likely deployment-related TBI history. The interview process was facilitated using responses to the Warrior Administered Retrospective Casualty Assessment Tool (WARCAT). Results: The sensitivity and specificity of the DOD screening tool (positive response to all four items) in comparison to the clinician-confirmed diagnosis was 60% and 96%, respectively. The sensitivity increased to 80%, with a slight decrease in specificity to 93%, for positive TBI screening when affirmative responses to questions 1 and 2 only were included. Conclusions: Affirmative responses to questions 1 and 2 of the DOD TBI screening tool demonstrated higher sensitivity for clinician-diagnosed deployment-related TBI. These two items perform better than positive responses to all four questions; the criteria presently being used for documentation and referral of a deployment-related TBI. These findings support further exploration of TBI screening and assessment procedures.
C1 [Terrio, Heidi P.] Evans Army Community Hosp, Def & Vet Brain Injury Ctr, Dept Deployment Hlth, Ft Carson, CO USA.
[Betthauser, Lisa M.] Univ Colorado Denver, Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA.
[Harwood, Jeri E.] Univ Colorado Denver, Dept Pediat, Sch Med, Denver, CO USA.
[Brenner, Lisa A.] Univ Colorado Denver, Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Sch Med, Denver, CO USA.
[Brenner, Lisa A.] Univ Colorado Denver, Dept Psychiat, Sch Med, Denver, CO USA.
[Brenner, Lisa A.] Univ Colorado Denver, Dept Neurol, Sch Med, Denver, CO USA.
[Brenner, Lisa A.] Univ Colorado Denver, Dept Phys Med & Rehabil, Sch Med, Denver, CO USA.
RP Terrio, HP (reprint author), USA, Western Reg Med Command, Bldg 2006,Liggett Ave,Room 317,Mail Stop 109,Box, Jblm, WA 98433 USA.
EM heidi.terrio@amedd.army.mil
NR 32
TC 22
Z9 22
U1 0
U2 1
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD FEB
PY 2011
VL 56
IS 1
BP 26
EP 31
DI 10.1037/a0022685
PG 6
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA 735LZ
UT WOS:000288417400003
PM 21401283
ER
PT J
AU Kettl, P
AF Kettl, Paul
TI Exploring the Mental Life and Home Life of Children: The Role of a
Television History
SO CHILD AND ADOLESCENT MENTAL HEALTH
LA English
DT Article
DE Television; video entertainment; child evaluation
ID CHILDHOOD OBESITY; MEDIA
AB Background: Media entertainment is a pervasive presence in the lives of our children. It presents a series of stories that a child can select as important or intriguing to him or her. Method: A good history of television and media viewing uses this omnipresent influence in a child's life to attempt to gain insight into the child's hopes and fears as well as information concerning the structure of the home. Conclusion: It is a useful exercise that could be done with each new child patient, and could provide a quick means to assess the child's thoughts as well as assessing the child's home environment.
C1 Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA 19104 USA.
RP Kettl, P (reprint author), Philadelphia VA Med Ctr, Behav Hlth Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM paul.kettl@va.gov
NR 12
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1475-357X
J9 CHILD ADOL MENT H-UK
JI Child Adolesc. Ment. Health
PD FEB
PY 2011
VL 16
IS 1
BP 60
EP 62
DI 10.1111/j.1475-3588.2010.00573.x
PG 3
WC Psychology, Clinical; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 727RH
UT WOS:000287818400009
ER
PT J
AU Goy, ER
Ganzini, L
AF Goy, Elizabeth R.
Ganzini, Linda
TI Prevalence and Natural History of Neuropsychiatric Syndromes in Veteran
Hospice Patients
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Hospice; veterans; mental disorders; anxiety; depression; suicide;
delirium; alcohol abuse; insomnia
ID ILL CANCER-PATIENTS; TERMINALLY-ILL; DEPRESSION; DISORDERS; CARE
AB Context. Prospective studies are needed to adequately describe the overall impact of neuropsychiatric syndromes on the course of hospice enrollment in outpatient settings.
Objectives. To determine the prevalence and natural history of delirium, cognitive impairment, alcohol abuse, anxiety, depression, and suicidal ideation (SI) in community-dwelling veteran hospice patients.
Methods. Home hospice patients were visited regularly from enrollment until their deaths, study withdrawal, or discharge from hospice. Family caregivers gave consent for those with Mini-Mental State Examination (MMSE) scores less than or equal to 23. Measures included the Structured Clinical Interview for DSM-IV for depression (past and current) and alcohol abuse; the Hospital Anxiety and Depression Scale; MMSE; and Confusion Assessment Method (CAM). A clinician-rated CAM item documented sleep disturbance, and participants were asked about SI at each visit.
Results. The median length of hospice enrollment was 81 days. Of 88 participants, 77 (88%) experienced at least one neuropsychiatric syndrome. Cognitive impairment was prevalent, with 60 (68%) registering MMSE less than or equal to 23 at least once. More than half of the participants developed delirium; the proportion with delirium, any cognitive impairment, sleep disturbance, or any neuropsychiatric syndrome increased significantly from first to last study visit. Twelve (14%) participants had SI during the study, and 30 (34%) participants were affected by depression overall. Sixteen patients who were not depressed on admission subsequently developed depression. Anxiety was present in 14 (16%) on at least one study visit. Active alcohol abuse remained relatively stable (8%) across visits.
Conclusions. Psychiatric syndromes are highly prevalent in hospice patients. Systematic case finding of psychiatric disorders may be necessary to improve quality of life in the last months of life. J Pain Symptom Manage 2011;41:394-401. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee.
C1 [Ganzini, Linda] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97207 USA.
Portland VA Med Ctr, Hlth Serv Res & Dev Program, Portland, OR 97207 USA.
Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
RP Ganzini, L (reprint author), Portland VA Med Ctr, Div Mental Hlth, R&D 66,POB 1034, Portland, OR 97207 USA.
EM linda.ganzini@va.gov
FU Department of Veterans Affairs; Veterans Health Administration Clinical
Sciences Research and Development Program; Health Services Research and
Development Program
FX This article is based on work supported by the Department of Veterans
Affairs, Veterans Health Administration Clinical Sciences Research and
Development Program and Health Services Research and Development
Program.
NR 14
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2011
VL 41
IS 2
BP 394
EP 401
DI 10.1016/j.jpainsymman.2010.04.015
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 736ZW
UT WOS:000288536300009
PM 20869843
ER
PT J
AU Reinke, LF
Slatore, CG
Udris, EM
Moss, BR
Johnson, EA
Au, DH
AF Reinke, Lynn F.
Slatore, Christopher G.
Udris, Edmunds M.
Moss, Brianna R.
Johnson, Eric A.
Au, David H.
TI The Association of Depression and Preferences for Life-Sustaining
Treatments in Veterans with Chronic Obstructive Pulmonary Disease
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Chronic obstructive pulmonary disease; COPD; depression; life-sustaining
preferences; cardiopulmonary resuscitation; CPR
ID QUALITY-OF-LIFE; SERIOUSLY ILL PATIENTS; RESPIRATORY QUESTIONNAIRE;
ADVANCED CANCER; SCREENING-TEST; PREVALENCE; HEALTH; END; MORTALITY;
COPD
AB Context. Depressive symptoms are common among patients with chronic obstructive pulmonary disease (COPD) and may modify patients' preferences for life-sustaining therapy. Examining the relationship between patient preferences for life-sustaining treatments and depressive symptoms is important for clinicians engaging in end-of-life care discussions.
Objectives. To assess whether a history of depression or active depressive symptoms is associated with preferences for life-sustaining therapies among veterans with COPD.
Methods. This was a cross-sectional study of 376 veterans who participated in a randomized trial to improve the occurrence and quality of end-of-life communication between providers and patients. Depressive symptoms were assessed by self-reported history and the Mental Health Index-5 survey. Preferences for mechanical ventilation (MV) and cardiopulmonary resuscitation (CPR) were assessed using standardized instruments. Multivariate logistic regression was conducted to adjust for potential confounding factors.
Results. Participants were older men with severe COPD. A substantial proportion of participants noted that they would want MV (64.2%) or CPR (77.8%). Depressive history and active symptoms were not associated with preferences for MV and CPR either before or after adjusting for confounding variables.
Conclusion. Depressive history and active symptoms among veterans with severe COPD were not associated with their decisions for life-sustaining treatments. Clinicians caring for patients with COPD should understand the importance of assessing and treating patients with depressive symptoms, yet recognize that depressive symptoms may not be predictive of a patient declining life-sustaining treatments. J Pain Symptom Manage 2011;41:402-411. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Reinke, Lynn F.; Udris, Edmunds M.; Moss, Brianna R.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv R&D, Seattle, WA 98101 USA.
[Au, David H.] Univ Washington, Dept Med, Seattle, WA USA.
[Johnson, Eric A.] Grp Hlth Res Inst, Seattle, WA USA.
[Slatore, Christopher G.] Portland VA Med Ctr, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
RP Reinke, LF (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv R&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM reinkl@u.washington.edu
OI Slatore, Christopher/0000-0003-0958-8122
FU Department of Veterans Affairs [IIR 02-292]
FX Funding for this study was provided by the Health Services Research and
Development Program, Department of Veterans Affairs (IIR 02-292). The
views expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs.
The authors declare no conflicts of interest.
NR 34
TC 8
Z9 10
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2011
VL 41
IS 2
BP 402
EP 411
DI 10.1016/j.jpainsymman.2010.05.012
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 736ZW
UT WOS:000288536300010
PM 21145201
ER
PT J
AU Weintraub, D
AF Weintraub, Daniel
TI A Failure to Communicate: Preliminary Evidence for Cortico-striatal
Dysconnection with Pathological Gambling in Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Editorial Material
ID IMPULSE CONTROL; BEHAVIORS
C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
NR 14
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD FEB 1
PY 2011
VL 26
IS 2
BP 193
EP 194
DI 10.1002/mds.23532
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 736AL
UT WOS:000288461800001
PM 21412827
ER
PT J
AU Amstadter, AB
Richardson, L
Meyer, A
Sawyer, G
Kilpatrick, DG
Trinh, LT
Lam, TT
Nguyen, TT
Tran, T
La, TB
Tran, TH
Tran, DT
Gaboury, M
Acierno, R
AF Amstadter, Ananda B.
Richardson, Lisa
Meyer, Alicia
Sawyer, Genelle
Kilpatrick, Dean G.
Trinh Luong Tran
Lam Tu Trung
Nguyen Thanh Tam
Tran Tuan
La Thi Buoi
Tran Thu Ha
Tran Duc Thach
Gaboury, Mario
Acierno, Ron
TI Prevalence and correlates of probable adolescent mental health problems
reported by parents in Vietnam
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Adolescents; Vietnam; Mental Health; Epidemiology
ID DIFFICULTIES-QUESTIONNAIRE SDQ; DEVELOPING-COUNTRIES; CHILD-PSYCHIATRY;
DSM-IV; STRENGTHS; DISORDERS; GENDER; PSYCHOPATHOLOGY; COMORBIDITY;
VERSION
AB The purpose of the present study was to estimate the prevalence of probable mental health problems in an epidemiologic study of Vietnamese adolescents. A secondary aim was to examine the correlates of probable mental health caseness.
Interviewers visited 1,914 households that were randomly selected to participate in a multi-agency study of mental health in select provinces of Vietnam. Semi-structured interviews assessed adolescent mental health problems using the Strengths and Difficulties Questionnaire (SDQ) parent informant version, and additionally the interviewers collected information on demographic variables (age, gender, ethnic group, religious affiliation, social capital). The final sample included data on 1,368 adolescents (aged 11-18 years).
The average score on the total problem composite of the SDQ scale was 6.66 (SD = 4.89), and 9.1% of the sample was considered a case (n = 124). Bivariate analyses were conducted to determine which demographic variables were related to the SDQ case/non-case score. All variables except gender were significant in bivariate analyses, and therefore were entered into a logistic regression. Results indicated that age, religion, and wealth remained significant predictors of probable caseness.
Overall, prevalence estimates of mental health problems generated by the SDQ were consistent with those reported in the US and other Western and non-Western samples. Results of the current study suggest some concordance of risk and protective factors between Western and Vietnamese youth (i.e., age and SES).
C1 [Amstadter, Ananda B.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Acierno, Ron] Ralph H Johnson VA Med Ctr, Dept Psychiat & Behav Sci, Charleston, SC USA.
[Gaboury, Mario] Oskar Schindler Humanities Fdn, New Haven, CT USA.
[Tran Tuan; La Thi Buoi; Tran Thu Ha; Tran Duc Thach] Res & Training Ctr Community Dev, Vong St Hanoi, Vietnam.
[Nguyen Thanh Tam] Vietnam Vet Amer Fdn, Washington, DC USA.
[Lam Tu Trung] Da Nang Mental Hlth Hosp, Da Nang, Vietnam.
[Trinh Luong Tran] Hlth Dept Da Nang City, Da Nang, Vietnam.
RP Amstadter, AB (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, 250852,67 President St, Charleston, SC 29425 USA.
EM amstadt@musc.edu
RI Tran, Thach/H-7734-2014
OI Tran, Thach/0000-0002-4686-8601
NR 35
TC 9
Z9 10
U1 1
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD FEB
PY 2011
VL 46
IS 2
BP 95
EP 100
DI 10.1007/s00127-009-0172-8
PG 6
WC Psychiatry
SC Psychiatry
GA 718DA
UT WOS:000287099000002
PM 20012859
ER
PT J
AU Barnes, DE
AF Barnes, Deborah E.
TI The Mediterranean Diet: Good for the Heart = Good for the Brain?
SO ANNALS OF NEUROLOGY
LA English
DT Editorial Material
ID ALZHEIMERS-DISEASE; COGNITIVE DECLINE; RANDOMIZED-TRIAL; STYLE DIET;
RISK; INTERVENTION; PREVENTION; DEMENTIA; ADHERENCE; MORTALITY
C1 [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
NR 26
TC 3
Z9 4
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD FEB
PY 2011
VL 69
IS 2
BP 226
EP 228
DI 10.1002/ana.22376
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 733TD
UT WOS:000288284900002
PM 21387364
ER
PT J
AU Goodman, M
Patil, U
Triebwasser, J
Hoffman, P
Weinstein, ZA
New, A
AF Goodman, Marianne
Patil, Uday
Triebwasser, Joseph
Hoffman, Perry
Weinstein, Zachary A.
New, Antonia
TI PARENTAL BURDEN ASSOCIATED WITH BORDERLINE PERSONALITY DISORDER IN
FEMALE OFFSPRING
SO JOURNAL OF PERSONALITY DISORDERS
LA English
DT Article
ID MENTAL-ILLNESS; PSYCHOLOGICAL DISTRESS; FAMILY-MEMBERS; RELATIVES;
DEPRESSION; EXPERIENCE; INVENTORY; APPRAISAL; COMMUNITY; SYMPTOMS
AB To identify aspects of parental burden associated with borderline personality disorder (BPD), an anonymous internet survey linked to BPD support websites was developed for parents to complete on their BPD offspring and unaffected siblings. The questions cover aspects of the child's life from pregnancy through young adulthood, and query about the impact of the child's BPD on six domains of the parent's life, including physical and emotional health, marriage, job, standard of living, social life, and career trajectory. Additionally, financial burden was assessed with questions pertaining to insurance and out-of pocket costs associated with the BPD disorder. BPD offspring were identified by meeting diagnostic criteria embedded within the survey and having been given a diagnosis of BPD by a professional at some point in their life.
We report on 233 female offspring meeting strict criteria for BPD. Parents of daughters with BPD endorsed varying levels of impact on the six domains comprising burden with the largest impact on emotional health which was impacted in over 88% of the respondents. Over 50% of parents endorsed four or greater of the six burden items. Particular aspects of the offspring's BPD symptom profile correlated with intensity of parental burden included including problems in adolescence with acting out behavior (p < .000), property destruction (.003), delusional symptoms (.007), and hallucinatory symptoms (.008).
A subgroup of respondents provided data on specific financial expenses. The average and median out-of-pocket expense was $60,087, and $10,000. Insurance costs totaled an average of $108,251 with a mean of $20,000. The average cost per year after diagnosis was $14,606 out-of-pocket and $45,573 billed to insurance. The median cost per year after diagnosis was $3,667 out-of-pocket, and $12,500 billed to insurance. After adjusting for household income, a female proband who had been raped incurred roughly $40,000 more in BPD-related costs, while a diagnosis of conduct disorder led to about $50,000 in additional costs.
Parents of female offspring with BPD experience burden in multiple domains of their life and many have incurred substantial financial expense. Increasing awareness of co-morbid conditions in the BPD proband that significantly increase parental burden may be indicators for the provision of increased family support.
C1 [Goodman, Marianne; Patil, Uday; Triebwasser, Joseph; Hoffman, Perry; Weinstein, Zachary A.; New, Antonia] Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
RP Goodman, M (reprint author), Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Marianne.Goodman@va.gov
NR 34
TC 10
Z9 11
U1 2
U2 12
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0885-579X
J9 J PERS DISORD
JI J. Pers. Disord.
PD FEB
PY 2011
VL 25
IS 1
BP 59
EP 74
PG 16
WC Psychiatry
SC Psychiatry
GA 717RB
UT WOS:000287064000005
PM 21309623
ER
PT J
AU Muir, ER
Duong, TQ
AF Muir, Eric R.
Duong, Timothy Q.
TI MRI of retinal and choroidal blood flow with laminar resolution
SO NMR IN BIOMEDICINE
LA English
DT Article
DE perfusion; arterial spin labeling (ASL); high-resolution MRI;
isoflurane; ketamine; xylazine; retinal diseases; ophthalmology
ID OPTICAL COHERENCE TOMOGRAPHY; HYDROGEN CLEARANCE; AUTONOMIC INNERVATION;
FUNCTIONAL MRI; RATS; EYE; DEGENERATION; CAT; MICROSPHERES; COEFFICIENT
AB The retina is nourished by two distinct circulations: the retinal vessels within the inner retina and the choroidal vessels behind the neural retina. The outer nuclear layer and the inner and outer segments of the photoreceptors in between are avascular. The aim of this study was to determine whether arterial spin labeling MRI could provide sufficient resolution to differentiate between quantitative retinal blood flow (rBF) and choroidal blood flow (chBF), and whether this technique is sufficiently sensitive to detect vascular-specific blood flow (BF) changes modulated by anesthetics. Arterial spin labeling MRI was performed at 42 x 42 x 400 mu m(3) in the mouse retina at 7 T, and was used to investigate the effects of isoflurane and ketamine/xylazine anesthesia on rBF and chBF. MRI yielded unambiguous differentiation of rBF, chBF and the avascular layer in between. Under isoflurane, chBF was 7.7 +/- 2.1 mL/g/min and rBF was 1.3 +/- 0.44 mL/g/min (mean +/- SD, n = 7, p < 0.01). Under ketamine/xylazine anesthesia in the same animals, chBF was 4.3 +/- 1.9 mL/g/min and rBF was 0.88 +/- 0.22 mL/g/min (p < 0.01). Under ketamine/xylazine anesthesia, rBF was lower by 29% (P < 0.01) and chBF by 42% (P < 0.01) relative to isoflurane. This study demonstrates, for the first time, the quantitative imaging of rBF and chBF in vivo, providing a new method to study basal values and alterations of rBF and chBF. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Radiol, San Antonio, TX 78229 USA.
[Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Physiol, San Antonio, TX 78229 USA.
[Muir, Eric R.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Muir, Eric/H-8830-2013
FU National Eye Institute/National Institutes of Health [R01 EY018855, R01
EY014211]; Department of Veterans Affairs; National Institutes of Health
[T32EB005969]
FX This work was supported in part by the National Eye Institute/National
Institutes of Health (R01 EY018855 and R01 EY014211) and the Department
of Veterans Affairs (VA MERIT Award). ERM was supported in part by
National Institutes of Health T32EB005969.
NR 47
TC 30
Z9 32
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-3480
EI 1099-1492
J9 NMR BIOMED
JI NMR Biomed.
PD FEB
PY 2011
VL 24
IS 2
BP 216
EP 223
DI 10.1002/nbm.1576
PG 8
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 732SG
UT WOS:000288209300013
PM 20821409
ER
PT J
AU Lee, JA
Zierler, BK
Liu, CF
Chapko, MK
AF Lee, Jung-Ah
Zierler, Brenda K.
Liu, Chuan-Fen
Chapko, Michael K.
TI Cost-Effective Diagnostic Strategies in Patients With a High,
Intermediate, or Low Clinical Probability of Pulmonary Embolism
SO VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Article
DE cost-effectiveness analysis; pulmonary embolism; diagnosis; clinical
probability; D-dimer; multislice computer tomographic angiography;
venous duplex ultrasonography
ID HELICAL COMPUTED-TOMOGRAPHY; DEEP VENOUS THROMBOSIS; D-DIMER; SPIRAL CT;
MANAGEMENT; THROMBOEMBOLISM; MODEL; ULTRASONOGRAPHY; ANGIOGRAPHY;
OUTPATIENTS
AB Rapid quantitative D-dimer assays (DD), lower extremity venous duplex ultrasonography (US), and multislice computed tomographic (CT) angiography have been shown to have adequate sensitivities and specificities for diagnostic purpose. The purpose of this study was to evaluate cost-effectiveness of diagnostic strategies for pulmonary embolism (PE) in patients with a high, intermediate, or low clinical probability of PE. A formal cost-effectiveness analysis for the diagnosis of PE was performed. The main outcome measure for effectiveness was 3-month expected survival. The strategy of DD followed by CT was cost-effective and had the lowest cost per life saved for all patients suspected with PE. The conventional strategy including ventilation and perfusion lung scanning followed by pulmonary angiography (PA) or CT was not cost-effective. The leg US after CT was not also cost-effective. In clinical practice, the individual patient's condition should be considered when choosing appropriate diagnostic tests.
C1 [Lee, Jung-Ah] Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci, Irvine, CA 92697 USA.
[Zierler, Brenda K.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA.
[Zierler, Brenda K.; Liu, Chuan-Fen; Chapko, Michael K.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Liu, Chuan-Fen; Chapko, Michael K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
RP Lee, JA (reprint author), Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci, 205B Irvine Hall, Irvine, CA 92697 USA.
EM jungahl@uci.edu
FU Agency for Healthcare Research and Quality [1 U18 HS015898]
FX The author(s) disclosed receipt of the following financial support for
the research and/or authorship of this article: This project was
partially supported by the Agency for Healthcare Research and Quality:
The Partnerships in Patient Safety grant number 1 U18 HS015898.
(Principal Investigator: Brenda K. Zierler, PhD).
NR 52
TC 3
Z9 3
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1538-5744
J9 VASC ENDOVASC SURG
JI Vasc. Endovasc. Surg.
PD FEB
PY 2011
VL 45
IS 2
BP 113
EP 121
DI 10.1177/1538574410380472
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 733TJ
UT WOS:000288285600001
PM 20810405
ER
PT J
AU Kudel, I
Cotton, S
Szaflarski, M
Holmes, WC
Tsevat, J
AF Kudel, Ian
Cotton, Sian
Szaflarski, Magda
Holmes, William C.
Tsevat, Joel
TI Spirituality and Religiosity in Patients with HIV: A Test and Expansion
of a Model
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Religious beliefs; Spirituality; Utilities; Quality of life; Coping
ID QUALITY-OF-LIFE; DEPRESSIVE SYMPTOMS; IMMUNE STATUS; OLDER ADULTS;
HIV/AIDS; HEALTH; DISTRESS; PEOPLE; WOMEN; VALIDATION
AB A causal model developed by Koenig suggests that higher levels of spirituality and religiosity effect intermediary variables and eventually result in better mental health, which then positively affects physical function.
Using structural equation modeling, we tested the model and expanded versions that use self-report data of patients with HIV (n = 345).
All models demonstrated good overall fit with significant parameters. The final model found that increased spirituality/religiosity predicted increased religious coping, which influenced social support. Social support, in turn, positively influenced depressed mood (as a measure of mental health); depressed mood affected fatigue; and both variables predicted self-reported physical function. These three variables predicted health rating/utility for one's health state. Additional analyses found that two covariates, religiosity and race, differentially predicted spirituality/religiosity and religious coping.
In patients with HIV, an expanded version of Koenig's model found that increased spirituality/religiosity is positively associated with self-reported outcomes.
C1 [Kudel, Ian; Tsevat, Joel] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA.
[Kudel, Ian; Cotton, Sian; Szaflarski, Magda; Tsevat, Joel] Univ Cincinnati, Cincinnati, OH USA.
[Holmes, William C.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Holmes, William C.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Tsevat, Joel] Univ Cincinnati, Coll Med, Dept Publ Hlth Sci, Cincinnati, OH USA.
RP Kudel, I (reprint author), Cincinnati Vet Affairs Med Ctr, 3200 Vine St, Cincinnati, OH USA.
EM ian.kudel2@va.gov
OI Szaflarski, Magdalena/0000-0002-6228-1405
FU NCCIH NIH HHS [K24AT001676, R01 AT01147]; NICHD NIH HHS [K23HD052639]
NR 54
TC 15
Z9 16
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD FEB
PY 2011
VL 41
IS 1
BP 92
EP 103
DI 10.1007/s12160-010-9229-x
PG 12
WC Psychology, Multidisciplinary
SC Psychology
GA 717KB
UT WOS:000287041400009
PM 21103963
ER
PT J
AU Toro, JJ
Varadarajan, P
Schneider, DL
Lee, S
Chao, JH
Frye, BL
Neumon, B
Haile, DJ
Freytes, CO
AF Toro, J. J.
Varadarajan, P.
Schneider, D. L.
Lee, S.
Chao, J. -H
Frye, B. L.
Neumon, B.
Haile, D. J.
Freytes, C. O.
TI ORAL AND SYSTEMIC COMPLICATIONS OF MYELOMA PATIENTS WITH
BISPHOSPHONATE-INDUCED OSTEONECROSIS OF THE JAW: A CASE-CONTROL STUDY
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT Annual Meeting of the
American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem
CY FEB 17-21, 2011
CL Honolulu, HI
SP Amer Soc Blood Marrow Transplantat, Ctr Int Blood Marrow Transplant Res
C1 [Toro, J. J.; Schneider, D. L.; Lee, S.; Chao, J. -H; Frye, B. L.; Neumon, B.; Haile, D. J.; Freytes, C. O.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Toro, J. J.; Varadarajan, P.; Freytes, C. O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2011
VL 17
IS 2
SU 2
MA 334
BP S275
EP S275
DI 10.1016/j.bbmt.2010.12.368
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 721JX
UT WOS:000287350500334
ER
PT J
AU Jakupcak, M
Varra, EM
AF Jakupcak, Matthew
Varra, Edward M.
TI Treating Iraq and Afghanistan War Veterans With PTSD Who Are at High
Risk for Suicide
SO COGNITIVE AND BEHAVIORAL PRACTICE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; VIETNAM
COMBAT VETERANS; BORDERLINE PERSONALITY-DISORDER; COGNITIVE PROCESSING
THERAPY; DIALECTICAL BEHAVIOR-THERAPY; HEALTH-CARE;
PSYCHIATRIC-DISORDERS; SEEKING SAFETY; US-VETERANS
AB Iraq and Afghanistan War veterans diagnosed with psychiatric disorders commit suicide at a higher rate than the general population (Kang & Bullman, 2008). Posttraumatic stress disorder (PTSD) has been identified as a risk factor for suicide in veterans (Bullman & Kang, 1994) and is the most common mental disorder among Iraq and Afghanistan veterans presenting for treatment at Veterans Affairs (VA) facilities (Kang, 2009). Therefore, it is critical for health providers to identify veterans with PTSD who are at high risk for suicide in order to more effectively intervene to promote safety, stabilization, and reduce psychiatric symptoms. In the following paper; we discuss risk for suicide in veterans with PTSD and application of cognitive behavioral therapies to reduce suicidality in high-risk patients. We also discuss pertinent clinical issues common to treating Iraq and Afghanistan War veterans with PTSD.
C1 [Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA 98108 USA.
[Varra, Edward M.] VA Puget Sound Hlth Care Syst, PTSD Outpatient Clin, Seattle, WA 98108 USA.
RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN Mental Illness Res Educ & Clin Ctr 20, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM matthew.jakupcak@va.gov
NR 70
TC 12
Z9 12
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1077-7229
J9 COGN BEHAV PRACT
JI Cogn. Behav. Pract.
PD FEB
PY 2011
VL 18
IS 1
BP 85
EP 97
DI 10.1016/j.cbpra.2009.08.007
PG 13
WC Psychology, Clinical
SC Psychology
GA 712EV
UT WOS:000286648400011
ER
PT J
AU Sayers, SL
AF Sayers, Steven L.
TI Family Reintegration Difficulties and Couples Therapy for Military
Veterans and Their Spouses
SO COGNITIVE AND BEHAVIORAL PRACTICE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS;
COGNITIVE-PROCESSING THERAPY; IRAQI FREEDOM VETERANS; MALE VIETNAM
VETERANS; US ARMY SOLDIERS; MARITAL-THERAPY; DOMESTIC VIOLENCE;
DEPLOYMENT; INTERVENTIONS
AB There is compelling evidence that mental health problems complicate the process of family reintegration of military service members after a wartime deployment. Couples in which one spouse has recently returned from military deployment in Iraq or Afghanistan and are experiencing marital problems can present a significant treatment challenge. There is little empirical evidence regarding effective treatments for this population, and these couples tend to exhibit a wide range of difficulties, including the following: conflicts about reintegration, problems with posttraumatic stress disorder and/or depression, chronic injury, infidelity, and personal and social challenges associated with rejoining civilian life Behavioral couples therapy provides a useful framework for intervention with these couples, combined with individual treatment and education about the impact of combat deployment. This paper discusses considerations for integrating these treatment approaches and future clinical and research needs for these couples.
C1 [Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Sayers, Steven L.] Univ Penn, Philadelphia, PA 19104 USA.
RP Sayers, SL (reprint author), Philadelphia Vet Affairs Med Ctr, MIRECC 116,3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM steven.sayers@va.gov
NR 52
TC 24
Z9 24
U1 6
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1077-7229
J9 COGN BEHAV PRACT
JI Cogn. Behav. Pract.
PD FEB
PY 2011
VL 18
IS 1
BP 108
EP 119
DI 10.1016/j.cbpra.2010.03.002
PG 12
WC Psychology, Clinical
SC Psychology
GA 712EV
UT WOS:000286648400013
ER
PT J
AU Merriam, GR
Koenig, JI
AF Merriam, George R.
Koenig, James I.
TI Stress Hypogonadism: Not Everything That Suppresses Must Converge
SO ENDOCRINOLOGY
LA English
DT Editorial Material
ID INSULIN-INDUCED HYPOGLYCEMIA; LUTEINIZING-HORMONE; FEMALE RATS;
OREXIN-A; AREA; PROJECTIONS; SECRETION; NEURONS; IMMUNOREACTIVITY;
INTEGRATION
C1 [Merriam, George R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98493 USA.
[Merriam, George R.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Seattle, WA 98493 USA.
[Merriam, George R.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Tacoma, WA 98493 USA.
[Merriam, George R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA.
[Koenig, James I.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA.
[Koenig, James I.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21228 USA.
RP Merriam, GR (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98493 USA.
NR 16
TC 1
Z9 1
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2011
VL 152
IS 2
BP 340
EP 342
DI 10.1210/en.2010-1405
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 709FA
UT WOS:000286422100002
PM 21252178
ER
PT J
AU Fargo, KN
Foecking, EM
Jones, KJ
AF Fargo, Keith N.
Foecking, Eileen M.
Jones, Kathryn J.
TI Muscle Matters-Dendrites Grow Up
SO ENDOCRINOLOGY
LA English
DT Editorial Material
ID MOSAIC ANDROGEN INSENSITIVITY; SPINAL NUCLEUS; PERINEAL MOTONEURONS;
RECEPTOR PROTEIN; MALE RATS; TESTOSTERONE; EXPRESSION; BULBOCAVERNOSUS;
MORPHOLOGY; ACCUMULATION
C1 [Fargo, Keith N.; Foecking, Eileen M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA.
[Foecking, Eileen M.] Loyola Univ Chicago, Stritch Sch Med, Dept Otolaryngol Head & Neck Surg, Maywood, IL 60153 USA.
[Fargo, Keith N.] Loyola Univ Chicago, Stritch Sch Med, Inst Neurosci, Maywood, IL 60153 USA.
[Jones, Kathryn J.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
[Jones, Kathryn J.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
RP Fargo, KN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
NR 23
TC 0
Z9 0
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2011
VL 152
IS 2
BP 346
EP 348
DI 10.1210/en.2010-1413
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 709FA
UT WOS:000286422100004
PM 21252180
ER
PT J
AU Osawa, R
Williams, KL
Singh, N
AF Osawa, Ryosuke
Williams, Kristi L.
Singh, Nina
TI The inflammasome regulatory pathway and infections: Role in
pathophysiology and clinical implications
SO JOURNAL OF INFECTION
LA English
DT Review
DE Innate immunity; Inflammasome; Infection; IL-1 beta
ID INTERLEUKIN-1-BETA CONVERTING-ENZYME; FAMILIAL MEDITERRANEAN FEVER;
CRYPTOCOCCUS-NEOFORMANS INFECTION; LEGIONELLA-PNEUMOPHILA INFECTION;
COLD AUTOINFLAMMATORY SYNDROME; PATHOGEN CANDIDA-ALBICANS; MESSENGER-RNA
EXPRESSION; NECROSIS-FACTOR-ALPHA; ANTHRAX LETHAL TOXIN; HOST-DEFENSE
AB The innate immune system serves to generate immediate host defenses against pathogens. Advance in the mechanism of innate immunity has provided new insights into host-pathogen microbial interactions. The cytosolic multi-protein complex called the inflammasome, which regulates the caspase-1 dependent processing of inflammatory cytokines IL-1 beta and IL-18, is critical for the innate defense against pathogens. We summarize the current knowledge regarding the regulatory functions of the inflammasome in the pathogenesis of infections by various microbes (e.g., bacteria, fungi, viruses, and protozoa), and discuss its potential application in a clinical setting. Understanding of the unique role of the inflammasome signaling pathway in initiating and regulating inflammation is pivotal for the development of innovative approaches to optimize management of these infections. (C) 2010 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
C1 [Singh, Nina] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Dept Med, Pittsburgh, PA 15240 USA.
[Osawa, Ryosuke; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
[Williams, Kristi L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Dept Med, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
FU Southeast Regional Center of Excellence for Emerging Infections and
Biodefense (SERCEB); NIH [R56 AI089756]; Center for Comparative Biology
of Vulnerable Populations (CCBVP)
FX KLW was supported by grants from Southeast Regional Center of Excellence
for Emerging Infections and Biodefense (SERCEB) and Center for
Comparative Biology of Vulnerable Populations (CCBVP), and the NIH (R56
AI089756).
NR 134
TC 15
Z9 16
U1 1
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD FEB
PY 2011
VL 62
IS 2
BP 119
EP 129
DI 10.1016/j.jinf.2010.10.002
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 716NR
UT WOS:000286981200002
PM 20950647
ER
PT J
AU Durant, RW
Legedza, AT
Marcantonio, ER
Freeman, MB
Landon, BE
AF Durant, Raegan W.
Legedza, Anna T.
Marcantonio, Edward R.
Freeman, Marcie B.
Landon, Bruce E.
TI Different Types of Distrust in Clinical Research Among Whites and
African Americans
SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
LA English
DT Article
DE trust; clinical research
ID HEALTH-CARE-SYSTEM; MEDICAL-RESEARCH; RACIAL-DIFFERENCES; PARTICIPATION;
TRIALS; TRUST; RACE; ATTITUDES; WILLINGNESS; PERCEPTIONS
AB Background: African Americans are thought to be more distrustful of clinical research compared to elderly whites, but it is unknown whether specific types of distrust in clinical research, such as interpersonal or societal distrust, vary according to race. The primary objective was to identify racial differences in interpersonal or societal distrust in clinical research among African Americans and whites.
Methods: Seven hundred seventy-six older African Americans and whites were surveyed about their interpersonal and societal distrust using a 7-item index of distrust in clinical research. We combined the 2 societal distrust items into a societal distrust subscale. We also assessed trust in primary care physicians, access to care, health/functional status, previous exposure to clinical research, awareness of the Tuskegee Syphilis Study, perceived discrimination in health care, and sociodemographic characteristics.
Results: High societal distrust was more common among African Americans compared to whites (21% vs 7% in the top quartile of the societal distrust, p < .0001), but there were no racial differences in responses to the individual interpersonal distrust index items. In sequentially built multivariable analyses, the relationship between African American race and societal distrust (odds ratio, 2.2; 95% CI, 1.2-3.7) was not completely explained by other factors such as trust in one's physician, previous discrimination, or awareness of the Tuskegee Syphilis Study.
Conclusions: Racial differences according to the type of distrust in clinical research may warrant assessing specific types of distrust separately among racially diverse populations in future studies.
C1 [Durant, Raegan W.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL 35205 USA.
Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Legedza, Anna T.] Vertex Pharmaceut, Biometr Dept, Cambridge, MA USA.
[Marcantonio, Edward R.; Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Freeman, Marcie B.] Inst Aging Res, Boston, MA USA.
[Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
RP Durant, RW (reprint author), Univ Alabama Birmingham, Div Prevent Med, 1717 11th Ave S,MT 607, Birmingham, AL 35205 USA.
EM rdurant@dopm.uab.edu
FU Health Resources and Services Administration [2 T32 HP11001-15];
National Institute on Aging [5 P01 AG04390]; Older Americans
Independence Center [2 P60 AG08812]; Massachusetts Alzheimer's Disease
Research Center [2 P50 AG05134]
FX Supported by a grants from the Health Resources and Services
Administration (2 T32 HP11001-15), National Institute on Aging (5 P01
AG04390), Older Americans Independence Center (2 P60 AG08812), and
Massachusetts Alzheimer's Disease Research Center (2 P50 AG05134).
NR 25
TC 18
Z9 20
U1 3
U2 14
PU NATL MED ASSOC
PI WASHINGON
PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA
SN 0027-9684
EI 1943-4693
J9 J NATL MED ASSOC
JI J. Natl. Med. Assoc.
PD FEB
PY 2011
VL 103
IS 2
BP 123
EP 130
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 728YI
UT WOS:000287910000005
PM 21443064
ER
PT J
AU Gerding, DN
Johnson, S
AF Gerding, Dale N.
Johnson, Stuart
TI CLOSTRIDIUM DIFFICILE INFECTION IN 2010 Advances in pathogenesis,
diagnosis and management of CDI
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Editorial Material
ID TOXIN-B; STRAIN
C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Johnson, Stuart] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA.
RP Gerding, DN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Bldg 1,Room C344,5000 S 5th Ave, Hines, IL 60141 USA.
EM dale.gerding2@va.gov
NR 10
TC 8
Z9 8
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD FEB
PY 2011
VL 8
IS 2
BP 67
EP 68
DI 10.1038/nrgastro.2010.215
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 716LL
UT WOS:000286970000001
PM 21293502
ER
PT J
AU Ko, CW
Mhsa, JAD
Green, P
Baldwin, LM
AF Ko, Cynthia W.
Mhsa, Jason A. DominitzMd
Green, Pam
Baldwin, Laura-Mae
TI Effect of Annual Colonoscopy Volume and Years in Practice on Polyp
Detection and Removal Reply
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Letter
ID ADENOMA DETECTION
C1 [Ko, Cynthia W.; Mhsa, Jason A. DominitzMd] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Mhsa, Jason A. DominitzMd] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Green, Pam; Baldwin, Laura-Mae] Univ Washington, Dept Family Med, Seattle, WA 98195 USA.
RP Ko, CW (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA.
NR 3
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD FEB
PY 2011
VL 124
IS 2
BP E17
EP E18
DI 10.1016/j.amjmed.2010.09.010
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 725PO
UT WOS:000287658100009
ER
PT J
AU Kuschner, WG
AF Kuschner, Ware G.
TI Palliative Care for Pulmonary Patients
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Letter
C1 [Kuschner, Ware G.] US Dept Vet Affairs, Palo Alto, CA USA.
[Kuschner, Ware G.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
RP Kuschner, WG (reprint author), US Dept Vet Affairs, Palo Alto, CA USA.
NR 1
TC 0
Z9 0
U1 0
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2011
VL 183
IS 3
BP 416
EP 416
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 720QD
UT WOS:000287294300025
PM 21288868
ER
PT J
AU Egede, LE
Gebregziabher, M
Hunt, KJ
Axon, RN
Echols, C
Gilbert, GE
Mauldin, PD
AF Egede, Leonard E.
Gebregziabher, Mulugeta
Hunt, Kelly J.
Axon, Robert N.
Echols, Carrae
Gilbert, Gregory E.
Mauldin, Patrick D.
TI Regional, Geographic, and Ethnic Differences in Medication Adherence
Among Adults with Type 2 Diabetes
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE cohort; diabetes mellitus; health disparities; medication adherence
ID ORAL HYPOGLYCEMIC AGENTS; BLOOD-GLUCOSE CONTROL; GLYCEMIC CONTROL;
HEALTH-CARE; RETROSPECTIVE COHORT; URBAN VETERANS; UNITED-STATES;
POPULATION; INSULIN; COMPLICATIONS
AB BACKGROUND: Medication adherence, a critical component of glycemic control for patients with type 2 diabetes, differs by race/ethnicity. However, few studies have examined regional and rural/urban differences in medication adherence and whether racial/ethnic differences persist after controlling for these differences.
OBJECTIVE: To examine regional, rural/urban, and racial/ethnic differences in medication adherence in a national sample of veterans with type 2 diabetes.
METHODS: We performed a cohort study of a national sample of veterans with diabetes (N = 690,968) receiving prescriptions for insulin or oral hypoglycemic agents in 2002. Patients were followed until death, loss to follow-up, or through December 2006. We calculated the annual medication possession ratio (MPR) for each veteran across 4 groups of medication users: individuals using (1) insulin only, (2) oral hypoglycemic agents only, (3) insulin combined with hypoglycemic agents, and (4) insulin or oral hypoglycemic agents (primary analysis).
RESULTS: In longitudinal models for the primary analysis, adjusting for relevant covariates and time trends, MPR was significantly lower among non-Hispanic blacks (NHBs), Hispanics, and individuals with other/missing/unknown race/ethnicity (6.07%, 1.76%, and 2.83% lower, respectively) relative to non-Hispanic whites (NHWs). MPR was also 2.0% higher in rural versus urban veterans and 1.28% higher in the mid-Atlantic, 2.04% higher in the Midwest, and 0.76% lower in the West, relative to the South. There was a significant race/ethnicity and urban/rural interaction. In NHWs and NHBs, MPR was 1.91% and 2.00% higher, respectively, in rural versus urban veterans; in contrast, in Hispanics, MPR was 1.0% lower in rural veterans relative to urban veterans.
CONCLUSIONS: In a national longitudinal cohort of veterans with type 2 diabetes, we found significant regional, rural/urban, and racial/ethnic differences in MPR. Rural/urban residence modified the effect of race/ethnicity on MPR. Recognition of these differences can enable clinicians to better allocate resources and target quality improvement programs.
C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Hunt, Kelly J.; Axon, Robert N.; Echols, Carrae; Gilbert, Gregory E.; Mauldin, Patrick D.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Mauldin, Patrick D.] S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, Charleston, SC USA.
RP Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
EM egedel@musc.edu
RI Gilbert, Gregory/C-7735-2016
OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher,
Mulugeta/0000-0002-4826-481X
FU Veterans Health Administration Health Services Research and Development
(HSRD) program [IIR-06-219]
FX This study was supported by grant IIR-06-219 funded by the Veterans
Health Administration Health Services Research and Development (HSR&D)
program. The funding agency did not participate in the design and
conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript.
NR 54
TC 19
Z9 19
U1 1
U2 6
PU HARVEY WHITNEY BOOKS CO
PI CINCINNATI
PA PO BOX 42696, CINCINNATI, OH 45242 USA
SN 1060-0280
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD FEB
PY 2011
VL 45
IS 2
BP 169
EP 178
DI 10.1345/aph.1P442
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 725GV
UT WOS:000287634100004
PM 21304026
ER
PT J
AU Koopmann, MC
Kudsk, KA
Szotkowski, MJ
Rees, SM
AF Koopmann, Matthew C.
Kudsk, Kenneth A.
Szotkowski, Molly J.
Rees, Susan M.
TI A Team-Based Protocol and Electromagnetic Technology Eliminate Feeding
Tube Placement Complications
SO ANNALS OF SURGERY
LA English
DT Article
ID WRONG-SITE SURGERY; CRITICALLY-ILL; PREVENTION; INSTRUMENTS; PATTERNS;
SPONGES; EVENTS; SAFETY
AB Objective: To examine whether feeding tube placement into high-risk patients using a team-based protocol and electromagnetic tube tracking reduces complications associated with blind tube placement and to evaluate safety of blind tube placement in alert, low-risk patients.
Background: Approximately 1.2 million feeding tubes with stylets are placed annually in the US. Serious complications during placement exceed the rates of retained sponges and wrong site surgery. Several suggested solutions to the problem have been proposed but none completely eliminate the serious complications and many are neither cost-effective nor practical.
Methods: In a retrospective, single center study, we compared complications after bedside feeding tube placement using a blind technique in 2005 to a hospital protocol mandating tube placement in high-risk patients by a Tube Team in 2007 using electromagnetic tracking. Outcome variables included airway placement, pneumothorax, death, and radiology resource utilization.
Results: The Tube Team protocol eliminated airway tube placement (0 of 1154 vs. 20 of 1822, P < 0.001), pneumothorax (0/715 vs. 11/1822, P = 0.009), and all mortality whereas improving placement (83.9% success vs. 60.5%, P<0.001) in high-risk patients compared to the 2005 study. The number of x-rays obtained per tube (1.07 +/- 0.01 vs. 1.49 +/- 0.026, P < 0.001) and need for fluoroscopy (2.1% vs. 10.9%, P < 0.001) significantly dropped with the Tube Team. A final comparison was made to low-risk patients considered acceptable for blind tube placement in 2007 due to their alertness and ability to cooperate and provide feedback during tube placement. Although no mortality occurred during blind placement in low risk, alert patients, blind placement resulted in significantly increased airway placement (3/143, p = 0.001) and pneumothorax (2 of 143, P = 0.01) compared to the Tube Team protocol. Most patients who would have required fluoroscopic placement of feeding tube due to failed blind technique had successful placement by the Team avoiding fluoroscopy.
Conclusion: Feeding tube placement by a dedicated team using electromagnetic tracking eliminates the morbidity and mortality of this common hospital procedure. Blind placement is not acceptable in awake, alert patients.
C1 [Koopmann, Matthew C.; Kudsk, Kenneth A.; Szotkowski, Molly J.] William S Middleton Mem Vet Adm Med Ctr, Dept Surg, Madison, WI USA.
[Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
[Rees, Susan M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
RP Kudsk, KA (reprint author), Univ Wisconsin, Clin Sci Ctr H4 736, 600 Highland Ave, Madison, WI 53706 USA.
EM kudsk@surgery.wisc.edu
FU Department of Surgery of the University of Wisconsin-Madison School of
Medicine and Public Health, Madison, Wisconsin
FX The authors declare no conflict of interest. There was no financial
sponsorship of this trial. The equipment was purchased by the University
of Wisconsin-Madison Hospitals and Clinics. Salary support for the Tube
Team members was assumed by the Department of Surgery of the University
of Wisconsin-Madison School of Medicine and Public Health, Madison,
Wisconsin. Neither Viasys nor any other industry source provided
sponsorship-financial or otherwise-nor did they have any involvement in
the design and conduct of the study, collection, management, analysis,
or interpretation of the data. No sponsorship is provided in the
preparation, review, or approval of the manuscript.
NR 18
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD FEB
PY 2011
VL 253
IS 2
BP 297
EP 302
DI 10.1097/SLA.0b013e318208f550
PG 6
WC Surgery
SC Surgery
GA 708OV
UT WOS:000286374400014
ER
PT J
AU Kuschner, WG
AF Kuschner, Ware G.
TI Passive leg raising for monitoring volume status and predicting fluid
responsiveness
SO CRITICAL CARE MEDICINE
LA English
DT Letter
ID CRITICALLY-ILL
C1 [Kuschner, Ware G.] Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA.
[Kuschner, Ware G.] US Dept Vet Affairs, Med Serv, Pulm & Crit Care Med Sect, Palo Alto Hlth Care Syst, Palo Alto, CA USA.
RP Kuschner, WG (reprint author), Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA.
NR 6
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD FEB
PY 2011
VL 39
IS 2
BP 420
EP 420
DI 10.1097/CCM.0b013e3181fd6936
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 709GN
UT WOS:000286426400040
PM 21248535
ER
PT J
AU El-Serag, HB
Graham, DY
AF El-Serag, Hashem B.
Graham, David Y.
TI Routine Polypectomy for Colorectal Polyps and Ablation for Barrett's
Esophagus Are Intellectually the Same
SO GASTROENTEROLOGY
LA English
DT Editorial Material
ID CANCER; SURVEILLANCE; MORTALITY
C1 [El-Serag, Hashem B.; Graham, David Y.] Houston VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[El-Serag, Hashem B.; Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA.
RP El-Serag, HB (reprint author), Houston VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
NR 12
TC 15
Z9 15
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2011
VL 140
IS 2
BP 386
EP 388
DI 10.1053/j.gastro.2010.12.019
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 711LR
UT WOS:000286593600012
PM 21172329
ER
PT J
AU Lipsky, BA
Itani, KMF
Weigelt, JA
Joseph, W
Paap, CM
Reisman, A
Myers, DE
Huang, DB
AF Lipsky, Benjamin A.
Itani, Kamal M. F.
Weigelt, John A.
Joseph, Warren
Paap, Christopher M.
Reisman, Arlene
Myers, Daniela E.
Huang, David B.
TI The role of diabetes mellitus in the treatment of skin and skin
structure infections caused by methicillin-resistant Staphylococcus
aureus: results from three randomized controlled trials
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Complicated skin and skin structure infection; Diabetes mellitus;
Linezolid; Methicillin-resistant Staphylococcus aureus; Vancomycin
ID FOOT INFECTIONS; SOFT-TISSUE; VANCOMYCIN; PENETRATION; BACTEREMIA
AB Objective: To compare outcomes of treating complicated skin and skin structure infections (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA) with linezolid versus vancomycin in diabetic and non-diabetic patients.
Methods: We pooled data from three prospective clinical trials in which 1056 patients were randomized to receive either linezolid (intravenous (IV) or oral) or vancomycin (IV) every 12 h, for 7-28 days.
Results: Diabetic (n = 349) and non-diabetic patients (n = 707) had comparable demographics and comorbidities. Clinical success rates were lower in diabetic than in non-diabetic patients (72.3% and 85.8%, respectively). Overall, non-diabetic patients had a shorter adjusted mean length of stay (LOS) compared with diabetic patients (8.2 and 10.7 days, respectively; p < 0.0001). Among diabetic patients, rates were comparable with linezolid and vancomycin treatment for clinical success (74% and 71%, respectively) and microbiological success (60% and 54%, respectively). Among non-diabetic patients, clinical and microbiological success rates were higher in linezolid-than in vancomycin-treated patients (90% and 81%, respectively, and 78% and 65%, respectively). Rates of drug-related adverse events were comparable in diabetic and non-diabetic patients and with linezolid and vancomycin treatment. Adjusted mean LOS was shorter with linezolid than with vancomycin treatment in diabetic patients (9.5 and 11.7 days, respectively; p = 0.03) and non-diabetic patients (7.6 and 8.9 days, respectively; p = 0.02).
Conclusions: Clinical success rates were lower in diabetic than non-diabetic patients with cSSSI caused by MRSA. Comparing linezolid and vancomycin, clinical and microbiological success rates were comparable in diabetic patients, but were better for linezolid than for vancomycin in non-diabetic patients. (C) 2010 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98108 USA.
[Lipsky, Benjamin A.] Univ Washington, Sch Med, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA.
[Itani, Kamal M. F.] Boston VA Hlth Care Syst, Boston, MA USA.
[Itani, Kamal M. F.] Boston Univ, Boston, MA 02215 USA.
[Weigelt, John A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Joseph, Warren] Roxborough Mem Hosp, Philadelphia, PA USA.
[Paap, Christopher M.; Reisman, Arlene; Myers, Daniela E.; Huang, David B.] Pfizer Inc, New York, NY USA.
RP Lipsky, BA (reprint author), VA Puget Sound Hlth Care Syst, Med Serv, 1880 S Columbian Way,S-111-GIMC, Seattle, WA 98108 USA.
EM balipsky@uw.edu
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Pfizer Inc.
FX This study was sponsored by Pfizer Inc. All authors collaborated in the
development of the study design, in the collection, analysis, and
interpretation of study data, in the writing of the manuscript, and in
the decision to submit the manuscript for publication. Editorial support
for this manuscript (technical writing) was provided by E.M. Wells of
PAREXEL and was funded by Pfizer Inc.
NR 19
TC 16
Z9 18
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD FEB
PY 2011
VL 15
IS 2
BP E140
EP E146
DI 10.1016/j.ijid.2010.10.003
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 715WR
UT WOS:000286924100006
PM 21134775
ER
PT J
AU Mamtani, M
Chatterjee, N
Mishra, A
Soni, R
Jawahirani, A
Das, K
Rughwani, V
Shrivastava, M
Kulkarni, H
AF Mamtani, M.
Chatterjee, N.
Mishra, A.
Soni, R.
Jawahirani, A.
Das, K.
Rughwani, V.
Shrivastava, M.
Kulkarni, H.
TI Hemoglobin F levels influence the results of NESTROFT: replication in
two surveys
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Letter
ID CELL OSMOTIC FRAGILITY; BETA-THALASSEMIA; INFANTS; NEWBORNS; PRETERM
C1 [Mamtani, M.; Kulkarni, H.] Lata Med Res Fdn, Nagpur, Maharashtra, India.
[Mamtani, M.; Kulkarni, H.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Mamtani, M.; Kulkarni, H.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & Infect HIV 1, San Antonio, TX USA.
[Chatterjee, N.; Mishra, A.; Soni, R.; Shrivastava, M.] Bhopal Mem Hosp & Res Ctr, Thalassaemia Unit, Dept Transfus Med, Bhopal, India.
[Jawahirani, A.; Rughwani, V.] Thalassemia Soc India, Nagpur, Maharashtra, India.
[Das, K.] Anthropol Survey India, Nagpur, Maharashtra, India.
RP Mamtani, M (reprint author), Lata Med Res Fdn, Nagpur, Maharashtra, India.
EM hemant_kulkarnius@yahoo.com
NR 13
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD FEB
PY 2011
VL 33
IS 1
BP 113
EP 115
DI 10.1111/j.1751-553X.2010.01252.x
PG 3
WC Hematology
SC Hematology
GA 704KW
UT WOS:000286052900014
PM 20633055
ER
PT J
AU Bloch, MJ
Basile, JN
AF Bloch, Michael J.
Basile, Jan N.
TI Patient Self-management Improves Blood Pressure Control
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
C1 [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Risk Reduct Ctr,St Marys Reg Med Ctr, Reno, NV 89503 USA.
[Basile, Jan N.] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Bloch, MJ (reprint author), Univ Nevada, Sch Med, Dept Internal Med, Risk Reduct Ctr,St Marys Reg Med Ctr, 645 N Arlington St,Suite 460, Reno, NV 89503 USA.
EM mbloch@aol.com
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD FEB
PY 2011
VL 13
IS 2
BP 138
EP 140
DI 10.1111/j.1751-7176.2010.00400.x
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 711ZE
UT WOS:000286630100010
PM 21272203
ER
PT J
AU Brown, WV
Goldberg, RB
Lopes-Virella, M
Reaven, P
AF Brown, W. Virgil
Goldberg, Ronald B.
Lopes-Virella, Maria
Reaven, Peter
TI Reducing vascular disease risk in the type 2 diabetic patientt
SO JOURNAL OF CLINICAL LIPIDOLOGY
LA English
DT Editorial Material
C1 [Brown, W. Virgil] Emory Univ, Sch Med, Atlanta, GA 30033 USA.
[Goldberg, Ronald B.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Diabet Res Inst, Miami, FL 33136 USA.
[Lopes-Virella, Maria] Med Univ S Carolina, Charleston, SC 29425 USA.
[Lopes-Virella, Maria] Ralph H Johnson VA Med Ctr, Nutr Support Team, Charleston, SC USA.
[Reaven, Peter] Arizona State Univ, Phoenix, AZ USA.
[Reaven, Peter] Univ Arizona, Phoenix, AZ USA.
RP Brown, WV (reprint author), Emory Univ, Sch Med, 1670 Clairmont Rd, Atlanta, GA 30033 USA.
EM editorjel@yahoo.corn
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1933-2874
J9 J CLIN LIPIDOL
JI J. Clin. Lipidol.
PD FEB
PY 2011
VL 5
IS 1
BP 3
EP 11
DI 10.1016/j.jacl.2010.11.005
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 716XD
UT WOS:000287005900002
PM 21262501
ER
PT J
AU Dhaliwal, G
AF Dhaliwal, Gurpreet
TI Going with Your Gut
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
DE clinical reasoning; decision making; intuition; pattern recognition
ID REASONING STRATEGIES; PHYSICIANS; DIAGNOSIS; MODEL
C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
RP Dhaliwal, G (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
EM gurpreet.dhaliwal@ucsf.edu
NR 22
TC 4
Z9 4
U1 2
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD FEB
PY 2011
VL 26
IS 2
BP 107
EP 109
DI 10.1007/s11606-010-1578-4
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 725TK
UT WOS:000287668800003
PM 21104451
ER
PT J
AU Diehl, J
Liang, LJ
Aquino, L
Chiu, M
AF Diehl, Joseph
Liang, Li-Jung
Aquino, Lisa
Chiu, Melvin
TI Association between Mohs surgery wait times and surgical defect size in
patients with squamous cell or basal cell carcinoma of the skin
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Meeting Abstract
CT 69th Annual Meeting of the American-Academy-of-Dermatology
CY FEB 04-08, 2011
CL New Orleans, LA
SP Amer Acad Dermatol
C1 [Diehl, Joseph; Chiu, Melvin] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA.
[Liang, Li-Jung] W Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90073 USA.
[Aquino, Lisa] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD FEB
PY 2011
VL 64
IS 2
SU 1
BP AB1
EP AB1
PG 1
WC Dermatology
SC Dermatology
GA 714AY
UT WOS:000286780500004
ER
PT J
AU Baddour, LM
Epstein, AE
Erickson, CC
Knight, BP
Levison, ME
Lockhart, PB
Masoudi, FA
Okum, EJ
Wilson, WR
Beerman, LB
Bolger, AF
Estes, NAM
Gewitz, M
Newburger, JW
Schron, EB
Taubert, KA
AF Baddour, Larry M.
Epstein, Andrew E.
Erickson, Christopher C.
Knight, Bradley P.
Levison, Matthew E.
Lockhart, Peter B.
Masoudi, Frederick A.
Okum, Eric J.
Wilson, Walter R.
Beerman, Lee B.
Bolger, Ann F.
Estes, N. A. Mark, III
Gewitz, Michael
Newburger, Jane W.
Schron, Eleanor B.
Taubert, Kathryn A.
CA Council Cardiovasc Disease Young
Council Cardiovasc Surg & Anesthe
Council Cardiovasc Nursing
Council Clinical Cardiology
Interdisciplinary Council Quality
TI A summary of the update on cardiovascular implantable electronic device
infections and their management A scientific statement from the American
Heart Association
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Article
DE American Heart Association scientific statements; infection; device;
cardiovascular implantable electronic device; pacemaker; defibrillator;
endocarditis; bacteremia; antibiotic prophylaxis
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; PERMANENT PACEMAKER IMPLANTATION;
ANTIBIOTIC-PROPHYLAXIS; CARDIOVERTER-DEFIBRILLATORS; ANTIMICROBIAL
PROPHYLAXIS; ENDOCARDIAL PACEMAKER; SUSTAINED BACTEREMIA; AUREUS
BACTEREMIA; DENTAL PROCEDURES; LEAD EXTRACTION
AB Background. The purpose of this statement is to update the recommendations by the American Heart Association (AHA) for cardiovascular implantable electronic device (CIED) infections and their management, which were last published in 2003.
Methods and Results. The AHA commissioned this scientific statement to educate clinicians about CIED infections, provide explicit recommendations for the care of patients with suspected or established CIED infections and highlight areas of needed research. The recommendations in this statement reflect analyses of relevant literature, to include recent advances in our understanding of the epidemiology, risk factors, microbiology, management and prevention of CIED infections.
Conclusion. There are no scientific data to support the use of antimicrobial prophylaxis for dental or other invasive procedures.
Clinical Implications. The concerns about life-threatening drug reactions, the development of resistant strains of bacterial pathogens, medicolegal issues and cost to the health care system are, thus, avoided.
C1 [Baddour, Larry M.] Carolinas Med Ctr, Dept Oral Med, Charlotte, NC 28232 USA.
[Baddour, Larry M.; Wilson, Walter R.] Mayo Clin, Div Infect Dis, Coll Med, Rochester, MN USA.
[Epstein, Andrew E.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Epstein, Andrew E.] Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA.
[Erickson, Christopher C.] Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE USA.
[Erickson, Christopher C.] Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE USA.
[Erickson, Christopher C.] Creighton Univ, Sch Med, Dept Pediat, Omaha, NE 68178 USA.
[Erickson, Christopher C.] Childrens Hosp & Med Ctr, Omaha, NE USA.
[Knight, Bradley P.] NW Med Ctr, Div Cardiol, Chicago, IL USA.
[Levison, Matthew E.] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA.
[Levison, Matthew E.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.
[Masoudi, Frederick A.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO USA.
[Okum, Eric J.] Cardiac Vasc & Thorac Surg, Cincinnati, OH USA.
[Beerman, Lee B.] Univ Pittsburgh, Div Pediat Cardiol, Childrens Hosp Pittsburgh, Ctr Med, Pittsburgh, PA 15260 USA.
[Bolger, Ann F.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Bolger, Ann F.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA USA.
[Estes, N. A. Mark, III] Tufts Med Ctr, Cardiac Arrhythmia Serv, Boston, MA USA.
[Gewitz, Michael] Maria Fareri Childrens Hosp, Westchester Med Ctr, Valhalla, NY USA.
[Gewitz, Michael] New York Med Coll, Valhalla, NY 10595 USA.
[Newburger, Jane W.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Schron, Eleanor B.] NEI, Vis Res Program, Natl Inst Hlth, Rockville, MD USA.
[Taubert, Kathryn A.] World Heart Federat, Geneva, NY USA.
RP Lockhart, PB (reprint author), Carolinas Med Ctr, Dept Oral Med, POB 32861, Charlotte, NC 28232 USA.
EM Peter.Lockhart@carolinashealthcare.org
FU St. Jude Medical, St. Paul, Minn; Boston Scientific, Natick, Mass
FX Dr. Erickson has received a research grant from St. Jude Medical, St.
Paul, Minn. Dr. Estes has received research support from Boston
Scientific, Natick, Mass.; is a consultant to Boston Scientific; and has
received honoraria from Boston Scientific and St. Jude Medical. None of
the other authors reported any disclosures.
NR 69
TC 15
Z9 16
U1 0
U2 1
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD FEB
PY 2011
VL 142
IS 2
BP 159
EP 165
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 716UU
UT WOS:000286999800017
PM 21282681
ER
PT J
AU Hebert, PL
Chassin, MR
Howell, EA
AF Hebert, Paul L.
Chassin, Mark R.
Howell, Elizabeth A.
TI The Contribution of Geography to Black/White Differences in the Use of
Low Neonatal Mortality Hospitals in New York City
SO MEDICAL CARE
LA English
DT Article
DE neonatal mortality; distance; quality; geography
ID RESIDENTIAL SEGREGATION; INFANT-MORTALITY; BIRTH-WEIGHT; CARE
PHYSICIANS; UNITED-STATES; HEALTH; DISPARITIES; POLICIES
AB Background: Racial differences in the use of high-quality hospital care contribute to racial disparities in mortality for very low birth weight (VLBW) neonates.
Objectives: We explored the role that geographic distribution of hospitals plays in the racial disparity in the use of top-tier hospitals by mothers of VLBW neonates in New York City.
Research Design: Retrospective analysis of Vital Statistics and administrative databases.
Subjects: VLBW deliveries in New York City from 1996 to 2001 to non-Hispanic Black (n = 4947) and non-Hispanic White (n = 1615) mothers.
Results: Black mothers were less likely to deliver in a top-tier hospitals (White = 44%, Black = 28%; P < 0.001) and top-tier hospitals were less likely to be located in Black mothers' neighborhoods (White = 40%, Black = 33%; P < 0.001). Distance, however, did not contribute to the disparity in use of top-tier hospitals. Non-Hispanic Black mothers lived marginally closer to a top-tier hospital than non-Hispanic White mothers (0.65 miles closer; P < 0.001), and mothers of both the races often bypassed their neighborhood hospital (Black = 62% bypassed, White = 71%; P < 0.001). Inattention to recommended prenatal behaviors was associated with using a closer hospital, suggesting that geographic proximity was most important to mothers of vulnerable neonates. Purported measures of hospital quality such as Neonatal Intensive Care Unit level and volume were more strongly associated with use of hospital for White mothers than for Black mothers.
Conclusions: The influence of geography on the use of top-tier hospitals for mothers of VLBW neonates is complex. Other personal and hospital characteristics, not just distance or geography, also influenced hospital use in New York City.
C1 [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, VA HSR&D, Seattle, WA 98101 USA.
[Hebert, Paul L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Chassin, Mark R.] Joint Commiss, Off President, Oak Brook Terrace, IL USA.
[Howell, Elizabeth A.] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA.
[Howell, Elizabeth A.] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA.
[Howell, Elizabeth A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, VA HSR&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Paul.Hebert2@va.gov
FU Agency for Health Care Research and Quality; Commonwealth Fund
FX Supported by Agency for Health Care Research and Quality and The
Commonwealth Fund.
NR 21
TC 4
Z9 4
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD FEB
PY 2011
VL 49
IS 2
BP 200
EP 206
DI 10.1097/MLR.0b013e3182019144
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 706BR
UT WOS:000286191000012
PM 21239954
ER
PT J
AU Livhits, M
Mercado, C
Yermilov, I
Parikh, JA
Dutson, E
Mehran, A
Ko, CY
Shekelle, PG
Gibbons, MM
AF Livhits, M.
Mercado, C.
Yermilov, I.
Parikh, J. A.
Dutson, E.
Mehran, A.
Ko, C. Y.
Shekelle, P. G.
Gibbons, M. M.
TI Is social support associated with greater weight loss after bariatric
surgery?: a systematic review
SO OBESITY REVIEWS
LA English
DT Article
DE Bariatric surgery; social support; support group; weight loss
ID Y GASTRIC BYPASS; PREDICTING SUCCESS; BEHAVIORAL-FACTORS; FOLLOW-UP;
GASTROPLASTY; ATTENDANCE; OBESITY
AB Social support may be associated with increased weight loss after bariatric surgery. The objective of this article is to determine impact of post-operative support groups and other forms of social support on weight loss after bariatric surgery. MEDLINE search (1988-2009) was completed using MeSH terms including bariatric procedures and a spectrum of patient factors with potential relationship to weight loss outcomes. Of the 934 screened studies, 10 reported on social support and weight loss outcomes. Five studies reported on support groups and five studies reported on other forms of social support (such as perceived family support or number of confidants) and degree of post-operative weight loss (total n = 735 patients). All studies found a positive association between post-operative support groups and weight loss. One study found a positive association between marital status (being single) and weight loss, while three studies found a non-significant positive trend and one study was inconclusive. Support group attendance after bariatric surgery is associated with greater post-operative weight loss. Further research is necessary to determine the impact of other forms of social support. These factors should be addressed in prospective studies of weight loss following bariatric surgery, as they may represent ways to improve post-operative outcomes.
C1 [Livhits, M.; Mercado, C.; Yermilov, I.; Parikh, J. A.; Dutson, E.; Mehran, A.; Ko, C. Y.; Shekelle, P. G.; Gibbons, M. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Livhits, M.; Yermilov, I.; Parikh, J. A.; Ko, C. Y.; Shekelle, P. G.; Gibbons, M. M.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Gibbons, M. M.] Olive View UCLA, Dept Surg, Sylmar, CA USA.
RP Livhits, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72-215 CHS, Los Angeles, CA 90095 USA.
EM mlivhits@mednet.ucla.edu
FU Robert Wood Johnson Physician Faculty Scholars programme; VA Department
of Surgery
FX We would like to acknowledge the VA Department of Surgery for providing
support for Dr Livhits and Dr Maggard. Dr Maggard's time was also
supported in part by a grant from the Robert Wood Johnson Physician
Faculty Scholars programme.
NR 29
TC 48
Z9 48
U1 3
U2 25
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1467-7881
J9 OBES REV
JI Obes. Rev.
PD FEB
PY 2011
VL 12
IS 2
BP 142
EP 148
DI 10.1111/j.1467-789X.2010.00720.x
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 725RE
UT WOS:000287662800007
PM 20158617
ER
PT J
AU Osorio, Y
Travi, BL
Renslo, AR
Peniche, AG
Melby, PC
AF Osorio, Yaneth
Travi, Bruno L.
Renslo, Adam R.
Peniche, Alex G.
Melby, Peter C.
TI Identification of Small Molecule Lead Compounds for Visceral
Leishmaniasis Using a Novel Ex Vivo Splenic Explant Model System
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INDIAN KALA-AZAR; ANTILEISHMANIAL ACTIVITY; PLASMODIUM-FALCIPARUM;
INTERFERON-GAMMA; T-CELLS; DRUG; DONOVANI; INFECTION; CYTOTOXICITY;
CHEMOTHERAPY
AB Background: New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial activity.
Methodology/Principal Findings: This model has advantages over in vitro systems in that it: 1) includes the whole cellular population involved in the host-parasite interaction; 2) is initiated at a stage of infection when the immunosuppressive mechanisms that lead to progressive VL are evident; 3) involves the intracellular form of Leishmania; 4) supports parasite replication that can be easily quantified by detection of parasite-expressed luciferase; 5) is adaptable to a high-throughput screening format; and 6) can be used to identify compounds that have both direct and indirect anti-parasitic activity. The assay showed excellent discrimination between positive (amphotericin B) and negative (vehicle) controls with a Z' Factor >0.8. A duplicate screen of 4 chemical libraries containing 4,035 compounds identified 202 hits (5.0%) with a Z score of < -1.96 (p<0.05). Eighty-four (2.1%) of the hits were classified as lead compounds based on the in vitro therapeutic index (ratio of the compound concentration causing 50% cytotoxicity in the HepG(2) cell line to the concentration that caused 50% reduction in the parasite load). Sixty-nine (82%) of the lead compounds were previously unknown to have anti-leishmanial activity. The most frequently identified lead compounds were classified as quinoline-containing compounds (14%), alkaloids (10%), aromatics (11%), terpenes (8%), phenothiazines (7%) and furans (5%).
Conclusions/Significance: The ex vivo splenic explant model provides a powerful approach to identify new compounds active against L. donovani within the pathophysiologic environment of the infected spleen. Further in vivo evaluation and chemical optimization of these lead compounds may generate new candidates for preclinical studies of treatment for VL.
C1 [Osorio, Yaneth; Travi, Bruno L.; Peniche, Alex G.; Melby, Peter C.] Res Serv, Dept Vet Affairs Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Osorio, Yaneth; Travi, Bruno L.; Peniche, Alex G.; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Renslo, Adam R.] Univ Calif San Francisco, Small Mol Discovery Ctr, Sandler Ctr Basic Res Parasit Dis, San Francisco, CA 94143 USA.
[Renslo, Adam R.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
[Melby, Peter C.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.
RP Osorio, Y (reprint author), Univ Texas Med Branch, Ctr Trop Dis, Dept Internal Med, Galveston, TX 77555 USA.
EM pcmelby@utmb.edu
OI Renslo, Adam/0000-0002-1240-2846
FU Department of Defense, Air Force [FA7014-07-C-0034]
FX This work was funded by Department of Defense, Air Force Contract No.
FA7014-07-C-0034 (P.C. Melby P.I.). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 59
TC 26
Z9 26
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2011
VL 5
IS 2
AR e962
DI 10.1371/journal.pntd.0000962
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 726CQ
UT WOS:000287696700012
PM 21358812
ER
PT J
AU Steeves, JD
Kramer, JK
Fawcett, JW
Cragg, J
Lammertse, DP
Blight, AR
Marino, RJ
Ditunno, JF
Coleman, WP
Geisler, FH
Guest, J
Jones, L
Burns, S
Schubert, M
van Hedel, HJA
Curt, A
AF Steeves, J. D.
Kramer, J. K.
Fawcett, J. W.
Cragg, J.
Lammertse, D. P.
Blight, A. R.
Marino, R. J.
Ditunno, J. F., Jr.
Coleman, W. P.
Geisler, F. H.
Guest, J.
Jones, L.
Burns, S.
Schubert, M.
van Hedel, H. J. A.
Curt, A.
CA EMSCI Study Grp
TI Extent of spontaneous motor recovery after traumatic cervical
sensorimotor complete spinal cord injury
SO SPINAL CORD
LA English
DT Article
DE assessment; clinical trial; outcomes; neurological recovery; upper
extremity motor score; motor level
ID CLINICAL-TRIALS; ICCP PANEL; INCOMPLETE TETRAPLEGIA; OUTCOME MEASURES;
GUIDELINES; CONDUCT; STRENGTH; RELIABILITY; MULTICENTER; STANDARDS
AB Study design: Retrospective, longitudinal analysis of motor recovery data from individuals with cervical (C4-C7) sensorimotor complete spinal cord injury (SCI) according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).
Objectives: To analyze the extent and patterns of spontaneous motor recovery over the first year after traumatic cervical sensorimotor complete SCI.
Methods: Datasets from the European multicenter study about SCI (EMSCI) and the Sygen randomized clinical trial were examined for conversion of American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade, change in upper extremity motor score (UEMS) or motor level, as well as relationships between these measures.
Results: There were no overall differences between the EMSCI and Sygen datasets in motor recovery patterns. After 1 year, up to 70% of subjects spontaneously recovered at least one motor level, but only 30% recovered two or more motor levels, with lesser values at intermediate time points. AIS grade conversion did not significantly influence motor level changes. At 1 year, the average spontaneous improvement in bilateral UEMS was 10-11 motor points. There was only moderate relationship between a change in UEMS and a change in cervical motor level (r(2)=0.30, P<0.05). Regardless of initial cervical motor level, most individuals recover a similar number of motor points or motor levels.
Conclusion: Careful tracking of cervical motor recovery outcomes may provide the necessary sensitivity and accuracy to reliably detect a subtle, but meaningful treatment effect after sensorimotor complete cervical SCI. The distribution of the UEMS change may be more important functionally than the total UEMS recovered. Spinal Cord (2011) 49, 257-265; doi:10.1038/sc.2010.99; published online 17 August 2010
C1 [Steeves, J. D.; Kramer, J. K.; Cragg, J.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, Vancouver, BC V5Z 1M9, Canada.
[Fawcett, J. W.] Univ Cambridge, Ctr Brain Repair, Cambridge, England.
[Lammertse, D. P.] Craig Hosp, Englewood, CO USA.
[Blight, A. R.] Acorda Therapeut, Hawthorne, NY USA.
[Marino, R. J.; Ditunno, J. F., Jr.] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA.
[Coleman, W. P.] WPCMath, Buffalo, NY USA.
[Geisler, F. H.] Rush Copley Med Ctr, Illinois Neurospine Ctr, Aurora, CO USA.
[Guest, J.] Neurol Surg & Miami Project Cure Paralysis, Miami, FL USA.
[Jones, L.] Geron Corp, Menlo Pk, CA USA.
[Burns, S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Schubert, M.; van Hedel, H. J. A.; Curt, A.] Balgrist Univ Hosp, Spinal Cord Injury Ctr, Zurich, Switzerland.
RP Steeves, JD (reprint author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, ICORD, 818 W 10th Ave, Vancouver, BC V5Z 1M9, Canada.
EM steeves@icord.org
OI Lammertse, Daniel/0000-0003-4590-2481; van Hedel,
Hubertus/0000-0002-9577-5049; Marino, Ralph/0000-0003-2670-4113;
Fawcett, James/0000-0002-7990-4568
FU ICCP; SCOPE; International Foundation for Research in Paraplegia,
Zurich, Switzerland (IFP, Zurich)
FX The support of ICCP (http://www.campaignforcure.org) and SCOPE
(http://www.scopesci.org) is gratefully acknowledged. We are grateful
for the constructive suggestions of Jose Zariffa. John Kramer is a
doctoral trainee of the Canadian Institute of Health Research and
Michael Smith Foundation for Health Research. EMSCI is supported by the
International Foundation for Research in Paraplegia, Zurich, Switzerland
(IFP, Zurich).
NR 29
TC 49
Z9 50
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
EI 1476-5624
J9 SPINAL CORD
JI Spinal Cord
PD FEB
PY 2011
VL 49
IS 2
BP 257
EP 265
DI 10.1038/sc.2010.99
PG 9
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 716LZ
UT WOS:000286971600016
PM 20714334
ER
PT J
AU Kremen, SA
Mendez, MF
Tsai, PH
Teng, E
AF Kremen, Sarah A.
Mendez, Mario F.
Tsai, Po-Heng
Teng, Edmond
TI Extrapyramidal Signs in the Primary Progressive Aphasias
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE primary progressive aphasia; parkinsonism; progressive nonfluent
aphasia; semantic dementia; logopenic aphasia
ID FRONTOTEMPORAL LOBAR DEGENERATION; CORTICOBASAL DEGENERATION; NONFLUENT
APHASIA; SUPRANUCLEAR PALSY; CLINICOPATHOLOGICAL CORRELATIONS;
GLUCOSE-METABOLISM; ALZHEIMER-DISEASE; 3 VARIANTS; DEMENTIA; PATHOLOGY
AB Background: Extrapyramidal signs (EPS) may vary across 3 major subtypes of primary progressive aphasia (PPA): progressive nonfluent aphasia (PNFA), semantic dementia (SD), and progressive logopenic aphasia (PLA). Methods: We reviewed initial neurological examinations from a clinical PPA cohort (PNFA = 49, SD = 26, PLA = 28) to determine the prevalence of specific categories of EPS. Results: The presence of any EPS was more common in PNFA (38.8%) and PLA (35.7%) than in SD (3.8%). The PNFA group exhibited the highest prevalence of bradykinesia (PNFA: 22.4%, SD: 3.8%, PLA: 0.0%) and rigidity (PNFA: 30.6%, SD: 0.0%, PLA: 10.7%). Calculated positive likelihood ratios indicated bradykinesia (12.1) or rigidity (5.5) was more strongly associated with PNFA than other PPAs. Conclusion: These findings suggest that on initial presentation, specific EPS may help distinguish PPA subtypes when linguistic and/or neuroimaging profiles are indistinct. Moreover, EPS could represent a marker of underlying tauopathy, linking clinical presentation to neuropathology in PPA.
C1 [Kremen, Sarah A.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Kremen, Sarah A.; Mendez, Mario F.; Tsai, Po-Heng; Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA.
[Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Kremen, SA (reprint author), Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, David Geffen Sch Med, Dept Neurol, 10911 Weyburn Ave,2nd Fl, Los Angeles, CA 90095 USA.
EM skremen@ucla.edu
FU VA Special Fellowship
FX The author(s) disclosed receipt of the following financial support for
the research and/or authorship of this article: supported by a VA
Special Fellowship for Geriatric Neurology (to S.A.K.)]).
NR 40
TC 10
Z9 10
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD FEB
PY 2011
VL 26
IS 1
BP 72
EP 77
DI 10.1177/1533317510391239
PG 6
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 713WZ
UT WOS:000286769400010
PM 21282281
ER
PT J
AU Church, S
Robinson, TN
Angles, EM
Tran, ZV
Wallace, JI
AF Church, Skotti
Robinson, Thomas N.
Angles, Erik M.
Tran, Zung V.
Wallace, Jeffrey I.
TI Postoperative falls in the acute hospital setting: characteristics, risk
factors, and outcomes in males
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Hospital falls; Geriatric surgery; Elderly; Hospital-acquired condition
ID DELIRIUM; INJURIES; CLASSIFICATION; CIRCUMSTANCES; PREVENTION;
PREDICTORS; SYSTEM
AB BACKGROUND: Hospital falls are an important cause of morbidity in older surgical patients. The objectives of this study were to describe the characteristics, risk factors, and outcomes for postoperative falls.
METHODS: A retrospective study was performed on patients who were admitted to the hospital for more than 23 hours after surgery. Patients who fell within 30 days of their surgery were considered to have experienced a postoperative fall.
RESULTS: Over 5 years and 9,625 inpatient surgical procedures, 154 patients experienced 190 falls. Injuries resulting from postoperative falls included major injury (hip fracture), less than 1%; injury requiring intervention, 2%; injury not requiring intervention, 27%; and no injury, 70%. Variables associated with postoperative falls included older age, functional dependence, lower albumin level, and higher American Society of Anesthesia score.
CONCLUSIONS: One or more postoperative falls occurred in 1.6% of surgical inpatients and can lead to significant morbidity. Recognition of fall risk factors will help design postoperative fall prevention programs by identifying patients at highest risk for postoperative falls. Published by Elsevier Inc.
C1 [Church, Skotti; Robinson, Thomas N.; Angles, Erik M.] Univ Colorado Denver, Sch Med, Hlth Sci Ctr, Dept Surg, Aurora, CO 80045 USA.
[Robinson, Thomas N.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA.
[Tran, Zung V.] Univ Colorado Denver, Sch Med, Dept Biometr, Aurora, CO 80045 USA.
[Wallace, Jeffrey I.] Univ Colorado Denver, Sch Med, Dept Geriatr Med, Aurora, CO 80045 USA.
RP Robinson, TN (reprint author), Univ Colorado Denver, Sch Med, Hlth Sci Ctr, Dept Surg, Mail Stop C313,12631 E 17th Ave,POB 6511, Aurora, CO 80045 USA.
EM thomas.robinson@ucdenver.edu
OI Tran, Zung/0000-0002-9322-9562
FU American Geriatric Society
FX This work was supported by the American Geriatric Society's Jahnigen
Scholars Award (T.N.R.) and the American Geriatric Society Geriatrics
for Specialty Residents Award (T.N.R. and J.I.W.).
NR 22
TC 15
Z9 15
U1 1
U2 6
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD FEB
PY 2011
VL 201
IS 2
BP 197
EP 202
DI 10.1016/j.amjsurg.2009.12.013
PG 6
WC Surgery
SC Surgery
GA 722KE
UT WOS:000287430300010
PM 20851375
ER
PT J
AU Sreeramoju, P
Porbandarwalla, NS
Arango, J
Latham, K
Dent, DL
Stewart, RM
Patterson, JE
AF Sreeramoju, Pranavi
Porbandarwalla, Nabilla S.
Arango, Jorge
Latham, Kerry
Dent, Daniel L.
Stewart, Ronald M.
Patterson, Jan E.
TI Recurrent skin and soft tissue infections due to methicillin-resistant
Staphylococcus aureus requiring operative debridement
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Staphylococcal skin infections; Staphylococcus aureus; Staphylococcal
infections; Abscess; Methicillin-resistant Staphylococcus aureus;
Epidemiology; Risk factors; Recurrence
ID RISK-FACTORS; EMERGENCY-DEPARTMENT; DOUBLE-BLIND; ABSCESSES; CHILDREN
AB BACKGROUND: The aim of this study was to examine clinical factors associated with the recurrence of community-onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.
METHODS: An observational case-comparison study based on a retrospective review of medical records was conducted in a public health system. All patients with community-onset skin and soft tissue infections caused by methicillin-resistant S aureus who underwent operative debridement from January 1999 to December 2003 were included. The outcome of interest was recurrence within 1 year.
RESULTS: Two hundred fifty-three patients met the criteria for inclusion. Fifty-three (21%) patients returned with recurrent episodes. These patients were compared with 200 patients (79%) who did not develop recurrence. On multivariate analysis, factors independently predictive of recurrence were medical history of abscess requiring surgical debridement within the previous year (adjusted odds ratio, 2.6; 95% confidence interval, 1.4-5.0; P = .002) and obesity (adjusted odds ratio, 3.4; 95% confidence interval, 1.4-8.8; P = .008).
CONCLUSIONS: Patients with obesity or histories of methicillin-resistant S aureus infection are at significantly increased risk for recurrent soft tissue infection. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Sreeramoju, Pranavi] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA.
[Porbandarwalla, Nabilla S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA.
[Arango, Jorge; Dent, Daniel L.; Stewart, Ronald M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX USA.
[Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX USA.
[Latham, Kerry] Dept Surg, Keesler AFB, MS USA.
[Patterson, Jan E.] S Texas Vet Healthcare Syst, Dept Med, San Antonio, TX USA.
RP Sreeramoju, P (reprint author), Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA.
EM pranavi.sreeramoju@utsouthwestern.edu
NR 19
TC 25
Z9 26
U1 0
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD FEB
PY 2011
VL 201
IS 2
BP 216
EP 220
DI 10.1016/j.amjsurg.2009.12.024
PG 5
WC Surgery
SC Surgery
GA 722KE
UT WOS:000287430300013
PM 20832054
ER
PT J
AU Gupta, SR
Phan, IT
Suhler, EB
AF Gupta, Seema R.
Phan, Isabella T.
Suhler, Eric B.
TI Successful Treatment of Refractory Sympathetic Ophthalmia in a Child
With Infliximab
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Letter
ID UVEITIS; THERAPY
C1 [Gupta, Seema R.; Phan, Isabella T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
RP Suhler, EB (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM suhlere@ohsu.edu
NR 6
TC 11
Z9 11
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2011
VL 129
IS 2
BP 250
EP 252
DI 10.1001/archophthalmol.2010.358
PG 3
WC Ophthalmology
SC Ophthalmology
GA 721CQ
UT WOS:000287329500025
PM 21320978
ER
PT J
AU Collins, J
AF Collins, Judith
TI Breastfeeding in Inflammatory Bowel Disease: Positive Results for Mother
and Child
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Editorial Material
ID RHEUMATOID-ARTHRITIS; PREGNANCY; RELAPSE; WOMEN
C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
RP Collins, J (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 7
TC 2
Z9 2
U1 1
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD FEB
PY 2011
VL 17
IS 2
BP 663
EP 664
DI 10.1002/ibd.21338
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 718JF
UT WOS:000287116500019
PM 20848522
ER
PT J
AU Garg, A
Baudendistel, TE
Dhaliwal, G
AF Garg, Amit
Baudendistel, Thomas E.
Dhaliwal, Gurpreet
TI In the Face of It All
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Editorial Material
ID HEPATIC AMYLOIDOSIS; CRANIAL NEUROPATHY; AL AMYLOIDOSIS; INVOLVEMENT;
FEATURES
C1 [Garg, Amit; Baudendistel, Thomas E.] Kaiser Oakland Med Ctr, Dept Med, Oakland, CA 94611 USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Garg, A (reprint author), Kaiser Oakland Med Ctr, Dept Med, 280 W MacArthur Blvd, Oakland, CA 94611 USA.
EM akgarg2@gmail.com
NR 16
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD FEB
PY 2011
VL 6
IS 2
BP 98
EP 102
DI 10.1002/jhm.862
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 722IT
UT WOS:000287426600010
PM 21290582
ER
PT J
AU Naliboff, BD
Wu, SM
Schieffer, B
Bolus, R
Pham, Q
Baria, A
Aragaki, D
Van Vort, W
Davis, F
Shekelle, P
AF Naliboff, Bruce D.
Wu, Stephen M.
Schieffer, Beatrix
Bolus, Roger
Pham, Quynh
Baria, Ariel
Aragaki, Dixie
Van Vort, Walter
Davis, Frederick
Shekelle, Paul
TI A Randomized Trial of 2 Prescription Strategies for Opioid Treatment of
Chronic Nonmalignant Pain
SO JOURNAL OF PAIN
LA English
DT Article
DE Chronic noncancer pain; opioid medications; substance abuse; addiction;
medication misuse
ID CHRONIC NONCANCER PAIN; BACK-PAIN; ADDICTION; EFFICACY; THERAPY; ABUSE
AB The use of opioid medications for treating chronic noncancer pain is growing; however, there is a lack of good evidence regarding their long-term effectiveness, association with substance abuse, and proper prescribing guidelines. The current study directly compares for the first time in a randomized trial the effectiveness of a conservative, hold the line (Stable Dose) prescribing strategy for opioid medications with a more liberal dose escalation (Escalating Dose) approach. This 2-arm, parallel, randomized pragmatic clinical trial followed 135 patients referred to a specialty pain clinic at a Veterans Affairs Hospital for 12 months (94% male and 74% with musculoskeletal pain). Primary outcomes included monthly or quarterly evaluations of pain severity, pain relief from medications, pain-related functional disability, and opioid misuse behaviors. All subjects received identical pain treatment except for the application of treatment group specific strategies for opioid prescriptions. No group differences were found for primary outcomes of usual pain or functional disability although the Escalating Dose group did show a small but significantly larger increase in self-rated pain relief from medications. About 27% of patients were discharged over the course of the study due to opioid misuse/noncompliance, but there were no group differences in rate of opioid misuse.
Perspective: The results of this study demonstrate that even in carefully selected patients there is a significant risk of problematic opioid misuse. Although in general there were no statistically significant differences in the primary outcomes between groups, the escalating dose strategy did lead to small improvements in self-reported acute relief from medications without an increase in opioid misuse, compared to the stable dose strategy. (C) 2011 by the American Pain Society
C1 [Naliboff, Bruce D.] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA.
[Naliboff, Bruce D.; Wu, Stephen M.; Bolus, Roger] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Naliboff, Bruce D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Pham, Quynh; Aragaki, Dixie; Shekelle, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Naliboff, BD (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Bldg 115,Rm 107,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM naliboff@ucla.edu
FU Department of Veterans Affairs, Health Services Research and Development
FX Grant support provided by Department of Veterans Affairs, Health
Services Research and Development.
NR 21
TC 24
Z9 24
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD FEB
PY 2011
VL 12
IS 2
BP 288
EP 296
DI 10.1016/j.jpain.2010.09.003
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 722IW
UT WOS:000287426900016
PM 21111684
ER
PT J
AU Enguidanos, S
Kogan, AC
Lorenz, K
Taylor, G
AF Enguidanos, Susan
Kogan, Alexis Coulourides
Lorenz, Karl
Taylor, George
TI Use of Role Model Stories to Overcome Barriers to Hospice among African
Americans
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES; OLDER-ADULTS; DEATH; CARE;
SERVICES; WOMEN; INTERVENTION; ASSOCIATIONS; DISCUSSIONS
AB Objectives: To test a brochure comprising hospice patient role model stories aimed at improving attitudes and knowledge of hospice among older African Americans.
Design: Pre-post community-based study.
Setting: Community-based organizations including senior centers, community exercise programs, churches, and senior care management services in greater Los Angeles area.
Participants: Seventy-one African Americans aged 65 and older.
Intervention: Hospice brochure containing theoretically driven role model stories portraying African Americans' experience with hospice, their initial attitudes and beliefs about hospice, factors influencing their enrollment in the program, and outcomes following enrollment.
Measurements: Change from baseline in attitudes toward, knowledge of, and intentions to enroll in hospice.
Results: Mean knowledge scores (range, 0-9) increased from 5.76 (standard deviation [SD] = 2.12) at pretest to 6.95 (SD = 1.90) at posttest (t = -6.14, p < 0.001). Average attitude toward hospice (range, 12-72) improved 12.5% from 41.16 (SD = 5.20) to 46.29 (SD = 5.45) (t = -7.52, p < 0.001). Intentions to enroll a family member in hospice increased from 84.5% to 92.9% (p = 0.002) and intentions to seek hospice care for themselves increased from 83.1% to 95.8% (p < 0.001).
Conclusion: This small pre-post pilot study found that exposure to a hospice brochure containing theoretically driven, culturally parallel, role model stories was effective in improving knowledge of and attitudes toward hospice as well as intentions to enroll a family member or self in hospice care. Further study is needed to determine the impact of using this brochure within a clinical setting.
C1 [Enguidanos, Susan; Kogan, Alexis Coulourides] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA.
[Enguidanos, Susan; Taylor, George] Partners Care Fdn, San Fernando, CA USA.
[Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA.
RP Enguidanos, S (reprint author), Univ So Calif, Davis Sch Gerontol, 3715 McClintock Ave,Gero 228-B, Los Angeles, CA 90089 USA.
EM Enguidan@usc.edu
OI Enguidanos, Susan/0000-0002-5112-288X
FU PacifiCare/United Healthcare
FX This research was supported by a grant from PacifiCare/United
Healthcare.
NR 36
TC 12
Z9 12
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD FEB
PY 2011
VL 14
IS 2
BP 161
EP 168
DI 10.1089/jpm.2010.0380
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 719UM
UT WOS:000287236200011
PM 21265628
ER
PT J
AU Porter, MP
Gore, JL
Wright, JL
AF Porter, Michael P.
Gore, John L.
Wright, Jonathan L.
TI Hospital volume and 90-day mortality risk after radical cystectomy: a
population-based cohort study
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article
DE Bladder cancer; Outcomes; Mortality; Survival; Hospital volume
AB Hospital cystectomy volume has been associated with in-hospital perioperative mortality in previous studies. In this study, we examine the relationship between hospital cystectomy volume and 90-day mortality in a population-based cohort of patients undergoing cystectomy for bladder cancer.
We performed a retrospective cohort study using population from the State of Washington Comprehensive Hospital Abstract Reporting System (CHARS) database. We examined the association between hospital cystectomy volume (categorized into volume tertiles) and cumulative 90-day mortality in patients undergoing cystectomy for bladder cancer. Multivariate regression was used to adjust for patient age, comorbid disease, year of surgery, and gender. Standard errors were clustered by discharge hospital.
We identified 823 patients who underwent cystectomy for bladder cancer at 39 unique hospitals in 2003-2007. The unadjusted cumulative 90-day cumulative mortality was 5.4, 6.9, and 8.4% for patients discharged from hospitals in the high, medium, and low volume tertiles, respectively (P = 0.35). In the multivariate analysis, the patients undergoing cystectomy who were discharged from hospitals in the highest volume tertile had a lower risk of death in the first 90 days postoperatively compared to patients discharged from hospitals in the low volume tertile, though the finding was not statistically significant (OR = 0.68, 95% CI 0.29-1.56).
Ninety-day cumulative mortality after cystectomy for bladder cancer is significant and may be associated with hospital cystectomy volume.
C1 [Porter, Michael P.; Wright, Jonathan L.] VA Puget Sound Hlth Care Syst, Div Urol, Seattle, WA 98108 USA.
[Porter, Michael P.; Gore, John L.; Wright, Jonathan L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
RP Porter, MP (reprint author), VA Puget Sound Hlth Care Syst, Div Urol, 1660 S Columbian Way,S-112-GU, Seattle, WA 98108 USA.
EM mporter@u.washington.edu
OI Gore, John/0000-0002-2847-5062
FU VA Puget Sound Health Care System, Seattle, Washington
FX This material is the result of work supported by resources from the VA
Puget Sound Health Care System, Seattle, Washington.
NR 0
TC 12
Z9 12
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-4983
J9 WORLD J UROL
JI World J. Urol.
PD FEB
PY 2011
VL 29
IS 1
BP 73
EP 77
DI 10.1007/s00345-010-0626-3
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 709TX
UT WOS:000286465400011
PM 21132553
ER
PT J
AU Fett, N
Werth, VP
AF Fett, Nicole
Werth, Victoria P.
TI Update on morphea Part I. Epidemiology, clinical presentation, and
pathogenesis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE autoimmune connective tissue disorder; fibrosing disorders; localized
scleroderma; morphea; scleroderma; systemic sclerosis
ID SCLEROSUS-ET-ATROPHICUS; OF-THE-LITERATURE; BORRELIA-BURGDORFERI
INFECTION; JUVENILE LOCALIZED SCLERODERMA; DISABLING PANSCLEROTIC
MORPHEA; PROGRESSIVE FACIAL HEMIATROPHY; POLYMERASE-CHAIN-REACTION;
SYSTEMIC-SCLEROSIS; RAYNAUDS-PHENOMENON; EN-COUP
AB Morphea, also known as localized scleroderma, is a rare fibrosing disorder of the skin and underlying tissues. Morphea is differentiated from systemic sclerosis based on the absence of sclerodactyly, Raynaud phenomenon, and nailfold capillary changes. Patients with morphea commonly have systemic symptoms, such as malaise, fatigue, arthralgias, and myalgias, as well as positive autoantibody serologies. However, involvement of morphea is almost uniformly limited to those tissues derived from the mesoderm. The underlying pathogenesis of morphea is incompletely understood at this time, but ultimately results in an imbalance of collagen production and destruction. (J Am Acad Dermatol 2011;64:217-28.)
C1 [Fett, Nicole] Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA.
Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Fett, N (reprint author), Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Ste 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM Nicole.Fett@uphs.upenn.edu
FU Department of Veterans Affairs Veterans Health Administration, Office of
Research and Development, Biomedical Laboratory Research and
Development; National Institutes of Health [NIH K24-AR 02207]
FX Supported in part by a Merit Review Grant from the Department of
Veterans Affairs Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development, and by the
National Institutes of Health (grant NIH K24-AR 02207) to Dr Werth.
NR 75
TC 76
Z9 80
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD FEB
PY 2011
VL 64
IS 2
BP 217
EP 228
DI 10.1016/j.jaad.2010.05.045
PG 12
WC Dermatology
SC Dermatology
GA 714AX
UT WOS:000286780400001
PM 21238823
ER
PT J
AU Amory, JK
Bush, MA
Zhi, H
Caricofe, RB
Matsumoto, AM
Swerdloff, RS
Wang, C
Clark, RV
AF Amory, John K.
Bush, Mark A.
Zhi, Hui
Caricofe, Ralph B.
Matsumoto, Alvin M.
Swerdloff, Ronald S.
Wang, Christina
Clark, Richard V.
TI Oral Testosterone With and Without Concomitant Inhibition of 5
alpha-Reductase by Dutasteride in Hypogonadal Men for 28 Days
SO JOURNAL OF UROLOGY
LA English
DT Article
DE testis; hypogonadism; administration; oral; testosterone; dutasteride
ID BONE-MINERAL DENSITY; LEAN BODY-MASS; PROSTATE-CANCER; OLDER MEN;
EXOGENOUS TESTOSTERONE; SERUM TESTOSTERONE; PLUS DUTASTERIDE; SEXUAL
FUNCTION; REPLACEMENT; FINASTERIDE
AB Purpose: Co-administration of the 5 alpha-reductase inhibitor dutasteride increases the oral testosterone bioavailability in men with experimentally induced hypogonadism. We examined oral testosterone with and without dutasteride administration in hypogonadal men for 28 days.
Materials and Methods: We randomly assigned 43 hypogonadal men to twice daily oral doses of 150, 250 or 400 mg testosterone with 0.25 mg dutasteride, 400 mg testosterone alone or 0.25 mg dutasteride alone for 28 days in a multicenter study. Subjects underwent pharmacokinetic profiling of serum hormones on days 1 and 28. A total of 32 men completed all study procedures.
Results: Serum testosterone increased in all groups on testosterone compared with that in the dutasteride only group. At the 400 mg dose the combination of testosterone and dutasteride resulted in average testosterone concentrations that were 2.7 and 4.6 times higher than in the testosterone only group on days 1 and 28, respectively (p < 0.01). On day 28 average testosterone was 20% to 30% lower in all groups on testosterone and dutasteride, and 50% lower in the testosterone only group compared with day 1. Serum dihydrotestosterone was suppressed in all groups on dutasteride and increased in the testosterone only group.
Conclusions: Oral testosterone administration resulted in a therapeutic serum testosterone concentration in hypogonadal men. Dutasteride improved the oral bioavailability of testosterone while suppressing dihydrotestosterone. Compared with day 1, testosterone was decreased after 28 days of administration. Additional study is warranted of oral testosterone with dutasteride for testosterone deficiency.
C1 [Clark, Richard V.] GlaxoSmithKline Res & Dev Ltd, Metab Discovery Med, Muscle Metab DPU, Metab Pathways CEDD, Res Triangle Pk, NC 27709 USA.
[Amory, John K.] Univ Washington, Seattle, WA 98195 USA.
[Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Swerdloff, Ronald S.; Wang, Christina] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
[Swerdloff, Ronald S.; Wang, Christina] Los Angeles Biomed Res Inst, Torrance, CA USA.
RP Clark, RV (reprint author), GlaxoSmithKline Res & Dev Ltd, Metab Discovery Med, Muscle Metab DPU, Metab Pathways CEDD, 5 Moore Dr,N2-3212,POB 13398, Res Triangle Pk, NC 27709 USA.
FU GlaxoSmithKline; National Institutes of Health Eunice Kennedy Shriver
National Institute of Child Health and Human Development [U54 HD
042454]; National Institutes of Health [M01-RR-00037, M01-RR-00425]
FX Supported by GlaxoSmithKline (JKA, AM, CW, RSS), National Institutes of
Health Eunice Kennedy Shriver National Institute of Child Health and
Human Development Grant U54 HD 042454 (JKA), and National Institutes of
Health Grants M01-RR-00037 and M01-RR-00425.
NR 29
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD FEB
PY 2011
VL 185
IS 2
BP 626
EP 632
DI 10.1016/j.juro.2010.09.089
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 704JH
UT WOS:000286047500085
PM 21168874
ER
PT J
AU Riggio, S
AF Riggio, Silvana
TI Psychiatry for the Neurologist Preface
SO NEUROLOGIC CLINICS
LA English
DT Editorial Material
C1 [Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Riggio, Silvana] James J Peters VA Med Ctr, Bronx, NY USA.
RP Riggio, S (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Pl,Box 1230, New York, NY 10029 USA.
EM silvana.riggio@mssm.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8619
J9 NEUROL CLIN
JI Neurol. Clin.
PD FEB
PY 2011
VL 29
IS 1
BP XI
EP XII
DI 10.1016/j.ncl.2010.11.003
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 714BA
UT WOS:000286780700001
PM 21172566
ER
PT J
AU Riggio, S
AF Riggio, Silvana
TI Traumatic Brain Injury and Its Neurobehavioral Sequelae
SO NEUROLOGIC CLINICS
LA English
DT Article
DE Traumatic brain injury; Postconcussive syndrome; Neuropsychiatric
disorders; Frontal lobe seizures
ID POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; CHRONIC PAIN;
PSYCHIATRIC-DISORDERS; SYMPTOMS; FATIGUE; ASSOCIATION; PREVALENCE;
CONCUSSION; DISABILITY
AB The neurobehavioral sequelae of TBI consist of a spectrum of somatic, neurologic, and psychiatric symptoms. The challenge for clinicians lies in understanding the interface of the various symptoms and how they interrelate with other entities. Specifically, the challenge is differentiating post-TBI-related symptoms from preexisting or de novo psychiatric, neurologic, and/or systemic disorders. A comprehensive evaluation and a multidisciplinary approach to evaluating patients are essential to be able to develop the differential diagnosis needed to design a management plan that maximizes recovery.
C1 [Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Riggio, Silvana] James J Peters VA Med Ctr, Bronx, NY USA.
RP Riggio, S (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
EM silvana.riggio@mssm.edu
NR 46
TC 14
Z9 15
U1 1
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8619
J9 NEUROL CLIN
JI Neurol. Clin.
PD FEB
PY 2011
VL 29
IS 1
BP 35
EP +
DI 10.1016/j.ncl.2010.10.008
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 714BA
UT WOS:000286780700004
PM 21172569
ER
PT J
AU Filley, CM
AF Filley, Christopher M.
TI White Matter: Beyond Focal Disconnection
SO NEUROLOGIC CLINICS
LA English
DT Article
DE Disconnection; Neural networks; Diffusion tensor imaging; White matter
dementia; Depression; Schizophrenia
ID CENTRAL-NERVOUS-SYSTEM; CHRONIC TOLUENE ABUSE; MULTIPLE-SCLEROSIS;
METACHROMATIC LEUKODYSTROPHY; DISCONNEXION SYNDROMES;
PSYCHIATRIC-DISORDERS; COGNITIVE DYSFUNCTION; BEHAVIORAL NEUROLOGY;
HUNTINGTONS-DISEASE; BIPOLAR DISORDER
AB The complex phenomenology of white matter dementia and many neuropsychiatric disorders implies that they originate from involvement of distributed neural networks, and white matter neuropathology is increasingly implicated in the pathogenesis of these network disconnection syndromes. White matter disorders produce functional asynchrony of interdependent cerebral regions subserving normal cognitive and emotional functions. Accumulating evidence suggests that white matter dementia primarily reflects disturbed frontal systems connectivity, whereas disruption of frontal and temporal lobe systems is implicated in the pathogenesis of neuropsychiatric disorders. Continued study of normal and abnormal white matter promises to help resolve challenging problems in behavioral neurology and neuropsychiatry.
C1 [Filley, Christopher M.] Univ Colorado, Sch Med, Behav Neurol Sect, Aurora, CO 80045 USA.
[Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Filley, CM (reprint author), Univ Colorado, Sch Med, Behav Neurol Sect, 12631 E 17th Ave,MS B185, Aurora, CO 80045 USA.
EM christopher.filley@ucdenver.edu
NR 103
TC 12
Z9 12
U1 1
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8619
J9 NEUROL CLIN
JI Neurol. Clin.
PD FEB
PY 2011
VL 29
IS 1
BP 81
EP +
DI 10.1016/j.ncl.2010.10.003
PG 18
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 714BA
UT WOS:000286780700007
PM 21172572
ER
PT J
AU Snyder, CW
Vandromme, MJ
Tyra, SL
Porterfield, JR
Clements, RH
Hawn, MT
AF Snyder, Christopher W.
Vandromme, Marianne J.
Tyra, Sharon L.
Porterfield, John R., Jr.
Clements, Ronald H.
Hawn, Mary T.
TI Effects of Virtual Reality Simulator Training Method and Observational
Learning on Surgical Performance
SO WORLD JOURNAL OF SURGERY
LA English
DT Article
ID OPERATING-ROOM; SKILLS; SURGERY; INSTRUCTION; PRINCIPLES; EDUCATION;
PARADIGM; FEEDBACK; FUTURE; EXPERT
AB Virtual reality (VR) simulators and Web-based instructional videos are valuable supplemental training resources in surgical programs, but it is unclear how to optimally integrate them into minimally invasive surgical training.
Medical students were randomized to proficiency-based training on VR laparoscopy and endoscopy simulators by two different methods: proctored training (automated simulator feedback plus human expert feedback) or independent training (simulator feedback alone). After achieving simulator proficiency, trainees performed a series of laparoscopic and endoscopic tasks in a live porcine model. Prior to their entry into the animal lab, all trainees watched an instructional video of the procedure and were randomly assigned to either observe or not observe the actual procedure before performing it themselves. The joint effects of VR training method and procedure observation on time to successful task completion were evaluated with Cox regression models.
Thirty-two students (16 proctored, 16 independent) completed VR training. Cox regression modeling with adjustment for relevant covariates demonstrated no significant difference in the likelihood of successful task completion for independent versus proctored training [Hazard Ratio (HR) 1.28; 95% Confidence Interval (CI) 0.96-1.72; p = 0.09]. Trainees who observed the actual procedure were more likely to be successful than those who watched the instructional video alone (HR 1.47; 95% CI 1.09-1.98; p = 0.01).
Proctored VR training is no more effective than independent training with respect to surgical performance. Therefore, time-consuming human expert feedback during VR training may be unnecessary. Instructional videos, while useful, may not be adequate substitutes for actual observation when trainees are learning minimally invasive surgical procedures.
C1 [Tyra, Sharon L.; Porterfield, John R., Jr.; Clements, Ronald H.; Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA.
[Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA.
RP Hawn, MT (reprint author), Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA.
EM mhawn@uab.edu
FU Olympus America Inc.
FX The authors acknowledge Joshua L. Argo and Wai M. A. Yeung for their
assistance with data acquisition. They are also grateful to Olympus of
America and Covidien for equipment donation and technical assistance.
The study received no external funding, although Christopher W. Snyder
received salary support under an educational grant from Olympus America
Inc.
NR 32
TC 19
Z9 20
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2313
J9 WORLD J SURG
JI World J.Surg.
PD FEB
PY 2011
VL 35
IS 2
BP 245
EP 252
DI 10.1007/s00268-010-0861-1
PG 8
WC Surgery
SC Surgery
GA 703RG
UT WOS:000285998400001
PM 21086125
ER
PT J
AU Horberg, MA
Aberg, JA
Cheever, LW
Renner, P
Kaleba, EO
Asch, SM
AF Horberg, Michael A.
Aberg, Judith A.
Cheever, Laura W.
Renner, Philip
Kaleba, Erin O'Brien
Asch, Steven M.
TI Development of National and Multiagency HIV Care Quality Measures
Response
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Horberg, Michael A.] Kaiser Permanente, HIV Interreg Initiat, Oakland, CA 94612 USA.
[Aberg, Judith A.] NYU, Sch Med, Dept Med, New York, NY USA.
[Cheever, Laura W.] HIV AIDS Bur, Hlth Resources & Serv Adm, Rockville, MD USA.
[Renner, Philip] Natl Comm Qual Assurance, Washington, DC USA.
[Kaleba, Erin O'Brien] Alliance Chicago Community Hlth Serv, Chicago, IL USA.
[Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, RAND Corp, Los Angeles, CA 90095 USA.
RP Horberg, MA (reprint author), Kaiser Permanente, HIV Interreg Initiat, 2000 Broadway, Oakland, CA 94612 USA.
EM michael.horberg@kp.org
NR 2
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB
PY 2011
VL 52
IS 4
DI 10.1093/cid/ciq181
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 712PD
UT WOS:000286677800024
ER
PT J
AU Lee, BY
McGlone, SM
Bailey, RR
Wettstein, ZS
Umscheid, CA
Muder, RR
AF Lee, Bruce Y.
McGlone, Sarah M.
Bailey, Rachel R.
Wettstein, Zachary S.
Umscheid, Craig A.
Muder, Robert R.
TI Economic Impact of Outbreaks of Norovirus Infection in Hospitals
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Editorial Material
ID NORWALK VIRUS; GASTROENTERITIS; VOLUNTEERS
C1 [Lee, Bruce Y.] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Pittsburgh, PA 15213 USA.
[Lee, Bruce Y.; McGlone, Sarah M.; Bailey, Rachel R.; Wettstein, Zachary S.] Univ Pittsburgh, Sch Med, Publ Hlth Computat & Operat Res, Pittsburgh, PA USA.
[Lee, Bruce Y.; McGlone, Sarah M.; Bailey, Rachel R.; Wettstein, Zachary S.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA USA.
[Lee, Bruce Y.; McGlone, Sarah M.; Bailey, Rachel R.; Wettstein, Zachary S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Umscheid, Craig A.] Univ Penn, Ctr Evidence Based Practice, Philadelphia, PA 19104 USA.
[Muder, Robert R.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
RP Lee, BY (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA.
EM BYL1@pitt.edu
OI Slayton, Rachel/0000-0003-4699-8040
FU NIGMS NIH HHS [U54 GM088491, 1U54GM088491-0109]; NLM NIH HHS [R01
LM009132, 5R01LM009132-02]
NR 10
TC 14
Z9 14
U1 0
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD FEB
PY 2011
VL 32
IS 2
BP 191
EP 193
DI 10.1086/657910
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 709QT
UT WOS:000286457200016
PM 21460478
ER
PT J
AU Bhatia, V
Dean, P
Iqbal, F
Mundkur, M
Heo, J
Iskandrian, AE
Hage, FG
AF Bhatia, V
Dean, P.
Iqbal, F.
Mundkur, M.
Heo, J.
Iskandrian, A. E.
Hage, F. G.
TI A BLUNTED HEART RATE RESPONSE TO ADENOSINE IS AN INDEPENDENT PROGNOSTIC
INDICATOR IN PATIENTS WITH DIABETES MELLITUS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Bhatia, V; Dean, P.; Iqbal, F.; Mundkur, M.; Heo, J.; Iskandrian, A. E.; Hage, F. G.] Univ Alabama, Birmingham, AL USA.
[Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 117
BP 405
EP 405
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500128
ER
PT J
AU Bains, SS
Egede, LE
AF Bains, S. S.
Egede, L. E.
TI ASSOCIATION OF HEALTH LITERACY WITH CAM USE IN ADULT PRIMARY CARE
PATIENTS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Bains, S. S.; Egede, L. E.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Bains, S. S.; Egede, L. E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 171
BP 420
EP 420
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500182
ER
PT J
AU Dean, PJ
Bhatia, V
Iqbal, F
McLarry, J
Heo, J
Iskandrian, AE
Hage, FG
AF Dean, P. J.
Bhatia, V
Iqbal, F.
McLarry, J.
Heo, J.
Iskandrian, A. E.
Hage, F. G.
TI A BLUNTED HEART RATE RESPONSE TO ADENOSINE IS AN INDEPENDENT PREDICTOR
OF MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Dean, P. J.; Bhatia, V; Iqbal, F.; McLarry, J.; Heo, J.; Iskandrian, A. E.; Hage, F. G.] Univ Alabama, Birmingham, AL USA.
[Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 358
BP 472
EP 472
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500368
ER
PT J
AU Hage, FG
Pierce, C
Zhang, W
Xing, D
Chen, Y
McCrory, MA
Oparil, S
Szalai, AJ
AF Hage, F. G.
Pierce, C.
Zhang, W.
Xing, D.
Chen, Y.
McCrory, M. A.
Oparil, S.
Szalai, A. J.
TI ALISKIREN INHIBITS THE VASCULAR INJURY RESPONSE ATTRIBUTABLE TO
C-REACTIVE PROTEIN
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Hage, F. G.; Pierce, C.; Zhang, W.; Xing, D.; Chen, Y.; McCrory, M. A.; Oparil, S.; Szalai, A. J.] Univ Alabama, Birmingham, AL USA.
[Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 385
BP 480
EP 480
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500395
ER
PT J
AU Kertesz, S
Steward, J
Johnson, K
Borden, A
Young, J
Stringfellow, E
Holt, C
Pollio, D
AF Kertesz, S.
Steward, J.
Johnson, K.
Borden, A.
Young, J.
Stringfellow, E.
Holt, C.
Pollio, D.
TI CROSSING THE PRIMARY CARE QUALITY CHASM FOR HOMELESS PATIENTS:
UNDERSTANDING THE PERSPECTIVES OF PATIENTS AND THEIR PROVIDERS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Kertesz, S.; Steward, J.; Johnson, K.; Borden, A.; Young, J.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Stringfellow, E.] Boston Hlth Care, Homeless Program, Boston, MA USA.
[Pollio, D.] Univ Alabama, Tuscaloosa, AL USA.
[Holt, C.] Univ Maryland, Baltimore, MD 21201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 575
BP 534
EP 534
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500584
ER
PT J
AU Huff, NG
Castiglioni, A
Snyder, E
Estrada, C
Kim, Y
Kertesz, S
Schumacher, J
AF Huff, N. G.
Castiglioni, A.
Snyder, E.
Estrada, C.
Kim, Y.
Kertesz, S.
Schumacher, J.
TI PRESCRIBING OPIATES FOR CHRONIC PAIN - EXPERIENCE MAY NOT ASSURE
ADEQUATE KNOWLEDGE
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Huff, N. G.; Castiglioni, A.; Snyder, E.; Estrada, C.; Kim, Y.; Kertesz, S.; Schumacher, J.] Univ Alabama, Birmingham, AL USA.
[Castiglioni, A.; Snyder, E.; Estrada, C.; Kertesz, S.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 587
BP 537
EP 538
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500596
ER
PT J
AU Huff, NG
Roy, B
Estrada, C
Castiglioni, A
Centor, R
Willett, L
Cohen, S
AF Huff, N. G.
Roy, B.
Estrada, C.
Castiglioni, A.
Centor, R.
Willett, L.
Cohen, S.
TI NOMINAL GROUP TECHNIQUE TO IDENTIFY ATTRIBUTES OF TOP ATTENDING
PHYSICIANS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Huff, N. G.; Roy, B.; Estrada, C.; Castiglioni, A.; Centor, R.; Willett, L.; Cohen, S.] Univ Alabama, Birmingham, AL USA.
[Estrada, C.; Castiglioni, A.; Centor, R.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 586
BP 537
EP 537
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500595
ER
PT J
AU Tarbox, LE
Wagner, B
AF Tarbox, L. E.
Wagner, B.
TI EFFECTS OF GADOLINIUM-BASED MRI CONTRAST ON ORGAN FIBROSIS IN PARTIALLY
NEPHRECTOMIZED RATS
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Southern Regional Meeting
CY FEB 17-19, 2011
CL New Orleans, LA
C1 [Tarbox, L. E.; Wagner, B.] UTHSCSA, San Antonio, TX USA.
[Wagner, B.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD FEB
PY 2011
VL 59
IS 2
MA 599
BP 541
EP 541
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 709SK
UT WOS:000286461500608
ER
PT J
AU Yu, J
Xu, YM
Khaoustov, V
Yoffe, B
AF Yu, Jing
Xu, Yumin
Khaoustov, Vladimir
Yoffe, Boris
TI Identification of components of grape powder with anti-apoptotic effects
SO TOXICOLOGY AND INDUSTRIAL HEALTH
LA English
DT Article
DE Freeze-dried grape powder; reactive oxygen species; phenolics;
anti-apoptosis
ID SEED PROANTHOCYANIDIN EXTRACT; PERMEABILITY TRANSITION; CELL-DEATH;
MITOCHONDRIA; ANTIOXIDANT; FLAVONOIDS; INDUCTION; (-)-EPICATECHIN;
ACTIVATION; MECHANISMS
AB This study is to investigate the mechanism underlying the anti-apoptotic effects of freeze-dried grape powder (FDGP) and identify the polyphenolic compounds involved. We examined apoptotic signaling pathways affected by FDGP and by its active components, including epicatechin, cyanidin, quercetin, and resveratrol, in human Huh7 hepatoma cells by assaying cell viability assays, the activities of caspase 3 and caspase 7, and the expression of endoplasmic reticulum stress-associated proteins. FDGP dramatically decreased taurodeoxycholic acid (TDCA)-induced production of reactive oxygen species (ROS). Assessment of individual active components revealed that at concentrations corresponding to 300 mu g/mL FDGP, only quercetin demonstrated cytoprotective effects against mitochondrial-mediated apoptosis. In contrast, increased concentrations of other individual polyphenolic compounds were required to produce measurable cytoprotective effect. Only combinations of all four polyphenolic compounds (epicatechin, cyanidin, quercetin, and resveratrol) restored a degree of the antiapoptotic effects seen with FDGP. The pretreatment of FDGP at 30 mu g/mL concentration could reverse the thapsigargin-induced effects on the expression of endoplasmic reticulum stress-associated proteins. In conclusion, FDGP reduced oxidative stress, endoplasmic reticulum stress, and apoptosis. The mechanisms involved in the anti-apoptotic effects of FDGP included reduced generation of ROS, and reduced processing of certain caspases. We demonstrated that quercetin, epicatechin, and cyanidin are active compounds within FDGP that attenuate apoptosis. These findings contribute to our understanding of the molecular mechanisms of antiapoptotic and anti-oxidant effects of grape and are expected to assist in developing clinical protocols to treat a variety of stress-mediated conditions.
C1 [Yu, Jing] Guangxi Tradit Chinese Med Univ, Dept Hepatol, Nanning 530023, Guangxi, Peoples R China.
[Xu, Yumin] Shanghai Jiao Tong Univ, Dept Infect Dis, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China.
[Khaoustov, Vladimir; Yoffe, Boris] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Yu, J (reprint author), Guangxi Tradit Chinese Med Univ, Dept Hepatol, 2 Ruan Hu St, Nanning 530023, Guangxi, Peoples R China.
EM jingy1237@126.com
FU Guangxi Scholarship; Texas Medical Center, Houston
FX This research was supported by the Guangxi Scholarship Fund and Dr Boris
Yoffe's Lab at the Texas Medical Center, Houston.
NR 34
TC 6
Z9 6
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-2337
J9 TOXICOL IND HEALTH
JI Toxicol. Ind. Health
PD FEB
PY 2011
VL 27
IS 1
BP 19
EP 28
DI 10.1177/0748233710380220
PG 10
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA 706FX
UT WOS:000286204500003
ER
PT J
AU Gheorghiade, M
Pang, PS
O'Connor, CM
Prasad, K
McMurray, J
Teerlink, JR
Fiuzat, M
Sabbah, H
Komajda, M
AF Gheorghiade, Mihai
Pang, Peter S.
O'Connor, Christopher M.
Prasad, Krishna
McMurray, John
Teerlink, John R.
Fiuzat, Mona
Sabbah, Hani
Komajda, Michel
TI Clinical development of pharmacologic agents for acute heart failure
syndromes: A proposal for a mechanistic translational phase
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; A(1) RECEPTOR ANTAGONIST;
COLLEGE-OF-CARDIOLOGY; DOUBLE-BLIND; RENAL IMPAIRMENT; INTRAVENOUS
LEVOSIMENDAN; VASOPRESSIN ANTAGONIST; SYSTOLIC DYSFUNCTION; ORAL
TOLVAPTAN; TEZOSENTAN
AB Hospitalization for acute heart failure syndromes (AHFS) predicts a poor prognosis, with postdischarge mortality and rehospitalization rates reaching 45% within 60 to 90 days. Despite the use of evidence-based therapies and adherence to national process measures, these event rates have largely remained the same over the past decade. Given the current and growing burden of AHFS, there exists a substantial unmet need for novel therapies that improve outcomes. However, attempts to improve symptoms and/or reduce postdischarge events have failed to produce positive results, either because of safety and/or efficacy. These negative results may be related to the drug itself, the protocol in terms of patient selection and/or end points, and/or the trial execution. Although experts may not agree on the exact reasons to explain the lack of success to date of phase III trials in AHFS, there is agreement that clinical benefits observed in phase II trials were not reproduced in phase III trials. A different approach may be needed. In November of 2009, a meeting was held at the Food and Drug Administration with the primary purpose of identifying the reasons why benefits observed during phase II did not translate into benefits in phase III to improve future trial design. Although multiple domains of trial design were discussed, the participants identified a lack of in-depth understanding of novel molecules before pivotal trials in AHFS as a possible contributor to the disappointing results of recent large trials. In this brief report, we outline the T1 or translational phase of research for AHFS clinical development as an important first step toward greater success in AHFS clinical trials. (Am Heart J 2011;161:224-32.)
C1 [Gheorghiade, Mihai; Pang, Peter S.] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
[Pang, Peter S.] Northwestern Univ, Feinberg Sch Med, Dept Emergency Med, Chicago, IL 60611 USA.
[O'Connor, Christopher M.; Fiuzat, Mona] Duke Univ, Med Ctr, Durham, NC USA.
[Prasad, Krishna] MHRA St Thomas Hosp, London, England.
[McMurray, John] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland.
[McMurray, John] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Sabbah, Hani] Wayne State Univ, Div Cardiol, Henry Ford Hosp, Detroit, MI USA.
[Komajda, Michel] Hop La Pitie Salpetriere, Dept Cardiol, Paris, France.
RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, Ctr Cardiovasc Innovat, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA.
EM m-gheorghiade@northwestern.edu
RI Teerlink, John/D-2986-2012
OI mcmurray, john/0000-0002-6317-3975
NR 45
TC 27
Z9 28
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD FEB
PY 2011
VL 161
IS 2
BP 224
EP 232
DI 10.1016/j.ahj.2010.10.023
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 719FX
UT WOS:000287188000004
PM 21315202
ER
PT J
AU Gellad, WF
Grenard, JL
Marcum, ZA
AF Gellad, Walid F.
Grenard, Jerry L.
Marcum, Zachary A.
TI A Systematic Review of Barriers to Medication Adherence in the Elderly:
Looking Beyond Cost and Regimen Complexity
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Review
DE barriers; elderly; medication adherence; systematic review
ID PRIMARY-CARE PATIENTS; OLDER-ADULTS; LONGITUDINAL COHORT; PART-D;
HEALTH; NONADHERENCE; PREDICTORS; SENIORS; ASSOCIATIONS; METAANALYSIS
AB Background: Medication nonadherence is a common problem among the elderly.
Objective: To conduct a systematic review of the published literature describing potential nonfinancial barriers to medication adherence among the elderly.
Methods: The PubMed and PsychINFO databases were searched for articles published in English between January 1998 and January 2010 that (1) described "predictors," "facilitators," or "determinants" of medication adherence or that (2) examined the "relationship" between a specific barrier and adherence for elderly patients (ie, years of age) in the United States. A manual search of the reference lists of identified articles and the authors' files and recent review articles was conducted. The search included articles that (1) reviewed specific barriers to medication adherence and did not solely describe nonmodifiable predictors of adherence (eg, demographics, marital status), (2) were not interventions designed to address adherence, (3) defined adherence or compliance and specified its method of measurement, and (4) involved US participants only. Nonsystematic reviews were excluded, as were studies that focused specifically on people who were homeless or substance abusers, or patients with psychotic disorders, tuberculosis, or HIV infection, because of the unique circumstances that surround medication adherence for each of these populations.
Results: Nine studies met inclusion criteria for this review. Four studies used pharmacy records or claims data to assess adherence, 2 studies used pill count or electronic monitoring, and 3 studies used other methods to assess adherence. Substantial heterogeneity existed among the populations studied as well as among the measures of adherence, barriers addressed, and significant findings. Some potential barriers (ie, factors associated with nonadherence) were identified from the studies, including patient-related factors such as disease-related knowledge, health literacy, and cognitive function; drug-related factors such as adverse effects and polypharmacy; and other factors including the patient-provider relationship and various logistical barriers to obtaining medications. None of the reviewed studies examined primary nonadherence or nonpersistence.
Conclusion: Medication nonadherence in the elderly is not well described in the literature, despite being a major cause of morbidity, and thus it is difficult to draw a systematic conclusion on potential barriers based on the current literature. Future research should focus on standardizing medication adherence measurements among the elderly to gain a better understanding of this important issue. (Am J Geriatr Pharmacother. 2011;9:11-23) Published by Elsevier HS Journals, Inc.
C1 [Gellad, Walid F.] RAND Hlth, Pittsburgh, PA 15213 USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med Gen Med, Pittsburgh, PA USA.
[Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Grenard, Jerry L.] Claremont Grad Univ, Sch Community & Global Hlth, San Dimas, CA USA.
[Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA USA.
RP Gellad, WF (reprint author), RAND Hlth, 4570 5th Ave,Suite 600, Pittsburgh, PA 15213 USA.
EM wgellad@rand.org
FU Agency for Healthcare Research and Quality [T32 HS00046-14]; National
Institute of Aging [T32 AG021885]; Mehlman Vogel Castagnetti
FX This study was supported by an Agency for Healthcare Research and
Quality grant (T32 HS00046-14), a National Institute of Aging Grant (T32
AG021885), and Mehlman Vogel Castagnetti. Dr. Gellad is additionally
supported by a VA HSR&D Career Development Award. The authors would like
to thank Joseph T. Hanlon, PharmD, MS, for his assistance with earlier
drafts of this manuscript.
NR 32
TC 129
Z9 134
U1 7
U2 43
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD FEB
PY 2011
VL 9
IS 1
BP 11
EP 23
DI 10.1016/j.amjopharm.2011.02.004
PG 13
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 754PA
UT WOS:000289866600002
PM 21459305
ER
PT J
AU Emanuel, JE
Lopez, OL
Houck, PR
Becker, JT
Weamer, EA
DeMichele-Sweet, MAA
Kuller, L
Sweet, RA
AF Emanuel, James E.
Lopez, Oscar L.
Houck, Patricia R.
Becker, James T.
Weamer, Elise A.
DeMichele-Sweet, Mary Ann A.
Kuller, Lewis
Sweet, Robert A.
TI Trajectory of Cognitive Decline as a Predictor of Psychosis in Early
Alzheimer Disease in the Cardiovascular Health Study
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT 63rd Annual Convention of the Society-of-Biological-Psychiatry
CY MAY 01-03, 2008
CL Washington, DC
SP Soc Biol Psychiat
DE Alzheimer disease; MCI (mild cognitive impairment); psychosis
ID INCREASED FAMILIAL RISK; NEUROPSYCHIATRIC INVENTORY; IMPAIRMENT;
SYMPTOMS; DEMENTIA; HALLUCINATIONS; DELUSIONS; PHENOTYPE
AB Objective: To compare the trajectories of cognitive decline between groups with, and without, the later development of psychotic symptoms during Alzheimer disease (AD) or mild cognitive impairment (MCI). Design: The authors examined cognitive function in a new analysis of an existing data set, the Cardiovascular Health Study, an epidemiologic, longitudinal follow-up study. Our analyses examined 9 years of follow-up data. Setting: Community. Participants: The authors examined subjects who were without dementia at study entry, received a diagnosis of AD or MCI during follow-up, and had been rated on the Neuropsychiatric Inventory for the presence of psychosis; 362 participants for the modified Mini-Mental State Examination (3MS) analysis and 350 participants for the digit symbol substitution test (DSST) analysis had sufficient follow-up data and apolipoprotein-epsilon (APOE) genotyping. Measurements: The 3MS and DSST were administered annually and analyzed using mixed-effects models including APOE4 status. Results: Mean 3MS and DSST scores did not differ between AD with psychosis (AD + P) and without psychosis groups at baseline. The 3MS and DSST scores decreased more rapidly in subjects who ultimately developed psychosis. Conclusions: Individuals who ultimately develop psychosis have more rapid cognitive deterioration during the earliest phases of AD than individuals with AD not developing psychosis. The genetic and other neurobiologic factors leading to the expression of AD + P may exert their effects by acceleration of the neurodegenerative process. (Am J Geriatr Psychiatry 2011; 19: 160-168)
C1 [Emanuel, James E.; Lopez, Oscar L.; Houck, Patricia R.; Becker, James T.; Weamer, Elise A.; DeMichele-Sweet, Mary Ann A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Lopez, Oscar L.; Becker, James T.; Weamer, Elise A.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA USA.
[Kuller, Lewis] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), 3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
OI Becker, James/0000-0003-4425-4726
FU NHLBI NIH HHS [N01 HC055222, N01 HC-55222, N01 HC015103, N01 HC035129,
N01 HC045133, N01 HC075150, N01 HC085079, N01 HC085080, N01 HC085081,
N01 HC085082, N01 HC085083, N01 HC085084, N01 HC085085, N01 HC085086,
N01-HC-75150, N01-HC-85079, N01-HC-85086, N01HC55222, N01HC75150,
N01HC85079, N01HC85086, U01 HL080295, U01 HL080295-04]; NIA NIH HHS
[AG027224, AG05133, AG15928, P50 AG005133, P50 AG005133-210020, R01
AG015928, R01 AG015928-02, R01 AG020098, R01 AG027224, R01 AG027224-04]
NR 29
TC 22
Z9 22
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD FEB
PY 2011
VL 19
IS 2
BP 160
EP 168
DI 10.1097/JGP.0b013e3181e446c8
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 709PU
UT WOS:000286453700008
PM 20808116
ER
PT J
AU Glasser, SP
Judd, S
Basile, J
Lackland, D
Halanych, J
Cushman, M
Prineas, R
Howard, V
Howard, G
AF Glasser, Stephen P.
Judd, Suzanne
Basile, Jan
Lackland, Dan
Halanych, Jewell
Cushman, Mary
Prineas, Ronald
Howard, Virginia
Howard, George
TI Prehypertension, Racial Prevalence and Its Association With Risk
Factors: Analysis of the REasons for Geographic And Racial Differences
in Stroke (REGARDS) Study
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE blood pressure; cardiovascular disease; hypertension; prehypertension;
risk factors
ID HIGH BLOOD-PRESSURE; JOINT NATIONAL COMMITTEE; 7TH REPORT; HYPERTENSION;
PROGRESSION; PREVENTION; PREDICTORS; ADULTS; HEALTH
AB BACKGROUND
There are few available data on the epidemiology of prehypertension (preHTN). To determine racial, clinical, and demographic differences in the prevalence of preHTN and its cross-sectional association with vascular risk factors.
METHODS
Cross-sectional analysis of 5,553 prehypertensives, 20,351 hypertensive's, and 4,246 nonhypertensive participants (age 45), from a population-based national cohort study (REasons for Geographic And Racial Differences in Stroke (REGARDS) total population 30,239, of whom 30,150 had adequate blood pressure (BP) measurements) enrolled from January 2003-October 2007 with oversampling from the southeastern stroke belt, and black individuals. Baseline data were collected using a combination of telephone interview and in-home evaluation. preHTN was defined according to The Seventh Report of the Joint national Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines.
RESULTS
The prevalence of preHTN was associated with age and black race (62.9% in blacks compared to 54.1% in whites). A higher prevalence of preHTN was observed in obese individuals, self-reported heart disease; and, those with elevated high-sensitivity C reactive protein (hsCRP), diabetes, and microalbuminuria compared to those without these factors. Heavy alcohol consumption in white participants was associated with increased odds of preHTN (odds ratio (OR) = 1.32) but was even greater in black participants (OR = 2.27).
CONCLUSION
The prevalence of preHTN increased by age and African American race. In addition, a higher prevalence of preHTN was observed with elevated hsCRP, diabetes, microalbuminuria, and those with heavy alcohol consumption compared to those without these factors.
C1 [Glasser, Stephen P.; Halanych, Jewell] Univ Alabama, Dept Internal Med, Div Prevent Med, Birmingham, AL USA.
[Judd, Suzanne; Howard, Virginia; Howard, George] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA.
[Basile, Jan] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Cushman, Mary] Univ Vermont, Burlington, VT USA.
[Prineas, Ronald] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA.
RP Glasser, SP (reprint author), Univ Alabama, Dept Internal Med, Div Prevent Med, Birmingham, AL USA.
EM sglasser@uab.edu
OI Glasser, Stephen/0000-0001-9620-6406
FU National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Department of Health and Human Services [U01
NS041588]; National Institute of Neurological Disorders and Stroke,
National Institutes of Health
FX This research project is supported by a cooperative agreement U01
NS041588 from the National Institute of Neurological Disorders and
Stroke, National Institutes of Health, Department of Health and Human
Services. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institute of Neurological Disorders and Stroke or the National
Institutes of Health. Representatives of the funding agency have been
involved in the review of the manuscript but not directly involved in
the collection, management, analysis or interpretation of the data. The
authors acknowledge the participating investigators and institutions for
their valuable contributions: The University of Alabama at Birmingham,
Birmingham, AL (Study PI, Statistical and Data Coordinating Center,
Survey Research Unit): G.H. DrPH, Leslie McClure PhD, V.H.PhD, Libby
Wagner MA, Virginia Wadley PhD, Rodney Go PhD, Monika Safford MD, Ella
Temple PhD, Margaret Stewart MSPH, J.David Rhodes BSN; University of
Vermont (Central Laboratory): M.C. MD; Wake Forest University (ECG
Reading Center): R.P. MD, PhD; Alabama Neurological Institute (Stroke
Validation Center, Medical Monitoring):Camilo Gomez MD, Susana Bowling
MD; University of Arkansas for Medical Sciences (Survey Methodology):
LeaVonne Pulley PhD; University of Cincinnati (Clinical
Neuroepidemiology): Brett Kissela MD, Dawn Kleindorfer MD; Examination
Management Services, Incorporated (In-Person Visits): Andra Graham;
Medical University of South Carolina (Migration Analysis Center): D.L.
DrPH; Indiana University School of Medicine (Neuropsychology Center):
Frederick Unverzagt PhD; National Institute of Neurological Disorders
and Stroke, National Institutes of Health (funding agency): Claudia Moy
PhD.
NR 20
TC 28
Z9 33
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0895-7061
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD FEB
PY 2011
VL 24
IS 2
BP 194
EP 199
DI 10.1038/ajh.2010.204
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 709PC
UT WOS:000286451600012
PM 20864944
ER
PT J
AU Plantinga, LC
Johansen, K
Crews, DC
Shahinian, VB
Robinson, BM
Saran, R
Burrows, NR
Williams, DE
Powe, NR
AF Plantinga, Laura C.
Johansen, Kirsten
Crews, Deidra C.
Shahinian, Vahakn B.
Robinson, Bruce M.
Saran, Rajiv
Burrows, Nilka Rios
Williams, Desmond E.
Powe, Neil R.
CA CDC CKD Surveillance Team
TI Association of CKD With Disability in the United States
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Chronic kidney disease; disability; activities of daily living;
limitations; employment; physical functioning; cognitive functioning
ID CHRONIC KIDNEY-DISEASE; CHRONIC RENAL-INSUFFICIENCY;
GLOMERULAR-FILTRATION-RATE; COGNITIVE FUNCTION; SERUM CREATININE;
NATIONAL-HEALTH; DIALYSIS; EQUATION; FRAILTY
AB Background: Little is known about disability in early-stage chronic kidney disease (CKD).
Study Design: Cross-sectional national survey (National Health and Nutrition Examination Survey 19992006).
Setting & Participants: Community-based survey of 16,011 noninstitutionalized US civilian adults (aged >20 years).
Predictor: CKD, categorized as no CKD, stages 1 and 2 (albuminuria and estimated glomerular filtration rate [eGFR] >= 60 mL/min/1.73 m(2)), and stages 3 and 4 (eGFR, 15-59 mL/min/1.73 m(2)).
Outcome: Self-reported disability, defined by limitations in working, walking, and cognition and difficulties in activities of daily living (ADL), instrumental ADL, leisure and social activities, lower-extremity mobility, and general physical activity.
Measurements: Albuminuria and eGFR assessed from urine and blood samples; disability, demographics, access to care, and comorbid conditions assessed using a standardized questionnaire.
Results: Age-adjusted prevalence of reported limitations generally was significantly greater with CKD: for example, difficulty with ADL was reported by 17.6%, 24.7%, and 23.9% of older (>= 65 years) and 6.8%, 11.9%, and 11.0% of younger (20-64 years) adults with no CKD, stages 1 and 2, and stages 3 and 4, respectively. CKD also was associated with greater reported limitations and difficulty in other activities after age adjustment, including instrumental ADL, leisure and social activities, lower-extremity mobility, and general physical activity. Other demographics, socioeconomic status, and access to care generally only slightly attenuated the observed associations, particularly in older individuals; adjustment for cardiovascular disease, arthritis, and cancer attenuated most associations such that statistical significance no longer was achieved.
Limitations: Inability to establish causality and possible unmeasured confounding.
Conclusion: CKD is associated with a higher prevalence of disability in the United States. Age and other comorbid conditions account for most, but not all, of this association. Am J Kidney Dis. 57(2):212-227. (C) 2011 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Plantinga, Laura C.; Powe, Neil R.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.
[Plantinga, Laura C.; Johansen, Kirsten; Powe, Neil R.] Univ Calif San Francisco, San Francisco, CA 94110 USA.
[Johansen, Kirsten] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Crews, Deidra C.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA.
[Shahinian, Vahakn B.; Saran, Rajiv] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
[Robinson, Bruce M.; Saran, Rajiv] Arbor Res Collaborat Hlth, Ann Arbor, MI USA.
[Burrows, Nilka Rios; Williams, Desmond E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
RP Plantinga, LC (reprint author), San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,Bldg 10,Fl 3, San Francisco, CA 94110 USA.
EM plantingal@medsfgh.ucsf.edu
FU Centers for Disease Control and Prevention (CDC) through the Association
of American Medical Colleges (AAMC) [U36/CCU319276, MM-0997-07/07,
MM-1143-10/10]; Robert Wood Johnson Foundation; National Institute of
Diabetes and Digestive and Kidney Diseases, Bethesda, MD [K24DK02643]
FX This project was supported under a cooperative agreement from the
Centers for Disease Control and Prevention (CDC) through the Association
of American Medical Colleges (AAMC), grant number U36/CCU319276, AAMC ID
numbers MM-0997-07/07 and MM-1143-10/10. Report contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the AAMC or CDC. Dr Crews is supported by the Harold
Amos Medical Faculty Development Program of the Robert Wood Johnson
Foundation. Dr Powe is partially supported by grant K24DK02643 from the
National Institute of Diabetes and Digestive and Kidney Diseases,
Bethesda, MD.
NR 26
TC 24
Z9 24
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD FEB
PY 2011
VL 57
IS 2
BP 212
EP 227
DI 10.1053/j.ajkd.2010.08.016
PG 16
WC Urology & Nephrology
SC Urology & Nephrology
GA 708OK
UT WOS:000286372700008
PM 21036441
ER
PT J
AU Keenan, RT
O'Brien, WR
Lee, KH
Crittenden, DB
Fisher, MC
Goldfarb, DS
Krasnokutsky, S
Oh, C
Pillinger, MH
AF Keenan, Robert T.
O'Brien, William R.
Lee, Kristen H.
Crittenden, Daria B.
Fisher, Mark C.
Goldfarb, David S.
Krasnokutsky, Svetlana
Oh, Cheongeun
Pillinger, Michael H.
TI Prevalence of Contraindications and Prescription of Pharmacologic
Therapies for Gout
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Comorbidity; Drug contraindication; Gout; Quality of care; Treatment
ID NUTRITION EXAMINATION SURVEY; METABOLIC SYNDROME; NATIONAL-HEALTH;
OLDER-ADULTS; HYPERURICEMIA; MANAGEMENT; CARE; ALLOPURINOL; POPULATION;
CLASSIFICATION
AB BACKGROUND: Patients with gout have comorbidities, but the impact of these comorbidities on treatment has not been studied.
METHODS: A total of 575 patients with gout were stratified according to certainty of diagnosis according to International Classification of Diseases, 9th Revision, Clinical Modification code alone (cohort I), American College of Radiology criteria (cohort II), and crystal diagnosis (cohort III). Comorbid conditions were defined according to International Classification of Diseases, 9th Revision, Clinical Modification codes, and stratified as either moderate or severe. Drug contraindications were defined as moderate or strong, based on Food and Drug Administration criteria and severity of disease.
RESULTS: The most common comorbidity was hypertension (prevalence 0.89). The presence of comorbidities resulted in a high frequency of contraindications to approved gout medications. More than 90% of patients had at least 1 contraindication to nonsteroidal anti-inflammatory drugs. Many patients demonstrated multiple contraindications to 1 or more gout medications. Frequently, patients were prescribed medications to which they harbored contraindications. The prevalence of patients prescribed colchicine despite having at least 1 strong contraindication was 30% (cohort I), 37% (cohort II), and 39.6% (cohort III).
CONCLUSION: Patients with gout typically harbor multiple comorbidities that result in contraindications to many of the medications available to treat gout. Frequently, despite contraindications to gout therapies, patients are frequently prescribed these medications. (C) 2011 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2011) 124, 155-163
C1 [Keenan, Robert T.; O'Brien, William R.; Lee, Kristen H.; Crittenden, Daria B.; Fisher, Mark C.; Krasnokutsky, Svetlana; Pillinger, Michael H.] New York Harbor Hlth Care Syst, Rheumatol Sect, US Dept Vet Affairs, New York, NY USA.
[Goldfarb, David S.] New York Harbor Hlth Care Syst, Nephrol Sect, US Dept Vet Affairs, New York, NY USA.
[Keenan, Robert T.; O'Brien, William R.; Lee, Kristen H.; Crittenden, Daria B.; Fisher, Mark C.; Krasnokutsky, Svetlana; Pillinger, Michael H.] NYU, Sch Med, Div Rheumatol, New York, NY USA.
[Goldfarb, David S.] NYU, Sch Med, Div Nephrol, New York, NY USA.
[Oh, Cheongeun] NYU, Sch Med, Div Biostat, New York, NY USA.
RP Keenan, RT (reprint author), Duke Univ, Med Ctr, Div Rheumatol, 200 Trent Dr,DUMC 3544, Durham, NC 27710 USA.
EM robert.keenan@duke.edu
OI Goldfarb, David/0000-0002-9215-1273; Pillinger,
Michael/0000-0003-3168-1542
FU National Institutes of Health [5T32AR007176]; Arthritis Foundation New
York Chapter
FX Drs Keenan and Fisher were supported by National Institutes of Health
T32 Training Grant 5T32AR007176. Dr Fisher also was the recipient of
Fellowship Training Award from the Arthritis Foundation New York
Chapter. No other external funding was used.
NR 39
TC 68
Z9 69
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD FEB
PY 2011
VL 124
IS 2
BP 155
EP 163
DI 10.1016/j.amjmed.2010.09.012
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 725PO
UT WOS:000287658100022
PM 21295195
ER
PT J
AU Garcia, AM
Dicianno, BE
AF Garcia, Angela M.
Dicianno, Brad E.
TI The Frequency of Lymphedema in an Adult Spina Bifida Population
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Meningomyelocele; Lymphedema; Hypertension; Obesity
ID PHYSICAL-ACTIVITY; HUMAN-DISEASE; YOUNG-ADULTS; LIFE-SPAN; BODY-FAT;
LYMPHANGIOGENESIS; OBESITY; ADOLESCENTS; PREVENTION; FITNESS
AB Garcia AM, Dicianno BE: The frequency of lymphedema in an adult spina bifida population. Am J Phys Med Rehabil 2011;90:89Y96.
Objective: In the United States, there are more than 100,000 people with spina bifida. There have been very few studies to date documenting the occurrence of lymphedema in the spina bifida population, despite a case series in 2001 that suggested that the occurrence may be higher than in the general population. Currently, approximately 1 million people have lymphedema in the United States. The purpose of this study was to document the occurrence of lymphedema and associated medical factors in a regional adult spina bifida population.
Design: A total of 240 electronic medical records from the Adult Spina Bifida Clinic from January 2005 to August 2008 were retrospectively reviewed. Subjects were divided into two groups based on the presence or absence of lymphedema. chi(2) analyses were used to compare lymphedema groups with respect to history of medical comorbidities and ethnicity. Fisher exact tests were used to compare groups with respect to mobility status and the presence of power wheelchair seat functions. Mann-Whitney U tests were used to compare groups with respect to age, anatomic lesion level, employment level, and income.
Results: Twenty-two (9.2%) patients had lymphedema. Mean T SD population age was 35.1 +/- 11.1 yrs. Lymphedema was associated with a history of trauma (P = 0.044), cellulitis (P < 0.001), cancer (P = 0.038), obesity (P < 0.001), wounds (P < 0.001), hypertension (P = 0.036), higher lesion level spina bifida (P = 0.049), and mobility status (P = 0.007). Hypertension and obesity were present in 38.3% and 37.5% of the total study population, respectively.
Conclusions: This is the first study to document the occurrence of lymphedema in a spina bifida patient population, which was almost 100 times higher than that in the general patient population. We also documented a high occurrence of hypertension and obesity in the total study population. These findings may help guide further prospective studies to more clearly delineate the risk factors for the development of lymphedema and to determine the appropriate therapies. Better screening, prevention and treatment algorithms are needed for hypertension and obesity in the spina bifida population.
C1 [Garcia, Angela M.; Dicianno, Brad E.] UPMC, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA.
[Dicianno, Brad E.] UPMC, Adult Outpatient Spina Bifida Clin, Pittsburgh, PA 15213 USA.
[Dicianno, Brad E.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Dicianno, Brad E.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.
RP Dicianno, BE (reprint author), UPMC, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.
OI Dicianno, Brad/0000-0003-0738-0192
FU UPMC Department of Physical Medicine and Rehabilitation
FX Funded by the UPMC Department of Physical Medicine and Rehabilitation.
Financial disclosure statements have been obtained, and no conflicts of
interest have been reported by the authors or by any individuals in
control of the content of this article.
NR 36
TC 6
Z9 6
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD FEB
PY 2011
VL 90
IS 2
BP 89
EP 96
DI 10.1097/PHM.0b013e318201753e
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 703QM
UT WOS:000285994800001
PM 21173682
ER
PT J
AU Wick, MJ
Buesing, EJ
Wehling, CA
Loomis, ZL
Cool, CD
Zamora, MR
Miller, YE
Colgan, SP
Hersh, LB
Voelkel, NF
Dempsey, EC
AF Wick, Marilee J.
Buesing, Erica J.
Wehling, Carol A.
Loomis, Zoe L.
Cool, Carlyne D.
Zamora, Martin R.
Miller, York E.
Colgan, Sean P.
Hersh, Louis B.
Voelkel, Norbert F.
Dempsey, Edward C.
TI Decreased Neprilysin and Pulmonary Vascular Remodeling in Chronic
Obstructive Pulmonary Disease
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE pulmonary hypertension; smooth muscle cell; smoking; oxidative stress;
protein degradation
ID SMOOTH-MUSCLE-CELLS; NEUTRAL ENDOPEPTIDASE; ARTERIAL-HYPERTENSION;
SEVERE EMPHYSEMA; OXIDATIVE STRESS; CIGARETTE-SMOKE; CHRONIC HYPOXIA;
LUNG-DISEASES; COPD; INACTIVATION
AB Rationale: Studies with genetically engineered mice showed that decreased expression of the transmembrane peptidase neprilysin (NEP) increases susceptibility to hypoxic pulmonary vascular remodeling and hypertension; in hypoxic wild-type mice, expression is decreased early in distal pulmonary arteries, where prominent vascular remodeling occurs. Therefore, in humans with smoke- and hypoxia-induced vascular remodeling, as in chronic obstructive pulmonary disease (COPD), pulmonary activity/expression of NEP may likewise be decreased.
Objectives: To test whether NEP activity and expression are reduced in COPD lungs and pulmonary arterial smooth muscle cells (SMCs) exposed to cigarette smoke extract or hypoxia and begin to investigate mechanisms involved.
Methods: Control and advanced COPD lung lysates (n = 13-14) were analyzed for NEP activity and protein and mRNA expression. As a control, dipeptidyl peptidase IV activity was analyzed. Lung sections were assessed for vascular remodeling and oxidant damage. Human pulmonary arterial SMCs were exposed to cigarette smoke extract, hypoxia, or H2O2, and incubated with antioxidants or lysosomal/proteasomal inhibitors.
Measurements and Main Results: COPD lungs demonstrated areas of vascular rarification, distal muscularization, and variable intimal and prominent medial/adventitial thickening. NEP activity was reduced by 76%; NEP protein expression was decreased in alveolar walls and distal vessels; mRNA expression was also decreased. In SMCs exposed to cigarette smoke extract, hypoxia, and H2O2, NEP activity and expression were also reduced. Reactive oxygen species inactivated NEP activity; NEP protein degradation appeared to be substantially induced.
Conclusions: Mechanisms responsible for reduced NEP activity and protein expression include oxidative reactions and protein degradation. Maintaining or increasing lung NEP may protect against pulmonary vascular remodeling in response to chronic smoke and hypoxia.
C1 [Wick, Marilee J.; Buesing, Erica J.; Loomis, Zoe L.; Dempsey, Edward C.] Univ Colorado Denver, Cardiovasc Pulm Res Lab, Aurora, CO 80045 USA.
[Wick, Marilee J.; Buesing, Erica J.; Loomis, Zoe L.; Zamora, Martin R.; Miller, York E.; Voelkel, Norbert F.; Dempsey, Edward C.] Univ Colorado Denver, Div Pulm Sci & Crit Care, Aurora, CO 80045 USA.
[Colgan, Sean P.] Univ Colorado Denver, Div Gastroenterol, Dept Med, Aurora, CO 80045 USA.
[Cool, Carlyne D.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA.
[Wick, Marilee J.; Wehling, Carol A.; Miller, York E.; Dempsey, Edward C.] Denver VA Med Ctr, Denver, CO USA.
[Cool, Carlyne D.] Natl Jewish Hlth, Dept Med, Denver, CO USA.
[Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lexington, KY USA.
RP Dempsey, EC (reprint author), Univ Colorado Denver, Cardiovasc Pulm Res Lab, Box B-133,12700 E 19th Ave, Aurora, CO 80045 USA.
EM edward.dempsey@ucdenver.edu
FU NIH/NHLBI [RO3 HL095439, RO1 HL078929, PPG HL14985]; National Cancer
Institute [CA58187]; Department of Veterans' Affairs; National
Institutes of Health (NIH) [NCI CA58187, NCI CA046934]; University of
Colorado Denver (UCD); DOM; State of CO; UCD Technology Transfer Office
(TTO); Alnylam Pharmaceuticals; Department of Veterans Affairs; Chemicon
Inter; Novartis
FX M.J.W. received more than $100,001 from the National Institutes of
Health (NIH) in sponsored grant support, $10,001-$50,000 from the
University of Colorado Denver (UCD) as a DOM small grant, and
$10,001-$50,000 from a State of CO and UCD Technology Transfer Office
(TTO) for a bioscience discovery grant. E.J.B. received $10,001-$50,000
from the NIH in sponsored grant support and $10,001-$50,000 from a State
of CO and UCD TTO for a bioscience discovery grant. C.A.W. does not have
a financial relationship with a commercial entity that has an interest
in the subject of this manuscript. Z.L.L. received $10,001-550,000 from
the NIH in sponsored grant support and $10,001-$50,000 from a State of
CO and UCD ITO for a bioscience discovery grant. C.D.C. received up to
$1,000 from UpToDate in royaltiesand more than $100,001 from the
NIH/NHLBI in sponsored grants for the Lung Tissue Research Consortium.
M.R.Z. received $10,001-$50,000 from CSL Behring in consultancy fees,
$10,001-$50,000 from CSL Behring, and $5,001-$10,000 from Roche in
lecture fees, and more than $100,001 from APT Pharmaceuticals and
$10,001-$50,000 from Alnylam Pharmaceuticals in industry-sponsored
grants for clinical trials. Y.E.M. received 51,001-55,000 in lecture
fees for an online CME course regarding lung cancer, received
550,001-$100,000 from Soma Logic, Inc. in industry-sponsored grants for
plasma-based lung cancer diagnostic tests, and holds a patent with UCD
for prostacyclin analogs for the prevention of cancer, and more than
$100,001 from the NIH in sponsored grants (NCI CA58187; NCI CA046934)
and more than $100,001 from the Department of Veterans Affairs in merit
review grants. S.P.C. does not have a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript. L.B.H. received more than $100,001 from Chemicon Inter, for
the sale of antisera. N.F.V. received $1,001-55,000 from Novartis in
lecture fees and a $100,000 grant from the NIH. E.C.D. received more
than $100,001 from the NIH and more than $100,001 from the State of CO
and UCD TTO for sponsored grants, and more than $100,001 in other
support from the Department of Veterans' Affairs. Supported by NIH/NHLBI
grants RO3 HL095439, RO1 HL078929, and PPG HL14985 (E.C.D.), National
Cancer Institute SPORE in Lung Cancer grant CA58187 (Y.E.M.), and the
Department of Veterans' Affairs.
NR 60
TC 13
Z9 14
U1 0
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2011
VL 183
IS 3
BP 330
EP 340
DI 10.1164/rccm.201002-0154OC
PG 11
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 720QD
UT WOS:000287294300009
PM 20813891
ER
PT J
AU Crothers, K
Huang, L
Goulet, JL
Goetz, MB
Brown, ST
Rodriguez-Barradas, MC
Oursler, KK
Rimland, D
Gibert, CL
Butt, AA
Justice, AC
AF Crothers, Kristina
Huang, Laurence
Goulet, Joseph L.
Goetz, Matthew Bidwell
Brown, Sheldon T.
Rodriguez-Barradas, Maria C.
Oursler, Krisann K.
Rimland, David
Gibert, Cynthia L.
Butt, Adeel A.
Justice, Amy C.
TI HIV Infection and Risk for Incident Pulmonary Diseases in the
Combination Antiretroviral Therapy Era
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE HIV; respiratory tract diseases; lung diseases; obstructive; pneumonia;
pneumonia; bacterial
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VETERANS AGING COHORT; BACTERIAL
PNEUMONIA; CIGARETTE-SMOKING; ADMINISTRATIVE DATA; NEGATIVE VETERANS;
MORTALITY-RATES; INDIVIDUALS; COMORBIDITY; PROGRESSION
AB Rationale In aging HIV-infected populations comorbid diseases are important determinants of morbidity and mortality. Pulmonary diseases have not been systematically assessed in the combination antiretroviral therapy (ART) era.
Objectives: To determine the incidence of pulmonary diseases in HIV-infected persons compared with HIV-uninfected persons.
Methods: We analyzed data from the Veterans Aging Cohort Study Virtual Cohort, consisting of 33,420 HIV-infected veterans and 66,840 age, sex, race and ethnicity, and site-matched HIV-uninfected veterans. Using Poisson regression, incidence rates and adjusted incidence rate ratios were calculated to determine the association of HIV with pulmonary disease. The Virtual Cohort was merged with the 1999 Veterans Large Health Survey to adjust for self-reported smoking in a nested sample (14%).
Measurements and Main Results: Incident chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, and pulmonary fibrosis, as well as pulmonary infections, were significantly more likely among HIV-infected patients compared with uninfected patients in adjusted analyses, although rates of asthma did not differ by HIV status. Bacterial pneumonia and chronic obstructive pulmonary disease were the two most common incident pulmonary diseases, whereas opportunistic pneumonias were less common. Absolute rates of most pulmonary diseases increased with age, although the relative differences between those with and without HIV infection were greatest in younger persons. Chronic obstructive pulmonary disease and asthma, as well as pulmonary infections, were less likely in those with lower HIV RNA levels and use of ART at baseline.
Conclusions: Pulmonary diseases among HIV-infected patients receiving care within the Veterans Affairs Healthcare System in the combination ART era reflect a substantial burden of non AIDS-defining and chronic conditions, many of which are associated with aging.
C1 [Crothers, Kristina] Univ Washington, Harborview Med Ctr, Sch Med, Div Pulm & Crit Care Med,Dept Med, Seattle, WA 98104 USA.
[Crothers, Kristina; Goulet, Joseph L.; Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, Dept Med, West Haven, CT USA.
[Huang, Laurence] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA.
[Huang, Laurence] Univ Calif San Francisco, Dept Med, Div HIV AIDS, San Francisco, CA USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Infect Dis Sect, Dept Med, Los Angeles, CA 90095 USA.
[Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Med Serv, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Oursler, Krisann K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Oursler, Krisann K.] Ctr Geriatr Res Educ & Clin, Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA.
[Rimland, David] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
[Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Gibert, Cynthia L.] George Washington Univ, Vet Affairs Med Ctr, Infect Dis Sect, Washington, DC 20052 USA.
[Gibert, Cynthia L.] George Washington Univ, Dept Med, Washington, DC 20052 USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Internal Med, Pittsburgh, PA USA.
[Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Justice, Amy C.] Yale Univ, Sch Publ Hlth, Dept Internal Med, New Haven, CT 06510 USA.
RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Div Pulm & Crit Care Med,Dept Med, 325 9th Ave,Box 359762, Seattle, WA 98104 USA.
EM crothk@uw.edu
OI Goetz, Matthew/0000-0003-4542-992X; Goulet, Joseph/0000-0002-0842-804X;
Crothers, Kristina/0000-0001-9702-0371
FU National Institutes of Health (NIH); Merck; Pfizer; Johns Hopkins
University; Valeant Pharma
FX K.C. received grant support from the National Institutes of Health (NIH)
(more than $100,001). L.H. received grant support from the NIH (more
than $100,001). J.L.G. does not have a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript. M.B.G. does not have a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript. S.T.B. received grant support (institutional) from Merck
($10,001-$50,000) and the NIH (more than $100,001). He owns stocks or
options of Pfizer ($5,001-$10,000). M.C.R.-B. received grant support
(institutional) from Pfizer ($1,001-$5,000). K.K.O. received lecture
fees from Johns Hopkins University (up to $1,000) and grant support from
the NIH ($50,001-$100,000 and $10,001-$50,000). D.R. received grant
support from Pfizer ($1,00145,000) and the CDC (more than $100,001).
C.L.G. does not have a financial relationship with a commercial entity
that has an interest in the subject of this manuscript. A.A.B. received
grant support from Valeant Pharma ($10,001-$50,000). A.C.J. does not
have a financial relationship with a commercial entity that has an
interest in the subject of this manuscript.
NR 58
TC 133
Z9 134
U1 1
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2011
VL 183
IS 3
BP 388
EP 395
DI 10.1164/rccm.201006-0836OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 720QD
UT WOS:000287294300016
PM 20851926
ER
PT J
AU Oates, JC
Halushka, PV
Hutchison, FN
Ruiz, P
Gilkeson, GS
AF Oates, Jim C.
Halushka, Perry V.
Hutchison, Florence N.
Ruiz, Philip
Gilkeson, Gary S.
TI Selective Cyclooxygenase-2 Inhibitor Suppresses Renal Thromboxane
Production but Not Proliferative Lesions in the MRL/lpr Murine Model of
Lupus Nephritis
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Lupus nephritis; Animal models; Cyclooxygenase-2; Nitric oxide;
Glomerular filtration rate; Thromboxane A(2)
ID SYNTHASE INHIBITOR; MICE; ERYTHEMATOSUS; INDOMETHACIN; ANTIBODIES;
THERAPY; RISK; GENE
AB Introduction: Proliferative lupus nephritis (LN) is marked by increased renal thromboxane (TX) A(2) production. Targeting the TXA(2) receptor or TXA(2) synthase effectively improves renal function in humans with LN and improves glomerular pathology in murine LN. This study was designed to address the following hypotheses: (1) TXA(2) production in the MRL/MpJ-Tnfrsf6(lpr)/J (MRL/lpr) model of proliferative LN is cyclooxygenase (COX)-2 dependent and (2) COX2 inhibitor therapy improves glomerular filtration rate (GFR), proteinuria, markers of innate immune response and glomerular pathology. Methods: Twenty female MRL/lpr and 20 BALB/cJ mice were divided into 2 equal treatment groups: (1) SC-236, a moderately selective COX2 inhibitor or (2) vehicle. After treatment from the age of 10 to 20 weeks, the effectiveness of inhibition of TXA(2) was determined by measuring urine TXB2. Response endpoints measured at the age of 20 weeks were renal function (GFR), proteinuria, urine nitrate + nitrite (NOx) and glomerular histopathology. Results: SC-236 therapy reduced surrogate markers of renal TXA(2) production during early, active glomerulonephritis. When this pharmacodynamic endpoint was reached, therapy improved GFR. Parallel reductions in markers of the innate immune response (urine NOx) during therapy were observed. However, the beneficial effect of SC-236 therapy on GFR was only transient, and renal histopathology was not improved in late disease. Conclusions: These data demonstrate that renal TXA(2) production is COX2 dependent in murine LN and suggest that NO production is directly or indirectly COX2 dependent. However, COX2 inhibitor therapy in this model failed to improve renal pathology, making COX2 inhibition a less attractive approach for treating LN.
C1 [Oates, Jim C.; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol, Dept Med, Charleston, SC 29425 USA.
[Oates, Jim C.; Hutchison, Florence N.; Gilkeson, Gary S.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA.
[Hutchison, Florence N.] Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA.
[Halushka, Perry V.] Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA.
[Ruiz, Philip] Univ Miami, Leonard M Miller Sch Med, Dept Surg, Miami, FL USA.
[Ruiz, Philip] Univ Miami, Leonard M Miller Sch Med, Dept Pathol, Miami, FL USA.
RP Oates, JC (reprint author), Med Univ S Carolina, Div Rheumatol, Dept Med, 96 Jonathan Lucas St,Suite 912,MSC 637, Charleston, SC 29425 USA.
EM oatesjc@musc.edu
FU Searle-Monsanto; National Institutes of Health, Bethesda, MD
[K08AR002193, R01AR045476]; Medical Research Service, Ralph H. Johnson
Veterans Affairs Medical Center, Charleston, SC
FX This study was supported by Searle-Monsanto; the National Institutes of
Health, Bethesda, MD, grants K08AR002193 and R01AR045476 (to JCO and
GSG); and Career Development, Research Enhancement Award Program, and
Merit Review grants from the Medical Research Service, Ralph H. Johnson
Veterans Affairs Medical Center, Charleston, SC.
NR 30
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD FEB
PY 2011
VL 341
IS 2
BP 101
EP 105
DI 10.1097/MAJ.0b013e3181f56d2c
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 714SD
UT WOS:000286828400005
PM 20924284
ER
PT J
AU Owens, DK
Qaseem, A
Chou, R
Shekelle, P
AF Owens, Douglas K.
Qaseem, Amir
Chou, Roger
Shekelle, Paul
CA Clinical Guidelines Comm Amer Coll
TI High-Value, Cost-Conscious Health Care: Concepts for Clinicians to
Evaluate the Benefits, Harms, and Costs of Medical Interventions
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID NONVALVULAR ATRIAL-FIBRILLATION; ADJUSTED LIFE-YEAR; LOW-BACK-PAIN;
PRACTICE GUIDELINES; AMERICAN-COLLEGE; GRADING QUALITY; UNITED-STATES;
ANTIRETROVIRAL THERAPY; DIAGNOSTIC-TESTS; HIV
AB Health care costs in the United States are increasing unsustainably, and further efforts to control costs are inevitable and essential. Efforts to control expenditures should focus on the value, in addition to the costs, of health care interventions. Whether an intervention provides high value depends on assessing whether its health benefits justify its costs. High-cost interventions may provide good value because they are highly beneficial; conversely, low-cost interventions may have little or no value if they provide little benefit.
Thus, the challenge becomes determining how to slow the rate of increase in costs while preserving high-value, high-quality care. A first step is to decrease or eliminate care that provides no benefit and may even be harmful. A second step is to provide medical interventions that provide good value: medical benefits that are commensurate with their costs.
This article discusses 3 key concepts for understanding how to assess the value of health care interventions. First, assessing the benefits, harms, and costs of an intervention is essential to understand whether it provides good value. Second, assessing the cost of an intervention should include not only the cost of the intervention itself but also any downstream costs that occur because the intervention was performed. Third, the incremental cost-effectiveness ratio estimates the additional cost required to obtain additional health benefits and provides a key measure of the value of a health care intervention.
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
Stanford Univ, Stanford, CA 94305 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
NR 49
TC 127
Z9 129
U1 0
U2 14
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 1
PY 2011
VL 154
IS 3
BP 174
EP +
DI 10.7326/0003-4819-154-3-201102010-00007
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 713HY
UT WOS:000286729200005
PM 21282697
ER
PT J
AU Chou, R
Qaseem, A
Owens, DK
Shekelle, P
AF Chou, Roger
Qaseem, Amir
Owens, Douglas K.
Shekelle, Paul
CA Clinical Guidelines Comm Amer Coll
TI Diagnostic Imaging for Low Back Pain: Advice for High-Value Health Care
From the American College of Physicians
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; LUMBAR SPINE; PATIENT EXPECTATIONS;
CLINICAL-EVALUATION; PRACTICE PATTERNS; NATIONAL-SURVEY; UNITED-STATES;
STRATEGIES; GUIDELINES; US
AB Diagnostic imaging is indicated for patients with low back pain only if they have severe progressive neurologic deficits or signs or symptoms that suggest a serious or specific underlying condition. In other patients, evidence indicates that routine imaging is not associated with clinically meaningful benefits but can lead to harms. Addressing inefficiencies in diagnostic testing could minimize potential harms to patients and have a large effect on use of resources by reducing both direct and downstream costs. In this area, more testing does not equate to better care. Implementing a selective approach to low back imaging, as suggested by the American College of Physicians and American Pain Society guideline on low back pain, would provide better care to patients, improve outcomes, and reduce costs.
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA.
Stanford Univ, Palo Alto, CA 94304 USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
FU Wellpoint; Palladian Health; Consumers Union; Blue Cross Blue Shield
Association; American Pain Society; Agency for Healthcare Research and
Quality
FX Dr. Chou: Consulting fee or honorarium: Wellpoint, Palladian Health,
Consumers Union, Blue Cross Blue Shield Association; Grants/grants
pending: American Pain Society; Payment for manuscript preparation:
American College of Physicians. Dr. Owens: Support for travel to
meetings for the study or other purposes: American College of
Physicians; Consultancy: Anthem/Wellpoint. Dr. Shekelle: Grants/grants
pending: Agency for Healthcare Research and Quality; Royalties:
UptoDate; Other: Unpaid advisor for a Wellpoint project that seeks to
identify and certify high-quality back pain centers of excellence.
Disclosures can also be viewed at
www.acponline.org/authors/icmje/ConflictOflnterestForms.do?msNum=M10-139
4. Any conflict of interest of the Clinical Guidelines Committee members
was declared, discussed, and resolved.
NR 82
TC 127
Z9 128
U1 4
U2 17
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 1
PY 2011
VL 154
IS 3
BP 181
EP +
DI 10.7326/0003-4819-154-3-201102010-00008
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 713HY
UT WOS:000286729200006
PM 21282698
ER
PT J
AU Kanwal, F
Bacon, BR
Asch, SM
AF Kanwal, Fasiha
Bacon, Bruce R.
Asch, Steven M.
TI Quality of Care in Patients With Chronic Hepatitis C Virus Infection
RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
ID ANTIVIRAL THERAPY; VETERANS; ELIGIBILITY
C1 [Kanwal, Fasiha] John Cochran Vet Affairs Med Ctr, St Louis, MO 63106 USA.
[Bacon, Bruce R.] St Louis Univ, Sch Med, St Louis, MO 63110 USA.
[Asch, Steven M.] Vet Affairs Greater Los Angeles Med Ctr, Los Angeles, CA 90073 USA.
RP Kanwal, F (reprint author), John Cochran Vet Affairs Med Ctr, St Louis, MO 63106 USA.
NR 5
TC 0
Z9 0
U1 0
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 1
PY 2011
VL 154
IS 3
BP 214
EP +
DI 10.7326/0003-4819-154-3-201102010-00019
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 713HY
UT WOS:000286729200016
ER
PT J
AU Sakurai, T
Dorr, NP
Takahashi, N
McInnes, LA
Elder, GA
Buxbaum, JD
AF Sakurai, Takeshi
Dorr, Nathan P.
Takahashi, Nagahide
McInnes, L. Alison
Elder, Gregory A.
Buxbaum, Joseph D.
TI Haploinsufficiency of Gtf2i, a Gene Deleted in Williams Syndrome, Leads
to Increases in Social Interactions
SO AUTISM RESEARCH
LA English
DT Article
DE social behavior; intellectual disability; autism; mouse model
ID BEUREN-SYNDROME; MICE; AUTISM
AB Identifying genes involved in social behavior is important for autism research. Williams-Beuren syndrome (WBS) is a developmental syndrome with unique neurocognitive features, including low IQ deficits in visuospatial and visual-motor abilities, hypersensitivity to sounds, hypersociability, and increased general anxiety. The syndrome is caused by a recurrent hemizygous deletion of the 7q11.23 region, containing about 28 genes. One of genes in the region, GTF2I, has been implicated in the hypersociability and visuospatial deficits of WBS based on genotype-phenotype correlation studies of patients with atypical deletions. In order to clarify the involvement of GTF2I in neurocognitive function, especially social behavior, we have developed and characterized Gtf2i-deficient mice. We found that homozygous deletion of Gtf2i causes lethality during embryonic development with neural tube closure defects and exencephaly, consistent with other reports. Gtf2i heterozygous animals show no gross changes in brain structure or development. Furthermore, heterozygous animals show no alterations in learning and memory, including spatial memory as assessed by the Morris water maze, but show alterations in the recognition of novel objects. Interestingly, they show increased social interaction with unfamiliar mice and do not show typical social habituation processes, reminiscent of the hypersociability observed in WBS patients. The mice do not appear to show increased anxiety, supporting a specific effect of Gtf2i on defined domains of the WBS phenotype. These data indicate that Gtf2i is involved in several aspects of embryonic development and the development of social neurocircuitry and that GTF2I haploinsufficiency could be a contributor to the hypersociability in WBS patients.
C1 [Sakurai, Takeshi; Dorr, Nathan P.; Takahashi, Nagahide; McInnes, L. Alison; Elder, Gregory A.; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Sakurai, Takeshi; McInnes, L. Alison; Buxbaum, Joseph D.] Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.
[Sakurai, Takeshi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Elder, Gregory A.] Vet Affairs Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY USA.
RP Buxbaum, JD (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA.
EM joseph.buxbaum@mssm.edu
OI Buxbaum, Joseph/0000-0001-8898-8313
FU Seaver Foundation; Office of Mount Sinai School of Medicine
FX Grant sponsor: The Seaver Foundation.; This research was supported by
the Seaver Foundation. T.S. and L.A.M. are current and prior Seaver
Fellows, respectively. The Mount Sinai Rat and Mouse Phenotyping Shared
Research Facility was supported in part by the Dean's Office of Mount
Sinai School of Medicine. The authors thank Dr. Ananda Roy for the
generous gift of an antibody.
NR 22
TC 31
Z9 31
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1939-3792
J9 AUTISM RES
JI Autism Res.
PD FEB
PY 2011
VL 4
IS 1
SI SI
BP 28
EP 39
DI 10.1002/aur.169
PG 12
WC Behavioral Sciences; Psychology, Developmental
SC Behavioral Sciences; Psychology
GA 729JP
UT WOS:000287945900004
PM 21328569
ER
PT J
AU Bischoff, DS
Sakamoto, T
Ishida, K
Makhijani, NS
Gruber, HE
Yamaguchi, DT
AF Bischoff, David S.
Sakamoto, Taylor
Ishida, Kenji
Makhijani, Nalini S.
Gruber, Helen E.
Yamaguchi, Dean T.
TI CXC receptor knockout mice: Characterization of skeletal features and
membranous bone healing in the adult mouse
SO BONE
LA English
DT Article
DE Murine; CXC Receptor; DXA; MicroCT; Cranial Defect; Bone Repair
ID EXPRESSION; PHENOTYPE; HOMOLOG; GROWTH; CELLS; CHEMOKINES; LINEAGE;
GENE; IL-8; KC
AB The potential role of CXC chemokines bearing the glu-leu-arg (ELR) motif in bone repair was studied using a cranial defect (CD) model in mice lacking the OCC receptor (mCXCR(-/-) knockout mice), which is homologous to knockout of the human CXC receptor 2 (CXCR2) gene. During the inflammatory stage of bone repair, ELR CXC chemokines are released by inflammatory cells and serve as chemotactic and angiogenic factors. mCXCR(-/-) mice were smaller in weight and length from base of tail to nose tip, compared to WT littermates. DE)(A analysis indicated that bone mineral density (BMD), bone mineral content (BMC), total area (TA), bone area (BA), and total tissue mass (TIM) were decreased in the mCXCR(-/-) mice at 6, 12, and 18 weeks of age. Trabecular bone characteristics in mCXCR(-/-) (% bone, connectivity, number, and thickness) were reduced, and trabecular spacing was increased as evidenced by mu CT. There was no difference in bone formation or resorption indices measured by bone histomorphometry. Trabecular BMD was not altered. Cortical bone volume. BMD, and thickness were reduced; whereas, bone marrow volume was increased in mCXCR(-/-). Decreased polar moment of inertia (J) in the tibias/femurs suggested that the mCXCR(-/-) long bones are weaker. This was confirmed by three-point bending testing of the femurs.
CDs created in 6-week-old male mCXCR(-/-) and WT littermates were not completely healed at 12 weeks; WT animals, however, had significantly more bone in-growth than mCXCR(-/-). New bone sites were identified using polarized light and assessed for numbers of osteocyte (0Cy) lacunae and blood vessels (BIV) around the original CD. In new bone, the number of BIV in WT was >2x that seen in mCXCR(-/-). Bone histomorphometry parameters in the cranial defect did not show any difference in bone formation or resorption markers.
In summary, studies showed that mCXCR(-/-) mice have (1) reduced weight and size; (2) decreased BMD and BMC; (3) decreased amounts of trabecular and cortical long bone; (4) decreased femur bone strength; and (5) significantly reduced intramembranous bone formation and number of BIV in new calvarial bone during bone repair. Published by Elsevier Inc.
C1 [Bischoff, David S.; Sakamoto, Taylor; Ishida, Kenji; Makhijani, Nalini S.; Yamaguchi, Dean T.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Gruber, Helen E.] Carolinas Med Ctr, Dept Orthopaed Surg, Charlotte, NC 28203 USA.
[Bischoff, David S.; Yamaguchi, Dean T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Yamaguchi, DT (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM dean.yamaguchi@med.va.gov
FU VA [1I01BX000170-01]; VHA Medical Research Service
FX Supported by VA Merit Review 1I01BX000170-01.; Grant Information: VHA
Medical Research Service Merit Review.
NR 29
TC 7
Z9 8
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD FEB 1
PY 2011
VL 48
IS 2
BP 267
EP 274
DI 10.1016/j.bone.2010.09.026
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 710UY
UT WOS:000286543700013
PM 20870046
ER
PT J
AU Vaid, M
Singh, T
Li, A
Katiyar, N
Sharma, S
Elmets, CA
Xu, H
Katiyar, SK
AF Vaid, Mudit
Singh, Tripti
Li, Anna
Katiyar, Nandan
Sharma, Samriti
Elmets, Craig A.
Xu, Hui
Katiyar, Santosh K.
TI Proanthocyanidins Inhibit UV-Induced Immunosuppression Through
IL-12-Dependent Stimulation of CD8(+) Effector T Cells and Inactivation
of CD4(+) T Cells
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID RADIATION-INDUCED IMMUNOSUPPRESSION; INDUCED OXIDATIVE STRESS; SKH-1
HAIRLESS MICE; CONTACT HYPERSENSITIVITY; ULTRAVIOLET-RADIATION; IN-VIVO;
SKIN CANCERS; GRAPE SEEDS; INTERLEUKIN-12; INDUCTION
AB The inhibition of UVB-induced immunosuppression by dietary grape seed proanthocyanidins (GSP) has been associated with the induction of interleukin (IL)-12 in mice, and we now confirm that GSPs do not inhibit UVB-induced immunosuppression in IL-12p40 knockout (IL-12 KO) mice and that treatment of these mice with recombinant IL-12 restores the inhibitory effect. To characterize the cell population responsible for the GSP-mediated inhibition of UVB-induced immunosuppression and the role of IL-12 in this process, we used an adoptive transfer approach. Splenocytes and draining lymph nodes were harvested from mice that had been administered dietary GSPs (0.5%-1.0%, w/w), exposed to UVB, and sensitized by the application of 2,4-dinitrofluorobenzene (DNFB) onto the UVB-exposed skin. CD8(+) and CD4(+) T cells were positively selected and transferred into naive mice that were subsequently challenged by application of DNFB on the ear skin. Naive recipients that received CD8(+) T cells from GSP-treated, UVB-irradiated donors exhibited full contact hypersensitivity (CHS) response. Naive mice that received CD4(+) suppressor T cells from GSP-treated, UVB-exposed mice could mount a CHS response after sensitization and subsequent challenge with DNFB. On culture, the CD8(+) T cells from GSP-treated, UVB-exposed mice secreted higher levels (5- to 8-fold) of Th1 cytokines than CD8(+) T cells from UVB-irradiated mice not treated with GSPs. CD4(+) T cells from GSP-treated, UVB-exposed mice secreted significantly lower levels (80%-100%) of Th2 cytokines than CD4(+) T cells from UVB-exposed mice not treated with GSPs. These data suggest that GSPs inhibit UVB-induced immunosuppression by stimulating CD8(+) effector T cells and diminishing regulatory CD4(+) T cells. Cancer Prev Res; 4(2); 238-47. (C)2010 AACR.
C1 [Vaid, Mudit; Singh, Tripti; Li, Anna; Katiyar, Nandan; Sharma, Samriti; Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA.
[Elmets, Craig A.; Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration; UAB Skin Diseases Research Center [AR050948-01]
FX This work was financially supported by the Veterans Administration Merit
Review Award (S.K. Katiyar, C.A. Elmets), and the UAB Skin Diseases
Research Center (AR050948-01).
NR 39
TC 12
Z9 12
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD FEB
PY 2011
VL 4
IS 2
BP 238
EP 247
DI 10.1158/1940-6207.CAPR-10-0224
PG 10
WC Oncology
SC Oncology
GA 715KH
UT WOS:000286882900008
PM 21075976
ER
PT J
AU Baddley, JW
Schain, DC
Gupte, AA
Lodhi, SA
Kayler, LK
Frade, JP
Lockhart, SR
Chiller, T
Bynon, JS
Bower, WA
AF Baddley, John W.
Schain, Denise C.
Gupte, Asmita A.
Lodhi, Sundus A.
Kayler, Liise K.
Frade, Joao P.
Lockhart, Shawn R.
Chiller, Tom
Bynon, J. Steve, Jr.
Bower, William A.
TI Transmission of Cryptococcus neoformans by Organ Transplantation
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID CORNEAL TRANSPLANTATION; FUNGAL-INFECTIONS; RECIPIENTS; DONOR; PATIENT
AB Background. This article describes transmission of Cryptococcus neoformans by solid organ transplantation.
Methods. We reviewed medical records and performed molecular genotyping of isolates to determine potential for donor transmission of Cryptococcus.
Results. Cryptococcosis was diagnosed in 3 recipients of organs from a common donor with an undifferentiated neurologic condition at the time of death. Cryptococcal meningoencephalitis was later diagnosed in the donor at autopsy. The liver and 1 kidney recipient developed cryptococcemia and pneumonia and the other kidney recipient developed cryptococcemia and meningitis; 2 patients recovered with prolonged antifungal therapy. We tested 4 recipient isolates with multilocus sequence typing and found they had identical alleles.
Conclusions. Our investigation documents the transmission of Cryptococcus neoformans by organ transplantation. Evaluation for cryptococcosis in donors with unexplained neurologic symptoms should be strongly considered.
C1 [Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Schain, Denise C.; Gupte, Asmita A.; Lodhi, Sundus A.; Kayler, Liise K.] Univ Florida, Dept Med, Sch Med, Gainesville, FL USA.
[Frade, Joao P.; Lockhart, Shawn R.; Chiller, Tom; Bower, William A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA.
EM jbad-dley@uab.edu
FU Pfizer
FX J.W.B. is an advisory board member at Merck and Co., a consultant for
Pfizer, and a Pfizer research grant recipient. All other authors: no
conflicts.
NR 26
TC 26
Z9 26
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB
PY 2011
VL 52
IS 4
BP E94
EP E98
DI 10.1093/cid/ciq216
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 712PD
UT WOS:000286677800002
PM 21220771
ER
PT J
AU Tamura, MK
Xie, DW
Yaffe, K
Cohen, DL
Teal, V
Kasner, SE
Messe, SR
Sehgal, AR
Kusek, J
DeSalvo, KB
Cornish-Zirker, D
Cohan, J
Seliger, SL
Chertow, GM
Go, AS
AF Tamura, Manjula Kurella
Xie, Dawei
Yaffe, Kristine
Cohen, Debbie L.
Teal, Valerie
Kasner, Scott E.
Messe, Steven R.
Sehgal, Ashwini R.
Kusek, John
DeSalvo, Karen B.
Cornish-Zirker, Denise
Cohan, Janet
Seliger, Stephen L.
Chertow, Glenn M.
Go, Alan S.
TI Vascular Risk Factors and Cognitive Impairment in Chronic Kidney
Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CARDIOVASCULAR HEALTH COGNITION; HEMODIALYSIS-PATIENTS; DIALYSIS
PATIENTS; DEMENTIA; BRAIN; ANEMIA; ADULTS; PERFORMANCE; COMMUNITY;
OUTCOMES
AB Background and objectives Cognitive impairment is common among persons with chronic kidney disease, but the extent to which nontraditional vascular risk factors mediate this association is unclear.
Design, setting, participants, & measurements We conducted cross-sectional analyses of baseline data collected from adults with chronic kidney disease participating in the Chronic Renal Insufficiency Cohort study. Cognitive impairment was defined as a Modified Mini-Mental State Exam score >1 SD below the mean score.
Results Among 3591 participants, the mean age was 58.2 +/- 11.0 years, and the mean estimated GFR (eGFR) was 43.4 +/- 13.5 ml/min per 1.73 m(2). Cognitive impairment was present in 13%. After adjustment for demographic characteristics, prevalent vascular disease (stroke, coronary artery disease, and peripheral arterial disease) and traditional vascular risk factors (diabetes, hypertension, smoking, and elevated cholesterol), an eGFR <30 ml /min per 1.73 m(2) was associated with a 47% increased odds of cognitive impairment (odds ratio 1.47, 95% confidence interval 1.05, 2.05) relative to those with an eGFR 45 to 59 ml/min per 1.73 m(2). This association was attenuated and no longer significant after adjustment for hemoglobin concentration. While other nontraditional vascular risk factors including C-reactive protein, homocysteine, serum albumin, and albuminuria were correlated with cognitive impairment in unadjusted analyses, they were not significantly associated with cognitive impairment after adjustment for eGFR and other confounders.
Conclusions The prevalence of cognitive impairment was higher among those with lower eGFR, independent of traditional vascular risk factors. This association may be explained in part by anemia. Clin J Am Soc Nephrol 6: 248-256, 2011. doi: 10.2215/CJN.02660310
C1 [Tamura, Manjula Kurella; Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA.
[Tamura, Manjula Kurella] Vet Affairs Palo Alto Geriatr Res & Educ Clin Ctr, Palo Alto, CA USA.
[Xie, Dawei; Teal, Valerie; Kasner, Scott E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, Dept Epidemiol, San Francisco, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Cohen, Debbie L.] Univ Penn, Renal Electrolyte Div, Philadelphia, PA 19104 USA.
[Kasner, Scott E.; Messe, Steven R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Sehgal, Ashwini R.] Case Western Reserve Univ, Div Nephrol, Cleveland, OH 44106 USA.
[Kusek, John] NIDDK, Div Kidney Urol & Hematol Dis, NIH, Bethesda, MD USA.
[DeSalvo, Karen B.] Tulane Univ, Sect Gen Internal Med & Geriatr, New Orleans, LA 70118 USA.
[Cornish-Zirker, Denise] Univ Michigan, Div Cardiovasc Med & Hypertens, Ann Arbor, MI 48109 USA.
[Cohan, Janet] Univ Illinois, Dept Med, Chicago, IL USA.
[Seliger, Stephen L.] Univ Maryland, Div Nephrol, Baltimore, MD 21201 USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, Dept Biostat, San Francisco, CA USA.
RP Tamura, MK (reprint author), Stanford Univ, Sch Med, Div Nephrol, 780 Welch Rd,Suite 106, Palo Alto, CA 94304 USA.
EM mktamura@stanford.edu
RI Kasner, Scott/C-6109-2011; Kurella Tamura, Manjula/C-8284-2014
OI Kurella Tamura, Manjula/0000-0001-5227-2479
FU National Institute of Diabetes and Digestive and Kidney Diseases
[5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028,
5U01DK60980, 5U01DK060963, 5U01DK060902, R01DK069406]; National
Institutes of Health [UL1RR024134, UL1RR025005, M01RR16500, UL1RR024989,
M01RR000042, UL1RR024986, UL1RR029879, RR05096, UL1RR024131]; National
Institute of Aging [K23AG028952]; Amgen
FX The CRIC Study is supported by cooperative agreement project grants
5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028,
5U01DK60980, 5U01DK060963, and 5U01DK060902 from the National Institute
of Diabetes and Digestive and Kidney Diseases and by grants UL1RR024134,
UL1RR025005, M01RR16500, UL1RR024989, M01RR000042, UL1RR024986,
UL1RR029879, RR05096, and UL1RR024131 from the National Institutes of
Health. Dr. Kurella Tamura received support from the National Institute
of Aging (grant K23AG028952). Dr. Yaffe was supported by R01DK069406,
also from the National Institute of Diabetes and Digestive and Kidney
Diseases. These results were presented in abstract form at the American
Society of Nephrology Meeting.; Dr. Kurella Tamura has previously
received grant support from Amgen.
NR 36
TC 42
Z9 47
U1 1
U2 9
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD FEB
PY 2011
VL 6
IS 2
BP 248
EP 256
DI 10.2215/CJN.02660310
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 722KJ
UT WOS:000287430800004
ER
PT J
AU Cunningham, M
Gilkeson, G
AF Cunningham, Melissa
Gilkeson, Gary
TI Estrogen Receptors in Immunity and Autoimmunity
SO CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
LA English
DT Review
DE Estrogen receptors; Autoimmunity; Gender prevalence
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; DENDRITIC CELL-DIFFERENTIATION;
PERIPHERAL-BLOOD MONOCYTES; ANTIGEN-PRESENTING CELLS; MRL LPR/LPR MICE;
B-LYMPHOPOIESIS; BONE-MARROW; T-CELLS; LYMPHOCYTE PRECURSORS; NEGATIVE
REGULATORS
AB Due to the female predominance of autoimmune diseases, the role of gender and sex hormones in the immune system is of long-term interest. Estrogen's primary effects are mediated via estrogen receptors alpha and beta (ER alpha/beta) that are expressed on most immune cells. ERs are nuclear hormone receptors that can either directly bind to estrogen response elements in gene promoters or serve as cofactors with other transcription factors (i.e., NFkB/AP1). Cytoplasmic ER and membrane associated ER impact specific kinase signaling pathways. ERs have prominent effects on immune function in both the innate and adaptive immune responses. Genetic deficiency of ER alpha in murine models of lupus resulted in significantly decreased disease and prolonged survival, while ER beta deficiency had minimal to no effect in autoimmune models. The protective effect of ER alpha in lupus is multifactoral. In arthritis models, ER alpha agonists appears to mediate a protective effect. The modulation of ER alpha function appears to be a potential target for therapy in autoimmunity.
C1 [Cunningham, Melissa; Gilkeson, Gary] Med Univ S Carolina, Med Res Serv, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
[Cunningham, Melissa; Gilkeson, Gary] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
RP Cunningham, M (reprint author), Med Univ S Carolina, Med Res Serv, Ralph H Johnson VAMC, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA.
EM gilkeson@musc.edu
OI Cunningham, Melissa/0000-0002-9207-1986
FU Veterans Administration Medical Research Service
FX This work was supported by a Merit Review Award and a REAP award from
the Veterans Administration Medical Research Service.
NR 93
TC 91
Z9 95
U1 2
U2 18
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1080-0549
J9 CLIN REV ALLERG IMMU
JI Clin. Rev. Allergy Immunol.
PD FEB
PY 2011
VL 40
IS 1
BP 66
EP 73
DI 10.1007/s12016-010-8203-5
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 712CH
UT WOS:000286639700008
PM 20352526
ER
PT J
AU Wang, CP
Hazuda, HP
AF Wang, Chen-Pin
Hazuda, Helen P.
TI Better Glycemic Control Is Associated With Maintenance of
Lower-Extremity Function Over Time in Mexican American and European
American Older Adults With Diabetes
SO DIABETES CARE
LA English
DT Article
ID WOMENS HEALTH; US ADULTS; DISABILITY; MORTALITY; DISEASE; GLUCOSE
AB OBJECTIVE-Diabetes is a major cause of functional decline among older adults, but the role of glycemic control remains unclear. This article assesses whether better glycemic control is associated with better maintenance of lower-extremity function over time in older adults with diabetes.
RESEARCH DESIGN AND METHODS-Participants (n = 119) in the San Antonio Longitudinal Study of Aging, ages 71-85, who met American Diabetes Association diabetes criteria were followed over a 36-month period. Seven measures of A1C (HbA(1c)) were obtained at 6-month intervals; three measures of lower-extremity function were obtained at 18-month intervals using the Short Physical Performance Battery (SPPB). A two-step analytic approach was used, first, to identify distinct glycemic control classes using latent growth mixture modeling and, second, to examine trajectories of lower-extremity function based on these classes using path analysis.
RESULTS-Two glycemic control classes were identified: a poorer control class with higher means (all >7%) and higher within-subject variability in HbA(1c) and a better control class with lower means (all <7%) and lower within-subject variability. The short-term and long-term maintenance of lower-extremity function, assessed by the association between the first and second SPPB measures and the first and third SPPB measures, were both greater in the better control class than in the poorer control class.
CONCLUSIONS-Among older adults with diabetes, better glycemic control may improve both short-term and long-term maintenance of lower-extremity function.
C1 [Hazuda, Helen P.] Audie Murphy Med Ctr, Dept Vet Affairs, Res Serv, San Antonio, TX USA.
[Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Hazuda, HP (reprint author), Audie Murphy Med Ctr, Dept Vet Affairs, Res Serv, San Antonio, TX USA.
EM hazuda@uthscsa.edu
FU National Institute on Aging (NIA) [1-R01-AG10444, 1-R01-AG16518];
National Institute of Diabetes and Digestive and Kidney Diseases [1-K25
DK075092]; National Center for Research Resources [M01-RR01346]
FX This study was supported by National Institute on Aging (NIA) Grant
1-R01-AG10444 (SALSA), NIA Grant 1-R01-AG16518 (Disablement in an Aging,
Bi-ethnic Cohort), National Institute of Diabetes and Digestive and
Kidney Diseases Grant 1-K25 DK075092, and National Center for Research
Resources Grant M01-RR01346 (Fredrick C. Bartter General Clinical
Research Center). This material is the result of work supported with
resources and the use of facilities at the Audie Murphy VA Medical
Center, San Antonio, TX.
NR 24
TC 14
Z9 14
U1 1
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2011
VL 34
IS 2
BP 268
EP 273
DI 10.2337/dc10-1405
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 722LO
UT WOS:000287433900004
PM 21216857
ER
PT J
AU Greenstein, RJ
Su, LY
Brown, ST
AF Greenstein, Robert J.
Su, Liya
Brown, Sheldon T.
TI Growth of M. avium Subspecies Paratuberculosis in Culture Is Enhanced by
Nicotinic Acid, Nicotinamide, and alpha and beta Nicotinamide Adenine
Dinucleotide
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Mycobacterium avium subspecies paratuberculosis; Tobacco; Crohn's
disease; Zoonosis; Emerging pathogens; Nicotine; Nicotinic acid;
Nicotinamide; alpha and beta nicotinamide adenine dinucleotide;
Inflammatory bowel disease
ID INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE;
MYCOBACTERIUM-PARATUBERCULOSIS; ULCERATIVE-COLITIS; CIGARETTE-SMOKING;
COWS MILK; PATHOGENS; DIAGNOSIS; COMPLEX; DRUGS
AB Without known mechanisms of action, Crohn's disease is exacerbated, and ulcerative colitis is improved, by the use of tobacco. Mycobacterium avium subspecies paratuberculosis (MAP) may be zoonotic. We hypothesized that tobacco components might alter the growth kinetics of MAP, explaining these divergent clinical observations.
The effect of nicotine, nicotinic acid, nicotinamide and alpha and beta nicotinamide adenine dinucleotide (alpha and beta NAD) were studied on eight strains of three mycobacterial species (MAP, M. avium and M. tb. complex). Data are obtained as "cumulative growth index," (cGI) and presented as "percent increase in cumulative GI" (% + Delta cGI).
Nicotinic acid enhances the two human MAP isolates (Dominic; 225% + Delta cGI and UCF-4; 92% + Delta cGI) and M. avium (ATCC 25291; 175% + Delta cGI). Nicotinamide (at 6.4 A mu g/ml) enhances the human MAP isolates (Dominic; 156% + Delta cGI and UCF-4; 79% + Delta cGI) and M. avium (ATCC 25291; 144% + Delta cGI.) Both alpha and beta NAD enhance Dominic; (135 and 150 % + Delta cGI) and UCF-4; (81 and 79% + Delta cGI). At the doses tested, nicotine has no effect on any strain studied.
We show enhancement of MAP growth by nicotinic acid, one of a parts per thousand yen4,000 tobacco-related molecules, its amide, nicotinamide and alpha and beta NAD. Pure nicotine has no enhancing effect at the doses studies.
C1 [Greenstein, Robert J.] James J Peters VAMC, Dept Surg, Bronx, NY 10468 USA.
[Greenstein, Robert J.; Su, Liya] James J Peters VAMC, Lab Mol Surg Res, Bronx, NY 10468 USA.
[Brown, Sheldon T.] James J Peters VAMC, Dept Med, Bronx, NY 10468 USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
RP Greenstein, RJ (reprint author), James J Peters VAMC, Dept Surg, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM BGAxis@aol.com; LyiaSu01@aol.com; Sheldon.Brown@va.gov
FU Division of Infectious Diseases at the James J. Peters VAMC, Bronx, NY
FX This material is the result of work supported with resources and the use
of facilities at the James J. Peters VAMC, Bronx, NY. This study was
supported by the Division of Infectious Diseases at the James J. Peters
VAMC, Bronx, NY.
NR 50
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD FEB
PY 2011
VL 56
IS 2
BP 368
EP 375
DI 10.1007/s10620-010-1301-7
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 712KF
UT WOS:000286664900015
PM 20585983
ER
PT J
AU Billings, CJ
Bennett, KO
Molis, MR
Leek, MR
AF Billings, Curtis J.
Bennett, Keri O.
Molis, Michelle R.
Leek, Marjorie R.
TI Cortical Encoding of Signals in Noise: Effects of Stimulus Type and
Recording Paradigm
SO EAR AND HEARING
LA English
DT Article
ID AUDITORY-EVOKED-POTENTIALS; EVENT-RELATED POTENTIALS; BROAD-BAND NOISE;
NORMAL-HEARING LISTENERS; WORD RECOGNITION; NEURAL REPRESENTATION;
TEMPORAL RESOLUTION; SPEECH CUES; RISE TIME; MASKING
AB Objectives: Perception-in-noise deficits have been demonstrated across many populations and listening conditions. Many factors contribute to successful perception of auditory stimuli in noise, including neural encoding in the central auditory system. Physiological measures such as cortical auditory-evoked potentials (CAEPs) can provide a view of neural encoding at the level of the cortex that may inform our understanding of listeners' abilities to perceive signals in the presence of background noise. To understand signal-in-noise neural encoding better, we set out to determine the effect of signal type, noise type, and evoking paradigm on the P1-N1-P2 complex.
Design: Tones and speech stimuli were presented to nine individuals in quiet and in three background noise types: continuous speech spectrum noise, interrupted speech spectrum noise, and four-talker babble at a signal-to-noise ratio of -3 dB. In separate sessions, CAEPs were evoked by a passive homogenous paradigm (single repeating stimulus) and an active oddball paradigm.
Results: The results for the N1 component indicated significant effects of signal type, noise type, and evoking paradigm. Although components P1 and P2 also had significant main effects of these variables, only P2 demonstrated significant interactions among these variables.
Conclusions: Signal type, noise type, and evoking paradigm all must be carefully considered when interpreting signal-in-noise evoked potentials. Furthermore, these data confirm the possible usefulness of CAEPs as an aid to understand perception-in-noise deficits.
C1 [Billings, Curtis J.; Bennett, Keri O.; Molis, Michelle R.; Leek, Marjorie R.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA.
RP Billings, CJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA.
EM curtis.billings2@va.gov
FU National Institute on Deafness and Other Communication Disorders [R01
DC00626]; VA Rehabilitation Research and Development Service; Senior
Research Career Scientist award
FX This work was supported by a grant from the National Institute on
Deafness and Other Communication Disorders (R01 DC00626), the VA
Rehabilitation Research and Development Service as Career Development
Awards (to C. J. B., M. R. M.), and a Senior Research Career Scientist
award (to M. R. L.).
NR 58
TC 16
Z9 18
U1 1
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-0202
J9 EAR HEARING
JI Ear Hear.
PD FEB
PY 2011
VL 32
IS 1
BP 53
EP 60
PG 8
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 698GF
UT WOS:000285581300007
PM 20890206
ER
PT J
AU Reavis, KM
McMillan, G
Austin, D
Gallun, F
Fausti, SA
Gordon, JS
Helt, WJ
Konrad-Martin, D
AF Reavis, Kelly M.
McMillan, Garnett
Austin, Donald
Gallun, Frederick
Fausti, Stephen A.
Gordon, Jane S.
Helt, Wendy J.
Konrad-Martin, Dawn
TI Distortion-Product Otoacoustic Emission Test Performance for Ototoxicity
Monitoring
SO EAR AND HEARING
LA English
DT Article
ID CISPLATIN-INDUCED OTOTOXICITY; SENSORINEURAL HEARING-LOSS;
HIGH-FREQUENCY AUDIOMETRY; CIS-DIAMMINEDICHLOROPLATINUM; AUDITORY
FUNCTION; IMPAIRED SUBJECTS; CANCER-PATIENTS; DOSE CISPLATIN;
RISK-FACTORS; SOUND-LEVEL
AB Introduction: A nonbehavioral method for monitoring ototoxicity in patients treated with cisplatin is needed because patients enduring chemotherapy may not be well or cooperative enough to undergo repeated hearing tests. Distortion-product otoacoustic emissions (DPOAEs) provide a nonbehavioral measure of auditory function that is sensitive to cisplatin exposure. However, interpreting DPOAE findings in the context of ototoxicity monitoring requires that their accuracy be determined in relation to a clinically accepted gold standard test.
Objectives: Among patients receiving cisplatin for the treatment of cancer, we sought to (1) identify the combination of DPOAE metrics and ototoxicity risk factors that best classified ears with and without ototoxic-induced hearing changes; and (2) evaluate the test performance achieved by the composite measure as well as by DPOAEs alone.
Design: Odds of experiencing hearing changes at a given patient visit were determined using data collected prospectively from 24 Veterans receiving cisplatin. Pure-tone thresholds were examined within an octave of each subject's high-frequency hearing limit. DPOAE were collected as a set of four response growth (input/output) functions near the highest f(2) frequency that yielded a robust response at L(2) = L(1) = 65 dB SPL. Logistic regression modeled the risk of hearing change using several DPOAE metrics, drug treatment factors, and other patient factors as independent variables. An optimal discriminant function was derived by reducing the model so that only statistically significant variables were included. Receiver operating characteristic curve analyses were used to evaluate test performance.
Results: At higher cisplatin doses, ears with better hearing at baseline were more likely to exhibit ototoxic hearing changes than those with poorer hearing. Measures of pre-exposure hearing, cumulative drug dose, and DPOAEs generated a highly accurate discriminant function with a cross-validated area under the receiver operating characteristic curve of 0.9. DPOAEs alone also provided an indication of ototoxic hearing change when measured at the highest DPOAE test frequency that yielded a robust response.
Conclusions: DPOAEs alone and especially in combination with pre-exposure hearing and cisplatin dose provide an indication of whether or not hearing has changed as a result of cisplatin administration. These promising results need to be validated in a separate sample.
C1 [Reavis, Kelly M.; McMillan, Garnett; Austin, Donald; Gallun, Frederick; Fausti, Stephen A.; Gordon, Jane S.; Helt, Wendy J.; Konrad-Martin, Dawn] Portland VA Med Ctr, NCRAR, VA RR&D, Portland, OR USA.
[McMillan, Garnett] Oregon Hlth & Sci Univ, Dept Publ Hlth & Preventat Med, Portland, OR 97201 USA.
[Austin, Donald; Gallun, Frederick; Fausti, Stephen A.; Konrad-Martin, Dawn] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.
RP Reavis, KM (reprint author), Univ Calif Irvine, Hearing & Speech Lab, 364 Med Surge 2, Irvine, CA 92697 USA.
EM reavisk@uci.edu
RI Gallun, Frederick/G-3792-2012
OI Gallun, Frederick/0000-0002-4145-2199
FU National Center for Rehabilitative Auditory Research; Office of
Rehabilitation Research and Development Service, Department of Veterans
Affairs [C3213R, C4447K]
FX This work was supported by the National Center for Rehabilitative
Auditory Research and the Office of Rehabilitation Research and
Development Service, Department of Veterans Affairs (Grants C3213R and
C4447K).
NR 82
TC 17
Z9 19
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-0202
J9 EAR HEARING
JI Ear Hear.
PD FEB
PY 2011
VL 32
IS 1
BP 61
EP 74
PG 14
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 698GF
UT WOS:000285581300008
PM 20625302
ER
PT J
AU German, JP
Thaler, JP
Wisse, BE
Oh-I, S
Sarruf, DA
Matsen, ME
Fischer, JD
Taborsky, GJ
Schwartz, MW
Morton, GJ
AF German, Jonathan P.
Thaler, Joshua P.
Wisse, Brent E.
Oh-I, Shinsuke
Sarruf, David A.
Matsen, Miles E.
Fischer, Jonathan D.
Taborsky, Gerald J., Jr.
Schwartz, Michael W.
Morton, Gregory J.
TI Leptin Activates a Novel CNS Mechanism for Insulin-Independent
Normalization of Severe Diabetic Hyperglycemia
SO ENDOCRINOLOGY
LA English
DT Article
ID PROTEIN-2 MESSENGER-RNA; GLUCOSE-PRODUCTION; GENE-EXPRESSION;
PROOPIOMELANOCORTIN NEURONS; PERIPHERAL-TISSUES; FOOD-INTAKE; RATS;
RESISTANCE; HYPERPHAGIA; SENSITIVITY
AB The brain has emerged as a target for the insulin-sensitizing effects of several hormonal and nutrient-related signals. The current studies were undertaken to investigate mechanisms whereby leptin lowers circulating blood glucose levels independently of insulin. After extending previous evidence that leptin infusion directly into the lateral cerebral ventricle ameliorates hyperglycemia in rats with streptozotocin-induced uncontrolled diabetes mellitus, we showed that the underlying mechanism is independent of changes of food intake, urinary glucose excretion, or recovery of pancreatic beta-cells. Instead, leptin action in the brain potently suppresses hepatic glucose production while increasing tissue glucose uptake despite persistent, severe insulin deficiency. This leptin action is distinct from its previously reported effect to increase insulin sensitivity in the liver and offers compelling evidence that the brain has the capacity to normalize diabetic hyperglycemia in the presence of sufficient amounts of central nervous system leptin. (Endocrinology 152: 394-404, 2011)
C1 [German, Jonathan P.; Thaler, Joshua P.; Wisse, Brent E.; Oh-I, Shinsuke; Sarruf, David A.; Matsen, Miles E.; Fischer, Jonathan D.; Schwartz, Michael W.; Morton, Gregory J.] Univ Washington, Diabet & Obes Ctr Excellence, Dept Med, Seattle, WA 98109 USA.
[Taborsky, Gerald J., Jr.] Dept Vet Affairs Med Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP German, JP (reprint author), Univ Washington, Diabet & Obes Ctr Excellence, Dept Med, Seattle, WA 98109 USA.
RI Schwartz, Michael/H-9950-2012
FU National Institutes of Health [DK083042, DK050154-13]; Veterans Affairs
Merit review; Nutrition Obesity Research Center at the University of
Washington [DK035816]; Mouse Metabolic Phenotyping Center at the
University of Washington [U24 DK076126]; AstraZeneca; American Heart
Association
FX This work was supported by National Institutes of Health Grants DK083042
(to M. W. S.) and DK050154-13 (to G.J.T.); the Veterans Affairs Merit
review (G.J.T.); the Nutrition Obesity Research Center Grant DK035816
and the Mouse Metabolic Phenotyping Center Grant U24 DK076126, at the
University of Washington; research funding from AstraZeneca; and an
American Heart Association Scientist Development grant (G.J.M.).
NR 56
TC 64
Z9 67
U1 1
U2 6
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2011
VL 152
IS 2
BP 394
EP 404
DI 10.1210/en.2010-0890
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 709FA
UT WOS:000286422100010
PM 21159853
ER
PT J
AU Virani, SS
Nambi, V
Hoogeveen, R
Wasserman, BA
Coresh, J
Gonzalez, F
Chambless, LE
Mosley, TH
Boerwinkle, E
Ballantyne, CM
AF Virani, Salim S.
Nambi, Vijay
Hoogeveen, Ron
Wasserman, Bruce A.
Coresh, Josef
Gonzalez, Franklyn, II
Chambless, Lloyd E.
Mosley, Thomas H.
Boerwinkle, Eric
Ballantyne, Christie M.
TI Relationship between circulating levels of RANTES (regulated on
activation, normal T-cell expressed, and secreted) and carotid plaque
characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid
MRI Study
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Atherosclerosis; Magnetic resonance imaging; Inflammation; RANTES;
High-sensitivity C-reactive protein
ID CHEMOKINE RECEPTORS; DISEASE; INFLAMMATION; ENDOTHELIUM; PLASMA;
RECRUITMENT; MECHANISMS; DEPOSITION; ARREST
AB Aims To assess the relationship between regulated on activation, normal T-cell expressed and secreted (RANTES) and carotid atherosclerotic plaque burden and plaque characteristics.
Methods and results Gadolinium-enhanced magnetic resonance imaging (MRI) of the carotid artery was performed in 1901 participants from the Atherosclerosis Risk in Communities (ARIC) Study. Wall thickness and volume, lipid-core volume, and fibrous cap thickness (by MRI) and plasma RANTES levels (by ELISA) were measured. Regression analysis was performed to study the associations between MRI variables and RANTES. Among 1769 inclusive participants, multivariable regression analysis revealed that total wall volume [beta-coefficient (beta) = 0.09, P = 0.008], maximum wall thickness (beta = 0.08, P = 0.01), vessel wall area (beta = 0.07, P = 0.02), mean minimum fibrous cap thickness (beta = 0.11, P = 0.03), and high-sensitivity C-reactive protein (beta = 0.09, P = 0.01) were positively associated with RANTES. Total lipid-core volume showed positive association in unadjusted models (beta = 0.18, P = 0.02), but not in fully adjusted models (beta = 0.13, P = 0.09). RANTES levels were highest in Caucasian females followed by Caucasian males, African-American females, and African-American males (P < 0.0001). Statin use attenuated the relationship between RANTES and measures of plaque burden.
Conclusion Positive associations between RANTES and carotid wall thickness and lipid-core volume (in univariate analysis) suggest that higher RANTES levels may be associated with extent of carotid atherosclerosis and high-risk plaques. Associations between fibrous cap thickness and RANTES likely reflect the lower reliability estimate for fibrous cap measurements compared with wall volume or lipid-core volume measurements. Statin use may modify the association between RANTES and carotid atherosclerosis. Furthermore, RANTES levels vary by race.
C1 [Virani, Salim S.] Baylor Coll Med, Ctr Cardiovasc Dis Prevent, Methodist DeBakey Heart & Vasc Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Wasserman, Bruce A.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA.
[Coresh, Josef] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Gonzalez, Franklyn, II; Chambless, Lloyd E.] Univ N Carolina, Chapel Hill, NC USA.
[Mosley, Thomas H.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
RP Virani, SS (reprint author), Baylor Coll Med, Ctr Cardiovasc Dis Prevent, Methodist DeBakey Heart & Vasc Ctr, Michael E DeBakey Vet Affairs Med Ctr, 6565 Fannin,Suite B157B,MS BCMA601, Houston, TX 77030 USA.
EM virani@bcm.tmc.edu
OI Virani, Salim/0000-0001-9541-6954
FU National Heart, Lung, and Blood Institute [N01-HC-55015, N01-HC-55016,
N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022,
U01HL075572-01]; Department of Veterans Affairs Health Services Research
and Development Service (HSRD) [CDA-09-028]
FX This work was supported by the National Heart, Lung, and Blood Institute
[Contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019,
N01-HC-55020, N01-HC-55021, and N01-HC-55022 (The Atherosclerosis Risk
in Communities study) and U01HL075572-01 (the ARIC Carotid MRI
examination)]. S. S. V. is supported by a Department of Veterans Affairs
Health Services Research and Development Service (HSR&D) Career
Development Award (grant number: CDA-09-028).
NR 30
TC 27
Z9 31
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD FEB
PY 2011
VL 32
IS 4
BP 459
EP 468
DI 10.1093/eurheartj/ehq367
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 723HD
UT WOS:000287496500018
PM 20943669
ER
PT J
AU Jang, YC
Van Remmen, H
AF Jang, Youngmok C.
Van Remmen, Holly
TI Age-associated alterations of the neuromuscular junction
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article; Proceedings Paper
CT 10th International Symposium on the Neurobiology and Neuroendocrinology
of Aging
CY JUL 25-30, 2010
CL Bregenz, AUSTRIA
DE Sarcopenia; Neuromuscular junction; Oxidative stress; Mitochondria;
Aging
ID RAT MEDIAL GASTROCNEMIUS; SKELETAL-MUSCLE FIBERS; MOTOR UNITS; OXIDATIVE
STRESS; NEUROTROPHIC FACTORS; CALORIE RESTRICTION; PERIPHERAL-NERVES;
MOUSE MUSCLE; SARCOPENIA; DEGENERATION
AB Age-related loss of muscle mass and function greatly affects quality of life in the elderly population. Several hypotheses have been proposed but accumulating evidence point to alterations in neuromuscular system during aging as a key event that leads to functional denervation, muscle wasting, and weakness. Over the past few decades, age-associated degeneration of the neuromuscular junction (NMJ) and its components have been well documented. With advancing age, pre-terminal portions of motor axons exhibit regions of abnormal thinning, distension, and sprouting whereas postsynaptic endplates decrease in size and reduce in number, length, and density of postsynaptic folds. Although the exact underlying mechanisms are still lacking, recent studies provided direct evidence that age-associated increase in oxidative stress plays a crucial role in NMJ degeneration and progression of sarcopenia. Homozygous deletion of an important antioxidant enzyme, Cu,Zn superoxide dismutase (CuZnSOD, SOD1) leads to acceleration of age-dependent muscle atrophy, with a significant NMJ degeneration similar to that seen in old wild-type sarcopenic animals. In this short review, we briefly summarize the current understanding of some of the cellular and molecular changes in the NMJ during aging and suggest a role for oxidative stress and mitochondrial dysfunction in age-related changes in the maintenance of neuromuscular innervation. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Jang, Youngmok C.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular, San Antonio, TX 78229 USA.
[Jang, Youngmok C.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Biol Struct, San Antonio, TX 78229 USA.
[Jang, Youngmok C.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
FU NIA NIH HHS [P01AG020591, P01 AG020591, P01 AG020591-080005]
NR 55
TC 55
Z9 57
U1 1
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
J9 EXP GERONTOL
JI Exp. Gerontol.
PD FEB-MAR
PY 2011
VL 46
IS 2-3
SI SI
BP 193
EP 198
DI 10.1016/j.exger.2010.08.029
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 720OQ
UT WOS:000287290400020
PM 20854887
ER
PT J
AU Jung, YH
Shiozawa, Y
Wang, JC
Patel, LR
Havens, AM
Song, JH
Krebsbach, PH
Roodman, GD
Taichman, RS
AF Jung, Younghun
Shiozawa, Yusuke
Wang, Jingcheng
Patel, Lalit R.
Havens, Aaron M.
Song, Junhui
Krebsbach, Paul H.
Roodman, G. David
Taichman, Russell S.
TI Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12
function in the hematopoietic stem cell endosteal niche
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID FACTOR-I; BONE-MARROW; HUMAN OSTEOBLASTS; G-CSF; PROGENITOR CELLS;
N-CADHERIN; CXCR4; SDF-1; MOBILIZATION; MAINTENANCE
AB Objective. Previously, we reported that annexin-2 (anxa2) plays an important role in hematopoietic stem cell (HSC) localization to the endosteal/osteoblastic marrow niche. This study explored the role that annexin-2 plays in presenting stromal cell-derived factor - 1 (or CXCL12) to HSCs.
Materials and Methods. Competitive long-term bone marrow transplant assays were used to determine if HSC engraftment is altered in annexin-2 - deficient animals. Colony-forming cell assays, CXCL12 enzyme-linked immunosorbent assay, and real-time reverse transcription polymerase chain reaction analyses were used to determine stem or progenitor cell mobilization by granulocyte colony-stimulating factor. Immunohistochemistry, immunoprecipitation, binding assays, and chemotactic assays were employed to determine if annexin-2 is associated with CXCL12. Degradation assays were also used to determine if annexin-2 and CXCL12 protect each other from proteolytic degradation.
Results. Anxa2(-/-) animals had fewer HSCs in their marrow, and the HSCs in anxa2(-/-) animals express less CXCR4 and CXCR7, suggesting a cell intrinsic defect. Transplantation studies of wild-type marrow into anxa2(-/-) animals demonstrated a cell-extrinsic defect in the anxa2(-/-) animals. CXCL12 binds directly to annexin-2, and this interaction facilitates presentation of CXCL12 to HSCs. Yet the binding of CXCL12 to annexin-2 did not protect CXCL12 from proteolytic cleavage after stem or progenitor cell mobilization by granulocyte colony-stimulating factor.
Conclusions. These results suggest that annexin-2 serves as an anchor for CXCL12 to help in the localization of HSCs to the niche. (C) 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
C1 [Jung, Younghun; Shiozawa, Yusuke; Wang, Jingcheng; Havens, Aaron M.; Taichman, Russell S.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
[Patel, Lalit R.] Univ Michigan, Sch Dent, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Patel, Lalit R.] Univ Michigan, Sch Dent, Dept Urol, Ann Arbor, MI 48109 USA.
[Havens, Aaron M.] Univ Michigan, Sch Dent, Dept Orthodont & Pediat Dent, Ann Arbor, MI 48109 USA.
[Song, Junhui; Krebsbach, Paul H.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
[Roodman, G. David] Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA USA.
[Roodman, G. David] Univ Pittsburgh, Dept Med Hematol Oncol, Pittsburgh, PA USA.
RP Taichman, RS (reprint author), Univ Michigan, Sch Dent, Dept Periodont, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM rtaich@umich.edu
OI Taichman, Russell S./0000-0002-7890-0020
FU Pediatric Oncology Research Fellowship; Department of Defense
[PC073952]; National Institutes of health [DK082481, DE020721,
1RC1DE020721, CA141426, CA09 3900]
FX We thank Dr. Katherine A. Hajjar (Weill Medical College of Cornell
University, New York, NY) for the anxa2-/- mice. This work
was directly supported by a Pediatric Oncology Research Fellowship
(Y.S.). This study was supported by grants from the Department of
Defense (PC073952) and National Institutes of health (DK082481,
DE020721, 1RC1DE020721, CA141426 and CA09 3900). No financial
interest/relationships to the topic of this article have been declared.
NR 46
TC 16
Z9 17
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD FEB
PY 2011
VL 39
IS 2
BP 151
EP 166
DI 10.1016/j.exphem.2010.11.007
PG 16
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 716JE
UT WOS:000286964100003
PM 21108988
ER
PT J
AU Patierno, S
Anselmi, L
Jaramillo, I
Scott, D
Garcia, R
Sternini, C
AF Patierno, Simona
Anselmi, Laura
Jaramillo, Ingrid
Scott, David
Garcia, Rachel
Sternini, Catia
TI Morphine Induces mu Opioid Receptor Endocytosis in Guinea Pig Enteric
Neurons Following Prolonged Receptor Activation
SO GASTROENTEROLOGY
LA English
DT Article
DE G-Protein-Coupled Receptors; Opioid Peptides; Opiate Drugs; Tolerant and
Naive Animals
ID PROTEIN-COUPLED RECEPTORS; MEMBRANE TRAFFICKING; ABDOMINAL-SURGERY;
BOWEL DYSFUNCTION; BETA-ARRESTIN; OPIATE DRUGS; SPINAL-CORD; IN-VIVO;
INTERNALIZATION; DESENSITIZATION
AB BACKGROUND & AIMS: The mu opioid receptor (mu OR) undergoes rapid endocytosis after acute stimulation with opioids and most opiates, but not with morphine. We investigated whether prolonged activation of mu OR affects morphine's ability to induce receptor endocytosis in enteric neurons. METHODS: We compared the effects of morphine, a poor mu OR-internalizing opiate, and (D-Ala2,MePhe4,Gly-ol5) enkephalin (DAMGO), a potent mu OR-internalizing agonist, on mu OR trafficking in enteric neurons and on the expression of dynamin and beta-arrestin immunoreactivity in the ileum of guinea pigs rendered tolerant by chronic administration of morphine. RESULTS: Morphine (100 mu mol/L) strongly induced endocytosis of mu OR in tolerant but not naive neurons (55.7% +/- 9.3% vs 24.2% +/- 7.3%; P < .001) whereas DAMGO (10 mu mol/L) strongly induced internalization of mu OR in neurons from tolerant and naive animals (63.6% +/- 8.4% and 66.5% +/- 3.6%). Morphine-or DAMGO-induced mu OR endocytosis resulted from direct interactions between the ligand and the mu OR because endocytosis was not affected by tetrodotoxin, a blocker of endogenous neurotransmitter release. Ligand-induced mu OR internalization was inhibited by pretreatment with the dynamin inhibitor, dynasore. Chronic morphine administration resulted in a significant increase and translocation of dynamin immunoreactivity from the intracellular pool to the plasma membrane, but did not affect beta-arrestin immunoreactivity. CONCLUSIONS: Chronic activation of mu ORs increases the ability of morphine to induce mu OR endocytosis in enteric neurons, which depends on the level and cellular localization of dynamin, a regulatory protein that has an important role in receptor-mediated signal transduction in cells.
C1 [Patierno, Simona; Anselmi, Laura; Scott, David; Garcia, Rachel; Sternini, Catia] Vet Adm Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA.
[Patierno, Simona; Anselmi, Laura; Jaramillo, Ingrid; Scott, David; Sternini, Catia] Univ Calif Los Angeles, Dept Med, Div Digest Dis, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Scott, David] Univ Calif Los Angeles, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Sternini, Catia] Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, Los Angeles, CA 90024 USA.
RP Sternini, C (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 224,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM csternin@ucla.edu
FU National Institutes of Health-National Institute on Drug Abuse Center
for Study of Opioid Receptors and Drugs of Abuse [DK54155, DK41301, P50
DA05010]
FX This research was supported by the National Institutes of Health grants
DK54155 (C. S.), DK41301 (Morphology/Imaging subsection, to C. S.), and
a pilot grant (to C. S.) from the National Institutes of Health-National
Institute on Drug Abuse Center for Study of Opioid Receptors and Drugs
of Abuse (P50 DA05010).
NR 54
TC 22
Z9 22
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2011
VL 140
IS 2
BP 618
EP 626
DI 10.1053/j.gastro.2010.11.005
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 711LR
UT WOS:000286593600040
PM 21070774
ER
PT J
AU Giardino, WJ
Pastor, R
Anacker, AMJ
Spangler, E
Cote, DM
Li, J
Stenzel-Poore, MP
Phillips, TJ
Ryabinin, AE
AF Giardino, W. J.
Pastor, R.
Anacker, A. M. J.
Spangler, E.
Cote, D. M.
Li, J.
Stenzel-Poore, M. P.
Phillips, T. J.
Ryabinin, A. E.
TI Dissection of corticotropin-releasing factor system involvement in
locomotor sensitivity to methamphetamine
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE Addiction; amphetamine; amygdala; corticotropin-releasing hormone;
urocortin
ID LONG-TERM POTENTIATION; ANXIETY-LIKE BEHAVIOR; TYPE-1 RECEPTOR
ANTAGONIST; EDINGER-WESTPHAL NUCLEUS; PITUITARY-ADRENAL AXIS; VENTRAL
TEGMENTAL AREA; CENTRAL-NERVOUS-SYSTEM; CRF-BINDING PROTEIN; RAT-BRAIN;
COCAINE WITHDRAWAL
AB Sensitivity to the euphoric and locomotor-activating effects of drugs of abuse may contribute to risk for excessive use and addiction. Repeated administration of psychostimulants such as methamphetamine (MA) can result in neuroadaptive consequences that manifest behaviorally as a progressive escalation of locomotor activation, termed psychomotor sensitization. The present studies addressed the involvement of specific components of the corticotropin-releasing factor (CRF) system in locomotor activation and psychomotor sensitization induced by MA (1, 2 mg/kg) by utilizing pharmacological approaches, as well as a series of genetic knockout (KO) mice, each deficient for a single component of the CRF system: CRF-R1, CRF-R2, CRF, or the CRF-related peptide Urocortin 1 (Ucn1). CRF-R1 KO mice did not differ from wild-type mice in sensitization to MA, and pharmacological blockade of CRF-R1 with CP-154,526 (15, 30 mg/kg) in DBA/2J mice did not selectively attenuate either the acquisition or expression of MA-induced sensitization. Deletion of either of the endogenous ligands of CRF-R1 (CRF, Ucn1) either enhanced or had no effect on MA-induced sensitization, providing further evidence against a role for CRF-R1 signaling. Interestingly, deletion of CRF-R2 attenuated MA-induced locomotor activation, elucidating a novel contribution of the CRF system to MA sensitivity, and suggesting the participation of the endogenous urocortin peptides Ucn2 and Ucn3. Immunohistochemistry for Fos was used to visualize neural activation underlying CRF-R2-dependent sensitivity to MA, identifying the basolateral and central nuclei of the amygdala as neural substrates involved in this response. Our results support further examination of CRF-R2 involvement in neural processes associated with MA addiction.
C1 [Giardino, W. J.; Pastor, R.; Anacker, A. M. J.; Spangler, E.; Cote, D. M.; Li, J.; Phillips, T. J.; Ryabinin, A. E.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
[Giardino, W. J.; Pastor, R.; Anacker, A. M. J.; Spangler, E.; Cote, D. M.; Li, J.; Phillips, T. J.; Ryabinin, A. E.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA.
[Pastor, R.] Univ Jaume 1, Area Psicobiol, Castellon de La Plana, Spain.
[Stenzel-Poore, M. P.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
[Phillips, T. J.] Portland VA Med Ctr, Res Serv, R&D32, Portland, OR USA.
RP Ryabinin, AE (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, L-470,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.
EM ryabinin@ohsu.edu
FU NIH [P50DA018165, RO3DA02854, T32DA007262]
FX This research was supported by NIH grants P50DA018165 (A. E. R.,
T.J.P.), RO3DA02854 (A. E. R.) and T32DA007262 (W.J.G.), and resources
were also provided by the Department of Veterans Affairs (T.J.P.). We
are grateful to Pfizer for their donation of their drug, CP-154,526, for
use in our work.
NR 80
TC 18
Z9 18
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1601-1848
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD FEB
PY 2011
VL 10
IS 1
BP 78
EP 89
DI 10.1111/j.1601-183X.2010.00641.x
PG 12
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 709VG
UT WOS:000286468900009
PM 20731720
ER
PT J
AU Groeneveld, PW
Epstein, AJ
Yang, FF
Yang, L
Polsky, D
AF Groeneveld, Peter W.
Epstein, Andrew J.
Yang, Feifei
Yang, Lin
Polsky, Daniel
TI Medicare's Policy On Carotid Stents Limited Use To Hospitals Meeting
Quality Guidelines Yet Did Not Hurt Disadvantaged
SO HEALTH AFFAIRS
LA English
DT Article; Proceedings Paper
CT Annual Research Meeting of the Academy-Health
CY JUN 28, 2010
CL Boston, MA
SP Acad Hlth
ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ENDARTERECTOMY; COVERAGE;
TECHNOLOGIES; POPULATION; TRIAL; COMPLICATIONS; DIFFUSION; STENOSIS;
OUTCOMES
AB Medicare began covering the use of carotid stents to treat arterial blockages in 2005 under an innovative policy requiring hospitals to meet quality-of-care benchmarks before seeking reimbursement. By restricting carotid stent provision to a smaller subset of US hospitals than those typically adopting new cardiovascular technologies, this policy could have disproportionately reduced the availability of this technology for minority, low-income, and rural patients. Such patients are often served by hospitals less able than others to meet increasingly stringent quality requirements. However, our analysis of hospitals that provided stents during 2005-07 demonstrated that although 21-38 percent fewer hospitals offered stents than offered other types of interventional cardiovascular procedures, such as heart bypass grafts, stents were no less available in localities with substantial poor, black, or rural populations than they were in other areas. Our study provides important evidence that the carotid stent coverage policy met its goal of limiting the adoption of the technology by hospitals that weren't well prepared to provide it-while still maintaining equitable availability of the technology. Therefore, it may be a useful model for future Medicare coverage decisions.
C1 [Groeneveld, Peter W.; Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Yang, Feifei; Yang, Lin] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Polsky, Daniel] Penns Wharton Sch, Philadelphia, PA USA.
[Polsky, Daniel] Whartons Leonard Davis Inst Hlth Econ, Philadelphia, PA USA.
RP Groeneveld, PW (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
EM petergro@mail.med.upenn.edu
FU AHRQ HHS [R01 HS018403, 1R01HS018403]; NHLBI NIH HHS [R01 HL086919,
1R01HL086919, R01 HL086919-03]
NR 36
TC 6
Z9 6
U1 0
U2 1
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD FEB
PY 2011
VL 30
IS 2
BP 312
EP 321
DI 10.1377/hlthaff.2010.0320
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 715KR
UT WOS:000286883900016
PM 21289353
ER
PT J
AU Dahi, S
Karliner, JS
Sarkar, R
Lovett, DH
AF Dahi, Sia
Karliner, Joel S.
Sarkar, Rajabrata
Lovett, David H.
TI Transgenic expression of matrix metalloproteinase-2 induces coronary
artery ectasia
SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE aneurysm; coronary artery ectasia; elastin; matrix metalloproteinase-2;
transgenic
ID ABDOMINAL AORTIC-ANEURYSM; CLINICAL-IMPLICATIONS; VASCULAR-DISEASE;
PROMOTER; MATRIX-METALLOPROTEINASE-2; POLYMORPHISMS; INFLAMMATION;
DYSFUNCTION; MMP-2
AB P>Coronary artery ectasia (CAE) is generally diagnosed in patients undergoing arteriography for presumptive atherosclerotic coronary artery disease. CAE is commonly considered as a variant of atherosclerotic disease; however, recent studies suggest that CAE is the result of a systemic vascular disorder. There is increasing evidence that aneurysmal vascular disease is a systemic disorder characterized by enhanced expression of pro-inflammatory cytokines and increased synthesis of enzymes capable of degrading elastin and other components of the vascular wall. Matrix metalloproteinase-2 degrades a number of extracellular substrates, including elastin and has been shown to play a critical role in the development of abdominal aortic aneurysms. This study characterizes the development of CAE in a unique murine transgenic model with cardiac-specific expression of active MMP-2. Transgenic mice were engineered to express an active form of MMP-2 under control of the alpha-myosin heavy chain promoter. Coronary artery diameters were quantified, along with studies of arterial structure, elastin integrity and vascular expression of the MMP-2 transgene. Latex casts quantified total coronary artery volumes and arterial branching. Mid-ventricular coronary luminal areas were increased in the MMP-2 transgenics, coupled with foci of aneurysmal dilation, ectasia and perivascular fibrosis. There was no evidence for atherogenesis. Coronary vascular elastin integrity was compromised and coupled with inflammatory cell infiltration. Latex casts of the coronary arteries displayed ectasia with fusiform dilatation. The MMP-2 transgenic closely replicates human CAE and supports a critical and initiating role for this enzyme in the pathogenesis of this disorder.
C1 [Dahi, Sia; Sarkar, Rajabrata] Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Surg, San Francisco, CA 94121 USA.
[Karliner, Joel S.; Lovett, David H.] Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, San Francisco Dept, San Francisco, CA 94121 USA.
No Calif Inst Res & Educ, San Francisco, CA USA.
RP Lovett, DH (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med 111J, 4150 Clement St, San Francisco, CA 94121 USA.
EM david.lovett@va.gov
FU National Heart, Lung and Blood Institute [PO-1-HL-68738]
FX This work was supported by National Heart, Lung and Blood Institute
Grant PO-1-HL-68738 to J. S. Karliner and D. H. Lovett.
NR 24
TC 11
Z9 14
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0959-9673
J9 INT J EXP PATHOL
JI Int. J. Exp. Pathol.
PD FEB
PY 2011
VL 92
IS 1
BP 50
EP 56
DI 10.1111/j.1365-2613.2010.00744.x
PG 7
WC Pathology
SC Pathology
GA 712MP
UT WOS:000286671200006
PM 21039989
ER
PT J
AU Deitiker, PR
Oshima, M
Smith, RG
Mosier, D
Atassi, MZ
AF Deitiker, P. R.
Oshima, M.
Smith, R. G.
Mosier, D.
Atassi, M. Z.
TI Association with HLA DQ of early onset myasthenia gravis in Southeast
Texas region of the United States
SO INTERNATIONAL JOURNAL OF IMMUNOGENETICS
LA English
DT Article
ID HIGH-RESOLUTION; ALLELES; DQB1-ASTERISK-0502; IDENTIFICATION;
POPULATION; HAPLOTYPES; ANTIBODY; JAPAN
AB P>Forty-four Caucasian American myasthenia gravis (MG) patients from Southeast Texas underwent high resolution HLA DQ analysis. For the majority of patients who were late onset or male, no significant associations with DQ were observed. However, associations with DQ increased in female patients and early onset patients. At the allele level, DQB1 *0503, *0604, *0502 and *0402 collectively contributed to a positive association of the DQ locus with early onset MG (EOMG), while individually failing to show significant association. At DQ level, the novel haplotype DQA1*0401:DQB1*0201 was the primary factor in the association of combined DQ loci with early onset. In addition, *0104:*0503, *0102:*0604, *0102:*0502 and *0303:*0402 collectively contributed to the positive association of the haplotype loci. DR3-DQ2.5cis, a well known risk factor for MG in Western Eurasia, was not found associated with disease in any group. For typical EOMG [early onset, no thymoma, anti-acetylcholine receptor (AChR) antibody (Ab) positive] no association with DQA1 locus was found, however DQB1*0604 demonstrated an 'uncorrected' positive association. A few DQ haplotype (DQA1:DQB1) were positively associated with typical EOMG; a positive individual association for *0401:*0201 was complimented by the contributions of *0102:*0604 and *0303:*0402 haplotypes. A small minority of patients that were atypical and EOMG had a strong genetic association with DQA1*0104:DQB1*0503, the group included an anti-MuSK Ab positive and an anti-AChR negative patient. This report finds common ground with European studies regarding MuSK association; however similarities in association for typical early onset disease resembled HLA risk factors in East Asia and Southern Europe.
C1 [Deitiker, P. R.; Oshima, M.; Atassi, M. Z.] Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA.
[Deitiker, P. R.; Oshima, M.; Atassi, M. Z.] Baylor Coll Med, Dept Mol Biol, Houston, TX 77030 USA.
[Mosier, D.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Atassi, M. Z.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.
[Smith, R. G.] Univ Texas Med Branch, Dept Neurol, Galveston, TX USA.
[Mosier, D.] ME DeBakey VA Med Ctr, Neurol & Med Res Serv, Houston, TX USA.
RP Atassi, MZ (reprint author), Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA.
EM matassi@bcm.edu
FU Welch Foundation; Muscular Dystrophy Association
FX The work was supported by the Welch Foundation due to the award of the
Robert A Welch Chair of Chemistry to MZ Atassi. This study was partly
supported by a grant from the Muscular Dystrophy Association. The
authors thank Dr. Maki Otani, Gerrit Heetderks, Laura Ouch, Lucy Tea and
Masooma Naqvi for their excellent technical assistance.
NR 18
TC 13
Z9 13
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1744-3121
J9 INT J IMMUNOGENET
JI Int. J. Immunogenet.
PD FEB
PY 2011
VL 38
IS 1
BP 55
EP 62
DI 10.1111/j.1744-313X.2010.00979.x
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 702FV
UT WOS:000285880900010
PM 21108743
ER
PT J
AU West, DS
Gorin, AA
Subak, LL
Foster, G
Bragg, C
Hecht, J
Schembri, M
Wing, RR
AF West, D. S.
Gorin, A. A.
Subak, L. L.
Foster, G.
Bragg, C.
Hecht, J.
Schembri, M.
Wing, R. R.
CA Program Reduce Incontinence Diet E
TI A motivation-focused weight loss maintenance program is an effective
alternative to a skill-based approach
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE weight maintenance; motivation; obesity treatment; autonomy;
motivational interviewing
ID DIABETES-PREVENTION-PROGRAM; SELF-DETERMINATION THEORY; LIFE-STYLE
INTERVENTION; PHYSICAL-ACTIVITY; WOMEN; SATISFACTION; OVERWEIGHT;
REDUCTION; GOALS; TRIAL
AB Objective: Maintaining weight loss is a major challenge in obesity treatment. Individuals often indicate that waning motivation prompts cessation of effective weight management behaviors. Therefore, a novel weight loss maintenance program that specifically targets motivational factors was evaluated.
Design: Overweight women (N = 338; 19% African American) with urinary incontinence were randomized to lifestyle obesity treatment or control and followed for 18 months. All participants in lifestyle (N = 226) received the same initial 6-month group behavioral obesity treatment and were then randomized to (1) a novel motivation-focused maintenance program (N = 113) or (2) a standard skill-based maintenance approach (N - 113).
Main Outcome Measure: Weight assessed at baseline, 6 and 18 months.
Results: Both treatment groups (motivation-focused and skill-based) achieved comparable 18-month weight losses (-5.48% for motivation-focused vs -5.55% in skill-based, P = 0.98), and both groups lost significantly more than controls (-1.51%; P = 0.0012 in motivation-focused and P = 0.0021 in skill-based).
Conclusions: A motivation-focused maintenance program offers an alternative, effective approach to weight maintenance expanding available evidence-based interventions beyond traditional skill-based programs.
C1 [West, D. S.] Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR USA.
[Gorin, A. A.] Univ Connecticut, Dept Psychol, Storrs, CT USA.
[Subak, L. L.; Schembri, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Subak, L. L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Foster, G.] Temple Univ, Dept Med, Philadelphia, PA 19122 USA.
[Foster, G.] Temple Univ, Dept Publ Hlth, Philadelphia, PA 19122 USA.
[Bragg, C.] Univ Alabama, Dept Prevent Med, Birmingham, AL USA.
[Hecht, J.] Miriam Hosp, Providence, RI 02906 USA.
[Wing, R. R.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
RP West, DS (reprint author), Univ Arkansas Med Sci, Dept Hlth Behav & Hlth Educ, Fay W Boozman Coll Publ Hlth, 4301 W Markham St,Mail Slot 820, Little Rock, AR USA.
EM WestDelia@uams.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[U01DK067860, U01 DK067861, U01 DK067862]; Office of Research on Women's
Health
FX This research was supported in part by grants U01DK067860, U01 DK067861
and U01 DK067862 from the National Institute of Diabetes and Digestive
and Kidney Diseases. Funding was also provided by the Office of Research
on Women's Health. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institute of Diabetes and Digestive and Kidney Diseases or the
National Institutes of Health. See online Supplementary materials for
full author acknowledgements.
NR 42
TC 46
Z9 47
U1 6
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
J9 INT J OBESITY
JI Int. J. Obes.
PD FEB
PY 2011
VL 35
IS 2
BP 259
EP 269
DI 10.1038/ijo.2010.138
PG 11
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 721LD
UT WOS:000287355000011
PM 20680012
ER
PT J
AU Gahramanov, S
Raslan, AM
Muldoon, LL
Hamilton, BE
Rooney, WD
Varallyay, CG
Njus, JM
Haluska, M
Neuwelt, EA
AF Gahramanov, Seymur
Raslan, Ahmed M.
Muldoon, Leslie L.
Hamilton, Bronwyn E.
Rooney, William D.
Varallyay, Csanad G.
Njus, Jeffrey M.
Haluska, Marianne
Neuwelt, Edward A.
TI POTENTIAL FOR DIFFERENTIATION OF PSEUDOPROGRESSION FROM TRUE TUMOR
PROGRESSION WITH DYNAMIC SUSCEPTIBILITY-WEIGHTED CONTRAST-ENHANCED
MAGNETIC RESONANCE IMAGING USING FERUMOXYTOL VS. GADOTERIDOL: A PILOT
STUDY
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Blood-brain barrier; Dynamic susceptibility-weighted contrast-enhanced
magnetic resonance imaging; Glioblastoma multiforme; Pseudoprogression;
Radiochemotherapy
ID CEREBRAL BLOOD-VOLUME; CENTRAL-NERVOUS-SYSTEM;
POSITRON-EMISSION-TOMOGRAPHY; CONCOMITANT RADIOCHEMOTHERAPY; RADIATION
NECROSIS; GRADE GLIOMAS; MR; PERFUSION; GLIOBLASTOMA; RADIOTHERAPY
AB Purpose: We evaluated dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging (DSC-MRI) using gadoteridol in comparison to the iron oxide nanoparticle blood pool agent, ferumoxytol, in patients with glioblastoma multiforme (GBM) who received standard radiochemotherapy (RCT).
Methods and Materials: Fourteen patients with GBM received standard RCT and underwent 19 MRI sessions that included DSC-MRI acquisitions with gadoteridol on Day 1 and ferumoxytol on Day 2. Relative cerebral blood volume (rCBV) values were calculated from DSC data obtained from each contrast agent. T1-weighted acquisition post-gadoteridol administration was used to identify enhancing regions.
Results: In seven MRI sessions of clinically presumptive active tumor, gadoteridol-DSC showed low rCBV in three and high rCBV in four, whereas ferumoxytol-DSC showed high rCBV in all seven sessions (p = 0.002). After RCT, seven MRI sessions showed increased gadoteridol contrast enhancement on T1-weighted scans coupled with low rCBV without significant differences between contrast agents (p = 0.9). Based on post-gadoteridol T1-weighted scans, DSC-MRI, and clinical presentation, four patterns of response to RCT were observed: regression, pseudoprogression, true progression, and mixed response.
Conclusion: We conclude that DSC-MRI with a blood pool agent such as ferumoxytol may provide a better monitor of tumor rCBV than DSC-MRI with gadoteridol. Lesions demonstrating increased enhancement on T1-weighted MRI coupled with low ferumoxytol rCBV are likely exhibiting pseudoprogression, whereas high rCBV with ferumoxytol is a better marker than gadoteridol for determining active tumor. These interesting pilot observations suggest that ferumoxytol may differentiate tumor progression from pseudoprogression and warrant further investigation. (C) 2011 Elsevier Inc.
C1 [Gahramanov, Seymur; Muldoon, Leslie L.; Varallyay, Csanad G.; Haluska, Marianne; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Raslan, Ahmed M.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA.
[Rooney, William D.; Njus, Jeffrey M.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA.
[Rooney, William D.; Njus, Jeffrey M.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA.
[Varallyay, Csanad G.] Univ Klinikum Wurzburg, Dept Neuroradiol, Wurzburg, Germany.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
FU Veterans Administration; National Institute of Health [CA 137488,
NS53468, NS44687]; AMAG Pharmaceuticals
FX Supported by a Veterans Administration merit review grant and by
National Institute of Health grants CA 137488, NS53468, and NS44687 to
EAN. Imaging efforts supported in part by the Oregon opportunity. There
is a sponsored research agreement to OHSU from AMAG Pharmaceuticals.
NR 31
TC 73
Z9 73
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD FEB 1
PY 2011
VL 79
IS 2
BP 514
EP 523
DI 10.1016/j.ijrobp.2009.10.072
PG 10
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 709OW
UT WOS:000286451000028
PM 20395065
ER
PT J
AU Hooker, CI
Tully, LM
Verosky, SC
Fisher, M
Holland, C
Vinogradov, S
AF Hooker, Christine I.
Tully, Laura M.
Verosky, Sara C.
Fisher, Melissa
Holland, Christine
Vinogradov, Sophia
TI Can I Trust You? Negative Affective Priming Influences Social Judgments
in Schizophrenia
SO JOURNAL OF ABNORMAL PSYCHOLOGY
LA English
DT Article
DE schizophrenia; paranoia; person perception; trustworthiness; social
cognition
ID EMOTIONAL FACIAL EXPRESSIONS; RECOGNITION; COGNITION; MOOD;
IDENTIFICATION; AMYGDALA; STATES; PERFORMANCE; PERCEPTION; DEPRESSION
AB Successful social interactions rely on the ability to make accurate judgments based on social cues as well as the ability to control the influence of internal or external affective information on those judgments. Prior research suggests that individuals with schizophrenia misinterpret social stimuli and this misinterpretation contributes to impaired social functioning. We tested the hypothesis that for people with schizophrenia, social judgments are abnormally influenced by affective information. Twenty-three patients with schizophrenia and 35 healthy control participants rated the trustworthiness of faces following the presentation of neutral, negative (threat-related), or positive affective primes. Results showed that all participants rated faces following negative affective primes as less trustworthy than faces following neutral or positive primes. Importantly, this effect was significantly more pronounced for participants with schizophrenia, suggesting that schizophrenia may be characterized by an exaggerated influence of negative affective information on social judgment. Furthermore, the extent that the negative affective prime influenced trustworthiness judgments was significantly associated with patients' severity of positive symptoms, particularly feelings of persecution. These findings suggest that for people with schizophrenia, negative affective information contributes to an interpretive bias, consistent with paranoid ideation, when judging the trustworthiness of others. This bias may contribute to social impairments in schizophrenia.
C1 [Hooker, Christine I.; Tully, Laura M.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Verosky, Sara C.] Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.
[Fisher, Melissa; Holland, Christine; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Fisher, Melissa; Holland, Christine; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Hooker, CI (reprint author), Harvard Univ, Dept Psychol, 820 William James Hall,33 Kirkland St, Cambridge, MA 02138 USA.
EM chooker@wjh.harvard.edu
OI Tully, Laura/0000-0002-2751-9887
FU NIMH NIH HHS [R01 MH068725, MH68725-02, MH71746, K08 MH071746-01, K08
MH071746]
NR 61
TC 24
Z9 25
U1 1
U2 17
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0021-843X
J9 J ABNORM PSYCHOL
JI J. Abnorm. Psychol.
PD FEB
PY 2011
VL 120
IS 1
BP 98
EP 107
DI 10.1037/a0020630
PG 10
WC Psychology, Clinical; Psychology, Multidisciplinary
SC Psychology
GA 717VB
UT WOS:000287074400009
PM 20919787
ER
PT J
AU Wu, GF
Shindler, KS
Allenspach, EJ
Stephen, TL
Thomas, HL
Mikesell, RJ
Cross, AH
Laufer, TM
AF Wu, Gregory F.
Shindler, Kenneth S.
Allenspach, Eric J.
Stephen, Tom L.
Thomas, Hannah L.
Mikesell, Robert J.
Cross, Anne H.
Laufer, Terri M.
TI Limited sufficiency of antigen presentation by dendritic cells in models
of central nervous system autoimmunity
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Dendritic cells; Experimental autoimmune; encephalomyelitis/MS;
Autoimmunity; Neuroimmunology; Immunopathology; Antigen presenting cells
ID B T-CELLS; MULTIPLE-SCLEROSIS; IN-VIVO; OPTIC NEURITIS; CNS
AUTOIMMUNITY; TRANSGENIC MICE; TH17 CELLS; ENCEPHALOMYELITIS; DEPLETION;
PEPTIDES
AB Experimental autoimmune encephalomyelitis (EAE), a model for the human disease multiple sclerosis (MS), is dependent upon the activation and effector functions of autoreactive CD4 T cells. Multiple interactions between CD4 T cells and major histocompatibility class II (MHCII)+ antigen presenting cells (APCs) must occur in both the periphery and central nervous system (CNS) to elicit autoimmunity. The identity of the MHCII+ APCs involved throughout this process remains in question. We investigated which APC in the periphery and CNS mediates disease using transgenic mice with MHCII expression restricted to dendritic cells (DCs). MHCII expression restricted to DCs results in normal susceptibility to peptide-mediated EAE. Indeed, radiation-sensitive bone marrow-derived DCs were sufficient for all APC functions during peptide-induced disease. However, DCs alone were inefficient at promoting disease after immunization with the myelin protein myelin oligodendrocyte glycoprotein (MOG), even in the presence of MHCII-deficient B cells. Consistent with a defect in disease induction following protein immunization, antigen presentation by DCs alone was incapable of mediating spontaneous optic neuritis. These results indicate that DCs are capable of perpetuating CNS-targeted autoimmunity when antigens are readily available, but other APCs are required to efficiently initiate pathogenic cognate CD4 T cell responses. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Wu, Gregory F.; Mikesell, Robert J.; Cross, Anne H.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA.
[Wu, Gregory F.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19004 USA.
[Shindler, Kenneth S.] Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19004 USA.
[Allenspach, Eric J.; Stephen, Tom L.; Thomas, Hannah L.; Laufer, Terri M.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19004 USA.
[Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19004 USA.
RP Wu, GF (reprint author), Washington Univ, Dept Neurol, Box 8111,600 S Euclid Ave, St Louis, MO 63110 USA.
EM wug@neuro.wustl.edu; tlaufer@mail.med.upenn.edu
OI Allenspach, Eric/0000-0001-7346-5835
FU NIH; National Multiple Sclerosis Society; Penn Center for Clinical
Immunology
FX The authors would like to thank Gary Koretzky, Avinash Bhandoola, and
Taku Kambayashi for helpful discussions and Angela Archambault, Taku
Kambayashi and Michael Racke for critical review of the manuscript. The
authors appreciate the technical expertise of Hua Ding from the Joseph
Stokes Jr. Research Institute, Children's Hospital of Philadelphia
protein core of Children's hospital of Philadelphia for generating MOG
protein. This research was supported by grants from the NIH and a Pilot
Research Award from the National Multiple Sclerosis Society to TML. GFW
was supported by a postdoctoral fellowship from the National Multiple
Sclerosis Society and a Penn Center for Clinical Immunology Jackson-Wade
Fellowship. These sponsors had no role in the study design, collection,
analysis and interpretation of data, writing of the manuscript or
decision to submit the paper for publication.
NR 50
TC 20
Z9 21
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
J9 J AUTOIMMUN
JI J. Autoimmun.
PD FEB
PY 2011
VL 36
IS 1
BP 56
EP 64
DI 10.1016/j.jaut.2010.10.006
PG 9
WC Immunology
SC Immunology
GA 727WB
UT WOS:000287832500008
PM 21095100
ER
PT J
AU Novgorodov, SA
Chudakova, DA
Wheeler, BW
Bielawski, J
Kindy, MS
Obeid, LM
Gudz, TI
AF Novgorodov, Sergei A.
Chudakova, Daria A.
Wheeler, Brian W.
Bielawski, Jacek
Kindy, Mark S.
Obeid, Lina M.
Gudz, Tatyana I.
TI Developmentally Regulated Ceramide Synthase 6 Increases Mitochondrial
Ca2+ Loading Capacity and Promotes Apoptosis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PERMEABILITY TRANSITION PORE; NERVE GROWTH-FACTOR; BRAIN MITOCHONDRIA;
CELL-DEATH; CYSTINE/GLUTAMATE ANTIPORTER; (DIHYDRO)CERAMIDE SYNTHASE;
SUBSTRATE-SPECIFICITY; N-ACYLTRANSFERASE; CALPAIN INHIBITOR; CNS
MITOCHONDRIA
AB Ceramides, which are membrane sphingolipids and key mediators of cell-stress responses, are generated by a family of (dihydro) ceramide synthases (Lass1-6/CerS1-6). Here, we report that brain development features significant increases in sphingomyelin, sphingosine, and most ceramide species. In contrast, C-16:0-ceramide was gradually reduced and CerS6 was down-regulated in mitochondria, thereby implicating CerS6 as a primary ceramide synthase generating C-16:0-ceramide. Investigations into the role of CerS6 in mitochondria revealed that ceramide synthase down-regulation is associated with dramatically decreased mitochondrial Ca2+-loading capacity, which could be rescued by addition of ceramide. Selective CerS6 complexing with the inner membrane component of the mitochondrial permeability transition pore was detected by immunoprecipitation. This suggests that CerS6-generated ceramide could prevent mitochondrial permeability transition pore opening, leading to increased Ca2+ accumulation in the mitochondrial matrix. We examined the effect of high CerS6 expression on cell survival in primary oligodendrocyte (OL) precursor cells, which undergo apoptotic cell death during early postnatal brain development. Exposure of OLs to glutamate resulted in apoptosis that was prevented by inhibitors of de novo ceramide biosynthesis, myriocin and fumonisin B1. Knockdown of CerS6 with siRNA reduced glutamate-triggered OL apoptosis, whereas knockdown of CerS5 had no effect: the pro-apoptotic role of CerS6 was not stimulus-specific. Knockdown of CerS6 with siRNA improved cell survival in response to nerve growth factor-induced OL apoptosis. Also, blocking mitochondrial Ca2+ uptake or decreasing Ca2+-dependent protease calpain activity with specific inhibitors prevented OL apoptosis. Finally, knocking down CerS6 decreased calpain activation. Thus, our data suggest a novel role for CerS6 in the regulation of both mitochondrial Ca2+ homeostasis and calpain, which appears to be important in OL apoptosis during brain development.
C1 [Obeid, Lina M.; Gudz, Tatyana I.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Chudakova, Daria A.; Wheeler, Brian W.; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Novgorodov, Sergei A.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Novgorodov, Sergei A.; Bielawski, Jacek; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
RP Gudz, TI (reprint author), 114 Doughty St, Charleston, SC 29425 USA.
EM gudz@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU National Institutes of Health for NCCR COBRE in Lipidomics and
Pathobiology [P20 RR 17677, AG16583]; Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health Grant P20 RR 17677 for NCCR COBRE in Lipidomics and Pathobiology
(to T. I. G.), Grant AG16583 (to L. M. O.), and Veterans Affairs
Rehabilitation Research and Development Merit Awards (to T. I. G. and M.
S. K.).
NR 79
TC 31
Z9 33
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB
PY 2011
VL 286
IS 6
BP 4644
EP 4658
DI 10.1074/jbc.M110.164392
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 716MW
UT WOS:000286975700064
PM 21148554
ER
PT J
AU Page, ST
Lin, DW
Mostaghel, EA
Marck, BT
Wright, JL
Wu, J
Amory, JK
Nelson, PS
Matsumoto, AM
AF Page, Stephanie T.
Lin, Daniel W.
Mostaghel, Elahe A.
Marck, Brett T.
Wright, Jonathan L.
Wu, Jennifer
Amory, John K.
Nelson, Peter S.
Matsumoto, Alvin M.
TI Dihydrotestosterone Administration Does Not Increase Intraprostatic
Androgen Concentrations or Alter Prostate Androgen Action in Healthy
Men: A Randomized-Controlled Trial
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID LATE-ONSET HYPOGONADISM; TESTOSTERONE REPLACEMENT; OLDER MEN;
TRANSDERMAL DIHYDROTESTOSTERONE; SERUM TESTOSTERONE; DOUBLE-BLIND;
CANCER; FINASTERIDE; CASTRATION; HYPERPLASIA
AB Context: Concern exists that androgen treatment might adversely impact prostate health in older men. Dihydrotestosterone (DHT), derived from local conversion of testosterone to DHT by 5 alpha-reductase enzymes, is the principal androgen within the prostate. Exogenous androgens raise serum DHT concentrations, but their effects on the prostate are not clear.
Objective: To determine the impact of large increases in serum DHT concentrations on intraprostatic androgen concentrations and androgen action within the prostate.
Design: Double-blind, randomized, placebo-controlled.
Setting: Single academic medical center.
Participants: 31 healthy men ages 35-55.
Intervention: Daily transdermal DHT or placebo gel.
Main Outcome Measures: Serum and prostate tissue androgen concentrations and prostate epithelial cell gene expression after 4 wk of treatment.
Results: Twenty-seven men completed all study procedures. Serum DHT levels increased nearly sevenfold, while testosterone levels decreased in men treated with daily transdermal DHT gel but were unchanged in the placebo-treated group (P < 0.01 between groups). In contrast, intraprostatic DHT and testosterone concentrations on d 28 were not different between groups (DHT: placebo = 2.8 +/- 0.2 vs. DHT gel = 3.1 +/- 0.5 ng/g; T: placebo = 0.6 +/- 0.2 vs. DHT gel = 0.4 +/- 0.1, mean +/- SE). Similarly, prostate volume, prostate-specific antigen, epithelial cell proliferation, and androgen-regulated gene expression were not different between groups.
Conclusions: Robust supraphysiologic increases in serum DHT, associated with decreased serum T, do not significantly alter intraprostatic levels of DHT, testosterone, or prostate epithelial cell androgen-regulated gene expression in healthy men. Changes in circulating androgen concentrations are not necessarily mimicked within the prostate microenvironment, a finding with implications for understanding the impact of androgen therapies in men. (J Clin Endocrinol Metab 96: 430-437, 2011)
C1 [Page, Stephanie T.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA.
[Lin, Daniel W.; Wright, Jonathan L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Lin, Daniel W.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Mostaghel, Elahe A.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol & Clin Res, Seattle, WA 98109 USA.
VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Marck, Brett T.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.
RP Page, ST (reprint author), Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Dept Med, Box 357138,1959 NE Pacific St, Seattle, WA 98195 USA.
EM page@u.washington.edu
FU National Institute of Aging [K23-AG027238]; Eunice Kennedy Shriver
National Institute of Child Health and Human Development [U54-HD-42454];
Pacific Northwest Prostate Cancer SPORE [P50-CA097186]; Endocrine
Society; BHR Pharma LLC; Prostate Cancer Foundation
FX This work was supported by the National Institute of Aging
(K23-AG027238), the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (U54-HD-42454), the Pacific Northwest
Prostate Cancer SPORE (P50-CA097186), an Endocrine Society Clinical
Research Award, an investigator-initiated grant from BHR Pharma LLC, and
the Prostate Cancer Foundation. S.T.P. received grant support from BHR
Pharma LLC.
NR 36
TC 28
Z9 28
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD FEB
PY 2011
VL 96
IS 2
BP 430
EP 437
DI 10.1210/jc.2010-1865
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 716MG
UT WOS:000286972500047
PM 21177791
ER
PT J
AU Bohanes, PO
Goldman, BH
Benedetti, J
Blanke, CD
Leichman, LP
Iqbal, S
Thomas, CR
Corless, CL
Gold, PJ
Lenz, H
AF Bohanes, P. O.
Goldman, B. H.
Benedetti, J.
Blanke, C. D.
Leichman, L. P.
Iqbal, S.
Thomas, C. R., Jr.
Corless, C. L.
Gold, P. J.
Lenz, H.
TI Association of excision repair cross-complementation group 1 (ERCC1)
gene expression (GE) with outcome in stage II-III esophageal
adenocarcinoma (EA) patients treated with preoperative platinum-based
chemoradiation (CRT) in a phase II cooperative study (SWOG 0356).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
SW Oncol Grp, Ctr Stat, Seattle, WA USA.
Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada.
Desert Reg Med Ctr, Ctr Comprehens Canc, Palm Springs, CA USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
Swedish Canc Inst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 1
PY 2011
VL 29
IS 4
SU S
MA 2
PG 1
WC Oncology
SC Oncology
GA V30WW
UT WOS:000208847100003
PM 27985783
ER
PT J
AU Bradley, KA
Rubinsky, AD
Sun, HL
Bryson, CL
Bishop, MJ
Blough, DK
Henderson, WG
Maynard, C
Hawn, MT
Tonnesen, H
Hughes, G
Beste, LA
Harris, AHS
Hawkins, EJ
Houston, TK
Kivlahan, DR
AF Bradley, Katharine A.
Rubinsky, Anna D.
Sun, Haili
Bryson, Chris L.
Bishop, Michael J.
Blough, David K.
Henderson, William G.
Maynard, Charles
Hawn, Mary T.
Tonnesen, Hanne
Hughes, Grant
Beste, Lauren A.
Harris, Alex H. S.
Hawkins, Eric J.
Houston, Thomas K.
Kivlahan, Daniel R.
TI Alcohol Screening and Risk of Postoperative Complications in Male VA
Patients Undergoing Major Non-cardiac Surgery
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE alcohol screening; surgical outcomes; AUDIT-C
ID PRIMARY-CARE VALIDATION; UPPER DIGESTIVE-TRACT; SURGICAL CARE; ELECTIVE
SURGERY; MALE VETERANS; USE DISORDERS; AUDIT-C; QUALITY; MORBIDITY;
SCORES
AB BACKGROUND: Patients who misuse alcohol are at increased risk for surgical complications. Four weeks of preoperative abstinence decreases the risk of complications, but practical approaches for early preoperative identification of alcohol misuse are needed.
OBJECTIVE: To evaluate whether results of alcohol screening with the Alcohol Use Disorders Identification Test -Consumption (AUDIT-C) questionnaire-up to a year before surgery-were associated with the risk of postoperative complications.
DESIGN: This is a cohort study.
SETTING AND PARTICIPANTS: Male Veterans Affairs (VA) patients were eligible if they had major noncardiac surgery assessed by the VA's Surgical Quality Improvement Program (VASQIP) in fiscal years 2004-2006, and completed the AUDIT-C alcohol screening questionnaire (0-12 points) on a mailed survey within 1 year before surgery.
MAIN OUTCOME MEASURE: One or more postoperative complication(s) within 30 days of surgery based on VASQIP nurse medical record reviews.
RESULTS: Among 9,176 eligible men, 16.3% screened positive for alcohol misuse with AUDIT-C scores >= 5, and 7.8% had postoperative complications. Patients with AUDIT-C scores >= 5 were at significantly increased risk for postoperative complications, compared to patients who drank less. In analyses adjusted for age, smoking, and days from screening to surgery, the estimated prevalence of postoperative complications increased from 5.6% (95% CI 4.8-6.6%) in patients with AUDIT-C scores 1-4, to 7.9% (6.3-9.7%) in patients with AUDIT-Cs 5-8, 9.7% (6.6-14.1%) in patients with AUDIT-Cs 9-10 and 14.0% (8.9-21.3%) in patients with AUDIT-Cs 11-12. In fully-adjusted analyses that included preoperative covariates potentially in the causal pathway between alcohol misuse and complications, the estimated prevalence of postoperative complications increased significantly from 4.8% (4.1-5.7%) in patients with AUDIT-C scores 1-4, to 6.9% (5.5-8.7%) in patients with AUDIT-Cs 5-8 and 7.5% (5.0-11.3%) among those with AUDIT-Cs 9-10.
CONCLUSIONS: AUDIT-C scores of 5 or more up to a year before surgery were associated with increased postoperative complications.
C1 [Bradley, Katharine A.; Rubinsky, Anna D.; Sun, Haili; Bryson, Chris L.; Blough, David K.; Maynard, Charles; Beste, Lauren A.; Hawkins, Eric J.; Kivlahan, Daniel R.] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
[Bradley, Katharine A.; Hawkins, Eric J.; Kivlahan, Daniel R.] Ctr Excellence Subst Abuse Treatment & Educ, Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
[Bradley, Katharine A.; Rubinsky, Anna D.; Maynard, Charles; Beste, Lauren A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Henderson, William G.; Hughes, Grant] Dept Vet Affairs Eastern Colorado Healthcare Syst, Denver, CO USA.
[Harris, Alex H. S.] Ctr Hlth Care Evaluat, Dept Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
[Houston, Thomas K.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, TX USA.
[Bishop, Michael J.] Anesthesia Serv, Dept Vet Affairs, Cent Off, Washington, DC USA.
[Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA.
[Bishop, Michael J.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.
[Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA.
[Hawn, Mary T.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA.
[Tonnesen, Hanne] Bispebjerg Hosp, WHO Collaborating Ctr Evidence Based Hlth Promot, Copenhagen, Denmark.
[Houston, Thomas K.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Hlth Informat & Implementat Sci, Worcester, MA USA.
[Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
RP Bradley, KA (reprint author), Dept Vet Affairs Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM willi@u.washington.edu
RI Houston, Thomas/F-2469-2013; Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
FU Department of Veterans Affairs; Veterans Health Administration; Office
of Research and Development; Health Services Research and Development
[IAC 06-021]
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development and Health Services Research and Development (project IAC
06-021). Dr. Bradley is an investigator at the VA Northwest HSR&D Center
of Excellence and at the Center of Excellence in Substance Abuse
Treatment and Education, VA Puget Sound Health Care System, Seattle, WA.
NR 52
TC 30
Z9 30
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD FEB
PY 2011
VL 26
IS 2
BP 162
EP 169
DI 10.1007/s11606-010-1475-x
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 725TK
UT WOS:000287668800015
PM 20878363
ER
PT J
AU Lyles, CR
Karter, AJ
Young, BA
Spigner, C
Grembowski, D
Schillinger, D
Adler, NE
AF Lyles, Courtney R.
Karter, Andrew J.
Young, Bessie A.
Spigner, Clarence
Grembowski, David
Schillinger, Dean
Adler, Nancy E.
TI Correlates of Patient-Reported Racial/Ethnic Health Care Discrimination
in the Diabetes Study of Northern California (DISTANCE)
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Race/ethnicity; discrimination; diabetes care; managed care
ID PERCEIVED DISCRIMINATION; RACIAL-DISCRIMINATION; PUBLIC-HEALTH;
MENTAL-HEALTH; SOCIAL-STATUS; DISPARITIES; POPULATION; ADULTS;
PERSONALITY; ASSOCIATION
AB Objectives. We examined possible determinants of self-reported health care discrimination. Methods. We examined survey data from the Diabetes Study of Northern California (DISTANCE), a race-stratified sample of Kaiser diabetes patients. Respondents reported perceived discrimination, and regression models examined socioeconomic, acculturative, and psychosocial correlates. Results. Subjects (n=17,795) included 20% Blacks, 23% Latinos, 13% East Asians, 11% Filipinos, and 27% Whites. Three percent and 20% reported health care and general discrimination. Health care discrimination was more frequently reported by minorities (ORs ranging from 2.0 to 2.9 compared with Whites) and those with poorer health literacy (OR=1.10, 95% CI: 1.04-1.16), limited English proficiency (OR=1.91, 95% CI: 1.32-2.78), and depression (OR=1.53, 95% CI: 1.10-2.13). Conclusions. In addition to race/ethnicity, health literacy and English proficiency may be bases of discrimination. Evaluation is needed to determine whether patients are treated differently or more apt to perceive discrimination, and whether depression fosters and/or follows perceived discrimination.
C1 [Lyles, Courtney R.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Young, Bessie A.] Univ Washington, Dept Nephrol, Seattle, WA 98195 USA.
[Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Schillinger, Dean] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Schillinger, Dean] San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA USA.
RP Lyles, CR (reprint author), Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Box 359455, Seattle, WA 98195 USA.
EM crees@u.washington.edu
FU AHRQ HHS [T32 HS013853, HS013853]; NICHD NIH HHS [R01 HD046113, R01
HD046113-01, R01 HD046113-02, R01 HD046113-03, R01 HD046113-04, R01
HD46113]; NIDDK NIH HHS [R01 DK065664, R01 DK065664-01A1, R01
DK065664-02, R01 DK065664-03, R01 DK065664-04, R01 DK065664-05, R01
DK081796, R01 DK081796-01A1, R01 DK081796-02, R01 DK081796-03, R01
DK081796-04, R01 DK65664, RC1 DK086178, RC1 DK086178-02]
NR 53
TC 16
Z9 16
U1 2
U2 9
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD FEB
PY 2011
VL 22
IS 1
BP 211
EP 225
PG 15
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 718ZK
UT WOS:000287165100016
PM 21317516
ER
PT J
AU Hou, Q
Jin, JF
Zhou, H
Novgorodov, SA
Bielawska, A
Szulc, ZM
Hannun, YA
Obeid, LM
Hsu, YT
AF Hou, Qi
Jin, Junfei
Zhou, Hui
Novgorodov, Sergei A.
Bielawska, Alicja
Szulc, Zdzislaw M.
Hannun, Yusuf A.
Obeid, Lina M.
Hsu, Yi-Te
TI Mitochondrially targeted ceramides preferentially promote autophagy,
retard cell growth, and induce apoptosis
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE ceramide; Bax; mitochondria
ID CYTOCHROME-C RELEASE; NECROSIS-FACTOR-ALPHA; BCL-X-L; PROTEIN-KINASE;
CONFORMATIONAL-CHANGE; ACID SPHINGOMYELINASE; BAX TRANSLOCATION;
CARCINOMA-CELLS; HUMAN HEAD; IN-VIVO
AB C(6)-pyridinium (D-erythro -2-N-[6'-(1 '' -pyridinium)hexanoyl]sphingosine bromide [LCL29]) is a cationic mitochondrion-targeting ceramide analog that promotes mitochondrial permeabilization and cancer cell death. In this study, we compared the biological effects of that compound with those of D -erythro-C(6)-ceramide, its non-mitochondrion-targeting analog. In MCF7 cells it was found that C(6) -pyridinium ceramide preferentially promoted autophagosome formation and retarded cell growth more extensively than its uncharged analog. This preferential inhibition of cell growth was also observed in breast epithelial cells and other breast cancer cells. In addition, this compound could promote Bax translocation to mitochondria. This redistribution of Bax in MCF7 cells could be blocked by the pan-caspase inhibitor zVAD-fmk but via a Bid-independent signaling pathway. Moreover, C(6) -pyridinium ceramide-induced translocation of Bax to mitochondria led to mitochondrial permeabilization and cell death. Overall, we show that mitochondrial targeting of C(6) -pyridinium ceramide significantly enhances cellular response to this compound.-Hou, Q., J. Jin, H. Zhou, S. A. Novgorodov, A. Bielawska, Z. M. Szulc, Y. A. Hannun, L. M. Obeid, and Y-T. Hsu. Mitochondrially targeted ceramides preferentially promote autophagy, retard cell growth, and induce apoptosis. J. Lipid Res. 2011. 52: 278-288.
C1 [Hou, Qi; Jin, Junfei; Zhou, Hui; Bielawska, Alicja; Szulc, Zdzislaw M.; Hannun, Yusuf A.; Hsu, Yi-Te] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Novgorodov, Sergei A.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Hou, Qi] Peking Union Med Coll, Inst Mat Med, Dept Pharmacol, Beijing 100050, Peoples R China.
Chinese Acad Med Sci, Beijing 100050, Peoples R China.
[Jin, Junfei] Univ S China, Res Ctr Life Sci, Hengyang 421001, Hunan, Peoples R China.
[Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Hsu, YT (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
EM hsuy@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU National Institutes of Health [NS-40932, AG-16583]; Office of Research
and Development, US Department of Veterans Affairs
FX This research was supported in part by National Institutes of Health
Grants NS-40932 (Y-T.H.) and AG-16583 (L. M. O.) and a MERIT Award (L.
M. O.) from the Office of Research and Development, US Department of
Veterans Affairs. Its contents are solely the responsibility of the
authors and do not necessarily represent the official views of the
National Institutes of Health or other granting agencies.
NR 48
TC 24
Z9 27
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD FEB
PY 2011
VL 52
IS 2
BP 278
EP 288
DI 10.1194/jlr.M012161
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 705ZZ
UT WOS:000286181400010
PM 21081756
ER
PT J
AU Paintlia, MK
Paintlia, AS
Singh, AK
Singh, I
AF Paintlia, Manjeet K.
Paintlia, Ajaib S.
Singh, Avtar K.
Singh, Inderjit
TI Synergistic activity of interleukin-17 and tumor necrosis factor-alpha
enhances oxidative stress-mediated oligodendrocyte apoptosis
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE apoptosis and multiple sclerosis; interleukin-17; oligodendrocyte; tumor
necrosis factor
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM;
ACTIVATED PROTEIN-KINASE; BRAIN-BARRIER DISRUPTION; KAPPA-B ACTIVATION;
INDUCED CELL-DEATH; MULTIPLE-SCLEROSIS; PROGENITOR CELLS; TNF-ALPHA;
DEMYELINATING DISEASES
AB P>Th1 cytokine-induced loss of oligodendrocytes (OLs) is associated with axonal loss in CNS demyelinating diseases such as multiple sclerosis (MS)that contributes to neurological disabilities in affected individuals. Recent studies indicated that, in addition to Th1-phenotype cytokines including tumor necrosis factor (TNF)-alpha, Th17 phenotype cytokine, interleukin (IL)-17 also involved in the development of MS. In this study, we investigated the direct effect of IL-17 on the survival of OLs in the presence of TNF-alpha and individually in vitro settings. Our findings suggest that IL-17 alone, however, was not able to affect the survival of OLs, but it exacerbates the TNF-alpha-induced OL apoptosis as compared with individual TNF-alpha treatment. This effect of cytokines was ascribed to an inhibition of cell-survival mechanisms, co-localization of Bid/Bax proteins in the mitochondrial membrane and caspase 8 activation mediated release of apoptosis inducing factor from mitochondria in treated OLs. In addition, cytokine treatment disturbed the mitochondrial membrane potential in OLs with corresponding increase in the generation of reactive oxygen species, which were attenuated by N-acetyl cysteine treatment. In addition, combining of these cytokines induced cell-cycle arrest at G1/S phases in OL-like cells and inhibited the maturation of OL progenitor cells that was attenuated by peroxisome proliferator-activated receptor-gamma/-beta agonists. Collectively, these data provide initial evidence that IL-17 exacerbates TNF-alpha-induced OL loss and inhibits the differentiation of OL progenitor cells suggesting that antioxidant- or peroxisome proliferator-activated receptor agonist-based therapies have potential to limit CNS demyelination in MS or other related demyelinating disorders.
C1 [Paintlia, Manjeet K.; Paintlia, Ajaib S.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA.
RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA.
EM singhi@musc.edu
OI Paintlia, Ajaib/0000-0003-4525-5333
FU NIH [NS-22576, NS-34741, NS-37766, C06-RR015455, C06-RR018823]
FX We thank Dr Jennifer G. Schnellmann for critical reading of this
manuscript and Ms Joyce Bryan and Ms Carrie Barnes for their technical
assistance. We would like to thank Dr. Shailendra Giri for performing
EMSA and DNA ladder analyses. This study was supported by grants from
the NIH (NS-22576, NS-34741, NS-37766, C06-RR015455, and C06-RR018823).
NR 66
TC 38
Z9 39
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD FEB
PY 2011
VL 116
IS 4
BP 508
EP 521
DI 10.1111/j.1471-4159.2010.07136.x
PG 14
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 715MK
UT WOS:000286888400005
PM 21143599
ER
PT J
AU Offner, H
Sinha, S
Burrows, GG
Ferro, AJ
Vandenbark, AA
AF Offner, Halina
Sinha, Sushmita
Burrows, Gregory G.
Ferro, Adolph J.
Vandenbark, Arthur A.
TI RTL therapy for multiple sclerosis: A Phase I clinical study
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE Experimental autoimmune encephalomyelitis (EAE); Multiple sclerosis
(MS); Recombinant T cell receptor ligand (RTL); Neuroprotection;
Clinical trial
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CELL-RECEPTOR LIGANDS;
ENCEPHALITOGENIC T-CELLS; CENTRAL-NERVOUS-SYSTEM; CHEMOKINE RECEPTORS;
PROMOTES RECOVERY; CYTOKINE SWITCH; MYELIN; CXCR2; ACTIVATION
AB A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 alpha 1 and beta 1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of <= 60 mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses <= 200 mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Offner, Halina; Sinha, Sushmita; Vandenbark, Arthur A.] Vet Affairs Med Ctr, Portland, OR 97239 USA.
[Offner, Halina; Sinha, Sushmita; Burrows, Gregory G.; Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Burrows, Gregory G.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.
[Burrows, Gregory G.; Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Tykeson MS Res Lab, Portland, OR 97239 USA.
[Ferro, Adolph J.] Artielle ImmunoTherapeut Inc, Portland, OR 97223 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU National Multiple Sclerosis Society [RG3794B, RG3794A, RG3468A]; NIH
[NS47661, AI43960, NS41965, NS46877]; Biomedical Laboratory RD Service;
Department of Veterans Affairs
FX This work was supported by the National Multiple Sclerosis Society
Grants RG3794B, RG3794A and RG3468A, NIH Grants NS47661, AI43960,
NS41965, and NS46877, and by the Biomedical Laboratory R&D Service,
Department of Veterans Affairs. The authors wish to thank Ms. Eva
Niehaus for assistance in preparing the manuscript and acknowledge the
contributions of Chunhe Wang and Shayne Andrew. Dr. Offner, Dr. Burrows
and Dr. Vandenbark have a significant financial interest in Artielle
ImmunoTherapeutics, Inc., a company that may have a commercial interest
in the result of this research and technology. This potential conflict
of interest has been reviewed and managed by the OHSU and VAMC Conflict
of Interest in Research Committees.
NR 22
TC 18
Z9 18
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD FEB
PY 2011
VL 231
IS 1-2
SI SI
BP 7
EP 14
DI 10.1016/j.jneuroim.2010.09.013
PG 8
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 744YT
UT WOS:000289131800003
PM 20965577
ER
PT J
AU Wang, YG
Neumann, M
Hansen, K
Hong, SM
Kim, S
Noble-Haeusslein, LJ
Liu, JL
AF Wang, Yonggang
Neumann, Melanie
Hansen, Katharina
Hong, Shuwhey M.
Kim, Sharon
Noble-Haeusslein, Linda J.
Liu, Jialing
TI Fluoxetine Increases Hippocampal Neurogenesis and Induces Epigenetic
Factors But Does Not Improve Functional Recovery after Traumatic Brain
Injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE controlled cortical impact; histone acetylation; memory; methyl-CpG
binding domain 1; selective serotonin reuptake inhibitor
ID FOCAL CEREBRAL-ISCHEMIA; HISTONE H3 ACETYLATION; LONG-TERM-MEMORY;
SYNAPTIC PLASTICITY; COGNITIVE DEFICITS; GENE-EXPRESSION; MOTOR
RECOVERY; ANIMAL-MODEL; WATER MAZE; CELL-DEATH
AB The selective serotonin reuptake inhibitor fluoxetine induces hippocampal neurogenesis, stimulates maturation and synaptic plasticity of adult hippocampal neurons, and reduces motor/sensory and memory impairments in several CNS disorders. In the setting of traumatic brain injury (TBI), its effects on neuroplasticity and function have yet to be thoroughly investigated. Here we examined the efficacy of fluoxetine after a moderate to severe TBI, produced by a controlled cortical impact. Three days after TBI or sham surgery, mice were treated with fluoxetine (10 mg/kg/d) or vehicle for 4 weeks. To evaluate the effects of fluoxetine on neuroplasticity, hippocampal neurogenesis and epigenetic modification were studied. Stereologic analysis of the dentate gyrus revealed a significant increase in doublecortin-positive cells in brain-injured animals treated with fluoxetine relative to controls, a finding consistent with enhanced hippocampal neurogenesis. Epigenetic modifications, including an increase in histone 3 acetylation and induction of methyl-CpG-binding protein, a transcription factor involved in DNA methylation, were likewise seen by immunohistochemistry and quantitative Western immunoblots, respectively, in brain-injured animals treated with fluoxetine. To determine if fluoxetine improves neurological outcomes after TBI, gait function and spatial learning and memory were assessed by the CatWalk-assisted gait test and Barnes maze test, respectively. No differences in these parameters were seen between fluoxetine- and vehicle-treated animals. Thus while fluoxetine enhanced neuroplasticity in the hippocampus after TBI, its chronic administration did not restore locomotor function or ameliorate memory deficits.
C1 [Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Noble-Haeusslein, Linda J.; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA.
[Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94121 USA.
[Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA USA.
[Wang, Yonggang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol Surg, Beijing, Peoples R China.
[Neumann, Melanie] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany.
RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.
EM jialing.liu@ucsf.edu
RI Liu, Jialing/A-8627-2012
OI Liu, Jialing/0000-0003-4420-4382
FU VA Merit award; Department of Defense collaborative in Neuroscience
Center of Excellence
FX This work was supported by a VA Merit award (to J.L.), and a Department
of Defense collaborative in Neuroscience Center of Excellence (to J.L.).
NR 57
TC 36
Z9 37
U1 1
U2 9
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD FEB
PY 2011
VL 28
IS 2
BP 259
EP 268
DI 10.1089/neu.2010.1648
PG 10
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 719UE
UT WOS:000287234700009
PM 21175261
ER
PT J
AU Fett, N
Werth, VP
AF Fett, Nicole
Werth, Victoria P.
TI Update on morphea Part II. Outcome measures and treatment
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE autoimmune connective tissue disorder; fibrosing disorders; localized
scleroderma; morphea; scleroderma; systemic sclerosis
ID LOCALIZED SCLERODERMA MORPHEA; ULTRAVIOLET A1 PHOTOTHERAPY; PUVA BATH
PHOTOCHEMOTHERAPY; LOW-DOSE METHOTREXATE; 1ST CASE SERIES; BROAD-BAND
UVA; SYSTEMIC-SCLEROSIS; MYCOPHENOLATE-MOFETIL; LINEAR SCLERODERMA;
DOUBLE-BLIND
AB Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1. (J Am Acad Dermatol 2011;64:231-42.)
C1 [Fett, Nicole] Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA.
Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Fett, N (reprint author), Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Ste 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM Nicole.Fett@uphs.upenn.edu
FU Department of Veterans Affairs Veterans Health Administration, Office of
Research and Development, Biomedical Laboratory Research and
Development; National Institutes of Health [NIH K24-AR 02207]
FX Supported in part by a Merit Review Grant from the Department of
Veterans Affairs Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development, and by the
National Institutes of Health (grant NIH K24-AR 02207) to Dr Werth.
NR 66
TC 48
Z9 51
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD FEB
PY 2011
VL 64
IS 2
BP 231
EP 242
DI 10.1016/j.jaad.2010.05.046
PG 12
WC Dermatology
SC Dermatology
GA 714AX
UT WOS:000286780400002
PM 21238824
ER
PT J
AU Whitson, HE
Thielke, S
Diehr, P
O'Hare, AM
Chaves, PHM
Zakai, NA
Arnold, A
Chaudhry, S
Ives, D
Newman, AB
AF Whitson, Heather E.
Thielke, Stephen
Diehr, Paula
O'Hare, Ann M.
Chaves, Paulo H. M.
Zakai, Neil A.
Arnold, Alice
Chaudhry, Sarwat
Ives, Diane
Newman, Anne B.
TI Patterns and Predictors of Recovery from Exhaustion in Older Adults: The
Cardiovascular Health Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE symptoms; frailty; fatigue; transition analysis
ID STUDIES DEPRESSION SCALE; CRITERION VALIDITY; FRAILTY CRITERIA; WOMENS
HEALTH; CES-D; DISABILITY; FATIGUE; DISEASE; CARE; PHENOTYPE
AB OBJECTIVES
To estimate the likelihood of, and factors associated with, recovery from exhaustion in older adults.
DESIGN
Secondary analysis of a cohort study.
SETTING
Six annual examinations in four U.S. communities.
PARTICIPANTS
Four thousand five hundred eighty-four men and women aged 69 and older.
MEASUREMENTS
Exhaustion was considered present when a participant responded "a moderate amount" or "most of the time" to either of two questions: "How often have you had a hard time getting going?" and "How often does everything seem an effort?"
RESULTS
Of the 964 participants who originally reported exhaustion, 634 (65.8%) were exhaustion free at least once during follow-up. When data from all time points were considered, 48% of those who reported exhaustion were exhaustion free the following year. After adjustment for age, sex, race, education, and marital status, 1-year recovery was less likely in individuals with worse self-rated health and in those who were taking six or more medications or were obese, depressed, or had musculoskeletal pain or history of stroke. In proportional hazards models, the following risk factors were associated with more persistent exhaustion over 5 years: poor self-rated health, six or more medications, obesity, and depression. Recovery was not less likely in participants with a history of cancer or heart disease.
CONCLUSION
Exhaustion is common in old age but is dynamic, even in those with a history of cancer and congestive heart failure. Recovery is especially likely in seniors who have a positive perception of their overall health, take few medications, and are not obese or depressed. These findings support the notion that resiliency is associated with physical and psychological well-being.
C1 [Whitson, Heather E.] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA.
[Whitson, Heather E.; Arnold, Alice] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA.
[Thielke, Stephen; Diehr, Paula; Arnold, Alice] Univ Washington Hlth Syst, Dept Psychiat, Seattle, WA USA.
[Thielke, Stephen; Diehr, Paula] Univ Washington Hlth Syst, Dept Biostat, Seattle, WA USA.
[Thielke, Stephen; O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA.
[Thielke, Stephen; O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA.
[Chaves, Paulo H. M.] Johns Hopkins Univ, Dept Med, Inst Med, Baltimore, MD USA.
[Chaves, Paulo H. M.] Johns Hopkins Univ, Dept Epidemiol, Inst Med, Baltimore, MD USA.
[Zakai, Neil A.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
[Zakai, Neil A.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
[Chaudhry, Sarwat] Yale Univ, Sch Med, Dept Internal Med, Med Genet Sect, New Haven, CT 06510 USA.
[Ives, Diane; Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Ctr Aging & Populat Hlth, Pittsburgh, PA 15261 USA.
RP Whitson, HE (reprint author), DUMC 3003, Durham, NC 27710 USA.
EM heather.whitson@duke.edu
RI Kim, Hyung Woo /G-7525-2011; Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU National Institutes of Health [AG-023629]; National Heart, Lung, and
Blood Institute [N01-HC-85079-N01-HC-85086, N01-HC-35129, N01 HC-15103,
N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; National
Institute on Aging [R01-AG-023629, R01 AG-15928, R01 AG-20098,
AG-027058]; National Institute of Neurological Disorders and Stroke;
National Heart, Lung and Blood Institute; University of Pittsburgh
Pepper Center [P30-AG-02482]; American Federation for Aging Research;
Duke Pepper Center [P30-AG-028716, K23-AG-032867]; John A. Hartford
Foundation; [K23 AG038345]; [K23-AG-030986]
FX This work was supported by the National Institutes of Health (AG-023629,
CHS was supported by Contracts N01-HC-85079 through N01-HC-85086,
N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, and
N01-HC-45133; Grant U01 HL080295 from the National Heart, Lung, and
Blood Institute, with additional contribution from the National
Institute on Aging (R01-AG-023629); National Institute of Neurological
Disorders and Stroke; R01 AG-15928, R01 AG-20098, and AG-027058 from the
National Institute on Aging; R01 HL-075366 from the National Heart, Lung
and Blood Institute; University of Pittsburgh Pepper Center
P30-AG-02482). A full list of principal CHS investigators and
institutions can be found at http://www.chs-nhlbi.org/pi.htm. Dr.
Whitson is supported by the American Federation for Aging Research, the
Duke Pepper Center (P30-AG-028716) and K23-AG-032867. Dr. Thielke
received support from the John A. Hartford Foundation and K23 AG038345.
Dr. Chaudhry is supported by K23-AG-030986.
NR 39
TC 9
Z9 9
U1 2
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2011
VL 59
IS 2
BP 207
EP 213
DI 10.1111/j.1532-5415.2010.03238.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 719VX
UT WOS:000287240700003
PM 21288229
ER
PT J
AU Lee, CG
Boyko, EJ
Nielson, CM
Stefanick, ML
Bauer, DC
Hoffman, A
Dam, TTL
Lapidus, JA
Cawthon, PM
Ensrud, KE
Orwoll, ES
AF Lee, Christine G.
Boyko, Edward J.
Nielson, Carrie M.
Stefanick, Marcia L.
Bauer, Douglas C.
Hoffman, AndrewR.
Dam, Thuy-Tien L.
Lapidus, Jodi A.
Cawthon, Peggy Mannen
Ensrud, Kristine E.
Orwoll, Eric S.
CA Osteoporotic Fractures Men Study G
TI Mortality Risk in Older Men Associated with Changes in Weight, Lean
Mass, and Fat Mass
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE mortality; older men; body composition; lean mass; fat mass
ID ALL-CAUSE MORTALITY; X-RAY ABSORPTIOMETRY; MIDDLE-AGED MEN;
BODY-COMPOSITION; MUSCLE MASS; LONGITUDINAL CHANGES; FOLLOW-UP;
OSTEOPOROTIC FRACTURES; PHYSICAL-ACTIVITY; ELDERLY-MEN
AB OBJECTIVES
To evaluate risk of all-cause mortality associated with changes in body weight, total lean mass, and total fat mass in older men.
DESIGN
Longitudinal cohort study.
SETTING
Six U.S. clinical centers.
PARTICIPANTS
Four thousand three hundred thirty-one ambulatory men aged 65 to 93 at baseline.
MEASUREMENTS
Repeated measurements of body weight and total lean and fat mass were taken using dual-energy X-ray absorptiometry 4.6 +/- 0.4 years apart. Percentage changes in these measures were categorized as gain (+5%), loss (-5%), or stable (-5% to +5%). Deaths were verified centrally according to death certificate reviews, and proportional hazard models were used to estimate the risk of mortality.
RESULTS
After accounting for baseline lifestyle factors and medical conditions, a higher risk of mortality was found for men with weight loss (hazard rat (HR)=1.84, 95% confidence interval (CI)=1.50-2.26), total lean mass loss (HR=1.78, 95% CI=1.45-2.19), and total fat mass loss (HR=1.72, 95% CI=1.34-2.20) than for men who were stable for each body composition measure. Men with total fat mass gain had a slightly greater mortality risk (HR=1.29, 95% CI=0.99-1.67) than those who remained stable. These associations did not differ according to baseline age, obesity, or self-reported health status (P for interactions >.10), although self-reported weight loss intent altered mortality risks with total fat mass (P for interaction=.04) and total lean mass (P for interaction=.09) change.
CONCLUSION
Older men who lost weight, total lean mass, or total fat mass had a higher risk of mortality than men who remained stable.
C1 [Lee, Christine G.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol Diabet & Clin Nutr, Portland, OR 97239 USA.
[Nielson, Carrie M.] Oregon Hlth & Sci Univ, Div Epidemiol, Portland, OR 97239 USA.
[Lapidus, Jodi A.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97239 USA.
[Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gen Internal Med, Seattle, WA USA.
[Stefanick, Marcia L.; Hoffman, AndrewR.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
[Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Dam, Thuy-Tien L.] Columbia Univ, Dept Med, Med Ctr, Div Geriatr Med & Aging, New York, NY USA.
[Cawthon, Peggy Mannen] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Ensrud, Kristine E.] Vet Affairs Med Ctr, Dept Med, Gen Internal Med Sect, Minneapolis, MN 55417 USA.
RP Lee, CG (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol Diabet & Clin Nutr, 3181 SW Sam Jackson Pk Rd,CR113, Portland, OR 97239 USA.
EM leechr@ohsu.edu
OI Orwoll, Eric/0000-0002-8520-7355; Boyko, Edward/0000-0002-3695-192X
FU National Institutes of Health [AG05394]; National Institute of Arthritis
and Musculoskeletal and Skin Diseases; National Institute on Aging;
National Center for Research Resources; NIH roadmap for Medical Research
[U01AR45580, U01AR45614, U01AR45632, U01AR45647, U01AR45654, U01AR45583,
U01AG18197, U01AG027810, UL1RR 024140]; Department of Veterans Affairs
FX MrOS is supported by National Institutes of Health funding. The
following institutes provide support: the National Institute of
Arthritis and Musculoskeletal and Skin Diseases, the National Institute
on Aging, the National Center for Research Resources, and the NIH
roadmap for Medical Research under the following grants: U01AR45580,
U01AR45614, U01AR45632, U01AR45647, U01AR45654, U01AR45583, U01AG18197,
U01AG027810, and UL1RR 024140. Dr. Ensrud has received funding from the
NIH (AG05394). Dr. Boyko is supported by the Department of Veterans
Affairs.
NR 49
TC 42
Z9 45
U1 3
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2011
VL 59
IS 2
BP 233
EP 240
DI 10.1111/j.1532-5415.2010.03245.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 719VX
UT WOS:000287240700006
PM 21288234
ER
PT J
AU Lee, SJ
Steinman, MA
Tan, EJ
AF Lee, Sei J.
Steinman, Michael A.
Tan, Erwin J.
TI Volunteering, Driving Status, and Mortality in US Retirees
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE mortality; volunteerism; driving
ID OLDER-ADULTS; SOCIAL INTEGRATION; EXPERIENCE CORPS; PROPENSITY SCORE;
PUBLIC-HEALTH; LATER LIFE; COMMUNITY; CESSATION; BENEFITS; SUPPORT
AB OBJECTIVES
To evaluate how accounting for driving status altered the relationship between volunteering and mortality in U.S. retirees.
DESIGN
Observational prospective cohort.
SETTING
Nationally representative sample from the Health and Retirement Study in 2000 and 2002 followed to 2006.
PARTICIPANTS
Retirees aged 65 and older (N=6,408).
MEASUREMENTS
Participants self-reported their volunteering, driving status, age, sex, race or ethnicity, presence of chronic conditions, geriatric syndromes, socioeconomic factors, functional limitations, and psychosocial factors. Death by December 31, 2006, was the outcome.
RESULTS
For drivers, mortality in volunteers (9%) and nonvolunteers (12%) was similar; for limited or non-drivers, mortality for volunteers (15%) was markedly lower than for nonvolunteers (32%). Adjusted results showed that, for drivers, the volunteering-mortality odds ratio (OR) was 0.90 (95% confidence interval (CI)=0.66-1.22), whereas for limited or nondrivers, the OR was 0.62 (95% CI=0.49-0.78) (interaction P=.05). The effect of driving status was greater for rural participants, with greater differences between rural drivers and rural limited or nondrivers (interaction P=.02) and between urban drivers and urban limited or nondrivers (interaction P=.81).
CONCLUSION
The influence of volunteering in decreasing mortality seems to be stronger in rural retirees who are limited or nondrivers. This may be because rural or nondriving retirees are more likely to be socially isolated and thus receive more benefit from the greater social integration from volunteering.
C1 [Lee, Sei J.; Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.
[Lee, Sei J.; Steinman, Michael A.] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Tan, Erwin J.] Corp Natl & Community Serv, Washington, DC USA.
RP Lee, SJ (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Bldg 1,Rm 211A,Box 181G, San Francisco, CA 94121 USA.
EM sei.lee@ucsf.edu
FU Hartford Geriatric Health Outcomes Research Scholars Award; Hellman
Family Foundation at the University of California at San Francisco;
National Center for Research Resources, NIH [KL2RR024130]; National
Institute of Aging (NIA); American Federation for Aging Research [K23
AG030999]; NIA Johns Hopkins Older Americans Independence Center
[P30-AG02133]; John A. Hartford Foundation
FX Dr. Lee was supported by the Hartford Geriatric Health Outcomes Research
Scholars Award, Hellman Family Foundation Award for Young Faculty
Scholars at the University of California at San Francisco and
KL2RR024130 from the National Center for Research Resources, a component
of the National Institutes of Health. Dr. Steinman was supported by a
Beeson Career Development Award from the National Institute of Aging
(NIA) and the American Federation for Aging Research (K23 AG030999). Dr.
Tan was supported by the NIA Johns Hopkins Older Americans Independence
Center (Contract P30-AG02133) and the John A. Hartford Foundation.
NR 48
TC 4
Z9 4
U1 3
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2011
VL 59
IS 2
BP 274
EP 280
DI 10.1111/j.1532-5415.2010.03265.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 719VX
UT WOS:000287240700011
PM 21314648
ER
PT J
AU Velagapudi, C
Bhandari, BS
Abboud-Werner, S
Simone, S
Abboud, HE
Habib, SL
AF Velagapudi, Chakradhar
Bhandari, Basant S.
Abboud-Werner, Sherry
Simone, Sinnona
Abboud, Hanna E.
Habib, Samy L.
TI The Tuberin/mTOR Pathway Promotes Apoptosis of Tubular Epithelial Cells
in Diabetes
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID OXIDATIVE DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; MAMMALIAN TARGET;
RHEB; ACTIVATION; RAPAMYCIN; COMPLICATIONS; GLYCOSYLASE; INHIBITION;
EXPRESSION
AB Apoptosis contributes to the development of diabetic nephropathy, but the mechanism by which high glucose (HG) induces apoptosis is not fully understood. Because the tuberin/mTOR pathway can modulate apoptosis, we studied the role of this pathway in apoptosis in type I diabetes and in cultured proximal tubular epithelial (PTE) cells exposed to HG. Compared with control rats, diabetic rats had more apoptotic cells in the kidney cortex. Induction of diabetes also increased phosphorylation of tuberin in association with mTOR activation (measured by p70S6K phosphorylation), inactivation of Bcl-2, increased cytosolic cytochrome c expression, activation of caspase 3, and cleavage of PARP; insulin treatment prevented these changes. In vitro, exposure of PTE cells to HG increased phosphorylation of tuberin and p70S6K, phosphorylation of Bcl-2, expression of cytosolic cytochrome c, and caspase 3 activity. High glucose induced translocation of the caspase substrate YY1 from the cytoplasm to the nucleus and enhanced cleavage of PARP. Pretreatment the cells with the mTOR inhibitor rapamycin reduced the number of apoptotic cells induced by HG and the downstream effects of mTOR activation noted above. Furthermore, gene silencing of tuberin with siRNA decreased cleavage of PARP. These data show that the tuberin/mTOR pathway promotes apoptosis of tubular epithelial cells in diabetes, mediated in part by cleavage of PARP by YY1.
C1 [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Abboud-Werner, Sherry] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Simone, Sinnona] Univ Bari, Dept Emergency & Transplantat, Bari, Italy.
[Habib, Samy L.] S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA.
RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MSC 7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM habib@uthscsa.edu
RI Velagapudi, Chakradhar/F-9750-2015
FU UTHSCSA; San Antonio Cancer Institute; VA merit review award; NIH [RO1
(DK 078971)]; Italian Society of Nephrology; American Heart Association;
South Texas Veterans Healthcare System
FX Confocal fluorescence microscopy and FAGS analysis were performed in the
core optical imaging facility supported by UTHSCSA and San Antonio
Cancer Institute and the immunostaining at the Morphology core of the
George O' Brien Kidney Research Center. We thank Dan Riley, M.D., for
reading the manuscript. This work was supported in part by grants from a
VA merit review award and NIH RO1 (DK 078971) (to H.E.A.), a Research
Scholar Award from The Italian Society of Nephrology (to S.S.), and the
American Heart Association, New Investigator Award and Merit Review
Award from South Texas Veterans Healthcare System (to S.L.H.).
NR 33
TC 33
Z9 48
U1 2
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD FEB
PY 2011
VL 22
IS 2
BP 262
EP 273
DI 10.1681/ASN.2010040352
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA 725VF
UT WOS:000287673600013
PM 21289215
ER
PT J
AU Zenati, MA
Shroyer, AL
Collins, JF
Hattler, B
Ota, T
Almassi, GH
Amidi, M
Novitzky, D
Grover, FL
Sonel, AF
AF Zenati, Marco A.
Shroyer, A. Laurie
Collins, Joseph F.
Hattler, Brack
Ota, Takeyoshi
Almassi, G. Hossein
Amidi, Morteza
Novitzky, Dimitri
Grover, Frederick L.
Sonel, Ali F.
TI Impact of endoscopic versus open saphenous vein harvest technique on
late coronary artery bypass grafting patient outcomes in the ROOBY
(Randomized On/Off Bypass) Trial
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID OFF-PUMP; ON-PUMP; SURGERY; PATENCY
AB Objective: In the Randomized On/Off Bypass (ROOBY) Trial, the efficacy of on-pump versus off-pump coronary artery bypass grafting was evaluated. This ROOBY Trial planned subanalysis compared the effects on postbypass patient clinical outcomes and graft patency of endoscopic vein harvesting and open vein harvesting.
Methods: From April 2003 to April 2007, the technique used for saphenous vein graft harvesting was recorded in 1471 cases. Of these, 894 patients (341 endoscopic harvest and 553 open harvest) also underwent coronary angiography 1 year after coronary artery bypass grafting. Univariate and multivariable analyses were used to compare patient outcomes in the endoscopic and open groups.
Results: Preoperative patient characteristics were statistically similar between the endoscopic and open groups. Endoscopic vein harvest was used in 38% of the cases. There were no significant differences in both short-term and 1-year composite outcomes between the endoscopic and open groups. For patients with 1-year catheterization follow-up (n = 894), the saphenous vein graft patency rate for the endoscopic group was lower than that in the open harvest group (74.5% vs 85.2%, P < .0001), and the repeat revascularization rate was significantly higher (6.7% vs 3.4%, P < .05). Multivariable regression documented no interaction effect between endoscopic approach and off-pump treatment.
Conclusions: In the ROOBY Trial, endoscopic vein harvest was associated with lower 1-year saphenous vein graft patency and higher 1-year revascularization rates, independent of the use of off-pump or on-pump cardiac surgical approach. (J Thorac Cardiovasc Surg 2011;141:338-44)
C1 [Zenati, Marco A.] Vet Affairs Boston Healthcare Syst, W Roxbury, MA USA.
[Zenati, Marco A.] Harvard Univ, Brigham & Womens Hosp, Div Cardiac Surg, Boston, MA 02115 USA.
[Shroyer, A. Laurie; Hattler, Brack; Grover, Frederick L.] Eastern Colorado Healthcare Syst, Dept Vet Affairs, Denver, CO USA.
[Shroyer, A. Laurie] Northport Vet Affairs Med Ctr, Northport, NY USA.
[Collins, Joseph F.] Vet Affairs Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA.
[Ota, Takeyoshi; Amidi, Morteza; Sonel, Ali F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Ota, Takeyoshi] Univ Pittsburgh, Med Ctr, Heart Lung & Esophageal Surg Inst, Pittsburgh, PA USA.
[Almassi, G. Hossein] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Almassi, G. Hossein] Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA.
[Novitzky, Dimitri] Univ S Florida, Dept Surg, Tampa, FL 33620 USA.
RP Zenati, MA (reprint author), BHS, Div Cardiac Surg, 1400 VFW Pkwy 112, W Roxbury, MA 02132 USA.
EM Marco_Zenati@hms.harvard.edu
RI Shroyer, Annie Laurie/B-8836-2016
OI Shroyer, Annie Laurie/0000-0001-6461-0623
FU Department of Veterans Affairs, Office of Research and Development;
Department of Veterans Affairs Central Office, Office of Patient Care
Services, Washington, DC
FX Supported by the Cooperative Studies Program of the Department of
Veterans Affairs, Office of Research and Development, and by the
Department of Veterans Affairs Central Office, Office of Patient Care
Services, Washington, DC.
NR 24
TC 53
Z9 60
U1 1
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD FEB
PY 2011
VL 141
IS 2
BP 338
EP 344
DI 10.1016/j.jtcvs.2010.10.004
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 706MP
UT WOS:000286222800009
PM 21130476
ER
PT J
AU Sonpavde, G
Khan, MM
Lerner, SP
Svatek, RS
Novara, G
Karakiewicz, PI
Skinner, E
Tilki, D
Kassouf, W
Fradet, Y
Dinney, CP
Fritsche, HM
Izawa, JI
Bastian, PJ
Ficarra, V
Schoenberg, M
Sagalowsky, AI
Lotan, Y
Shariat, SF
AF Sonpavde, Guru
Khan, Myrna M.
Lerner, Seth P.
Svatek, Robert S.
Novara, Giacomo
Karakiewicz, Pierre I.
Skinner, Eila
Tilki, Derya
Kassouf, Wassim
Fradet, Yves
Dinney, Colin P.
Fritsche, Hans-Martin
Izawa, Jonathan I.
Bastian, Patrick J.
Ficarra, Vincenzo
Schoenberg, Mark
Sagalowsky, Arthur I.
Lotan, Yair
Shariat, Shahrokh F.
TI Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall
Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive
Bladder Cancer
SO JOURNAL OF UROLOGY
LA English
DT Article
DE urinary bladder neoplasms; cystectomy; disease-free survival
ID TRANSITIONAL-CELL CARCINOMA; 18 RANDOMIZED-TRIALS; NEOADJUVANT
CHEMOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
COLON-CANCER; END-POINTS; METAANALYSIS; GUIDELINES; OUTCOMES
AB Purpose: The conventional primary end point in trials of perioperative systemic therapy for muscle invasive bladder cancer is 5-year overall survival. We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival.
Materials and Methods: We retrospectively analyzed a multicenter database containing records of 2,724 patients treated with radical cystectomy for muscle invasive bladder cancer with negative margins. Of these patients 844 had received adjuvant chemotherapy. We evaluated the association of disease-free survival at 2 and 3 years with overall survival at 5 years using Cox proportional hazards modeling and the kappa statistic.
Results: Overall 2-year/3-year disease-free survival was 0.63/0.57 and 5-year overall survival was 0.47. The overall agreement between 2-year disease-free survival and 5-year overall survival was 79%, and between 3-year disease-free survival and 5-year overall survival was 81%. Agreements were similar when analyzed within pathological substages, radical cystectomy decades and adjuvant chemotherapy subgroups. The kappa statistic was 0.57 (95% CI 0.53-0.60) for 2-year disease-free survival/5-year overall survival and 0.61 (95% CI 0.58-0.64) for 3-year disease-free survival/5-year overall survival, indicating moderate agreement. The hazard ratio for disease-free survival as a time dependent variable was 12.7 (95% CI 11.60-13.90), indicating a strong relationship between disease-free and overall survival.
Conclusions: Disease-free survival rates at 2 and 3 years correlate with and are potential intermediate surrogates for 5-year overall survival in patients treated with radical cystectomy for muscle invasive bladder cancer regardless of adjuvant chemotherapy. These data warrant external validation and may expedite the development of adjuvant systemic therapy. In addition, they may be applicable to the neoadjuvant setting.
C1 [Sonpavde, Guru; Khan, Myrna M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Sonpavde, Guru; Khan, Myrna M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Svatek, Robert S.; Dinney, Colin P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Sagalowsky, Arthur I.; Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Novara, Giacomo; Ficarra, Vincenzo] Univ Padua, Padua, Italy.
[Karakiewicz, Pierre I.] Univ Montreal, Montreal, PQ, Canada.
[Kassouf, Wassim] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Fradet, Yves] Univ Laval, Quebec City, PQ, Canada.
[Izawa, Jonathan I.] Univ Western Ontario, London, ON, Canada.
[Skinner, Eila] Univ So Calif, Los Angeles, CA USA.
[Tilki, Derya; Bastian, Patrick J.] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany.
[Fritsche, Hans-Martin] Univ Regensburg, Regensburg, Germany.
[Schoenberg, Mark] Johns Hopkins Univ, Baltimore, MD USA.
[Shariat, Shahrokh F.] Weill Cornell Med Ctr, Dept Urol, New York, NY USA.
RP Sonpavde, G (reprint author), 501 Med Ctr Blvd, Webster, TX 77598 USA.
EM gurus@bcm.edu
RI Izawa, Jonathan/C-1111-2015
FU Sanofi-Aventis; Novartis; Pfizer-Wyeth; Bioniche/Parexel; Abbott;
Inverness
FX Financial interest and/or other relationship with Sanofi-Aventis,
Novartis and Pfizer-Wyeth.; Financial interest and/or other relationship
with Bioniche/Parexel.; Financial interest and/or other relationship
with Abbott and Inverness.
NR 30
TC 32
Z9 32
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD FEB
PY 2011
VL 185
IS 2
BP 456
EP 461
DI 10.1016/j.juro.2010.09.110
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 704JH
UT WOS:000286047500021
PM 21167527
ER
PT J
AU Miller, RA
Harrison, DE
Astle, CM
Baur, JA
Boyd, AR
de Cabo, R
Fernandez, E
Flurkey, K
Javors, MA
Nelson, JF
Orihuela, CJ
Pletcher, S
Sharp, ZD
Sinclair, D
Starnes, JW
Wilkinson, JE
Nadon, NL
Strong, R
AF Miller, Richard A.
Harrison, David E.
Astle, C. M.
Baur, Joseph A.
Boyd, Angela Rodriguez
de Cabo, Rafael
Fernandez, Elizabeth
Flurkey, Kevin
Javors, Martin A.
Nelson, James F.
Orihuela, Carlos J.
Pletcher, Scott
Sharp, Zelton Dave
Sinclair, David
Starnes, Joseph W.
Wilkinson, J. Erby
Nadon, Nancy L.
Strong, Randy
TI Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of
Genetically Heterogeneous Mice
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE TOR; Rapamycin; Life span; Resveratrol
ID CANCER-THERAPY; C-ELEGANS; DROSOPHILA-MELANOGASTER;
CAENORHABDITIS-ELEGANS; REDUCTASE INHIBITOR; DIETARY RESTRICTION;
ENDOTHELIAL-CELLS; SIGNALING PATHWAY; DWARF MICE; MTOR
AB Rapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including maximum life span, at each of three test sites. Median survival was extended by an average of 10% in males and 18% in females. Rapamycin attenuated age-associated decline in spontaneous activity in males but not in females. Causes of death were similar in control and rapamycin-treated mice. Resveratrol (at 300 and 1200 ppm food) and simvastatin (12 and 120 ppm) did not have significant effects on survival in male or female mice. Further evaluation of rapamycin's effects on mice is likely to help delineate the role of the mammalian target of rapamycin complexes in the regulation of aging rate and age-dependent diseases and may help to guide a search for drugs that retard some or all of the diseases of aging.
C1 [Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Miller, Richard A.; Pletcher, Scott] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA.
[Miller, Richard A.] Ann Arbor VA Med Ctr, Grad Res Educ & Clin Ctr, Ann Arbor, MI USA.
[Harrison, David E.; Astle, C. M.; Flurkey, Kevin] Jackson Lab, Bar Harbor, ME 04609 USA.
[Baur, Joseph A.] Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA.
[Baur, Joseph A.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
[Boyd, Angela Rodriguez; Orihuela, Carlos J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[de Cabo, Rafael] NIA, Lab Expt Gerontol, Baltimore, MD 21224 USA.
[Fernandez, Elizabeth; Javors, Martin A.; Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Fernandez, Elizabeth; Javors, Martin A.; Nelson, James F.; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Pletcher, Scott] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
[Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78229 USA.
[Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
[Sinclair, David] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Starnes, Joseph W.] Univ N Carolina, Dept Kinesiol, Greensboro, NC 27412 USA.
[Wilkinson, J. Erby] Univ Michigan, Sch Med, Unit Lab Anim Med, Ann Arbor, MI USA.
[Nadon, Nancy L.] NIA, Biol Aging Program, Bethesda, MD 20892 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
RP Miller, RA (reprint author), Univ Michigan, Dept Pathol, BSRB Room 3001,Box 2200,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM millerr@umich.edu
RI Baur, Joseph/D-8163-2011; de Cabo, Rafael/J-5230-2016
OI de Cabo, Rafael/0000-0002-3354-2442; Baur, Joseph/0000-0001-8262-6549;
Sinclair, David/0000-0002-9936-436X; , rafael/0000-0003-2830-5693
FU National Institute on Aging at the National Institutes of Health
[U01-AG022303, U01-AG025707, U01-AG022308, R21-AG029313, U01-AG022307,
R01-AG13319]; Department of Veterans Affairs; National Institute on
Aging
FX This work was supported by the National Institute on Aging at the
National Institutes of Health (U01-AG022303 to R.A.M., U01-AG025707 and
U01-AG022308 to D.E.H., R21-AG029313 to C.J.O., and U01-AG022307 and
R01-AG13319 to R.S.); and the Department of Veterans Affairs (R.A.M. and
R.S.). R.d.C. is supported by the Intramural Research Program of the
National Institute on Aging.
NR 51
TC 353
Z9 358
U1 2
U2 32
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD FEB
PY 2011
VL 66
IS 2
BP 191
EP 201
DI 10.1093/gerona/glq178
PG 11
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 710TZ
UT WOS:000286541200005
PM 20974732
ER
PT J
AU Komers, R
Oyama, TT
Beard, DR
Tikellis, C
Xu, B
Lotspeich, DF
Anderson, S
AF Komers, Radko
Oyama, Terry T.
Beard, Douglas R.
Tikellis, Chris
Xu, Bei
Lotspeich, Daniel F.
Anderson, Sharon
TI Rho kinase inhibition protects kidneys from diabetic nephropathy without
reducing blood pressure
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE connective tissue growth factor; diabetic nephropathy; fasudil;
glomerulosclerosis; Rho-associated kinases (ROCK); transforming growth
factor-beta
ID EPITHELIAL-MESENCHYMAL TRANSITION; MESSENGER-RNA TRANSLATION;
SPONTANEOUSLY HYPERTENSIVE-RATS; PROXIMAL TUBULAR CELLS; E-CADHERIN
EXPRESSION; INDUCED RENAL INJURY; SMOOTH-MUSCLE-CELLS;
GROWTH-FACTOR-BETA; ANGIOTENSIN-II; HIGH GLUCOSE
AB Rho-associated kinases (ROCK) are activated in the kidney as well as in cultured cells of diabetic models and have been implicated in renal pathophysiology. To explore whether inhibition of ROCK is protective, we studied its role in a model of accelerated diabetic nephropathy where uninephrectomized rats were made diabetic by streptozotocin. After establishing diabetes, rats were treated with the ROCK inhibitor fasudil continuously or for the final 6 weeks of an 18-week experimental period. The results were compared to similar rats given losartan, an established treatment of clinical and experimental diabetic nephropathy, or a combination of both agents. Vehicle-treated diabetic and non-diabetic uninephrectomized rats served as controls. Diabetes resulted in a rapid development of albuminuria, higher glomerulosclerosis and interstitial fibrosis scores, lower glomerular filtration rates, and increased expression of several molecular markers of diabetic nephropathy. Eighteen weeks of fasudil treatment reduced renal ROCK activity, and ameliorated diabetes-induced structural changes in the kidney and expression of the molecular markers in association with a modest anti-proteinuric effect but no change in blood pressure. Late intervention with fasudil reduced glomerulosclerosis, but did not influence proteinuria. Most effects of fasudil were comparable to those of losartan, although losartan lowered blood pressure and further lowered proteinuria. The combination of both treatments was no different than losartan alone. Thus, ROCK inhibition protected the kidney from diabetic nephropathy even though it did not reduce the blood pressure. Kidney International (2011) 79, 432-442; doi:10.1038/ki.2010.428; published online 20 October 2010
C1 [Komers, Radko; Oyama, Terry T.; Xu, Bei; Lotspeich, Daniel F.; Anderson, Sharon] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA.
[Beard, Douglas R.; Anderson, Sharon] Portland VA Med Ctr, Portland, OR USA.
[Tikellis, Chris] Juvenile Diabet Res Fdn, Danielle Alberti Mem Ctr Diabet Complicat, Baker Med Res Inst, Melbourne, Vic, Australia.
RP Komers, R (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM komersr@ohsu.edu
FU Juvenile Diabetes Research Foundation [RK 1-2008-314]
FX These studies were supported by the Juvenile Diabetes Research
Foundation (RK 1-2008-314).
NR 62
TC 48
Z9 55
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD FEB
PY 2011
VL 79
IS 4
BP 432
EP 442
DI 10.1038/ki.2010.428
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA 713HL
UT WOS:000286726500009
PM 20962741
ER
PT J
AU Ostrosky-Zeichner, L
Kullberg, BJ
Bow, EJ
Hadley, S
Leon, C
Nucci, M
Patterson, TF
Perfect, JR
AF Ostrosky-Zeichner, Luis
Kullberg, Bart Jan
Bow, Eric J.
Hadley, Susan
Leon, Cristobal
Nucci, Marcio
Patterson, Thomas F.
Perfect, John R.
TI Early treatment of candidemia in adults: a review
SO MEDICAL MYCOLOGY
LA English
DT Review
DE antifungals; candidemia; invasive candidiasis; empirical therapy;
pre-emptive therapy
ID INTENSIVE-CARE-UNIT; INVASIVE FUNGAL-INFECTIONS; BETA-D-GLUCAN; ILL
SURGICAL-PATIENTS; PLACEBO-CONTROLLED TRIAL; BLOOD-STREAM INFECTION;
HUMAN SEPTIC SHOCK; ANTIFUNGAL THERAPY; FLUCONAZOLE PROPHYLAXIS;
TRANSPLANT RECIPIENTS
AB Invasive candidiasis is associated with high mortality, particularly in adults. Retrospective studies show that shorter times to treatment are correlated with a lower risk of death. A number of factors can be used to predict which patients would benefit from antifungal prophylaxis or early (pre-emptive or empirical) therapy. Detection of the fungal cell wall component (1 -> 3)-beta-D-glucan (BDG) shows promise as an early biomarker of invasive fungal infection and may be useful in identifying patients who would benefit from early antifungal treatment. To date, no consistent early treatment strategy has evolved. Proof-of-concept studies are needed to assess the role of pre-emptive and empirical therapy in ICU patients and the relevance of BDG as an early marker of infection.
C1 [Ostrosky-Zeichner, Luis] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Kullberg, Bart Jan] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
[Bow, Eric J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada.
[Bow, Eric J.] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.
[Hadley, Susan] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Leon, Cristobal] Univ Seville, Univ Hosp Valme, Seville, Spain.
[Nucci, Marcio] Univ Fed Rio de Janeiro, Univ Hosp, Rio De Janeiro, Brazil.
[Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Perfect, John R.] Duke Univ, Sch Med, Durham, NC USA.
RP Ostrosky-Zeichner, L (reprint author), Univ Texas Houston, Sch Med, 6431 Fannin,MSB 2-112, Houston, TX 77030 USA.
EM Luis.Ostrosky-Zeichner@uth.tmc.edu
RI Nucci, Marcio/G-4515-2012; Kullberg, Bart Jan/C-8520-2013
OI Nucci, Marcio/0000-0003-4867-0014;
FU Pfizer Inc.; Merck; Astellas; Basilea; Gilead; Associates of Cape Cod;
Merck-Frosst; Amgen; Wyeth Pharmaceuticals; Schering-Plough; Bayer;
Enzon; Pfizer
FX This manuscript summarizes the proceedings of a clinical advisory board
on early antifungal therapy sponsored by Pfizer Inc. Editorial support
was provided by D. Wolf, MSc, of PAREXEL, and was funded by Pfizer Inc.;
Dr Ostrosky-Zeichner has received research grants and has been a
consultant or speaker for the following companies: Pfizer, Merck,
Astellas, Basilea, Gilead, and Associates of Cape Cod; Dr Kullberg has
received research grants from Pfizer and has been a consultant or
speaker for the following companies: Astellas, Basilea, and Pfizer; Dr
Bow has received research grants and served as a consultant or speaker
for the following companies: Pfizer, Merck-Frosst, Astellas, Amgen,
Wyeth Pharmaceuticals, and Schering-Plough; Dr Hadley received research
support, consulting fees or speaker honoraria from Pfizer,
Schering-Plough, Merck and Astellas; Dr Leon has received research
grants and has been a consultant or speaker for the following companies:
Pfizer, Merck, Astellas, and Gilead; Dr Nucci has received research
grants and has been a consultant or speaker for the following companies:
Pfizer, Merck, Astellas, Gilead, and Bayer; Dr Patterson has received
research grants to the University of Texas Health Science Center at San
Antonio from Basilea, Merck, Pfizer, and Schering-Plough, and consulting
fees or honoraria from Basilea and Pfizer; Dr Perfect has received
research support, consulting fees, and honoraria from Pfizer,
Schering-Plough, Merck, Astellas, Enzon, and Basilea.
NR 54
TC 30
Z9 32
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1369-3786
J9 MED MYCOL
JI Med. Mycol.
PD FEB
PY 2011
VL 49
IS 2
BP 113
EP 120
DI 10.3109/13693786.2010.512300
PG 8
WC Infectious Diseases; Mycology; Veterinary Sciences
SC Infectious Diseases; Mycology; Veterinary Sciences
GA 722RH
UT WOS:000287451500001
PM 20818922
ER
PT J
AU Dosa, E
Guillaume, DJ
Haluska, M
Lacy, CA
Hamilton, BE
Njus, JM
Rooney, WD
Kraemer, DF
Muldoon, LL
Neuwelt, EA
AF Dosa, Edit
Guillaume, Daniel J.
Haluska, Marianne
Lacy, Cynthia A.
Hamilton, Bronwyn E.
Njus, Jeffrey M.
Rooney, William D.
Kraemer, Dale F.
Muldoon, Leslie L.
Neuwelt, Edward A.
TI Magnetic resonance imaging of intracranial tumors: intra-patient
comparison of gadoteridol and ferumoxytol
SO NEURO-ONCOLOGY
LA English
DT Article
DE brain tumors; ferumoxyrol; magnetic resonance imaging; ultrasmall
superparamagnetic iron oxide nanoparticles
ID SUPERPARAMAGNETIC IRON-OXIDES; NEPHROGENIC SYSTEMIC FIBROSIS;
BLOOD-VOLUME MAPS; BRAIN-TUMORS; MALIGNANT GLIOMAS; MR; PERFUSION;
NANOPARTICLES; CHEMOTHERAPY; PROGRESSION
AB This study aims to compare gadoteridol with ferumoxytol for contrast-enhanced and perfusion-weighted (PW) MR1 of intracranial tumors. The final analysis included 26 patients, who underwent 3 consecutive days of 3T MRI. Day 1 consisted of anatomical pre- and postcontrast images, and PW MRI was acquired using gadoteridol (0.1 mmol/kg). On Day 2, the same MRI sequences were obtained with ferumoxytol (510 mg) and on Day 3, the anatomical images were repeated to detect delayed ferumoxytol-induced signal changes. The T(1)-weighted images were evaluated qualitatively and quantitatively for enhancement volume and signal intensity (SI) changes; PW data were used to estimate the relative cerebral blood volume (rCBV). All 26 lesions showed 24-hour T(1)-weighted ferumoxytol enhancement; 16 also had T(2)-weighted hypointensities. In 6 patients, ferumoxytol-induced signal changes were noted in areas with no gadoteridol enhancement. Significantly greater (P < .0001) SI changes were seen with gadoteridol, and qualitative analyses (lesion border delineation, internal morphology, contrast enhancement) also showed significant preferences (P = .0121; P = .0015; P < .0001, respectively) for this agent. There was no significant difference in lesion enhancement volumes between contrast materials. The ferumoxytol-rCBV values were significantly higher (P = .0016) compared with the gadoteridol-rCBV values. In conclusion, ferumoxytol provides important information about tumor biology that complements gadoteridol imaging. The rCBV measurements indicate areas of tumor undergoing rapid growth, whereas the 24-hour scans mark the presence of inflammatory cells. Both of these functions provide useful information about tumor response to treatment. We suggest that dynamic and anatomical imaging with ferumoxytol warrant further assessment in brain tumor therapy.
C1 [Dosa, Edit; Haluska, Marianne; Lacy, Cynthia A.; Muldoon, Leslie L.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Guillaume, Daniel J.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA.
[Hamilton, Bronwyn E.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA.
[Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
[Njus, Jeffrey M.; Rooney, William D.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA.
[Kraemer, Dale F.] Oregon State Univ, Dept Pharm Practice, Portland, OR USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
FU AMAG Pharmaceuticals
FX OHSU has received a sponsored research agreement from AMAG
Pharmaceuticals to conduct clinical trials of MRI with ferumoxytol. None
of the authors has financial interest in this agent or in its developer
AMAG Pharmaceuticals.
NR 29
TC 21
Z9 21
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD FEB
PY 2011
VL 13
IS 2
BP 251
EP 260
DI 10.1093/neuonc/noq172
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 716VX
UT WOS:000287002700011
PM 21163809
ER
PT J
AU Liu, H
Li, WJ
Ahmad, M
Miller, TM
Rose, ME
Poloyac, SM
Uechi, G
Balasubramani, M
Hickey, RW
Graham, SH
AF Liu, Hao
Li, Wenjin
Ahmad, Muzamil
Miller, Tricia M.
Rose, Marie E.
Poloyac, Samuel M.
Uechi, Guy
Balasubramani, Manimalha
Hickey, Robert W.
Graham, Steven H.
TI Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone
prostaglandins exacerbates hypoxic injury
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Ubiquitin-proteasome pathway; Ubiquitin-C-terminal hydrolase L1;
Cyclopentenone prostaglandins; Protein post-translational modification;
Arachidonic acid; Hypoxic neuronal injury
ID PROLIFERATOR-ACTIVATED RECEPTOR; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN
J(2); PARKINSONS-DISEASE; PROTEIN AGGREGATION; NEURONAL APOPTOSIS;
ENDOGENOUS ELECTROPHILE; NEUROBLASTOMA-CELLS; CEREBRAL-ISCHEMIA;
PROTEASOME SYSTEM; UCH-L1
AB Cyclopentenone prostaglandins (CyPGs), such as 15-deoxy-Delta(12,14) -prostaglandin J(2) (15d-PGJ(2)), are active prostaglandin metabolites exerting a variety of biological effects that may be important in the pathogenesis of neurological diseases. Ubiquitin-C-terminal hydrolase L1 (UCH-L1) is a brain specific deubiquitinating enzyme whose aberrant function has been linked to neurodegenerative disorders. We report that [15d-PGJ(2)] detected by quadrapole mass spectrometry (MS) increases in rat brain after temporary focal ischemia, and that treatment with 15d-PGJ(2) induces accumulation of ubiquitinated proteins and exacerbates cell death in normoxic and hypoxic primary neurons. 15d-PGJ(2) covalently modifies UCH-L1 and inhibits its hydrolase activity. Pharmacologic inhibition of UCH-L1 exacerbates hypoxic neuronal death while transduction with a TAT-UCH-L1 fusion protein protects neurons from hypoxia. These studies indicate that UCH-L1 function is important in hypoxic neuronal death and that excessive production of CyPGs after stroke may exacerbate ischemic injury by modification and inhibition of UCH-L1. Published by Elsevier Inc.
C1 [Liu, Hao; Li, Wenjin; Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Liu, Hao; Li, Wenjin; Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA.
[Miller, Tricia M.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
[Uechi, Guy; Balasubramani, Manimalha] Univ Pittsburgh, Genom & Prote Core Labs, Pittsburgh, PA 15260 USA.
[Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA.
RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr GR H 00, Highland Dr, Pittsburgh, PA 15206 USA.
EM sgra@pitt.edu
FU NIH NINDS [R0137549]; VA Merit Review program
FX This work was supported by NIH NINDS R0137549 and the VA Merit Review
program (SHG). The authors thank Pat Strickler for secretarial support,
Drs. Jun Chen and Guodong Cao (University of Pittsburgh, Pittsburgh) for
providing the TAT-containing plasmid, and Dr. Billy W. Day (University
of Pittsburgh, Pittsburgh) for helpful discussions.
NR 53
TC 21
Z9 22
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD FEB
PY 2011
VL 41
IS 2
BP 318
EP 328
DI 10.1016/j.nbd.2010.09.020
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 705QZ
UT WOS:000286154300010
PM 20933087
ER
PT J
AU Perez, SE
He, B
Muhammad, N
Oh, KJ
Fahnestock, M
Ikonomovic, MD
Mufson, EJ
AF Perez, Sylvia E.
He, Bin
Muhammad, Nadeem
Oh, Kwang-Jin
Fahnestock, Margaret
Ikonomovic, Milos D.
Mufson, Elliott J.
TI Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic
mice
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Alzheimer's disease; Amyloid; Cholinergic; Nerve growth factor; ChAT;
proNGF; p75(NTR); Transgenic mice; TrkA; Aging
ID NERVE GROWTH-FACTOR; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE
IMPAIRMENT; NICOTINIC ACETYLCHOLINE-RECEPTOR; CHOLINE-ACETYLTRANSFERASE
ACTIVITY; ALZHEIMERS-DISEASE; MOUSE MODEL; A-BETA; NUCLEUS BASALIS;
PRESYNAPTIC BOUTONS
AB The cholinotrophic system, which is dependent upon nerve growth factor and its receptors for survival, is selectively vulnerable in Alzheimer's disease (AD). But, virtually nothing is known about how this deficit develops in relation to the hallmark lesions of this disease, amyloid plaques and tau containing neurofibrillary tangles. The vast majority of transgenic models of AD used to evaluate the effect of beta amyloid deposition upon the cholinotrophic system over-express the amyloid precursor protein (APP). However. nothing is known about how this system is affected in triple transgenic (3xTg)-AD mice, an AD animal model displaying A beta, plaque- and tangle-like pathology in the cortex and hippocampus, which receive extensive cholinergic innervation. We performed a detailed morphological and biochemical characterization of the cholinotrophic system in young (2-4 months), middle-aged (13-15 months) and old (18-20 months) 3xTg-AD mice. Cholinergic neuritic swellings increased in number and size with age, and were more conspicuous in the hippocampal-subicular complex in aged female than in 3xTg-AD male mice. Stereological analysis revealed a reduction in choline acetyltransferase (ChAT) positive cells in the medial septum/vertical limb of the diagonal band of Broca in aged 3xTg-AD mice. ChAT enzyme activity levels decreased significantly in the hippocampus of middle-aged 3xTg-AD mice compared to age-matched non-transgenic (or wild type) mice. ProNGF protein levels increased in the cortex of aged 3xTg-AD mice, whereas TrkA protein levels were reduced in a gender-dependent manner in aged mutant mice. In contrast, p75(NTR) protein cortical levels were stable but increased in the hippocampus of aged 3xTg-AD mice. These data demonstrate that cholinotrophic alterations in 3xTg-AD mice are age- and gender-dependent and more pronounced in the hippocampus, a structure more severely affected by A beta plaque pathology. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Perez, Sylvia E.; He, Bin; Muhammad, Nadeem; Oh, Kwang-Jin; Mufson, Elliott J.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Fahnestock, Margaret] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada.
[Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA.
RP Mufson, EJ (reprint author), Rush Univ, Med Ctr, Alla V & Solomon Jesmer Chair Aging, 1735 W Harrison St,Suite 300, Chicago, IL 60612 USA.
EM sylvia_e_perez@rush.edu; binhe_2000@yahoo.com; Muhammad_Nadeem@rush.edu;
sp8472@gmail.com; fahnest@mcmaster.ca; ikonomovicmd@upmc.edu;
emufson@rush.edu
OI Fahnestock, Margaret/0000-0002-6815-0529
FU Shapiro Foundation; [AG10688]
FX This work was supported by the Shapiro Foundation and AG10688. The
authors thank K. Schafernak for editing the manuscript.
NR 91
TC 28
Z9 30
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD FEB
PY 2011
VL 41
IS 2
BP 338
EP 352
DI 10.1016/j.nbd.2010.10.002
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 705QZ
UT WOS:000286154300012
PM 20937383
ER
PT J
AU De La Garza, BH
Muir, ER
Li, GA
Shih, YYI
Duong, TQ
AF De La Garza, Bryan H.
Muir, Eric R.
Li, Guang
Shih, Yen-Yu I.
Duong, Timothy Q.
TI Blood oxygenation level-dependent (BOLD) functional MRI of visual
stimulation in the rat retina at 11.7 T
SO NMR IN BIOMEDICINE
LA English
DT Article
DE laminar specificity; high magnetic field; high-resolution fMRI; choroid;
dark and light adaptation; blood flow
ID GLIAL-CELLS; FLOW; EYE
AB Although optically based imaging techniques provide valuable functional and physiological information of the retina, they are mostly limited to the probing of the retinal surface and require an unobstructed light path. MRI, in contrast, could offer physiological and functional data without depth limitation. Blood oxygenation level-dependent functional MRI (BOLD fMRI) of the thin rat retina is, however, challenging because of the need for high spatial resolution, and the potential presence of eye movement and susceptibility artifacts. This study reports a novel application of high-resolution (111 x 111 x 1000 mu m(3)) BOLD fMRI of visual stimulation in the anesthetized rat retina at 11.7 T. A high-field MRI scanner was utilized to improve the signal-to-noise ratio, spatial resolution and BOLD sensitivity. Visual stimuli (8 Hz diffuse achromatic light) robustly increased BOLD responses in the retina [5.0 +/- 0.8% from activated pixels and 3.1 +/- 1.1% from the whole-retina region of interest (mean +/- SD), n = 12 trials on six rats, p < 0.05 compared with baseline]. Some activated pixels were detected surrounding the pupil and ciliary muscle because of accommodation reflex to visual stimuli, and were reduced with atropine and phenylephrine eye drops. BOLD fMRI scans without visual stimulations showed no significantly activated pixels (whole-retina BOLD changes were 0.08 +/- 0.34%, n = 6 trials on five rats, not statistically different from baseline, p > 0.05). BOLD fMRI of visual stimulation has the potential to provide clinically relevant data to probe hemodynamic neurovascular coupling and dysfunction of the retina with depth resolution. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [De La Garza, Bryan H.; Muir, Eric R.; Li, Guang; Shih, Yen-Yu I.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Muir, Eric R.; Duong, Timothy Q.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA.
[Li, Guang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Li, Guang/C-9539-2011; Duong, Timothy/B-8525-2008; Muir,
Eric/H-8830-2013
OI Li, Guang/0000-0002-7648-0464; Shih, Yen-Yu Ian/0000-0001-6529-911X
FU National Institutes of Health [R01EY014211, R01EY018855]; VA MERIT
FX The authors thank Bill Rogers of the Research Imaging Institute for
building the visual stimulation unit used in this study, Dr Joseph M.
Harrison of Ophthalmology for his help with luminance measurements, and
Dr Carlos Rosende of Ophthalmology for helpful discussions. This work
was supported by the National Institutes of Health (R01EY014211,
R01EY018855) and VA MERIT.
NR 30
TC 13
Z9 13
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-3480
J9 NMR BIOMED
JI NMR Biomed.
PD FEB
PY 2011
VL 24
IS 2
BP 188
EP 193
DI 10.1002/nbm.1571
PG 6
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 732SG
UT WOS:000288209300009
PM 21344533
ER
PT J
AU Burke, LE
Conroy, MB
Sereika, SM
Elci, OU
Styn, MA
Acharya, SD
Sevick, MA
Ewing, LJ
Glanz, K
AF Burke, Lora E.
Conroy, Molly B.
Sereika, Susan M.
Elci, Okan U.
Styn, Mindi A.
Acharya, Sushama D.
Sevick, Mary A.
Ewing, Linda J.
Glanz, Karen
TI The Effect of Electronic Self-Monitoring on Weight Loss and Dietary
Intake: A Randomized Behavioral Weight Loss Trial
SO OBESITY
LA English
DT Article
ID HAND-HELD COMPUTERS; LOSS PROGRAM; OBESITY; INTERVENTION; DIARIES
AB Technology may improve self-monitoring adherence and dietary changes in weight loss treatment. Our study aimed to investigate whether using a personal digital assistant (PDA) with dietary and exercise software, with and without a feedback message, compared to using a paper diary/record (PR), results in greater weight loss and improved self-monitoring adherence. Healthy adults (N = 210) with a mean BMI of 34.01 kg/m(2) were randomized to one of three self-monitoring approaches: PR (n = 72), PDA with self-monitoring software (n = 68), or PDA with self-monitoring software and daily feedback messages (PDA+FB, n = 70). All participants received standard behavioral treatment. Self-monitoring adherence and change in body weight, waist circumference, and diet were assessed at 6 months; retention was 91%. All participants had a significant weight loss (P < 0.01) but weight loss did not differ among groups. A higher proportion of PDA+FB participants (63%) achieved >= 5% weight loss in comparison to the PR group (46%) (P < 0.05) and PDA group (49%) (P = 0.09). Median percent self-monitoring adherence over the 6 months was higher in the PDA groups (PDA 80%; PDA+FB 90%) than in the PR group (55%) (P < 0.01). Waist circumference decreased more in the PDA groups than the PR group (P = 0.02). Similarly, the PDA groups reduced energy and saturated fat intake more than the PR group (P < 0.05). Self-monitoring adherence was greater in the PDA groups with the greatest weight change observed in the PDA+FB group.
C1 [Burke, Lora E.; Sereika, Susan M.; Elci, Okan U.; Styn, Mindi A.; Acharya, Sushama D.] Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15261 USA.
[Burke, Lora E.; Conroy, Molly B.; Styn, Mindi A.; Acharya, Sushama D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Conroy, Molly B.; Sevick, Mary A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA.
[Sereika, Susan M.; Elci, Okan U.; Sevick, Mary A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Sevick, Mary A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth & Equ Res & Promot, Pittsburgh, PA USA.
[Ewing, Linda J.] Univ Pittsburgh, Sch Med, Dept Psychol, Pittsburgh, PA 15261 USA.
[Ewing, Linda J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Glanz, Karen] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Glanz, Karen] Univ Penn, Sch Nursing, Family & Community Hlth Div, Philadelphia, PA 19104 USA.
RP Burke, LE (reprint author), Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15261 USA.
EM lbu100@pitt.edu
FU National Institutes of Health [RO1-DK71817, NR010742]; Data Management
Core of the Center for Research in Chronic Disorders NIH-NINR
[P30-NR03924]; General Clinical Research Center, NIH-NCRR-GCRC
[5MO1-RR00056]; Clinical Translational Research Center, NIH/NCRR/CTSA,
University of Pittsburgh [UL1 RR024153]
FX We gratefully acknowledge the participants in this study who so
willingly gave of their time to complete the assessments. This study was
supported by National Institutes of Health grants #RO1-DK71817 and
partial support for L.E.B. by NIH K24 Award, NR010742. The conduct of
the study was also supported by the Data Management Core of the Center
for Research in Chronic Disorders NIH-NINR #P30-NR03924 and the General
Clinical Research Center, NIH-NCRR-GCRC #5MO1-RR00056 and the Clinical
Translational Research Center, NIH/NCRR/CTSA Grant UL1 RR024153 at the
University of Pittsburgh.
NR 28
TC 74
Z9 74
U1 2
U2 24
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD FEB
PY 2011
VL 19
IS 2
BP 338
EP 344
DI 10.1038/oby.2010.208
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 712FW
UT WOS:000286651400017
PM 20847736
ER
PT J
AU Gossec, L
Paternotte, S
Maillefert, JF
Combescure, C
Conaghan, PG
Davis, AM
Gunther, KP
Hawker, G
Hochberg, M
Katz, JN
Kloppenburg, M
Lim, K
Lohmander, LS
Mahomed, NN
March, L
Pavelka, K
Punzi, L
Roos, EM
Sanchez-Riera, L
Singh, JA
Suarez-Almazor, ME
Dougados, M
AF Gossec, L.
Paternotte, S.
Maillefert, J. F.
Combescure, C.
Conaghan, P. G.
Davis, A. M.
Gunther, K. -P.
Hawker, G.
Hochberg, M.
Katz, J. N.
Kloppenburg, M.
Lim, K.
Lohmander, L. S.
Mahomed, N. N.
March, L.
Pavelka, K.
Punzi, L.
Roos, E. M.
Sanchez-Riera, L.
Singh, J. A.
Suarez-Almazor, M. E.
Dougados, M.
CA OARSI-OMERACT Task Force Total Art
TI The role of pain and functional impairment in the decision to recommend
total joint replacement in hip and knee osteoarthritis: an international
cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task
Force on total joint replacement
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Knee; Hip; Osteoarthritis; Joint replacement; Surgery; Symptom
ID RADIOGRAPHIC FEATURES; PHYSICAL-FUNCTION; OUTCOME MEASURE; ARTHROPLASTY;
SEVERITY; SURGERY; TRIALS; PRIORITIZATION; ASSOCIATION; PREDICTORS
AB Objective: To assess the pain and functional disability levels corresponding to an indication for total joint replacement (TJR) in hip and knee osteoarthritis (OA).
Methods: Design: International cross-sectional study in 10 countries. Patients: Consecutive outpatients with definite hip or knee OA attending an orthopaedic outpatient clinic. Gold standard measure for recommendation for TJR: Surgeon's decision that TJR is justified. Outcome measures: Pain (ICOAP: intermittent and constant osteoarthritis pain, 0-100) and functional impairment (HOOS-PS/KOOS-PS: Hip/Knee injury and Osteoarthritis Outcome Score Physical function Short-form, 0-100). Analyses: Comparison of patients with vs without surgeons' indication for TJR. Receiver Operating Characteristic (ROC) curve analyses and logistic regression were applied to determine cut points of pain and disability defining recommendation for TJR.
Results: In all, 1909 patients were included (1130 knee/779 hip OA). Mean age was 66.4 [standard deviation (SD) 10.9] years, 58.1% were women; 628/1130 (55.6%) knee OA and 574/779 (73.7%) hip OA patients were recommended for TJR. Although patients recommended for TJR (yes vs no) had worse symptom levels [pain, 55.5 (95% confidence interval 54.2, 56.8) vs. 44.9 (43.2, 46.6), and functional impairment, 59.8 (58.7, 60.9) vs. 50.9 (49.3, 52.4), respectively, both P < 0.0001]. there was substantial overlap in symptom levels between groups, even when adjusting for radiographic joint status. Thus, it was not possible to determine cut points for pain and function defining 'requirement for TJR'.
Conclusion: Although symptom levels were higher in patients recommended for TJR, pain and functional disability alone did not discriminate between those who were and were not considered to need TJR by the orthopaedic surgeon. (C) 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Gossec, L.] Paris Descartes Univ, Hop Cochin, APHP, Fac Med,Rheumatol Dept B,Serv Rhumatol B, F-75014 Paris, France.
[Maillefert, J. F.] Dijon Univ Hosp, Dept Rheumatol, F-21078 Dijon, France.
[Maillefert, J. F.] Univ Burgundy, F-21079 Dijon, France.
[Maillefert, J. F.] INSERM, U887, F-21079 Dijon, France.
[Combescure, C.] Univ Geneva, CH-1211 Geneva 4, Switzerland.
[Conaghan, P. G.] Univ Leeds, Sect Musculoskeletal Dis, Leeds, W Yorkshire, England.
[Conaghan, P. G.] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England.
[Davis, A. M.] Toronto Western Res Inst, Div Hlth Care & Outcomes Res & Arthrit, Toronto, ON, Canada.
[Davis, A. M.] Toronto Western Res Inst, Community Res & Evaluat Unit, Toronto, ON, Canada.
[Davis, A. M.] Univ Toronto, Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada.
[Davis, A. M.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada.
[Gunther, K. -P.] Univ Dresden, Dept Orthopaed Surg, Dresden, Germany.
[Hawker, G.] Univ Toronto, Div Rheumatol, Dept Med, Womens Coll Hosp, Toronto, ON M5S 1A1, Canada.
[Hawker, G.] Univ Toronto, Clin Epidemiol & Hlth Care Res Program, Dept Hlth Policy Management & Evaluat, Fac Med, Toronto, ON M5S 1A1, Canada.
[Hochberg, M.] Univ Maryland, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA.
[Hochberg, M.] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Div Gerontol, Baltimore, MD 21201 USA.
[Katz, J. N.] Harvard Univ, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA.
[Katz, J. N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Katz, J. N.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Kloppenburg, M.] Leiden Univ Med Ctr, Dept Rheumatol, Leiden, Netherlands.
[Kloppenburg, M.] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.
[Lim, K.] St Vincents Hosp, Dept Rheumatol, Melbourne, Vic, Australia.
[Lim, K.] Western Hosp, Melbourne, Vic, Australia.
[Lohmander, L. S.] Lund Univ, Dept Orthopaed, Lund, Sweden.
[Mahomed, N. N.] Univ Toronto, Toronto Western Hosp, Div Orthopaed Surg, Toronto, ON M5T 2S8, Canada.
[March, L.] Univ Sydney, Royal N Shore Hosp, Inst Bone & Joint Res, St Leonards, NSW 2065, Australia.
[Pavelka, K.] Charles Univ Prague, Inst Rheumatol, CR-11636 Prague 1, Czech Republic.
[Punzi, L.] Univ Padua, Rheumatol Unit, Dept Clin & Expt Med, I-35100 Padua, Italy.
[Roos, E. M.] Univ So Denmark, Inst Sports & Clin Biomech, Odense, Denmark.
[Sanchez-Riera, L.] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia.
[Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Suarez-Almazor, M. E.] Univ Texas MD Anderson Canc Ctr, Rheumatol Sect, Houston, TX 77030 USA.
RP Gossec, L (reprint author), Paris Descartes Univ, Hop Cochin, APHP, Fac Med,Rheumatol Dept B,Serv Rhumatol B, 27 Rue Faubourg St Jacques, F-75014 Paris, France.
EM laure.gossec@cch.aphp.fr
RI Roos, Ewa/A-5416-2012; Lohmander, Stefan/I-8326-2012; DOUGADOS,
MAXIME/P-5287-2016; Pavelka, Karel/E-6578-2017
OI Roos, Ewa/0000-0001-5425-2199; Pavelka, Karel/0000-0003-1952-8422;
PUNZI, LEONARDO/0000-0002-8853-516X; Lohmander,
Stefan/0000-0002-5424-9448; singh, jasvinder/0000-0003-3485-0006
FU Servier; Allergan; Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals
FX Lyn March has received a speaker honorarium and travel grant from
Servier.; JAS has received speaker honoraria from Abbott; research and
travel grants from Allergan, Takeda, Savient, Wyeth and Amgen; and
consultant fees from Savient and URL pharmaceuticals.
NR 41
TC 64
Z9 65
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD FEB
PY 2011
VL 19
IS 2
BP 147
EP 154
DI 10.1016/j.joca.2010.10.025
PG 8
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 722YG
UT WOS:000287470600002
PM 21044689
ER
PT J
AU Jain, S
Siegle, GJ
Gu, C
Moore, CG
Ivanco, LS
Jennings, JR
Steinhauer, SR
Studenski, S
Greenamyre, JT
AF Jain, Samay
Siegle, Greg J.
Gu, Chen
Moore, Charity G.
Ivanco, Larry S.
Jennings, J. Richard
Steinhauer, Stuart R.
Studenski, Stephanie
Greenamyre, J. Timothy
TI Autonomic insufficiency in pupillary and cardiovascular systems in
Parkinson's disease
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Non-motor features; Parkinson's disease; Pupillography; Pupil; Cardiac
physiology; Autonomic dysfunction
ID HEART-RATE-VARIABILITY
AB Background: In Parkinson's disease (PD), neurodegenerative changes have been observed in autonomic pathways involving multiple organ systems. We explore pupillary and cardiac autonomic measures as physiological manifestations of PD neurodegeneration.
Methods: Pupil measures (pupillary unrest (spontaneous changes of pupil diameter in darkness), constriction velocity and redilation velocity) were assessed in 35 participants (17 PD, 18 controls). Simultaneous cardiac measures (respiratory sinus arrythmia during deep breathing, Valsalva ratio, resting heart rate variability (HRV), orthostatic change in blood pressure and orthostatic change in heart rate) were obtained. Nonparametric statistics were used to compare PD with control participants and to calculate correlation coefficients between pupillary and cardiac measures.
Results: Pupillary unrest and orthostatic decreases in systolic blood pressure were greater in PD than controls. Respiratory sinus arrythmia during deep breathing and resting HRV were lower in PD. Among all participants, there was a negative correlation between HRV and redilation velocity and a positive correlation between orthostatic change in heart rate and pupillary unrest. A modifying effect of PD was found on the association between high frequency HRV and pupillary unrest.
Conclusions: Results demonstrate simultaneous autonomic dysfunction in both pupillary and cardiac systems in PD. The correlations between pupillary and cardiac measures suggest shared central centers of autonomic integration, while the modifying effect of PD may reflect autonomic effects of PD-related pathology not present in controls. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Jain, Samay; Siegle, Greg J.; Gu, Chen; Moore, Charity G.; Ivanco, Larry S.; Jennings, J. Richard; Steinhauer, Stuart R.; Studenski, Stephanie; Greenamyre, J. Timothy] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
[Steinhauer, Stuart R.; Greenamyre, J. Timothy] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Jain, Samay; Greenamyre, J. Timothy] Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA USA.
RP Jain, S (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, 3471 5th Ave,Suite 811,Kaufmann Med Bldg, Pittsburgh, PA 15213 USA.
EM jains@upmc.edu
OI Greenamyre, J. Timothy/0000-0003-3468-7878; Moore,
Charity/0000-0002-0060-0124
FU NIH [KL2 RR024154, KMH082998, MH55762, P30 AG-024826, UL1 RR024153];
Dept. of Veterans Affairs; American Parkinson's Disease Association
Center for Advanced Research at the University of Pittsburgh
FX NIH grants KL2 RR024154, KMH082998, MH55762, P30 AG-024826, UL1
RR024153, Dept. of Veterans Affairs, and the American Parkinson's
Disease Association Center for Advanced Research at the University of
Pittsburgh.
NR 12
TC 15
Z9 16
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD FEB
PY 2011
VL 17
IS 2
BP 119
EP 122
DI 10.1016/j.parkreldis.2010.11.005
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 736FB
UT WOS:000288475000009
PM 21115264
ER
PT J
AU Wijsman, EM
Pankratz, ND
Choi, Y
Rothstein, JH
Faber, KM
Cheng, R
Lee, JH
Bird, TD
Bennett, DA
Diaz-Arrastia, R
Goate, AM
Farlow, M
Ghetti, B
Sweet, RA
Foroud, TM
Mayeux, R
AF Wijsman, Ellen M.
Pankratz, Nathan D.
Choi, Yoonha
Rothstein, Joseph H.
Faber, Kelley M.
Cheng, Rong
Lee, Joseph H.
Bird, Thomas D.
Bennett, David A.
Diaz-Arrastia, Ramon
Goate, Alison M.
Farlow, Martin
Ghetti, Bernardino
Sweet, Robert A.
Foroud, Tatiana M.
Mayeux, Richard
CA NIA-LOAD NCRAD Family Study Grp
TI Genome-Wide Association of Familial Late-Onset Alzheimer's Disease
Replicates BIN1 and CLU and Nominates CUGBP2 in Interaction with APOE
SO PLOS GENETICS
LA English
DT Article
ID AGE-AT-ONSET; HARDY-WEINBERG EQUILIBRIUM; APOLIPOPROTEIN-E GENOTYPE;
ALLELE-SPECIFIC PCR; LINKAGE DISEQUILIBRIUM; CARIBBEAN HISPANICS;
VASCULAR DEMENTIA; GENE; LOCI; RISK
AB Late-onset Alzheimer's disease (LOAD) is the most common form of dementia in the elderly. The National Institute of Aging-Late Onset Alzheimer's Disease Family Study and the National Cell Repository for Alzheimer's Disease conducted a joint genome-wide association study (GWAS) of multiplex LOAD families (3,839 affected and unaffected individuals from 992 families plus additional unrelated neurologically evaluated normal subjects) using the 610 IlluminaQuad panel. This cohort represents the largest family-based GWAS of LOAD to date, with analyses limited here to the European-American subjects. SNPs near APOE gave highly significant results (e. g., rs2075650, p = 3.2 x 10(-81)), but no other genome-wide significant evidence for association was obtained in the full sample. Analyses that stratified on APOE genotypes identified SNPs on chromosome 10p14 in CUGBP2 with genome-wide significant evidence for association within APOE epsilon 4 homozygotes (e.g., rs201119, p = 1.5 x 10(-8)). Association in this gene was replicated in an independent sample consisting of three cohorts. There was evidence of association for recently-reported LOAD risk loci, including BIN1 (rs7561528, p = 0.009 with, and p = 0.03 without, APOE adjustment) and CLU (rs11136000, p = 0.023 with, and p = 0.008 without, APOE adjustment), with weaker support for CR1. However, our results provide strong evidence that association with PICALM (rs3851179, p = 0.69 with, and p = 0.039 without, APOE adjustment) and EXOC3L2 is affected by correlation with APOE, and thus may represent spurious association. Our results indicate that genetic structure coupled with ascertainment bias resulting from the strong APOE association affect genome-wide results and interpretation of some recently reported associations. We show that a locus such as APOE, with large effects and strong association with disease, can lead to samples that require appropriate adjustment for this locus to avoid both false positive and false negative evidence of association. We suggest that similar adjustments may also be needed for many other large multi-site studies.
C1 [Wijsman, Ellen M.; Rothstein, Joseph H.; Bird, Thomas D.] Univ Washington, Div Med Genet, Seattle, WA 98195 USA.
[Wijsman, Ellen M.; Choi, Yoonha] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Pankratz, Nathan D.; Faber, Kelley M.; Foroud, Tatiana M.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA.
[Cheng, Rong; Lee, Joseph H.; Mayeux, Richard] Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, Gertrude H Sergievsky Ctr, New York, NY USA.
[Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Bennett, David A.] Rush Univ, Rush Alzheimers Dis Ctr, Med Ctr, Chicago, IL 60612 USA.
[Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.
[Goate, Alison M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Farlow, Martin] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Ghetti, Bernardino] Indiana Univ Sch Med, Div Neuropathol, Dept Pathol, Indianapolis, IN USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
RP Wijsman, EM (reprint author), Univ Washington, Div Med Genet, Seattle, WA 98195 USA.
EM wijsman@u.washington.edu
RI Lee, Joseph/D-2441-2012
OI Lee, Joseph/0000-0002-2000-4821; Wijsman, Ellen/0000-0002-2725-6669
FU National Institute of Aging [U24AG026395]; National Cell Repository for
Alzheimer's Disease [U24AG021886]; University of Pittsburgh
[R01AG027224, P50AG005133]; Rush University Medical Center [P30AG10161];
Boston University [P30AG013846]; Columbia University [P50AG08702,
P01AG07232, R37AG015473]; Duke University [P30AG028377, P50AG05128];
Indiana University [P30AG010133]; Massachusetts General Hospital
[P50AG05134]; Mayo Clinic, Rochester, and Mayo Clinic, Jacksonville
[P50AG165574]; Mount Sinai School of Medicine [P01AG05138, P01AG02219,
P50AG05138]; Northwestern University Medical School [P30AG13854]; Oregon
Health and Science University [P30AG008017]; University of Alabama at
Birmingham [P50AG016582]; David Geffen School of Medicine, University of
California Los Angeles [P50AG016579]; University of Kentucky, Lexington
[P30AG028383]; University of Pennsylvania [P30AG10124]; University of
Southern California [P50AG05142]; University of Texas Southwestern
Medical Center [P30AG12300]; University of Washington [P50AG05136];
Washington University School of Medicine [P50AG05681, P01AG03991];
National Institutes of Health [HHSN268200782096C]
FX This study was supported by the following federal grants from the
National Institute of Aging: U24AG026395 (NIA-LOAD Family Study);
U24AG021886 (National Cell Repository for Alzheimer's Disease);
R01AG027224 and P50AG005133 University of Pittsburgh; P30AG10161 Rush
University Medical Center; P30AG013846 Boston University; P50AG08702,
P01AG07232, and R37AG015473 Columbia University; P30AG028377 and
P50AG05128 Duke University; P30AG010133 Indiana University; P50AG05134
Massachusetts General Hospital; P50AG165574 Mayo Clinic, Rochester, and
Mayo Clinic, Jacksonville; P01AG05138, P01AG02219, and P50AG05138 Mount
Sinai School of Medicine; P30AG13854 Northwestern University Medical
School; P30AG008017 Oregon Health and Science University; P50AG016582
University of Alabama at Birmingham; P50AG016579 David Geffen School of
Medicine, University of California Los Angeles; P30AG028383 University
of Kentucky, Lexington; P30AG10124 University of Pennsylvania;
P50AG05142 University of Southern California; P30AG12300 The University
of Texas Southwestern Medical Center; P50AG05136 University of
Washington; and P50AG05681 and P01AG03991 Washington University School
of Medicine. Genotyping services were provided by the Center for
Inherited Disease Research (CIDR). CIDR is fully funded through a
federal contract from the National Institutes of Health to The Johns
Hopkins University, contract number HHSN268200782096C. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript, but did review the manuscript
prior to submission.
NR 101
TC 110
Z9 113
U1 4
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD FEB
PY 2011
VL 7
IS 2
AR e1001308
DI 10.1371/journal.pgen.1001308
PG 19
WC Genetics & Heredity
SC Genetics & Heredity
GA 726CV
UT WOS:000287697300023
PM 21379329
ER
PT J
AU Sharpless, BA
Barber, JP
AF Sharpless, Brian A.
Barber, Jacques P.
TI A Clinician's Guide to PTSD Treatments for Returning Veterans
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE PTSD; posttraumatic stress disorder; post-traumatic stress disorder;
psychotherapy; psychopharmacology
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY;
EYE-MOVEMENT DESENSITIZATION; NATIONAL COMORBIDITY SURVEY; PROLONGED
EXPOSURE; REPROCESSING EMDR; TRIAL; PSYCHOTHERAPY; VICTIMS; TRAUMA
AB What options are available to mental health providers helping clients with posttraumatic stress disorder (PTSD)? In this paper we review many of the current pharmacological and psychological interventions available to help prevent and treat PTSD with an emphasis on combat-related traumas and veteran populations. There is strong evidence supporting the use of several therapies including prolonged exposure (PE), eye movement desensitization and reprocessing (EMDR), and cognitive processing therapies (CPT), with PE possessing the most empirical evidence in favor of its efficacy. There have been relatively fewer studies of nonexposure based modalities (e.g., psychodynamic, interpersonal, and dialectical behavior therapy perspectives), but there is no evidence that these treatments are less effective. Pharmacotherapy is promising (especially paroxetine, sertraline, and venlafaxine), but more research comparing the relative merits of medication vs. psychotherapy and the efficacy of combined treatments is needed. Given the recent influx of combat-related traumas due to ongoing conflicts in Iraq and Afghanistan, there is clearly an urgent need to conduct more randomized clinical trials research and effectiveness studies in military and Department of Veterans Affairs PTSD samples. Finally, we provide references to a number of PTSD treatment manuals and propose several recommendations to help guide clinicians' treatment selections.
C1 [Sharpless, Brian A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.
[Barber, Jacques P.] Univ Penn, Ctr Psychotherapy Res, Philadelphia, PA 19104 USA.
[Barber, Jacques P.] Philadelphia VA Med Ctr, CESATE, Philadelphia, PA USA.
RP Sharpless, BA (reprint author), Penn State Univ, Dept Psychol, 314 Moore Bldg, University Pk, PA 16802 USA.
EM bas171@psu.edu
RI Schueter, nicos/A-3625-2014
OI barber, jacques/0000-0002-8762-2595
FU NIMH NIH HHS [R01 MH070664-01A2, R01 MH070664]
NR 48
TC 13
Z9 14
U1 5
U2 27
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD FEB
PY 2011
VL 42
IS 1
SI SI
BP 8
EP 15
DI 10.1037/a0022351
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA 733TE
UT WOS:000288285100002
PM 21475611
ER
PT J
AU Katzman, MA
Copeland, A
Klassen, LJ
Chokka, P
Brawman-Mintzer, O
AF Katzman, Martin A.
Copeland, Alex
Klassen, Larry J.
Chokka, Pratap
Brawman-Mintzer, Olga
TI Pharmacotherapy for Generalized Anxiety Disorder
SO PSYCHIATRIC ANNALS
LA English
DT Article
ID VENLAFAXINE EXTENDED-RELEASE; PLACEBO-CONTROLLED TRIAL; RANDOMIZED
CONTROLLED-TRIAL; NATIONAL-COMORBIDITY-SURVEY; QUALITY-OF-LIFE;
DOUBLE-BLIND; MAJOR DEPRESSION; BEHAVIORAL-INHIBITION; CLINICAL-TRIALS;
DULOXETINE TREATMENT
C1 [Katzman, Martin A.; Copeland, Alex] START Clin Mood & Anxiety Disorders, Toronto, ON M5G 1N8, Canada.
[Katzman, Martin A.] Univ Toronto, Dept Psychiat, Fac Med, Toronto, ON M5S 1A1, Canada.
[Katzman, Martin A.] Lakehead Univ, Dept Psychol, Thunder Bay, ON P7B 5E1, Canada.
[Klassen, Larry J.] Univ Manitoba, Dept Psychiat, Fac Med, Winnipeg, MB R3T 2N2, Canada.
[Chokka, Pratap] Univ Alberta, Fac Med, Edmonton, AB T6G 2M7, Canada.
[Brawman-Mintzer, Olga] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Katzman, MA (reprint author), START Clin Mood & Anxiety Disorders, 900-790 Bay St, Toronto, ON M5G 1N8, Canada.
EM mkatzman@startclinic.ca
NR 83
TC 3
Z9 3
U1 3
U2 11
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD FEB
PY 2011
VL 41
IS 2
BP 95
EP U48
DI 10.3928/00485713-20110203-08
PG 11
WC Psychiatry
SC Psychiatry
GA 884XT
UT WOS:000299742900008
ER
PT J
AU Mancuso, F
Horan, WP
Kern, RS
Green, MF
AF Mancuso, Francesco
Horan, William P.
Kern, Robert S.
Green, Michael F.
TI Social cognition in psychosis: Multidimensional structure, clinical
correlates, and relationship with functional outcome
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Social cognition; Neurocognition; Positive symptoms;
Negative symptoms; Functional outcome
ID PSYCHIATRIC RATING-SCALE; SCHIZOPHRENIA-PATIENTS; QUALITY-ASSURANCE;
MIND DEFICITS; HIGH-RISK; NEUROCOGNITION; ATTRIBUTIONS; PERFORMANCE;
RELEVANCE; DECEPTION
AB Social cognitive impairments are common, detectable across a wide range of tasks, and appear to play a key role in explaining poor outcome in schizophrenia and related psychotic disorders. However, little is known about the underlying factor structure of social cognition in people with psychotic disorders due to a lack of exploratory factor analyses using a relatively comprehensive social cognitive assessment battery. In a sample of 85 outpatients with psychosis, we examined the factor structure and clinical/functional correlates of eight indexes derived from five social cognition tasks that span the domains of emotional processing, social perception, attributional style, and Theory of Mind. Exploratory factor analysis revealed three factors with relatively low inter-correlations that explained a total of 54% of the variance: (1) Hostile attributional style, (2) Lower-level social cue detection, and (3) Higher-level inferential and regulatory processes. None of the factors showed significant correlations with negative symptoms. Factor 1 significantly correlated with clinical symptoms (positive, depression-anxiety, agitation) but not functional outcome, whereas Factors 2 and 3 significantly correlated with functional outcome (functional capacity and real-world social and work functioning) but not clinical symptoms. Furthermore, Factor 2 accounted for unique incremental variance in functional capacity, above and beyond non-social neurocognition (measured with MATRICS Consensus Cognitive Battery) and negative symptoms. Results suggest that multiple separable dimensions of social cognition can be identified in psychosis, and these factors show distinct patterns of correlation with clinical features and functional outcome. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Mancuso, Francesco; Horan, William P.; Kern, Robert S.; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Mancuso, Francesco; Horan, William P.; Kern, Robert S.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, MIRECC VISN22, Los Angeles, CA USA.
[Mancuso, Francesco] Univ Naples SUN, Dept Psychiat, Naples, Italy.
RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Behav Sci, David Geffen Sch Med, 300 UCLA Med Plaza,Suite 2255, Los Angeles, CA 90095 USA.
EM horan@ucla.edu
FU Veterans Affairs; NIMH [MH043292]; Mental Illness Research Education
Clinical Center [VA VISN-22]
FX Funding for this project came from a Veterans Affairs Merit Grant and
NIMH grant MH043292 (both to Dr. Green), and the VA VISN-22 Mental
Illness Research Education Clinical Center. The VA had no further role
in study design; in the collection, analysis and interpretation of data;
in the writing of the report; and in the decision to submit the paper
for publication.
NR 68
TC 94
Z9 100
U1 2
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD FEB
PY 2011
VL 125
IS 2-3
BP 143
EP 151
DI 10.1016/j.schres.2010.11.007
PG 9
WC Psychiatry
SC Psychiatry
GA 733ZW
UT WOS:000288304000006
PM 21112743
ER
PT J
AU Jonker, MA
Hermsen, JL
Gomez, FE
Sano, Y
Kudsk, KA
AF Jonker, Mark A.
Hermsen, Joshua L.
Gomez, F. Enrique
Sano, Yoshifumi
Kudsk, Kenneth A.
TI Injury Induces Localized Airway Increases in Pro-Inflammatory Cytokines
in Humans and Mice
SO SURGICAL INFECTIONS
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
American-Society-of-Parenteral-and-Enteral-Nutrition
CY FEB 01-04, 2009
CL New Orleans, LA
SP Amer Soc Parenter & Enter
ID TUMOR-NECROSIS-FACTOR; RESPIRATORY-DISTRESS-SYNDROME; FACTOR-KAPPA-B;
NOSOCOMIAL PNEUMONIA; SECRETORY COMPONENT; FACTOR-ALPHA; TRAUMA;
IMMUNOGLOBULIN; RECEPTOR; INTERLEUKIN-6
AB Background: Secretory immunoglobulin A (sIgA) increases in the airways of humans and mice after injury to protect against infection. The pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and IL-6 are linked molecularly to sIgA production and secretion and are required for sIgA increases in the airway after injury in a mouse model. We investigated the injury effect on airway and serum concentrations to determine the source of the cytokines involved in the airway IgA response.
Methods: In the first experiment, TNF-alpha, IL-1 beta, and IL-6 concentrations in bronchoalveolar lavage (BAL) fluid and serum obtained from 11 ventilated trauma patients within 30 h of admission were compared with those in eight elective surgical patients. In the second experiment, male ICR mice received no injury (n=7) or injury with sham celiotomy and neck incisions (n=8) with sacrifice of all animals at 8 h for BAL fluid and serum cytokine measurements by enzyme-linked immunosorbent assay.
Results: Injured patients had significantly higher BAL fluid and serum TNF-alpha, IL-1 beta, and IL-6 concentrations, with greater increases in the BAL fluid than in the serum. Injured mice had significantly increased BAL fluid concentrations of TNF-alpha, IL-1 beta, and IL-6 without significant changes in serum TNF-alpha or IL-1 beta. Serum IL-6 increased significantly.
Conclusions: Injury significantly increases human and mouse airway TNF-alpha, IL-1 beta, and IL-6. Increases are greater in the airway than in serum, implying a local rather than a systemic stress response to injury.
C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA.
[Jonker, Mark A.; Hermsen, Joshua L.; Sano, Yoshifumi; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
[Gomez, F. Enrique] Inst Nutr Salvador Zubiran, Dept Nutr Physiol, Tlalpan, DF, Mexico.
RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA.
EM kudsk@surgery.wisc.edu
FU NIGMS NIH HHS [R01 GM53439]
NR 38
TC 7
Z9 8
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-2964
J9 SURG INFECT
JI Surg. Infect.
PD FEB
PY 2011
VL 12
IS 1
BP 49
EP 56
DI 10.1089/sur.2010.040
PG 8
WC Infectious Diseases; Surgery
SC Infectious Diseases; Surgery
GA 768LN
UT WOS:000290936300008
PM 21166596
ER
PT J
AU Pergam, SA
Forsberg, CW
Boeckh, MJ
Maynard, C
Limaye, AP
Wald, A
Smith, NL
Young, BA
AF Pergam, S. A.
Forsberg, C. W.
Boeckh, M. J.
Maynard, C.
Limaye, A. P.
Wald, A.
Smith, N. L.
Young, B. A.
TI Herpes zoster incidence in a multicenter cohort of solid organ
transplant recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE herpes zoster; infection; liver transplantation; kidney transplantation;
African American
ID HEALTH-CARE-SYSTEM; VARICELLA-ZOSTER; VETERANS-AFFAIRS;
LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; ADMINISTRATIVE DATABASES;
INFECTIOUS COMPLICATIONS; HEART-TRANSPLANTATION; LUNG TRANSPLANTATION;
CELL TRANSPLANTATION
AB Background
Immunosuppressed patients are at increased risk for herpes zoster (HZ), but incidence in solid organ transplant (SOT) recipients has varied in multiple studies. To assess incidence of HZ, we examined patients who underwent SOT and received follow-up care within the large multicenter US Department of Veteran's Affairs healthcare system.
Methods
Incident cases of HZ were determined using ICD-9 coding from administrative databases. A multivariable Cox proportional hazards model, adjusted for a priori risk factors, was used to assess demographic factors associated with development of HZ.
Results
Among the 1077 eligible SOT recipients, the cohort-specific incidence rate of HZ was 22.2 per 1000 patient-years (95% confidence interval [CI], 18.1-27.4). African Americans (37.6 per 1000 [95% CI, 25.0-56.6]) and heart transplants recipients (40.0 per 1000 [95% CI, 23.2-68.9]) had the highest incidence of HZ. Patients transplanted between 2005 and 2007 had the lowest incidence (15.3 per 1000 [95% CI, 8.2-28.3]). In a multivariable model, African Americans (hazard ratio [HR] 1.88; 95% CI: 1.12, 3.17) and older transplant recipients (HR 1.13; 95% CI: 1.01, 1.27 [per 5-year increment]) had increased relative hazards of HZ.
Conclusions
These data demonstrate that HZ is a common infectious complication following SOT. Future studies focused on HZ prevention are needed in this high-risk population.
C1 [Pergam, S. A.; Boeckh, M. J.; Limaye, A. P.; Wald, A.; Young, B. A.] Univ Washington, Dept Med, Seattle, WA USA.
[Pergam, S. A.; Boeckh, M. J.; Wald, A.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
[Forsberg, C. W.; Maynard, C.; Smith, N. L.; Young, B. A.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Maynard, C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Limaye, A. P.; Wald, A.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Wald, A.; Smith, N. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Young, B. A.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
RP Pergam, SA (reprint author), Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, 1100 Fairview Ave N,D3-100,POB 19024, Seattle, WA 98109 USA.
EM spergam@fhcrc.org
RI Pergam, Steven/C-2286-2008; Wald, Anna/B-6272-2012; Maynard,
Charles/N-3906-2015
OI Pergam, Steven/0000-0002-6333-5196; Wald, Anna/0000-0003-3486-6438;
Maynard, Charles/0000-0002-1644-7814
FU Office of Research and Development Cooperative Studies Program,
Department of Veterans Affairs; Puget Sound VA Epidemiologic Research
and Information Center, VA Research & Development, Seattle, WA; Joel
Meyers Foundation; NIH [K23HL096831, CA18029, K24HL093294, RO1
DK079745]; American Society of Blood and Marrow Transplant/Viropharma,
Inc.; [K24AI071113]
FX The authors would like to thank Ted Gooley, PhD and Amelia Margaret, PhD
for their assistance with the statistical analyses in this manuscript,
and Ernie Ayers, MPTH for his administrative support. This material is
based on work supported in part by the Office of Research and
Development Cooperative Studies Program, Department of Veterans Affairs
and the use of facilities at the VA Puget Sound Health Care System. The
views expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs.;
This study was supported in part by the Puget Sound VA Epidemiologic
Research and Information Center, VA Research & Development, Seattle, WA.
S.A.P. is supported by the Joel Meyers Foundation, NIH grant
K23HL096831, and an American Society of Blood and Marrow
Transplant/Viropharma, Inc. New Investigator Award. M.J.B is supported
by NIH grant CA18029 (core C), and K24HL093294. A.W. is supported by
K24AI071113. B.A.Y. is supported by NIH grant RO1 DK079745.
NR 70
TC 20
Z9 21
U1 1
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD FEB
PY 2011
VL 13
IS 1
BP 15
EP 23
DI 10.1111/j.1399-3062.2010.00547.x
PG 9
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 718AX
UT WOS:000287093100003
PM 20636480
ER
PT J
AU Hwang, I
Yoon, T
Kim, C
Cho, B
Lee, S
Song, MK
AF Hwang, Inkyung
Yoon, Taeho
Kim, Changhoon
Cho, Byungmann
Lee, Sooil
Song, Moon K.
TI Different roles of zinc plus arachidonic acid on insulin sensitivity
between high fructose- and high fat-fed rats
SO LIFE SCIENCES
LA English
DT Article
DE Insulin resistance; Diabetes; Hepatic glucose output; Hyperinsulinemic
euglycemic clamp; Arachidonic acid; Zinc
ID MAGNETIC-RESONANCE-SPECTROSCOPY; DEPENDENT DIABETES-MELLITUS; DEGRADING
ENZYME GENE; METABOLIC SYNDROME; GLUCOSE-OXIDATION; LINOLEIC ACID; CORN
SYRUP; HIS-PRO; RESISTANCE; MECHANISMS
AB Aims: This study was to determine the effects of zinc plus arachidonic acid (ZA) treatment on the insulin action in the specific ZA target organs using hyperinsulinemic euglycemic clamp method.
Main methods: 18 Sprague-Dawley rats weighing similar to 130 g were divided into 3 groups of 6 rats and treated them with 1) normal rat chow, 2) high fructose (60.0%) diet only, or 3) the same fructose diet plus drinking water containing 10 mg zinc plus 50 mg arachidonic acid (AA)/L In a separate study, male Wistar rats weighing similar to 250 g were fed normal rat chow (n = 4) or high fat (66.5%) diet with drinking water containing zero (n = 9) or 10 mg AA plus 20 mg zinc /L (n = 9). After 4 week treatment, insulin action was assessed using the hyperinsulinemic eguglycemic clamp technique.
Key findings: High fructose feeding impaired suppression of hepatic glucose output by insulin compared to controls during the clamp procedure (4.39 vs. 2.35 mg/kg/min; p<0.05). However, ZA treatment in high fructose-fed rats showed a significant improvement of hepatic insulin sensitivity compared to non-treatment controls (4.39 vs. 2.18 mg/kg/min; p<0.05). Glucose infusion rates in Wistar rats maintained on a high fat diet (HFD) were significantly lower compared to control rats (22.8 +/- 1.3 vs. 31.9 +/- 1.4 mg/kg/min; p<0.05). ZA treatment significantly improved (similar to 43%) peripheral tissue insulin sensitivity in HFD fed animals (26.7 +/- 1.3 [n=9] vs. 22.8 +/- 1.3 mg/kg/min; p<0.05).
Significance: These data demonstrate that ZA treatment is effective in improving glucose utilization in hyperglycemic rats receiving either a high-fructose or a high-fat diet. Published by Elsevier Inc.
C1 [Song, Moon K.] VA Great Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Song, Moon K.] Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
[Hwang, Inkyung; Yoon, Taeho; Kim, Changhoon; Cho, Byungmann; Lee, Sooil] Pusan Natl Univ, Coll Med, Dept Prevent Med, Pusan 609735, South Korea.
RP Song, MK (reprint author), VA Great Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
EM mksong@earthlink.net
FU Medical Research Institute; Pusan National University Hospital; Korean
Scientific Foundation
FX This study was supported by a Medical Research Institute Grant, Pusan
National University Hospital, and the Korean Scientific Foundation. We
are very grateful to Dr. Eain Cornford, Professor of Neurology at the
UCLA School of Medicine, for his most valuable comments and editorial
help in the preparation of this final version of manuscript.
NR 66
TC 3
Z9 3
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PD JAN 31
PY 2011
VL 88
IS 5-6
BP 278
EP 284
DI 10.1016/j.lfs.2010.12.007
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 714FK
UT WOS:000286792700012
PM 21167181
ER
PT J
AU Quintana, J
Lee, J
Marcus, M
Kee, K
Wong, T
Yerevanian, A
AF Quintana, Javier
Lee, Junghee
Marcus, Michael
Kee, Kimmy
Wong, Tiffany
Yerevanian, Armen
TI Brain dysfunctions during facial discrimination in schizophrenia:
Selective association to affect decoding
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Cognitive deficits; Social cognition; Facial information processing;
Compensatory mechanisms
ID FUSIFORM FACE AREA; AFFECT RECOGNITION; EMOTION; FMRI; PERCEPTION;
EXPRESSIONS; INFORMATION; CORTEX; ROBUST; OPTIMIZATION
AB Schizophrenia patients exhibit impaired facial affect perception, yet the exact nature of this impairment remains unclear. We investigated neural activity related to processing facial emotional and non-emotional information and complex images in 12 schizophrenia patients and 15 healthy controls using functional magnetic resonance imaging. All subjects performed a facial information processing task with three conditions: matching facial emotion, matching facial identity, and matching complex visual patterns. Patients and controls showed comparable behavioral performance in all task conditions. The neural activation patterns in schizophrenia patients and healthy controls were distinctly different while processing affect-related facial information but not other non-emotional facial features. During emotion matching, orbital frontal cortex and left amydala activations were found in controls but not in patients. When comparing emotion versus identity matching, controls activated the fusiform and middle temporal gyri, left superior temporal gyrus, and right inferior and middle frontal gyrus, whereas schizophrenia patients only activated the middle and inferior frontal gyri, the frontal operculi and the right insular cortex. Our findings suggest that schizophrenia patients and healthy controls may utilize different neural networks when processing facial emotional information. Published by Elsevier Ireland Ltd.
C1 [Quintana, Javier] Univ Calif Los Angeles, Dept Psychiat, Greater Los Angeles VA Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC VSN22, Los Angeles, CA 90073 USA.
[Quintana, Javier; Lee, Junghee; Marcus, Michael; Kee, Kimmy; Wong, Tiffany; Yerevanian, Armen] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Kee, Kimmy] Calif State Univ Channel Isl, Dept Psychol, Camarillo, CA 93012 USA.
RP Quintana, J (reprint author), Univ Calif Los Angeles, Dept Psychiat, Greater Los Angeles VA Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC VSN22, 11301 Wilshire Blvd,Bldg 210A MIRECC,Room 128, Los Angeles, CA 90073 USA.
EM xquintan@ucla.edu
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU Veterans Administration Medical Research Service; Northstar Fund
FX This research was partially supported by a Merit Review Award from the
Veterans Administration Medical Research Service to J. Quintana. We
would like to thank Jonathan Osowsky and Nicolle Ma for their helpful
assistance.; We also thank the Brain Mapping Medical Research
Organization, Brain Mapping Support Foundation, Pierson-Lovelace
Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel
Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin
Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies
Charitable Foundation, Robson Family, and Northstar Fund for their
generous support of the UCLA Brain Mapping Center.
NR 50
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD JAN 30
PY 2011
VL 191
IS 1
BP 44
EP 50
DI 10.1016/j.pscychresns.2010.09.005
PG 7
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 737TM
UT WOS:000288591100007
PM 21145212
ER
PT J
AU Echchgadda, I
Chang, TH
Sabbah, A
Bakri, I
Ikeno, Y
Hubbard, GB
Chatterjee, B
Bose, S
AF Echchgadda, Ibtissam
Chang, Te-Hung
Sabbah, Ahmed
Bakri, Imad
Ikeno, Yuji
Hubbard, Gene B.
Chatterjee, Bandana
Bose, Santanu
TI Oncolytic targeting of androgen-sensitive prostate tumor by the
respiratory syncytial virus (RSV): consequences of deficient
interferon-dependent antiviral defense
SO BMC CANCER
LA English
DT Article
ID RNA VIRUSES; CANCER; RESISTANT; CELLS; RECEPTOR; REPLICATION;
ACTIVATION; INFECTION; DEFECTS
AB Background: Oncolytic virotherapy for cancer treatment utilizes viruses for selective infection and death of cancer cells without any adverse effect on normal cells. We previously reported that the human respiratory syncytial virus (RSV) is a novel oncolytic virus against androgen-independent PC-3 human prostate cancer cells. The present study extends the result to androgen-dependent prostate cancer, and explores the underlying mechanism that triggers RSV-induced oncolysis of prostate cancer cells.
Methods: The oncolytic effect of RSV on androgen-sensitive LNCaP human prostate cancer cells and on androgen-independent RM1 murine prostate cancer cells was studied in vitro in culture and in vivo in a xenograft or allograft tumor model. In vitro, cell viability, infectivity and apoptosis were monitored by MTT assay, viral plaque assay and annexin V staining, respectively. In vivo studies involved virus administration to prostate tumors grown in immune compromised nude mice and in syngeneic immune competent C57BL/6J mice. Anti-tumorogenic oncolytic activity was monitored by measuring tumor volume, imaging bioluminescent tumors in live animals and performing histopathological analysis and TUNEL assay with tumors
Results: We show that RSV imposes a potent oncolytic effect on LNCaP prostate cancer cells. RSV infectivity was markedly higher in LNCaP cells compared to the non-tumorigenic RWPE-1 human prostate cells. The enhanced viral burden led to LNCaP cell apoptosis and growth inhibition of LNCaP xenograft tumors in nude mice. A functional host immune response did not interfere with RSV-induced oncolysis, since growth of xenograft tumors in syngeneic C57BL/6J mice from murine RM1 cells was inhibited upon RSV administration. LNCaP cells failed to activate the type-I interferon (IFN alpha/beta)-induced transcription factor STAT-1, which is required for antiviral gene expression, although these cells could produce IFN in response to RSV infection. The essential role of IFN in restricting infection was further borne out by our finding that neutralizing IFN activity resulted in enhanced RSV infection in non-tumorigenic RWPE-1 prostate cells.
Conclusions: We demonstrated that RSV is potentially a useful therapeutic tool in the treatment of androgen-sensitive and androgen-independent prostate cancer. Moreover, impaired IFN-mediated antiviral response is the likely cause of higher viral burden and resulting oncolysis of androgen-sensitive prostate cancer cells.
C1 [Echchgadda, Ibtissam; Bakri, Imad; Chatterjee, Bandana] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA.
[Chang, Te-Hung; Sabbah, Ahmed; Bose, Santanu] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Ikeno, Yuji; Hubbard, Gene B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ikeno, Yuji; Chatterjee, Bandana] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chatterjee@uthscsa.edu; bose@uthscsa.edu
FU American Lung Association [RG-49629-N]; NIH [AI069062, AI083387,
CA129246, AG10486, AG19660]; UTHSCSA-UTSA SALSI; VA Merit Review;
UTHSCSA IIMS; NIH NIDCR [DE14318]; Cancer Center Program [CA54174
(NIH-P30)]; Cancer Therapy and Research Center at the University of
Texas Health Science Center-San Antonio through the NCI Cancer Center [2
P30 CA054174-17]
FX We would like to thank Jesus Segovia for technical assistance. This work
was supported in part by the American Lung Association National
Biomedical Research grant (RG-49629-N) (S. Bose), NIH grants AI069062
(SB), AI083387 (SB), CA129246 (SB; BC), AG10486 & AG19660 (BC),
UTHSCSA-UTSA SALSI Grant (SB; BC), VA Merit Review Grant (BC). The work
was also supported by Translational Technology Resources Award (to IE)
from UTHSCSA IIMS. AS was supported by NIH NIDCR grant DE14318 for the
COSTAR program. BC is a VA Senior Research Career Scientist. FACS at the
UTHSCSA Core Facility was supported by the Cancer Center Program grant
CA54174 (NIH-P30). Financial assistance was also provided to SB and BC
by the Cancer Therapy and Research Center at the University of Texas
Health Science Center-San Antonio through the NCI Cancer Center Support
Grant (2 P30 CA054174-17).
NR 33
TC 10
Z9 11
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 28
PY 2011
VL 11
AR 43
DI 10.1186/1471-2407-11-43
PG 18
WC Oncology
SC Oncology
GA 720WY
UT WOS:000287314600002
PM 21276246
ER
PT J
AU Zhong, SP
Machida, K
Tsukamoto, H
Johnson, DL
AF Zhong, Shuping
Machida, Keigo
Tsukamoto, Hide
Johnson, Deborah L.
TI Alcohol Induces RNA Polymerase III-dependent Transcription through c-Jun
by Co-regulating TATA-binding Protein (TBP) and Brf1 Expression
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ONCOGENIC TRANSFORMATION; CELL-PROLIFERATION; INHIBITION; ACTIVATION;
STRESS; TFIIIB; ELK-1; JNK1
AB Chronic alcohol consumption is associated with steatohepatitis and cirrhosis, enhancing the risk for hepatocellular carcinoma. RNA polymerase (pol) III transcribes a variety of small, untranslated RNAs, including tRNAs and 5S rRNAs, which determine the biosynthetic capacity of cells. Increased RNA pol III-dependent transcription, observed in transformed cells and human tumors, is required for oncogenic transformation. Given that alcohol consumption increases risk for liver cancer, we examined whether alcohol regulates this class of genes. Ethanol induces RNA pol III-dependent transcription in both HepG2 cells and primary mouse hepatocytes in a manner that requires ethanol metabolism and the activation of JNK1. This regulatory event is mediated, at least in part, through the ability of ethanol to induce expression of the TFIIIB components, Brf1, and the TATA-binding protein (TBP). Induction of TBP, Brf1, and RNA pol III-dependent gene expression is driven by enhanced c-Jun expression. Ethanol promotes a marked increase in the direct recruitment of c-Jun to TBP, Brf1, and tRNA gene promoters. Chronic alcohol administration in mice leads to enhanced expression of TBP, Brf1, tRNA, and 5S rRNA gene transcription in the liver. These alcohol-dependent increases are more pronounced in transgenic animals that express the HCV NS5A protein that display increased incidence of liver tumors. Together, these results identify a new class of genes that are regulated by alcohol through the co-regulation of TFIIIB components and define a central role for c-Jun in this process.
C1 [Tsukamoto, Hide] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Tsukamoto, Hide] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
[Machida, Keigo] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
[Zhong, Shuping; Johnson, Deborah L.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
[Zhong, Shuping; Johnson, Deborah L.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
RP Zhong, SP (reprint author), 2011 Zonal Ave,HMR 605 MC 9097, Los Angeles, CA 90033 USA.
EM szhong@usc.edu
FU National Institutes of Health through the Southern California Research
Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis [P50
AA011999]; National Institutes of Health [AA017288, CA108614]
FX This work was supported, in whole or in part, by National Institutes of
Health Grant P50 AA011999 (to S.Z.) through the Southern California
Research Center for Alcoholic Liver and Pancreatic Diseases and
Cirrhosis and National Institutes of Health Grants AA017288 (to S.Z.)
and CA108614 (to D.L.J.).
NR 27
TC 10
Z9 10
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 28
PY 2011
VL 286
IS 4
BP 2393
EP 2401
DI 10.1074/jbc.M110.192955
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 709TM
UT WOS:000286464300003
PM 21106530
ER
PT J
AU Zou, CB
Butler, PL
Coon, TA
Smith, RM
Hammen, G
Zhao, YT
Chen, BB
Mallampalli, RK
AF Zou, Chunbin
Butler, Phillip L.
Coon, Tiffany A.
Smith, Rebecca M.
Hammen, Gary
Zhao, Yutong
Chen, Bill B.
Mallampalli, Rama K.
TI LPS Impairs Phospholipid Synthesis by Triggering beta-Transducin
Repeat-containing Protein (beta-TrCP)-mediated Polyubiquitination and
Degradation of the Surfactant Enzyme Acyl-CoA:Lysophosphatidylcholine
Acyltransferase I (LPCAT1)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; GLYCOGEN-SYNTHASE KINASE-3;
ADULT-RAT LUNG; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; REGULATORY
ENZYME; CELLS; PHOSPHORYLATION; EXPRESSION; PHOSPHATIDYLCHOLINE;
TRANSCRIPTION
AB Acyl-CoA: lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a relatively newly described and yet indispensable enzyme needed for generation of the bioactive surfactant phospholipid, dipalmitoylphosphatidylcholine (DPPtdCho). Here, we show that lipopolysaccharide (LPS) causes LPCAT1 degradation using the Skp1-Cullin-F-box ubiquitin E3 ligase component, beta-transducin repeat-containing protein (beta-TrCP), that polyubiquitinates LPCAT1, thereby targeting the enzyme for proteasomal degradation. LPCAT1 was identified as a phosphoenzyme as Ser(178) within a phosphodegron was identified as a putative molecular recognition site for glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylation that recruits beta-TrCP docking within the enzyme. beta-TrCP ubiquitinates LPCAT1 at an acceptor site (Lys(221)), as substitution of Lys(221) with Arg abrogated LPCAT1 polyubiquitination. LPS profoundly reduced immunoreactive LPCAT1 levels and impaired lung surfactant mechanics, effects that were overcome by siRNA to beta-TrCP and GSK-3 beta or LPCAT1 gene transfer, respectively. Thus, LPS appears to destabilize the LPCAT1 protein by GSK-3 beta-mediated phosphorylation within a canonical phosphodegron for beta-TrCP docking and site-specific ubiquitination. LPCAT1 is the first lipogenic substrate for beta-TrCP, and the results suggest that modulation of the GSK-3 beta-SCF beta(TrCP) E3 ligase effector pathway might be a unique strategy to optimize dipalmitoylphosphatidylcholine levels in sepsis.
C1 [Mallampalli, Rama K.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA.
[Hammen, Gary] Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA.
RP Mallampalli, RK (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Acute Lung Injury Ctr Excellence, 628 NW Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA.
EM mallampallirk@upmc.edu
FU NHLBI NIH HHS [R01 HL098174, HL098174, R01 HL091916-02, R01 HL097376,
R01 HL091916, HL096376, R01 HL096376, HL097376]
NR 26
TC 26
Z9 26
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 28
PY 2011
VL 286
IS 4
BP 2719
EP 2727
DI 10.1074/jbc.M110.192377
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 709TM
UT WOS:000286464300038
PM 21068446
ER
PT J
AU Jani, A
Zimmerman, M
Martin, J
Lu, L
Turkmen, K
Ravichandran, K
Pacic, A
Ljubanovic, D
Edelstein, CL
AF Jani, Alkesh
Zimmerman, Michael
Martin, Jessica
Lu, Li
Turkmen, Kultigin
Ravichandran, Kameswaran
Pacic, Arijana
Ljubanovic, Danica
Edelstein, Charles L.
TI Perfusion Storage Reduces Apoptosis in a Porcine Kidney Model of
Donation After Cardiac Death
SO TRANSPLANTATION
LA English
DT Article
DE Deceased cardiac donation; Perfusion storage; Apoptosis
ID ACUTE TUBULAR-NECROSIS; ACUTE-RENAL-FAILURE; EXPANDED CRITERIA DONORS;
COLD-STORAGE; MACHINE-PERFUSION; PULSATILE PERFUSION;
CASPASE-1-DEFICIENT MICE; ORGAN PROCUREMENT; PROSPECTIVE TRIAL;
UNITED-STATES
AB Background. Donation after cardiac death (DCD) kidneys suffer a high incidence of delayed graft function attributable to warm ischemia and cold ischemia (CI). Neither the mechanism of injury nor type of cell death has been described. Clinical studies suggest that perfusion storage (PS) of DCD kidneys may reduce injury although the mechanism of protection is unknown. In a porcine model of DCD, we hypothesized that DCD kidneys have increased caspase-1 due to warm ischemia (WI) and increased caspase-3 and apoptosis due to CI.
Methods. Male Yorkshire pigs subjected to cardiac death were perfused with cold University of Wisconsin solution. The perfused kidneys were removed and stored in cold University of Wisconsin solution for 24 hr. Kidney biopsies were obtained before cardiac death and at 0 and 24 hr of CI.
Results. There was an increase in caspase-1 activity due to WI before cold preservation. CI was associated with a massive increase in apoptosis, caspase-3/7 activity, and caspase-3 protein expression. Next, we hypothesized that PS would protect against apoptosis. We compared DCD kidneys subjected to static versus PS for 24 hr. PS significantly reduced proximal tubular apoptosis and was associated with increased B-cell lymphoma-extra large, and hypoxia-inducible transcription factor-1 alpha.
Conclusions. These findings suggest that in DCD kidneys, WI preferentially activates caspase-1, whereas CI activates caspase-3 and causes apoptosis. PS may protect DCD kidneys through activation of antiapoptotic pathways involving B-cell lymphoma-extra large and hypoxia-inducible transcription factor-1 alpha.
C1 [Jani, Alkesh; Lu, Li] Denver Vet Affairs Med Ctr, Renal Sect, Denver, CO USA.
[Zimmerman, Michael; Martin, Jessica; Turkmen, Kultigin; Ravichandran, Kameswaran; Edelstein, Charles L.] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA.
[Pacic, Arijana; Ljubanovic, Danica] Univ Zagreb SOM, Zagreb Univ Hosp Dubrava, Zagreb, Croatia.
RP Jani, A (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, 12700 E 19th Ave,C281, Aurora, CO 80045 USA.
EM Alkesh.jani@ucdenver.edu
FU NIH [K08DK69512, RO1-DK-056851, RO1-DK-074835]
FX This work was supported by NIH grant K08DK69512 (A.J.) and NIH grants
RO1-DK-056851 and RO1-DK-074835 (C.L.E.).
NR 42
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD JAN 27
PY 2011
VL 91
IS 2
BP 169
EP 175
DI 10.1097/TP.0b013e3182013753
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 706BM
UT WOS:000286190100013
PM 21200363
ER
PT J
AU Dubin, R
Cushman, M
Folsom, AR
Fried, LF
Palmas, W
Peralta, CA
Wassel, C
Shlipak, MG
AF Dubin, Ruth
Cushman, Mary
Folsom, Aaron R.
Fried, Linda F.
Palmas, Walter
Peralta, Carmen A.
Wassel, Christina
Shlipak, Michael G.
TI Kidney function and multiple hemostatic markers: cross sectional
associations in the multi-ethnic study of atherosclerosis
SO BMC NEPHROLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; FACTOR PATHWAY INHIBITOR; VON-WILLEBRAND-FACTOR;
CARDIOVASCULAR-DISEASE; CYSTATIN-C; TISSUE FACTOR; ELDERLY PERSONS;
INFLAMMATORY BIOMARKERS; SOLUBLE THROMBOMODULIN; VENOUS THROMBOEMBOLISM
AB Background: Defined as estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2, chronic kidney disease (CKD) is strongly and independently associated with cardiovascular and overall mortality. We hypothesized that reduced kidney function would be characterized by abnormalities of hemostasis.
Methods: We tested cross-sectional associations between (eGFR) and multiple hemostatic markers among 6751 participants representing a broad spectrum of kidney function in the Multi-Ethnic Study of Atherosclerosis (MESA). Kidney function was measured using cystatin C (eGFRcys) or creatinine, using CKD Epidemiology Collaboration (eGFRcr). Hemostatic markers included soluble thrombomodulin (sTM), soluble tissue factor (sTF), D-Dimer, von Willebrand factor (vWF), factor VIII, plasmin-antiplasmin complex (PAP), tissue factor pathway inhibitor (TFPI), plasminogen activator inhibitor-1 (PAI-1), and fibrinogen. Associations were tested using multivariable linear regression with adjustment for demographics and comorbidities.
Results: In comparison to persons with eGFRcys >90 ml/min/1.73 m(2), subjects with eGFRcys < 60 ml/min/1.73 m(2) had adjusted levels of sTM, sTF, D-Dimer, PAP, Factor VIII, TFPI, vWF and fibrinogen that were respectively 86%, 68%, 44%, 22%, 17%, 15%, 12% and 6% higher. Subjects with eGFRcys 60-90 ml/min/1.73 m(2) had adjusted levels that were respectively 16%, 14%, 12%, 6%, 6%, 6%, 11% and 4% higher (p < 0.05 for all). Percent differences were not significantly different when groups were categorized by eGFRcr.
Conclusions: Throughout a broad spectrum of kidney function, lower eGFR was associated with higher levels of hemostatic markers. Dysregulation of hemostasis may be a mechanism by which reduced kidney function promotes higher cardiovascular risk.
C1 [Dubin, Ruth; Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94143 USA.
[Cushman, Mary] Fletcher Allen Hlth Care, Thrombosis & Hemostasis Program, Hematol Oncol Clin, Burlington, VT 05401 USA.
[Folsom, Aaron R.] Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
[Fried, Linda F.] 7E121 VA Pittsburgh Healthcare Syst, Div Nephrol, Univ Dr Ctr, Pittsburgh, PA 15240 USA.
[Palmas, Walter] Columbia Univ, Presbyterian Hosp, Dept Internal Med, New York, NY 10032 USA.
[Wassel, Christina] UCSD Sch Med, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA.
RP Dubin, R (reprint author), Univ Calif San Francisco, Div Nephrol, Dept Med, 521 Parnassus Ave,Room C443, San Francisco, CA 94143 USA.
EM ruth.dubin@ucsf.edu
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169]
FX This research was supported by contracts N01-HC-95159 through
N01-HC-95169 from the National Heart, Lung, and Blood Institute. The
authors thank the other investigators, the staff, and the participants
of the MESA study for their valuable contributions. A full list of
participating MESA investigators and institutions can be found at
http://www.mesa-nhlbi.org.
NR 44
TC 26
Z9 32
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD JAN 26
PY 2011
VL 12
AR 3
DI 10.1186/1471-2369-12-3
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 946MI
UT WOS:000304355400001
PM 21269477
ER
PT J
AU Hashimoto, JG
Forquer, MR
Tanchuck, MA
Finn, DA
Wiren, KM
AF Hashimoto, J. G.
Forquer, M. R.
Tanchuck, M. A.
Finn, D. A.
Wiren, K. M.
TI IMPORTANCE OF GENETIC BACKGROUND FOR RISK OF RELAPSE SHOWN IN ALTERED
PREFRONTAL CORTEX GENE EXPRESSION DURING ABSTINENCE FOLLOWING CHRONIC
ALCOHOL INTOXICATION
SO NEUROSCIENCE
LA English
DT Article
DE alcoholism; chronic ethanol; abstinence; relapse; microarray; gene
expression
ID CORTICOTROPIN-RELEASING-FACTOR; ETHANOL WITHDRAWAL; C57BL/6J MICE;
CELL-PROLIFERATION; GENDER-DIFFERENCES; NUCLEUS-ACCUMBENS;
SEX-DIFFERENCES; FAMILY-HISTORY; FRONTAL-CORTEX; USE DISORDERS
AB Alcoholism is a relapsing disorder associated with excessive consumption after periods of abstinence. Neuro-adaptations in brain structure, plasticity and gene expression occur with chronic intoxication but are poorly characterized. Here we report identification of pathways altered during abstinence in prefrontal cortex, a brain region associated with cognitive dysfunction and damage in alcoholics. To determine the influence of genetic differences, an animal model was employed with widely divergent responses to alcohol withdrawal, the Withdrawal Seizure-Resistant (WSR) and Withdrawal Seizure-Prone (WSP) lines. Mice were chronically exposed to highly intoxicating concentrations of ethanol and withdrawn, then left abstinent for 21 days. Transcriptional profiling by microarray analyses identified a total of 562 genes as significantly altered during abstinence. Hierarchical cluster analysis revealed that the transcriptional response correlated with genotype/withdrawal phenotype rather than sex. Gene Ontology category overrepresentation analysis identified thyroid hormone metabolism, glutathione metabolism, axon guidance and DNA damage response as targeted classes of genes in low response WSR mice, with acetylation and histone deacetylase complex as highly dimorphic between WSR and WSP mice. Confirmation studies in WSR mice revealed both increased neurotoxicity by histopathologic examination and elevated triidothyronine (T3) levels. Most importantly, relapse drinking was reduced by inhibition of thyroid hormone synthesis in dependent WSR mice compared to controls. These findings provide in vivo physiological and behavioral validation of the pathways identified. Combined, these results indicate a fundamentally distinct neuroadaptive response during abstinence in mice genetically selected for divergent withdrawal severity. Identification of pathways altered in abstinence may aid development of novel therapeutics for targeted treatment of relapse in abstinent alcoholics. Published by Elsevier Ltd on behalf of IBRO.
C1 [Hashimoto, J. G.; Forquer, M. R.; Finn, D. A.; Wiren, K. M.] Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA.
[Hashimoto, J. G.; Tanchuck, M. A.; Finn, D. A.; Wiren, K. M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
[Wiren, K. M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
RP Wiren, KM (reprint author), VA Med Ctr, Res Serv P3R&D 39, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM wirenk@ohsu.edu
OI Wiren, Kristine/0000-0002-6159-4450
FU Department of Veterans Affairs; National Institute on Alcohol Abuse and
Alcoholism [R01 AA013194, R01 AA012439]
FX The authors gratefully acknowledge the support of Drs. John Crabbe and
Pamela Metten for providing the WSR and WSP mice and for assistance with
chronic alcohol exposure. This work was made possible by grants from the
Department of Veterans Affairs Merit Review program (KMW) and the
National Institute on Alcohol Abuse and Alcoholism R01 AA013194 (KMW)
and R01 AA012439 (DAF). All work was performed in facilities provided by
the Department of Veterans Affairs.
NR 85
TC 11
Z9 11
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD JAN 26
PY 2011
VL 173
BP 57
EP 75
DI 10.1016/j.neuroscience.2010.11.006
PG 19
WC Neurosciences
SC Neurosciences & Neurology
GA 710BX
UT WOS:000286487000005
PM 21081154
ER
PT J
AU Vickrey, BG
Koroshetz, WJ
AF Vickrey, Barbara G.
Koroshetz, Walter J.
TI Ensuring that the fruits of clinical trial research translate to
equitable care
SO NEUROLOGY
LA English
DT Editorial Material
C1 [Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
[Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Koroshetz, Walter J.] NINDS, Bethesda, MD 20892 USA.
RP Vickrey, BG (reprint author), Univ Calif Los Angeles, Dept Neurol, C-109 RNRC,Box 951769, Los Angeles, CA 90095 USA.
EM bvickrey@ucla.edu
NR 10
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JAN 25
PY 2011
VL 76
IS 4
BP 314
EP 315
DI 10.1212/WNL.0b013e31820c7509
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 711IA
UT WOS:000286581500006
PM 21209371
ER
PT J
AU Johansen, KL
AF Johansen, Kirsten L.
TI Choice of Dialysis Modality in the United States
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID PERITONEAL-DIALYSIS; HEMODIALYSIS; SELECTION; THERAPY
C1 [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA.
RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect 111J, 4150 Clement St, San Francisco, CA 94121 USA.
EM Kirsten.johansen@ucsf.edu
NR 17
TC 4
Z9 4
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JAN 24
PY 2011
VL 171
IS 2
BP 107
EP 109
DI 10.1001/archinternmed.2010.370
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 710OB
UT WOS:000286520000006
PM 20876395
ER
PT J
AU Bains, M
Zaegel, V
Mize-Berge, J
Heidenreich, KA
AF Bains, Mona
Zaegel, Vincent
Mize-Berge, Janna
Heidenreich, Kim A.
TI IGF-I stimulates Rab7-RILP interaction during neuronal autophagy
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Autophagy; Rab7; IGF-I; Neurons
ID LYSOSOMAL PROTEIN; RAB34 INTERACTION; PURKINJE NEURONS; CELL-DEATH;
FUSION; RILP; ACTIVATION; RECEPTOR; ACCUMULATION; MICROTUBULES
AB Restoration of autophagy represents a potential therapeutic target for neurodegenerative disorders, but factors that regulate autophagic flux are largely unknown. When deprived of trophic factors, cultured Purkinje neurons die by an autophagy associated cell death mechanism. The accumulation of autophagic vesicles and cell death of Purkinje neurons is inhibited by insulin-like growth factor, by a mechanism that enhances autophagic vesicle turnover. In this report, we identify Rab7 as an IGF-I regulated target during neuronal autophagy. Purkinje neurons transfected with EGFP-Rab7-WT and constitutively active EGFP-Rab7-Q67L contained few RFP-LC3 positive autophagosomes and little co-localization with GFP-Rab7 under control conditions. Upon induction of autophagy. RFP-LC3 positive autophagosomes increased and co-localized with GFP-Rab7. Conversely, expression of the dominant negative mutant EGFP-Rab7-T22N increased the accumulation of autophagosomes under control conditions, which accumulated even further during trophic factor withdrawal. There was no vesicular co-localization between Rab7-T22N and RFP-LC3 under control or trophic factor withdrawal conditions. During prolonged trophic factor withdrawal, a condition that leads to the accumulation of autophagic vesicles and cell death, Rab7 activity decreased significantly. IGF-I, added at the time of trophic factor withdrawal, prevented the deactivation of Rab7 and increased the interaction of Rab7 with its interacting protein (RILP), restoring autophagic flux. These results provide a novel mechanism by which IGF-I regulates autophagic flux during neuronal stress. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Bains, Mona; Zaegel, Vincent; Mize-Berge, Janna; Heidenreich, Kim A.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA.
[Heidenreich, Kim A.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Bains, M (reprint author), Univ Colorado Denver, Dept Pharmacol, MS 8303,POB 6511, Aurora, CO 80045 USA.
EM mona.bains@ucdenver.edu
FU Department of Veterans Affairs; NIH [NS045560]; NIH/NINDS
[1F32NS062534-01A1]; NIH DERC [P30-DK57516]
FX We are grateful to Dr. Bo van Deurs for the Rab7 plasmids, Dr. Aimee
Edinger for the GST-RILP plasmid and Dr. Aviva M. Tolkovsky for the
adeno-RFP-LC3. This work was supported by Department of Veterans Affairs
Merit Award, NIH grant NS045560 and NIH/NINDS grant 1F32NS062534-01A1.
Molecular Biology Core Services were supported by the NIH DERC grant
P30-DK57516.
NR 29
TC 21
Z9 22
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JAN 20
PY 2011
VL 488
IS 2
BP 112
EP 117
DI 10.1016/j.neulet.2010.09.018
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 715CQ
UT WOS:000286858400002
PM 20849920
ER
PT J
AU Yaffe, K
Weston, A
Graff-Radford, NR
Satterfield, S
Simonsick, EM
Younkin, SG
Younkin, LH
Kuller, L
Ayonayon, HN
Ding, JZ
Harris, TB
AF Yaffe, Kristine
Weston, Andrea
Graff-Radford, Neill R.
Satterfield, Suzanne
Simonsick, Eleanor M.
Younkin, Steven G.
Younkin, Linda H.
Kuller, Lewis
Ayonayon, Hilsa N.
Ding, Jingzhong
Harris, Tamara B.
TI Association of Plasma beta-Amyloid Level and Cognitive Reserve With
Subsequent Cognitive Decline
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ALZHEIMERS-DISEASE; CARDIOVASCULAR HEALTH; OLDER PERSONS; RISK;
IMPAIRMENT; DEMENTIA; PROTEIN; EDUCATION; LITERACY; MEMORY
AB Context Lower plasma beta-amyloid 42 and 42/40 levels have been associated with incident dementia, but results are conflicting and few have investigated cognitive decline among elders without dementia.
Objective To determine if plasma beta-amyloid is associated with cognitive decline and if this association is modified by measures of cognitive reserve.
Design, Setting, and Participants We studied 997 black and white community-dwelling older adults from Memphis, Tennessee, and Pittsburgh, Pennsylvania, who were enrolled in the Health ABC Study, a prospective observational study begun in 1997-1998 with 10-year follow-up in 2006-2007. Participant mean age was 74.0 (SD, 3.0) years; 55.2% (n=550) were female; and 54.0% (n=538) were black.
Main Outcome Measures Association of near-baseline plasma beta-amyloid levels (42 and 42/40 measured in 2010) and repeatedly measured Modified Mini-Mental State Examination (3MS) results.
Results Low beta-amyloid 42/40 level was associated with greater 9-year 3MS cognitive decline (lowest beta-amyloid tertile: mean change in 3MS score, -6.59 [95% confidence interval [CI], -5.21 to -7.67] points; middle tertile: -6.16 [95% CI, -4.92 to -7.32] points; and highest tertile: -3.60 [95% CI, -2.27 to -4.73] points; P<.001). Results were similar after multivariate adjustment for age, race, education, diabetes, smoking, and apolipoprotein E [APOE] e4 status and after excluding the 72 participants with incident dementia. Measures of cognitive reserve modified this association whereby among those with high reserve (at least a high school diploma, higher than sixth-grade literacy, or no APOE e4 allele), beta-amyloid 42/40 was less associated with multivariate adjusted 9-year decline. For example, among participants with less than a high school diploma, the 3MS score decline was -8.94 (95% CI, -6.94 to -10.94) for the lowest tertile compared with -4.45 (95% CI, -2.31 to -6.59) for the highest tertile, but for those with at least a high school diploma, 3MS score decline was -4.60 (95% CI, -3.07 to -6.13) for the lowest tertile and -2.88 (95% CI, -1.41 to -4.35) for the highest tertile (P=.004 for interaction). Interactions were also observed for literacy (P=.005) and for APOE e4 allele (P=.02).
Conclusion Lower plasma beta-amyloid 42/40 is associated with greater cognitive decline among elderly persons without dementia over 9 years, and this association is stronger among those with low measures of cognitive reserve. JAMA. 2011; 305(3): 261-266
C1 [Yaffe, Kristine; Weston, Andrea] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Yaffe, Kristine; Ayonayon, Hilsa N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Graff-Radford, Neill R.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Younkin, Steven G.; Younkin, Linda H.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.
[Satterfield, Suzanne] Univ Tennessee, Dept Prevent Med, Memphis, TN USA.
[Simonsick, Eleanor M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Baltimore, MD 21224 USA.
[Kuller, Lewis] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Ding, Jingzhong] Wake Forest Univ, Med Ctr, Dept Gerontol & Geriatr Med, Winston Salem, NC USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 181,4150 Clement St, San Francisco, CA 94121 USA.
EM kristine.yaffe@ucsf.edu
FU National Institute on Aging [N01-AG62101, N01-AG62103, N01-AG62106,
K24AG031155]
FX This study was funded by National Institute on Aging contracts
N01-AG62101, N01-AG62103, and N01-AG62106. This research was supported
in part by the Intramural Research Program of the National Institute on
Aging. Dr Yaffe is supported in part by National Institute on Aging
grant K24AG031155 and by an anonymous foundation.
NR 33
TC 93
Z9 96
U1 3
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JAN 19
PY 2011
VL 305
IS 3
BP 261
EP 266
DI 10.1001/jama.2010.1995
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 707YY
UT WOS:000286328700021
PM 21245181
ER
PT J
AU Wang, J
Ferruzzi, MG
Varghese, M
Qian, XJ
Cheng, A
Xie, M
Zhao, W
Ho, L
Pasinetti, GM
AF Wang, Jun
Ferruzzi, Mario G.
Varghese, Merina
Qian, Xianjuan
Cheng, Alice
Xie, Mathew
Zhao, Wei
Ho, Lap
Pasinetti, Giulio M.
TI Preclinical study of dimebon on beta-amyloid-mediated neuropathology in
Alzheimer's disease
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
ID MOUSE MODEL; TRANSGENIC MICE; PROTEIN; OLIGOMERS; COGNITION; MEMORY;
BRAIN; LATREPIRDINE; MITOCHONDRIA; INHIBITION
AB Background: Dimebon is a retired non-selective antihistamine drug currently being investigated as a therapeutic agent for the treatment of Alzheimer's disease (AD). Results from several completed clinical trials are mixed and contradictory. Proper interpretations of these clinical observations, as well as future development of dimebon in AD treatment are complicated by the lack of concrete information on the mechanisms by which dimebon might benefit AD.
Results: The present studies are designed specifically to assess whether dimebon might modulate beta-amyloid (A beta)-mediated responses which are central to the development and progression of AD dementia. We found that dimebon is bioavailable in the brains of mice following oral administration. AD mice chronically treated with dimebon exhibited a trend of improvement in spatial memory function without affecting the levels of total A beta as well as soluble oligomeric A beta in the brain. The same trend of behavior improvement is also seen in wild type animals chronically treated with dimebon.
Conclusion: Collectively, our preclinical studies using the TgCRND8 AD mouse model demonstrated that dimebon might have some beneficial effect in improving cognitive function independent of Alzheimer's disease-type A beta-related mechanisms or global energy metabolism in the brain. Observations from our study and others suggesting dimebon might improve cognition in wild type mice and rats raises the possibility that dimebon might be able to benefit cognitive function in patients with other neurodegenerative disorders, such as Huntington's disease, or in the aging population. Additional studies will be necessary to clarify the mechanisms by which dimebon might directly or indirectly benefit cognitive function.
C1 [Wang, Jun; Varghese, Merina; Qian, Xianjuan; Cheng, Alice; Xie, Mathew; Zhao, Wei; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Wang, Jun; Varghese, Merina; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Ferruzzi, Mario G.] Purdue Univ, Dept Food Sci & Foods & Nutr, W Lafayette, IN 47907 USA.
[Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
RI Zhao, Wei/B-3220-2010
FU Mount Sinai School of Medicine
FX This work was supported by discretionary funds to GMP from Mount Sinai
School of Medicine
NR 30
TC 21
Z9 21
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD JAN 19
PY 2011
VL 6
AR 7
DI 10.1186/1750-1326-6-7
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 718UD
UT WOS:000287150900001
PM 21247479
ER
PT J
AU Castillo, LS
Williams, BA
Hooper, SM
Sabatino, CP
Weithorn, LA
Sudore, RL
AF Castillo, Lesley S.
Williams, Brie A.
Hooper, Sarah M.
Sabatino, Charles P.
Weithorn, Lois A.
Sudore, Rebecca L.
TI Lost in Translation: The Unintended Consequences of Advance Directive
Law on Clinical Care
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID OF-LIFE CARE; SURROGATE DECISION-MAKING; HEALTH LITERACY; END; DEATH;
COMMUNICATION; PREFERENCES; BARRIERS; SHE
AB Background: Advance directive law may compromise the clinical effectiveness of advance directives.
Purpose: To identify unintended legal consequences of advance directive law that may prevent patients from communicating end-of-life preferences.
Data Sources: Advance directive legal statutes for all 50 U. S. states and the District of Columbia and English-language searches of LexisNexis, Westlaw, and MEDLINE from 1966 to August 2010.
Study Selection: Two independent reviewers selected 51 advance directive statutes and 20 articles. Three independent legal reviewers selected 105 legal proceedings.
Data Extraction: Two reviewers independently assessed data sources and used critical content analysis to determine legal barriers to the clinical effectiveness of advance directives. Disagreements were resolved by consensus.
Data Synthesis: Legal and content-related barriers included poor readability (that is, laws in all states were written above a 12th-grade reading level), health care agent or surrogate restrictions (for example, 40 states did not include same-sex or domestic partners as default surrogates), and execution requirements needed to make forms legally valid (for example, 35 states did not allow oral advance directives, and 48 states required witness signatures, a notary public, or both). Vulnerable populations most likely to be affected by these barriers included patients with limited literacy, limited English proficiency, or both who cannot read or execute advance directives; same-sex or domestic partners who may be without legally valid and trusted surrogates; and unbefriended, institutionalized, or homeless patients who may be without witnesses and suitable surrogates.
Limitation: Only appellate-level legal cases were available, which may have excluded relevant cases.
Conclusion: Unintended negative consequences of advance directive legal restrictions may prevent all patients, and particularly vulnerable patients, from making and communicating their end-of-life wishes and having them honored. These restrictions have rendered advance directives less clinically useful. Recommendations include improving readability, allowing oral advance directives, and eliminating witness or notary requirements.
Primary Funding Source: U.S. Department of Veterans Affairs and the Pfizer Foundation. Ann Intern Med. 2011;154:121-128.
C1 [Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
Univ Calif San Francisco, Hastings Coll Law, San Francisco, CA 94102 USA.
Amer Bar Assoc, Washington, DC 20013 USA.
RP Sudore, RL (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St,151R, San Francisco, CA 94121 USA.
EM Rebecca.Sudore@ucsf.edu
FU Veterans Affairs Career Development Award; Pfizer; University of
California, Hastings College of the Law; U.S. Department of Veterans
Affairs; Pfizer Foundation; National Institutes of Health; University of
California, San Francisco; Hartford Foundation Center of Excellence
FX Ms. Castillo and Dr. Sudore are supported by a Veterans Affairs Career
Development Award and a Pfizer Fellowship in Clear Health Communication.
Ms. Hooper is supported by the University of California, Hastings
College of the Law.r U.S. Department of Veterans Affairs and the Pfizer
Foundation.r Dr. Williams: Grants received (money to institution):
National Institutes of Health and University of California, San
Francisco, Hartford Foundation Center of Excellence; Consultancy:
Independent Medical Monitor of Michigan and Disability Legal Rights
Center of Southern California; Expert testimony: University of Denver
Student Law Office, Hunton & Williams LLP, and Holland & Knight LLP. Ms.
Hooper: Consulting fee or honorarium (money to institution): Department
of Veterans Affairs; Payment for writing or reviewing the manuscript
(money to institution): Department of Veterans Affairs. Dr. Sudore:
Grants received (money to institution): Pfizer Foundation. Disclosures
can also be viewed at www.acponline.org/authors/icmje/ConflictOf
InterestForms.do?msNum=M10-1985.
NR 64
TC 37
Z9 37
U1 3
U2 20
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JAN 18
PY 2011
VL 154
IS 2
BP 121
EP +
DI 10.7326/0003-4819-154-2-201101180-00012
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 706MW
UT WOS:000286223500007
PM 21242368
ER
PT J
AU Ueno, K
Hirata, H
Shahryari, V
Chen, Y
Zaman, MS
Singh, K
Tabatabai, ZL
Hinoda, Y
Dahiya, R
AF Ueno, K.
Hirata, H.
Shahryari, V.
Chen, Y.
Zaman, M. S.
Singh, K.
Tabatabai, Z. L.
Hinoda, Y.
Dahiya, R.
TI Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and
decreases invasion ability in human clear cell renal cell carcinoma
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE miRNA-584; motility; RCC; ROCK-1
ID RHO-ASSOCIATED-KINASE; PROTEIN-KINASE; KIDNEY CANCER; IDENTIFICATION;
PATHWAY; GENOME; GENES; PROGRESSION; MIRNA
AB BACKGROUND: The purpose of this study was to identify new tumour suppressor microRNAs (miRs) in clear cell renal cell carcinoma (ccRCC), carry out functional analysis of their suppressive role and identify their specific target genes.
METHODS: To explore suppressor miRs in RCC, miR microarray and real-time PCR were performed using HK-2 and A-498 cells. Cell viability, invasion and wound healing assays were carried out for functional analysis after miR transfection. To determine target genes of miR, we used messenger RNA (mRNA) microarray and target scan algorithms to identify target oncogenes. A 3'UTR luciferase assay was also performed. Protein expression of target genes in ccRCC tissues was confirmed by immunohistochemistry and was compared with miR-584 expression in ccRCC tissues.
RESULTS: Expression of miR-584 in RCC (A-498 and 769-P) cells was downregulated compared with HK-2 cells. Transfection of miR-584 dramatically decreased cell motility. The ROCK-1 mRNA was inhibited by miR-584 and predicted to be target gene. The miR-584 decreased 3'UTR luciferase activity of ROCK-1 and ROCK-1 protein expression. Low expression of miR-584 in ccRCC tissues was correlated with high expression of ROCK-1 protein. The knockdown of ROCK-1 by siRNA inhibited cell motility.
CONCLUSION: miR-584 is a new tumour suppressor miR in ccRCC and inhibits cell motility through downregulation of ROCK-1. British Journal of Cancer (2011) 104, 308-315. doi: 10.1038/sj.bjc.6606028 www.bjcancer.com Published online 30 November 2010 (C) 2011 Cancer Research UK
C1 [Ueno, K.; Hirata, H.; Shahryari, V.; Chen, Y.; Zaman, M. S.; Singh, K.; Dahiya, R.] Univ Calif San Francisco, Dept Urol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[Tabatabai, Z. L.] Univ Calif San Francisco, Dept Pathol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[Hinoda, Y.] Yamaguchi Univ, Dept Oncol & Lab Med, Grad Sch Med, Yamaguchi, Japan.
RP Dahiya, R (reprint author), Univ Calif San Francisco, Dept Urol, San Francisco Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
RI Chen, Yi /J-4807-2012
FU NIH [R01CA130860, R01CA138642, R01CA111470, R01CA154374, T32DK007790];
VA Research Enhancement Award Program (REAP); Merit Review grants
FX We thank Dr Roger Erickson for his support and assistance with the
preparation of the manuscript. This study was supported by Grants
R01CA130860, R01CA138642, R01CA111470, R01CA154374, T32DK007790 from the
NIH, VA Research Enhancement Award Program (REAP), and Merit Review
grants.
NR 31
TC 44
Z9 49
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD JAN 18
PY 2011
VL 104
IS 2
BP 308
EP 315
DI 10.1038/sj.bjc.6606028
PG 8
WC Oncology
SC Oncology
GA 708NZ
UT WOS:000286370900011
PM 21119662
ER
PT J
AU Desai, RV
Ahmed, MI
Mujib, M
Aban, IB
Zile, MR
Ahmed, A
AF Desai, Ravi V.
Ahmed, Mustafa I.
Mujib, Marjan
Aban, Inmaculada B.
Zile, Michael R.
Ahmed, Ali
TI Natural History of Concentric Left Ventricular Geometry in
Community-Dwelling Older Adults Without Heart Failure During Seven Years
of Follow-Up
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID NORMAL EJECTION FRACTION; CARDIOVASCULAR HEALTH; HYPERTROPHY;
PREDICTORS; MORTALITY
AB Presence of concentric left ventricular (LV) geometry has important pathophysiologic and prognostic implications. However, little is known about its natural history in older adults. Of the 5,795 community-dwelling adults >= 65 years of age in the Cardiovascular Health Study, 1,871 without baseline heart failure had data on baseline and 7-year echocardiograms. Of these 343 (18%) had baseline concentric LV geometry (concentric remodeling 83%, concentric LV hypertrophy [LVH] 17%) and are the focus of the present study. LV geometry at year 7 was categorized into 4 groups based on LVH (LV mass indexed for height >51 g/m(2.7)) and relative wall thickness (RWT): eccentric hypertrophy (RWT <= 0.42 with LVH), concentric hypertrophy (RWT >0.42 with LVH), concentric remodeling (RWT >0.42 without LVH), and normal (RWT.0.42 without LVH). At year 7, LV geometry normalized in 57%, remained unchanged in 35%, and transitioned to eccentric hypertrophy in 7% of participants. Incident eccentric hypertrophy occurred in 4% and 25% of those with baseline concentric remodeling and concentric hypertrophy, respectively, and was associated with increased LV end-diastolic volume and decreased LV ejection fraction at year 7. Previous myocardial infarction and baseline above-median LV mass (>39 g/m(2.7)) and RWT (>0.46) had significant unadjusted associations with incident eccentric LVH; however, only LV mass >39 g/m(2.7) (odds ratio.17.52, .95% confidence interval 3.91 to 78.47, p <0.001) and previous myocardial infarction (odds ratio 4.73, 95% confidence interval 1.16 to 19.32, p = 0.031) had significant independent associations. In conclusion, in community-dwelling older adults with concentric LV geometry, transition to eccentric hypertrophy was uncommon but structurally maladaptive. Published by Elsevier Inc. (Am J Cardiol 2011;107:321-324)
C1 [Desai, Ravi V.; Ahmed, Mustafa I.; Mujib, Marjan; Aban, Inmaculada B.; Ahmed, Ali] Univ Alabama, Birmingham, AL USA.
[Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Ahmed, Ali] Vet Affairs Med Ctr, Birmingham, AL USA.
RP Ahmed, A (reprint author), Univ Alabama, Birmingham, AL USA.
EM aahmed@uab.edu
RI Mujib, Marjan/J-2709-2013
OI Mujib, Marjan/0000-0002-3261-8599
FU National Heart, Lung, and Blood Institute [R01-HL085561, R01-HL097047];
Research Service of the Department of Veterans Affairs, Washington, DC
FX Dr. Ahmed is supported by the National Institutes of Health, Bethesda,
Maryland through Grants R01-HL085561 and R01-HL097047 from the National
Heart, Lung, and Blood Institute and a generous gift from Ms. Jean B.
Morris of Birmingham, Alabama. Dr. Zile is funded by the Research
Service of the Department of Veterans Affairs, Washington, DC.
NR 13
TC 12
Z9 12
U1 0
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD JAN 15
PY 2011
VL 107
IS 2
BP 321
EP 324
DI 10.1016/j.amjcard.2010.09.019
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 714EB
UT WOS:000286789200029
PM 21129719
ER
PT J
AU Mandal, CC
Ganapathy, S
Gorin, Y
Mahadev, K
Block, K
Abboud, HE
Harris, SE
Ghosh-Choudhury, G
Ghosh-Choudhury, N
AF Mandal, Chandi C.
Ganapathy, Suthakar
Gorin, Yves
Mahadev, Kalyankar
Block, Karen
Abboud, Hanna E.
Harris, Stephen E.
Ghosh-Choudhury, Goutam
Ghosh-Choudhury, Nandini
TI Reactive oxygen species derived form Nox4 mediate BMP2 gene
transcription and osteoblast differentiation
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE bone morphogenetic protein-2 (BMP-2); bone morphogenetic protein-2 gene
autoregulation; bone morphogenetic protein-2 signalling; osteoblast
differentiation; reactive oxygen species
ID BONE MORPHOGENETIC PROTEIN-2; KAPPA-B LIGAND; PHOSPHATIDYLINOSITOL
3-KINASE; SIGNAL-TRANSDUCTION; NADPH OXIDASE; NAD(P)H OXIDASE; MESANGIAL
CELLS; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; EXPRESSION
AB BMP-2 (bone morphogenetic protein-2) promotes differentiation of osteoblast precursor cells to mature osteoblasts that form healthy bone. In the present study, we demonstrate a novel mechanism of BMP-2-induced osteoblast differentiation. The antioxidant NAC (N-acetyl-L-cysteine) and the flavoprotein enzyme NAD(P)H oxidase inhibitor DPI (diphenyleneiodonium) prevented BMP-2-stimulated alkaline phosphatase expression and mineralized bone nodule formation in mouse 2T3 pre-osteoblasts. BMP-2 elicited a rapid generation of ROS (reactive oxygen species) concomitant with increased activation of NAD(P)H oxidase. NAC and DPI inhibited BMP-2-induced ROS production and NAD(P)H oxidase activity respectively. NAD(P)H oxidases display structurally similar catalytic subunits (Nox1-5) with differential expression in various cells. We demonstrate that 2T3 pre-osteoblasts predominantly express the Nox4 isotype of NAD(P)H oxidase. To extend this finding, we tested the functional effects of Nox4. Adenovirus-mediated expression of dominant-negative Nox4 inhibited BMP-2-induced alkaline phosphatase expression. BMP-2 promotes expression of BMP-2 for maintenance of the osteoblast phenotype. NAC and DPI significantly blocked BMP-2-stimulated expression of BMP2 mRNA and protein due to a decrease in BMP2 gene transcription. Dominant-negative Nox4 also mimicked this effect of NAC and DPI. Our results provide the first evidence for a new signalling pathway linking BMP-2-stimulated Nox4-derived physiological ROS to BMP-2 expression and osteoblast differentiation.
C1 [Mandal, Chandi C.; Ganapathy, Suthakar; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Gorin, Yves; Block, Karen; Abboud, Hanna E.; Ghosh-Choudhury, Goutam] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Mahadev, Kalyankar] Univ Penn, Dept Med, Inst Diabet Obes & Metab, Philadelphia, PA USA.
[Harris, Stephen E.] S Texas Vet Hlth Care Syst, VA Res, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Goutam; Ghosh-Choudhury, Nandini] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
RP Ghosh-Choudhury, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
EM choudhury@uthscsa.edu
RI Ganapathy, Suthakar/C-1266-2013
OI Ganapathy, Suthakar/0000-0003-3828-5382
FU National Institutes of Health [R01 AR52425, R01 DK50190]; VA Research
Service Merit Review; Department of Veterans Affairs; Juvenile Diabetes
Research Foundation [1-2008-185]
FX This work was supported by the National Institutes of Health [grant
number R01 AR52425]; and the VA Research Service Merit Review (to
N.G.-C.). G.G.-C. is the recipient of a Senior Research Career Scientist
Award from the Department of Veterans Affairs. G.G.-C. is supported by
the National Institutes of Health [grant number R01 DK50190]; VA
Research Service Merit Review; and the Juvenile Diabetes Research
Foundation [grant number 1-2008-185].
NR 52
TC 40
Z9 40
U1 0
U2 7
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD JAN 15
PY 2011
VL 433
BP 393
EP 402
DI 10.1042/BJ20100357
PN 2
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 757AI
UT WOS:000290055800014
PM 21029048
ER
PT J
AU Babik, JM
Cohan, D
Monto, A
Hartigan-O'Connor, DJ
McCune, JM
AF Babik, Jennifer M.
Cohan, Deborah
Monto, Alexander
Hartigan-O'Connor, Dennis J.
McCune, Joseph M.
TI The Human Fetal Immune Response to Hepatitis C Virus Exposure in Utero
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID TO-CHILD TRANSMISSION; CORD BLOOD; INTERFERON-GAMMA; LIVER-DISEASE;
INFECTION; CELLS; ACTIVATION; EXPRESSION; MOTHERS; IMMUNOGLOBULINS
AB Background. Although the rate of mother-to-child transmission of hepatitis C virus (HCV) is low, the effect of HCV exposure in utero on the fetal immune system is unknown.
Methods. Umbilical cord blood was obtained from 7 neonates born to HCV-seropositive, HCV RNA-positive women and 8 neonates born to HCV-seronegative women. Cord blood mononuclear cells were analyzed by immunophenotyping and by intracellular cytokine staining after HCV-specific and polyclonal stimulation. Plasma was analyzed for anti-HCV immunoglobulin M (IgM), cytokine/granzyme concentrations, and indoleamine 2,3-dioxygenase (IDO) activity.
Results. HCV-exposed neonates had significantly lower levels of regulatory T cells expressing HLA-DR, lower CD4(+) and CD8(+) T cell activation, and lower plasma levels of pro-inflammatory markers than did controls. However, CD4(+) and CD8(+) T cells from HCV-exposed neonates had higher IFN-gamma production in response to polyclonal stimulation than did T cells from controls. IDO activity was similar between groups. No HCV-specific T cell responses or anti-HCV IgM were detected in any neonates.
Conclusions. HCV-exposed neonates showed a relative suppression of immune activation and pro-inflammatory markers, which was counterbalanced by an increased production capacity for IFN-gamma. These results suggest that HCV encounters the fetal immune system in utero, and alters the balance between suppressive and pro-inflammatory responses.
C1 [Babik, Jennifer M.; Hartigan-O'Connor, Dennis J.; McCune, Joseph M.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
[Babik, Jennifer M.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA.
[Cohan, Deborah] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Cohan, Deborah] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Monto, Alexander] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA.
[Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA.
RP McCune, JM (reprint author), Univ Calif San Francisco, Dept Med, Div Expt Med, Box 1234, San Francisco, CA 94143 USA.
EM mike.mccune@ucsf.edu
FU Ruth L. Kirschstein National Research Service Award [T32 AI007641-06A2];
UCSF Liver Center [P30 DK026743]; NIH/NCRR [UL1 RR024131]; UCSF - GIVI
Center for AIDS Research [P30 AI0277631]; Harvey V. Berneking Living
Trust; NIH; NIH Roadmap for Medical Research [DPI 0D00329]
FX This work was supported in part by a Ruth L. Kirschstein National
Research Service Award (T32 AI007641-06A2 to J.M.B), a Pilot/Feasibility
grant from the UCSF Liver Center (P30 DK026743 to J.M.M.), NIH/NCRR UCSF
- CTSI Grant Number UL1 RR024131, a grant to the UCSF - GIVI Center for
AIDS Research (P30 AI0277631, and the Harvey V. Berneking Living Trust.
J.M.M. is a recipient of the NIH Director's Pioneer Award Program, part
of the NIH Roadmap for Medical Research, through grant DPI 0D00329.
NR 46
TC 13
Z9 14
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 15
PY 2011
VL 203
IS 2
BP 196
EP 206
DI 10.1093/infdis/jiq044
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 705XB
UT WOS:000286172900010
PM 21288819
ER
PT J
AU Catano, G
Chykarenko, ZA
Mangano, A
Anaya, JM
He, WJ
Smith, A
Bologna, R
Sen, L
Clark, RA
Lloyd, A
Shostakovich-Koretskaya, L
Ahuja, SK
AF Catano, Gabriel
Chykarenko, Zoya A.
Mangano, Andrea
Anaya, J-M
He, Weijing
Smith, Alison
Bologna, Rosa
Sen, Luisa
Clark, Robert A.
Lloyd, Andrew
Shostakovich-Koretskaya, Ludmila
Ahuja, Sunil K.
TI Concordance of CCR5 Genotypes that Influence Cell-Mediated Immunity and
HIV-1 Disease Progression Rates
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DELAYED-TYPE HYPERSENSITIVITY; ACTIVE
ANTIRETROVIRAL THERAPY; HEPATITIS-B-VIRUS; IN-VITRO; PROMOTER
POLYMORPHISM; CHEMOKINE RECEPTOR-5; CD4(+) LYMPHOCYTES;
GENETIC-VARIATION; TYPE-1 INFECTION
AB We used cutaneous delayed-type hypersensitivity responses, a powerful in vivo measure of cell-mediated immunity, to evaluate the relationships among cell-mediated immunity, AIDS, and polymorphisms in CCR5, the HIV-1 coreceptor. There was high concordance between CCR5 polymorphisms and haplotype pairs that influenced delayed-type hypersensitivity responses in healthy persons and HIV disease progression. In the cohorts examined, CCR5 genotypes containing -2459G/G (HHA/HHA, HHA/HHC, HHC/HHC) or -2459A/A (HHE/HHE) associated with salutary or detrimental delayed-type hypersensitivity and AIDS phenotypes, respectively. Accordingly, the CCR5-Delta 32 allele, when paired with non-Delta 32-bearing haplotypes that correlate with low (HHA, HHC) versus high (HHE) CCR5 transcriptional activity, associates with disease retardation or acceleration, respectively. Thus, the associations of CCR5-Delta 32 heterozygosity partly reflect the effect of the non-Delta 32 haplotype in a background of CCR5 haploinsufficiency. The correlations of increased delayed-type hypersensitivity with -2459G/G-containing CCR5 genotypes, reduced CCR5 expression, decreased viral replication, and disease retardation suggest that CCR5 may influence HIV infection and AIDS, at least in part, through effects on cell-mediated immunity.
C1 [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, VA HIV AIDS Ctr, Dept Med, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Catano, Gabriel; He, Weijing; Clark, Robert A.; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA.
[Chykarenko, Zoya A.; Shostakovich-Koretskaya, Ludmila] Dnepropetrovsk State Med Acad, Dept Gen Pediat & Pediat Infect Dis, Dnepropetrovsk, Ukraine.
[Mangano, Andrea; Bologna, Rosa; Sen, Luisa] Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, Buenos Aires, DF, Argentina.
[Mangano, Andrea; Bologna, Rosa; Sen, Luisa] Hosp Pediat JP Garrahan, Serv Infectol, Buenos Aires, DF, Argentina.
[Anaya, J-M] Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Bogota, Colombia.
[Smith, Alison] Univ Western Sydney, Sch Psychol, Penrith, NSW, Australia.
[Lloyd, Andrew] Univ New S Wales, Sch Med Sci, CIIR, Sydney, NSW, Australia.
RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, VA HIV AIDS Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM ahujas@uthscsa.edu
RI Anaya, Juan-Manuel/J-1960-2016
OI Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392
FU US Civilian Research and Development Foundation [UKB1-2931-DN-08];
Veterans Administration Center on AIDS and HIV infection of the South
Texas Veterans Health Care System; National Institutes of Health
[R37-AI046326, R01-AI043279]; VA MERIT award; Burroughs Wellcome
Clinical Scientist Award in Translational Research; Doris Duke
Distinguished Clinical Scientist Award
FX This work was supported by the US Civilian Research and Development
Foundation (UKB1-2931-DN-08 to L.S.-K.), the Veterans Administration
Center on AIDS and HIV infection of the South Texas Veterans Health Care
System, and the National Institutes of Health (R37-AI046326 and
R01-AI043279 to S.K.A.). S.K.A. is also supported by a VA MERIT award
and is a recipient of the Elizabeth Glaser Scientist Award, the
Burroughs Wellcome Clinical Scientist Award in Translational Research,
and the Doris Duke Distinguished Clinical Scientist Award.
NR 50
TC 17
Z9 17
U1 3
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 15
PY 2011
VL 203
IS 2
BP 263
EP 272
DI 10.1093/infdis/jiq023
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 705XB
UT WOS:000286172900018
PM 21288827
ER
PT J
AU Okano-Matsumoto, S
McRoberts, JA
Tache, Y
Adelson, DW
AF Okano-Matsumoto, Shiho
McRoberts, James A.
Tache, Yvette
Adelson, David W.
TI Electrophysiological evidence for distinct vagal pathways mediating
CCK-evoked motor effects in the proximal versus distal stomach
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; URETHANE-ANESTHETIZED RATS; EFFERENT FIBER
DISCHARGE; GASTRIC-ACID SECRETION; APOLIPOPROTEIN-A-IV;
GASTROINTESTINAL-TRACT; CHOLECYSTOKININ-OCTAPEPTIDE; AFFERENT RESPONSES;
ENDOGENOUS CHOLECYSTOKININ; FUNCTIONAL DYSPEPSIA
AB Non-technical summary
Gut activity is controlled by the vagus nerves. In anaesthetized rats, both sensory and motor nerve activity evoked by intravenous injection of the gut hormone cholecystokinin were recorded in separate sub-branches of the gastric vagus nerve that supply the forestomach and hindstomach, respectively. Activity in the forestomach branch has not been studied before. Motor nerve activity in response to cholecystokinin differed between the two branches, in both timing and direction. Motor output to the forestomach paralleled sensory input from the hindstomach, while motor output to the hindstomach paralleled sensory input from the intestines. The data suggest that cholecystokinin released in the intestines after a meal immediately influences churning and propulsion of food by the hindstomach, via reflexes initiated by nearby intestinal sensory nerve terminals, but may influence gastric capacity only later, once circulating levels of cholecystokinin rise to levels capable of activating sensors in the hindstomach.Intravenous cholecystokinin octapeptide (CCK-8) elicits vago-vagal reflexes that inhibit phasic gastric contractions and reduce gastric tone in urethane-anaesthetized rats. A discrete proximal subdivision of the ventral gastric vagus nerve (pVGV) innervates the proximal stomach, but the fibre populations within it have not been characterized previously. We hypothesized that i.v. CCK-8 injection would excite inhibitory efferent outflow in the pVGV, in contrast to its inhibitory effect on excitatory efferent outflow in the distal subdivision (dVGV), which supplies the distal stomach. In each VGV subdivision, a dual-recording technique was used to record afferent and efferent activity simultaneously, while also monitoring intragastric pressure (IGP). CCK-8 dose dependently (100-1000 pmol kg-1, i.v.) reduced gastric tone, gastric contractile activity and multi-unit dVGV efferent discharge, but increased pVGV efferent firing. Single-unit analysis revealed a minority of efferent fibres in each branch whose response differed in direction from the bulk response. Unexpectedly, efferent excitation in the pVGV was significantly shorter lived and had a significantly shorter decay half-time than did efferent inhibition in the dVGV, indicating that distinct pathways drive CCK-evoked outflow to the proximal vs. the distal stomach. Efferent inhibition in the dVGV began several seconds before, and persisted significantly longer than, simultaneously recorded dVGV afferent excitation. Thus, dVGV afferent excitation could not account for the pattern of dVGV efferent inhibition. However, the time course of dVGV afferent excitation paralleled that of pVGV efferent excitation. Similarly, the duration of CCK-8-evoked afferent responses recorded in the accessory celiac branch of the vagus (ACV) matched the duration of dVGV efferent responses. The observed temporal relationships suggest that postprandial effects on gastric complicance of CCK released from intestinal endocrine cells may require circulating concentrations to rise to levels capable of exciting distal gastric afferent fibres, in contrast to more immediate effects on distal gastric contractile activity mediated via vago-vagal reflexes initiated by paracrine excitation of intestinal afferents.
C1 [McRoberts, James A.; Tache, Yvette; Adelson, David W.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[McRoberts, James A.; Tache, Yvette; Adelson, David W.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Div Digest Dis, Los Angeles, CA 90095 USA.
[McRoberts, James A.; Tache, Yvette; Adelson, David W.] W Los Angeles Vet Affairs Med Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Okano-Matsumoto, Shiho] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Pharmaceut Res Labs, Osaka, Japan.
RP Adelson, DW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
EM dadelson@ucla.edu
OI Adelson, David/0000-0002-4623-6030
FU NIH [R21 DK074736-01, DK 41301]; VA Research Career Scientist Award;
Takeda Pharmaceutical Co., Ltd, Pharmaceutical Research Division
FX The authors wish to thank Dr Jen Yu Wei, whose innovative work formed
the foundation for the approaches used here. The work was supported by
NIH R21 DK074736-01 (D.W.A.), DK 41301 (Animal Core, Y.T., D.W.A.), a VA
Research Career Scientist Award (Y.T.) and by Takeda Pharmaceutical Co.,
Ltd, Pharmaceutical Research Division.
NR 100
TC 12
Z9 12
U1 0
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3751
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD JAN 15
PY 2011
VL 589
IS 2
BP 371
EP 393
DI 10.1113/jphysiol.2010.196832
PG 23
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 706JG
UT WOS:000286213900008
PM 21078593
ER
PT J
AU Ulldemolins, M
Restrepo, MI
Rello, J
AF Ulldemolins, Marta
Restrepo, Marcos I.
Rello, Jordi
TI Pharmacologic measures for the prevention of mechanical
ventilation-associated pneumonia
SO MEDICINA CLINICA
LA Spanish
DT Review
DE Nosocomial infection; Intensive care unit; Infection prevention;
Antibiotics; Mechanical ventilation
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; SELECTIVE DIGESTIVE
DECONTAMINATION; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL;
NOSOCOMIAL PNEUMONIA; DOUBLE-BLIND; RISK-FACTORS; ORAL DECONTAMINATION;
RESISTANT-BACTERIA
AB Ventilator associated pneumonia is the principal infectious complication in the Intensive Care Unit (ICU), and represents the main infectious cause of morbidity and mortality. Its diagnosis and management is complex. Consequently, its prevention becomes a cornerstone in daily clinical practice. Daily interruption of sedation, oral and digestive decontamination, prophylactic administration of systemic and/or inhaled antibiotics, glycemic control, stress ulcer prophylaxis, transfusion policy and timing and adequacy of antibiotic treatment are the main suggested pharmacologic interventions.
The aim of this review is to critically describe the principal pharmacologic interventions for the prevention of ventilator associated pneumonia, focusing on the degree of the evidence and the appropriateness for daily clinical practice. (C) 2009 Elsevier Espana, S.L. All rights reserved.
C1 [Restrepo, Marcos I.] VERDICT, S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
[Ulldemolins, Marta; Rello, Jordi] Hosp Univ Tarragona Joan XXIII, IISPV, Serv Med Intens, Tarragona, Spain.
[Ulldemolins, Marta] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld 4072, Australia.
[Ulldemolins, Marta; Rello, Jordi] Univ Rovira & Virgili, Tarragona, Spain.
RP Restrepo, MI (reprint author), VERDICT, S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
RI Lee, H/E-7918-2010; Restrepo, Marcos/H-4442-2014
OI Rello, Jordi/0000-0003-0676-6210
FU NCATS NIH HHS [UL1 TR000149, KL2 TR000118]; NCRR NIH HHS [UL1 RR025767,
KL2 RR025766]
NR 60
TC 1
Z9 2
U1 0
U2 3
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0025-7753
EI 1578-8989
J9 MED CLIN-BARCELONA
JI Med. Clin.
PD JAN 15
PY 2011
VL 136
IS 1
BP 21
EP 25
DI 10.1016/j.medcli.2009.10.012
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 714HM
UT WOS:000286798500006
PM 20022067
ER
PT J
AU Nair, G
Tanaka, Y
Moon, K
Olson, DE
Thule, PM
Pardue, MT
Duong, TQ
AF Nair, Govind
Tanaka, Yoji
Kim, Moon
Olson, Darin E.
Thule, Peter M.
Pardue, Machelle T.
Duong, Timothy Q.
TI MRI reveals differential regulation of retinal and choroidal blood
volumes in rat retina
SO NEUROIMAGE
LA English
DT Article
ID CARBON-DIOXIDE; FOVEAL REGION; OCULAR FUNDUS; RCS RAT; FLOW;
HEMODYNAMICS; STIMULATION; INNERVATION; FLUORESCEIN; DYSTROPHY
AB The retina is nourished by two unique (retinal and choroidal) circulations. The lack of depth-resolved blood volume (BV) imaging techniques hampers investigation of vascular-specific regulation of the retina in vivo. This study presents a high-resolution, laminar-specific magnetic resonance imaging (MRI) study to image retinal and choroidal BVs, their responses to physiologic challenges in normal and Royal-College-of-Surgeons (RCS) rats (a model of retinal degeneration). Retinal and choroidal BVs were imaged by MRI (30 x 30 x 800 pm) with intravascular administration of monocrystalline iron oxide nanocolloid (MION) contrast agent. Relative baseline BV and BV changes due to physiologic challenges were calculated in normal and RCS rat retinas. BV-MRI revealed two well-resolved retinal and choroidal vascular layers located on either side of the retina and an intervening avascular layer. The ratio of choroidal:retinal BV in normal rats at baseline was 9.8 +/- 3.2 in control rat retinas (N = 7). Hyperoxia decreased retinal BV ( 51 +/- 17%. p<0.05) more than choroidal BV (-28 +/- 14%), and hypercapnia increased retinal BV (52 +/- 11%, p<0.01) more than choroidal BV (12 +/- 11%). BV-MRI in degenerated retinas of RCS rats (N = 7) revealed thinning of the avascular layer and an increase in relative baseline retinal and choroidal BVs. Only hypercapnia-induced BV changes in the retinal vasculature of RCS rats were significantly different (smaller) from controls (p<0.05).
These findings suggest that BV in both retinal vasculatures is regulated. The relative baseline BV in both vasculatures increased in retinal degeneration. BV-MRI provides clinically relevant data that may prove useful for early detection and longitudinal probing of retinal diseases, and could complement optical imaging techniques. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Duong, Timothy Q.] Univ Texas Hlth Sci, Dept Ophthalmol, Res Imaging Inst, MRI Div, San Antonio, TX 78229 USA.
[Nair, Govind] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA USA.
[Nair, Govind; Tanaka, Yoji] Emory Univ, Yerkes Imaging Ctr, Atlanta, GA 30322 USA.
[Olson, Darin E.; Thule, Peter M.] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
[Pardue, Machelle T.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
[Kim, Moon; Olson, Darin E.; Thule, Peter M.; Pardue, Machelle T.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci, Dept Radiol, Res Imaging Inst, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci, Dept Physiol, Res Imaging Inst, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci, Dept Ophthalmol, Res Imaging Inst, MRI Div, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU NIH/NEI [R01EY014211, R01EY018855]; VA; Research to Prevent Blindness
FX The following funding sources are acknowledged: NIH/NEI (R01EY014211,
R01EY018855) to TQD, VA Career Development (TQD and DEO), VA MERIT (TQD,
PMT and MTP), Research to Prevent Blindness (MTP).
NR 35
TC 15
Z9 15
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JAN 15
PY 2011
VL 54
IS 2
BP 1063
EP 1069
DI 10.1016/j.neuroimage.2010.09.020
PG 7
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 697AW
UT WOS:000285486000031
PM 20850550
ER
PT J
AU Ryan, L
Walther, K
Bendlin, BB
Lue, LF
Walker, DG
Glisky, EL
AF Ryan, Lee
Walther, Katrin
Bendlin, Barbara B.
Lue, Lih-Fen
Walker, Douglas G.
Glisky, Elizabeth L.
TI Age-related differences in white matter integrity and cognitive function
are related to APOE status
SO NEUROIMAGE
LA English
DT Article
DE Diffusion tensor imaging; Aging; Cognition; APOE
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; EARLY
ALZHEIMERS-DISEASE; E E4 CARRIERS; APOLIPOPROTEIN-E; OLDER-ADULTS;
FRACTIONAL ANISOTROPY; EPSILON-4 ALLELE; EXECUTIVE FUNCTION; BRAIN
ATROPHY
AB While an extensive literature is now available on age-related differences in white matter integrity measured by diffusion MRI, relatively little is known about the relationships between diffusion and cognitive functions in older adults. Even less is known about whether these relationships are influenced by the apolipoprotein (APOE) epsilon 4 allele, despite growing evidence that epsilon 4 increases cognitive impairment in older adults. The purpose of the present study was to examine these relationships in a group of community-dwelling cognitively normal older adults. Data were obtained from a sample of 126 individuals (ages 52-92) that included 32 epsilon 4 heterozygotes, 6 epsilon 4 homozygotes, and 88 noncarriers. Two measures of diffusion, the apparent diffusion coefficient (ADC) and fractional anisotropy (FA), were obtained from six brain regions frontal white matter, lateral parietal white matter, the centrum semiovale, the genu and splenium of the corpus callosum, and the temporal stem white matter-and were used to predict composite scores of cognitive function in two domains, executive function and memory function. Results indicated that ADC and FA differed with increasing age in all six brain regions, and these differences were significantly greater for epsilon 4 carriers compared to noncarriers. Importantly, after controlling for age, diffusion measures predicted cognitive function in a region-specific way that was also influenced by epsilon 4 status. Regardless of APOE status, frontal ADC and FA independently predicted executive function scores for all participants, while temporal lobe ADC additionally predicted executive function for 4 carriers but not noncarriers. Memory scores were predicted by temporal lobe ADC but not frontal diffusion for all participants, and this relationship was significantly stronger in epsilon 4 carriers compared to noncarriers. Taken together, age and temporal lobe ADC accounted for a striking 53% of the variance in memory scores within the epsilon 4 carrier group.
The results provide further evidence that APOE epsilon 4 has a significant impact on the trajectory of age-related cognitive functioning in older adults. Possible mechanisms are discussed that could account for the associations between epsilon 4, diffusion, and cognitive function, including the influence of 4 on neural repair, oxidative stress, and the health of myelin-producing oligodendroglia. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Ryan, Lee] Univ Arizona, Dept Psychol, Cognit & Neuroimaging Labs, Evelyn F McKnight Brain Inst, Tucson, AZ 85721 USA.
[Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Lue, Lih-Fen; Walker, Douglas G.] Banner Sun Hlth Res Inst, Sun City, AZ USA.
RP Ryan, L (reprint author), Univ Arizona, Dept Psychol, Cognit & Neuroimaging Labs, Evelyn F McKnight Brain Inst, POB 210068, Tucson, AZ 85721 USA.
EM ryant@email.arizona.edu
RI Yue, Chunlin/B-3554-2014
OI Yue, Chunlin/0000-0002-2261-6725; Bendlin, Barbara/0000-0002-0580-9875;
Kennedy, Kristen/0000-0001-5373-9026
FU Arizona Biomedical Research Commission; Arizona Alzheimer's Research
Consortium (Dept. of Health Services, Arizona) [HB 2354]; Evelyn F.
McKnight Brain Institute; National Institute on Aging (Arizona
Alzheimer's Disease Core Center) [P30 AG19610]; National Institute on
Neurologic Disorder and Stroke [RO1 NSO44107]
FX The project was supported by the Arizona Biomedical Research Commission,
the Arizona Alzheimer's Research Consortium (HB 2354, Dept. of Health
Services, Arizona), the Evelyn F. McKnight Brain Institute, the National
Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core
Center), and the National Institute on Neurologic Disorder and Stroke
(RO1 NSO44107). We thank Ms. Kristina Irwin for coordinating and
administering neuropsychological testing, and Dr. Thomas Beach at Banner
Sun Health Research Institute for his generous support.
NR 110
TC 36
Z9 36
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JAN 15
PY 2011
VL 54
IS 2
BP 1565
EP 1577
DI 10.1016/j.neuroimage.2010.08.052
PG 13
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 697AW
UT WOS:000285486000080
PM 20804847
ER
PT J
AU DaSilva, JK
Lei, YL
Madan, V
Mann, GL
Ross, RJ
Tejani-Butt, S
Morrison, AR
AF DaSilva, Jamie K.
Lei, Yanlin
Madan, Vibha
Mann, Graziella L.
Ross, Richard J.
Tejani-Butt, Shanaz
Morrison, Adrian R.
TI Fear conditioning fragments REM sleep in stress-sensitive Wistar-Kyoto,
but not Wistar, rats
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Review
DE Fear conditioning; Posttraumatic stress disorder; REMS
microarchitecture; Sleep; Wistar-Kyoto rat
ID WKY RATS; DEPRESSIVE BEHAVIOR; ANIMAL-MODELS; BRAIN NOREPINEPHRINE;
DEPENDENT PLASTICITY; AMBIENT-TEMPERATURE; AVOIDANCE BEHAVIOR; STRAIN
DIFFERENCES; LOCUS-COERULEUS; COMBAT VETERANS
AB Pavlovian conditioning is commonly used to investigate the mechanisms of fear learning. Because the Wistar-Kyoto (WKY) rat strain is particularly stress-sensitive, we investigated the effects of a psychological stressor on sleep in WKY compared to Wistar (WIS) rats. Male WKY and WIS rats were either fear-conditioned to tone cues or received electric foot shocks alone. In the fear-conditioning procedure, animals were exposed to 10 tones (800 Hz, 90 dB, 5 s), each co-terminating with a foot shock (1.0 mA, 0.5 s), at 30-s intervals. In the shock stress procedure, animals received 10 foot shocks at 30-s intervals, without tones. All subjects underwent a tone-only test both 24h (Day 1) and again two weeks (Day 14) later. Rapid eye movement sleep (REMS) continuity was investigated by partitioning REMS episodes into single (inter-REMS episode interval >3 min) and sequential (interval min) episodes. In the fear-conditioned group, freezing increased from baseline in both strains, but the increase was maintained on Day 14 in WKY rats only. In fear-conditioned WIN rats, total REMS amount increased on Day 1, sequential REMS amount increased on Day 1 and Day 14, and single REMS amount decreased on Day 14. Alterations were due to changes in the number of sequential and single REMS episodes. Shock stress had no significant effect on REMS microarchitecture in either strain. The shift toward sequential REMS in fear-conditioned WKY rats may represent REMS fragmentation, and may provide a model for investigating the neurobiological mechanisms of sleep disturbances reported in posttraumatic stress disorder. (C) 2010 Elsevier Inc. All rights reserved.
C1 [DaSilva, Jamie K.; Lei, Yanlin; Tejani-Butt, Shanaz] Univ Sci Philadelphia, Dept Pharmaceut Sci, Philadelphia, PA 19104 USA.
[Madan, Vibha; Mann, Graziella L.; Ross, Richard J.; Morrison, Adrian R.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.
[Ross, Richard J.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Ross, Richard J.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
RP DaSilva, JK (reprint author), Univ Sci Philadelphia, Dept Pharmaceut Sci, Box 80,600 S 43rd St, Philadelphia, PA 19104 USA.
EM jdasilva@mail.usp.edu
FU USPHS [MH072897, AA015921]
FX These studies were supported by USPHS grants MH072897 to Adrian R.
Morrison and AA015921 to Shanaz Tejani-Butt. The content of this article
does not reflect the views of the Department of Veterans Affairs or of
the U.S. Government. We also gratefully acknowledge the contributions of
Benjamin M. Laitman.
NR 65
TC 19
Z9 20
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD JAN 15
PY 2011
VL 35
IS 1
BP 67
EP 73
DI 10.1016/j.pnpbp.2010.08.023
PG 7
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 720HL
UT WOS:000287271400009
PM 20832443
ER
PT J
AU Campbell, EC
DeJesus, M
Herman, BK
Cuffel, BJ
Sanders, KN
Dodge, W
Dhopesh, V
Caroff, SN
AF Campbell, E. Cabrina
DeJesus, Melissa
Herman, Barry K.
Cuffel, Brian J.
Sanders, Kafi N.
Dodge, William
Dhopesh, Vasant
Caroff, Stanley N.
TI A pilot study of antipsychotic prescribing decisions for acutely-Ill
hospitalized patients
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Review
DE Antipsychotic drugs; Metabolic syndrome; Prescribing decisions;
Schizophrenia; Schizoaffective disorder; Bipolar disorder
ID CORONARY-HEART-DISEASE; ATYPICAL ANTIPSYCHOTICS; CHRONIC-SCHIZOPHRENIA;
METABOLIC SYNDROME; CLINICAL JUDGMENT; PHYSICIANS; DRUGS; RISK;
OLANZAPINE; WEIGHT
AB Background: Evidence on antipsychotic prescribing decisions is limited. This pilot study quantified factors considered in choosing an antipsychotic and evaluated the influence of metabolic status on treatment decisions.
Methods: Prescribing decisions by 4 psychiatrists were examined based on 80 adult patients initiated on antipsychotic medication diagnosed with schizophrenia, schizoaffective disorder or bipolar disorder by DSM-IV criteria, who were admitted to an acute inpatient psychiatric program of an urban Veterans Affairs Medical Center. The primary analysis examined the association between antipsychotic treatment choice and predictions of symptom control and metabolic risk. Secondary analyses included comparison of the chosen and next best treatments in predicted symptom control and metabolic risk, the frequency of reasons cited for drug choice, and the association between treatment choice and patients' baseline metabolic parameters. Mean differences and odds-ratios (OR) with 95% confidence intervals were used to compare relationships between treatment choice, ratings of risk and metabolic data.
Results: Antipsychotic choice correlated significantly with ratings of predicted symptom control (OR = .92, p = 0.02) and metabolic risk (OR = .88, p = 0.01). Mean differences between the chosen and next best drugs were significant but small in predicted symptom control (F = 2.81, df = 3, 76; p<0.05) compared with larger differences in anticipated metabolic risk (F = 14.80, df = 3, 76; p = 0.0001). Nevertheless, among 24 identified reasons influencing drug selection, anticipated metabolic risk of chosen antipsychotics was cited less often than efficacy measures. In contrast to psychiatrists' expectations of metabolic risk with selected treatments, we found that patients' actual baseline BMI, fasting glucose, blood pressure, and Framingham risk levels did not necessarily predict antipsychotic treatment choice independent of other factors.
Conclusion: In the context of an acute psychiatric hospitalization, pilot data suggest that predictions of symptom control and metabolic risk correlated significantly with antipsychotic choice, but study psychiatrists were willing to assume relative degrees of metabolic risk in favor of effective symptom control. However, prescribing decisions were influenced by numerous patient and treatment factors. These findings support the potential utility of the ATCQ questionnaire in quantifying antipsychotic prescribing decisions. Further validation studies of the ATCQ questionnaire could enhance translation of research findings and application of treatment guidelines. Published by Elsevier Inc.
C1 [Campbell, E. Cabrina; DeJesus, Melissa; Dhopesh, Vasant; Caroff, Stanley N.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Campbell, E. Cabrina; DeJesus, Melissa; Dhopesh, Vasant; Caroff, Stanley N.] Univ Penn, Sch Med, VA Med Ctr 116A, Philadelphia, PA 19104 USA.
[Herman, Barry K.] Sunov Pharmaceut Inc, Clin Res & Med Affairs, Marlborough, MA 01752 USA.
[Cuffel, Brian J.; Sanders, Kafi N.; Dodge, William] Pfizer Inc, New York, NY 10017 USA.
RP Campbell, EC (reprint author), Philadelphia Vet Affairs Med Ctr, Univ & Woodland Aves, Philadelphia, PA 19104 USA.
EM Cabrina.campbell@va.gov
FU Pfizer Inc.; Department of Veterans Affairs, Veterans Health
Administration, Office of Research Development
FX This study was sponsored by Pfizer Inc. This material is based upon work
also supported in part by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research Development, with resources
and the use of facilities at the Philadelphia Veterans Affairs Medical
Center. The content of this work does not represent the views of the
Department of Veterans Affairs or the United States Government.
NR 29
TC 2
Z9 2
U1 3
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD JAN 15
PY 2011
VL 35
IS 1
BP 246
EP 251
DI 10.1016/j.pnpbp.2010.11.018
PG 6
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 720HL
UT WOS:000287271400036
PM 21108980
ER
PT J
AU Shlipak, MG
Li, YM
Fox, C
Coresh, J
Grunfeld, C
Whooley, M
AF Shlipak, Michael G.
Li, Yongmei
Fox, Caroline
Coresh, Josef
Grunfeld, Carl
Whooley, Mary
TI Uromodulin concentrations are not associated with incident CKD among
persons with coronary artery disease
SO BMC NEPHROLOGY
LA English
DT Article
ID TAMM-HORSFALL PROTEIN; SERUM CREATININE; CYSTATIN-C; RISK
AB Background: A common variant of the UMOD gene was linked with prevalent chronic kidney disease (CKD) in large, genomics consortia. One community-based study found that urine concentrations of the uromodulin protein forecast risk of incident CKD. This study within persons with known coronary artery disease (CAD) evaluated whether uromodulin concentrations could distinguish CKD risk.
Methods: In the Heart and Soul Study, the UMOD snp (12917707) was genotyped in 879 individuals with baseline creatinine clearance (CrCl) measured from a 24-hour urine collection. Uromodulin protein was measured from stored urine specimens among a subset of 120 participants, balanced by genotype. Incident CKD cases (N = 102) were defined by an initial CrCl > 70 ml/min and a 5-year follow-up CrCl < 60 ml/min; controls (N = 94) were matched on age, sex, and race.
Results: Among 527 self-described White participants with DNA, 373 (71%) were homozygous for the dominant allele (G/G), 133 (25%) were heterozygous (G/T) and only 21 (4%) were homozygous for the minor allele (T/T). The T/T genotype had an approximately 11 ml/min higher CrCl than the other 2 groups, but this difference did not reach statistical significance (p = 0.20). The T/T genotype had significantly lower uromodulin levels than the common G/G genotype, and the G/T genotype had intermediate levels. However, uromodulin concentrations were similar between cases and controls (44 vs. 48 mg/dL, p = 0.88).
Conclusions: This study among a cohort of persons with established CAD found no association between urine uromodulin and incident CKD, although UMOD genotype was associated with urine uromodulin concentrations.
C1 [Shlipak, Michael G.; Li, Yongmei; Whooley, Mary] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
[Shlipak, Michael G.; Grunfeld, Carl; Whooley, Mary] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Fox, Caroline] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Fox, Caroline] Brigham & Womens Hosp, Div Endocrinol Metab & Diabet, Dept Med, Boston, MA 02115 USA.
[Fox, Caroline] Harvard Univ, Sch Med, Boston, MA USA.
[Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Grunfeld, Carl] San Francisco VA Med Ctr, Div Metab & Endocrine Sect, San Francisco, CA USA.
RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
EM michael.shlipak@ucsf.edu
FU [R01 HL079235]; [R01 DK066488]
FX This work was supported by R01 HL079235 (PI: M.W) and R01 DK066488 (PI:
M.S.).
NR 14
TC 9
Z9 9
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD JAN 14
PY 2011
VL 12
AR 2
DI 10.1186/1471-2369-12-2
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 946MF
UT WOS:000304355100002
PM 21235779
ER
PT J
AU McRoberts, JA
Ennes, HS
Marvizon, JCG
Fanselow, MS
Mayer, EA
Vissel, B
AF McRoberts, J. A.
Ennes, H. S.
Marvizon, J. C. G.
Fanselow, M. S.
Mayer, E. A.
Vissel, B.
TI SELECTIVE KNOCKDOWN OF NMDA RECEPTORS IN PRIMARY AFFERENT NEURONS
DECREASES PAIN DURING PHASE 2 OF THE FORMALIN TEST
SO NEUROSCIENCE
LA English
DT Article
DE NMDA receptor; dorsal root ganglia; hyperalgesia; nociception;
presynaptic
ID D-ASPARTATE RECEPTORS; DORSAL-ROOT GANGLIA; RAT SPINAL-CORD; PRIMARY
SENSORY NEURONS; SUBSTANCE-P RELEASE; GLUTAMATE RECEPTORS; INDUCED
BEHAVIORS; MASSETER MUSCLE; PERIPHERAL NMDA; EVOKED RELEASE
AB The role of NMDA receptors (NMDARs) expressed by primary afferent neurons in nociception remains controversial. The aim of this study was to develop mice with a tissue selective knockdown of NMDARs in these neurons and to evaluate their behavioral responses to different types of painful stimuli. Mice with floxed NMDAR NR1 subunit gene (fNR1) were crossed with mice expressing Cre recombinase under the control of the peripherin promotor (Prph-Cre). Male Prph-Cre+ floxed NR1 mice were compared to Cre- littermates. Both quantitative RT/PCR and Western blotting indicated a similar to 75% reduction in NR1 expression in dorsal root ganglia (DRG) extracts with no effect on NR1 expression in spinal cord, brain or the enteric nervous system. Immunocytochemistry with antibodies to NR1 revealed decreased staining in all size classes of DRG neurons. NMDA produced a detectable increase in [Ca(2+)](i) in 60% of DRG neurons cultured from Cre mice, but only 15% of those from Cre+ mice. Furthermore, the peak [Ca2+](i) responses were 64% lower in neurons from Cre+ mice. There was no significant difference between Cre+ and Cre- mice in response latencies to the hotplate or tail withdrawal tests of thermal nociception, nor was there a difference in withdrawal thresholds to mechanical stimuli of the tail or paw. However, compared to Cre- littermates, Cre+ knockdown mice had a 50% decrease in the phase 2 response to formalin injection (P<0.001). There was no effect on phase 1 responses. These results suggest that NMDA receptors expressed by primary afferent nerves play an important role in the development of sensitized pain states. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [McRoberts, J. A.; Ennes, H. S.; Marvizon, J. C. G.; Fanselow, M. S.; Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[McRoberts, J. A.; Ennes, H. S.; Marvizon, J. C. G.; Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Marvizon, J. C. G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Fanselow, M. S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychol, Los Angeles, CA 90095 USA.
[Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
[Vissel, B.] St Vincents Hosp, Garvan Inst Med Res, Neurobiol Res Program, Darlinghurst, NSW 2010, Australia.
RP McRoberts, JA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Warren Hall,Room 14-103,900 Vet Ave, Los Angeles, CA 90095 USA.
EM mcrobert@ucla.edu
RI Messier, Claude/A-2322-2008
OI Messier, Claude/0000-0002-4791-1763
FU NIH [DK 58173, 1 P50 DK64539]; VA Rehabilitation Research & Development
Service [847661]; NHMRC Australia [188819]; NSW State Government; NSW
Spinal Cord Injury and Related Neurological Conditions Research; Amadeus
Energy Ltd. Western Australia; Bill and Laura Gruy
FX The authors wish to thank Yash Mittal, Brian Nguyen, Nan Yi Zhang,
Murphy Bergstrom, and Samantha Jagannathan for their assistance in the
behavioral testing, Mareike Kuypers, T. Cheung, S. Stayte, S. Wu, C.
Leong, and Ed Cairns for help with breeding and genotyping, and Dr. E.
Matthew Hoffman for help with the image analysis. This work was
supported by NIH grants DK 58173 (JM) and 1 P50 DK64539 (EM), VA
Rehabilitation Research & Development Service 847661 (JCM), NHMRC
Australia Grant 188819 (BV), NSW State Government's BioFirst Award and a
NSW Spinal Cord Injury and Related Neurological Conditions Research
Grant (BV), Amadeus Energy Ltd. Western Australia (BV), Bill and Laura
Gruy (BV).
NR 46
TC 19
Z9 19
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD JAN 13
PY 2011
VL 172
BP 474
EP 482
DI 10.1016/j.neuroscience.2010.10.045
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 705RC
UT WOS:000286154600045
PM 20974228
ER
PT J
AU Xu, X
Jackson, PL
Tanner, S
Hardison, MT
Roda, MA
Blalock, JE
Gaggar, A
AF Xu, Xin
Jackson, Patricia L.
Tanner, Scott
Hardison, Matthew T.
Roda, Mojtaba Abdul
Blalock, James Edwin
Gaggar, Amit
TI A Self-Propagating Matrix Metalloprotease-9 (MMP-9) Dependent Cycle of
Chronic Neutrophilic Inflammation
SO PLOS ONE
LA English
DT Article
ID SMOOTH-MUSCLE-CELLS; CYSTIC-FIBROSIS; GELATINASE-B; SIGNALING PATHWAYS;
PROTEIN-KINASES; TNF-ALPHA; P38 MAPK; KAPPA-B;
MATRIX-METALLOPROTEINASE-9; CHEMOATTRACTANT
AB Background: Chronic neutrophilic inflammation is a poorly understood feature in a variety of diseases with notable worldwide morbidity and mortality. We have recently characterized N-acetyl Pro-Gly-Pro (Ac-PGP) as an important neutrophil (PMN) chemoattractant in chronic inflammation generated from the breakdown of collagen by the actions of MMP-9. MMP-9 is present in the granules of PMNs and is differentially released during inflammation but whether Ac-PGP contributes to this ongoing proteolytic activity in chronic neutrophilic inflammation is currently unknown.
Methodology/Principal Findings: Utilizing isolated primary blood PMNs from human donors, we found that Ac-PGP induces significant release of MMP-9 and concurrently activates the ERK1/2 MAPK pathway. This MMP-9 release is attenuated by an inhibitor of ERK1/2 MAPK and upstream blockade of CXCR1 and CXCR2 receptors with repertaxin leads to decreased MMP-9 release and ERK 1/2 MAPK activation. Supernatants obtained from PMNs stimulated by Ac-PGP generate more Ac-PGP when incubated with intact collagen ex vivo; this effect is inhibited by an ERK1/2 pathway inhibitor. Finally, clinical samples from individuals with CF demonstrate a notable correlation between Ac-PGP (as measured by liquid chromatography-tandem mass spectrometry) and MMP-9 levels even when accounting for total PMN burden.
Conclusions/Significance: These data indicate that ECM-derived Ac-PGP could result in a feed-forward cycle by releasing MMP-9 from activated PMNs through the ligation of CXCR1 and CXCR2 and subsequent activation of the ERK1/2 MAPK, highlighting for the first time a matrix-derived chemokine (matrikine) augmenting its generation through a discrete receptor/intracellular signaling pathway. These findings have notable implications to the development unrelenting chronic PMN inflammation in human disease.
C1 [Xu, Xin; Jackson, Patricia L.; Hardison, Matthew T.; Blalock, James Edwin; Gaggar, Amit] Univ Alabama, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
[Xu, Xin; Jackson, Patricia L.; Blalock, James Edwin; Gaggar, Amit] Univ Alabama, Gregory Fleming James CF Ctr, Birmingham, AL 35294 USA.
[Tanner, Scott] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
[Roda, Mojtaba Abdul] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol & Pathophysiol, Utrecht, Netherlands.
[Gaggar, Amit] Birmingham VA Med Ctr, Pulm Serv, Birmingham, AL USA.
RP Xu, X (reprint author), Univ Alabama, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
EM agaggar@uab.edu
OI Tanner, Scott/0000-0002-7717-5293; Blalock, J. Edwin/0000-0001-5303-8123
FU University of Alabama; Cystic Fibrosis Foundation [GAGGAR07A0];
NIH/NHLBI [HL07783, HL090999, HL087824, HL102371-01A1]
FX This work was supported by the University of Alabama Clinical
Investigator Fellowship Award, the Cystic Fibrosis Foundation (Grant
GAGGAR07A0 to AG) and NIH/NHLBI (HL07783, HL090999, and HL087824 (to
JEB) and HL102371-01A1 (to AG). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 46
TC 58
Z9 62
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 13
PY 2011
VL 6
IS 1
AR e15781
DI 10.1371/journal.pone.0015781
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 710ME
UT WOS:000286515000008
PM 21249198
ER
PT J
AU Ringman, JM
Gylys, KH
Medina, LD
Fox, M
Kepe, V
Flores, DL
Apostolova, LG
Barrio, JR
Small, G
Silverman, DH
Siu, E
Cederbaum, S
Hecimovic, S
Malnar, M
Chakraverty, S
Goate, AM
Bird, TD
Leverenz, JB
AF Ringman, John M.
Gylys, Karen H.
Medina, Luis D.
Fox, Michelle
Kepe, Vladimir
Flores, Deborah L.
Apostolova, Liana G.
Barrio, Jorge R.
Small, Gary
Silverman, Daniel H.
Siu, Erin
Cederbaum, Stephen
Hecimovic, Silva
Malnar, Martina
Chakraverty, Suma
Goate, Alison M.
Bird, Thomas D.
Leverenz, James B.
TI Biochemical, neuropathological, and neuroimaging characteristics of
early-onset Alzheimer's disease due to a novel PSEN1 mutation
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Alzheimer's disease; PSEN1; S212Y; Amyloid imaging; FDDNP; Cerebrospinal
fluid; FDG; Positron emission tomography; Tau; Beta-amyloid; Striatum
ID PRESENILIN-1 MUTATION; FAMILIES; BETA
AB Familial Alzheimer's disease (AD) due to PSEN1 mutations provides an opportunity to examine AD biomarkers in persons in whom the diagnosis is certain. We describe a 55 year-old woman with clinically probable AD and a novel PSEN1 mutation who underwent genetic, clinical, biochemical and magnetic resonance and nuclear imaging assessments. We also describe neuropathological findings in her similarly affected brother. Neuropsychological testing confirmed deficits in memory, visuospatial and language function. CSF t-tau and p-tau181 were markedly elevated and A beta(42) levels reduced. FDG-PET revealed hypometabolism in the left parietotemporal cortex. FDDNP-PET showed increased binding of tracer in medial temporal and parietal lobes and in the head of the caudate and anterior putamen bilaterally. Neuropathological examination of her brother showed the typical findings of AD and the striatum demonstrated amyloid pathology and marked neurofibrillary pathology beyond that typically seen in late-onset AD. A novel S212Y substitution in PSEN1 was present in the index patient and her affected brother but not in an older unaffected sister. An in vitro assay in which the S212Y mutation was introduced in cell culture confirmed that it was associated with increased production of A beta(42). We describe biochemical, imaging, and neuropathological changes in a pedigree with a novel PSEN1 mutation. This allows us to validate the pathogenicity of this mutation and the indices used to assess AD. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Ringman, John M.; Small, Gary; Cederbaum, Stephen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Semel Inst Psychiat, Los Angeles, CA 90095 USA.
[Ringman, John M.; Gylys, Karen H.; Medina, Luis D.; Apostolova, Liana G.] Univ Calif Los Angeles, Dept Neurol, Mary S Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA.
[Fox, Michelle; Cederbaum, Stephen] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA.
[Kepe, Vladimir; Barrio, Jorge R.; Silverman, Daniel H.; Siu, Erin] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Flores, Deborah L.] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA.
[Hecimovic, Silva; Malnar, Martina] Rudjer Boskovic Inst, Dept Mol Med, Zagreb, Croatia.
[Chakraverty, Suma; Goate, Alison M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Bird, Thomas D.; Leverenz, James B.] Univ Washington, VA Puget Sound Hlth Care Syst, Educ Clin Ctr, Mental Illness & Parkinsons Dis Res, Seattle, WA 98195 USA.
RP Ringman, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Semel Inst Psychiat, 10911 Weyburn Ave,200, Los Angeles, CA 90095 USA.
EM jringman@mednet.ucla.edu
FU Elan; Wyeth; Pfizer Pharmaceuticals; FDDNP; PHS [K08 AG-22228];
California DHS [04-35522]; NIA [P50 AG-16570, M01-RR00865]; Sidell Kagan
Foundation; Easton Consortium for Alzheimer's Disease Drug Discovery and
Biomarkers
FX Dr. Ringman has received compensation for serving on an advisory board
for Akeso Pharmaceuticals and is receiving research grants from Elan,
Wyeth, and Pfizer Pharmaceuticals. Drs. Small and Barrio are
co-inventors of and have financial interests in FDDNP. Silva Hecimovic,
Martina Malnar, Suma Chakraverty, Alison M. Goate, Stephen Cederbaum,
Luis Medina, Michelle Fox, Vladimir Kepe, Deborah Flores, Daniel
Silverman, Erin Siu, Karen Gylys, and James Leverenz have nothing to
disclose.; This study was supported by PHS K08 AG-22228 and California
DHS #04-35522, NIA P50 AG-16570, M01-RR00865, the Sidell Kagan
Foundation, and the Easton Consortium for Alzheimer's Disease Drug
Discovery and Biomarkers.
NR 19
TC 22
Z9 22
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JAN 10
PY 2011
VL 487
IS 3
BP 287
EP 292
DI 10.1016/j.neulet.2010.10.039
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 712WQ
UT WOS:000286697400008
PM 21094210
ER
PT J
AU Pandya, GA
McEllistrem, MC
Venepally, P
Holmes, MH
Jarrahi, B
Sanka, R
Liu, J
Karamycheva, SA
Bai, Y
Fleischmann, RD
Peterson, SN
AF Pandya, Gagan A.
McEllistrem, M. Catherine
Venepally, Pratap
Holmes, Michael H.
Jarrahi, Behnam
Sanka, Ravi
Liu, Jia
Karamycheva, Svetlana A.
Bai, Yun
Fleischmann, Robert D.
Peterson, Scott N.
TI Monitoring the Long-Term Molecular Epidemiology of the Pneumococcus and
Detection of Potential 'Vaccine Escape' Strains
SO PLOS ONE
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; SURFACE PROTEIN;
UNITED-STATES; SEQUENCE-ANALYSIS; INVASIVE DISEASE; HETEROLOGOUS PSPA;
VIRULENCE FACTORS; GENOME SEQUENCE; DIVERSITY
AB Background: While the pneumococcal protein conjugate vaccines reduce the incidence in invasive pneumococcal disease (IPD), serotype replacement remains a major concern. Thus, serotype-independent protection with vaccines targeting virulence genes, such as PspA, have been pursued. PspA is comprised of diverse clades that arose through recombination. Therefore, multi-locus sequence typing (MLST)-defined clones could conceivably include strains from multiple PspA clades. As a result, a method is needed which can both monitor the long-term epidemiology of the pneumococcus among a large number of isolates, and analyze vaccine-candidate genes, such as pspA, for mutations and recombination events that could result in 'vaccine escape' strains.
Methodology: We developed a resequencing array consisting of five conserved and six variable genes to characterize 72 pneumococcal strains. The phylogenetic analysis of the 11 concatenated genes was performed with the MrBayes program, the single nucleotide polymorphism (SNP) analysis with the DNA Sequence Polymorphism program (DnaSP), and the recombination event analysis with the recombination detection package (RDP).
Results: The phylogenetic analysis correlated with MLST, and identified clonal strains with unique PspA clades. The DnaSP analysis correlated with the serotype-specific diversity detected using MLST. Serotypes associated with more than one ST complex had a larger degree of sequence polymorphism than a serotype associated with one ST complex. The RDP analysis confirmed the high frequency of recombination events in the pspA gene.
Conclusions: The phylogenetic tree correlated with MLST, and detected multiple PspA clades among clonal strains. The genetic diversity of the strains and the frequency of recombination events in the mosaic gene, pspA were accurately assessed using the DnaSP and RDP programs, respectively. These data provide proof-of-concept that resequencing arrays could play an important role within research and clinical laboratories in both monitoring the molecular epidemiology of the pneumococcus and detecting 'vaccine escape' strains among vaccine-candidate genes.
C1 [Pandya, Gagan A.; Venepally, Pratap; Holmes, Michael H.; Jarrahi, Behnam; Sanka, Ravi; Liu, Jia; Karamycheva, Svetlana A.; Bai, Yun; Fleischmann, Robert D.; Peterson, Scott N.] J Craig Venter Inst, Pathogen Funct Genom Resource Ctr, Rockville, MD USA.
[McEllistrem, M. Catherine] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Pandya, GA (reprint author), J Craig Venter Inst, Pathogen Funct Genom Resource Ctr, Rockville, MD USA.
EM scottp@jcvi.org
FU NIAID [N01-AI-15447]; [K23 AI01788-05]
FX This work was supported by the NIAID contract No. N01-AI-15447 to
Pathogen Functional Genomics Resource Center and K23 AI01788-05 (MCM).
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 62
TC 4
Z9 5
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 10
PY 2011
VL 6
IS 1
AR e15950
DI 10.1371/journal.pone.0015950
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 710LL
UT WOS:000286513100021
PM 21264340
ER
PT J
AU Eaddy, AC
Schnellmann, RG
AF Eaddy, Andre C.
Schnellmann, Rick G.
TI Visualization and quantification of endoplasmic reticulum Ca2+ in renal
cells using confocal microscopy and Fluo5F
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Calcium; Endoplasmic reticulum; Confocal microscopy; Kidney; Fluo5f
ID MITOCHONDRIAL PERMEABILITY TRANSITION; CA2+-INDEPENDENT PHOSPHOLIPASE
A(2); INTRACELLULAR CALCIUM; DEATH; APOPTOSIS; IDENTIFICATION;
AUTOPHAGY; CULTURE; CALPAIN; INJURY
AB Sarcoplasmic/endoplasmic reticulum (ER) Ca2+ is the most abundant store of intracellular Ca2+, and its release is an important trigger of physiological and cell death pathways. Previous work in our laboratory revealed the importance of ER Ca2+ in toxicant-induced renal proximal tubular cell (RPTC) death. The purpose of this study was to evaluate the use of confocal microscopy and Fluo5F, a low affinity Ca2+ indicator, to directly monitor changes in RPTC ER Ca2+. Fluo5F staining reflected ER Ca2+, resolved ER structure, and showed no colocalization with tetramethyl rhodamine methyl ester (TMRM), a marker of mitochondrial membrane potential. Thapsigargin, an ER Ca2+ pump inhibitor, decreased ER fluorescence by 30% and 55% at 5 and 15 min, respectively, whereas A23187, a Ca2+ ionophore caused more rapid ER Ca2+ release (55% and 75% decrease in fluorescence at 5 and 15 min).
Carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), a mitochondrial uncoupler, added at the end of the experiment, further decreased ER fluorescence after thapsigargin treatment, revealing that thapsigargin did not release all ER Ca2+. In contrast, FCCP did not decrease ER fluorescence after A23187 treatment, suggesting complete ER Ca2+ release. ER Ca2+ release in response to A23187 or thapsigargin resulted in a modest but significant decrease in mitochondrial membrane potential. These data provide evidence that confocal microscopy and Fluo5F are useful and effective tools for directly monitoring ER Ca2+ in live cells. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Eaddy, Andre C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr Charleston, Charleston, SC 29401 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC 140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU NIH [F30 ES015964, DK-062028, C06 RR-015455]; Biomedical Laboratory
Research and Development Program of the Department of Veterans Affairs;
[P30 CA138313]
FX This work was supported by an NIH fellowship (F30 ES015964) to AE and
NIH grant (DK-062028) to RGS, and by the Biomedical Laboratory Research
and Development Program of the Department of Veterans Affairs. Animal
facilities were funded by NIH grant C06 RR-015455 and Cell and Molecular
Imaging (CMI) facility was supported, in part, by grant P30 CA138313 to
the Hollings Cancer Center, Medical University of South Carolina. The
authors also thank Dr. Venkat Ramshesh and Dr. John Lemasters (Medical
University of South Carolina) for their advice and constructive
discussions during the execution of these experiments.
NR 23
TC 3
Z9 3
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 7
PY 2011
VL 404
IS 1
BP 424
EP 427
DI 10.1016/j.bbrc.2010.11.137
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 710CE
UT WOS:000286487700075
PM 21130732
ER
PT J
AU Shi, YJ
Frost, P
Hoang, B
Benavides, A
Gera, J
Lichtenstein, A
AF Shi, Yijiang
Frost, Patrick
Hoang, Bao
Benavides, Angelica
Gera, Joseph
Lichtenstein, Alan
TI IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells
CRITICAL ROLE OF CYTOPLASMIC LOCALIZATION OF THE RNA-BINDING PROTEIN
hnRNP A1
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INTERNAL RIBOSOME ENTRY; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-A1;
TRANS-ACTING FACTOR; HNRNP A1; MESSENGER-RNA; BINDING PROTEIN;
GENE-EXPRESSION; SITE FUNCTION; RELOCALIZATION; ACTIVATION
AB Prior work indicates that IL-6 can stimulate c-Myc expression in multiple myeloma (MM) cells, which is independent of effects on transcription and due to enhanced translation mediated by an internal ribosome entry site in the 5'-UTR of the c-Myc RNA. The RNA-binding protein hnRNP A1 (A1) was also critical to IL-6-stimulated translation. Because A1 shuttles between nucleus and cytoplasm, we investigated whether the ability of IL-6 to enhance Myc translation was mediated by stimulation of A1 shuttling. In MM cell lines and primary specimens, IL-6 increased A1 cytoplasmic localization. In contrast, there was no effect on the total cellular levels of A1. Use of a dominant negative A1 construct, which prevents endogenous A1 from nucleus-to-cytoplasm transit, prevented the ability of IL-6 to enhance Myc internal ribosome entry site activity, Myc protein expression, and MM cell growth. IL-6-stimulated cytoplasmic localization was mediated by alterations in the C-terminal M9 peptide of A1, and this correlated with the ability of IL-6 to induce serine phosphorylation of this domain. A p38 kinase inhibitor prevented IL-6-induced A1 phosphorylation. Thus, IL-6 activates c-Myc translation in MM cells by inducing A1 phosphorylation and cytoplasmic localization in a p38-dependent fashion. These data suggest A1 as a potential therapeutic target in MM.
C1 [Shi, Yijiang; Frost, Patrick; Hoang, Bao; Benavides, Angelica; Gera, Joseph; Lichtenstein, Alan] Univ Calif Los Angeles, Div Hematol Oncol, Greater Los Angeles Vet Affairs Healthcare Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA.
RP Lichtenstein, A (reprint author), W Los Angeles VA Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM alan.lichtenstein@med.va.gov
OI Frost, Patrick/0000-0003-3348-5983
FU National Institutes of Health [RO1 CA109312, RO1 CA111448]; Department
of Defense; Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health Grants RO1 CA109312 and RO1 CA111448. This work was also
supported by research funds from the Department of Defense and the
Department of Veterans Affairs.
NR 38
TC 20
Z9 20
U1 1
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 7
PY 2011
VL 286
IS 1
BP 67
EP 78
DI 10.1074/jbc.M110.153221
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 700YZ
UT WOS:000285782800008
PM 20974848
ER
PT J
AU Vergnes, L
Chin, R
Young, SG
Reue, K
AF Vergnes, Laurent
Chin, Robert
Young, Stephen G.
Reue, Karen
TI Heart-type Fatty Acid-binding Protein Is Essential for Efficient Brown
Adipose Tissue Fatty Acid Oxidation and Cold Tolerance
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MITOCHONDRIAL UNCOUPLING PROTEIN; INSULIN-RESISTANCE; MICE LACKING;
ADAPTIVE THERMOGENESIS; GENE DELETION; UP-REGULATION; ADULT HUMANS;
OBESITY; EXPRESSION; ADIPOCYTE
AB Brown adipose tissue has a central role in thermogenesis to maintain body temperature through energy dissipation in small mammals and has recently been verified to function in adult humans as well. Here, we demonstrate that the heart-type fatty acid-binding protein, FABP3, is essential for cold tolerance and efficient fatty acid oxidation in mouse brown adipose tissue, despite the abundant expression of adiposetype fatty acid-binding protein, FABP4 (also known as aP2). Fabp3(-/-) mice exhibit extreme cold sensitivity despite induction of uncoupling and oxidative genes and hydrolysis of brown adipose tissue lipid stores. However, using FABP3 gain-and loss-of-function approaches in brown adipocytes, we detected a correlation between FABP3 levels and the utilization of exogenous fatty acids. Thus, Fabp3(-/-) brown adipocytes fail to oxidize exogenously supplied fatty acids, whereas enhanced Fabp3 expression promotes more efficient oxidation. These results suggest that FABP3 levels are a determinant of fatty acid oxidation efficiency by brown adipose tissue and that FABP3 represents a potential target for modulation of energy dissipation.
C1 [Vergnes, Laurent; Chin, Robert; Young, Stephen G.; Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
[Vergnes, Laurent; Chin, Robert; Young, Stephen G.; Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Vergnes, Laurent; Chin, Robert; Reue, Karen] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Reue, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Gonda 6506A,695 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM reuek@ucla.edu
FU National Institutes of Health [P01 HL90553, U01 HL66621]; American Heart
Association [09BGIA2080363]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants P01 HL90553 (to K. R. and S. G. Y.) and U01 HL66621 (to S.
G. Y.). This work was also supported by American Heart Association Grant
09BGIA2080363 (to L. V.).
NR 61
TC 35
Z9 37
U1 2
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 7
PY 2011
VL 286
IS 1
BP 380
EP 390
DI 10.1074/jbc.M110.184754
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 700YZ
UT WOS:000285782800041
PM 21044951
ER
PT J
AU Goldstein-Daruech, N
Cope, EK
Zhao, KQ
Vukovic, K
Kofonow, JM
Doghramji, L
Gonzalez, B
Chiu, AG
Kennedy, DW
Palmer, JN
Leid, JG
Kreindler, JL
Cohen, NA
AF Goldstein-Daruech, Natalia
Cope, Emily K.
Zhao, Ke-Qing
Vukovic, Katarina
Kofonow, Jennifer M.
Doghramji, Laurel
Gonzalez, Bernardo
Chiu, Alexander G.
Kennedy, David W.
Palmer, James N.
Leid, Jeffery G.
Kreindler, James L.
Cohen, Noam A.
TI Tobacco Smoke Mediated Induction of Sinonasal Microbial Biofilms
SO PLOS ONE
LA English
DT Article
ID ENDOSCOPIC SINUS SURGERY; CHRONIC RHINOSINUSITIS; BACTERIAL BIOFILMS;
EPITHELIAL-CELLS; STAPHYLOCOCCUS-EPIDERMIDIS; COTININE LEVELS; AIRWAY;
LIPOPOLYSACCHARIDE; ACTIVATION; EXPRESSION
AB Cigarette smokers and those exposed to second hand smoke are more susceptible to life threatening infection than nonsmokers. While much is known about the devastating effect tobacco exposure has on the human body, less is known about the effect of tobacco smoke on the commensal and commonly found pathogenic bacteria of the human respiratory tract, or human respiratory tract microbiome. Chronic rhinosinusitis (CRS) is a common medical complaint, affecting 16% of the US population with an estimated aggregated cost of $6 billion annually. Epidemiologic studies demonstrate a correlation between tobacco smoke exposure and rhinosinusitis. Although a common cause of CRS has not been defined, bacterial presence within the nasal and paranasal sinuses is assumed to be contributory. Here we demonstrate that repetitive tobacco smoke exposure induces biofilm formation in a diverse set of bacteria isolated from the sinonasal cavities of patients with CRS. Additionally, bacteria isolated from patients with tobacco smoke exposure demonstrate robust in vitro biofilm formation when challenged with tobacco smoke compared to those isolated from smoke naive patients. Lastly, bacteria from smoke exposed patients can revert to a non-biofilm phenotype when grown in the absence of tobacco smoke. These observations support the hypothesis that tobacco exposure induces sinonasal biofilm formation, thereby contributing to the conversion of a transient and medically treatable infection to a persistent and therapeutically recalcitrant condition.
C1 [Goldstein-Daruech, Natalia; Zhao, Ke-Qing; Kofonow, Jennifer M.; Doghramji, Laurel; Chiu, Alexander G.; Kennedy, David W.; Palmer, James N.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Goldstein-Daruech, Natalia] Pontificia Univ Catolica Chile, PhD Program Med Sci, Santiago, Chile.
[Goldstein-Daruech, Natalia; Gonzalez, Bernardo] Univ Adolfo Ibanez, Fac Ingn & Ciencia, Santiago, Chile.
[Cope, Emily K.; Leid, Jeffery G.] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA.
[Zhao, Ke-Qing] Fudan Univ, Dept Otorhinolaryngol Head & Neck Surg, Eye & ENT Hosp, Sch Shanghai Med, Shanghai 200433, Peoples R China.
[Vukovic, Katarina] Univ Hosp Ctr, Dept Otorhonolaryngol Head & Neck Surg, Zagreb, Croatia.
[Kreindler, James L.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Kreindler, James L.] Univ Penn, Sch Med, Dept Pediat, Div Pulm Med, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA.
RP Goldstein-Daruech, N (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
EM cohenn@uphs.upenn.edu
RI Chiu, Alexander/J-1230-2014
OI Chiu, Alexander/0000-0002-7592-6575; Cohen, Noam/0000-0002-9462-3932
FU Flight Attendants Medical Research Institute; Comision Nacional de
investigacion cientifica y tecnologica de Chile (CONICYT);
Cotutela/Codireccion 2009-2010 Pontificia Universidad Catolica de Chile
FX This work was funded by the Flight Attendants Medical Research Institute
as well as training fellowship grants from Comision Nacional de
investigacion cientifica y tecnologica de Chile (CONICYT), and
Cotutela/Codireccion 2009-2010 Pontificia Universidad Catolica de Chile.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 59
TC 38
Z9 40
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 6
PY 2011
VL 6
IS 1
AR e15700
DI 10.1371/journal.pone.0015700
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 710KZ
UT WOS:000286511900008
PM 21253587
ER
PT J
AU Sugawara, M
Ohye, H
Tomoda, C
Kogai, T
Kamata, Y
Pezeshkpour, GH
Moatamed, F
AF Sugawara, Masahiro
Ohye, Hidemi
Tomoda, Chisato
Kogai, Takahiko
Kamata, Yoshimasa
Pezeshkpour, Gholam H.
Moatamed, Farhad
TI A Novel Role for Niemann-Pick Disease Type 2C Protein in Papillae
Formation
SO PLOS ONE
LA English
DT Article
ID APOPTOSIS; NPC2
AB Background: Despite the presence of papillary structures and papillary tumors in humans, the mechanism of papillae formation is unknown. We describe herein a novel role for Niemann-Pick disease type 2C (NPC2) protein, a cholesterol binding protein in the lysosome, in papillae formation.
Methodology/Principal Finding: We examined NPC2 protein expression in surgical samples of papillary tissues by immunohistochemical stain, and all papillary tissues expressed NPC2 protein in the epithelium. To examine our hypothesis of NPC2 protein-mediated papillae formation, we carried out xenograft experiments using wild H460 cells (large cell lung carcinoma cell line) that constitutively expressed abundant NPC2 protein and NPC2 protein-depleted H460 cells by NPC2 shRNA. The xenografts of wild H460 cells and empty shRNA vector cells showed distinct papillae formation, whereas NPC2 protein-depleted H460 cells displayed markedly reduced or no papillae. Since all papillary tissues have open spaces we examined whether NPC2 protein might also contribute to the creation of open spaces. The TUNEL assay in the xenografts of wild and empty shRNA vector H460 cells showed massive cell death, and NPC2 protein-depleted cells displayed minimal cell death. Measurement of caspase 3/7 activities in cultured H460 cells supported NPC2 protein-mediated apoptotic cell death. The presence of excess NPC2 protein, however, did not always produce papillae as seen in the xenografts of CHO cells that were stably transfected with NPC2.
Conclusions/Significance: The NPC2 protein of certain cells forms papillae coupled with apoptosis that creates open space. This protein may have future applications to modulate papillae formation and papillary growth in tumor tissues.
C1 [Sugawara, Masahiro; Ohye, Hidemi; Tomoda, Chisato; Kogai, Takahiko] Univ Calif Los Angeles, David Geffen Sch Med, Endocrinol & Diabet Div, Dept Med,Vet Affairs Greater Los Angeles Hlth Car, Los Angeles, CA 90095 USA.
[Sugawara, Masahiro] Univ Calif Los Angeles, David Geffen Sch Med, Primary Care Serv, Dept Med,Vet Affairs Greater Los Angeles Hlth Car, Los Angeles, CA 90095 USA.
[Kamata, Yoshimasa] Hirosaki Univ, Sch Med, Dept Pathol, Hirosaki, Aomori 036, Japan.
[Pezeshkpour, Gholam H.; Moatamed, Farhad] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA.
RP Sugawara, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Endocrinol & Diabet Div, Dept Med,Vet Affairs Greater Los Angeles Hlth Car, Los Angeles, CA 90095 USA.
EM msugawar@ucla.edu
FU Veterans Affairs
FX This work was supported by a Veterans Affairs Merit Review grant. The
funders had no role in study design, data collection and analysis,
decision to publish or preparation of the manuscript.
NR 8
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 6
PY 2011
VL 6
IS 1
AR e15777
DI 10.1371/journal.pone.0015777
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 710KZ
UT WOS:000286511900010
PM 21253586
ER
PT J
AU Kurihara, N
Hiruma, Y
Yamana, K
Michou, L
Rousseau, C
Morissette, J
Galson, DL
Teramachi, J
Zhou, H
Dempster, DW
Windle, JJ
Brown, JP
Roodman, GD
AF Kurihara, Noriyoshi
Hiruma, Yuko
Yamana, Kei
Michou, Laetitia
Rousseau, Come
Morissette, Jean
Galson, Deborah L.
Teramachi, Jumpei
Zhou, Hua
Dempster, David W.
Windle, Jolene J.
Brown, Jacques P.
Roodman, G. David
TI Contributions of the Measles Virus Nucleocapsid Gene and the
SQSTM1/p62(P392L) Mutation to Paget's Disease
SO CELL METABOLISM
LA English
DT Article
ID MARROW CULTURES; TRANSGENIC MICE; GIANT-CELLS; BONE; OSTEOCLASTS;
SEQUESTOSOME-1; EXPRESSION; INTERLEUKIN-6; INCREASES; ANTIGENS
AB Paget's disease (PD) is characterized by abnormal osteoclasts (OCL) that secrete high IL-6 levels and induce exuberant bone formation. Because measles virus nucleocapsid gene (MVNP) and the p62(P392L)-mutation are implicated in PD, marrows from 12 PD patients harboring p62(P392L) and eight normals were tested for MVNP expression and pagetic OCL formation. Eight out of twelve patients expressed MVNP and formed pagetic OCL in vitro, which were inhibited by antisense-MVNP. Four out of twelve patients lacked MVNP and formed normal OCL that were hyperresponsive to RANKL but unaffected by antisense-MVNP. Similarly, mice expressing only p62(P394L) formed normal OCL, while mice expressing MVNP in OCL, with or without p62(P394L), developed pagetic OCL and expressed high IL-6 levels dependent on p38MAPK activation. IL-6 deficiency in MVNP mice abrogated pagetic OCL development in vitro. Mice coexpressing MVNP and p62(P394L) developed dramatic Paget's-like bone lesions. These results suggest that p62(P394L) and IL-6 induction by MVNP play key roles in PD.
C1 [Kurihara, Noriyoshi; Hiruma, Yuko; Galson, Deborah L.; Teramachi, Jumpei; Roodman, G. David] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
[Yamana, Kei] Teijin Biomed Res, Tokyo 1918512, Japan.
[Michou, Laetitia; Rousseau, Come; Morissette, Jean; Brown, Jacques P.] Univ Laval, CHUQ CHUL Res Ctr, Quebec City, PQ G1V 4G2, Canada.
[Zhou, Hua; Dempster, David W.] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA.
[Dempster, David W.] Columbia Univ, Dept Pathol, Coll Phys & Surg, New York, NY 10993 USA.
[Windle, Jolene J.] Virginia Commonwealth Univ, Richmond, VA 23298 USA.
[Roodman, G. David] VA Pittsburgh Healthcare Syst, Med Hem Onc, Pittsburgh, PA 15240 USA.
RP Roodman, GD (reprint author), Univ Pittsburgh, Pittsburgh, PA 15213 USA.
EM roodmangd@upmc.edu
RI Galson, Deborah/E-9370-2010
OI Galson, Deborah/0000-0002-2045-8807; Windle, Jolene/0000-0001-6690-385X
FU NIAMS, NIH/NCRR/CTSA [PO1-AR049363, R01 AR057308, R01 AR057310, RO1
AR053537]; NIH/NCRR/GCRC [UL1 RR024153]; Paget's Foundation; Massey
Cancer Center [P30 CA016059]; Novartis; [M01 RR000056]
FX We thank Dr. Fujinami, Ph.D., University of Utah, for providing the
AS-MVNP construct, and Donna Gaspich for preparing the manuscript. We
also thank all patients who participated in this study, and Danielle
Poulin for her outstanding support in clinical data collection and
analysis. We thank Dr. Ramesh Ramakrishnan for assistance with
statistical analyses. The research was funded by grant PO1-AR049363
(G.D.R.), R01 AR057308 (G.D.R.), R01 AR057310 (D.L.G.), and RO1 AR053537
(J.J.W.) from NIAMS, NIH/NCRR/CTSA Grant UL1 RR024153 and NIH/NCRR/GCRC
Grant M01 RR000056, and by a grant from the Paget's Foundation. The
materials are the result of work supported with resources and the use of
facilities at the VA Pittsburgh Healthcare System, Research and
Development, and the VCU Transgenic/Knockout Mouse Core, supported in
part by the Massey Cancer Center Support Grant P30 CA016059. J.P.B.
reports having served as a consultant to Amgen, Sanofi-Aventis,
Warner-Chilcott, Merck, E. Lily, Novartis, Servier. G.D.R. reports
having served as a consultant to Amgen, Novartis, Celgene, and
Millennium and received grant support from Novartis as well.
NR 27
TC 41
Z9 43
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD JAN 5
PY 2011
VL 13
IS 1
BP 23
EP 34
DI 10.1016/j.cmet.2010.12.002
PG 12
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 716KL
UT WOS:000286967400007
PM 21195346
ER
PT J
AU Imam, SZ
Zhou, Q
Yamamoto, A
Valente, AJ
Ali, SF
Bains, M
Roberts, JL
Kahle, PJ
Clark, RA
Li, SL
AF Imam, Syed Z.
Zhou, Qing
Yamamoto, Ayako
Valente, Anthony J.
Ali, Syed F.
Bains, Mona
Roberts, James L.
Kahle, Philipp J.
Clark, Robert A.
Li, Senlin
TI Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine
Phosphorylation: Implications for Parkinson's Disease
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID UBIQUITIN LIGASE ACTIVITY; PROTECTIVE FUNCTION; S-NITROSYLATION; PROTEIN
LIGASE; CELL-DEATH; MUTATIONS; SUBSTRATE; STRESS; NEURODEGENERATION;
PATHOGENESIS
AB Mutations in parkin, an E3 ubiquitin ligase, are the most common cause of autosomal-recessive Parkinson's disease (PD). Here, we show that the stress-signaling non-receptor tyrosine kinase c-Abl links parkin to sporadic forms of PD via tyrosine phosphorylation. Under oxidative and dopaminergic stress, c-Abl was activated in cultured neuronal cells and in striatum of adult C57BL/6 mice. Activated c-Abl was found in the striatum of PD patients. Concomitantly, parkin was tyrosine-phosphorylated, causing loss of its ubiquitin ligase and cytoprotective activities, and the accumulation of parkin substrates, AIMP2(aminoacyl tRNA synthetase complex-interacting multifunctional protein 2) (p38/JTV-1) and FBP-1.STI-571, a selective c-Abl inhibitor, prevented tyrosine phosphorylation of parkin and restored its E3 ligase activity and cytoprotective function both in vitro and in vivo. Our results suggest that tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that leads to loss of parkin function and disease progression in sporadic PD. Moreover, inhibition of c-Abl offers new therapeutic opportunities for blocking PD progression.
C1 [Imam, Syed Z.; Zhou, Qing; Valente, Anthony J.; Clark, Robert A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Imam, Syed Z.; Bains, Mona; Roberts, James L.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Imam, Syed Z.; Roberts, James L.; Clark, Robert A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Imam, Syed Z.; Clark, Robert A.; Li, Senlin] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Yamamoto, Ayako; Kahle, Philipp J.] Univ Clin Tubingen, Lab Funct Neurogenet, Dept Neurodegenerat, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany.
[Ali, Syed F.] US FDA, Neurochem Lab, Div Neurotoxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
RP Imam, SZ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM imam@uthscsa.edu; lis1@uthscsa.edu
FU US National Institutes of Health; Department of Veterans Affairs;
Michael J. Fox Foundation; Parkinson's Disease Foundation; San Antonio
Area Foundation; American Parkinson Disease Association; Executive
Research Council of University of Texas Health Science Center; San
Antonio (UTHSCSA); German National Genome Research Network [NGFN-2];
European Union
FX This work was supported by grants from the US National Institutes of
Health, Department of Veterans Affairs, Michael J. Fox Foundation,
Parkinson's Disease Foundation, San Antonio Area Foundation, American
Parkinson Disease Association, Executive Research Council of University
of Texas Health Science Center, San Antonio (UTHSCSA), the German
National Genome Research Network (NGFN-2), and the European Union
(N)EUROPARK consortium. The technical assistance of Xuyean Liao, Doran
Pearson, Lora Judge, Heather Dudley, and Wuqiong Ma is acknowledged. We
thank F. Fiesel (Hertie Institute, Tubingen, Germany) for helpful
suggestions, and S.T. Weintraub and K. Hakala for MS analyses (UTHSCSA
Institutional Mass Spectrometry Laboratory). Parkin plasmids and
constructs, antibodies to AIMP2, and postmortem human samples were kind
gifts from Ted M. Dawson (Johns Hopkins University, Baltimore, MD). We
also thank Dr. Dawson's lab for processing of some human samples. c-Abl
and Arg constructs were kind gifts from B. Li (Institute of Molecular
and Cell Biology, Singapore), D. Kufe (Dana-Farber Cancer Institute,
Harvard Medical School, Cambridge, MA), and Z. M. Yuan (Harvard School
of Public Health). Recombinant tyrosine kinase fragment of c-Abl was a
kind gift from M. Seeliger and J. Kuriyan (Howard Hughes Medical
Institute, University of California, Berkeley, CA). FBP-1 cDNA was
kindly provided by D. Levens (National Cancer Institute, National
Institutes of Health, Bethesda, MD). Lenti-shRNA to parkin was kindly
provided by P. Aebischer and R. Zuffrey (Ecole Polytechnique Federale
Lausanne, Lausanne, Switzerland). STI-571 was provided by Novartis
Pharma.
NR 30
TC 61
Z9 61
U1 0
U2 6
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JAN 5
PY 2011
VL 31
IS 1
BP 157
EP 163
DI 10.1523/JNEUROSCI.1833-10.2011
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 702SH
UT WOS:000285915100018
PM 21209200
ER
PT J
AU Thompson, EM
Frenkel, EP
Neuwelt, EA
AF Thompson, Eric M.
Frenkel, Eugene P.
Neuwelt, Edward A.
TI The paradoxical effect of bevacizumab in the therapy of malignant
gliomas
SO NEUROLOGY
LA English
DT Review
ID HIGH-GRADE GLIOMAS; NEWLY-DIAGNOSED GLIOBLASTOMA; PHASE-II TRIAL; PLUS
IRINOTECAN; RECURRENT GLIOBLASTOMA; BRAIN-TUMORS; ANTIANGIOGENIC
THERAPY; PROGRESSION; SURVIVAL; EFFICACY
AB One rationale behind the use of agents that inhibit vascular endothelial growth factor in the therapy of primary CNS malignancies is based upon the concept that normalization of tumor vasculature with a decrease in tumor interstitial pressure will improve access of cytoreductive drugs and improve radiotherapy efficacy due to increased oxygen delivery. However, several studies have raised the concern that these agents may both rapidly restore the low permeability characteristics of the blood-brain barrier and counteract the beneficial effect of pseudoprogression. The result may be decreased therapeutic efficacy while increasing infiltration by co-opting normal vessels. In this discussion, we examine both histologic and radiographic tumor progression in the context of antiangiogenic agents. Issues dealing with the safety of bevacizumab (Avastin (R), Genentech, South San Francisco, CA) and its potential to decrease efficacy of standard radiochemotherapy when used to treat patients with newly diagnosed malignant glioma are emphasized. Neurology (R) 2011; 76:87-93
C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Blood Brain Barrier Program, Portland, OR 97239 USA.
[Thompson, Eric M.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
[Frenkel, Eugene P.] Univ Texas SW Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dept Hematol Oncol, Dallas, TX 75390 USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Blood Brain Barrier Program, 3181 Sam Jackson Pkwy Rd,L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
FU NIH; US Department of Veterans Affairs
FX Dr. Thompson reports no disclosures. Dr. Frenkel serves as an Associate
Editor for Clinical and Applied Thrombosis/Hemostasis; may accrue
revenue on a patent re: Synergistic interaction of cyclic histone
deactylase inhibitor with EGFR targeted drugs; and serves as a
consultant for Shionogi & Co., Ltd. Dr. Neuwelt receives research
support from the NIH and from the US Department of Veterans Affairs.
NR 52
TC 39
Z9 50
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JAN 4
PY 2011
VL 76
IS 1
BP 87
EP 93
DI 10.1212/WNL.0b013e318204a3af
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 699SJ
UT WOS:000285682800017
PM 21205697
ER
PT J
AU Pugh, MJ
Berlowitz, DR
Rao, JK
Shapiro, G
Avetisyan, R
Hanchate, A
Jarrett, K
Tabares, J
Kazis, LE
AF Pugh, Mary Jo
Berlowitz, Dan R.
Rao, Jaya K.
Shapiro, Gabriel
Avetisyan, Ruzan
Hanchate, Amresh
Jarrett, Kelli
Tabares, Jeffrey
Kazis, Lewis E.
TI The quality of care for adults with epilepsy: an initial glimpse using
the QUIET measure
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; MOOD DISORDERS; SPECIALIST PHYSICIANS;
OLDER PATIENTS; BONE MASS; GENERALIST; HEALTH; ASSOCIATION; MANAGEMENT;
KNOWLEDGE
AB Background: We examined the quality of adult epilepsy care using the Quality Indicators in Epilepsy Treatment (QUIET) measure, and variations in quality based on the source of epilepsy care.
Methods: We identified 311 individuals with epilepsy diagnosis between 2004 and 2007 in a tertiary medical center in New England. We abstracted medical charts to identify the extent to which participants received quality indicator (QI) concordant care for individual QI's and the proportion of recommended care processes completed for different aspects of epilepsy care over a two year period. Finally, we compared the proportion of recommended care processes completed for those receiving care only in primary care, neurology clinics, or care shared between primary care and neurology providers.
Results: The mean proportion of concordant care by indicator was 55.6 (standard deviation = 31.5). Of the 1985 possible care processes, 877 (44.2%) were performed; care specific to women had the lowest concordance (37% vs. 42% [first seizure evaluation], 44% [initial epilepsy treatment], 45% [chronic care]). Individuals receiving shared care had more aspects of QI concordant care performed than did those receiving neurology care for initial treatment (53% vs. 43%; X(2) = 9.0; p = 0.01) and chronic epilepsy care (55% vs. 42%; X(2) = 30.2; p < 0.001).
Conclusions: Similar to most other chronic diseases, less than half of recommended care processes were performed. Further investigation is needed to understand whether a shared-care model enhances quality of care, and if so, how it leads to improvements in quality.
C1 [Pugh, Mary Jo; Tabares, Jeffrey] VERDICT REAP, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Berlowitz, Dan R.; Kazis, Lewis E.] Vet Adm Med Ctr, CHQOER, Bedford, MA 01730 USA.
[Berlowitz, Dan R.; Shapiro, Gabriel; Avetisyan, Ruzan; Jarrett, Kelli] Boston Univ, Sch Publ Hlth Hlth Policy & Management, Boston, MA 02118 USA.
[Rao, Jaya K.] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
[Shapiro, Gabriel] Univ Montreal, Hop St Justine, Montreal, PQ H3T 1C5, Canada.
[Hanchate, Amresh] Boston Vet Adm Med Ctr, Ctr Org Leadership & Management Res, Jamaica Plain, MA 02130 USA.
[Kazis, Lewis E.] Boston Univ, Sch Publ Hlth, Ctr Assessment Pharmaceut Practices CAPP, Dept Hlth Policy & Management, Boston, MA 02118 USA.
[Kazis, Lewis E.] Boston Univ, Sch Publ Hlth, Pharmaceut Assessment Management & Policy PAMP, Dept Hlth Policy & Management, Boston, MA 02118 USA.
RP Pugh, MJ (reprint author), VERDICT REAP, S Texas Vet Hlth Care Syst, 7400 Merton Minter, San Antonio, TX 78229 USA.
EM pughm@uthscsa.edu
OI Hanchate, Amresh/0000-0002-7038-4463; Kazis, Lewis/0000-0003-1800-5849;
Pugh, Mary Jo/0000-0003-4196-7763
FU Centers for Disease Control and Prevention
FX Funding for this study was provided by the Centers for Disease Control
and Prevention (PI: Dr. Lewis Kazis). We thank David Thurman, MD, MPH
for his thoughtful review of this manuscript. This material is the
result of work supported with resources and the use of facilities at the
South Texas Veterans Health Care System and the Center for Health
Quality, Outcomes and Economic Research (CHQOER), Edith Nourse Rogers VA
Medical Center Hospital. The views expressed in this article are those
of the authors and do not necessarily reflect the position or policy of
the Centers for Disease Control and Prevention or the Department of
Veterans Affairs or the United States government.
NR 28
TC 18
Z9 18
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD JAN 3
PY 2011
VL 11
AR 1
DI 10.1186/1472-6963-11-1
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 709HH
UT WOS:000286428600001
PM 21199575
ER
PT J
AU Aguado, JM
Singh, N
AF Aguado, Jose M.
Singh, Nina
BE Schlossberg, D
TI Tuberculosis and Organ Transplantation
SO TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIAL INFECTIONS, 6TH EDITION
LA English
DT Article; Book Chapter
ID MULTIDRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS;
LIVER-TRANSPLANTATION; RISK-FACTORS; RENAL-TRANSPLANTATION;
SINGLE-CENTER; POSTTRANSPLANT TUBERCULOSIS; ISONIAZID CHEMOPROPHYLAXIS;
CLINICAL CHARACTERISTICS; LUNG TRANSPLANTATION
C1 [Aguado, Jose M.] Univ Hosp 12 Octubre, Infect Dis Unit, Madrid 28041, Spain.
[Singh, Nina] Univ Pittsburgh, Med Ctr, Infect Dis Sect 2A 137, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
RP Aguado, JM (reprint author), Univ Hosp 12 Octubre, Infect Dis Unit, Avda Andalucia Km 5,400, Madrid 28041, Spain.
NR 81
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA
BN 978-1-55581-713-8
PY 2011
BP 498
EP 508
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA BYN83
UT WOS:000299465700034
ER
PT J
AU Church, P
Judson, MA
AF Church, Preston
Judson, Marc A.
BE Schlossberg, D
TI Paradoxical Reactions and the Immune Reconstitution Inflammatory
Syndrome
SO TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIAL INFECTIONS, 6TH EDITION
LA English
DT Article; Book Chapter
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS;
IMMUNODEFICIENCY-VIRUS-INFECTION; MYCOBACTERIUM-AVIUM COMPLEX; PULMONARY
SARCOIDOSIS; MILIARY TUBERCULOSIS; INTERFERON-GAMMA; RISK-FACTORS;
ACQUIRED-IMMUNODEFICIENCY; INTRACRANIAL TUBERCULOMAS
C1 [Church, Preston] Ralph H Johnson VAMC, Charleston, SC 29425 USA.
[Judson, Marc A.] Med Univ S Carolina, Div Pulm & Crit Care Med, Charleston, SC 29425 USA.
RP Church, P (reprint author), Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 98
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA
BN 978-1-55581-713-8
PY 2011
BP 509
EP 521
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA BYN83
UT WOS:000299465700035
ER
PT J
AU Silverstein, NM
Gottlieb, AG
Eby, DW
Molnar, LJ
Kwan, N
Materdey, T
Adler, G
Van Ranst, E
AF Silverstein, Nina M.
Gottlieb, Alison G.
Eby, David W.
Molnar, Lisa J.
Kwan, Ngai
Materdey, Tomas
Adler, Geri
Van Ranst, Elizabeth
TI Do Memory-Impaired Drivers and Their Family Members Agree on Driving
Ability and Behaviors?
SO TRANSPORTATION RESEARCH RECORD
LA English
DT Article
ID OLDER DRIVERS; DEMENTIA; DISEASE; ADULTS; RISK
AB It is estimated that approximately one-third of people with dementia continue to drive. Compared with the general driving population, drivers with dementia are at an increased risk of unsafe motor vehicle operation. Self-screening is often the basis for self-regulation of driving. It is not known how well self-screening as a predominant strategy works for drivers with memory impairment. This descriptive study explored the perceptions of 22 dyads of drivers with memory impairment and their family members through 44 structured telephone interviews within 4 months after specialized driving assessment to gain insights into their level of agreement on the driver's health, functioning, and critical driving behaviors. Drivers and family members were in fair agreement about current driving patterns and driver self-regulation (such as avoiding driving at night, in bad weather, or in unfamiliar areas). However, when reports of functional ability (such as vision, strength, and flexibility) were compared, drivers rated their fitness more highly than those abilities were rated by their family members on most measures. Moreover, there was poor agreement between drivers and family members on reported occurrence of driving behaviors suggestive of impairment in critical driving skills. These results have implications for health care and other professionals engaged in determining driver fitness. The findings suggest limited value in self-screening or in family reports when assessing fitness to drive in persons with memory impairment. Professionals should exercise caution in relying on reports from family members or drivers, especially with respect to reported driving fitness and driving behaviors.
C1 [Silverstein, Nina M.; Gottlieb, Alison G.; Kwan, Ngai; Van Ranst, Elizabeth] Univ Massachusetts, Inst Gerontol, Boston, MA 02125 USA.
[Materdey, Tomas] Univ Massachusetts, Dept Engn, Boston, MA 02125 USA.
[Eby, David W.; Molnar, Lisa J.] Univ Michigan, Transportat Res Inst, Michigan Ctr Adv Safe Transportat Lifespan, Ann Arbor, MI 48109 USA.
[Adler, Geri] Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA.
RP Silverstein, NM (reprint author), Univ Massachusetts, Inst Gerontol, 100 Morrissey Blvd, Boston, MA 02125 USA.
EM Nina.silverstein@umb.edu
FU Transportation Center, University of Massachusetts, Amherst
FX This study was supported, in part, by a grant from the Transportation
Center, University of Massachusetts, Amherst. The following individuals
and driving assessment centers are gratefully acknowledged for their
assistance in subject recruitment: Margaret O'Connor and Lissa Kapust of
the Drive Wise Program, Harvard Beth Israel Deaconness Medical Center,
Boston, Massachusetts; the Driver Evaluation and Rehabilitation Program
at the Cleveland Clinic, Cleveland, Ohio, with cooperation from Barbara
Messinger-Rapport and Patrick Baker; Michael Justiss of Easter Seals
Clinic, Indianapolis, Indiana; and Mariano Pedroni and Beth Anderson
Gibson of the Freedom and Mobility Clinic, Atlanta, Georgia. Finally,
Robert Geary of the Gerontology Institute, University of Massachusetts,
Boston, is thanked for his assistance with manuscript preparation.
NR 34
TC 6
Z9 6
U1 4
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0361-1981
J9 TRANSPORT RES REC
JI Transp. Res. Record
PY 2011
IS 2265
BP 200
EP 206
DI 10.3141/2265-23
PG 7
WC Engineering, Civil; Transportation; Transportation Science & Technology
SC Engineering; Transportation
GA 918TO
UT WOS:000302274200024
ER
PT J
AU Widome, R
Kehle, SM
Carlson, KF
Laska, MN
Gulden, A
Lust, K
AF Widome, Rachel
Kehle, Shannon M.
Carlson, Kathleen F.
Laska, Melissa Nelson
Gulden, Ashley
Lust, Katherine
TI Post-traumatic Stress Disorder and Health Risk Behaviors Among
Afghanistan and Iraq War Veterans Attending College
SO AMERICAN JOURNAL OF HEALTH BEHAVIOR
LA English
DT Article
DE veterans; tobacco; alcohol; health behaviors; OEF/OIF
ID TRAUMATIC BRAIN-INJURY; COMBAT DEPLOYMENT; AGGRESSION; DIAGNOSES;
SYMPTOMS; STUDENTS; SMOKING; COHORT; PTSD; CARE
AB Objective: To determine if posttraumatic stress disorder (PTSD) is associated with health risk behaviors among Operations Enduring and Iraqi Freedom (OEF/OIF) veterans attending college. Method: Using 2008 Boynton College Student Health Survey data, we tested associations between self-reported PTSD diagnosis and self-reported risk behaviors (n=406). Results: We found PTSD diagnosis to be significantly associated with reporting involvement in a physical fight in the past year (ARR = 3.1; 95% CI: 2.2, 4.4) and marginally associated with high-risk drinking (ARR = 1.3; 95% CI: 1.1, 1.6). However, no association was seen between PTSD and the tobacco use and other safety behaviors that we examined. Conclusion: PTSD is likely a factor that contributes to the relationship between military service and certain health risk behaviors.
C1 [Widome, Rachel; Kehle, Shannon M.; Gulden, Ashley] Univ Minnesota, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55455 USA.
[Widome, Rachel] Univ Minnesota, Dept Med, Minneapolis, MN USA.
[Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97201 USA.
[Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Preventat Med, Portland, OR 97201 USA.
[Laska, Melissa Nelson] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Lust, Katherine] Univ Minnesota, Boynton Hlth Serv, Minneapolis, MN USA.
RP Widome, R (reprint author), Univ Minnesota, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55455 USA.
EM chel@umn.edu
RI Schueter, nicos/A-3625-2014
OI Laska, Melissa/0000-0002-3836-0269
FU NCI NIH HHS [U54 CA116849, U54CA116849]
NR 24
TC 16
Z9 16
U1 1
U2 14
PU PNG PUBLICATIONS
PI OAK RIDGE
PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA
SN 1945-7359
J9 AM J HEALTH BEHAV
JI Am. J. Health Behav.
PY 2011
VL 35
IS 4
BP 387
EP 392
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 909MA
UT WOS:000301567400001
PM 22040585
ER
PT J
AU Curtis, JR
Baddley, JW
Yang, S
Patkar, N
Chen, L
Delzell, E
Mikuls, TR
Saag, KG
Singh, J
Safford, M
Cannon, GW
AF Curtis, Jeffrey R.
Baddley, John W.
Yang, Shuo
Patkar, Nivedita
Chen, Lang
Delzell, Elizabeth
Mikuls, Ted R.
Saag, Kenneth G.
Singh, Jasvinder
Safford, Monika
Cannon, Grant W.
TI Derivation and preliminary validation of an administrative claims-based
algorithm for the effectiveness of medications for rheumatoid arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE rheumatoid arthritis; comparative effectiveness; administrative claims
data; biologic
ID POSITIVE PREDICTIVE-VALUE; ACUTE MYOCARDIAL-INFARCTION;
DISEASE-ACTIVITY; HIP-REPLACEMENT; ICD-9-CM CODES; ACCURACY; DATABASES;
DIAGNOSES; VETERANS; ADHERENCE
AB Introduction: Administrative claims data have not commonly been used to study the clinical effectiveness of medications for rheumatoid arthritis (RA) because of the lack of a validated algorithm for this outcome. We created and tested a claims-based algorithm to serve as a proxy for the clinical effectiveness of RA medications.
Methods: We linked Veterans Health Administration (VHA) medical and pharmacy claims for RA patients participating in the longitudinal Department of Veterans Affairs (VA) RA registry (VARA). Among individuals for whom treatment with a new biologic agent or nonbiologic disease-modifying agent in rheumatic disease (DMARD) was being initiated and with registry follow-up at 1 year, VARA and administrative data were used to create a gold standard for the claims-based effectiveness algorithm. The gold standard outcome was low disease activity (LDA) (Disease Activity Score using 28 joint counts (DAS28) <= 3.2) or improvement in DAS28 by > 1.2 units at 12 +/- 2 months, with high adherence to therapy. The claims-based effectiveness algorithm incorporated biologic dose escalation or switching, addition of new disease-modifying agents, increase in oral glucocorticoid use and dose as well as parenteral glucocorticoid injections.
Results: Among 1,397 patients, we identified 305 eligible biologic or DMARD treatment episodes in 269 unique individuals. The patients were primarily men (94%) with a mean (+/- SD) age of 62 +/- 10 years. At 1 year, 27% of treatment episodes achieved the effectiveness gold standard. The performance characteristics of the effectiveness algorithm were as follows: positive predictive value, 76% (95% confidence interval (95% CI) = 71% to 81%); negative predictive value, 90% (95% CI = 88% to 92%); sensitivity, 72% (95% CI = 67% to 77%); and specificity, 91% (95% CI = 89% to 93%).
Conclusions: Administrative claims data may be useful in evaluating the effectiveness of medications for RA. Further validation of this effectiveness algorithm will be useful in assessing its generalizability and performance in other populations.
C1 [Curtis, Jeffrey R.; Baddley, John W.; Yang, Shuo; Patkar, Nivedita; Chen, Lang; Delzell, Elizabeth; Saag, Kenneth G.; Singh, Jasvinder; Safford, Monika] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Baddley, John W.; Singh, Jasvinder] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35233 USA.
[Mikuls, Ted R.] Omaha VA Med Ctr, Div Rheumatol, Omaha, NE 68105 USA.
[Mikuls, Ted R.] Univ Nebraska Med Ctr, Div Rheumatol, Omaha, NE 68198 USA.
[Cannon, Grant W.] George E Wahlen VA Med Ctr, Salt Lake City, UT 84148 USA.
[Cannon, Grant W.] Univ Utah, Div Rheumatol, Salt Lake City, UT 84132 USA.
RP Curtis, JR (reprint author), Univ Alabama, Dept Med, 510 20th St S,FOT 805D, Birmingham, AL 35294 USA.
EM jcurtis@uab.edu
RI YANG, SHUO/D-2695-2014
OI YANG, SHUO/0000-0002-4999-0506; singh, jasvinder/0000-0003-3485-0006
FU Agency for Healthcare Research and Quality (AHRQ) [U18 HS106956, R01
HS018517]; National Institutes of Health [AR-053351]; VA Health Services
Research & Development (HSRD) [SHP 08-172]; VHA (VA Merit); VHA; Abbott
Laboratories; Bristol-Myers Squibb
FX We thank Mike Connor and Sheryl Berryman at the Birmingham VA Medical
Center for their assistance in working with the Decision Support System
data. This work was supported by the Agency for Healthcare Research and
Quality (AHRQ) (U18 HS106956). Dr. Curtis receives support from the
National Institutes of Health (grant AR-053351) and the AHRQ (grant R01
HS018517). Dr. Cannon receives funding from a VA Health Services
Research & Development (HSR&D) grant (SHP 08-172). Dr. Mikuls receives
research support from the VHA (VA Merit). The VARA Registry has received
research support from the HSR&D Program of the VHA in addition to
unrestricted research funds from Abbott Laboratories and Bristol-Myers
Squibb.
NR 39
TC 14
Z9 14
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2011
VL 13
IS 5
AR R155
DI 10.1186/ar3471
PG 9
WC Rheumatology
SC Rheumatology
GA 904DR
UT WOS:000301174600015
PM 21933396
ER
PT J
AU Zhang, J
Delzell, E
Xie, FL
Baddley, JW
Spettell, C
Mcmahan, RM
Fernandes, J
Chen, L
Winthrop, K
Curtis, JR
AF Zhang, Jie
Delzell, Elizabeth
Xie, Fenglong
Baddley, John W.
Spettell, Claire
Mcmahan, Raechele M.
Fernandes, Joaquim
Chen, Lang
Winthrop, Kevin
Curtis, Jeffrey R.
TI The use, safety, and effectiveness of herpes zoster vaccination in
individuals with inflammatory and autoimmune diseases: a longitudinal
observational study
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; OLDER-ADULTS; INFECTED CHILDREN; UNITED-STATES;
VARICELLA; RISK; THERAPY; RATES; HIV; AGE
AB Introduction: Zostavax, a live attenuated vaccine, has been approved in the United States for use in older individuals to reduce the risk and severity of herpes zoster (HZ), also known as shingles. The vaccine is contraindicated in individuals taking anti-tumor necrosis factor alpha (anti-TNF) therapies or other biologics commonly used to treat autoimmune diseases because of the safety concern that zoster vaccine may be associated with a short-term HZ risk. The objective of the study was to examine the use, safety (short-term HZ risk after vaccination), and effectiveness of zoster vaccine in individuals with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and/or inflammatory bowel diseases.
Methods: We conducted a cohort study of patients aged 50 years and older with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and/or inflammatory bowel diseases by using administrative claims data from a nationwide health plan from January 1, 2005, to August 31, 2009. We examined the extent to which zoster vaccine was used; assessed factors associated with vaccine use (Cox proportional hazards regression); and compared the incidence rates of herpes zoster (HZ) between vaccinated and unvaccinated patients.
Results: Among 44,115 patients with the autoimmune diseases, 551 (1.2%) received zoster vaccine, and 761 developed HZ. Zoster vaccine use increased continuously after approval in 2006. Younger and healthier patients, those who had an HZ infection within the past 6 months, and those who were not using anti-TNF therapies were more likely to receive the vaccine. Approximately 6% of vaccinated patients were using anti-TNF therapies at the time of vaccination. The incidence rates of HZ were similar in vaccinated and unvaccinated patients (standardized incidence ratio, 0.99; 95% confidence interval, 0.29 to 3.43).
Conclusions: Use of the zoster vaccine was uncommon among older patients with autoimmune diseases, including those not exposed to immunosuppressive medications. The short-term risk of HZ did not appear to be increased in vaccinated patients, even among those using immunosuppressive therapies (for example, biologics) at the time of vaccination. However, our study was limited by the small number of vaccinated patients, and further evidence is needed to confirm the vaccine's safety and efficacy in this population.
C1 [Zhang, Jie; Delzell, Elizabeth; Curtis, Jeffrey R.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Xie, Fenglong; Chen, Lang; Curtis, Jeffrey R.] Univ Alabama, Sch Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Baddley, John W.] Univ Alabama, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
[Spettell, Claire; Fernandes, Joaquim] Aetna Informat, Blue Bell, PA 19422 USA.
[Mcmahan, Raechele M.] Aetna Specialty Pharm, Orlando, FL 32809 USA.
[Winthrop, Kevin] Oregon Hlth & Sci Univ, Div Infect Dis, Dept Med, Portland, OR 97239 USA.
RP Curtis, JR (reprint author), Univ Alabama, Sch Publ Hlth, Dept Epidemiol, 1665 Univ Blvd, Birmingham, AL 35294 USA.
EM jcurtis@uab.edu
FU Agency for Healthcare Research and Quality [R01HS018517, T32HS013852];
Doris Duke Charitable Foundation; National Institutes of Health
[AR053351]; Amgen; Pfizer; Centoco; Bristol Myers Squibb; Abbott; UCB;
Genentech; Roche; BMS; Merck
FX This work was supported by the Agency for Healthcare Research and
Quality (R01HS018517) and the Doris Duke Charitable Foundation. JRC
received support from the National Institutes of Health (AR053351); JZ
received support from the Agency for Healthcare Research and Quality
(T32HS013852).; ED receives research funding from Amgen; JWB is a Board
Member of Merck, is a consultant to Pfizer, and receives research
funding from Pfizer; RMM's institution receives funding from Centocor,
Bristol Myers Squibb, and Abbott; JF receives a salary from Aetna; and
JRC has received research grants and consulting fees from Amgen, UCB,
Abbott, Genentech, Roche, Centocor, BMS, and Merck.
NR 24
TC 26
Z9 26
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2011
VL 13
IS 5
AR R174
DI 10.1186/ar3497
PG 9
WC Rheumatology
SC Rheumatology
GA 904DR
UT WOS:000301174600033
PM 22024532
ER
PT J
AU Wu, MF
Nienhuis, R
Maidment, N
Lam, HA
Siegel, JM
AF Wu, M. -F.
Nienhuis, R.
Maidment, N.
Lam, H. A.
Siegel, J. M.
TI Cerebrospinal fluid hypocretin (orexin) levels are elevated by play but
are not raised by exercise and its associated heart rate, blood
pressure, respiration or body temperature changes
SO ARCHIVES ITALIENNES DE BIOLOGIE
LA English
DT Article
DE REM sleep; Breathing canine
ID KNOCKOUT MICE; ARTERIAL-PRESSURE; DEFENSE RESPONSE; NARCOLEPTIC DOGS;
SLEEP; NEURONS; STRESS; OREXIN/HYPOCRETIN; MODULATION; EXPRESSION
AB Hypocretin (Hcrt) has been implicated in the control of motor activity and in respiration and cardiovascular changes. Loss of Hcrt in narcolepsy is linked to sleepiness and to cataplexy, a sudden loss of muscle tone which is triggered by sudden strong emotions. In the current study, we have compared the effects of treadmill running to yard play on cerebrospinal fluid (CSF) Hcrt level in normal dogs. We find that treadmill locomotion, at a wide range of speeds, does not increase Hcrt level beyond baseline, whereas yard play produces a substantial increase in Hcrt, even though both activities produce comparable increases in heart rate, respiration and body temperature. We conclude that motor and cardiovascular changes are not sufficient to elevate CSF levels of Hcrt and we hypothesize that the emotional aspects of yard play account for the observed increase in Hcrt.
C1 [Wu, M. -F.; Nienhuis, R.; Siegel, J. M.] Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA 91343 USA.
[Maidment, N.; Lam, H. A.; Siegel, J. M.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
[Siegel, J. M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
RP Siegel, JM (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA 91343 USA.
EM jsiegel@ucla.edu
FU Medical Research Service of the Department of Veterans Affairs;
[MH64109]; [NS14610]
FX Supported by MH64109, NS14610 and the Medical Research Service of the
Department of Veterans Affairs
NR 39
TC 14
Z9 14
U1 1
U2 8
PU UNIV PISA
PI PISA
PA LUNGARNO A PACINOTTI 43, 56100 PISA, ITALY
SN 0003-9829
J9 ARCH ITAL BIOL
JI Arch. Ital. Biol.
PY 2011
VL 149
IS 4
SI SI
BP 492
EP 498
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 909MW
UT WOS:000301569800011
PM 22205595
ER
PT J
AU Nowling, TK
Gilkeson, GS
AF Nowling, Tamara K.
Gilkeson, Gary S.
TI Mechanisms of tissue injury in lupus nephritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Review
ID NITRIC-OXIDE SYNTHASE; MRL-LPR/LPR MICE; AUTOIMMUNE MRL-FAS(LPR) MICE;
CELL DEPLETION THERAPY; NZB/W F-1 MICE; MRL/LPR MICE; RENAL-DISEASE;
MURINE LUPUS; FC-GAMMA; T-CELLS
AB Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage. Nephritis, a major cause of morbidity and mortality in patients with lupus, occurs in approximately 50% of lupus patients. In the present review, we provide an overview of the current research and knowledge concerning mechanisms of renal injury in both lupus-prone mouse models and human lupus patients.
C1 [Nowling, Tamara K.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Nowling, Tamara K.; Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29401 USA.
RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, 96 Jonathan Lucas St,CSB 912,MSC 637, Charleston, SC 29425 USA.
EM gilkeson@musc.edu
NR 110
TC 56
Z9 62
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2011
VL 13
IS 6
AR 250
DI 10.1186/ar3528
PG 9
WC Rheumatology
SC Rheumatology
GA 904EB
UT WOS:000301175700046
PM 22192660
ER
PT S
AU Quigley, EMM
Jacobson, BC
Lenglinger, J
Rubenstein, JH
El-Serag, H
Cicala, M
McCallum, RW
Levine, MS
Gore, RM
AF Quigley, Eamonn M. M.
Jacobson, Brian C.
Lenglinger, Johannes
Rubenstein, Joel H.
El-Serag, Hashem
Cicala, Michele
McCallum, Richard W.
Levine, Marc S.
Gore, Richard M.
BA Giuli, R
BF Giuli, R
TI Barrett's esophagus: clinical features, obesity, and imaging
SO BARRETT'S ESOPHAGUS: THE 10TH OESO WORLD CONGRESS PROCEEDINGS
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 10th World Congress of the World Organization for Specialized Studies on
Diseases of the Esophagus (OESO)
CY AUG 28-31, 2010
CL Boston, MA
DE Gastroesophageal reflux disease; Barrett's esophagus; adiponectin;
lectin; esophageal adenocarcinoma; BMI; serum leptin; inflammation;
diabetes; ghrelin; IGF-1; IGF binding protein; esophagography;
esophagitis; central obesity; esophageal reflux; gastric banding;
PET/CT; fluoro deoxyglucose
ID BODY-MASS INDEX; GROWTH-FACTOR-I; GASTROESOPHAGEAL-REFLUX DISEASE;
GASTRIC CARDIA; INTESTINAL METAPLASIA; ABDOMINAL OBESITY;
EPITHELIAL-CELLS; F-18-FDG UPTAKE; RISK-FACTORS; ADENOCARCINOMA
AB The following includes commentaries on clinical features and imaging of Barrett's esophagus (BE); the clinical factors that influence the development of BE; the influence of body fat distribution and central obesity; the role of adipocytokines and proinflammatory markers in carcinogenesis; the role of body mass index (BMI) in healing of Barrett's epithelium; the role of surgery in prevention of carcinogenesis in BE; the importance of double-contrast esophagography and cross-sectional images of the esophagus; and the value of positron emission tomography/computed tomography.
C1 [Quigley, Eamonn M. M.] Cork Univ Hosp, Dept Med, Alimentary Pharmabiot Ctr, Cork, Ireland.
[Jacobson, Brian C.] Boston Univ, Med Ctr, Sect Gastroenterol, Boston, MA USA.
[Lenglinger, Johannes] Med Univ Vienna, Dept Surg, Vienna, Austria.
[Rubenstein, Joel H.] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Rubenstein, Joel H.] Univ Michigan, Sch Med, Div Gastroenterol, Ann Arbor, MI USA.
[El-Serag, Hashem] Houston Vet Affairs Med Ctr, Sect Gastroenterol, Houston, TX USA.
[El-Serag, Hashem] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA.
[El-Serag, Hashem] Baylor Coll Med, Houston, TX 77030 USA.
[Cicala, Michele] Campus Biomed Univ, Dipartimento Malattie Apparato Digerente, Rome, Italy.
[McCallum, Richard W.] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Internal Med, El Paso, TX USA.
[Levine, Marc S.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Gore, Richard M.] Univ Chicago, N Shore Univ Hlth Syst, Evanston Hosp, Dept Radiol, Evanston, IL USA.
RP Quigley, EMM (reprint author), Cork Univ Hosp, Dept Med, Alimentary Pharmabiot Ctr, Clin Sci Bldg, Cork, Ireland.
OI Jacobson, Brian/0000-0001-7064-2357; cicala, michele/0000-0002-5370-2642
NR 71
TC 1
Z9 1
U1 0
U2 7
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
BN 978-1-57331-829-7
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1232
BP 36
EP 52
DI 10.1111/j.1749-6632.2011.06044.x
PG 17
WC Gastroenterology & Hepatology; Multidisciplinary Sciences
SC Gastroenterology & Hepatology; Science & Technology - Other Topics
GA BZD71
UT WOS:000301188400004
PM 21950806
ER
PT S
AU Parise, P
Rosati, R
Savarino, E
Locatelli, A
Ceolin, M
Dua, KS
Tatum, RP
Braghetto, I
Gyawali, CP
Hejazi, RA
McCallum, RW
Sarosiek, I
Bonavina, L
Wassenaar, EB
Pellegrini, CA
Jacobson, BC
Canon, CL
Badaloni, A
del Genio, G
AF Parise, Paolo
Rosati, Riccardo
Savarino, Edoardo
Locatelli, Andrea
Ceolin, Martina
Dua, Kulwinder S.
Tatum, Roger P.
Braghetto, Italo
Gyawali, C. Prakash
Hejazi, Reza A.
McCallum, Richard W.
Sarosiek, Irene
Bonavina, Luigi
Wassenaar, Eelco B.
Pellegrini, Carlos A.
Jacobson, Brian C.
Canon, Cheri L.
Badaloni, Adolfo
del Genio, Gianmattia
BA Giuli, R
BF Giuli, R
TI Barrett's esophagus: surgical treatments
SO BARRETT'S ESOPHAGUS: THE 10TH OESO WORLD CONGRESS PROCEEDINGS
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 10th World Congress of the World Organization for Specialized Studies on
Diseases of the Esophagus (OESO)
CY AUG 28-31, 2010
CL Boston, MA
DE antireflux surgery; metaplastic epithelium; dysplasia; LES pressure;
manometry; esophageal motility; peristalsis; Nissen wrap; dysphagia;
highly selective vagotomy; truncal vagotomy; duodenal switch;
preoperative HRM; LES; achalasia; esophageal body; spastic disorders;
gastric emptying; TLESR; post-vagotomy gastroparesis; gastric electrical
stimulation; gastric emptying test; gastrostomy; jejunostomy; bariatric
surgery; asymptomatic reflux; preoperative endoscopy; short esophagus;
slipped wrap; Collis gastroplasty; impedance
ID GASTROESOPHAGEAL-REFLUX DISEASE; LAPAROSCOPIC ANTIREFLUX SURGERY;
MULTICHANNEL INTRALUMINAL IMPEDANCE; GASTRIC ELECTRICAL-STIMULATION;
HIGHLY SELECTIVE VAGOTOMY; PARIETAL-CELL VAGOTOMY; NISSEN
FUNDOPLICATION; HIATAL-HERNIA; INTESTINAL METAPLASIA; FOLLOW-UP
AB The following on surgical treatments for Barrett's esophagus includes commentaries on the indications for antireflux surgery after medical treatment; the effects of the various procedures on the lower esophageal sphincter; the role of impaired esophageal motility and delayed gastric emptying in the choice of the surgical procedure; indications for associated highly selective vagotomy, duodenal switch, and gastric electrical stimulation; therapeutic strategies for detection and treatment of shortened esophagus; the role of antireflux surgery on the regression of metaplastic mucosa and the risk of malignant progression; the detection of asymptomatic reflux brfore bariatric surgery; the role of non-GERD symptoms on the results of surgery; and the indications of Collis gastroplasty and choice of the type of fundoplication.
C1 [Parise, Paolo] Reg Referal Ctr Esophageal Pathol, Dept Gen Surg 4, Pisa, Italy.
[Savarino, Edoardo] Univ Milan, IRCCS, Ist Clin Humanitas, Gastroenterol Unit, Milan, Italy.
[Rosati, Riccardo; Locatelli, Andrea; Ceolin, Martina] Univ Milan, Dept Surg, Milan, Italy.
[Dua, Kulwinder S.] Med Coll Wisconsin, Div Gastroenterol & Hepatol, Dept Med, Milwaukee, WI 53226 USA.
[Tatum, Roger P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Braghetto, Italo] Univ Clin Hosp Jose Joaquin Aguirre, Dept Surg, Santiago, Chile.
[Gyawali, C. Prakash] Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO 63110 USA.
[Hejazi, Reza A.; McCallum, Richard W.] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, El Paso, TX USA.
[Sarosiek, Irene] Texas Tech Univ, Dept Internal Med, Paul L Foster Sch Med, El Paso, TX USA.
[Bonavina, Luigi] Univ Milan, Sch Med, IRCCS Policlin San Donato, Dept Surg, Milan, Italy.
[Wassenaar, Eelco B.; Pellegrini, Carlos A.] Univ Washington, Sch Med, Dept Surg, Hlth Sci Ctr, Seattle, WA 98195 USA.
[Jacobson, Brian C.] Boston Univ, Coll Med, Gastroenterol Sect, Boston, MA 02215 USA.
[Canon, Cheri L.] Univ Alabama, Dept Radiol, Birmingham, AL USA.
[Badaloni, Adolfo] Univ Favaloro, Clin San Camilo, Buenos Aires, DF, Argentina.
[del Genio, Gianmattia] Univ Naples 2, Ctr Esophagogastr & Obes Surg, Naples, Italy.
RP Parise, P (reprint author), Reg Referal Ctr Esophageal Pathol, Dept Gen Surg 4, Pisa, Italy.
RI Tolone, Salvatore/K-2031-2012
OI Tolone, Salvatore/0000-0002-1653-9903; Jacobson,
Brian/0000-0001-7064-2357; Savarino, Edoardo/0000-0002-3187-2894;
Bonavina, Luigi/0000-0002-4880-1670
NR 102
TC 0
Z9 0
U1 0
U2 4
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
BN 978-1-57331-829-7
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1232
BP 175
EP 195
DI 10.1111/j.1749-6632.2011.06051.x
PG 21
WC Gastroenterology & Hepatology; Multidisciplinary Sciences
SC Gastroenterology & Hepatology; Science & Technology - Other Topics
GA BZD71
UT WOS:000301188400011
PM 21950813
ER
PT S
AU Twaddell, WS
Wu, PC
Verhage, RJJ
Feith, M
Ilson, DH
Schuhmacher, CP
Luketich, JD
Brucher, B
Vallbohmer, D
Hofstetter, WL
Krasna, MJ
Kandioler, D
Schneider, PM
Wijnhoven, BPL
Sontag, SJ
AF Twaddell, William S.
Wu, Peter C.
Verhage, Roy J. J.
Feith, Marcus
Ilson, David H.
Schuhmacher, Christoph P.
Luketich, James D.
Bruecher, Bjoern
Vallboehmer, Daniel
Hofstetter, Wayne L.
Krasna, Mark Jonathan
Kandioler, Daniela
Schneider, Paul M.
Wijnhoven, Bas P. L.
Sontag, Stephen J.
BA Giuli, R
BF Giuli, R
TI Barrett's esophagus: treatments of adenocarcinomas II
SO BARRETT'S ESOPHAGUS: THE 10TH OESO WORLD CONGRESS PROCEEDINGS
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 10th World Congress of the World Organization for Specialized Studies on
Diseases of the Esophagus (OESO)
CY AUG 28-31, 2010
CL Boston, MA
DE sentinel node; gamma probe; PET tracer; esophageal cancer; minimally
invasive esophagectomy; lymphadenectomy; robot assisted
thoracolaparoscopic esophagectomy; robotic surgery; sentinel lymph
nodes; Barrett's esophagus; neoadjuvant chemotherapy; radiotherapy;
chemoradiotherapy; adenovirus vector; adenocarcinoma; prognosis; Siewert
's classification; AEG; two-stade esophagectomy; high risk patients; FDG
PET scan; integrated PET/CT scan; chemoradiation; residual disease;
molecular markers; gefitinib; R0 resection; p53; cisplatin; 5-FU;
FOLFOX; EGFR; HER2; submucosal invasion; multimodality therapy
ID SENTINEL LYMPH-NODE; POSITRON-EMISSION-TOMOGRAPHY; NEOADJUVANT
CHEMORADIATION; GASTROESOPHAGEAL JUNCTION; ESOPHAGOGASTRIC JUNCTION;
HISTOPATHOLOGIC RESPONSE; GASTROINTESTINAL CANCER; PATHOLOGICAL
RESPONSE; SURGICAL THERAPY; TARGETED AGENTS
AB The following topics are explored in this collection of commentaries on treatments of adenocarcinomas related to Barrett's esophagus: the importance of intraoperative frozen sections of the margins for the detection of high dysplasia; the preferable way for sentinel node dissection; the current role of robotic surgery and of video-endoscopic approach; the value of the Siewert's classification of adenocarcinomas; the indications of two-step esophagectomy; the evaluation of pathological complete response; the role of PET scan in staging and response assessment; the role of p53 in the selection of adenocarcinomas patients; chemotherapy regimens for adenocarcinomas; the use of monoclonal antibodies in the control of cell proliferation; he attempt to define a stagespecific strategy, and the possible indications of selective therapy; and changes in mortality rates from esophageal cancer.
C1 [Twaddell, William S.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
[Wu, Peter C.] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care, Seattle, WA USA.
[Verhage, Roy J. J.] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands.
[Feith, Marcus] Tech Univ Munich, Klinikum Rechts Isar, Dept Surg, D-8000 Munich, Germany.
[Ilson, David H.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Schuhmacher, Christoph P.] Tech Univ Munich, Klinikum Rechts Isar, Chirurg Klin & Poliklin, D-8000 Munich, Germany.
[Luketich, James D.] Univ Pittsburgh, Dept Cardiothorac Surg, Med Ctr, Pittsburgh, PA USA.
[Bruecher, Bjoern] Univ Tubingen, Ctr Comprehens Canc, Tubingen Dept Surg, Tubingen, Germany.
[Hofstetter, Wayne L.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Krasna, Mark Jonathan] St Joseph Med Ctr, Div Thorac Surg, Towson, MD USA.
[Vallboehmer, Daniel] Univ Cologne, Dept Gen Visceral & Canc Surg, D-50931 Cologne, Germany.
[Krasna, Mark Jonathan] Med Univ Vienna, Dept Surg, Vienna, Austria.
[Schneider, Paul M.] Univ Zurich Hosp, Div Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland.
[Wijnhoven, Bas P. L.] Erasmus Med Ctr MC, Dept Surg, Rotterdam, Netherlands.
[Sontag, Stephen J.] Edward Hines Jr VA Hosp, Hines, IL 60141 USA.
RP Twaddell, WS (reprint author), Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
RI huang, simon/H-3756-2012; Brucher, Bjorn/C-3441-2008
OI Brucher, Bjorn/0000-0002-3930-6416
NR 91
TC 1
Z9 1
U1 0
U2 7
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
BN 978-1-57331-829-7
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1232
BP 265
EP 291
DI 10.1111/j.1749-6632.2011.06056.x
PG 27
WC Gastroenterology & Hepatology; Multidisciplinary Sciences
SC Gastroenterology & Hepatology; Science & Technology - Other Topics
GA BZD71
UT WOS:000301188400016
PM 21950818
ER
PT S
AU Bauman, WA
Langhoff, E
AF Bauman, William A.
Langhoff, Erik
GP Annals NY Acad Sci
TI Rosalyn Sussman Yalow: Bronx gal who made great
SO SKELETAL BIOLOGY AND MEDICINE I
SE Annals of the New York Academy of Sciences
LA English
DT Editorial Material
CT 4th New York Skeletal Biology and Medicine Conference
CY APR 27-30, 2011
CL Mt Sinai Sch Med, New York, NY
HO Mt Sinai Sch Med
C1 [Bauman, William A.; Langhoff, Erik] James J Peters VA Med Ctr, Bronx, NY USA.
RP Bauman, WA (reprint author), James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 2
Z9 2
U1 0
U2 4
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077-8923
BN 978-1-57331-846-4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1237
BP 1
EP 3
DI 10.1111/j.1749-6632.2011.06214.x
PG 3
WC Multidisciplinary Sciences; Physiology
SC Science & Technology - Other Topics; Physiology
GA BZE87
UT WOS:000301292200001
PM 22082358
ER
PT S
AU Jacobs, PG
El Youssef, J
Castle, JR
Engle, JM
Branigan, DL
Johnson, P
Massoud, R
Kamath, A
Ward, WK
AF Jacobs, Peter G.
El Youssef, Joseph
Castle, Jessica R.
Engle, Julia M.
Branigan, Deborah L.
Johnson, Phillip
Massoud, Ryan
Kamath, Apurv
Ward, W. Kenneth
GP IEEE
TI Development of a fully automated closed loop artificial pancreas control
system with dual pump delivery of insulin and glucagon
SO 2011 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE
AND BIOLOGY SOCIETY (EMBC)
SE IEEE Engineering in Medicine and Biology Society Conference Proceedings
LA English
DT Proceedings Paper
CT 33rd Annual International Conference of the IEEE
Engineering-in-Medicine-and-Biology-Society (EMBS)
CY AUG 30-SEP 03, 2011
CL Boston, MA
SP IEEE, Engn Med & Biol Soc (EMBS)
ID BLOOD-GLUCOSE; SUGAR; MANAGEMENT; ALGORITHM
AB Patients with diabetes have difficulty controlling their blood sugar and suffer from acute effects of hypoglycemia and long-term effects of hyperglycemia, which include disease of the eyes, kidneys and nerves/feet. In this paper, we describe a new system that is used to automatically control blood sugar in people with diabetes through the fully automated measurement of blood glucose levels and the delivery of insulin and glucagon via the subcutaneous route. When a patient's blood sugar goes too high, insulin is given to the patient to bring his/her blood sugar back to a normal level. To prevent a patient's blood sugar from going too low, the patient is given a hormone called glucagon which raises the patient's blood sugar. While other groups have described methods for automatically delivering insulin and glucagon, many of these systems still require human interaction to enter the venous blood sugar levels into the control system. This paper describes the development of a fully automated closed-loop dual sensor bi-hormonal artificial pancreas system that does not require human interaction. The system described in this paper is comprised of two sensors for measuring glucose, two pumps for independent delivery of insulin and glucagon, and a laptop computer running a custom software application that controls the sensor acquisition and insulin and glucagon delivery based on the glucose values recorded. Two control algorithms are designed into the software: (1) an algorithm that delivers insulin and glucagon according to their proportional and derivative errors and proportional and derivative gains and (2) an adaptive algorithm that adjusts the gain factors based on the patient's current insulin sensitivity as determined using a mathematical model. Results from this work may ultimately lead to development of a portable, easy to use, artificial pancreas device that can enable far better glycemic control in patients with diabetes.
C1 [Jacobs, Peter G.] Jacobs Technol LLC, Portland VA Med Ctr, Portland, OR 97239 USA.
RP Jacobs, PG (reprint author), Jacobs Technol LLC, Portland VA Med Ctr, Portland, OR 97239 USA.
EM peter.jacobs@va.gov
NR 20
TC 12
Z9 12
U1 0
U2 4
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1557-170X
BN 978-1-4244-4122-8
J9 IEEE ENG MED BIO
PY 2011
BP 397
EP 400
PG 4
WC Engineering, Biomedical; Engineering, Electrical & Electronic
SC Engineering
GA BYH52
UT WOS:000298810000095
ER
PT S
AU Ramachandran, DP
Luo, C
Ma, TS
Clark, JW
AF Ramachandran, Deepa P.
Luo, Chuan
Ma, Tony S.
Clark, John W., Jr.
GP IEEE
TI Modeling Study of the Failing Heart and its Interaction with an
Implantable Rotary Blood Pump
SO 2011 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE
AND BIOLOGY SOCIETY (EMBC)
SE IEEE Engineering in Medicine and Biology Society Conference Proceedings
LA English
DT Proceedings Paper
CT 33rd Annual International Conference of the IEEE
Engineering-in-Medicine-and-Biology-Society (EMBS)
CY AUG 30-SEP 03, 2011
CL Boston, MA
SP IEEE, Engn Med & Biol Soc (EMBS)
ID VENTRICULAR ASSIST DEVICE; FAILURE
AB The effectiveness of clinical diagnosis and treatment of heart failure is a direct function of clinical signs that can be measured in a patient within cost and safety constraints. Large-scale mathematical modeling can be a key tool in revealing important, measurable clinical signs of heart failure, furthering medical understanding and development of treatment. In the first part of this study we have created two models of left heart failure - diastolic and systolic, using our human cardiovascular-respiratory system (H-CRS) model, and we present a comparison of the two types with emphasis on novel and differentiating clinical signs, such as tricuspid flow and septal motion. In the event of compromised left ventricular performance, mechanical left ventricular assist devices (LVAD) are often implanted to augment or completely replace the pumping action of the left ventricle (LV). One such type is the implantable rotary blood pump (iRBP). Several design issues related to the iRBP are difficult to study experimentally due to procedure complexity and limitations in animal models of heart failure [2]. Therefore, modeling has become a key tool in iRBP development. In the second part of this study, we have introduced an iRBP model based on [1]-[2] in the systolic failing heart to study the interactions. We consider optimal motor settings for different levels of LV assistance, the effects of the iRBP on the right heart, septum, and pulmonary circulation. Our model results align with those reported in [1]-[2]. Improvement in cardiac output, pulmonary congestion, and heart work are seen with the iRBP. We observe lowered septal assistance to RV and LV ejection with increasing pump speeds, elevating right ventricular (RV) work, reducing LVET, and causing ventricular mechanical dyssynchrony in ejection. These results suggest right heart compromise via the septum's reduced role with the introduction of an iRBP. This work emphasizes the critical role of modeling in heart failure and treatment studies.
C1 [Ramachandran, Deepa P.; Luo, Chuan; Clark, John W., Jr.] Rice Univ, Houston, TX 77005 USA.
[Ma, Tony S.] VA Med Ctr, Div Cardiol, Houston, TX 77030 USA.
RP Ramachandran, DP (reprint author), Rice Univ, Houston, TX 77005 USA.
EM dpr2@rice.edu; urania@rice.edu; ma.tonys@va.gov; jwc@rice.edu
FU Keck Center for Interdisciplinary Bioscience Training of the Gulf Coast
Consortia (NLM) [5T15LM07093]
FX This work was supported in part by a training fellowship from the Keck
Center for Interdisciplinary Bioscience Training of the Gulf Coast
Consortia (NLM Grant No. 5T15LM07093).
NR 10
TC 4
Z9 4
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1557-170X
BN 978-1-4244-4122-8
J9 IEEE ENG MED BIO
PY 2011
BP 2403
EP 2409
PG 7
WC Engineering, Biomedical; Engineering, Electrical & Electronic
SC Engineering
GA BYH52
UT WOS:000298810002037
ER
PT J
AU Akl, EA
Labedi, N
Terrenato, I
Barba, M
Sperati, F
Sempos, EV
Muti, P
Cook, D
Schunemann, H
AF Akl, Elie A.
Labedi, Nawman
Terrenato, Irene
Barba, Maddalena
Sperati, Francesca
Sempos, Elena V.
Muti, Paola
Cook, Deborah
Schuenemann, Holger
TI Low molecular weight heparin versus unfractionated heparin for
perioperative thromboprophylaxis in patients with cancer
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; POSTOPERATIVE VENOUS
THROMBOEMBOLISM; FATAL PULMONARY-EMBOLISM; DOUBLE-BLIND TRIAL;
GENERAL-SURGERY; GYNECOLOGICAL SURGERY; STANDARD HEPARIN;
ABDOMINAL-SURGERY; MULTICENTER TRIAL
AB Background
The choice of the appropriate perioperative thromboprophylaxis in patients with cancer depends on the relative benefits and harms of low molecular weight heparin (LMWH) and unfractionated heparin (UFH).
Objectives
To systematically review the evidence for the relative efficacy and safety of LMWH and UFH for perioperative thromboprophylaxis in patients with cancer.
Search strategy
A comprehensive search for trials of anticoagulation in cancer patients including a February 2010 electronic search of: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and ISI Web of Science.
Selection criteria
Randomized controlled trials (RCTs) that enrolled cancer patients undergoing a surgical intervention and compared the effects of LMWH to UFH on mortality, deep venous thrombosis (DVT), pulmonary embolism(PE), bleeding outcomes, and thrombocytopenia.
Data collection and analysis
Two review authors used a standardized form to independently extract in duplicate data on risk of bias, participants, interventions and outcomes of interest. Where possible, we conducted meta-analyses using the random-effects model.
Main results
Of 8187 identified citations, we included 16 RCTs with 11,847 patients in the meta-analyses, all using preoperative prophylactic anticoagulation. The overall quality of evidence was moderate. The meta-analysis did not conclusively rule out either a beneficial or harmful effect of LMWH compared to UFH for the following outcomes: mortality (RR = 0.90; 95% CI 0.73 to 1.10), symptomatic DVT (RR = 0.73; 95% CI 0.23 to 2.28), PE (RR = 0.59; 95% CI 0.25 to1.41), minor bleeding (RR = 0.88; 95% CI 0.47 to 1.66) and major bleeding (RR = 0.84; 95% CI 0.52 to 1.36). LMWH was associated with lower incidence of wound hematoma (RR = 0.60; 95% CI 0.43, 0.84) while UFH was associated with higher incidence of intra-operative transfusion (RR = 1.16; 95% CI 0.69,1.62).
Authors' conclusions
We found no difference between perioperative thromboprophylaxis with LMWH verus UFH in their effects on mortality and embolic outcomes in patients with cancer. Further trials are needed to more carefully evaluate the benefits and harms of different heparin thromboprophylaxis strategies in this population.
C1 [Akl, Elie A.; Labedi, Nawman] SUNY Buffalo, Dept Med, Buffalo, NY 14215 USA.
[Terrenato, Irene; Barba, Maddalena; Sperati, Francesca; Muti, Paola] Natl Canc Inst Regina Elena, Dept Epidemiol, Rome, Italy.
[Sempos, Elena V.] US Dept Vet Affairs, Perry Point, MD USA.
[Schuenemann, Holger] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
RP Akl, EA (reprint author), SUNY Buffalo, Dept Med, ECMC CC-142,462 Grider St, Buffalo, NY 14215 USA.
EM elieakl@buffalo.edu
RI Sperati, Francesca/K-5843-2016
OI Sperati, Francesca/0000-0002-6038-2798
FU Sate University of New York at Buffalo, Department of Medicine, USA,
USA; McMaster University, Department of Clincial Epidemiology and
Biostatistics, Canada; Cochrane Gyanccological Cancer Review Group, UK
FX Internal sources; Sate University of New York at Buffalo, Department of
Medicine, USA, USA.; McMaster University, Department of Clincial
Epidemiology and Biostatistics, Canada.; External sources; Cochrane
Gyanccological Cancer Review Group Update Incentive Award, UK.
NR 67
TC 10
Z9 10
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2011
IS 11
AR CD009447
DI 10.1002/14651858.CD009447
PG 54
WC Medicine, General & Internal
SC General & Internal Medicine
GA 846BH
UT WOS:000296871700069
PM 22071865
ER
PT J
AU Hagan, M
Bosch, W
Moore, M
Prestidge, B
Paulus, R
Galvin, J
Sandler, H
Winter, K
Michalski, J
AF Hagan, M.
Bosch, W.
Moore, M.
Prestidge, B.
Paulus, R.
Galvin, J.
Sandler, H.
Winter, K.
Michalski, J.
TI Analysis Of Brachytherapy Plans For Regulatory Compliance: Application
Of Expected Doses To Organs At Risk
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Meeting Abstract
C1 [Hagan, M.] Virginia Hosp, Coll Med, Richmond, VA USA.
[Hagan, M.] Dept Vet Affairs, Washington, DC USA.
[Bosch, W.; Michalski, J.] Washington Univ, St Louis, MO USA.
[Moore, M.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Prestidge, B.] Mem Hermann SW Hosp, Houston, TX USA.
[Paulus, R.; Galvin, J.; Winter, K.] Radiat Therapy Oncol Grp RTOG Headquarters, Philadelphia, PA USA.
[Sandler, H.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PY 2011
VL 81
IS 2
SU S
BP S387
EP S388
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 840AX
UT WOS:000296411700800
ER
PT J
AU Hung, AY
Farris, PE
Beer, T
Garzotto, M
AF Hung, A. Y.
Farris, P. E.
Beer, T.
Garzotto, M.
TI Phase I/II Study of Preoperative Radiation and Docetaxel Activity Study
for High-Risk Prostate Cancer
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Meeting Abstract
C1 [Hung, A. Y.; Farris, P. E.; Beer, T.; Garzotto, M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Garzotto, M.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PY 2011
VL 81
IS 2
SU S
BP S390
EP S390
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 840AX
UT WOS:000296411700806
ER
PT J
AU Habib, SL
AF Habib, Samy L.
TI Diabetes and the risk of Renal Cell carcinoma
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Meeting Abstract
C1 [Habib, Samy L.] S Texas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PY 2011
VL 28
SU 1
MA 305
BP S56
EP S56
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 827IR
UT WOS:000295422700207
ER
PT B
AU Videlock, EJ
Chang, L
AF Videlock, Elizabeth J.
Chang, Lin
BE Parkman, HP
McCallum, RW
Rao, SSC
TI IRRITABLE BOWEL SYNDROME
SO GI MOTILITY TESTING: A LABORATORY AND OFFICE HANDBOOK
LA English
DT Article; Book Chapter
ID RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; BACTERIAL OVERGROWTH; RECTAL
DISTENSION; HEALTHY-SUBJECTS; DISORDERS; PLACEBO; CONSTIPATION;
EFFICACY; PAIN
C1 [Videlock, Elizabeth J.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90095 USA.
[Videlock, Elizabeth J.; Chang, Lin] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Videlock, EJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90095 USA.
NR 51
TC 0
Z9 0
U1 1
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA
BN 978-1-55642-958-3
PY 2011
BP 399
EP 410
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA BSA22
UT WOS:000284022100037
ER
PT B
AU Holzer, AM
Yusuf, N
Tisdale, B
Katiyar, SK
Elmets, CA
AF Holzer, Aton M.
Yusuf, Nabiha
Tisdale, Brandon
Katiyar, Santosh K.
Elmets, Craig A.
BE Krutmann, J
Humbert, P
TI Systemic and Topical Use of Green Tea Polyphenols for Healthy Skin
SO NUTRITION FOR HEALTHY SKIN: STRATEGIES FOR CLINICAL AND COSMETIC
PRACTICE
LA English
DT Article; Book Chapter
ID NF-KAPPA-B; HUMAN EPIDERMAL-KERATINOCYTES; ACTIVATED PROTEIN-KINASE;
MIGRATION INHIBITORY FACTOR; INDUCED OXIDATIVE STRESS; DECREASED TISSUE
FAT; SKH-1 HAIRLESS MICE; FOS GENE-EXPRESSION; MOUSE SKIN;
ULTRAVIOLET-LIGHT
C1 [Holzer, Aton M.; Yusuf, Nabiha; Tisdale, Brandon; Katiyar, Santosh K.; Elmets, Craig A.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.; Elmets, Craig A.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Holzer, AM (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
EM celmets@uab.edu
NR 114
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
BN 978-3-642-12263-7
PY 2011
BP 71
EP 83
DI 10.1007/978-3-642-12264-4_7
D2 10.1007/978-3-642-12264-4
PG 13
WC Dermatology
SC Dermatology
GA BTH16
UT WOS:000286921700007
ER
PT B
AU Eiseman, B
AF Eiseman, Ben
BE Rosenthal, RA
Zenilman, ME
Katlic, MR
TI Principles and Practice of Geriatric Surgery Second Edition Invited
Commentary
SO PRINCIPLES AND PRACTICE OF GERIATRIC SURGERY, SECOND EDITION
LA English
DT Editorial Material; Book Chapter
C1 Univ Hosp, Denver Vet Affairs Hosp, Dept Surg, Denver, CO 80220 USA.
RP Eiseman, B (reprint author), Univ Hosp, Denver Vet Affairs Hosp, Dept Surg, 1055 Clermont St, Denver, CO 80220 USA.
EM Ben.eiseman@va.gov
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
BN 978-1-4419-6998-9
PY 2011
BP 233
EP 234
DI 10.1007/978-1-4419-6999-6_19
D2 10.1007/978-1-4419-6999-6
PG 2
WC Geriatrics & Gerontology; Surgery
SC Geriatrics & Gerontology; Surgery
GA BWC28
UT WOS:000293421700019
ER
PT B
AU Albo, D
Anaya, DA
Berger, DH
AF Albo, Daniel
Anaya, Daniel A.
Berger, David H.
BE Rosenthal, RA
Zenilman, ME
Katlic, MR
TI Gastric Cancer in the Elderly
SO PRINCIPLES AND PRACTICE OF GERIATRIC SURGERY, SECOND EDITION
LA English
DT Article; Book Chapter
ID ADJUVANT CHEMOTHERAPY; 1ST-LINE CHEMOTHERAPY; CURATIVE RESECTION;
PHASE-II; NEOADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIALS; ONCOLOGY-GROUP;
PREOPERATIVE CHEMORADIOTHERAPY; GASTROESOPHAGEAL CANCER; COMBINED
5-FLUOROURACIL
C1 [Albo, Daniel] Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, OCL 112A, Houston, TX 77030 USA.
[Anaya, Daniel A.; Berger, David H.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
[Berger, David H.] Baylor Coll Med, Chief Div Gen Surg & Surg Oncol, Houston, TX 77030 USA.
RP Albo, D (reprint author), Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, OCL 112A, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM albo@bcm.tmc.edu
NR 62
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
BN 978-1-4419-6998-9
PY 2011
BP 781
EP 792
DI 10.1007/978-1-4419-6999-6_62
D2 10.1007/978-1-4419-6999-6
PG 12
WC Geriatrics & Gerontology; Surgery
SC Geriatrics & Gerontology; Surgery
GA BWC28
UT WOS:000293421700062
ER
PT B
AU Forrest, GN
AF Forrest, Graeme N.
BE Safdar, A
TI Controversies in Antimicrobial Stewardship
SO PRINCIPLES AND PRACTICE OF CANCER INFECTIOUS DISEASES
SE Current Clinical Oncology Series
LA English
DT Article; Book Chapter
DE Antimicrobial management; Antimicrobial resistance; Antibiotic cycling;
Outpatient antibiotic therapy; VRE; Clostridium difficile
ID VANCOMYCIN-RESISTANT ENTEROCOCCI; DIFFICILE-ASSOCIATED-DIARRHEA;
BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE BACILLI; INTENSIVE-CARE-UNIT;
CELL TRANSPLANT RECIPIENTS; CLOSTRIDIUM-DIFFICILE; RISK-FACTORS;
PSEUDOMONAS-AERUGINOSA; CANCER-PATIENTS
AB Antimicrobial stewardship programs are recommended by the Infectious Diseases Society of America as a method to control antimicrobial costs and resistance. These programs are usually implemented hospital wide, but there is little evidence on their effects in oncology units. Three controversial areas of antimicrobial stewardship in oncology units include whether these programs decrease antimicrobial resistance when antimicrobial restriction is implemented, the role of antimicrobial cycling on Gram-negative resistance and that these programs rarely control outpatient antimicrobial therapy. This review will discuss these controversial areas with regard to the evidence, strength of trial design, and the generalizability of their outcomes.
C1 Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA.
RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW Us Vet Hosp Rd, Portland, OR 97239 USA.
EM forrestg@ohsu.edu
NR 83
TC 1
Z9 1
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
BN 978-1-60761-643-6
J9 CURR CLIN ONCOL
PY 2011
BP 499
EP 506
DI 10.1007/978-1-60761-644-3_44
D2 10.1007/978-1-60761-644-3
PG 8
WC Oncology; Infectious Diseases
SC Oncology; Infectious Diseases
GA BVO36
UT WOS:000292077800044
ER
PT B
AU Swenson, ER
AF Swenson, Erik R.
BE Yuan, JXJ
Garcia, JGN
Hales, CA
Rich, S
Archer, SL
West, JB
TI High-Altitude Pulmonary Edema
SO TEXTBOOK OF PULMONARY VASCULAR DISEASE
LA English
DT Article; Book Chapter
DE High altitude pulmonary edema; Hypoxia; Alveolar fluid balance; Alveolar
capillary barrier; Microvascular hydrostatic pressure; Capillary stress
failure
ID ACUTE MOUNTAIN-SICKNESS; ENDOTHELIAL GROWTH-FACTOR; EXHALED
NITRIC-OXIDE; ALVEOLAR EPITHELIAL FUNCTION; I/D GENE POLYMORPHISM;
BLOOD-GAS BARRIER; VASCULAR-RESISTANCE; BRONCHOALVEOLAR LAVAGE;
INFLAMMATORY PROCESSES; POTENTIAL DIFFERENCE
AB High-altitude pulmonary edema (HAPE) is an uncommon form of pulmonary edema that occurs in healthy individuals within a few days of arrival at altitudes above 2,500-3,000 m. The crucial pathophysiology is an excessive hypoxia-mediated rise in pulmonary vascular resistance (PVR) or hypoxic pulmonary vasoconstriction (HPV) leading to increased microvascular hydrostatic pressures despite normal left atrial pressure. The resultant hydrostatic stress can cause both dynamic changes in the permeability of the alveolar capillary barrier and mechanical damage leading to leakage of large proteins and erythrocytes into the alveolar space in the absence of inflammation. Bronchoalveolar lavage (BAL) and pulmonary artery (PA) and microvascular pressure measurements in humans confirm that high capillary pressure induces a high-permeability non-inflammatory-type lung edema; a concept termed "capillary stress failure." Measurements of endothel in and nitric oxide (NO) in exhaled air, NO metabolites in BAL fluid, and NO-dependent endothelial function in the systemic circulation all point to reduced NO availability and increased endothelin in hypoxia as a major cause of the excessive hypoxic PA pressure rise in HAPE-susceptible individuals. Other hypoxia-dependent differences in ventilatory control, sympathetic nervous system activation, endothelial function, and alveolar epithelial sodium and water reabsorption likely contribute additionally to the phenotype of HAPE susceptibility. Recent studies using magnetic resonance imaging in humans strongly suggest nonuniform regional hypoxic arteriolar vasoconstriction as an explanation for how HPV occurring predominantly at the arteriolar level can cause leakage. This compelling but not yet fully proven mechanism predicts that in areas of high blood flow due to lesser vasoconstriction edema will develop owing to pressures that exceed the structural and dynamic capacity of the alveolar capillary barrier to maintain normal alveolar fluid balance. Numerous strategies aimed at lowering HPV and possibly enhancing active alveolar fluid reabsorption are effective in preventing and treating HAPE. Much has been learned about HAPE in the past four decades such that what was once a mysterious alpine malady is now a well-characterized and preventable lung disease. This chapter will relate the history, pathophysiology, and treatment of HAPE, using it not only to illuminate the condition, but also for the broader lessons it offers in understanding pulmonary vascular regulation and lung fluid balance.
C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.
RP Swenson, ER (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM eswenson@u.washington.edu
NR 169
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
BN 978-0-387-87428-9
PY 2011
BP 871
EP 888
DI 10.1007/978-0-387-87429-6_61
D2 10.1007/978-0-387-87429-6
PG 18
WC Cardiac & Cardiovascular Systems; Medicine, General & Internal
SC Cardiovascular System & Cardiology; General & Internal Medicine
GA BVA19
UT WOS:000290881400061
ER
PT J
AU Goldstein, G
Incagnoli, TM
Puente, AE
AF Goldstein, Gerald
Incagnoli, Theresa M.
Puente, Antonio E.
BE Goldstein, G
Incagnoli, TM
Puente, AE
TI Contemporary Neurobehavioral Syndromes Introduction
SO CONTEMPORARY NEUROBEHAVIORAL SYNDROMES
LA English
DT Editorial Material; Book Chapter
C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Goldstein, Gerald] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Puente, Antonio E.] Univ N Carolina, Chapel Hill, NC 27515 USA.
RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI LONDON
PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND
BN 978-0-20382-965-3
PY 2011
BP 1
EP 12
PG 12
WC Psychology, Biological; Psychiatry
SC Psychology; Psychiatry
GA BUM37
UT WOS:000289774000002
ER
PT J
AU Goldstein, G
Incagnoli, TM
Puente, AE
AF Goldstein, Gerald
Incagnoli, Theresa M.
Puente, Antonio E.
BE Goldstein, G
Incagnoli, TM
Puente, AE
TI Contemporary Neurobehavioral Syndromes Preface
SO CONTEMPORARY NEUROBEHAVIORAL SYNDROMES
LA English
DT Editorial Material; Book Chapter
C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Puente, Antonio E.] Univ N Carolina, Wilmington, NC 28401 USA.
[Goldstein, Gerald] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI LONDON
PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND
BN 978-0-20382-965-3
PY 2011
BP IX
EP XI
PG 3
WC Psychology, Biological; Psychiatry
SC Psychology; Psychiatry
GA BUM37
UT WOS:000289774000001
ER
PT J
AU Griebling, J
Williams, DL
Goldstein, G
Minshew, NJ
AF Griebling, Jessica
Williams, Diane L.
Goldstein, Gerald
Minshew, Nancy J.
BE Goldstein, G
Incagnoli, TM
Puente, AE
TI Reconceptualization of autism and autism spectrum disorders as
neurodevelopmental disorders
SO CONTEMPORARY NEUROBEHAVIORAL SYNDROMES
LA English
DT Article; Book Chapter
ID HIGH-FUNCTIONING AUTISM; PERVASIVE DEVELOPMENTAL DISORDERS; EARLY
INFANTILE-AUTISM; FUSIFORM FACE AREA; EXECUTIVE FUNCTION;
YOUNG-CHILDREN; HEAD CIRCUMFERENCE; IMAGING GENETICS; WORKING-MEMORY;
SENTENCE COMPREHENSION
C1 [Griebling, Jessica; Minshew, Nancy J.] Univ Pittsburgh, Ctr Excellence Autism Res, Pittsburgh, PA 15260 USA.
[Williams, Diane L.] Duquesne Univ, Pittsburgh, PA 15219 USA.
[Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Griebling, J (reprint author), Univ Pittsburgh, Ctr Excellence Autism Res, Pittsburgh, PA 15260 USA.
RI Williams, Diane/B-4128-2017
NR 155
TC 0
Z9 0
U1 6
U2 11
PU TAYLOR & FRANCIS LTD
PI LONDON
PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND
BN 978-0-20382-965-3
PY 2011
BP 33
EP 70
PG 38
WC Psychology, Biological; Psychiatry
SC Psychology; Psychiatry
GA BUM37
UT WOS:000289774000004
ER
PT B
AU Goldstein, G
AF Goldstein, Gerald
BE Goldstein, G
Incagnoli, TM
Puente, AE
TI Persian Gulf and other "deployment" syndromes
SO CONTEMPORARY NEUROBEHAVIORAL SYNDROMES
LA English
DT Article; Book Chapter
ID AMYOTROPHIC-LATERAL-SCLEROSIS; POSTTRAUMATIC-STRESS-DISORDER; PROTON MR
SPECTROSCOPY; WAR VETERANS; NEUROBEHAVIORAL DEFICITS; MYCOPLASMAL
INFECTIONS; HEALTH CONSEQUENCES; DEPLETED URANIUM; ILLNESS; ALS
C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 55
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI LONDON
PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND
BN 978-0-20382-965-3
PY 2011
BP 131
EP 150
PG 20
WC Psychology, Biological; Psychiatry
SC Psychology; Psychiatry
GA BUM37
UT WOS:000289774000007
ER
PT J
AU Goldstein, G
Lopez, RV
Puente, AE
AF Goldstein, Gerald
Lopez, Raquel V.
Puente, Antonio E.
BE Goldstein, G
Incagnoli, TM
Puente, AE
TI Comorbid disorders
SO CONTEMPORARY NEUROBEHAVIORAL SYNDROMES
LA English
DT Article; Book Chapter
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MILD COGNITIVE
IMPAIRMENT; MOTOR-VEHICLE ACCIDENTS; SUBSTANCE USE DISORDERS;
ALCOHOL-USE DISORDERS; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE;
HIPPOCAMPAL ATROPHY; ADDICTIVE-DISORDERS
C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Lopez, Raquel V.] Univ Granada, Granada, Spain.
[Puente, Antonio E.] Univ N Carolina, Wilmington, NC 28401 USA.
RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 137
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI LONDON
PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND
BN 978-0-20382-965-3
PY 2011
BP 175
EP 194
PG 20
WC Psychology, Biological; Psychiatry
SC Psychology; Psychiatry
GA BUM37
UT WOS:000289774000009
ER
EF